Abstract Book

Society of Surgical Oncology 67th Annual Cancer Symposium

Phoenix, Arizona March 12-15, 2014

Electronic supplement to *Annals of Surgical Oncology* An Oncology Journal for Surgeons



Society of Surgical Oncology

March 12-15, 2014 • Phoenix, Arizona

Annals of Surgical Oncology An Oncology Journal for Surgeons

The Official Journal of the Society of Surgical Oncology

Abstract Book

Society of Surgical Oncology 67th Annual Cancer Symposium Phoenix, Arizona March 12-15, 2014

CONTENTS

Volume 21, Supplement 1, February 2014

S3: Session Titles and Abstracts Contents
S5: Abstracts of Plenary, Parallel and Video Sessions
S43: Abstracts of Poster Presentations
S181: Conflict of Interest Disclosures
S187: Author Index

This supplement was not sponsored by outside commercial interests.

Session Titles and Abstract Contents

Session Title	Abstract Numbers	Pages
Oral Presentations		
Plenary Session I	1, 2, 3	6
Plenary Session II	4, 5, 6 (7 withdrawn)	6 - 7
Parallel Sessions: Breast Cancer	8 - 17	8-11
Parallel Sessions: Colorectal Cancer	18 - 28	12 - 15
Parallel Sessions: Endocrine Cancer	29 - 38	15 - 18
Parallel Sessions: Hepatobiliary Cancer	39 - 48	19 - 22
Parallel Sessions: Melanoma	49 - 58	22 - 26
Parallel Sessions: Quality Improvement/Clinical Outcome	es 59 - 68	26 - 29
Parallel Sessions: Sarcoma	69 - 78	29 - 33
Parallel Sessions: Thoracic/Esophageal	79 - 88	33 - 36
Parallel Sessions: Upper Gastrointestinal Cancer	89 - 98	36 - 40
Top Rated Videos	V1 – V8	41 - 42
Poster Presentations		
Posters: Breast Cancer	P1 – P94	44 - 76
Posters: Colorectal Cancer	P95 – P135 (P100 withdrawn)	76 - 90
Posters: Endocrine Cancer	P136 – P157	90 - 97
Posters: Hepatobiliary Cancer	P158 – P195 (P185 withdrawn)	97 - 109
Posters: Melanoma	P196 – P242	109 - 125

Posters: Melanoma P196 - P242Posters: Other (Urology/Head and Neck/Thoracic) P243 – P254 125 - 128 Posters: Quality Improvement/Clinical Outcomes P255 - P296 128 - 142Posters: Sarcoma P297 – P318 (P302 withdrawn) 142 - 150Posters: Thoracic/Esophageal P319 – P332 150 - 155Posters: Upper Gastrointestinal Cancer P333 - P407 155 - 180(P339, P352, P369 withdrawn)

ABSTRACTS

Accepted for PLENARY, PARALLEL and VIDEO SESSIONS

67th Annual Cancer Symposium Society of Surgical Oncology March 12–15, 2014 Phoenix, Arizona Randomized Controlled Trial of Irinotecan Drug Eluting Beads with Simultaneous FOLFOX and Bevacizamab for Patients with Unresectable Colorectal Liver-limited Metastasis R. Martin,^{1*} M. Schreeder,² J. Kauh,³ W. Rilling,⁴ C. Laing,⁵ T. Crocenz,⁷ S. Stras-

berg.⁶ 1. University of Louisville, Louisville, KY; 2. Clearview Cancer Center, Huntsville, AL; 3. Emory University - Winship Cancer Institute, Atlanta, GA; 4. Froedtert Medical Colleg, Milwaukee, WI; 5. Radiological Associates of Sacramento, Sacramento, CA; 6. Washington University, St Louis, MO; 7. Providence Medical Center, Portland, OR.

Background: Reports have demonstrated the activity of combining both Irinotecan & Oxaliplatin into a FOLFOXIRI therapy. An option to gain similar benefits & less toxicity to FOLFOXIRI would be to administer the irinotecan through an hepatic arterial apporach. The aim of this study was to assess the maximal response and adverse event rates of Irinotecan Drug Eluting Beads (DEBIRI) with FOLFOX & Bevacizumab(Bev) as a first line treatment for unresectable colorectal liver metastasis (CLMs). Methods: Metachronous & Synchronous CLMs were randomly assigned to mFOLFOX6/Bev or mFOL-FOX6, Bev & DEBIRI (FOLFOXDEBIRI). Primary end point was optimal response rates & adverse events. Secondary endpoints were patients(pts) converted to resection & survival. Results: The intention-to-treat population comprised 70 pts, 40 pts randomly assigned to the FOLFOXDEBIRI arm & 30 pts to FOLFOX/Bev arm. Both were similar with synchronous disease (50%vs36%), extent liver involvement (35%vs31%), but greater percentage in the FOLFOXDEBIRI arm of ECOG 1/2 (57%vs31%),p=0.04) & extrahepatic disease (51%vs 36%,p=0.02). Median number chemotherapy cycles was similar in both arms of 8, with a similar Grade 3/4 adverse event rate of 54% FOLFOXDEBIRI & 46% FOLFOX/Bev arm. The overall response rate was significantly greater in the FOLFOXDEBIRI arm vs FOLFOX/BEV at 2months (78% vs 54%, 4 mon (95% v 70%) and 6 mon (76% vs 60%)(p=0.03). Significantly greater downsizing to resection in the FOLFOXDEBIRI arm vs FOLFOX/Bev (35%vs16%,p=0.05), with an improved median progression free survival (15.3 mon vs7.6 mon). Overall improvement in hepatic specific progression free survival was seen in the treatment arm(12.8 mon vs 10.5 mon). Conclusions: Simultaneous mFOLFOX6 with bevacizumab and hepatic arterial irinotecan drug eluting beads is safe, without causing chemotherapy delivery delays and without increasing chemotherapy toxicity. Simultaneous FOL-FOXDEBIRI leads to improved overall response rates, improved hepatic progression free survival, and more durable overall progression free survival in patients downsized to resection.

2

Intensified Follow-up in Colorectal Cancer Patients using Frequent Carcinoembryonic (CEA) Measurements and CEA-triggered Imaging C. Verberne,* E. Van den Heuvel, G.H. De Bock, I. Grossmann, T. Wiggers. University Medical Center Groningen, Groningen, Netherlands.

Background - For colorectal cancer (CRC), there is need for an evidencebased follow-up schedule defining frequency of blood tests and imaging to detect recurrent disease as early as possible. The trial CEA Watch assesses the value of frequent CEA measurements and imaging in case of a rise in CEA for detecting recurrent disease in CRC patients and aims to increase the rate of curable recurrences amongst all detected recurrences from 10 % to 25%. Methods - This was a randomized-controlled multicenter prospective study using a stepped wedge cluster design. Eleven Dutch hospitals were timed one after another to change their follow-up "care as usual" into an intensified followup schedule for all patients in follow-up after non-metastasized CRC. The intervention protocol consisted of CEA measurements every 2 months, with repetition of the CEA measurement after 1 month in case of a 20% rise and imaging in case of 2 subsequent rises. A sample size calculation was performed and 1,600 patients were needed given a recurrence rate of 25%. Results - 3,223 patients were included; 243 recurrences were detected (7.5%), 104 (43%) recurrences were found while the patient participated in the control follow-up and 139 (57%) recurrences in the intervention follow-up. In total, 90 (37.0%) of the found recurrences could be treated with curative intent. The rate of detected recurrences which could be treated with curative intent was significantly higher for the intervention protocol than for the control protocol (42% v 30%, p=0.027). Analyses of these treatments with curative intent will be added. Survival data are to be awaited. Conclusions - The CEA Watch protocol detects recurrent

disease after colorectal cancer in a phase that a significantly higher proportion of recurrences can be treated with curative intent.

	Total n(%)	Control n(%)	Intervention n(%)	Effect (p-value)
Recurrent Disease	243 (7.5)	104 (43)	139 (57)	0.015
Curable Recurrent Disease	90 (37)	31 (30)	58 (42)	0.027

3

Long-term Incidence of Lymphedema after Sentinel Lymph Node Dissection for Early Stage Breast Cancer: ACOSOG Z0010 (Alliance) M. Teshome, ^{1*} K.V. Ballman,² L.M. McCall,³ J.N. Cormier, ¹ A.E. Giuliano,⁴ K.K. Hunt.¹ 1. The University of Texas M.D. Anderson Cancer Center, Houston, TX; 2. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; 3. Alliance Statistics and Data Center; Duke University, Durham, NC; 4. Samuel Oschin Comprehensive Cancer Institute, Cedar-Sinai Medical Center; Los Angeles, CA.

Introduction: Sentinel lymph node (SLN) dissection has an established role as minimally invasive axillary staging with decreased morbidity in early breast cancer. The American College of Surgeons Oncology Group (ACOSOG) Z0010 trial, a prospective multicenter study to evaluate the prognostic significance of micrometastasis in SLNs of women with early stage breast cancer, previously reported a 7% incidence of lymphedema at 6 months. This study examines the long-term incidence of lymphedema in this cohort. Methods: Eligible patients for ACOSOG Z0010 included women with clinical T1-2 N0 M0 breast cancer. In this trial 5,210 women underwent SLN dissection; of those, 885 had completion axillary lymph node dissection (ALND) and were included for comparison. Post-operative symptoms assessment and examination were completed at 30 days, 6 months, and annually for 5 years. Lymphedema was evaluated subjectively as ipsilateral arm swelling and objectively as an increase of ≥ 2 cm from the pre-operative arm measurement. A multivariate Cox regression analysis was conducted to examine associations between clinical factors and lymphedema. Results: The cumulative incidence of lymphedema after SLN dissection was 3.7% at 1 year, 8.9% at 3 years and 11.9% at 5 years by subjective assessment (n=3,993) and 10.5% at 1 year, 17.4% at 3 years and 24.1% at 5 years by objective arm measurements (n= 3,918). Following ALND, the incidence of lymphedema was 14.0% at 1 year, 32.9% at 3 years and 41.0% at 5 years by subjective assessment (n=865) and 17.0% at 1 year, 30.6% at 3 years and 40.3% at 5 years by objective arm measurement (n= 853). On multivariate analysis, significant predictors of objective lymphedema included increasing age (OR=1.01, [95% CI: 1.01-1.02], p<0.0001), BMI ≥ 30 kg/m2 (OR=1.81 [1.59-2.06], p<0.0001) and ALND (OR=1.74 [1.50-2.02], p<0.0001). After axillary surgery, decreased range of motion and paresthesias occurred more often than lymphedema. Conclusions: Lymphedema after SLN dissection in women with early stage clinically node negative breast cancer occurs more frequently than clinically suspected and with increasing incidence over time.

Table 1. Cumulative incidence (%) of lymphedema, decreased range of motion and axillary paresthesia in SLN and ALND groups over time.

	SLN (%)				ALND (%)	
	1 year	3 years	5 years	1 year	3 years	5 years
Subjective lymphedema	3.7	8.9	11.9	14.0	32.9	41.0
Objective lymphedema	10.5	17.4	24.1	17.0	30.6	40.3
Decreased range of motion	15.9	18.9	22.1	45.3	48.7	51.3
Axillary paresthesia	18.8	25.9	29.1	60.2	73.1	76.6

4

Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcomas of the Extremity: 20-year follow-up of a Randomized Prospective Trial J.D. Beane,^{1*} J.C. Yang,¹ D. White,¹ S. Steinberg,² S.A. Rosenberg,¹ U. Rudloff.¹ *1. Surgery Branch, National Cancer Institute, Bethesda, MD; 2. Biostatistics and Data Management Sections, National Cancer Institute, Bethesda, MD.*

Background Randomized prospective trials have demonstrated the ability of adjuvant radiation therapy (XRT) to enhance local control following limbsparing surgery for soft tissue sarcoma (STS), but this has not translated into improved overall survival (OS). Patients treated with XRT are at increased risk for developing functional deficits, and the natural history of these deficits has not been reported. To address the effect of XRT on long term overall survival and limb function, we present a twenty-year follow-up of our randomized prospective study of the benefit of adjuvant radiation in the treatment of soft tissue sarcomas of the extremity. Methods Patients with extremity STS and a limb-sparing surgical operation were randomized to receive postoperative XRT or surgery alone. Initially, quality of life, functional data, and OS information were collected in a prospective fashion. This report completes long term follow up through medical records and telephone contacts. Results A total of 141 patients with extremity STS of either high or low grade were randomized to receive postoperative XRT (n=70) or surgery alone (n=71). Median follow up was 17.9 years. Ten and 20-year survival was 77% and 64% for patients receiving surgery alone and 82% and 71% for patients receiving adjuvant XRT (p=0.2). There was no difference in overall survival between treatment arms when analyzing patients with high-grade or low-grade tumors separately. Patients treated with postoperative XRT tend to be more debilitated (4% vs 0%, p=0.8), have clinically significant edema (25% vs 12% p=0.2), and suffer from late wound complications (17% vs 12%, p=0.7), but these did not reach statistical significance when compared to patients receiving surgery alone. Late findings included limb loss (n=2, both following XRT), pathological fractures (n=4, three following XRT) and local recurrence (n=1, surgery alone). Conclusion Adjuvant external beam radiation therapy following surgery for soft tissue sarcoma of the extremity improves local control, is associated with some long term limb complications and does not improve overall survival.



Figure 1. Overall survival of all patients with STS randomized to treatment with surgery and adjuvant chemotherapy versus surgery, chemotherapy, and XRT.

5

Phase I/II Trial of Autophagy Inhibition in Combination with Neoadjuvant Gemcitabine in High-risk Pancreatic Adenocarcinoma: Safety, Clinical Response, and Correlative Studies

B.A. Boone,^{1*} M.T. Lotze, ¹A.H. Zureikat, ¹N. Bahary, ¹A.D. Singhi, ¹ D.L. Bartlett, ¹V. Espina, ²L.A. Liotta, ²H.J. Zeh. ¹ *1. Surgery, University* of Pittsburgh, Pittsburgh, PA; 2. George Mason University, Manassas, VA.

Introduction: Autophagy is a cell survival mechanism that is up-regulated in patients with pancreatic ductal adenocarcinoma. Increased autophagy correlates adversely with response to therapy and prognosis. Use of the autophagy inhibitor hydroxychloroquine (HCQ) represents a novel treatment strategy in pancreatic cancer. Methods: A Phase I/II trial examining pre-operative gemcitabine with HCO in the treatment of patients with high-risk pancreatic adenocarcinoma. Eligibility was limited to only those predicted to have limited survival advantage following surgical resection. Two doses of fixed dose gemcitabine (1500mg/m2) were administered with oral HCQ (200mg/day-1200mg/day) for 31 consecutive days until day of surgery. Dose escalation followed a Storer phase 1 design. The primary endpoint was safety and tolerability. Secondary endpoints were clinical response as assessed by resectablility rate, R0 resection rates and CA 19-9. Measures of autophagy and apoptosis (LC3 and cleaved caspase 3) were assessed in resected tumors and correlated with clinical response. Results: Thirty-five patients were enrolled in the trial. Two patients withdrew consent prior to initiating treatment and two patients were removed from the protocol due to a stroke and allergic rash, resulting in 31 patients (89%) completing treatment. There were no dose limiting toxicities

and no treatment delays. 14 patients (45%) had a decrease in CA 19-9 of more than 50% following treatment. 29 patients (94%) underwent surgical resection as scheduled and the R0 resection rate was 81%. Treatment with HCQ led to an increase in pancreatic cancer cell LC3 staining, consistent with suppression of autophagic flux. There was a trend towards increased apoptosis with increasing doses of HCQ. Conclusion: Pre-operative autophagy inhibition with HCQ in combination with gemcitabine is safe and tolerable. When compared with historical controls the regimen appears to have promise as a biologically active strategy. Future trials will examine HCQ in combination with more active neoadjuvant chemotherapy regimens.

6

RCT Comparing Gastrectomy (Gx) plus Chemotherapy (CTX) with CTX Alone in Advanced Gastric Cancer (AGC) with a Single Non-curable Factor: JCOG 0705/KGCA01 Study K. Fujitani,^{1*} Y. Han-Kwang,⁸ J. Mizusawa,² K. Young-Woo,⁹ M. Terashima,³ S. Han,¹⁰ Y. Iwasaki,⁴ W. Hyung,¹¹ A. Takagane,⁵ B. Park,⁸ T. Tsujinaka,⁶ S. Hahn,⁸ M. Sasako,⁷ Y. Bang.⁸ 1. Osaka Prefectural General Medical Center, Osaka, Japan; 2. JCOG Data Center, Tokyo, Japan; 3. Shizuoka Cancer Center, Shizuoka, Japan; 4. Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; 5. Hakodate Goryokaku Hospital, Hakodate, Japan; 6. Kaizuka Municipal Hospital, Osaka, Japan; 7. Hyogo Medical College, Nishinomiya, Japan; 8. Seoul National University College of Medicine, Seoul, Korea, Republic of; 9. National Cancer Center, Seoul, Korea, Republic of; 10. Ajou University College of Medicine, Seoul, Korea, Republic of; 11. Yonsei University College of Medicine, Seoul, Korea, Republic of.

Background: The prognosis of AGC with non-curable factors is poor. Gx is sometimes employed, even in the absence of any serious symptoms, based on the literature showing a survival benefit of Gx (MST 8.0-12.2 M with Gx vs. 2.4-6.7 M without Gx). CTX alone has recently shown MST over 1y in AGC. Based on these situations, we conducted an international RCT among Japan, Korea, and Singapore to investigate the role of Gx for incurable AGC. Methods: Eligibility criteria included histologically proven primary gastric adenocarcinoma, presence of a single non-curable factor confined to either liver (H1), peritoneum (P1), or para-aortic lymph node (16a1/b2) confirmed by both CT scan and laparoscopy/laparotomy, clinical T1-3, no other distant metastasis than H1, P1 or LN 16a1/b2, aged 20-75, PS 0-1. Eligible patients were randomized to Gx followed by CTX or CTX alone. Gx with D1 dissection was performed without resection of metastatic lesions. Patients were placed on a CTX regimen, S-1+CDDP (S-1 80 mg/m2/day for 3 consecutive weeks followed by a 2-week rest, CDDP 60 mg/m2 on Day 8, repeated every 5 weeks). The primary endpoint was OS. The planned sample size was 330, 165 cases per arm, with one-sided alpha of 5%, and an 80% power detecting a 2y-survival difference of 10%, 20% with CTX vs. 30% with Gx. Results: Between Feb 2008 and Apr 2013, 164 patients (82 in Japan, 82 in Korea) were randomized. The first interim analysis was performed in Sep 2013, with 37% (110/294) of the planned events observed. The 2y-survival were 25.7 (95% CI: 15.7 to 36.9) % with Gx plus CTX and 31.4 (95% CI: 20.4 to 42.9) % with CTX alone. Hazard ratio for Gx was 1.08 (95% CI: 0.74 to 1.58) with predictive probability in favor of gastrectomy of 13.2% at the final analysis. Although some interactions favoring Gx plus CTX were suggested on nation and some other factors, JCOG DSMC recommended early termination of the trial. Conclusions: In all randomized patients, Gx followed by CTX has no survival benefit over CTX alone for AGC patients with a single non-curable factor. Detailed analyses on interactions will be presented in the meeting.

Axillary Reverse Mapping: Redefining Axillary Surgery E. Tummel,* D. Ochoa, K. Gallagher, R. Betzold, L. Adkins, S. Korourian, V. Klimberg. *UAMS, Little Rock, AR.*

Introduction: Axillary status in breast cancer patients continues to serve as a major predictor of outcome while also influencing decisions for adjuvant therapy. High morbidity rates in both sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) are thought to be due to unrecognized variations in arm lymphatic drainage in the axilla. Axillary reverse mapping (ARM) facilitates identification and avoidance of arm lymphatics which has significantly improved our rates of lymphedema. Methods: This IRB-approved study, from June 2007 to April 2013 involved patients undergoing SLNB with or without ALND, or ALND alone. Our technique involves subareolar injection of technetium for localization of the SLN. Lymphazurin (5ml) is injected in the ipsilateral upper arm for localization of nonbreast lymphatics. Data were collected on identification and preservation of arm lymphatics, crossover rates, metastases, axillary recurrence, and lymphedema as measured by volume displacement. Results: 447 patients underwent SLNB and/or ALND. 433 patients underwent a SLNB. Of those, 303/433 (70%) had a SLNB only and 130/433 (30%) went on to an ALND due to a positive axilla. 14/447 (3.1%) had ALND due to a positive axilla preoperatively. In 294/303 (97%) of patients with SLNB only, breast SLNs were hot but not blue; crossover (hot and blue) was seen in 9/303 (3%)SLNB and 20/144 (14%) ALND patients. Metastases were identified in 0/9 crossover SLN and 3/20 (15%) of ALND crossover nodes. Blue lymphatics were identified in 101/303 (33.3%) of SLNB and in 111/144 (77%) ALND. Median follow-up was 24 months (range 3 to 54 months). Overall lymphedema rates for SLNB and ALND were 0.33% and 5.5% respectively. During the follow up, 0/303 of the SLNB patients, and 1/144 (0.7%) ALND patients had an axillary recurrence. Conclusions: ARM allows frequent identification of arm lymphatics in the axilla which would have been transected during surgery. Rates of metastases in crossover nodes and axillary recurrence are low. Lymphedema rates are dramatically reduced using ARM when compared to accepted standards. This currently is the largest series to date regarding ARM and its efficacy in minimizing the morbidity of axillary surgery.

The Extent of Extracapsular Extension (ECE) may Influence the Need for Axillary Lymph Node Dissection (ALND) in Patients with T1-T2 Breast Cancer J. Gooch,* T. King, A. Eaton, M. Stempel, A. Corben, L.T. Dengel, M. Morrow. *MSKCC, New York City, NY.*

Introduction: Whether or not the presence of ECE in the sentinel lymph node (SLN) is an indication for ALND in patients managed according to ACOSOG Z0011 criteria is controversial. In this study we examined the correlation between ECE in the SLN and disease burden in the axilla. Methods: From a prospectively maintained database of 11,730 patients treated for invasive breast cancer from 2006-2013, we selected those with clinicopathologic features meeting ACOSOG Z0011 criteria, specifically pT1-T2, clinically N0 patients with metastases in <3 SLN. Records were reviewed to document the presence and extent of ECE. Patients receiving neoadjuvant chemotherapy were excluded. Characteristics of patients with <2mm or >2mm ECE were compared with Fisher's exact test and Wilcoxon rank sum test. Results: Three hundred seventy six (3.2%) patients had pT1-T2, clinically N0 disease with <3 positive SLN and the presence of ECE. Of these, 324 (86%) had ECE size data available. Characteristics of patients with $\leq 2mm$ (n=164) and $\geq 2mm$ (n=160) of ECE are compared in Table 1. Median tumor size was 1.8cm for ≤2mm ECE and 2.1 cm for >2mm ECE (p=0.0003) and patients with ≤2mm ECE were more likely to have only 1 positive SLN (p=0.012). ALND was performed in 68% of patients with ≤2mm ECE and 79% of patients with > 2mm ECE (p=0.03), yielding a median of 0 (range 0-29) additional positive nodes in the ≤2mm ECE group and a median of 2 (range 0-32) additional positive nodes in the >2mm ECE group (p<0.0001). No additional positive nodes were found in 59% of patients with ≤2mm ECE versus 32% of patients with >2mm ECE, 1-3 additional positive nodes were found in 33% and 31%, and ≥4 additional positive nodes were found in 8% and 36% of patients with ≤2mm and >2mm ECE respectively (p<0.0001). Conclusion: In this large series of consecutively treated patients meeting Z0011 criteria, the extent of ECE was significantly correlated with nodal tumor burden at ALND. Other tumor characteristics were similar between groups. These data suggest that >2mm of ECE may be an indication for ALND when applying Z0011 criteria to patients with metastases in <3 SLNs.

Characteristic	≤2mm (n	=164)	>2mm (n	=160)	p-value
	n	%	n	%	1
Age <45 >45	27 137	16% 84%	25 135	16% 84%	0.880
Pathologic T stage T1 T2	100 64	61% 39%	70 90	44% 56%	0.0026
Nuclear Grade (n=295) 1 2 3	21 81 53	14% 52% 34%	28 65 47	20% 46% 34%	0.3176
Hormone Receptor Subtype (n=322) HR+/Her2- HR+/Her2+ HR-/Her2+ HR-/Her2-	139 14 5 6	85% 9% 1% 4%	138 8 3 9	87% 5% 2% 6%	0.4678
Number of positive SLN removed 1 2	126 38	77% 23%	96 64	60% 40%	0.012
Median number positive SLN (range)	1 (1-2)		1 (1-2)		0.012
Median number total SLN removed (range)	2 (1-13)		2 (1-10)		0.1814
Number additional positive axillary nodes (n=239) 0 1-3 ≥4	66 37 9	59% 33% 8%	41 40 46	32% 31% 36%	<0.000
Median number additional positive ALN (range)	0 (0-29)		2 (0-32)		<0.000

Table 1

The Effect of Margin Status on Local Recurrence and Cost Analysis using a Decision Tree Model S.E. Abe,* J.S. Hill, K. Carpenter, Y. Han, J. Symanowski, R. White. *Carolinas Medical Center/Levine Cancer Institute, Charlotte, NC.*

Introduction: The definition of an adequate surgical margin for breast conservation therapy (BCT) continues to be controversial. Studies have not consistently demonstrated that reexcision to obtain wider margins, with its attendant increased cost, results in decreased local recurrence (LR). We designed a decision tree model to analyze LR and surgical costs based on margin status. Methods:A decision tree model was developed for the management of margins after BCT for invasive cancer. Data from 10 published studies (3,930 subjects) was used to determine the proportion of patients who fall into 3 margin status groups: positive, close ($\leq 2mm$) and negative ($\geq 2mm$). Data from 15 studies (6,014 subjects) was used to determine 5 year LR rate for each group. The model assumed 140,000 initial BCT (230,000 new breast cancer patients/year with ~60% BCT), that all patients with a positive margin underwent reexcision, that only one reexcision was required to obtain negative margins, and that mastectomy was performed after LR. Simulation cycles compared a strategy where all patients with close margins underwent reexcision (Strategy 1) versus one where they did not (Strategy 2). Number needed to treat was calculated comparing these strategies. Surgical costs were estimated using 2013 Medicare reimbursement rates. Results: In our model, 19.6% had positive margins, 21.8% had close margins and 58.7% had negative margins. Strategy 1 resulted in overall LR of 5.1%, with total surgical cost of \$45,243,228 (reexcision \$37,932,875, mastectomy \$7,310,353). Strategy 2 resulted in overall LR of 5.5%, with total surgical cost of \$25,826,684 (reexcision \$17,974,347, mastectomy \$7,852,337). Excess surgical cost associated with Strategy 1 was \$19,416,544. Number of reexcisions in close margin patients needed to prevent one recurrence was 57. Conclusion: In our model, LR did not markedly differ between the two strategies. However, the strategy to obtain margin widths >2mm resulted in total excess cost of ~\$20 million. This does not include hospital costs, the cost of surgical complications after reexcision, nor the reality of multiple reexcisions or mastectomy performed to obtain negative margins.

11

Redefining the Breast Tumor Margin through Genomics of the Cancer: Stromal Interaction S. Dhage,* A. Ernlund, J. Wang, R. Berman, D. Axelrod, D. Roses, R. Schneider. *Surgery, NYUSOM, Ny, NY*

Objectives: Breast tumors can enact cancer-like gene expression changes in the peri-tumoral stroma, making the stroma genomically similar to the tumor. Genetic alterations in the tumor-free stroma may impact upon disease progression and treatment effectiveness. We characterized alterations of gene expression in the cancer-free peri-tumoral tissue by distance from the primary tumor. Methods: Tumor samples and stroma every 5mm in two directions from tumor-stroma interface, to 20mm from the tumor margin were analyzed and pathologist verified as devoid of cancer cells from 32 patients undergoing mastectomy for invasive ductal cancer. 108 specimens were analyzed by Affymetrix U133A 2+ gene arrays. SVM, ANOVA and PCA were performed. Results: Gene expression patterns demonstrated that the 5 mm stromal region was identical or highly related to malignant breast cancer gene expression profiles in all patients. All stroma showed significant but reduced similarity with distance, to tumor gene expression even up to 20 mm. Similarity in genomic expression between stroma and tumor is most significant within 5mm of the tumor edge compared to further distances. A tumor specific gene expression profile was distinct from the stroma at any distance. Stroma at any distance from the tumor has a different gene expression pattern from reductive mammoplasty specimens that were cancer naïve. Pathway/GO analyses showed that stroma at any distance from cancer-free margins shares tumor expression of key cell transforming pathways, including WNT signaling, cancer progression, and trans-endothelial migration. Conclusion: Breast tissue in the post-surgical margin devoid of tumor cells is genomically highly related to tumor, most significantly within 5mm, less so but even up to 20mm. These data suggest that in a subset of patients, cancer cell-free stromal tissue is very highly related to cancer in gene expression, consistent with a potential for increased recurrence or de novo cancer development. The impact of the stromal cell gene profile, particularly at a 5mm distance, may be as important for making and personalizing surgical and adjuvant therapeutic decisions as the absence of tumor cells

Fig 1. Gene expression in zones 1 and 2 (tumor&5mm) are similar, but different from zones 3, 4, 5 (10mm, 15mm, 20mm) but similar to each other



12

Improved Survival with Contralateral Prophylactic Mastectomy R. Kauffmann,* R. Nelson, D. Smith, S. Chen, C. Vito, J. Yim, L. Kruper. *City of Hope, Duarte, CA*.

Background: Rates of contralateral prophylactic mastectomy (CPM) in women with breast cancer have been steadily increasing. The utility of this procedure has been scrutinized, however, as most studies fail to show a survival benefit. We evaluated the survival differences among CPM patients compared to patients undergoing single mastectomy (SM) alone for treatment of unilateral, non-metastatic breast cancer. Methods: The Surveillance Epidemiology and End Results database was used to identify newly diagnosed unilateral breast cancer patients who underwent mastectomy with or without CPM from 1998-2010. A 1:1 matched nested case-control analysis was performed with CPM cases matched to SM controls based on age group, race/ethnicity, grade, T stage, N status, AJCC stage, estrogen receptor (ER) status, and propensity score. Survival analyses included Kaplan-Meier estimation and univariate and multivariate Cox proportional hazard models to determine factors associated with overall survival (OS). Results: 28,015 CPM patients were identified. The CPM rate among all mastectomy patients increased from 4% in 1998 to 22% in 2010. On multivariate regression analysis, in addition to increasing T stage and older age, African-American race (OR 1.46, 95% CI 1.32-1.62), poorly differentiated grade (OR 1.80, 95% CI 1.60-2.01), positive nodal status (OR 1.85, 95% CI 1.73-1.97) and ER negative status (OR 1.53, 95% CI 1.39-1.67) were associated with increased risk of death. Patients who underwent CPM had a lower risk of death (OR 0.77, 95% CI 0.73-0.82) relative to patients with SM alone. 10-year OS rates were greater for CPM vs. SM patients, with the greatest effect seen in patients with stage II (79% for CPM vs. 75% for SM p<0.0001) and stage III disease (63% for CPM vs. 60% for SM p=0.0014). Conclusions: CPM rates continue to rise in the US. Along with other known prognostic factors, CPM is associated with a survival benefit. These findings support the indication for CPM in patients seeking treatment for unilateral breast cancer.

13

Characteristics of Multifocal and Multicentric Breast Cancers

P. Kanumuri,* B. Hayse, A.B. Chagpar, N.R. Horowitz, B. Killelea, D.R. Lannin. Yale University School of Medicine, New Haven, CT.

Introduction: Multifocal [MF] and multicentric [MC] breast cancers are being increasingly recognized and are known to behave differently compared to unifocal (UF) cancers. However, the significance of focality is ignored in the current staging systems and relatively little is known about the biology of these cancers. Most studies have combined MF and MC disease when comparing it to UF disease. Methods: A retrospective review was performed of invasive breast cancers from a prospectively collected database at a tertiary care academic medical center from 2004 – 2011. MF and MC cancers were defined as two or more lesions in the same or different quadrants, respectively, separated by normal breast tissue. Characteristics of MF and MC cancers were compared to UF cancers using chi-square tests and predictors of lymph node positivity were evaluated using multivariate logistic regression. Results: A total of 1503 cases were analyzed, of which 1231 (81.9%) were

UF, 178 (11.8%) were MF, and 94 (6.3%) were MC cancers. There were biological differences among the groups when MF and MC cancers were compared to UF cancers (Table). MC but not MF cancers were associated with young age at diagnosis, larger tumor size and node positivity. On the other hand, MF but not MC tumors showed differences by molecular type; they had a greater association with ER/PR+Her2+ tumors and a smaller percent of triple negative cancers in comparison to UF tumors. There were also differences by histology, with MF more likely to be infiltrating ductal carcinomas with an extensive intraductal component and MC more likely to be infiltrating lobular carcinomas. MF and MC cancers had no significant association with tumor grade or lymphovascular invasion (LVI). When adjusted for tumor size, age at diagnosis, grade, and LVI, multicentricity was an independent predictor of node positivity. Conclusion: Our data infer that MF and MC tumors represent biologically different diseases. MC is clinicopathologically more aggressive than MF disease and is significantly associated with younger age and larger tumor size. It was also noted that MC cancers are an independent predictor of node positivity.

Characteristics of Unifocal, Multifocal and Multicentric Breast Cancer
--

Factor		Unifocal	Multifocal		Multicentric	
		N (%)	N(%)	P value vs Unifocal	N (%)	P value vs Unifocal
Age	< 50 years	382 (34%)	60 (37%)	0.221	44 (48%)	0.010
	51 - 65 years	472 (41%)	55 (34%)		33 (36%)	
	>65 years	288 (25%)	46 (29%)		14 (15%)	
Tumor Size	Т1	755 (63%)	110 (63%)	0.952	40 (44%)	0.001
	T2	361 (30%)	51 (29%)		40 (44%)	
	T3	83 (7%)	13 (8%)		11 (12%)	
Lymph Nodes	Negative	792 (69%)	118 (71%)	0.628	34 (38%)	0.000
	Positive	352 (31%)	48 (29%)		56 (62%)	
Histology	Infiltrating Ductal	720 (59%)	85 (48%)	0.000	40 (43%)	0.013
	Infitrating Ductal with Extensive Intraductal Component	223 (18%)	60 (34%)		22 (23%)	
	Infiltrating Lobular	121 (10%)	14 (8%)		18 (19%)	
	Mixed Ductal and Lobular	65 (5%)	9 (5%)		5 (5%)	
	Other	102 (8%)	10 (6%)		9 (10%)	
Molecular Markers	ER/PR+ Her2 -	707 (71%)	105 (73%)	0.018	57 (75%)	0.864
	ER/PR+Her2+	77 (8%)	20 (14%)		6 (8%)	
	ER/PR-Her2+	61 (6%)	7 (5%)		4 (5%)	
	ER/PR-Her2-	150 (15%)	12 (8%)		9 (12%)	

14

The Cumulative Impact of Breast Irradiation on Chest Wall Angiosarcoma: A 40-year Outcome Study A. Mackey,^{1*} K. Arbeev,¹ I. Akushevich,¹ R. Greenup,¹ G. Georgiade,¹ J. Horton,¹ M.F. Brennan,² E.S. Hwang.¹ I. Surgery, Duke University Medical Center, Durham, NC; 2. Memorial Sloan-Kettering Cancer Center, New York, NY.

INTRODUCTION: In the past 40 years, adjuvant radiation therapy (RT) for breast cancer (BC) has been widely used. This study was to determine if the burden of radiation-related angiosarcoma has increased with the use of adjuvant RT and if this risk is greater for women undergoing lumpectomy or mastectomy. METHODS: SEER Registry(1973-2009) used for data analyses. Angiosarcoma cases identified using site ICD-O-3 codes (C40,C49,C50) and histology ICD-O-3 codes (912.0,917.0). BC cases identified using C50 codes. For cases of multiple BC diagnoses per person, the earliest date of RT (or date of diagnosis if no RT) was recorded. The Cox proportional hazards model was used to evaluate angiosarcoma hazard ratio (HR) for BC patients with (vs. with out) RT or/and lumpectomy vs. mastectomy as a time-dependent risk. In all cases, estimates of HRs were adjusted for age at BC diagnosis. RESULTS: 1,428 (868 female) cases of angiosarcoma were identified from 1973 to 2009.

77.5%(124/160) were associated with history of adjuvant RT for BC at least 2 years prior to diagnosis of angiosarcoma. The age adjusted incidence rate of all angiosarcomas increased from 1973 to 2009. Median time from RT to diagnosis of angiosarcoma was 7 years (range:3-19 years). Among 1,070,769 women diagnosed with BC during this period, receipt of RT increased the odds of developing angiosarcoma (HR=6.5;95% CI(4.5, 9.5)). For women who developed angiosarcoma, the stage distribution at BC diagnosis was 3.1%, 75.5%, 21.4% for in situ, localized, and regional stages respectively. Stage nor age at diagnosis affected odds of developing subsequent angiosarcoma. Risk of angiosarcoma was not greater in women undergoing RT after lumpectomy (HR=0.72,95% CI(0.29,1.81)) compared with RT after mastectomy. The median survival following diagnosis of radiation-associated breast/chest angiosarcoma was 2.3 years. CONCLUSIONS: The incidence of angiosarcoma has increased from 1973 to 2009 with the increasing use of adjuvant RT for BC. Surgery type did not impact incidence of angiosarcoma. This important, rare consequence of adjuvant RT should be considered, particularly in patients with early stage BC with an excellent prognosis.



Fig. 1: Age-adjusted incidence rates of all angiosarcoma in SEER data (± s.e.). Solid line denotes linear fit: rate = $\alpha + \beta^*$ year (parameters α and β are estimated by weighted least squares taking into account that s.e. differ by years); p is p-value for H0: β =0.

15

Loss of CD4 T Cell Response is Critically Involved in Breast Tumorigenesis and Reversed by Immunization but not Targeted Therapies J. Datta,* A.M. Brod, R.L. Yang, R. Mick, E. Fitzpatrick, S. Xu, B.J. Czerniecki. Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

INTRODUCTION: Anti-HER2 CD4 T cell responses (CD4resp) involved in breast tumorigenesis are poorly understood. We (1) examined differences in blood CD4resp between healthy donors (HD) and HER2+-DCIS or invasive breast cancer (IBC) patients (pts); (2) compared CD4resp after HER2pulsed dendritic cell immunization or chemotherapy/Herceptin (C/H) treatment in IBC pts, to those in untreated IBC pts. METHOD: CD4resp of pts enrolled in our neoadjuvant immunization trial for HER2⁺-DCIS and found to have Stage I IBC at surgery (n=12), were analyzed pre-/post-immunization and compared with CD4resp in HD (n=10), DCIS pts (n=27), or Stage I-III IBC pts after C/H treatment (n=31). CD4resp were generated from PBMCs pulsed with 6 HER2 MHC class II-binding peptides, by measuring IFN-y production using ELISPOT. CD4resp measures were: (i) overall anti-HER2 response rate. (ii) mean number of reactive peptides (repertoire), and (iii) cumulative response across 6 peptides (spot-forming cells/10⁶ cells). RESULTS: Eighty subjects with mean age 50.4±1.4 years met study criteria. Significant stepwise decrements in overall response rate (100% vs 82% vs 25%; p<0.001), response repertoire (5.1±0.3 vs 1.9±0.3 vs 0.4±0.2; p<0.001), and cumulative response (248.6±38.1 vs 125.9±27.9 vs 41.6±14.0 SFC/106, p<0.001) were observed among HD, DCIS, and IBC cohorts respectively (Fig). Post-hoc comparison of HD and DCIS groups revealed a significant difference in response repertoire (p<0.001), but not overall or cumulative responses. DCIS and IBC groups differed significantly in overall response rates (p=0.001) and repertoire (p=0.03), but not cumulative response rates (p=0.001) and repertoire (p=0.03), but not cumulative response (p=0.08). After immunizing IBC pts, significant improvements were observed in overall response rates (92% vs 25%, p=0.008), repertoire (3.5 vs 0.4, p<0.001), and cumulative response (166.7 vs 41.6 SFC/106, p<0.001). No differences were observed between C/H-treated and untreated IBC pts (all p=NS). CONCLUSION: Anti-HER2 CD4resp are progressively lost in breast tumorigenesis. HER2-pulsed immunization – but not conventional therapies – restores CD4resp in IBC, providing justification for immunization in these pts.



16

Induced Immunity Correlates with and may Predict Clinical Benefit in the Phase II Clinical Trial of the Anti-HER2 (GP2) Vaccine to Prevent Recurrence in High-risk Breast Cancer Patients

A. Trappey,^{1*} J.S. Berry,¹ E. Schneble,¹ J. Aden,¹ T.J. Vreeland,¹ D.F. Hale,¹ A. Sears,¹ R. Brown,¹ S. Perez,⁴ G.T. Clifton,⁵ M. Papamichael,⁴ S. Ponniah,³ E. Mittendorf,² G.E. Peoples.¹ 1. San Antonio Military Medical Center, Fort Sam Houston, TX; 2. MD Anderson Cancer Center, Houston, TX; 3. Cancer Vaccine Development Lab, Bethesda, MD; 4. Cancer Immunology and Immunotherapy Center, St. Savas, Greece; 5. Blanchfield Army Community Hospital, Fort Campbell, KY.

BACKGROUND: A prospective, randomized, multi-center, placebocontrolled, single-blinded, phaseII trial was designed to evaluate the safety and clinical efficacy of GP2, an HLA-A2 restricted HER2-derived peptide vaccine, in breast cancer patients (pts). We have previously demonstrated through immunoassay analysis that induced immunity is required for clinical benefit after vaccination with the E75 peptide. Here we report analysis of risk factors for recurrence using logistic regression modeling (LRM) of immunologic factors previously shown to correlate with positive response to E75. METHODS: Clinically disease-free, node positive or high-risk node negative pts with any level of HER2 expression were enrolled after standard of care therapy. Pts receive 6 monthly (mo) intradermal inoculations (R0-R6) of GP2+GM-CSF during the primary vaccine series followed by four boosters every 6 mo. Ex-vivo immune responses were measured by GP2:Ig dimer assay at R0 and R6 and reported as mean dimer index (mdi). Means were compared using student's t-test and portions using Fisher's Exact Test. A LRM with backwards elimination of demographics and dimer assays was used to predict recurrence. RESULTS: There were 70 pts available for analysis with a median follow-up of 30mo; 65/70 had an R6 dimer. Mdi significantly increased from R0-R6 (0.81+/-0.09mdi v 1.12+/-0.10mdi, p<0.05). No pts with R0mdi <0.32 (n=23) recurred;6/47 patients with R0 mdi >0.32 recurred (p=0.16). No pts with R6mdi >0.61 (n=39) recurred;4/26 patients with R6 mdi < 0.61 recurred (p=0.02). There was no difference in demographics between patients who recurred and those who did not. The optimal modeling variables were R0 and R6 dimer (table 1). CONCLU-

SION: Similar to our E75 analysis, lower pre-existing and higher postvaccination peptide-specific CTL levels correlate with fewer recurrences suggesting that induction of GP2 immunity correlates with clinical outcome in the adjuvant setting. These correlations have been difficult to prove with vaccines in the metastatic setting, but may be predictive in the adjuvant setting.

Table 1

Variables in the Optimal Model	Odds Ratio (p-value)	Sensitivity, Specificity	Area Under the Curve
R0	1.37 (0.60)	100%,34% (R0=0.32 mdi)	0.62
R6	2.48 (0.11)	100%,65% (R6=0.61 mdi)	0.80

17

Tyrosine-kinase Expression Predicts Response to Sunitinib in Breast Cancer P.M. Spanheimer,* M.V. Kulak, J.C. Carr, G.W. Wood-

field, J.P. De Andrade, S.L. Sugg, R.J. Weigel. Surgery, University of Iowa, Iowa City, IA.

Introduction: Tyrosine kinase inhibitors (TKI) reduce Erk phosphorylation and proliferation. Preliminary data indicate that TKIs function through RET in breast cancer, however, TKIs are not specific and can block several receptor tyrosine kinases (RTK). We used cell lines and primary breast cancer specimens to determine factors associated with TKI response. Methods: Proliferation was assessed after siRNA knockdown with or without sunitinib in breast cancer cell lines by MTT. Breast cancer tissue and matched normal breast was obtained from 30 women with invasive breast carcinoma. Gene expression was assessed by RT-PCR. Fresh tissue was treated in vitro with sunitinib or control media for 30 minutes and response was assessed by phosphorylation specific western blot. Results: Gene knockdown of EGFR, VEGFR1, or VEGFR2 had no effect on proliferation in MCF-7 or BT-474. Sunitinib treatment caused a similar reduction in proliferation independent of gene knockdown in both cell lines. Twenty primary tumors were ER positive, eight triple negative (TN), and four over-expressed HER2. Expression of FGFR1 was highest in ER+ tumors compared to other tumors and normal breast (p=0.03). Expression of EGFR and VEGFR1 were increased in TN tumors compared to normal breast (p<0.05). FGFR4 was expressed highest in HER2+ tumors (p=0.02). The Erk phosphatase DUSP4 was under-expressed in all subtypes compared to normal breast, with the lowest expression in TN tumors (p=0.01). Reduction in Erk activation with in vitro sunitinib was significantly higher in tumors compared to normal tissue (p<0.001). ER positivity and low EGFR expression were associated with reduction in Erk activation after sunitinib treatment (p<0.05). Clinical variables including stage and nodal status were not associated with response to sunitinib. Conclusion: Breast cancer subtypes have characteristic RTK expression patterns. Knockout of EGFR, VEGFR1 or VEGFR2 did not affect growth or TKI responsiveness in luminal breast cancer cell lines and expression in primary breast cancer did not correlate with in vitro sunitinib response. Based on these data, RET remains the most predictive marker of TKI response in breast cancer.



Isolated Tumor Cells are a Negative Prognostic Factor for Diseasefree and Overall Survival in Stage I & II Colon Cancer Patients: A Propensity Score Analysis B. Weixler, ¹* R. Warschkow, ⁵ U. Gueller, ³ A. Zettl, ⁴ B.M. Schmied, ⁶ C.T. Viehl, ¹ U. Von Holzen, ¹ M. Zuber.² *1. Department of Surgery, University Hospital Basel, Basel, Switzerland; 2. Department of Surgery Cantonal Hospital Olten, Olten, Switzerland; 3. Divsion of Oncology & Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; 4. Viollier AG, Histopathology/Cytology, Basel, Switzerland; 5. Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany; 6. Department of Surgery, Cantonal Hospital St. Gallen, St.*

Gallen, Switzerland.

Background: Lymph node (LN) involvement is the most important prognostic factor in stage I & II colon cancer patients. Despite complete surgical resection up to 20% of these allegedly curatively treated patients will develop disease recurrence within five years. The objective of the present prospective investigation was to assess the prognostic impact of isolated tumor cells (ITC) in sentinel lymph nodes of stage I & II colon cancer patients. Methods: In this prospective single center study 74 stage I & II colon cancer patients were operated between 2005 - 2011. LN at highest risk of harboring ITC were identified via the in vivo sentinel lymph node procedure. LN were analyzed with multilevel sectionning, conventional H&E, and immunohistochemical CK-19 staining. The correlation between ITC and survival was assessed using Cox regression and propensity score analyses. Results: The median follow-up was 4.6 years. ITC were detected in 23 patients (31.1%). ITC in sentinel lymph nodes were associated with an increased risk for disease recurrence in unadjusted (hazard ratio [HR] = 2.82, p=0.043), in risk-adjusted (HR = 4.73, p=0.005) and in propensity score-adjusted analyses (HR = 5.24, p=0.022). Similarly, ITC were an independent significant prognostic factor for overall survival after riskadjusting in multivariable Cox regression analysis (HR = 3.50, p=0.043), in a backward variable selection procedure (HR = 4.48, p=0.010), and in propensity score adjusted analysis (HR = 4.12, p=0.041). Conclusions: This is the first prospective cohort study applying both multivariable and propensity-scoring analyses to assess the putative impact of ITC on disease-free and overall survival in stage I & II colon cancer patients. The present investigation provides compelling evidence that ITC represent a negative prognostic factor in stage I & II colon cancer patients for disease-free and overall survival. The presence of ITC in SLN of stage I & II colon cancer patients should be classified as a high risk factor and therefore may identify patients who benefit from adjuvant chemotherapy.

19

Single Nucleotide Polymorphisms in XRCC1, XPD, and TGF β Predict the Risk of Proctitis in Patients Receiving Radiation Therapy for Rectal Cancer S. Milgrom,* C. Chen, J. Smith, K.A. Goodman, J. Garcia-Aguilar. *Memorial Sloan-Kettering Cancer Center, New York, NY.*

Background: Researchers have identified single nucleotide polymorphisms (SNP's) that are significantly associated with toxicity in patients receiving radiation therapy (RT) for rectal cancer. This study aimed to validate these findings in an independent cohort. Methods: Our study population consisted of patients who received RT for rectal cancer at a single institution from 2006 to 2012. All eligible patients had banked tissue available for analysis and had toxicity information recorded before initiating RT and during the final 2 weeks of RT, at a minimum. Proctitis was defined as severe if patients required opioids during RT. Exclusion criteria included severe proctitis before starting RT and treatment for recurrent disease. Ultimately, 166 patients were eligible. DNA was extracted from normal tissue in the proctectomy specimens. iPLEX SNP Genotyping using the MassArray platform (Sequenom) was used to evaluate 4 SNP's: XRCC1 R399Q, XPD K751Q, TP53 R72P, and TGFβ R25P. Results: The median RT dose was 50.4 Gy (range 3780-5600), and 155 patients (93%) received concurrent 5-flourouracil or capecitabine. Severe proctitis during RT occurred in 39 patients (23%). The XRCC1 Q399 allele was present in 101 patients (61%), the XPD Q751 allele in 98 (59%), the TP53 P72 allele in 68 (41%), and the TGFβ P25 allele in 26 (16%). Severe proctitis was significantly more likely in patients carrying the XRCC1 Q399 (p = 0.018) and TGF β P25 (p = 0.003) alleles, and less likely in patients carrying XPD Q751 (p =0.035). In a multivariate model incorporating RT dose and self-reported ethnicity, the risk of toxicity imparted by each additional minor allele was 2.53

for XRCC1 Q399 (p = 0.001), 3.69 for TGF β P25 (p = 0.003), and 0.69 for XPD Q751 (p = 0.14). Discussion: In this independent cohort of 166 rectal cancer patients, we have validated the association of SNP's in XRCC1, XPD, and TGF β with radiation-induced toxicity. This information may ultimately contribute to treatment recommendations for locally advanced rectal cancer patients.

20

Genome-wide Sequencing Reveals Signature Mutational Events and Therapeutic Opportunities in Mucinous Carcinoma of the Appendix (MAC) H. Alakus, ¹* M.L. Babicky, ¹ S. Yost, ² K. Jespen, ² P. Ghosh, ³ Y. Dai, ² A. Arias, ² M.L. Samuels, ⁶ E.S. Mose, ¹ R.B. Schwab, ⁴ M.R. Peterson, ⁵ K.A. Frazer, ² O. Harismendy, ² A.M. Lowy. ¹ I. Division of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA; 2. Division of Genome Information Sciences, University of California San Diego, La Jolla, CA; 3. Department of Medicine, University of California San Diego, La Jolla, CA; 5. Department of Pathology, University of California San Diego, La Jolla, CA; 6. RainDance Technologies, Lexington, MA.

INTRODUCTION MAC most commonly gives rise to Pseudomyxoma Peritonei. The primary treatment of this disease is cytoreductive surgery (CRS)/HIPEC. Therapy for advanced MAC is poorly effective and often consists of drug regimens validated in colorectal cancer (CRC). We hypothesized that using next generation sequencing, we would identify common mutations in MAC that could suggest novel therapeutic opportunities for PMP patients. METHODS MAC samples were collected at CRS. Laser capture was used to enrich tumor cell content. Matched DNA from 10 MAC's [9 low grade (LG), 1 high grade (HG)] and peripheral blood was isolated, and whole exomes were sequenced on a HiSeq platform. For replication, ultra-deep-targeted sequencing and digital droplet PCR were performed on 19 additional samples (14 low grade, 5 high grade). IHC was performed on FFPE-samples to confirm activation of altered pathways. RESULTS Mutational analysis revealed an average of 54 nonsilent mutations in MAC. Nearly all MAC harbor oncogenic mutations in KRAS (26/29) and GNAS (21/29). While KRAS mutation was observed in LG (21/23) and HG (5/6) MAC's, GNAS mutation was predominantly seen in LG MAC's (20/23) versus HG (1/6), p <0.05. This strongly suggests MAC's most often arise from a KRAS mutant progenitor, and that HG MAC's do not arise from LG. IHC revealed that canonical signaling pathways downstream of KRAS (MEK/ERK,PI3K/AKT) and GNAS (Protein kinase A) were activated in nearly all MAC's. Mutations activating TGF-beta signaling were observed in 70% of MAC's. While MAC's share some genetic alterations with CRC, mutations in TP53 and APC, common in CRC, are rare in MAC. CONCLUSIONS Genome-wide mutational analysis revealed signature genetic alterations in MAC that are distinct from CRC. Instead, MAC's share genetic features with pancreatic IPMN, a similarly indolent mucinous lesion. Our findings; 1) suggest MEK and PKA inhibition as new therapeutic opportunities in this disease, 2) define that HG MAC does not evolve from LG and 3) due to the frequency of KRAS mutation, suggest that EGFR monoclonal antibody therapy should be used with caution in MAC patients.



Low-grade Mucinous Carcinoma of the Appendix and mutational profile of 9 low-grade samples

Value of Primary Tumor Gene Signature in Colon Cancer when National Quality Standards are Adhered to: Preliminary Results of an International Prospective Multicenter Trial A.J. Bilchik,^{1*} Z.A. Wainberg,² A. Stojadinovic,³ D.J. Slamon,² M. Protic,³ D. Halle,⁴ H. Chen,² A. Nissan.³ *1. John Wayne Cancer Institute, Santa Monica, CA*; *2. University of California at Los Angeles, Los Angeles, CA*; *3. United States Military Cancer Institute, Washington, DC*; *4. Hadassah-Hebrew University, Ein Kerem, Jerusalem, Israel.*

Objective: To determine if gene signatures are informative in colon cancer (CC) in a multicenter prospective trial with adherence to National Quality Standards. Several studies have demonstrated the prognostic potential of gene signatures in primary CC. This has never been evaluated prospectively with adherence to National Quality Standards (≥12 lymph nodes [LNs]). Methods: Eligibility criteria included: a) no evidence of metastatic disease: b) ≥ 12 LNs: c) no adjuvant chemotherapy for LN-negative CC; d) focused pathologic analysis of LNs including immunohistochemistry (IHC) for LNs negative by H&E. RNA extraction was done from primary frozen tumor samples and samples were only considered reliable if RIN was >9. Using an Agilent whole human genome array, 44,000 genes were analyzed in primary tumors for differential gene expression. ANOVA was applied at 2-fold expression level in at least 8 experiments to obtain the differentially expressed genes. Results: Of 150 patients enrolled, molecular analysis has been completed in the first 128. At a median follow-up of 27 months, 14% of patients have recurred. There was a significant differential increase in a panel of genes involved in cellular proliferation and a decrease in a pro-differentiating gene panel in those that recurred (p<0.01). The up-regulation of the cysteine protease legumain (LGMN) was found to be significantly associated with recurrence in stage II CC patients following surgery (p<0.01). These genetic signatures did not correlate with T or N stage. Conclusions: This is the first prospective trial to evaluate gene signatures in CC with adherence to the 12-node minimum quality standard. Certain molecular pathways may be prognostically relevant if both surgery and pathology are standardized, regardless of T and N stage. Careful consideration should be made to include surgical quality measures when planning clinical trials to evaluate the true effect of molecular markers in CC.

22

Five-year Survival after Incorporation of Pre-treatment CEA Levels into AJCC Staging for Colon Cancer P. Thirunavukarasu,¹* C. Talati,² S. Munjal,² S. Singla,¹ K. Attwood,¹ V. Francescutti.¹ *1. Sur-*

c. ratati, S. Munjai, S. Singia, K. Auwood, V. Francescutti. *1. Sur*gical Oncology, Roswell Park Cancer Institute, Buffalo, NY; 2. University of Pittsburgh, Pittsburgh, PA.

Background: The American Joint Committee for Cancer (AJCC) has advocated incorporating pre-treatment serum CEA level (C-stage) into the conventional TNM staging system. The latter has been shown to result in significant prognostic stage migration between early and advanced colon cancer. We aimed to study this effect with 5-year overall (OS) and disease-specific (DSS) survival. Methods: We analyzed 16,619 patients diagnosed with colon cancer diagnosed in 2004 and 2005, with a median followup of 71 months. We stratified each AJCC stage as either C0(normal) or C1(elevated) based on the serum CEA prior to first therapy. Results: C1-stage was independently associated with a 51% and 58% increased risk of overall (HR 1.51, 1.43-1.58, p<0.001) and disease-specific mortality (HR 1.58, 1.49-1.69, p<.001). Significant stage overlap and migration was seen between C1-associated lower and C0-associated higher AJCC stages. For example, the 5-year OS for Stage IC1(68.3%, 63.9-72.2%; HR 2.0) was similar to IIA C0 (63.6%, 61.1-65.9%, HR 2.2) but significantly worse than IIA C0(76.4%,74.8-77.9%, HR 1.4) and IIIA C0(83.7%, 79.5-87.1%, HR 0.8). The 5-year DSS for Stage I C1 (91.7%, 88.7-94.0%, HR 2.6) was similar to IIA C0 (91.1%,89.9-92.2%,HR 2.7), and IIIA C0 (91.7%,88.3-94.2%, HR 2.3), but Stage IIIA C0 was significantly better than IIA C1(84.7%,82.7-86.6%, HR 4.5), IIB C1(69.5%,61.1-76.4%,HR10.3) or IIC C1(66.6%,58.0-73.9%, HR 10.5). Multivariate analysis of non-metastatic colon cancers showed that 5-yr OS of N0C1 cancers (62.8%,60.8-64.7%,HR 1.8) was worse than N1aC0(70.9%,68.0-73.6%,HR 1.3) but similar to N1bC0 (64.7%, 61.5-67.7%, HR 1.6). Similarly the 5-yr DSS of N1aC0 (82.2%, 79.6-85.5, HR 2.4) was better than N1bC1 (62.3%, 58.3-66.0, HR 5.8). Conclusion: C1-stage identifies a subset of patients in each AJCC stage who suffer a prognosis worse than or similar to C0-stage patients of the higher AJCC stages, resulting in significant stage overlap and migration between cancers. This difference in OS and DSS related to C-stage may have bearing on recommendations for those patients who would not routinely be offered systemic therapy, but may potentially benefit from it.



23

NSABP FC-6: Phase II Study to Determine Surgical Conversion Rate in Patients (pts) Receiving Neoadjuvant (NA) mFOLFOX7 Plus Dose-escalating Cetuximab (C) for Unresectable K-RAS Wildtype (WT) Colorectal Cancer with Metastases (mCRC) Confined to the Liver L.D. Wagman,^{1*} D.A. Geller,² S.A. Jacobs,³ N.J. Petrelli,⁴ C.J. Allegra,⁵ M. Buyse,⁶ N. Wolmark,⁷ M.J. O'Connell.⁸ *1. National* Surgical Adjuvant Breast and Bowel Project (NSABP), and St Joseph Hospital, Orange, CA; 2. NSABP, and the University of Pittsburgh Medical Center; UPMC Liver Cancer Center; Pittsburgh, PA; 3. NSABP, and the University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA; 4. NSABP, and Christiana Care Health Service / Helen F. Graham Cancer Center, Newark, DE; 5. NSABP, and the University of Florida, Gainesville, FL; 6. International Drug Development Institute, Brussels, Belgium; 7. NSABP, and Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA; 8. NSABP, Pittsburgh, PA.

Based on pre-defined endpoints, the purpose of the FC-6 study is to determine the surgical conversion rate for liver-only metastatic CRC in KRAS WT pts treated with neoadjuvant mFOLFOX7 plus dose-escalating cetuximab. Eligibility: Untreated KRAS WT mCRC confined to liver. Initial unresectability was determined by an experienced surgical oncologist based on liver metastases that cannot be resected/ablated to R0 with >40% and/or 3 uninvolved segments of liver remaining. Prior adjuvant therapy was allowed if chemo-free interval >6 months. Treatment: Oxaliplatin 85 mg/m2 iv, leucovorin 400 mg/m2 iv, 5-FU 3000 mg/m2 iv continuous infusion over 46 hours, C 500 mg/m2 iv (C escalated by 100 mg/m2 q 2 wks to max dose of 800 mg/m2) on d 1, 15, 29, and 43 of each 8-wk cycle. Prophylactic doxycycline 100 mg po bid and application of topical emollient bid was required. A total of 3 cycles were planned, including pre-and post-operative cycles. Pts were evaluated after each cycle for resectability. Results: Of 20 pts enrolled, 2 had prior adjuvant therapy. 17 of 20 had at least one dose of escalated C (median dose intensity 632 mg/m2/2-wk). 18 of 20 underwent attempt at surgical resection; all pts were evaluable for toxicity. Grade 4 adverse events included neutropenia (1) and thrombocytopenia (1), sepsis and pulmonary embolism (1). Grade 3 rash occurred in 4 pts. Six, 8, and 4 pts were deemed resectable after cycles 1, 2, and 3 respectively. Four were found to be unresectable at surgery. Time from end of chemo to OR: 20-217d (median 35d). Best response to neoadjuvant chemotherapy: CR 1, PR 15, SD 3, and PROG 1. 14 of 20 had surgical R0 for conversion rate of 70%. Surgical-specific G3/4 morbidity occurred in 2 pts. Conclusion: mFOLFOX plus escalated C is highly active and resulted in excellent conversion rate with manageable toxicity. It is too early to project longterm survival. In selected KRAS WT pts with mCRC, mFOLFOX7 plus C therapy is worthy of investigation as a first-line option. Support: BMS

A Comparison of Rectal Cancer Clinical Practice Guidelines Z.M. Abdelsattar,* S.L. Wong. *Center for Healthcare Outcomes and*

Policy, University of Michigan, Ann Arbor, MI.

BACKGROUND: Delivery of high quality cancer care involves the explicit and judicious use of the best available evidence. Because the medical literature is so broad, clinicians often rely upon clinical practice guidelines (CPGs) to inform decision making. For rectal cancer, there are several CPGs available, but it is unknown which CPG is most reliable. We qualitatively and quantitatively compare rectal cancer CPGs. METHODS: Five rectal cancer CPGs were selected for qualitative and quantitative analysis. The most up-to-date versions were compared in the following 4 qualitative domains: development process, structure, content, and dissemination strategies. Quantitative comparison was based on the Appraisal of Guidelines Research & Evaluation (AGREE II), a validated CPG appraisal tool which assesses 6 domains: scope & purpose; stakeholder involvement; rigor of development; clarity & presentation; applicability; and editorial independence. Treatment recommendations were further analyzed to determine supporting levels of evidence and scientific agreement. RESULTS: Rectal cancer CPGs from ASCRS, CCO, ESMO, NCCN and NICE showed variation in all domains. The development processes included a systematic review of the literature in only 3 CPGs. Algorithms or clinical pathways were included in the structure of 3 CPGs. Citations ranged from 28 to 348 references, with randomized controlled trials representing a small proportion of citations (median 16%, range 15-39%). AGREE II scores were highly variable (Figure); for example in the Rigor domain, scores ranged from 18.8 to 88.5%. Importantly, there were major disagreements in recommendations and in the interpretation of evidence. For example, some CPGs strongly recommend adjuvant therapy for Stage II/III patients who were previously treated with neoadjuvant therapy, while other CPGs were unable to make a recommendation in this regard. CONCLUSIONS: There is variation in development processes, evidence interpretation and recommendations between widely used rectal cancer CPGs. These differences mean that there is no comprehensive resource for the management of rectal cancer, which may pose challenges for physicians trying to deliver high quality evidence-based care.



25

The American Society of Peritoneal Surface Malignancies (ASPSM) Multi-institution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,048 Patients with Colorectal Cancer with Peritoneal Carcinomatosis J. Esquivel, ^{1*} A.M. Lowy,³ M. Markman.² 1. St Agnes Hospital, Baltimore, MD; 2. Cancer Treatment Centers of America, Philadelphia, PA; 3. University of California, San Diego, San Diego, CA.

Background Extensive clinical experience suggests that hyperthermic intraperitoneal chemotherapy (HIPEC) may play an important role in the management of colorectal cancer patients with peritoneal carcinomatosis (CRCPC). However, there remains no established non-surgical process to rationally select patients for this management, either for inclusion/stratification in clinical trials or as a component of standard-of-care. The Peritoneal Surface Disease Severity Score (PSDSS) was introduced as a basis to improve patient selec-

tion. Materials and Methods The ASPSM conducted a retrospective review of 1,048 CRCPC patients. The PSDSS was evaluated on 3 specific criteria obtained before surgery (symptoms; extent of peritoneal dissemination; and primary tumor histology). Overall survival was analyzed according to four tiers of disease severity and a comparison was made between patients who underwent cytoreductive surgery + HIPEC and those who did not undergo HIPEC. Results The PSDSS was calculated on 903 patients (81%). Median survival of 293 patients not undergoing HIPEC based on their PSDSS: I (n=9), II (n=100), III (n=62) and IV (n=122) was 39, 21, 7, and 6 months, respectively. Median survival of 610 patients who underwent HIPEC based on their PSDSS: I (n=78), II (n=302), III (n=79) and IV (n=151) was 81, 49, 33 and 27 months, respectively. Conclusion These data support that the PSDSS, undertaken prior to surgery, is capable of defining CRCPC populations who have a statistically-defined high or considerably lower likelihood of long-term survival following HIPEC. The PSDSS can be quite useful in the decision to enter CRCPC patients into. and their stratification within, clinical trials.

26

Evaluation of a New Staging Classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 210 Patients with Mucinous Appendiceal Neoplasms with or without Peritoneal Dissemination J. Esquivel, ^{1*} S. Sanchez-Garcia, ² W. Hicken.¹ *1. St Agnes Hospital, Baltimore, MD; 2. Hospital Universitario, Ciudad Real, Spain.*

Introduction There exists a wide variety of classifications of mucinous appendiceal neoplasms (MAN). Most of them are based on the type of peritoneal dissemination and do not take into consideration the type or primary tumor or the burden of peritoneal disease. The Peritoneal Surface Disease Severity Score (PSDSS) was introduced as a basis to improve patient selection for current therapies in patients with colorectal cancer with peritoneal dissemination. Materials and methods We conducted a retrospective evaluation of 210 patients with MAN. The severity of their disease (PSDSS) was analyzed on a 3-point scale that included: 1) The primary appendiceal tumor, 2) The type of peritoneal dissemination, and 3) The burden of disease. Overall survival was analyzed according to 5 tiers of estimated disease severity based on the above parameters. Results There were 13, 59, 59, 40, and 39 patients with PSDSS 0, I, II, III, and IV respectively. One hundred and sixty five patients underwent cytoreductive surgery (CRS) and HIPEC. Overall survival was 78 months in this group with 5-yr survival of 100%, 82%, 28%, and 5% in patients with PSDSS I, II, III, and IV respectively (p<0.001). On multivariate analysis, female sex (HR 0.4), PSDSS stage (HR 2.4) and type of peritoneal dissemination (HR 5.6), were identified as independent predictors of survival. Conclusions The PSDSS appears to be an important prognostic indicator in patients with mucinous appendiceal neoplasms with or without peritoneal dissemination and may improve selection of patients for appropriate therapy from the time of diagnosis.

27

Pharmacological Modulation of Tumor Interstitial Fluid Pressure to Enhance Tissue Penetration of Intraperitoneal Chemotherapy in a Mouse Colorectal Carcinomatosis Model F. Gremonprez,^{1*} A. Izmer,² F. Vanhaecke,² W. Ceelen.¹ *1. GI Surgery, UZ Gent, Ghent, Belgium; 2. Department of Analytical Chemistry, Ghent University, Ghent, Belgium.*

Background Intraperitoneal chemotherapy (IPC) utilizes a pharmacokinetic advantage conferred by the presence of the peritoneal-plasma barrier, which permits the use of very high drug concentrations intraperitoneally whilst systemic absorption (and resulting toxicity) is limited. However, the raised interstitial fluid pressure (IFP) in tumors hinders the penetration and uptake of cytotoxic drugs. Experimental studies have shown that reduction of the IFP by anti-VEGF and/or anti-PDGFR therapy enhances delivery of systemic chemotherapy. It is unknown, whether these effects could also enhance the efficacy of intraperitoneally administered cytotoxic drugs. Methods Bilateral subperitoneal injections of 1.5 x 106 HT-29 cells in 40 µl Matrigel were administered to 4 groups of 7 Foxn1nu nude athymic mice (Harlan). After 10 days, pretreatment with either placebo, Imatinib (50 mg/kg daily), Pazopanib (100 mg/kg daily), and Bevacizumab (5 mg/kg 2x) was started. At day 15, each mouse underwent an open IPC procedure with 150 mg/m2 Oxaliplatin for 60' at 37°C. Intraoperative measurements of tumor IFP (Samba Preclin®) and pO2 (Oxylite®) were performed. Tumor, blood, and perfusate samples were taken

postoperatively. Pt penetration (LA-ICP-MS) and IHC analysis (MVD, vessel maturation, hypoxia) of tumor are in progress. Results Tumor IFP was significantly lower in the Bevacizumab and Pazopanib pretreatment groups (Fig. 1). Interestingly, the hypoxic fraction (pO2 <5 mmHg) was also significantly increased in the Bevacizumab group. Mouse body weight, tumor size, and blood Pt concentration did not differ between groups. Conclusions Treatment with Bevacizumab and Pazopanib leads to a markedly reduced IFP in colorectal xenograft tumors. This effect may allow for deeper penetration and higher concentration of Oxaliplatin in peritoneal tumors. IHC and Pt analysis are currently ongoing and the results will be presented. Further research will explore therapy effect through a tumor growth delay study and microenvironment mapping with DCE-MRI.



Figure 1 A: Bilateral peritoneal tumor nodules two weeks after subperitoneal injection with 1.5×10^6 HT29 cells in Matrigel solution. No additional metastatic nodules were observed in any mice B: Schematic of experimental IPC procedure in mice (open or coliseum technique). B' Schematic of experimental IPC procedure in mice (open or consetum technique). C: IFP differed significantly between treatment groups (p < 0,00; Kruskal-Wallis). Both the Bevacizumab as the Pazopanib group showed a reduced IFP compared to placebo (p < 0,05; Dunn's Method). D: The hypoxic fraction (percentage of measurements <5 mmHg) also showed a significant difference (p = 0,025; Kruskal-Wallis). Compared to placebo, only the Bevacizumab group had an increased hypoxic fraction (p < 0,05; Dunn's Method).

28

Surgery-induced Expansion of Myeloid Derived Suppressor Cells Leads to Natural Killer Cell Dysfunction and Postoperative Metastases S.A. Bennett,¹* L. Tai,² A. Alkayyal,² S. Sahi,² J. Zhang,² A.A. Ananth,² C. Tanese de Souza,² R.A. Auer.² 1. University of Ottawa, Ottawa, ON, Canada; 2. Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Rationale: Surgical resection induces natural killer (NK) cell dysfunction which has been linked to the development of postoperative metastases. Myeloid derived suppressor cells (MDSC) are a heterogeneous population of immune regulatory cells that have been shown to expand in cancer patients and suppress the effector function of immune cells, including NK cells. We hypothesize that surgery-induced MDSC expansion impairs NK cells thereby promoting the formation of postoperative metastases. Methods: Surgical stress was induced by laparotomy and nephrectomy in a murine model of experimental (B16 melanoma) and spontaneous (4T1 breast) lung metastases. Mice were euthanized at specific time points and metastases were quantified. The level of MDSC expansion following surgery was quantified by flow cytometry and NK cell cytotoxicity by 51Cr release assay. Murine MDSC were depleted in vivo with anti-Gr1 mAb. In cancer surgery patients, MDSC quantification by flow cytometry was performed pre-operatively and at various time points postoperatively. Results: In both murine models surgery resulted in significant suppression of NK cells in the immediate postoperative period and a 2-4 fold increase in lung metastases. Surgery in both mice and human cancer patients also resulted in significantly elevated MDSCs and NK cell suppression one day after surgery. In humans, this normalized by day 3. In MDSC-depleted mice

there was a partial recovery of postoperative NK cell dysfunction as well as a 10 fold reduction in the number of lung metastases. Conclusion: Surgically-induced MDSC expansion leads to NK cell dysfunction and increased metastases in mice. Human data demonstrate MDSC expansion and NK cell dysfunction postoperatively. The perioperative period presents an opportunity for therapeutic attenuation of MDSCs with the potential to decrease metastases.

Depletion of MDSC rescues removal of tumor metastases



Fig 1. Graph demonstrating decreased tumor metastases in MDSCdepleted mice following surgery

29

Preoperative Pancreastatin Predicts Survival in Neuroendocrine Tumors S.K. Sherman,¹* J.E. Maxwell,¹ T.M. O'Dorisio,² J.R. Howe. 1. University of Iowa Department of Surgery, Iowa City, IA; 2. University of Iowa Department of Internal Medicine, Iowa City, IA.

Introduction: Levels of neurokininA (NKA), chromograninA (CgA), serotonin (5HT), and pancreastatin (PT) reflect tumor burden in neuroendocrine tumors (NET). Levels of NKA, CgA, and PT have been reported to correlate with outcomes, but these series included multiple primary NET sites and patients treated with or without surgery. We set out to determine whether preoperative (preop) levels of these markers correlate with survival in surgically-managed small bowel (SBNET) and pancreatic (PNET) neuroendocrine tumors. Methods: Clinical data were collected with IRB approval for patients undergoing surgery at one center. Progression-free (PFS) and overall survival (OS) were calculated from time of surgery. Median event times were estimated by Kaplan-Meier method. Preop laboratory values were log-transformed and tested as continuous and categorical (normal vs. elevated) variables for correlation with outcomes using a multivariate Cox model with adjustment for confounders. Results: Included were 80 SBNET and 73 PNET. Median follow-up was 3.3 years; 60.8% of cases had metastatic disease. SBNET had lower median PFS than PNET (2.6 vs. 5.6 years, p=0.02). Median OS was 10.5 years for PNET and not reached for SBNET. Preop NKA, CgA, PT, and 5HT levels were recorded in 52, 98, 109, and 115 patients. Preop 5HT and NKA did not correlate with PFS or OS (p>0.1 for all). Preop CgA correlated with PFS but not OS (p=0.03 and 0.09). PT most strongly correlated with outcomes, with higher levels predicting worse PFS and OS (p<0.0001 and 0.04). After multivariate adjustment for primary tumor type and presence of metastases, PT, but not CgA, remained a significant independent predictor of worse PFS (p<0.001) and OS (p=0.03). 5-year PFS was 58% in patients with normal preop PT, vs. 16% in patients with elevated preop PT (Figure). Conclusions: Higher preop PT, but not NKA, 5HT, or CgA, is significantly associated with worse PFS and OS in SBNET and PNET. This effect is independent of primary tumor site and presence of metastatic disease. Measurement of preop PT provides valuable prognostic information and identifies surgical patients at high risk of recurrence who could benefit most from novel or more aggressive therapies.





30 Impact of Extent of Surgery on Survival in Patients with Small Non-functional Pancreatic Neuroendocrine Tumors in the U.S

L. Gratian,* J. Pura, S. Roman, S. Reed, J.A. Sosa. *Duke University Medical Center, Durham, NC.*

Introduction: Pancreatic neuroendocrine tumors (PNETs) <2cm have unclear malignant potential and optimal treatment remains unclear. Objectives of this study were to better understand the malignant potential of these tumors, describe national treatment patterns, and report effect of surgical resection on 5-year overall survival (OS). Methods: Patients with non-functional PNETs ≤2cm were identified from the National Cancer Data Base (1998-2011). Descriptive statistics were used for patient characteristics and surgical resection patterns. 5-year OS was estimated using Kaplan-Meier analyses across extent of surgery and compared using the log-rank test. Cox proportional regression modeling was used to test the association between survival and extent to surgery. Results: 1366 patients with non-functional PNETs ≤2cm were included. The incidence of these increased 10 fold from 1998 to 2011. 75% of patients underwent resection of the primary tumor, and of those, 72% had lymphadenectomy; a median of 5 lymph nodes were examined. Chemotherapy and/or radiation was administered in 4% of patients. Based on tumor size (<0.5cm, >0.5 to \leq 1, and >1 to \leq 2cm), there was no difference in rates of distant metastases (11%, 9%, and13%, respectively p=0.17) or regional nodal metastases (34%, 21%, and 29%, respectively p=0.11). Pancreaticoduodenectomy was associated with increased risk of death compared to partial pancreatectomy (HR: 2.68, 95% CI: 1.05-6.88, P=0.04). Positive margin status and poorly differentiated grade were associated with decreased 5year OS (p=0.016 and p<0.001, respectively). OS for patients who did not undergo surgery was 26.7% at 5 years, after excluding patients with distant metastases and those who were not offered surgery due to patient risk factors. There was no significant difference in OS based on the addition of regional lymphadenectomy (p=0.16). Conclusions: Small non-functional PNETs have a significant risk of nodal and distant metastases. Surgical resection of the primary tumor is associated with improved 5-year overall survival. There was no significant difference in 5-year OS with the addition of regional lymphadenectomy.

31

Incidence of Additional Malignancies in Patients with Pancreatic Neuroendocrine and Carcinoid Tumors R. Kauffmann,¹ L. Wang,² S. Phillips,² K. Idrees,² E. Liu,² N. Merchant,² A. Parikh.^{2*} *1. City of Hope Cancer Center, Duarte, CA; 2. Vanderbilt University, Nashville, TN.*

Background: It is known that the incidence of additional malignancies is higher in patients with a prior malignancy. Although the incidence of neuroendocrine tumors (NET), including both pancreatic neuroendocrine tumors (PNET) and carcinoid, is increasing, there have been no large, populationbased studies to determine the incidence of and risk factors associated with additional malignancies in these patients. Methods: We determined the incidence of additional non-NET primary cancers that developed before or after a patient's incident diagnosis of PNET or carcinoid (1978-2008) using the Surveillance, Epidemiology, and End Results (SEER) database and compared these to expected cancer rates among the general U.S. population. Using multivariable regression modeling, factors affecting the risk of an additional malignancy were analyzed. Results: A total of 9727 patients were identified within the SEER database (974 PNET and 8753 carcinoid); 2723 additional primary cancers were identified in 2508 patients. The most common sites of additional malignancies were colorectal (21.1%), prostate (14.5%), breast (13.3%), and lung (11.6%). In patients with PNET, the incidence of nearly all cancers was equal to or less than expected rates, while in patients with carcinoid, the observed incidence of nearly all malignancies, especially colon (4.3x higher) and gastric (4.1x higher) exceeded that of the general population. Age 70 vs. 50 (OR 2.08, 1.09-3.93 for PNET, OR 1.60, 1.32-1.93 for carcinoid), and early vs. late stage NET primary (OR 3.4, 1.61-7.14 for PNET, OR 2.3, 1.82-2.78 for carcinoid) were associated with an increased risk of additional malignancy after PNET or carcinoid. Conclusions: Approximately 25% of patients with NET develop an additional malignancy. Patients with carcinoid are at increased risk of additional malignancies, especially of the colon and stomach, while patients with PNET do not appear to be at increased risk. In patients with a history of carcinoid tumor, particularly older patients or those with localized disease, increased surveillance should be considered. Further studies investigating common etiologic pathways are also warranted.

32

Octreoscan versus PET for Neuroendocrine Tumor Staging: A Biological Approach M.H. Squires, ¹* N. Adsay,² D.M. Schuster, ³ M.C. Russell, ¹ K. Cardona, ¹ J.M. Sarmiento, ¹ B. El-Rayes, ⁴ C.A. Staley, ¹ S.K. Maithel, ¹ D.A. Kooby.¹ *I. Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA; 2. Department of Pathology, Emory University, Atlanta, GA; 3. Division of Nuclear Medicine, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA; 4. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.*

Background: Clinicians may order Octreoscan or positron emission tomography (PET) scan for staging patients with neuroendocrine tumors (NET). Octreoscan identifies tumors by somatostatin receptor targeting, while PET is based on tumor glucose metabolism. We correlated the results of each nuclear imaging modality with pathologic tumor features of NET to clarify which test offers greater sensitivity. Methods: We identified all patients diagnosed with NET of gut or pancreatic origin who underwent nuclear imaging staging by 111In-Octreoscan and/or PET from 2000 to 2013. Pathology specimens were reviewed to correlate tumor differentiation and World Health Organization (WHO) grade (based on mitotic rate and Ki-67 index) with the sensitivity of results by Octreoscan versus PET. Results: Nuclear imaging and pathology results were identified for 153 patients. Of these, 131 patients underwent Octreoscan, 43 underwent PET, and 21 patients underwent both. Overall sensitivity of Octreoscan and PET for NET detection was similar (77% vs. 72%; p=NS). For well-differentiated NET, Octreoscan (n=124) demonstrated sensitivity of 82%, versus only 60% (p=0.28) for PET (n=30). For poorly-differentiated NET, Octreoscan (n=7) proved significantly less sensitive than PET (n=13), (57% vs. 100%; p=0.02). The sensitivity of Octreoscan versus PET varied similarly when analyzed by WHO tumor grade: Grade 1 (80% vs. 52%; p=NS), Grade 2 (85% vs. 86%; p=NS), and Grade 3 (57% vs. 100%; p=0.02). Conclusion: Tumor differentiation can be used to guide selection of nuclear imaging modalites for staging gastrointestinal and pancreatic neuroendocrine tumors (NET). Octreoscan appears more sensitive than PET for well-differentiated

NET, whereas PET demonstrates superior sensitivity for poorly-differentiated NET.

Risk Factors Associated with Complications following Adrenal Surgery A. Hauch,* Z. Al-Qurayshi, D. Slakey, E. Kandil. Surgery, Tulane University School of Medicine, New Orleans, LA.

Background: Surgeon experience has been shown to result in better outcomes following a variety of advanced operations. Less information is available regarding adrenal surgery. We sought to compare the outcomes following adrenalectomy for a variety of indications and to determine the effect of surgeon's volume. Methods: Cross-sectional analysis using ICD-9 codes included in the Nationwide Inpatient Sample (NIS) from '03-'09 to identify all adult patients who underwent adrenalectomy. Logistic regression models were used to control for confounders and to test for interaction between surgeon volume (low= 1, low-medium= 2-3, intermediate= 4-5, and high> 5 adrenalectomies/year). Results: 7,829 adrenalectomies were included in this analysis. Rate of complication for low and medium-low volume surgeons was 18.8% and 18.2% respectively, and were significantly higher when compared to high volume surgeons (11.6%, p<0.001). Bilateral adrenalectomies accounted for only 2.9% of total procedures. Risk of complication was 23.4% while unilateral procedures had a 15.0% risk (OR: 2.15, 95%CI: 1.33, 3.48). Following unilateral surgery, higher rate of complication occurred among low and lowmedium volume surgeons compared to the high volume group (p<0.001). Malignancy was associated with higher risk of complication (OR: 1.66, 95%CI: 1.35, 2.05). Low and low-medium volume surgeons had significantly higher risk of complications following operations for non-malignant lesions (17.8% and 15.2% of complications respectively) compared to high volume surgeons (10.4%). Low-medium and intermediate volume surgeons had higher risk for malignant lesions (28.5%, and 24.6% respectively) compared to the high volume group (17.0%, p<0.05 for both groups). LOS was shorter for high volume surgeons compared to the other groups (3.38days vs. 6.10days for low volume, p<0.01). Similarly, charges were less for high volume surgeons (\$32,337 vs. \$45,190 for low volume, p<0.01). Conclusions: Low surgeon volumes and adrenal surgery for malignant or bilateral disease are associated with increased risk of postoperative complications. LOS and charges were significantly less following operation by high volume surgeons.

Procedure Type	Surgeon Volume	Complication Rate (%)	OR: (95% CI)	p-Value
	Low	18.2	1.86: (1.38, 2.50)	< 0.0001
	Low-Medium	18.1	1.90: (1.38, 2.62)	< 0.0001
Unilateral	Intermediate	11.4	1.18: (0.85, 1.64)	0.325
	High	11.0	Reference	Reference
	Low	47.2	0.62: (0.017, 21.94)	0.793
D11	Low-Medium	26.1	1.05: (0.027, 41.26)	0.979
Bilateral	Intermediate	16.2	0.36: (0.004, 35.30)	0.659
	High	20.5	Reference	Reference

Initial Recurrence Patterns and Survival in Patients Undergoing Curative Resection for Adrenal Cortical Carcinoma: The Prognostic Value of Local Recurrence B.R. Untch,* C.D. Jakubowski, M. Imnadze, D. Reidy-Lagunes, P. Allen, D.G. Coit, J.A. Coleman, M.F. Brennan, V.E. Strong. Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.

Introduction: Adrenal cortical carcinoma (ACC) is a rare tumor with high rates of local and distant recurrence. This study describes initial recurrence patterns and subsequent survival of patients with resected ACC. Methods: Patients were identified from a prospective adrenal resection database. Those undergoing initial curative resection at a single institution were retrospectively reviewed. Imaging studies and/or biopsy identified initial recurrence. Local recurrences were defined as those in the adrenal bed/retroperitoneum. Results: A total of 87 patients were resected with curative intent from 1975-2013. The overall median disease-specific survival was 67 months with a median follow-up of 44 months. There were 49 (56%) recurrences. Initial recurrences were local only in 17 (20%) patients and distant in 32 (37%) patients. Distant metasas were identified in the lung (47%), liver (22%), bone (12%), peritoneum (6%) and other (13%). When compared by initial recurrence patterns (local

only vs distant) there was no difference in age, gender, operative approach, tumor size, margin positivity, or Weiss criteria. However, median recurrencefree survival was significantly less in the local recurrence group (8 months) as compared those with distant metastases (18 months, hazard ratio for local recurrence 1.8, 95% CI: 1.1-4.4, p=0.028). Additionally, median disease-specific survival was shorter in the local recurrence group (38 months) as compared to the distant metastases group (100 months, hazard ratio for local recurrence 2.2, 95% CI: 1.3-6, p=0.01, Figure 1). Conclusions. Patients that have undergone curative resection for ACC are at high risk for local recurrence and distant metastases. Initial local recurrence is a prognostic factor for aggressive disease biology.



35

The Bethesda System for Reporting Thyroid Cytopathology: A Single Center Experience over Five Years C.M. Kiernan,* J.T. Broome, C.C. Solorzano. *General Surgery, Vanderbilt University, Nashville, TN.*

Background: The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) was developed to refine fine needle aspiration (FNA) cytology definitions, improve communication and clinical management. This study evaluates the impact of the BSRTC five years after its adoption at a single institution. Methods: A total of 1625 patients undergoing thyroidectomy for all indications in the pre-(group-1: 7/07-1/09) and post-BSRTC (group-2: 2/09-9/13) periods were reviewed. Cytologic diagnoses in group-1 included nondiagnostic, benign, follicular/Hürthle neoplasm, suspicious for cancer and cancer. Atypia/follicular lesion of undetermined significance (AUS/FLUS) was included in group-2. The proportions of each FNA category, malignancy rate per cytologic diagnosis, overall malignancy rate, and rate of indeterminate FNAs were compared. Results: Fifty-four percent (187/347) of group-1 patients had a preoperative FNAs vs. 61% (777/1278) in group-2 (p=0.02). Group-1 FNA results included 3% nondiagnostic, 48% benign, 17% follicular/Hürthle, 13% suspicious for cancer and 19% cancer. Group-2 results included 3% nondiagnostic, 36% benign, 9% follicular/Hürthle, 8% suspicious for cancer, 18% cancer and 26% AUS/FLUS. In group-2, the proportions of benign, follicular/Hürthle and suspicious for cancer FNAs decreased significantly (p<0.05). In group-2, there were more indeterminate FNA diagnoses overall (30% vs. 43%, p<0.001). The rate of cancer in suspicious for cancer FNA lesions increased from 44% to 65% (p=0.07) but remained stable for other categories. The AUS/FLUS malignancy rate in patients undergoing thyroidectomy was 15%. The overall rate of thyroid malignancy was 30% and did not change between time periods. Conclusions: Since the adoption of the BSRTC at our institution, the rate of thyroid cancer at the time of surgery has not changed. Although the proportion of indeterminate FNAs has increased due mostly to AUS/FLUS lesions, the diagnostic accuracy of the suspicious for cancer category has improved. AUS/FLUS appears to separate out a class of nodules with a different malignant potential allowing better diagnostic clarity when evaluating the malignant risk of nodules.

The Use of Fine Needle Aspiration Thyroglobulin Washout for Detecting Metastatic Disease in Patients with Recurrent Papillary Thyroid Cancer H. Mohamed, * D. Dali, S.H. Mohamed, Z. Al-Qurayshi, A. Deniwar, K. Moroz, E. Kandil. Surgery, Tulane University, New orleans. LA.

Objective: For many years the standard of care for the workup of cervical lymph nodes suspicious for metastasis has been fine-needle aspiration (FNA). FNA- Thyroglobulin (TG) washout measurement has recently been proven to be useful adjunct in the management of patients with suspicious lymphadenopathy. We hypothesize that surgeon-performed ultrasound using TG washout for suspicious lymphadenopathy would increase the accuracy of diagnosing metastatic disease in patients with recurrent papillary thyroid cancer. Methods: This is a retrospective study of prospectively collected database for patients with thyroid cancer who underwent preoperative FNA-cytology and FNA-TG washout followed by selective neck dissection by one surgeon at an academic institution. Results of both preoperative FNA cytology and FNA-TG washout were then correlated with the final pathology results of the dissected lymph nodes. Data was then collected to compare the sensitivity and specificity of FNA-cytology alone to that of FNA-cytology in adjunct to FNA-TG. Results: Fifty-three lymph nodes from 45 patients were included in this study. Twenty-two modified radical neck dissection (MRND), 19 had a central lymph node dissection (CLND), and 4 had a MRND in addition to CLND. The average serum thyroglobulin is 62.28 +/- 13.76ng/ml, however, the average FNA-TG washout levels was 2349.5 +/- 957.73ng/ml. The FNA-cytology alone showed a sensitivity of 80.49%, specificity of 81.82% with a negative predictive value (NPV) of 52.94%. In contrast, FNA-TG had a sensitivity of 100%, specificity of 83.33% with a NPV of 100%. FNA- TG washout led to change in the plan of surgical management in eight patients (15%) with negative FNAcytology. Combination of the FNA-cytology with FNA-TG revealed a sensitivity of 100%, specificity of 100% with a NPV of 100%. Conclusion: Surgeon Performed FNA-TG washout increases the diagnostic accuracy in detecting metastatic disease in patients with recurrent papillary thyroid cancer. Routine performance of US-guided FNA-TG as an adjunct to FNA-cytology should be considered in-patients with suspicious metastatic lymphadenopathy.

37

Development of an Index to Predict Single Gland Parathyroid Disease and Selectively Eliminate Intraoperative Parathyroid Hormone Testing M. Kukar,^{1*} E. Cho,¹ T. Platz,¹ K. Attwood,² A. Abdelhalim,³ S. Kumar,¹ W.G. Cance.¹ *1. Roswell Park Cancer Institute, Surgical Oncology, Buffalo, NY; 2. Roswell Park Cancer Institute, Biostatistics, Buffalo, NY; 3. Roswell Park Cancer Institute, Radiology, Buffalo, NY.*

Introduction: Assessing intraoperative parathyroid hormone (iPTH) helps confirm single gland disease during minimally invasive parathyroidectomy. With improved preoperative localization, this study may not be necessary. Our objective was to create a predictive index using clinicopathologic, biochemical and imaging characteristics to accurately predict single gland disease and avoid routine use of iPTH. Methods: Our study cohort included 150 consecutive patients with primary hyperparathyroidism (HPTH) who underwent surgery at our institution between January 2011 and March 2013. All patients underwent four dimensional computerized tomography (4DCT), reviewed by a single blinded neuroradiologist. Using prospectively collected data, a prognostic model was developed. First, the sample was stratified by single versus multiple gland disease and logistic regression models were used to evaluate discriminatory ability. 4DCT was identified as the most significant predictor of single gland disease. Second, within the 4DCT positive patients, logistic regression models were used to evaluate each variable's utility. Preoperative calcium added the most prognostic utility. The Youden index criterion was then used to identify the optimal calcium threshold. Results: Stratifying by single gland versus multiple gland disease yielded 4DCT (p<0.001), preoperative calcium (p=0.005) and preoperative PTH (p=0.0047) as significant variables. Further stratification by 4DCT status vielded preoperative calcium {OR 4.04 (1.36-11.97), p 0.012} and PTH {OR 1.03 (1.01-1.05), p=0.007} as significant variables. Using the prognostic model, a predictive index using specific 4DCT characteristics (intense enhancement and rapid washout, usual anatomical location, no evidence of multinodular goiter or thyroiditis) and preoperative calcium greater than 10.8 yielded a PPV of 100 % (92.3-100). For validation, the index was applied to the following 30 patients undergoing surgery for primary HPTH and yielded a 100% PPV (87.7-100.0). Conclusions: This predictive index can accurately determine single gland parathyroid disease and avoid the use of routine iPTH testing.

38

What Can We Learn from Failed Parathyroid Operations? H. Wachtel,* I. Cerullo, D.R. Farquhar, E. Bartlett, G.C. Karakousis, R.R. Kelz, D.L. Fraker. *Dept. of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.*

Introduction: Increasing emphasis is placed on the role of imaging in the surgical management of primary hyperparathyroidism (pHPT). We studied our large series of parathyroidectomies to identify factors associated with failed operative intervention with attention to preoperative imaging results. Methods: We performed a retrospective cohort study of all consecutive patients who underwent initial parathyroidectomy for pHPT with intraoperative parathyroid hormone (PTH) monitoring (2002-2012). Characteristics examined included age, gender, preoperative serum calcium and PTH level, prior thyroid surgery, preoperative localization by sestamibi or ultrasound, histopathology, size and weight of resected gland, and ectopic gland location. The primary outcome was biochemical cure. Univariate analysis was performed using the rank-sum test, Student's t-test or Fisher's exact test, as appropriate. A multivariable regression model was developed. Results: 1809 consecutive patients met inclusion criteria; the overall cure rate was 98.5%. On univariate analysis cured patients had higher preoperative calcium levels (10.8 vs. 10.6 mg/dl, p=0.010) than patients who failed operative intervention (Table I). Cured patients also had a higher proportion of single adenomas (82.8 vs. 32.1%, p<0.001), and a lower rate of hyperplasia (8.2 vs. 25.0%, p=0.007). Median gland size and weight were greater in cured patients (1.5 vs. 1.0 cm, p<0.001; 400.5 vs. 136 mg, p<0.001). Analysis of the use of imaging showed that rates of sestamibi (94.3 vs. 96.4%, p=1.000) and ultrasound (70.5 vs. 64.3%, p=0.532) were similar between cohorts. Cured patients were more likely to have gland localization by sestamibi (53.3 vs. 25.0%, p=0.001). Non-localized patients had a high cure rate (97.3 vs. 99.3%). On multivariate analysis, the only preoperative factor associated with a greater likelihood of cure was localization by sestamibi (OR=4.3, p=0.022). Conclusion: Positive sestamibi scan was associated with a slightly higher, yet clinically insignificant difference in cure rate. As only 2.7% of non-localized patients failed surgical intervention, the decision to operate should be based upon clinical indications and not be influenced by localization studies.

outcome			1999	
	Total (1809)	(1781)	(28)	P-value
Age, years				
Mean (SD)	58.5 (13.1)	58.5 (13.1)	59.1 (15.3)	0.786
Gender				
Female (%)	1399 (77.3)	1376 (77.3)	23 (82.1)	0.654
Male (%)	410 (22.7)	405 (22.7)	5 (17.9)	0.654
Redo neck (%)	26 (1.4)	25 (1.4)	1 (3.6)	0.335
Imaging				
Localized (%)	1127 (62.3)	1116 (62.7)	11 (39.3)	0.017
Sestamibi performed (%)	1706 (94.3)	1679 (94.3)	27 (96.4)	1.000
Localized by sestamibi (%)	957 (52.9)	950 (53.3)	7 (25.0)	0.001
Ultrasound performed (%)	1274 (70.4)	1256 (70.5)	18 (64.3)	0.532
Localized by ultrasound (%)	483 (37.9)	478 (26.8)	5 (17.9)	0.478
Concordant imaging (%)	744 (49.6)	731 (49.5)	13 (52.0)	0.428
Pre-op Calcium, mg/dl				
Median (IQR)	0.8 (10.4-11.2)	10.8 (10.4-11.2)	10.6 (10.1-11.0)	0.010
Pre-op PTH, pg/ml				
Median (IQR)	100 (75-135)	100 (75-136)	87.4 (69-108.7)	0.065
Pre-op Creatinine, mg/dl				
Median (IQR)	0.8 (0.7-1.0)	0.81 (0.7-1.0)	0.91 (0.75-0.98)	0.680
Pathology				
Single Adenoma (%)	1483 (82.0)	1474 (82.8)	9 (32.1)	< 0.001
Double Adenoma (%)	160 (8.8)	156 (8.8)	4 (14.3)	0.304
Hyperplasia (%)	153 (8.5)	146 (8.2)	7 (25.0)	0.007
Negative exploration (%)	13 (0.7)	5 (0.3)	8 (28.6)	
Gland size, cm				
Median (IQR)	1.5 (1.1-2.0)	1.5 (1.1-2.0)	1.0 (0.8-1.5)	< 0.001
Gland weight, mg				
Median (IQR)	395 (199-849)	400.5 (205-852)	136 (81.5-271.5)	< 0.001
Estanla aland (0/)	00 /5 4)	07 (5 5)	4 (2.6)	4.000

Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets T. Pawlik,^{1*}

D. Borger,² Y. Kim,¹ D. Cosgrove,¹ S. Alexandrescu,³ R.T. Groeschl,⁴ V. Deshpand,³ J.M. Lindberg,⁵ C.R. Ferrone,² C. Sempoux,⁶ I. Propescu,³ T. Bauer,⁵ T.C. Gamblin,⁴ J. Gigot,⁶ R. Anders,¹ A. Zhu.² *I. Surgery, Johns Hopkins Hospital, Baltimore, MD; 2. Massachusetts General Hospital, Boston, MA; 3. Fundeni Clnical Institute of Disgestive, Bucharest, Romania; 4. Medical College of Wisconsin, Milwaukee, WI; 5. University of Virginia, Charlottesville, VA; 6. Cliniques Universitaires Saint-Luc, Brussels, Belgium.*

Background: The molecular alterations that drive tumorigenesis in intrahepatic cholangiocarcinoma(ICC) remain poorly defined. We sought to define the incidence and prognostic significance of mutations associated with ICC among patients undergoing surgical resection. Methods: 138 patients who underwent resection at 6 centers in the United States and Europe were included. Mutational profiling was performed using nucleic acids that were extracted from resected ICC tumor specimens; mutations were identified using a multiplexed mutational profiling platform. The frequency of mutations was ascertained and the impact on outcome determined. Results: Most patients had a solitary tumor(82%) and median tumor size was 6.0cm. Most patients had R0 resection(89%); 19% patients had N1 disease, while 15% had microscopic vascular invasion. A minority received adjuvant therapy(30%). The majority(55%) of patients had no genetic mutation identified. Among the 62(45%) patients with a genetic mutation, only a small number of gene mutations were identified with a frequency of >5%: IDH1(17.4%), KRAS(8.7%), BRAF(5.8%), PIK3CA(5.1%). In contrast, other genetic mutations were identified in very low frequency: IDH2(3.6%), NRAS(3.6%), TP53(2.2%), MAP2K1(1.5%), CTNNB1(0.7%), and PTEN(0.7%). Approximately 7% of IDH1-mutant tumors were associated with a concurrent PIK3CA gene mutation, and to a much lower extent, a mutation in MAP2K1(2%). No concurrent mutations in IDH1 and KRAS were noted. Compared with ICC tumors that had no identified mutation, IDH1-mutant tumors were more often bilateral(OR 3.46), while KRASmutant tumors were more likely to be associated with perineural invasion(OR 5.72)(both P<0.05). While clinicopathological features such as tumor number and nodal status were associated with survival, no specific mutation was associated with prognosis. Conclusions: Most patients with resected ICC had no somatic mutation identified on multiplexed mutational profiling. IDH1 and KRAS were the most common mutations noted. While certain mutations were associated with ICC clinicopathological features, mutational status did not seemingly impact long-term prognosis.

40

Hepatic Immunotherapy for Metastases (HITM): A Phase I Trial of Anti-CEA Genetically Modified T Cells for Unresectable Adenocarcinoma S.C. Katz,* E. McCormack, R.A. Burga, L. Wang, J.W. Mooring, R. Davies, B.F. Stainken, E.O. Assanah, P.D. Khare, Q. Ma, R.P. Junghans, N. Espat. Surgery, Roger Williams Medical Center, Providence, RI.

INTRODUCTION: We tested the safety of genetically modified "designer" T cell (dTc) hepatic artery infusions (HAI) for patients with CEA+ liver metastases (LM). We hypothesized dTc HAI would limit systemic toxicity and improve delivery to LM. METHODS: Eight patients with unresectable, progressing LM were enrolled and 6 completed the protocol. The first 3 patients received anti-CEA dTc HAI as an intrapatient dose escalation (1e8, 1e9, and 1e10) without IL2. The last 3 patients received 3 dTc doses (1e10) with IL2 by outpatient continuous infusion. Responses were assessed by MRI and PET. Liver biopsies were performed to score necrosis and fibrosis. RESULTS: Five patients presented with colorectal LM and a single patient with ampullary LM. The median age was 54.5 (51-66), 4 were men, and subjects received an average of 2.8 prior chemotherapy regimens. Three patients presented with synchronous LM, the average size of the largest LM was 8.9 cm (1.7-14.4), and 4 had more than 10 LM. HAI of dTc was well tolerated, with 1.7 grade 3 adverse events (AE) per patient. There were no grade 3 or higher hepatobiliary AEs and no grade 4/5 AEs. DTc were not detected in the peripheral blood of any patient and biopsies confirmed dTc within LM. Five patients died of progressive disease and 1 patient is alive with disease at 11 months. The median survival time from enrollment was 4.5 months (range, 2-11). Radiographic progression was noted in 4 patients, 1 patient had stable disease, and 1 patient did not obtain follow up imaging. An increase in tumor necrosis or fibrosis was noted in 4 patients. The patients who did not receive IL2 had a mean CEA increase of $63\pm125\%$ from baseline. In contrast, those who received IL2 + HAI dTc demonstrated a mean decrease in CEA of $37\pm9\%$ (p=0.10). **CONCLU-SIONS**: HAI of anti-CEA dTc were well tolerated in heavily pre-treated patients with unresectable LM. Clinical activity was demonstrated serologically in patients who received IL2 with dTc, although most patients progressed by mRECIST. Further clinical testing is warranted to determine the efficacy of dTc HAI for LM. Sponsored by the SSO Clinical Investigator Award.

41

Mitogen-activated Protein Kinase (MAPK) Pathway Mutations Impact Phenotype and Survival in Colorectal Liver Metastases T.L. Frankel,^{1*} E. Vakiani,² R. DeMatteo,² P. Allen,² Y. Fong,² T. Kingham,² W. Jarnagin,² D. Solit,² M. D'Angelica.² 1. University of Michigan, Ann Arbor, MI; 2. Memorial Sloan-Kettering Cancer Center, New York, NY.

Despite improved outcomes in patients undergoing hepatic colorectal metastasectomy, little is known about the biology of those who are cured or relapse early. We sought to determine the impact of MAPK mutation status on tumor phenotype and survival in patients undergoing curative hepatectomy. K/NRAS, BRAF, PIK3CA and p53 mutation analysis was performed using Sequenom genotyping assay and Sanger sequencing on 165 surgical specimens following R0 hepatic metastasectomy. Clinical characteristics and survival data were retrospectively analyzed from a prospective database and correlated with mutation status. We identified 69 (42%) K/NRAS (55 in exon 2, 8 in exon 3 and 6 in exon 4), 5 (3%) BRAF, 18 (11%) PIK3CA and 100 (61%) p53 mutations in resected specimens. Preoperative characteristics and operative details did not differ significantly between various mutation subsets. There was no impact of p53 or PIK3CA mutation on survival, however, BRAF mutant patients had significantly shorter disease free survival compared to wild-type (median = 3 vs 14 mos, p=.05). Patients with K/NRAS exon 2 mutations had similar disease free survival to wild-type patients (12 vs 14 mos, p=NS) while exon 3 and exon 4 mutations were associated with significantly shorter (5 mos) and longer (not reached) survivals, respectively (figure 1)(p<.05). When assessing phenotype, tumors with K/NRAS exon 4 mutations tended to be large (mean = 6.8cm) and few (mean number = 2) while exon 3 mutated tumors were small (mean = 3.3 cm) and numerous (mean number = 4.7) (P<.05). Time from resection of primary to liver metastases (disease free interval) also varied significantly with wild-type, K/NRAS exon 2, 3, and 4 mutations recurring at a median time of 8, 7, 4, and 24 months, respectively (p<.05). Using gene mutation analysis we identified biologically unique subsets of colorectal liver metastases associated with very good (K/NRAS exon 4) and poor (BRAF and K/NRAS exon 3) oncologic outcomes. The impact of mutation status on survival as well as phenotypic differences such as size, multiplicity and disease free interval warrants further investigation.



Figure 1 - Disease free survival for wild-type and K/NRAS mutations by exon location

42

Liver Metastases Suppress Intrahepatic B Cell Immunostimulatory Function M. Thorn,* R.A. Burga, C. Nguyen, N. Espat, S.C. Katz. *Roger Williams Medical Center, Providence, RI.*

Background: We and others have found that liver metastases (LM) alter the immune microenvironment to promote immunosuppression. Hepatic B cells (HBC) make up a significant proportion of liver lymphocytes but their

role in the progression of LM is poorly defined. Therefore, we attempted to define the features of HBC in the setting of LM. Methods: We used a murine model of CEA+ colorectal LM to study the effects of the tumor microenvironment on HBC. Tumor cells were injected into the portal circulation of C57BL/6 mice to establish LM, and HBC were analyzed after two weeks. Results: HBC comprised 46±10% of lymphocytes in normal livers, and their absolute numbers were similar in mice with LM (see table). A significant increase (2.2-fold, p=0.04) in the frequency of IgMloIgDhi mature B cells was observed in mice with LM, which was associated with an increase in HBC proliferation in response to TLR4, TLR9, or BCR stimulation. HBC exhibited significant down-regulation MHCII and CD80 (2.5-fold, p=0.01, 6-fold, p=0.0006, respectively) following in vivo exposure to tumor. HBC downregulation of CD80 and MHCII was reversible, as these markers recovered to normal levels during ex vivo culture. HBC from tumor-bearing livers that were fixed to maintain their in vivo state induced significantly less CD4+ T cell proliferation compared to normal HBC. We implicated myeloid derived suppressor cells (MDSC) and liver T cells derived from tumor-bearing livers as mediators of HBC downmodulation of CD80 and MHCII, respectively. MDSC induced CD80 downregulation was dependent on direct contact with HBC. Conclusion: The immune function of HBC may be compromised in the setting of LM as evidenced by the diminished expression of MHCII and CD80. Targeting of MDSC and liver T cells represents a potential strategy for rescuing HBC antitumor function.

Phenotype of HBC in tumor-bearing livers compared to normal HBC

Parameter	NORMAL (±SEM)	LM (±SEM)	p value
Overall HBC (%)	46±10	25±3	0.04
Absolute HBC number	3.6±1x10^5	5.5±1.9x10^5	0.4
Mature HBC (%)	24.0±1.5	53.3±9.2	0.03
CD80+ (%)	20.8±0.7	3.4±0.9	0.0006
MHCII+ (%)	80.9±1.5	31.3±11.6	0.01
T cell stimulation (%)	12.2±0.7	5.3±1.9	0.002

HBC=hepatic B cells; LM=liver metastases.

43

Minnelide as a Novel Therapy for Hepatocellular Cancer O. Alsaied,* V. Sangwan, S. Banerjee, R. Chugh, A. Saluja, S. Vickers,

E.H. Jensen. Surgery, University of Minnesota, Minneapolis, MN.

Introduction Sorafenib is the only FDA approved therapy for metastatic hepatocellular carcinoma (HCC) even though it provides minimal survival benefit. In this study, we examined Minnelide (and its metobolite, triptolide) as a novel therapy for HCC, alone and in combination with sorafanib, using in vitro and in vivo models. Methods HuH7 and PLC cells were treated with triptolide (T50 nM), sorafenib [S1.25 uM (HuH7) or 2.5 uM (PLC)] or combination (C) of both. Cell viability assay (WST-8, Dojindo), caspase 3/7 activation (Promega), and proliferation assay (ECIS, Applied BioPhysics) were performed. For in vivo studies, forty mice were implanted with subcutaneous HuH7 tumors and divided into four treatment groups (n=10); saline control, sorafenib 10 mg/kg PO daily (S), Minnelide (a prodrug of triptolide) 0.21 mg/kg IP daily (M), and combination of both (C). Treatment began 7 days after implantation. Tumor volumes were assessed weekly. After 2 weeks, 7/10 control mice were crossed over to treatment with combination therapy. Results In HuH7 cells, the combination of triptolide and sorafenib was superior to either drug alone in inducing caspase 3/7 activity (T=670%, S=208%, C=1534% at 48 hours), and decreasing viability (T=45%, S=38%, C=18% at 48 hours) and proliferation (T=90%, S=90%, C=75% at 24 hours). Similarly in the more resistant PLC cells, caspase 3/7 activity was (T=443%, S=254%, C=1263%), and cell viability was (T=52%, S=58%, C=41%) at 48 hours. Figure 1 shows tumor progression in our mouse model. At 2 weeks, efficacy of Minnelide was similar to sorafanib while combination therapy was superior to either drug alone, with tumor growth inhibition rates of S=59%, M=84%, and C=93%. Control tumor volumes were increased 9-fold. Subsequently, 7/10 control mice were crossed over to combination therapy. At 6 weeks, crossover mice had similar tumor control as combination therapy mice. All control mice expired by day 17. All but one crossover mouse survived until day 42 (experiment end). Conclusion Minnelide is a novel therapy for HCC with similar

efficacy to sorafanib in vitro and in vivo. Combination therapy is significantly more effective than either drug alone and may be a new option for treatment of HCC.



44

Quality of Life (QOL) Improvement and Enhanced Efficacy with Hepatic Arterial Therapy of Doxorubicin-loaded Beads (DEBDOX) in the Treatment of Liver Metastases from Ocular Melanoma: Results from a Phase I Trial R. Martin,^{1*} A. Tam,² K.M. McMasters,¹ C.R. Scoggins,¹ S. Gupta,² T. Sato.³ *1. University of Louisville, Louisville, KY; 2. MD Anderson Cancer Center, Houston, TX; 3. Thomas Jefferson University - Kimmel Cancer Center, Philadelphia, PA.*

Background:Recent reports have demonstrated the safety & efficacy of hepatic arterial therapy using doxorubicin drug eluting beads. Yttrium-90. & melphalan. The aim of this study was to demonstrate the safety, efficacy, & QOL of patients with unresectable hepatic metastases from melanoma treated with drug-eluting beads loaded with doxorubicin (DEB-DOX). Methods: A multi-center prospective FDA IDE approved (ClinTrials.gov G090097) Phase 1 study of DEBDOX(100-300 micron beads) in patients with hepatic metastases from melanoma from 1/2010-9/2011. Safety, efficacy, cardiac function & QOL(FACT-Hep and Doxorubicin Toxicity) were the main end-points. Results: A total of 20 patients with, 60% men, 19 Caucasian, median age of 60 years(range 29-81), with 95% from ocular primary, & median time of diagnosis to liver disease being 36 months (0 to 110 months). Majority, 65% had liver only disease, with liver tumor burden being a median of 40%(range 20-55%), median total lesion size of 11.1cm (2.8 to 31.0cm), with median ejection fraction of 67%. All patients underwent at least 2 DEBDOX, with 75% patients undergoing at least 3 or more for a median doxorubicin exposure of 400mg (300-625). A DEBDOX dose limiting toxicity was not reached is this study. After a median follow up of 9-months, overall response rates of 100%, 80% and 60% were observed at 3,6, and 12-months respectively. Patients reported little to NO doxorubicin QOL side effects and minimal overall QOL changes(Figure 1). A median hepatic specific progression free survival of 9.4 months and a overall survival of 11.8 months after initial DEBDOX treatment has been observed(Figure 1). Conclusion:Initial results from this prospective study of DEBDOX in metastatic melanoma to the liver are a safe & well-tolerated treatment option with favorable early response rates & survival. Given the similar survival (approx 12 months) reports with monotherapy T-cell and BRAF inhibitors, combination therapy with these active agents and hepatic arterial therapy with DEBDOX should be considered in liver dominant disease



45

Combination of Bavituximab and Sorafenib Inhibits HCC Growth: Results of Preclinical Data and a Phase I Study A. Yopp,* R. Brekken, X. Cheng, L. Li, P. Thorpe, X. Huang. UT Southwestern Medical Center; Dallas, TX.

HCC, the fastest growing cause of cancer deaths, presents at advanced stage and few therapy options. Bavituximab is a novel antibody targeting phosphatidylserine (PS), a membrane lipid externalized on cells promoting immune tolerence and immunosuppression. We hypothesize that sorafenib will upregulate PS exposure on HCC tumors providing targets for bavituximab shifting an immunosuppressive to immunoreactive milieu. In addition, we will demonstrate combination bavituximab and sorafenib can be given safely in patients with advanced HCC. Methods:Immunocompromised mice with orthotopic human HCC tumors (Huh7, C3A, or LC/PRF/5), were treated with sorafenib and tumors harvested and analyzed by IHC for vascular endothelium (anti-CD31) and PS exposure (2aG4, murine bavituximab analogue). Efficacy of sorafenib or 2aG4 or combination was evaluated in mice bearing LC/PRF/5 tumors. Tumor volume measured and microvascular density (anti-CD31) and macrophage recruitment and phenotype determined by IHC. In the phase I study, patients with advanced HCC and Child-Pugh A received escalating doses of bavituximab weekly (0.3, 1.0, and 3.0 mg/kg) and sorafenib 400 mg bid for 28 days. Results:Sorafenib treatment of HCC xenografts increased PS exposure in 1.7-2.9 fold compared to control in each model tested (p<0.01). Sorafenib and 2aG4 inhibited tumors more then single agent therapy (p<0.01). MVD was reduced 30% in combination therapy compared to sorafenib alone (p<0.01). Combination therapy increased M1 (pro-inflammatory) macrophages and sorafenib alone increased M2 (anti-inflammatory) macrophages. Phase I trial demonstrated maximum tolerated bavituximab dose of 3.0 mg/kg weekly and 400 mg BID sorafenib with no dose limiting toxicities. Toxicities were related to sorafenib and included hand-foot syndrome (22% grade II), fatigue (33% grade I) and anorexia (22% grade I). Conclusions: Sorafenib increases PS exposure on HCC vascular endothelium and when given in combination with the murine bavituximab analogue inhibits tumor growth greater than sorafenib alone by reactivating innate immunity. Bavituximab and sorafenib can be given safely in patients with advanced HCC.

46

Novel Antibody-targeted Zirconium-89 PET Imaging of Hepatocellular Carcinoma J.G. Sham,* F. Kievit, J. Grierson, R. Miyaoka, M. Yeh, M. Zhang, R. Yeung, S. Minoshima, J. Park. University of Washington, Seattle, WA.

Introduction: Hepatocellular carcinoma (HCC) is a devastating malignancy in which imperfect imaging plays a primary role in diagnosis. Preoperative assessment for hepatectomy or orthotopic liver transplantation based on suboptimal imaging negatively impacts patient outcome. Furthermore, small, indeterminate lesions can lead to incorrect diagnosis, staging or delayed treatment. Glypican-3 (GPC3) is an HCC-specific cell surface proteoglycan over-expressed in the majority of HCCs. This study presents the first use of a Zirconium-89 (89Zr) conjugated monoclonal antibody against GPC3 (αGPC3) for intrahepatic tumor localization using micro positron emission tomography

(micro-PET). Methods: Radioactive 89Zr was conjugated to homegrown α GPC3 using the chelator p-isothiocyanato-benzyldesferrioxamine. In vitro binding, in vivo biodistribution and micro-PET studies using this conjugate were performed in GPC3-expressing HepG2 and GPC3 non-expressing HLF cells and RH7777 orthotopic xenografts established in athymic nude mice. Tumor size was evaluated by histology. Results: 89Zr-αGPC3 demonstrated highly sensitive, antibody-dependent and antigen-specific tumor binding. HepG2 liver tumors exhibited high peak micro-PET signal (836.6 ± 86.5%ID/g) compared with background liver $(27.5 \pm 1.6\% ID/g)$. Tumor-to-liver contrast ratio was high and peaked at 32.5 on day 3. Day 7 radioactivity was still substantial in HepG2 tumors (466.3 ± 87.5%ID/g) compared with control RH7777 tumors (3.8% ±1.2%ID/g, p<0.01) indicating antigen-specificity of 89ZrαGPC3. Animals treated with heat-denatured 89Zr-αGPC3 or co-injected with an excess of unlabeled α GPC3 as a competition assay demonstrated markedly lower tumor uptake $(3.9 \pm 1.3\% ID/g, 29.0 \pm 8.6\% ID/g,$ respectively) confirming antibody-dependency. The largest tumor measured 3.8mm on histologic examination. Conclusions: This study demonstrates the feasibility of utilizing a 89Zr-aGPC3 PET imaging probe to image minute HCCs in the liver with high specificity. Clarifying the identify of conventionally indeterminate liver lesions would enhance the accuracy of the surgeon's preoperative evaluation and therefore warrants further investigation for clinical translation.



47

The Paradigm Shift of Neoadjuvant FOLFIRINOX: Surgical Outcomes of Borderline Resectable and Unresectable Pancreatic Cancer D. Dias-Santos,* T.S. Hong, J. Faris, E. Kwak, V. Deshpand, J. Wo, J. Wargo, J. Allen, L. Blaszkowsky, D. Ting, D.P. Ryan, D. Forcione, S.P. Thayer, C. Fernandez-del Castillo, A.L. Warshaw, K.D. Lillemoe, C.R. Ferrone. *Massachusetts General Hospital, Boston, MA.*

Purpose: Neoadjuvant FOLFIRINOX followed by chemoradiation has resulted in a paradigm shift when managing patients with locally advanced or borderline resectable pancreatic adenocarcinoma (PDAC). This study evaluates the short-term postoperative outcomes of patients undergoing surgical resection after neoadjuvant FOLFIRINOX with or without chemoradiation. Methods: The operative database was used to collect clinicopathologic data for patients with PDAC surgically explored after neoadjuvant treatment with

FOLFIRINOX +/- chemoradiation between 7/10-8/13. Results: After receiving neoadjuvant treatment with FOLFIRINOX 24 patients were explored and 20 also received chemoradiation. Pre-operative post-treatment imaging deemed 13/24 patients locally advanced and 4/24 patients borderline by a senior surgeon. Imaging demonstrated persistent arterial involvement in 15/16 patients. A decrease in CA 19-9 occurred in all patients, with normalization in 12 patients. Sixteen patients underwent pancreaticoduodenectomy, 4 underwent distal pancreatectomy, 2 were deemed unresectable due to local invasion and 2 had metastatic disease. Two patients underwent venous resections. Grade 1/2 complications were seen in 20% of patients and grade 3/4 in 5%. No 90-day postoperative deaths occurred. No patients developed pancreatic fistulas or required re-exploration. Median length of stay was 6 days and rate of readmission was 15%. An R0 resection was achieved in 90% of patients (18/20). Moderate to extensive histologic treatment effect was seen in 55% of the patients. Only 45% of patients had positive lymph nodes, despite a median lymph node retrieval of 20. Conclusion: Resection following neoadjuvant FOLFIRINOX with or without chemoradiation is not associated with an increase in peri-operative mortality, median length of stay or post-operative complications. Negative margins were accomplished in the majority of patients, despite imaging

48

suggesting an unresectable or borderline tumor.

Liver Resection for Metastatic Disease after Y90 Radioembolization: A Case Series with Longterm Follow-up L.R. Henry,^{1*} R. Hostetter,¹ B. Ressler,¹ I. Bowser,¹ M. Yan,¹ H. Vaghefi,¹ J. Abad,¹ S. Gulec,² R.E. Schwarz.¹ *1. Surgical Oncology, IU Health, Goshen Center for Cancer Care, Goshen, IN; 2. Florida International University, North Miami Beach, FL.*

Introduction: There are few reports of liver resections for metastatic disease in patients previously treated with Y-90 radioembolization (RE), and longterm outcome data are sparse. We reviewed our center's experience in patients undergoing hepatectomy after RE. Methods: A retrospective chart review of patients undergoing RE from 2004 to 2011 was performed. Demographic, clinico-pathologic, operative, and long-term outcomes variables were collected. A review of tumor necrosis and normal liver tissue grading of fibrosis and inflammation after resection was performed. Data are expressed as medians and ranges. Results: RE was delivered to 106 patients with primary and metastatic disease of the liver, of whom 9 (6 males, 3 females, median age 54 years (47-76)) with metastatic disease (colorectal: n=4, neuroendocrine: n=3, GIST: n=1, cervical: n=1) underwent resection. RE administration included the right liver in 5, the left liver in 1, and to the whole liver in 3. Six patients had previously received several infusions of cytotoxic therapy. The operations occurred at a median of 115 days (56-245) after RE and included right lobectomy (5), left lobectomy (1), left lateral sectionectomy (1) and bi-lobar wedge resections (2). Median blood loss was 900 ml (250 - 3600). Grade 3 or higher complications occurred in 7 cases (78%). Follow-up was complete in all patients. Three patients (33%) died within 30 days of resection. All remaining had disease recurrence (time to recurrence: 202 days (54 - 315)), and all have died (overall survival: 584 days (127 - 1230)). Pathologic review demonstrated median tumor necrosis of 70% (20-90). In non-tumor bearing liver, fibrosis grade (0-4) and inflammation score (0-4) was 2 or less in all specimens. Conclusion: In this small cohort of highly selected and heavily treated patients, long term survival after resection following RE appears possible, but the operations may carry substantial risks. Additional reports with long-term outcomes are needed to further clarify the impact of RE on post op complications and death.

49

A Multi-center Phase I Dose Escalation Trial to Evaluate Safety and Tolerability of Intra-arterial Temozolomide for Patients with Advanced Extremity Melanoma using Normothermic Isolated Limb Infusion G. Beasley,¹* P.J. Speicher,¹ C. Augustine,² B. Jiang,¹ P.C. Dobler,² B.L. Peterson,³ P.J. Mosca,¹ R.E. Royal,⁴ M.I. Ross,⁴ J.S. Zager,⁵ D.S. Tyler.¹ *1. Department of Surgery, Duke University, Durham, NC; 2. VA Medical Center, Durham, NC; 3. Cancer Statistical Center, Duke University, Durham, NC; 4. The University of Texas MD Anderson Cancer Center, Houston, TX; 5. Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL.*

Background: L-phenylalanine mustard (LPAM) has been the standard for use in regional chemotherapy (RC) for unresectable in-transit melanoma. Preclinical data demonstrated that regional temozolomide (TMZ) may be more effective. Methods: Patients with AJCC Stage IIIB, or IIIC extremity melanoma who failed previous LPAM based RC were treated with TMZ via isolated limb infusion (ILI) according to a modified accelerated titration design. Drug pharmacokinetic (PK) analysis, tumor gene expression, methylation status of the O6-methylguanine methyltransferase (MGMT) promoter, and MGMT expression were evaluated. Primary objectives were: 1) determine dose limiting toxicities (DLT's) and maximum tolerated dose (MTD) of TMZ via ILI using CTCAE v4.03 and 2) explore biomarker correlates of response. Results: 28 patients completed treatment over 2.5 years at 3 institutions. 19 patients were treated at the MTD defined as 3200 mg/m2 (multiplied by 0.09 (arm), 0.18 (leg)). 2 of 5 patients had DLTs at the 3600 mg/m2 level while only grade 1 (n=15) and grade 2 (n=4) clinical toxicities occurred at the MTD. At 3 months post-ILI, 10.5% (2/19) had a CR, 5.3% (1/19) had PR, 15.8% (3/19) had SD, 68.4% (13/19) had PD. Figure 1 shows the change in tumor sum of longest diameter (SOLD) stratified by dose level. Neither PK parameters of TMZ nor MGMT levels were associated with response or toxicity. Conclusion: In this first ever use of intra arterial TMZ in ILI for melanoma, the MTD was determined. While we could not define a marker for TMZ response, the minimal toxicity of TMZ ILI may allow for repeated treatments to increase the response rate as well as clarify the role of MGMT expression in determining response.



50

Australian National Multi-Center Study of Isolated Limb Infusion Chemotherapy for Extremity Melanoma H.M. Kroon,²* B.J. Coventry,² M.H. Giles,² M. Henderson,³ B. Smithers,⁴ J. Serpell,⁵ J.F. Thompson.¹ I. Melanoma Institute Australia, North Sydney, NSW, Australia; 2. Royal Adelaide Hospital, Adelaide, SA, Australia; 3. Peter MacCallum Cancer Center, Melbourne, VIC, Australia; 4. Princess Alexandra Hospital, Brisbane, QLD, Australia; 5. The Alfred Hospital, Melbourne, VIC, Australia.

Introduction: Isolated limb infusion (ILI) is a minimally invasive alternative to isolated limb perfusion (ILP) for delivering high dose regional chemotherapy to an extremity. ILI is now progressively performed in many tertiary referral centers worldwide to treat patients with locally advanced limb melanoma. We investigated the results of ILI in a national Australian multicenter study. Methods: ILIs in 316 patients in five Australian institutions (1992 - 2008) were collectively analyzed. All 5 institutions used the Melanoma Institute Australia ILI protocol. Melphalan and actinomycin D was circulated in the isolated limb for 20-30 minutes. Cancer response was determined using the WHO criteria and limb toxicity was assessed using the Wieberdink Scale. Results: The median patient age was 74 years (range 28 - 100) and 59% were female. Overall response rate to ILI was 75%, consisting of a complete response of 33% and a partial response of 42%. Stable disease was seen in 18% and progressive disease in 7%. Wieberdink toxicity grade III or higher was seen in 30% of the cases. No toxicity-related amputations occurred. Median followup was 22 months and median survival was 48 months. In patients with a CR, median survival was 80 months (p = 0.014). In the univariate analysis a younger age, lower-limb procedures, low Breslow thickness of the primary melanoma and intra-operatively higher achieved intramuscular temperatures were associated with a favorable response. On multivariate analysis Breslow thickness

and lower-limb ILI remained significant predictors for response. Conclusion: This Australian national ILI multi-center study is the largest to date. Toxicity and response rates as well as survival are comparable to other studies reporting results following both ILI and conventional ILP. ILI can widely be implemented and safely applied across tertiary referral centers for successful management of advanced extremity melanoma.

Disease Burden Predicts Response to Melphalan-based Isolated Limb Infusion in Melanoma D.J. Muilenburg,¹* G.M. Beasley,² Z.J. Thompson,¹ J. Lee,¹ D.S. Tyler,² J.S. Zager.¹ 1. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; 2. Duke University, Durham, NC.

Background: Isolated limb infusion (ILI) with melphalan is a minimally invasive, effective treatment for intransit melanoma. However, results are variable: some patients (pts) exhibit dramatic responses while others progress immediately after ILI. While part of this variation is likely due to inherent differences in individual tumor biology, we hypothesized that burden of disease (BOD) may correlate with treatment response. Methods: We analyzed a prospectively collected database from two academic centers. BOD was stratified as high or low (less than 10 lesions, none > 2cm). Response rates were measured at 3 months post-ILI, based on modified RECIST criteria for cutaneous lesions. Multivariable analysis (MV) was used to evaluate the association between response rate and BOD, while adjusting for potential confounding factors. Kaplan-Meier methods with log-rank tests and multivariable Cox proportional hazard models were used to analyze overall survival (OS) and progression free survival (PFS). Results: A total of 160 pts were included, mean age was 67, 57% were male. Sixty (38%) pts had low and 100 (62%) high BOD. Median follow up time was 17.3 months. Patients with low BOD had an overall response rate (ORR) of 73%, with 50% CR; compared to an ORR of 47% with 24% CR in patients with high BOD (p= 0.002). As seen in Table 1, MV analysis of relevant preop, intraop, and postop parameters showed no significant impact on response at 3 months. Pts with a CR at 3 months demonstrated increased PFS over the remainder of the cohort (PR, SD, PD) (12 vs. 5.9, 5.1, 2.7 months respectively, p<0.001); however this did not translate to a difference in OS. Compared to pts with high BOD, those with low BOD had an increase in median PFS of 6.9 vs 3.8 months (p= 0.047), and an increased median OS, 38.4 vs. 30.9 months, although the latter was not statistically significant. Conclusions: Lower BOD is associated with an increased ORR and CR rate, with significantly improved PFS in patients undergoing ILI for intransit melanoma. BOD provides prognostic information that can be useful in patient counseling and also as a marker to stratify patient risk groups in future research studies.

Demographic,	clinicopatho	ologic vai	riables, a	ind o	utcomes

	Low BOD	High BOD	p value
N, % of total N	60, 38%	100, 62%	
Mean Age (range)	67 (29-89)	68 (34-88)	0.619
Upper Extremity (n, %)	9,15%	23, 23%	0.212
Lower Extremity (n, %)	51,85%	77, 77%	0.312
Peri-operative Factors- mean (sd)			
pH @30 min	7.2 (0.1)	7.2 (0.1)	0.759
Base excess @ 30 min	-9.8 (3.2)	-9.4 (4.2)	0.529
Ischemia time (min)	64.2 (14.7)	64.6 (17.5)	0.879
Post-operative CPK peak	2180 (3505)	1218 (1883)	0.068
ORR @ 3 months (95% Confidence Interval) [CI]	73.3 (60.3, 83.9)	47 (36.9, 57.2)	
CR	50 (36.8, 63.2)	24 (16, 33.6)	1
PR	23.3 (13.4, 36)	23 (15.2, 32.5)	0.002
SD	3.3 (0.4, 11.5)	14 (7.9, 22.4)	1
PD	23.3 (13.4, 36)	39 (29.4, 49.3)	1
Median Follow Up: Months, (range)	19.9 (2.8-70.1)	14.9 (0.5-68.9)	
Median overall survival: Months (95% CI)	38.4 (33.2, NA)	30.9 (23.5, NA)	0.146
Median Progression Free Survival: Months (95% CI)	6.9 (5.7, 9.6)	3.8 (3.0, 4.6)	0.047
Progression Free Survival by Respo	onse: months (95%	CI)	
CR	12 (8.	2, 22)	
PR	5.1 (4.	0-9.8)	
SD	5.9 (4.)	0, NA)	<0.001
PD	2.7 (2.	5, 3.0)	1

52

Responses of Injected and Uninjected Lesions to Intralesional Talimogene Laherparepvec (T-VEC) in the OPTiM Study and the Contribution of Surgery to Response R.H. Andtbacka,^{1*} M.I. Ross,² K. Delman,³ D. Noyes,⁴ J.S. Zager,⁵ E. Hsueh,⁶ D.W. Ollila,⁷ T. Amatruda,⁸ L. Chen,⁹ A. VanderWalde,⁹ H. Kaufman.¹⁰ 1. University of Utah Huntsman Cancer Institute, Salt Lake City, UT; 2. MD Anderson Cancer Center, Houston, TX; 3. Emory University, Atlanta, GA; 4. University of Utah School of Medicine, Salt Lake City, UT; 5. Moffitt Cancer Center, Tampa, FL; 6. Saint Louis University Cancer Center, Saint Louis, MO; 7. University of North Carolina Medical Center, Chapel Hill, NC; 8. Minnesota Oncology-Fridley, Fridley, MN; 9. Amgen Inc., Thousand Oaks, CA; 10. Rush University Medical Center, Chicago, IL.

Introduction: T-VEC is an oncolvtic modified type 1 herpes simplex virus designed to selectively replicate in tumors, produce systemic human GM-CSF, and elicit a response in injected and non-injected tumors. As reported in a melanoma phase 3 trial, T-VEC compared to subcutaneous GM-CSF had a significantly greater durable response rate (primary endpoint). While overall responses were previously reported, individual lesion responses and the utility of surgery as an adjunct to therapy are reported here. Methods: Bidimensional measurements were recorded for all measurable lesions every 4-12 weeks and classified as either injected, uninjected non-visceral, or uninjected visceral. Injection frequency has been described (ASCO 2013). Melanoma-related surgeries on study were distinguished from confirmatory biopsies. Surgical pathology reports and pre- and post-surgery response assessments were used to classify surgeries as palliative, no evidence of disease (NED) following surgery, or pathologic complete response (pCR) at the time of surgery. Results: 286 patients (pts) treated with T-VEC had at least 1 tumor lesion with serially recorded measurements. In total, measurements were recorded in 3219 lesions (mean=11.3 lesions per pt). Of these 3219 lesions, 2043 were injected with T-VEC at least once, 1022 were uninjected non-visceral, and 154 were uninjected visceral lesions. A \ge 50% reduction in tumor size from baseline was seen in 64% of injected, 32% of uninjected non-visceral, and 16% of uninjected visceral lesions. 6 pts converted from unresectable to resectable disease while on T-VEC therapy per investigators. Melanoma-related surgery was performed on-study 37 times: 19 were palliative in nature, 15 led to NED following surgery, and 3 showed a pCR at the time of surgery. Surgery contributed to the best response recorded by the investigator in 3 pts. Conclusions: While surgery did not appear to have a substantial impact in outcome in this trial, T-VEC was associated with responses in injected, uninjected non-visceral, and uninjected visceral lesions and represents a potential new melanoma treatment agent.

53

Predictors of Survival in Contemporary Era Patients (pts) with Thin Melanoma who underwent Sentinel Node Biopsy (SNB) G. Boland,* A. Caudle, C. Warneke, V. Prieto, J.E. Lee, J. Curry, J.N. Cormier, R.E. Royal, M.I. Ross, J.E. Gershenwald. *MD Anderson Cancer Center, Houston, TX.*

Introduction: Although SNB is a well established staging practice in pts with primary cutaneous melanoma with tumor thickness >1 mm, the role and prognostic significance of SNB in pts with thin melanoma is not well defined. We assessed associations of multiple clinicopathological factors with survival in pts with thin melanoma undergoing SNB in the contemporary SNB era. Methods: From a prospective database, we identified 874 pts with clinically node negative melanomas ≤1mm who had wide excision and SNB during a contemporary time period (1999-2009). We explored associations of known and putative clinicopathological risk factors with respect to melanoma-specific survival (MSS) and recurrence-free survival (RFS). Results: The median pt age was 50y and median Breslow thickness was 0.70 mm; 3% of primary tumors were ulcerated and 45% had ≥1 mitosis/mm2. Overall, 5.2% of pts had ≥ 1 positive sentinel node (SN). At a median follow-up (f/u) of 6.9y among all pts alive at the end of f/u (n=809), 10y MSS was 95.2% (95%CI 91.6-97.2%) and 10y RFS was 94.7% (95% CI 92.6%-96.2%). A positive SN was the strongest univariate predictor of MSS (HR 30.9, 95%CI 12.6-75.8, P<.0001)(Figure) and RFS (HR=14.3, 95%CI 7.3-28.0, P<.0001) of those factors investigated. Additional significant predictors of poorer MSS and RFS were mitotic activity, thicker tumors, and T1b (vs. T1a) substage; ulceration was associated with RFS but not MSS. No significant associations were identified for regression, tumor infiltrating lymphocytes, growth phase, Clark level, melanoma histologic type, tumor location, or gender. In multivariate analyses, SN status was the dominant independent predictor of MSS. Conclusion: Despite the overall low risk of a positive SN, SN status is the most powerful predictor of MSS in pts with thin melanoma. Since thin melanoma pts represent the most common presentation of invasive melanoma, this small high-risk subset represents a significant proportion of pts who will die of melanoma. Therefore, further studies are warranted to identify factors associated with SN involvement in an effort to develop integrated risk models to personalize clinical care.



Disease-specific survival stratified according to sentinel lymph node (SLN) status.

54

Improved Survival in Patients with Thin Melanoma after Positive Sentinel Node versus Clinical Nodal Recurrence M.B. Faries, ¹* G.C. Karakousis,² E. Bartlett,² M. Peters,² P. Gimotty,² M. Sim,¹ D.L. Fraker,² B.J. Czerniecki,² D.L. Morton.¹ *1. John Wayne Cancer Institute, Santa Monica, CA; 2. University of Pennsylvania, Philadelphia, PA.*

Introduction: The value of sentinel lymph node biopsy (SLNB) in intermediate depth melanoma includes its prognostic value and possible survival benefit for patients who harbor nodal metastases. Randomized clinical trials are not feasible in patients with thin (<1mm) melanoma due to the low frequency of nodal disease. We compared outcomes of patients with thin melanoma presenting with sentinel node metastases to those who developed subsequent clinical nodal recurrence (NR). Methods: Two independent cohorts with thin melanoma and either SLN metastasis or clinical NR were identified from prospective databases at two centers. In center 1, (1986-2012) patients with a positive SLNB (SLN+) were compared to patients presenting with clinical NR (1971-2010) after an initially negative nodal evaluation (either clinically or by SLNB). In center 2, SLN+ (1996-2011) were compared to a pre-SLN cohort (1973-1989) with NR. Univariate and multivariate Cox regression analyses determined factors associated with melanoma-specific survival (MSS) and Kaplan-Meier curves were developed. Results: In center 1, 427 patients with NR were compared to 91 SLN+ patients. SLN+ patients were older (53 vs. 31% >50 yrs old) and more frequently had ulcerated tumors (9.9 vs. 6.8%) and elevated Clark level (39.6% vs.14.8% level IV-V) (all p<0.0001). The 5and 10-yr survival for the SLN+ group was 88 and 84% respectively, compared to 72 and 49% in the NR group (p<0.0001). By multivariate analysis, age>50 (HR=1.5, CI=1.2-1.9), present (HR=1.9, CI=1.2-2.9) or unknown (HR=1.6, CI=1.3-2.1) ulceration, truncal site (HR=1.6, CI=1.2-2.2), and NR (HR=3.3, CI=1.8-6.0) were all significantly associated with decreased MSS (each p<0.01). In center 2, 29 SLN+ patients were compared to 39 NR patients. The 5-yr MSS survival was remarkably similar to that of center 1 at 88% in the SLN+ group and 76% in the NR group (p=0.09). Figure 1. Conclusion: Identification of a metastasis in the SLN of patients with thin melanoma is associated with improved MSS compared to the development of clinical NR. This may be a reflection of tumor biology, patient selection, or potential therapeutic efficacy of the SLNB.



Figure 1. Melanoma-Specific Survival across Two Centers Stratified by Nodal Positivity at Time of SLNB versus Nodal Recurrence.

55

Melanoma Patient Quality of Life Outcomes after Sentinel Lymph Node Biopsy, Completion Lymphadenectomy, and Adjuvant Interferon M.E. Egger,^{1*} C. Kimbrough,¹ A.J. Stromberg,² A.R. Quillo,¹ R. Martin,¹ C.R. Scoggins,¹ K.M. McMasters.¹ *1. Department of Sur*gery, University of Louisville, Louisville, KY; 2. University of Kentucky, Lexington, KY.

Patient-centered outcomes for melanoma are important to consider when making recommendations for treatment and adjuvant therapy. Quality of life (QOL) and physical condition (PC) outcomes after sentinel lymph node biopsy (SLNB), completion lymph node dissection (CLND), and adjuvant therapy with interferon alfa-2b (IFN) were evaluated in this study. Self-reported QOL and PC scores were evaluated in patients enrolled in a prospective, multi-center randomized clinical trial evaluating adjuvant IFN in patients with melanoma ≥1.0 mm Breslow thickness. After SLN biopsy, patients with a positive SLN underwent CLND then were randomized to adjuvant IFN for 12 months or observation. QOL and PC scores were compared between patients who underwent SLNB alone, CLND without IFN, and CLND with IFN. Time to return to baseline QOL and PC scores reported at the time of SLNB was recorded. Absolute, changes, and time to return to baseline in QOL and PC scores were compared between groups. The study evaluated 490 patients with a median follow-up of 36.5 months. At baseline, there were no significant differences in reported QOL and PC scores between the 3 treatment groups. After 3 months, there were no statistically significant differences in changes in QOL and PC scores between SLNB and CLND; IFN was associated with significantly worse QOL and PC at 3, 6, 9, and 12 months. There were statistically significant differences in time to return to baseline QOL and PC scores across the three treatment groups (FIGURE, p=0.0018). Median times to return to baseline QOL were 7, 8, and 15 months for SLNB, CLND, and IFN, respectively. Median times to return to baseline PC were 6, 6, and 14 months for SLNB, CLND, and IFN, respectively. Only after an additional 12 months following conclusion of IFN did the proportion of patients reporting return to baseline QOL and PC approach that of SLNB and CLND. CLND is well-tolerated with a similar effect on self-reported QOL outcomes in both the short and long term compared to SLNB alone. IFN therapy is associated with worse QOL outcomes compared to SLNB and CLND, an effect that may be sustained following cessation of adjuvant IFN.



Figure. Time to return to baseline for (A) Quality of Life (QOL) and (B) Physical Condition (PC) scores by treatment groups: sentinely lymph node biopsy alone (SLNB), completion lymph node dissection (CLND), and adjuvant interferon (IFN).

Cost-effectiveness Analysis of Staging Strategies in Patients with Regionally Metastatic Melanoma N. Look Hong,* T. Petrella, K. Chan. *Surgical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.*

Background Considerable variability exists regarding optimal staging for asymptomatic pathologically node-positive melanoma. Options include combinations of physical examination (PE), radiography, computed tomography (CT), and positron emission tomography (PET). Cost-effectiveness of these staging regimens has never been investigated. Methods A modeled cost-effectiveness analysis was performed to examine the cost per surgery performed and per accurate diagnosis achieved with three staging regimens (PE/chest radiography, CT, PET/CT) for node-positive melanoma. Costs for approved systemic chemotherapy regimens were considered. Incremental cost effectiveness ratios were used to compare regimens. Deterministic sensitivity analysis was undertaken to estimate the effect of varying key parameters. Costs are direct, from the perspective of the Canadian single-payer system, and 2012 valuations. Results As seen in Table 1, staging with PE/radiography is the least cost-effective option, resulting in greater costs than CT alone, more surgery, and fewer accurate diagnoses. Compared to CT alone, PET/CT incurs a greater incremental cost (\$902.81 CAD), but results in 4% fewer lymphadenectomies and 4% more accurate diagnoses. PET/CT costs \$22,570.25 CAD for each additional accurate diagnosis achieved compared to CT alone. Sensitivity analyses demonstrate that the preferred staging strategy is influenced by diagnostic test characteristics and the willingness to pay threshold, but is robust to all other varied parameters. Conclusion PE/radiography appears to be the least cost effective staging regimen and results in fewer accurate diagnoses. However, the benefit of PET/CT over CT alone depends on a health system's priorities and willingness to pay.

Table 1: Cost and effectiveness measures for each modeled staging regimen

	PE/Radiography	CT	PET/CT
Total Cost (CAD)	70,623.52	69,931.93	70,834.74
Probability of surgery	0.94	0.78	0.74
Probability of accurate diagnosis	0.74	0.90	0.94
Incremental change in cost (CAD)		-691.59	902.81
Incremental change in surgeries completed		-0.16	-0.04
Incremental change in accurate diagnoses achieved		0.16	0.04

57

Inflammatory Adverse Events are Associated with CD8+ T Cell Response and Disease-free Survival following Multipeptide Melanoma Vaccines Y. Hu,* M.E. Smolkin, E.J. White, G.R. Petroni, P.Y. Neese, C.L. Slingluff. University of Virginia, CHAR-LOTTESVILLE, VA.

BACKGROUND: Administration of multipeptide vaccines may produce adverse events with an inflammatory physiology. The purpose of this study is to determine the relationships among inflammatory adverse events (IAE), immune responsiveness (IR), and clinical outcomes in the setting of multipeptide vaccination for high risk melanoma. We hypothesize that IAE's are associated with a higher rate of IR and improved clinical outcomes. METH-ODS: Adult patients with resected, high-risk (stage IIB-IV) melanoma were entered into one of three multipeptide vaccine trials (Mel43, Mel44, Mel48). All patients received a vaccination of 12 melanoma peptides comprised of Class I MHC-restricted epitopes (12MP). IAE's were recorded, and included pulmonary, dermatologic, and constitutional subtypes. A separate category for hypopigmentation (vitiligo) was also assessed. CD8+ T cell immune response was assessed by direct IFN-gamma ELIspot. Overall survival and diseasefree survival were analyzed by Cox proportional hazard modeling for age, stage, gender, and the presence of IAE, IR, and vitiligo. RESULTS: Out of 333 total participants, 56 developed a total of 70 IAE's, the majority of which were dermatologic. Hypopigmentation developed in 23 patients (7%). 175 patients (53%) developed a CD8+ T cell response. Presence of IAE was significantly associated with development of IR (70% vs 49%, p = 0.005), while vitiligo was not. Development of IAE was associated with increased diseasefree survival under multiple regression (HR 0.63, p = 0.037), while hypopigmentation and presence of IR showed no such association (Figure 1). CON-CLUSIONS: Inflammatory adverse events are associated with a higher rate of CD8+T-cell response following multipeptide vaccination therapy for high-risk melanoma. Because disease-free survival is associated with IAE but not with

IR, our findings suggest either that antitumor activity of Class I-restricted peptide vaccines depend on immunologic effects beyond simple expansion of CD8+ T-cells or that the intrinsic inflammatory response contributes to clinical outcome in melanoma.

Disease Free Survival



58

Gene Expression Profiles of Human Primary and Metastatic Melanoma Reveal UBE2C as a Potential Therapeutic Target Gene for BRAF Resistant Cells R. Essner,^{1*} K. Gong,² H. Chen,² C. Ginther,² J. Dering,² E. Von Euw,² B. Chmielowski,² R. Finn,² D.J. Slamon.² 1. Surgical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA; 2. UCLA, Los Angeles, CA.

Introduction: Ubiquitin-conjugating enzyme E2C (UBE2C) participates in cell cycle progression and checkpoint control by targeted degradation of shortlived proteins. Gene expression of UBE2C is elevated in various cancers including melanoma. Microarray analysis from primary and metastatic melanoma tissues showed that UBE2C mRNA expression was up-regulated in metastatic as compared to primary melanoma (relative expression: 1.23±0.14 vs. 0.64±0.07 p<0.01) demonstrating the relevance of this gene. Human melanoma cell lines also demonstrate UBE2C gene expression unrelated to BRAF and NRAS mutation status. We hypothesized that UBE2C may be a novel target for treatment of melanoma through a BRAF independent pathway. Methods: We performed western blot analysis of the human melanoma cell lines: M207, M328 and M375; each of them resistant to BRAF inhibitor treatment (PLX4032). All three express UBE2C. When these cell lines are treated with PLX4032 we noted less down-regulation of UBE2C gene expression than seen from BRAF inhibitor sensitive cell lines. BRAF resistant cell lines (M207 and M375) were chosen for UBE2C gene silencing based on their high level of UBEC2 expression. Results: UBE2C protein level was reduced by 73.7% and 80.5%, respectively in M207 and M375 cell lines at day 4 after UBE2C siRNA gene silencing and cell proliferation was reduced by 60.4% and 73.8 %. Flow cytometry demonstrated there were higher percentage of apoptotic cells after UBE2C siRNA gene silencing as compared to controls (40.9%±4.4% vs 14.3%±1.5%, p=0.001). M207 was treated with PLX4032 at variable concentrations. There was no down-regulation of UBE2C or ERK phosphorylation from PLX4032. In the BRAF and NRAS mutated M328, PLX4032 inhibited

the cell proliferation by 25.1% at day 5. The combination of PLX4032 and UBE2C siRNA gene silencing inhibited cell proliferation by 52.5% (p<0.001) suggesting the synergy of the combination. Conclusions: While BRAF and NRAS signalling pathways have been shown to be important targets for therapy in melanoma, our data suggest UBE2C may be an additional site for design of treatment in resistant melanoma.

59

Coordinated Cancer Care Reduces Costs and Hospital Length of Stay with High Patient Satisfaction M. Heslin,* W. Smedley, L. Leach, F. Guyton, M. Thompson, S. McNeil, G. McGwin, K.I. Bland, E. Partridge. *Surgery, UAB, Birmingham, AL.*

Introduction: Navigating complex cancer care for the average patient and family is difficult. Moreover, there are no billing codes to subsidize this service and therefore the costs are not externally reimbursed. We sought to analyze the potential benefits of pre-hospitalization nurse navigation on hospital costs, length of stay and patient satisfaction. Methods: From 8/2007 thru 9/2012 there were 16,514 patients electively admitted to the hospital either as "in" or outpatients with a cancer related primary diagnosis. Of this group, 4,258 patients underwent pre-hospitalization navigation by an Integrated Multidisciplinary Cancer Care Program (IMCCP) nurse that coordinated physician visits in surgery, medical and radiation oncology; in addition to identification of social service needs. The Wilcoxon rank-sum test was used to compare hospital cost and length of stay, significance defined as p <0.05 (two sided). Satisfaction surveys were obtained from only the navigation patients. Results: After adjusting for cancer diagnosis, payer mix and whether surgery was performed as an "in" or outpatient there was a statistically significant decrease in the average hospital cost and length of stay of \$200 and 0.05 days, resp.(p<0.05). If these average savings were applied to all patients that were not coordinated during this time period, the potential cumulative benefit would be \$2.45million and 600 inpatient days. Nearly all (99%) of the participants were satisfied and would recommend this program to friends and family. Conclusions: The IMCCP nurse navigation program resulted in decreased costs and fewer hospital days with excellent patient satisfaction. New cancer patients would benefit from this cost effective service.

60

Hospital Surgical Volume and Cost of Cancer Surgery in the Elderly H. Nathan,* C. Atoria, P.B. Bach, E.B. Elkin. *Memorial Sloan-Ket*tering Cancer Center, New York, NY.

Introduction: Hospital surgical volume has been shown to correlate with short-term outcomes and long-term survival after cancer surgery, but the relationship between volume and cost of care is unclear. We quantified variation in the cost of cancer surgery in the elderly in order to understand its relationship to hospital volume. Methods: Using 2000-2007 SEER-Medicare data, we assessed Medicare payments in the 30 days after surgery for patients >65 years old undergoing 6 cancer resection procedures. Payments were adjusted for year, procedure code, patient demographics and comorbidities, cancer stage, receipt of chemotherapy, admission acuity, and pre-operative length of stay. Payments for the index hospitalization, readmissions, physician services, ER visits, and post-discharge ancillary care were analyzed, as well as data on 30-day mortality and complications. Results: The analysis included 2670 cystectomies, 31,191 colectomies, 10,151 pulmonary lobectomies, 1514 pancreatectomies, 12,228 prostatectomies, and 2607 proctectomies. There was significant variation in cost: the difference between the 1st and 3rd terciles of cost ranged from \$3418 (28% variation, prostatectomy) to \$17,658 (38% variation, pancreatectomy). Most variation (66-82%) was attributable to payment for the index admission rather than readmissions (6-13%) or physician services (7-15%). Complications ranged from 10% (proctectomy) to 56% (lobectomy), readmissions from 4.6% (prostatectomy) to 28% (cystectomy), and mortality from 0.2% (prostatectomy) to 3.4% (pancreatectomy). Both total cost and variation in cost were higher for patients who had complications or mortality. Higher

hospital volume correlated with decreased mortality for cystectomy and lobectomy only and with decreased complications for prostatectomy only (P<0.01). There were no meaningful differences in cost with respect to hospital volume (Table). **Conclusions:** There is significant variation in the cost of cancer surgery in the elderly. This variation is largely attributable to the cost of the index admission and is not associated with hospital volume. Volume-based referral of cancer surgery should not be expected to result in significant cost savings.

	Mean Adjusted 30-Da	v Costs b	v Hospital	Volume	Tercile
--	---------------------	-----------	------------	--------	---------

Development Const Trans	Cost in Do	ollars by Ho	Cost Difference Between		
Procedure and Cost Type	Overall	Low	Mid	High	1st and 3rd Terciles (%)
Cystectomy					
Total	42,386	41,701	42,983	42,480	779 (1.8)*
Index Admission	29,140	29,173	29,531	28,718	-455 (-1.5)
Readmissions	3303	2961	3432	3520	559 (18.8)
Colectomy					
Total	31,738	30,957	32,561	31,719	762 (2.4)
Index Admission	24,412	23,870	25,102	24,281	411 (1.7)
Readmissions	1937	1901	1969	1941	39 (2.0)
Pulmonary Lobectomy					
Total	39,412	39,311	39,875	39,058	-253 (-0.6)
Index Admission	29,883	29,941	30,331	29,384	-556 (-1.8)
Readmissions	2605	2602	2593	2620	18 (0.6)
Pancreatectomy					
Total	56,587	56,836	57,997	54,932	-1904 (-3.3)
Index Admission	44,502	44,942	45,733	42,832	-2110 (-4.6)
Readmissions	3858	3901	3909	3763	-138 (-3.5)
Prostatectomy					
Total	14,161	14,014	14,265	14,205	191 (1.3)*
Index Admission	9943	9797	10,044	9990	193 (1.9)
Readmissions	925	928	921	925	-3 (-0.3)
Proctectomy					
Total	33,759	32,676	34,224	34,386	1709 (5.2)
Index Admission	23,343	22,777	23,737	23,519	742 (3.2)
Readmissions	2467	2354	2472	2575	221 (9.3)

61

A Simplified Risk Score for Predicting the Incidence of Major Complications after Complex Abdominal-pelvic Resections A. Bennett, R. Sharma, G.C. Balch, A. Yopp, J.C. Mansour.* *Surgery, UT Southwestern, Dallas, TX.*

Background: The POSSUM system is used to predict risk of complications following general surgical procedures. This 17-factor instrument has been challenging to apply to most surgical oncology patient populations. Our aim is to develop a simplified scoring system which was highly correlated with the incidence of major complications. Methods: We queried a single-institution IRBapproved prospective database from a surgical oncology population from January 2008 to December 2012. We identified patients undergoing complex abdominal or pelvic resections and factors associated with the development of major (Clavien >= 3) complications. Factors not included in the POSSUM system were incorporated into a new scoring system based on univariate correlation with complication rates (Chi-square). A composite scoring system (POSSUM-SO) was compared to standard POSSUM predictions using ROC analysis. Optimal binning generated an ideal cut-off value associated with major complications. Results: We identified 831 patients undergoing pancreatic (23%), hepatic (23%), colorectal (22%), esophagogastric (16%), retroperitoneal (4%), combined (3%), or other type (10%) of resection. Major complications occurred in 17% of patients. Two original POSSUM factors were included in the new POSSUM-SO model (cardiac history and EBL). Four factors improved correlation with complication rate: gender (female/male-1/3 points); BMI (underweight or morbidly obese/others-4/1 points); operation type (retroperitoneal/ pancreatic or rectal/others-4/2/1 points); and cancer (no cancer/cancer-1/2 points). ROC analysis generated a greater AUC for the simplified 6-factor system than standard 17-factor POSSUM (AUC: 0.658 vs 0.631, See Figure 1). A model including the 5 preoperative factors generated a similar AUC compared to the original POSSUM (AUC: 0.622 vs. 0.631). Patients with POSSUM-SO \geq 12 had a higher risk of major complications (22% vs 9%, p-value < 0.001). Conclusions: A simplified composite scoring system is more closely associated with short term surgical outcomes than the POSSUM

index. Validation in a large, independent dataset is necessary before the system can be widely applied.





ROC analysis of scoring systems and association with major complications

62

Young Age-at-diagnosis Influences Quality of Life Among Longterm Survivors of Colorectal Cancer H. Tran Cao,* C. Bailey, C. Hu, G.J. Chang, B. Feig, M.A. Rodriguez-Bigas, S. Nguyen, J.M. Skibber, Y. You. *The University of Texas M.D. Anderson Cancer Center, Houston, TX.*

INTRODUCTION: The incidence of colorectal cancer (CRC) has decreased overall, but continues to rise among young adults (aged 18-50). Cancer diagnosis can disrupt normal adulthood and impact long-term survivorship. The unique needs of long-term survivors from CRC diagnosed at age 18-50 (young survivors, YS) vs. after age 50 (later survivors, LS) have not been examined. METHODS: CRC survivors >5 years from diagnosis were identified from the institutional tumor registry. YS were matched 1:2 to LS for tumor site (colon vs. rectum) and treatments (surgery, chemotherapy, radiation). A matched cross-sectional survey study was conducted in 1,215 survivors (415 YS and 801 LS) using the self-administered Quality of Life in Adult Cancer Survivors (QLACS), a validated instrument for long-term cancer survivors. Standardized mean scores from 13 domains were compared between YS and LS by two-sample t-test. Bonferroni adjustment for multiple comparisons denoted p-value < 0.004 as statistically significant. RESULTS: 830 survivors (282 YS and 548 LS) responded (response rate: 68% in both YS and LS) at a mean of 10.8±3 years (10.6 in YS; 10.9 in LS) from diagnosis. The mean age-at-diagnosis was 43±6 vs. 63±7 years in YS vs. LS (p<0.001). The cohorts were balanced for the matched variables tumor site (p=0.699) and treatments (surgery, p=0.121; chemotherapy, p=0.365; radiation, p=0.864). Significant differences were found in 7 of the 13 domains with significantly worse scores for YS in Negative feeling, Social avoidance, Financial problems, Appearance concern, Recurrence distress, and Family distress, although YS reported greater sense of Benefit (p < 0.001; Figure). Missing responses were most frequent regarding sexual interest and function (missing 4.9% (YS) vs. 17.7% (LS) and 5.6% (YS) vs. 13.3% (LS), respectively). CON-CLUSIONS: Long-term survivors of CRC show good adaptation, but young-onset survivors experience unique QOL deficiencies that persist even 10 years into cancer survivorship. Relative to patients diagnosed at later ages, these young adults may benefit from more attention and support in these specific areas throughout their cancer experience, including late survivorship.



63

Multi-institutional Assessment of Sphincter Preservation for Rectal Cancer Z.M. Abdelsattar,¹* S.L. Wong,¹ N.J. Birkmeyer,¹ R.K. Cleary,² M.L. Times,⁴ R.E. Figg,³ N. Peters,¹ R.W. Krell,¹ D.A. Campbell Jr,¹ S. Hendren.¹ *I. Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor, MI; 2. St Joseph Mercy Hospital, Ann Arbor, MI; 3. Spectrum Health, Grand Rapids, MI; 4. Henry Ford Hospital, Detroit, MI.*

BACKGROUND: Rates of sphincter preserving surgery (SPS) have been proposed as a quality measure for rectal cancer (RC) surgery. However, administrative and registry-based SPS rates often lack critical patient and tumor characteristics, rendering it unclear if variations in SPS rates are due to unmeasured case-mix differences or selection criteria. The aim of this study was to determine whether hospitals' SPS rates differ after accounting for clinical characteristics. METHODS: As part of a RC quality project, 10 hospitals in the Michigan Surgical Quality Collaborative retrospectively collected RC-specific data from 2007-2012. We assessed for SPS predictors using multivariable regression. Patients were categorized as "definitely SPS eligible" a priori if they did not have any of the following: poor sphincter control, stoma preference, sphincter involvement, tumor <6 cm from the anal verge (an intentionally conservative cut-off) or metastatic disease. We compared hospital performance with and without clinical data using Spearman's correlations. RESULTS: In total, 349 patients underwent surgery for RC in 10 hospitals (5/10 high volume and 6/10 major teaching). Of those, 74% had SPS (range by hospital 50%-91%). On multivariable analysis, only pre-op radiation, tumor location, hospital teaching status and hospital ID were independent predictors of SPS, but not age, sex, BMI, AJCC stage, ASA class, or hospital CRC surgery volume. Analyses of the "definitely eligible" patients revealed an overall SPS rate of 88% (65-100%). Hospital SPS rankings using crude versus clinicallyadjusted SPS rates proved to be highly correlated (Spearman's $\rho = 0.9$). Tumor locations suggest differing selection criteria for SPS in different hospitals (Table). CONCLUSIONS: Rates of SPS vary by hospital, even after correcting for definitely eligible patients by detailed chart review. These data suggest missed opportunities for SPS, and refute the general hypothesis that hospital variation in SPS rates in previous studies is due to unmeasured case-mix differences.

Sphincter Preserving Surgery Rates by Hospital an							and T	umor Lo	cation	
Tumor Location (cm)	Α	B	C	D	E	F	G	H	I	J
<6	20%	23%	25%	50%	53%	57%	57%	69%	75%	78%
6-12	67%	62%	78%	100%	95%	84%	91%	83%	100%	100%
>12	75%	80%	50%	N/A	100%	93%	100%	N/A	100%	100%

Quality of Colorectal Cancer Care Among Veterans: A 10-year Retrospective Cohort R.A. Snyder,^{1*} R. Mainthia,¹ R.K. Patel,¹ R.S. Dittus,² C.L. Roumie,² 1. Department of Surgery, Vanderbilt University, Nashville, TN; 2. Veterans Health Administration-Tennessee Valley Healthcare System Geriatric Research, Education and Clinical Center; Nashville, TN.

Introduction: Nearly 5,000 patients within the Veterans Health Administration (VHA) are diagnosed with colorectal cancer (CRC) annually. However, the linkage between performance on CRC practice guidelines and subsequent patient outcomes is unclear. The purpose of this study was to evaluate the quality of non-metastatic CRC care in a large VHA system by assessing adherence to National Comprehensive Cancer Network (NCCN) practice guidelines and to determine if receipt of these metrics was associated with improvement in 5-year all-cause mortality. Methods: We performed a retrospective cohort study of all patients who underwent resection for non-metastatic CRC at VHA Tennessee Valley Healthcare System (TVHS) between 2001 and 2010. We defined "excellent" care as receipt of at least 75% of eligible NCCN metrics. We also examined time to treatment and used a Cox proportional hazard model to investigate the relationship between excellent care and all-cause mortality. Results: A total of 331 patients underwent resection for CRC within the study period. Only 47% of CRC patients received excellent care and 9% received 100% of eligible metrics. The median time from diagnosis to definitive treatment was 22 days (IQR 12, 41) and 37 days (IQR 24, 56) among colon and rectal cancer patients, respectively. The likelihood of receiving excellent care increased significantly over the study period (2009 vs. 2002, OR 2.93 [1.51-5.67]). However, there was no association between receipt of excellent care and 5-year all-cause mortality (HR 0.85 [95% CI 0.53-1.36]). Conclusions: Although patients treated at TVHS received timely care overall consistent with those in other health systems, less than half of all CRC patients received "excellent care," or care consistent with at least 75% of eligible NCCN metrics. The degree of variation in care found in this closed healthcare system suggests that systematic coordination of care is a critical component of quality improvement in CRC. Although receipt of excellent care was not associated with all-cause mortality in this setting, further research will be necessary to identify specific quality metrics likely to influence patient outcomes in CRC.

65

Distance Travelled is an Unrecognized Bias for Short and Longterm Outcomes following Complex Gastrointestinal Cancer Surgery: Results from the National Cancer Database N. Wasif,* B.A. Pockaj, R.J. Gray, D.A. Etzioni. Surgery, Mayo Clinic Arizona, Phoenix. AZ.

Introduction Patients travelling significant distances to participate in phase II oncology trials have better outcomes compared to those enrolling locally. We postulate a similar unrecognized effect exists for patients travelling to undergo complex surgery for gastrointestinal cancers. Methods Patients undergoing surgery for gastrointestinal cancer between 2003-2006 were extracted from the National Cancer Database. The distance in miles between the patient's residence and the treating facility was calculated using zip code centroids. The association between distance traveled and overall survival was explored using adjusted Cox regression analyses by controlling for age, race, sex, insurance status, income, education, chemotherapy, radiation therapy, pathological stage, and hospital type. Results Our population consisted of 28,394 patients with the diagnosis of esophageal (8,953; 32%), liver (7,990; 28%) and pancreatic cancer (11,451; 40%). Patients traveling >50 miles were in the fourth quartile of distance travelled overall and had a lower 30 day mortality for esophageal (3.3% vs. 4.7%, p = 0.011), pancreatic (3.4% vs. 4.7%, p= 0.009) and liver (4.6% vs. 5.7%, p= 0.057) surgery compared to those traveling <50 miles. Travel >50 miles was associated with lower 3 year mortality for patients with liver (38% vs. 44%, p <0.001) and esophageal cancer (43% vs. 52%, p<0.001); Figure 1. The proportion of patients traveling >50 miles was 6% for community hospitals, 13% for community cancer centers, 30% for academic hospitals and 60% for other cancer centers (p <0.001). Adjusted hazard ratios for mortality were significantly lower for patients traveling >50 miles vs. <50 miles for liver [0.85 (95% CI 0.78-0.92)], esophageal [0.90 (95% CI 0.84-0.98)], and pancreatic cancer [0.92 (95% CI 0.87- 0.97)]. Conclusions In patients with upper gastrointestinal cancers, traveling >50 miles for treatment is associated with improved outcomes. Our findings have implications for regionalization of upper gastrointestinal cancer care as distance bias is an unrecognized confounder for survival outcomes.



66

Readmission after Pancreaticoduodenectomy: The Influence of the Volume Effect beyond Mortality J.M. Sutton,* G.C. Wilson, K. Wima, D.J. Hanseman, I.M. Paquette, S.A. Shah, J.J. Sussman, S.A. Ahmad, D.E. Abbott. *Cincinnati Clinical Research Group in Surgery, University of Cincinnati College of Medicine, Cincinnati, OH.*

INTRODUCTION: As increased focus is placed on quality of care in surgery, readmission is an increasingly important metric by which hospital quality is measured. For complex pancreatic surgery, we hypothesized that increased pancreaticoduodenectomy (PD) volume may mitigate readmission rates. METHODS: The University Healthsystems Consortium database was queried for all patients undergoing PD (ICD9 code 52.7) from 2009 through 2011. Hospitals were stratified into quintiles based on number of cases performed annually. Univariate and multivariate logistic regression analyses were performed to identify factors associated with readmission. RESULTS: The 30-day readmission rate for the 9805 patients undergoing PD was 18.7%. Stratified by volume, hospitals performing the highest two quintiles of PDs annually ($n \ge 56$ cases) had a significantly lower readmission rate than those hospitals performing the lowest quintile ($n \le 23$ cases) (16.7 and 18.0% vs. 20.9%, p<0.05). On univariate analysis, readmitted patients tended to have higher severity of illness (p<0.01), experienced post-operative complications (p<0.01), and longer index admission (10 vs. 9 days, p<0.01). Age and insurance status had no significant association with readmission. Multivariate analysis demonstrated that higher severity of illness (OR 1.36, 95% CI 1.04-1.77, p=0.02), discharge to rehab (OR 1.41, 95% CI 1.19-1.66, p<0.001), and surgery at the lowest volume hospitals (OR 1.28, 95% CI 1.08-1.51, p=0.004) were factors independently associated with readmission. CONCLUSIONS: These data, for the first time, demonstrate that lower hospital volume is a significant risk factor for readmission after pancreaticoduodenectomy. To minimize the excess resource utilization that accompanies readmission, patients undergoing complex oncologic pancreatic surgery should be directed to hospital systems most experienced in caring for this patient population.

67

Modifications to the AJCC 7th Edition are Essential to Improve Staging Accuracy in Gastric Cancer G.B. Deutsch,* V. O'Connor, M. Sim, J. Lee, A. Bilchik. Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA.

Introduction Although D2 lymphadenectomy improves staging accuracy and survival in gastric cancer, lymph node (LN) number is not included in the most recent (sixth and seventh) editions of the American Joint Commission on Cancer (AJCC) staging system. We hypothesized that addition of LN number would improve the accuracy of AJCC-based staging for gastric cancer. Methods The Surveillance, Epidemiology and End Results (SEER) Program database was queried to identify all patients who underwent gastrectomy for

gastric cancer between 1988 and 2010. Gastric cancer was staged according to both the sixth and seventh editions of the AJCC. We excluded any patient with an unspecified number of resected LNs. Multivariate regression analyses were performed with and without LN number (< versus > 15 nodes), and subsequently compared with the likelihood ratio test. Results A total of 27,464 patients met the inclusion criteria. Five-year DSS and OS were 67.1% and 53.0%, respectively, for 9,515 patients with \geq 15 nodes examined, versus 61.4% and 40.3%, respectively, for 17,949 patients with <15 sampled nodes (p<0.0001). The number of patients per substage (IA-IIIC) was significantly different (p<0.0001) when staging was based on sixth versus seventh AJCC editions. The latter demonstrated a superior fit (p<0.0001). The addition of LN number to the seventh AJCC edition improved prediction of DSS and OS (p<0.0001), independent of stage (see table). Conclusions While the newest AJCC staging system is more accurate than the prior version, it does not account for all potential causes of discrepancy in survival. Because the addition of LN number (< versus > 15 nodes) to the AJCC staging system more accurately predicts five-year DSS and OS in patients with gastric cancer, current surgical guidelines (D2 gastrectomy) should be incorporated in the AJCC-based staging of gastric cancer.

5-Year Disease-Sp		Specific Survival	5-Year Overall Survival			
Stage	AJCC 7 < 15 nodes	AJCC 7 ≥ 15 nodes	AJCC 7 < 15 nodes	AJCC 7 ≥ 15 nodes		
0	88.6%	97.2%	73.1%	80.2%		
IA*	85.3%	91.2%	65.2%	79.4%		
IB*	71.4%	80.8%	50.2%	65.7%		
IIA*	57.8%	74.2%	39.3%	61.4%		
IIB*	41.7%	58.1%	26.9%	45.3%		
IIIA*	29.3%	44.3%	17.7%	31.4%		
IIIB*	21.2%	29.2%	13.2%	21.0%		
IIIC*	14.0%	22.8%	7 7%	15 3%		

*The addition of the 15-LN evaluation significantly influenced diseasespecific and overall survival (≤ 0.0003).

68

Conditional Survival-based "Abbreviated" Cancer Surveillance for Sentinel Node-negative Stage IB Melanoma M. Kukar,^{1*} R. May,¹ E. Cho,¹ M. Lichtenthal,¹ A. Groman,² V. Francescutti,¹ J. Skitzki,¹ J. Kane.¹ I. Roswell Park Cancer Institute, Surgical Oncology, Buffalo, NY; 2. Roswell Park Cancer Institute, Biostatistics, Buffalo, NY.

Introduction: Melanoma cancer surveillance recommendations are vague and often stage independent. Given the high prognostic value of sentinel lymph node biopsy (SLNB), we instituted an "abbreviated" cancer surveillance for SLNB negative stage IB melanoma due to a calculated low risk for recurrence/metastases. Beginning in 2006, cancer surveillance for this subset changed to Q6 months for 5 years and then 1 annual visit (total of 6 years as conditional survival after that point is 98-99%). Most patients underwent routine surveillance chest x-ray (CXR), which was discontinued in 2008. Methods: Retrospective review of SLNB negative stage IB melanoma patients at a single institution from 2006-2008 to provide an actual follow-up ≥ 5 vears. Patient/tumor characteristics, recurrence, and follow-up data were analyzed. Results: 87 patients were identified. Median age was 55.4 years (range 31-85 years) and 50.6% were male. Median Breslow thickness was 1.1 mm (range 0.5-2.0mm) and 1.1% ulcerated. 89% were Clark Level IV. Primary tumor site: 49% extremities, 39% trunk, and 12% head/neck. Median followup was 55 months (range 1-80 months). The 5 year recurrence-free, disease specific, and overall survival were 87%, 94%, and 85%, respectively. Surveillance CXR was "suspicious" in 2.5% patients; further workup was negative for pulmonary metastases. During follow-up, 10 patients had "concerning" symptoms/physical findings where the subsequent workup was negative for metastases. There were only 3 true melanoma recurrences (at 20, 26, and 44 months); all were widespread hematogenous metastases (including brain). All were symptomatic and presented at an unscheduled visit between follow-ups. Conclusions: SLNB negative stage IB melanoma has a survival similar to clinical stage IA. There were very few recurrences; all were widespread, symptomatic, and would not have been "salvaged" by routine studies. Conditional survival based "abbreviated" cancer surveillance with no routine ancillary studies is an evidence-based, cost effective strategy for this low risk population.

69

Open versus Minimally Invasive Management of Gastric Gastrointestinal Stromal Tumors: An International Multi-institutional Analysis of Short- and Long-term Outcomes D. Bischof,¹ Y. Kim,¹ D.G. Blazer III,⁷ S.K. Maithel,² T.C. Gamblin,³ T. Bauer,⁴ P. Karanicolas,⁵ C. Law,⁵ F. Quereshy,⁶ T. Pawlik.^{1*} *1. Surgery, Johns Hopkins Hospital, Baltimore, MD; 2. Winship Cancer Institute, Emory University, Atlanta, GA; 3. Medical College of Wisconsin, Milwaukee, WI; 4. University of Virginia, Charlottesville, VA; 5. Odette Cancer Centre, Sunnybrook Health Sciences Centre; University of Toronto, Toronto, ON, Canada; 6. Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada; 7. Duke University Medical Center, Durham, NC.*

Background: Overall surgical experience with minimally invasive surgery (MIS) has increased, however, published reports on MIS resection of gastrointestinal stromal tumors (GIST) are currently limited to small, single institution experiences. Methods: 397 patients who underwent resection of a gastric GIST between 1998 and 2012 were identified from an international, multi-center database. The impact of the MIS approach on recurrence and survival was analyzed by the use of propensity-score matching by comparing clinicopathologic factors between patients who underwent open vs MIS resection. Results: Median patient age was 65 years and 50% were female. Median tumor size was 4.3cm (IQR 3.0-7.6cm). A minority of patients received neoadjuvant therapy (6%). Overall, 186 (47%) patients had a MIS approach: laparoscopic (89%), laparoscopic hand assist (4%), combined laparo-endoscopic (3%) and robotic (4%). There were 19 (10%) conversions to open; the most common reasons for conversion were tumor more extensive than anticipated (26%) and unclear anatomy (16%). Patients who underwent MIS resections had smaller tumors (MIS: 3.5cm vs open: 5.8cm; p<0.01). MIS resections were associated with minimal blood loss (MIS: 50cc vs open: 225cc) and shorter operative time (MIS: 160min vs open: 201min) (both p<0.01). There was no difference in tumor rupture rates (MIS: 1% vs open: 1%; p=0.81). An R0 resection was achieved in the majority of patients (MIS: 98% vs open: 92%; p=0.07). MIS patients had a lower incidence of grade 3 or 4 complications (MIS: 3% vs open: 10%; p=0.01) and a shorter length of stay (MIS: 3d vs open: 8d; p<0.01). After propensity score matching for age, sex, tumor size, mitotic rate and tumor rupture, there was no difference in risk of recurrence or overall survival for the MIS treated group vs. the open group (HR 0.65 & HR 0.76, respectively; both p>0.05). Conclusions: An MIS approach for gastric GIST is associated with a low incidence of complications and a comparable R0 resection rate. The long-term oncological outcome following MIS is excellent and thus MIS approach should be considered preferable.

70

A Decade of Experience with Postoperative Imatinib Mesylate for Gastrointestinal Stromal Tumors: Does the Duration of Treatment Increase Long-term Survival? V. O'Connor,¹* G.B. Deutsch,¹ E.A. Arena,¹ J. Albright,¹ R.P. O'Connor,² M. Sim,¹ A. Bilchik,¹ J.D. Ellenhorn.¹ I. John Wayne Cancer Institute, Santa Monica, CA; 2. U.S. Army Reserve, Los Angeles, CA.

Introduction: Few population-based studies have addressed the impact of adjuvant imatinib mesylate (IM), particularly postoperative IM, on the survival of patients with gastrointestinal stromal tumor (GIST). Patient selection, usage patterns, and optimal duration of IM therapy also are not well-defined. Methods: We used Surveillance Epidemiology and End Results (SEER)-Medicare data to identify all patients who underwent surgical resection of GIST from 2001 to 2010. Demographic and tumor characteristics were reviewed to compare patients according to whether or not they received postoperative adjuvant IM. Multivariate analysis evaluated the impact of treatment duration on overall survival (OS) up to 8 years. Results: Of 1,043 GIST patients, 244 received postoperative adjuvant IM (54.5% males, 45.5% females; White 71%, Black 18%, other 11%; T1 4%, T2 14%, T3 32%, T4 40%, unknown-10%; primary site stomach 53%, small intestine 36%, colon/rectum 6%, other 5%). During the decade under study, IM use progressively increased from 18.6% to 31.4% (p=0.0001). The IM group was more likely to be >65 years old (p < 0.000) and to present with T4 tumors (p <0.0002). Overall survival at 1-, 3-, and 5years without IM was 86%, 71%, and 59%, respectively, as compared with 95%, 85%, and 67%, respectively, with IM. Adjusted for age, marital status, T stage, grade, and primary site, the survival benefits of IM remained significant 8 years after surgery. Each six-month increase in duration of adjuvant IM reduced relative risk of death (p <0001). Each day of therapy was associated with a 0.2% decreased risk of death as compared with no IM (HR=0.998, P<0.0001). Conclusions: This study, the first direct analysis of adjuvant IM for GIST based on national data, indicates that postoperative IM is more prevalent but still underutilized, not only in terms of the number of patients but also in terms of the duration of treatment. Duration of treatment significantly influences survival of patients receiving adjuvant IM after surgical resection of GIST.

Multivariate regression analysis of incremental increases in imatinib mesylate (IM) therapy duration associated with relative risk of death

Duration of IM Therapy	P	HR	95% CI
1 - 6 months	0.9272	0.982	0.662 - 1.456
6 - 12 months	0.0119	0.404	0.200 - 0.819
12 - 18 months	0.0080	0.384	0.189 - 0.779
> 18 months	< 0.0001	0.268	0.160 - 0.448

Abbreviation: HR, hazard ratio.

71

Comparison of Perioperative Radiation Therapy and Surgery versus Surgery Alone in 204 Patients with Primary Retroperitoneal Sarcoma: A Two-institution Study K.J. Kelly,^{1*} S.S. Yoon,¹ D. Kuk,¹ L. Qin,¹ K. Dukleska,¹ K.K. Chang,² Y. Chen,² M.F. Brennan,¹ T.F. Delaney,² S. Singer.¹ *1. Memorial Sloan-Kettering Cancer Center*, *New York, NY; 2. Massachusetts General Hospital, Boston, MA.*

Background: The role of radiation therapy (RT) for retroperitoneal and pelvic sarcomas (RPS) is controversial. We examined the association of perioperative, advanced-modality RT with outcomes in patients (pts) with primary RPS. Methods: Prospective databases were reviewed to compare primary RPS pts treated at two institutions between 2003 and 2011. Clinicopathologic variables were analyzed with endpoints of local recurrence-free survival (LRFS) and disease-specific survival (DSS). Results: At one institution 172 pts were treated with surgery alone, while at the other 32 pts were treated with surgery and perioperative proton beam (PBRT) or intensity-modulated RT (IMRT) ± intra-operative electron-beam RT (IOERT). RT was delivered pre-operatively for 30 pts and post- for 2 pts. External beam RT was delivered by IMRT, PBRT. or both at a median dose of 50 Gy. IOERT was given to 15 pts at a median dose of 10Gy. The groups were similar in age, gender, tumor grade, tumor size, and margin status (p = NS). The RT group had a lower percentage of retroperitoneal versus pelvic tumors and leiomyo/liposarcoma versus other histologies (p < 0.050). Morbidity was higher in the RT group (41% vs 17%; p = 0.004). After a median follow-up of 39 months, 5-year predicted LRFS was 91% (95% CI, 79-100%) in the RT group and 65% (57-74%) in the surgery only group (p=0.024). On multivariate analysis, RT was significantly associated with better LRFS (p = 0.026) (Table). Other independent predictors of LRFS were high grade and non-leiomyosarcoma histology. Five-year predicted DSS was 93% (95% CI, 82-100%) in the RT group and 84% (78-91%) in the surgery only group (p = 0.261). The only independent predictor of DSS was age. Conclusions: The addition of advanced-modality RT to surgery for primary RPS was associated with improved LRFS, but this did not translate into a statistically significant improvement in DSS. The association between RT and LRFS in this study may have been due to selection bias inherent in the retrospective design, but this treatment strategy is currently under investigation in a randomized, prospective trial.

Anavsis of Factors Potentiall	Associated with	Local Recurrence
-------------------------------	-----------------	------------------

	Univar	iate Analys	is	Multiva	ariate Analy	ysis
Variable	Hazard Ratio	95% C.I.	p Value	Hazar Ratio	95% C.I.	p Value
Age	1.00	0.98 - 1.02	0.994	-	-	-
Gender	1.55	0.89 - 2.68	0.121	-	-	-
RT (Yes vs No)	0.38	0.14 - 1.06	0.024	0.26	0.08 - 0.86	0.026
Grade (High vs Low)	2.42	1.22 - 4.82	0.012	3.78	1.86 - 7.70	< 0.001
Site (Pelvis vs RP)	0.37	0.12 - 1.18	0.094	0.81	0.23 - 2.78	0.735
Size (>/= 18 cm vs < 18 cm)	2.71	1.50 - 4.90	0.001	1.62	0.85 - 3.09	0.147
Margin Status (R1/2 vs R0)	2.01	1.17 - 3.46	0.012	1.70	1.96 - 3.00	0.068
Histology						
Fibroblastic vs Liposarcoma	0.99	0.14 - 7.25	0.995		-	-
Leiomyosarcoma vs Liposarcoma	0.22	0.09 - 0.56	0.002	0.19	0.06 - 0.58	0.004
MPNST vs Liposarcoma	0.35	0.33 - 5.61	0.679		-	-
MFH / Sarcoma NOS vs Liposarcoma	0.76	0.11 - 5.52	0.786	-		-

C.I.: Confidence Interval; RP: Retroperitoneum; MPNST: Malignant peripheral nerve sheath tumor; MFH: Malignant fibrous histiocytoma; NOS: Not otherwise specified

72

Post-relapse Outcome of Retroperitoneal Sarcoma (RPS) Treated by Primary Extended Resection: Tumor Biology Trumps All A. Gronchi,^{1*} M. Allard,² R. Miceli,¹ D. Callegaro,¹ C. Le Pechoux,² M. Fiore,¹ C. Honor,² R. Sanfilippo,¹ S. Coppola,² S. Stacchiotti,¹ P. Terrier,² P. Casali,¹ A. Le Cesne,² C. Colombo,¹ S. Bonvalot.² *1. Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy; 2. Institut Gustave Roussy, Villejuif, France.*

Background: To explore the outcome after relapse in patients with RPS primarily treated by extended resection in two European referral centers. Methods: All consecutive patients, affected by primary RPS (Jan 2002-Dec 2011) were included. 5yr overall survival (OS) and crude cumulative incidence (CCI) of local recurrence (LR) and distant metastases (DM) were calculated as well as multivariate analyses. Post-relapse OS and prognostic factors were investigated from the time of LR. Results: 377 patients were identified. Median FU from the time of primary surgery was 44 months (IQ, 27-82). 5-yr OS was 64% (95% CI 0.588-0710). CCI of LR and DM were 23.6% (95% CI 18.9-29.4) and 21.9% (95% CI 17.6-27.3). Grading was a significant prognosticator for LR, DM and OS; size and quality of surgery (R0/R1 vs R2) for LR and OS, while histotype for DM alone, although a clear difference in CCI of LR among histotypes was observed (DD lipo 40.4%, WD lipo 18.6%, leiomyosarcoma 5.8% and SFT 4.2% at 5 yr). Moreover, a worse trend in DM according to the grading was observed in DD lipo (5 ys 9.5% in DD lipo G2 vs 44% DD lipo G3). 76 patients developed LR (first event). Median post-relapse FU was 27 months (IQ, 10-58). 21 patients (27%) underwent a second surgical resection (complete in 18), while 55 (73%) did not (19 multifocal, 17 inoperable, 3 controlateral, 2 early relapse, 14 other causes). Median post-relapse OS was 17 months (IQ,7-31). WD lipo histology (3ys post-relapse OS WD lipo 63% vs 10% DD lipo vs 40% other) and a long previous disease-free interval (DFI) predicted post-relapse OS (3 ys post-relapse OS 6% vs 56%), while surgical resection did not, although a trend in favor of surgically resected patients was observed (5vs post-relapse OS 20.8% vs 26.7%)(Fig. 1).Conclusions: LR after primary extended resection in RPS is associated with poor outcome. Once quality of initial surgery is optimized, resectability of recurrence is low and biology of disease dominates the outcome (LR and DM). DFI and histological subtype (and grading especially for DD lipo, G2 vs G3) are key factors to personalize initial adjuvant treatment and post-relapse strategies.



73

MicroRNA-26a Regulates Growth and Autophagy and Imparts Sensitivity to AMPK Activation in Liposarcoma D.W. Jones,* Y. Mazzu, A.Y. Lee, T. Okada, A.M. Crago, S. Singer. *Memorial Sloan*

Y. Mazzu, A.Y. Lee, I. Okada, A.M. Crago, S. Singer. Memorial Sloan Kettering Cancer Center, New York, NY.

INTRODUCTION: In well-differentiated and dedifferentiated liposarcoma (WDLS/DDLS), microRNA-26a (miR-26a) is amplified and overexpressed by >3 fold. We sought to characterize the role of miR-26a overexpression in WDLS/DDLS. METHODS: Primary WDLS/DDLS samples were assessed by CGH. For phenotype tests, oligonucleotide mimics and inhibitors of miR-26a were transfected into adipocytic stem cells (ASCs) or WDLS/DDLS cell lines. Lipid droplets were quantified after Oil red O staining. Direct miR-26a targeting was tested by dual luciferase reporter assays. RESULTS: For 60 patients with primary WDLS/DDLS, greater amplification of miR-26a correlated with worse recurrence-free survival after adjusting for histologic subtype (HR=2.2; p=0.03). Transfection of 3 miR-26a overexpressing WDLS/DDLS cell lines with miR-26a inhibitor caused a 21-24% decrease in proliferation (p<0.01), while transfection of ASCs with miR-26a mimic caused a 33% increase (p<0.001). miR-26a mimic in ASCs also decreased adipocytic differentiation as measured by differentiation marker mRNA (CEBPA, PPARG, FABP4) and by number of lipid droplets (p<0.001). mRNA expression profiles of cells transfected with miR-26a mimic or miR-26a inhibitor showed significant dysregulation of STRADB and ULK1; reporter assays confirmed these as direct miR- 26a targets. STRADB and ULK1 are positive regulators of autophagy. All 5 WDLS/DDLS cell lines overexpressed p62 protein compared to ASCs suggesting an autophagy defect. Treatment of WDLS cells with miR-26a inhibitor decreased p62 levels and increased LC3 turnover, restoring autophagy. As cells with impaired autophagy are sensitive to metabolic stress imparted by AMPK activation, we assessed sensitivity to phenformin, an AMPK activator. Phenformin caused greater growth inhibition in a WDLS and a DDLS cell line than in ASCs (Figure, p<0.001) and induced substantial apoptosis (Figure; p<0.001). CONCLUSIONS: miR-26a amplification occurs early in liposarcomagenesis and serves to drive proliferation, inhibit autophagy, and block adipocyte differentiation. Small-molecule inducers of autophagy such as phenformin and miR-26a inhibitors may have therapeutic utility in WDLS/DDLS.



Effects of phenformin on liposarcoma cells.

A, Phenformin IC50 in ASCs and two liposarcoma cell lines. IC50 were calculated from the inhibition of cell proliferation following 48h treatment in 6 replicate experiments. *p<0.001 compared to ASCs. B, Apoptosis induced by phenformin. Triplicate cell cultures were treated with 2mM phenformin, and apoptosis was assessed 24 hours later. Total Annexin V staining cells are shown. **p<0.001 compared to ASCs treated with phenformin.

74

Fat-induced Retroperitoneal Soft Tissue Sarcoma (STS) Tumorigenesis N. Lubezky, S. Lowenstein, J. Klausner, G. Lahat.* *Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.*

Background: Research regarding the association between obesity and different types of cancer is relatively scarce. To date, there is no comprehensive data concerning possible local effects of fat on cancer cells. Since retroperitoneal STS and retroperitoneal fat cells are typically co-localized we sought to evaluate such potential interplay utilizing STS as a model. Methods: A xenograft nude mouse model was used to evaluate the in vivo effects of human retroperitoneal on STS cell line growth. Tissue explants were prepared from retroperitoneal fat. Explants conditioned media (CM) was utilized for various in vitro experiments evaluating STS and endothelial cell lines growth, survival, migration and invasion as well as for mass spectometry in order to identify secreted pro-tumorigenic factors. Results: Initially, we evaluated the clinical association between retroperitoneal fat (RF) and retroperitoneal STS patients outcomes demonstrating that high RF content is an independent predictor of local recurrence and mortality. Next, we used a xenograft mouse model in-vivo experiment to show an increased STS tumor growth rate of SK-LMS1 cells co-localized with human RF as compared to cancer cells only (p<0.05). Utilizing an in vitro model, we found that RF conditioned medium (CM) increased STS cellular growth and reduced apoptosis induced by doxorubicin. In addition, RF enhanced STS cells migration and invasion. Since endothelial cells are of mesenchymal origin we expected similar results; our data depict that RF CM significantly enhanced endothelial cells tube formation, suggesting its role as a pro- angiogenic factor in STS tumor microenvironment. Next, using a robust proteomic approach we identified various potential molecules secreted into the RF CM associated with various pro-tumorigenic biological processes. Conclusion: Our data imply that RF may directly interact with STS cells by secreting specific adipokines into the tumor microenvironment, thus enhancing STS tumor cell proliferation and invasiveness. Fat- induced STS molecular deregulations should be studied to identify new potential prognostic and therapeutic targets.

Prognostic Value of CTNNB1-gene Mutation in Primary Extraabdominal Aggressive Fibromatosis D. Van Broekhoven,¹* C. Verhoef,¹ D. Grünhagen,¹ J. Van Gorp,² T. Van Dalen.² 1. Erasmus Medical Centre, Rotterdam, Netherlands; 2. Diakonessenhuis, Utrecht, Netherlands.

Introduction: Aggressive fibromatosis (desmoid) is a tumor with varying biological behavior. Tumor localization appears to influence the risk of recurrence, while the effect of margin width and radiotherapy are disputed. Genetic tumor characteristics may be predictive of recurrence, hence the prognostic value of 3 desmoid-specific mutations on the CTNNB1-gene was evaluated. Methods: A multi-institutional retrospective cohort study was done in patients with primary extra-abdominal aggressive fibromatosis who underwent surgical treatment. The original pathology specimens were retrieved and analyzed addressing the presence of the T41A-, S45F- and 45P- mutations on the CTNNB1-gene. The risk of recurrence was analyzed using the Kaplan-Meier method and log-rank test. Results: Eighty-seven patients were analyzed. During a median follow-up of 40 months, 10 recurrences were detected (5-year recurrence rate was 15.7%). A localization in the abdominal wall was associated with a low risk of recurrence (0/29; P=0.031). Other clinicopathological variables, the result of surgery (R0 vs R1) and addition of radiotherapy were not associated with recurrence. The pathology specimens of these patients were analyzed. A desmoid-specific CTNNB1-mutation was found in 69 patients, and the majority of these patients had a T41A-mutation (n=45). CTNNB1-mutations were associated with the risk of recurrence. The presence of S45F resulted in a 5-year cumulative risk of recurrence of 41% vs 7.1% when this mutation was absent (P<0.001). No recurrences were observed, when CTNNB1-mutations were absent. Abdominal wall desmoids were associated with a lower frequency of S45F-mutations and a higher frequency of T41A-mutations (P=0.041 Chi-square). Conclusion: CTNNB1-mutation appear to impact the risk of recurrence following surgical treatment for primary extra-abdominal aggressive fibromatosis. In particular S45F-mutation increases the risk of recurrence.



Figure 1. Kaplan–Meier analysis showing the association between the CTNNB1-mutation and local recurrence following surgery for extraabdominal desmoid-type fibromatosis. P =0.002 (log rank test)

76

Radiation-associated Unclassified Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes compared to Sporadic Lesions S. Dineen, ¹* G. Al Sannaa,² C. May,¹ R. Feig,¹ D. Ingram,² W. Wang,² V. Ravi,³ K.K. Hunt,¹ J.N. Cormier,¹ B. Feig,¹ A. Lazar,² K. Torres.¹ *1. Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX; 2. Department of Pathology, MD Anderson Cancer Center, Houston, TX; 3. Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX.*

Introduction: Radiation therapy is increasingly included in the management of patients with various cancers. However, adverse events can be associated with such treatment, including the development of a radiation-associated soft tissue sarcoma (RA-STS). Unclassified pleomorphic sarcoma (UPS), previously termed malignant fibrous histiocytoma, is the most common histologic type of RA-STS. In general, RA-STS are frequently associated with poor prognosis compared with sporadic STS. The purpose of this study was to specifically compare clinical outcomes of patients with RA-UPS and sporadic UPS and to evaluate the expression of potential molecular targets. Methods: A comprehensive search of our institutional tumor registry was used to identify patients with UPS (n = 1481). A tissue microarray was developed for subsequent analysis including both RA-UPS (n = 54) and sporadic UPS (n = 170) cases. Clinicopathologic variables were assessed for impact on overall (OS) and disease-specific survival (DSS). Results: There was no significant gender or age or tumor size difference in RAS vs sporadic cohort. There was a higher percentage of trunk location in the RAS group. Median survival for the entire UPS cohort included in the TMA was 58 ± 18.2 months. The 5-year OS for RA-UPS was 30.6 ± 7.1% versus 54.5 ± 4.3% for sporadic-UPS patients (Figure 1, p < 0.01). DSS was also significantly lower in patients with RA-UPS $(64.9 \pm 4.3\%$ sporadic, $39.6\% \pm 7.4$ RA-UPS; p < 0.01). There was no differential pattern of expression for molecular markers between the RA-UPS and sporadic cohorts. However, high expression levels of pAKT (HR 1.72; CI 1.08 -2.57; p = 0.02), high levels of p53 (HR 2.02; CI 1.26-3.25; p = 0.015), absence of PTEN (HR 13.15; CI 3.80 - 45.53; p < 0.0001), and weak expression of pS6RP (HR 1.87; CI 1.21 - 2.88; p = 0.005) correlated with worse patient outcomes. Conclusions: We found that survival outcomes are significantly worse following a diagnosis of RA-UPS compared with sporadic UPS. Future investigation of molecular markers such as pAKT, PTEN, p53 and pS6RP should be examined prospectively to determine prognostic value.





77 Leiomyosarcoma: One Disease or Distinct Biologic Entities based on Site of Origin? D.J. Worhunsky,* M. Gupta, S. Gholami, K.N. Ganjoo, M. Van de Rijn, B.C. Visser, J.A. Norton, G. Poultsides. *Stanford University Medical Center, Stanford, CA.*

INTRODUCTION: Leiomyosarcoma (LMS) is a common form of sarcoma, known to originate from almost any site of smooth muscle in the body, including the retroperitoneum, uterus, extremity, and trunk. It is unclear whether these tumors share a unified behavior or represent discrete biologic entities based on their site of origin. We sought to compare clinicopathologic features. survival, and recurrence patterns following surgical resection of LMS stratified by site of origin. METHODS: Patients with LMS undergoing resection at a single academic institution were retrospectively reviewed. Patients with GIST were excluded. Clinicopathologic variables were compared using Fisher's exact and ANOVA tests. Survival was calculated using the Kaplan Meier method and compared using the log rank test. Factors associated with survival were evaluated using Cox regression analysis. RESULTS: From 1983 to 2011, 138 patients underwent surgical resection for LMS at our institution, 95 (69%) at initial presentation, 22 (16%) for persistent disease shortly after incomplete resection at an outside institution, and 21 (15%) for recurrent disease following resection at an outside institution (after a median interval of 35 months). Clinical, pathologic, and outcome comparisons are shown (Table). Retroperitoneal and uterine LMS were significantly larger, of higher grade, and associated with synchronous metastases. However, disease-specific survival, recurrence-free survival, and patterns of failure were not significantly different among the 4 anatomic sites. Similarly, in multivariate analysis, synchronous metastases (HR 3.3, P=0.001), but not site of origin, size or grade were associated with reduced DSS. A significant number of recurrences and diseaserelated deaths were noted beyond the 5-year mark following resection. CON-CLUSION: Although larger and of higher grade, retroperitoneal and uterine LMS share similar survival outcomes and recurrence patterns with their trunk and extremity counterparts. LMS of various anatomic sites do not appear to represent biologically distinct disease processes. The presence of synchronous metastatic disease remains the most important prognostic factor for LMS.

	All	Retroperitoneum	Uterine	Extremity	Trunk a	P
Male Gender	39 (28%)	14 (29%)	0 (0%)	18 (69%)	7 (32%)	< 0.001
Age, years, median (range)	54 (17-90)	56 (34-90)	50 (34-85)	59 (17-87)	54 (27-84)	0.24
Primary resection at our institution	95 (69%)	38 (78%)	26 (63%)	14 (54%)	17 (78%)	0.02
Size, cm, median (range)	7.5 (0.5-45.0)	11.0 (2.0-40.0)	9.0 (1.6-45.0)	3.2 (0.6-27.5)	6.5 (0.5-17.0)	<0.001
Deep to investing superficial fascia	124 (90%)	49 (100%)	41 (100%)	16 (64%)	18 (82%)	<0.001
High grade (G3)	77 (56%)	29 (59%)	29 (71%)	8 (31%)	11 (50%)	0.01
Negative margin b	102 (77%)	31 (65%)	31 (79%)	23 (92%)	17 (81%)	0.058
Synchronous metastases	33 (24%)	15 (31%)	13 (32%)	5 (19%)	0 (0%)	0.007
5-yr DSS ^c	64%	72%	58%	94%	75%	0.21
10-yr DSS ^c	36%	30%	39%	67%	63%	0.31
5-yr RFS ^c	43%	26%	36%	70%	54%	
10-yr RFS ^c	21%	6%	11%	42%	43%	0.14
Recurrence pattern ^d (Distant/Local/Both)	34/14/7	12/5/3	11/6/2	5/2/0	6/1/2	0.89
Most common site of distant	Lung	Lung (73%)	Lung	Lung	Lung	0.13

^a Includes chest wall, groin and thoracic sites

^b Margin status was not available for 5 patients

^c Disease-specific survival (DSS) and Recurrence-free survival (RFS) were calculated on the cohort of patients without synchronous metastatic disease (n=105)

^d Recurrence was noted in 55 patients after complete resection

78

Cytoreduction with Intraoperative and Dwell Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: An Intention to Treat Series M.D. Kluger, ¹* J. Leinwand, ¹A. Greene, ¹ P.N. Tauh² I. Chabot ¹ I. Surgary, New York Preshutarian Hospital

R.N. Taub,² J. Chabot.¹ I. Surgery, New York-Presbyterian Hospital-College of Physicians and Surgeons, New York, NY; 2. Department of Medicine, New York-Presbyterian Hospital-College of Physicians and Surgeons, New York, NY.

Introduction: Overall and progression-free survival for patients with malignant peritoneal mesothelioma (MPM) is maximized with operative cytoreduction and intraperitoneal chemotherapy. We report the largest single-institution series of MPM patients treated accordingly, to identify realistic expectations for patients with MPM. Methods: All patients with MPM who initiated our protocol from 5/1995 to 1/2012 were prospectively studied. Under this protocol, initial cytoreductive operation (with heated intraperitoneal chemotherapy (HIPEC) after completion of Phase I/II trials) and intraperitoneal catheter placement followed by outpatient dwell chemotherapy is followed by a second-look operative cytoreduction with HIPEC. The primary endpoint was overall survival and the secondary endpoint was Clavien surgical complications. Cox regression analyses were used to identify independent predictors of overall survival. Follow-up was through 1/2013. Results: 169 patients underwent initial cytoreductive surgery. Second-look surgery was performed in 110. 86 patients received HIPEC during initial cytoreduction, and 97 received HIPEC during second-look surgery. 22 patients were treated for both chest and abdominal disease. The median overall survival was 30 months; median follow-up was 49 months. One-, three- and five-year overall survival rates were 64%, 45% and 37%, respectively. After initial cytoreduction, post-operative morbidity occurred in 38% and mortality in 4% of patients. After second-look surgery, post-operative morbidity occurred in 30%; mortality occurred in 2%. Independent predictors of overall survival were female sex, age <70 years, clinical trial subject, resectable disease (attempted debulking after exploration at first surgery), HIPEC at initial cytoreduction, and no bulky residual disease (tumor nodules >0.5cm in depth or plaques >0.5cm in diameter) after initial cytoreduction. Conclusion: On an intention-to-treat basis, this protocol results in durable survival with acceptable operative morbidity and mortality for MPM patients as demonstrated in the largest single-center series to date.

Independent Predictors of Overall Survival in 169 Patients Treated for MPM on an Intention to Treat Basis

Covariate	Hazard Ratio	95% CI	P-value
Female sex	0.54	0.35 - 0.82	0.004
Age < 70 years	0.52	0.31 - 0.87	0.013
Epithelioid histology	0.63	0.37 - 1.06	0.081
Resectable disease*	0.26	0.13 - 0.55	< 0.001
Non-bulky residual disease**	0.32	0.19 - 0.53	< 0.001
HIPEC	0.40	0.23 - 0.71	0.002
Clinical trial subject	0.56	0.24 0.02	0.026

 * Initial cytoreduction could be performed (i.e. not an open-close operation)

** Tumor nodules >0.5 cm in depth or plaques >0.5 cm in diameter after initial cytoreduction

79

Induction Therapy does not Influence Perioperative Outcomes in Patients with Locally Advanced Esophageal Adenocarcinoma: A Propensity Matched Analysis K.S. Nason,^{1*} J.D. Luketich,¹ H. Zahoor,¹ N.A. Christie,¹ R.M. Levy,¹ D. Winger,¹ M.K. Gibson,² B. Weksler.¹ I. Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; 2. Case Medical Center, Cleveland, OH.

BACKGROUND: Multimodality therapy is commonly used in the treatment of esophageal adenocarcinoma but induction therapy may increase risk for postoperative adverse events. Our study aimed to determine whether induction therapy significantly impacted postoperative outcome in patients undergoing minimally invasive esophagectomy for esophageal adenocarcinoma using propensity-matched analysis. METHOD: From our prospectively maintained database we abstracted demographics, comorbidities, tumor, treatment and outcome variables for patients with stage II or higher esophageal adenocarcinoma (n=375) undergoing IT-MIE (n=197, 53%) or MIE (n=178, 47%) between 1997 and 2009. Using multiple pre-treatment predictor variables 81 propensitymatched pairs (n=162 patients) were identified. Postoperative outcomes were compared overall and within the propensity-matched groups. Significance was defined as p<0.05. RESULTS: Overall, the unmatched groups differed in age (median 63 for IT-MIE and 67 for MIE alone; p<0.001), symptoms at presentation (e.g. dysphagia and gastrointestinal bleeding; 96% versus 86%, p<0.001), clinical disease stage (Stage III 48% versus 43 % and Stage IV 16% versus 3%; p<0.001). Comorbid diseases were more common in the MIE alone group with 40% having an age-adjusted Charleston comorbidity index score of >3 compared to 30% of the IT-MIE group (p=0.043). Following propensity matching, there were no significant differences between the 81 match pairs. There were no significant differences in the rate of major postoperative adverse outcome between IT-MIE and MIE (21% and 30%, respectively; p=0.278) or any postoperative adverse event (31% and 40%, respectively; p=0.324) after propensity matching. Pulmonary complications were the most common adverse outcomes. (Table 2) Postoperative length of stay was 8 days for both groups. Combined in-hospital and 30 day mortality was 2% for IT-MIE and 3% for MIE alone (p=0.318). CONCLUSIONS: In a propensity-matched analysis, induction therapy had minimal effects on postoperative outcomes in patients undergoing minimally invasive esophagectomy for esophageal adenocarcinoma

Table 1

Outcome	IT-MIE	MIE	р
Major morbidity	17 (21%)	24 (30%)	0.278
Pneumonia	7 (9%)	12 (15%)	0.329
Reintubation	10 (13%)	15 (19%)	0.385
Tracheostomy	7 (9%)	12 (15%)	0.329
ARDS	2 (2%)	1 (1%)	1.000
Chylothorax	2 (2%)	0 (0%)	0.497
Anastomotic leak	6(7%)	5 (5%)	0.746
Gastric tube necrosis	1 (1%)	2 (2%)	1.000
Intraoperative blood transfusion	22 (33%)	16 (22%)	0.185
30 days readmission	13 (16%)	19 (23%)	0.324
Reoperation in hospital/30 days	13 (16%)	11 (14%)	0.825
Length of stay (days)	8	8	0.825
30 days/in hospital mortality	3 (2%)	6 (3%)	0.318

Relative Delta SUV of Less than 45% on F 18- FDG Positron Emission Tomography (PET) Predicts Residual Disease in Patients with Locally Advanced Esophageal Adenocarcinoma Undergoing Neoadjuvant Chemoradiotherapy M. Kukar,^{1*} R.M. Alnaji,² F. Jabi,³ T.A. Platz,¹ K. Attwood,¹ K.S. May,⁵ K. Ben-David,⁴ K. Kanehira,⁶ J. Gannon,³ S.N. Hochwald.¹ I. Roswell Park Cancer Institute, Department of Surgical Oncology, Buffalo, NY; 2. University at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY; 3. Roswell Park Cancer Institute, Department of Nuclear Medicine, Buffalo, NY; 4. University of Florida, Department of Surgery, Gainesville, FL; 5. Roswell Park Cancer Institute, Department of Radiation Oncology, Buffalo, NY; 6. Roswell Park Cancer Institute, Department of Pathology, Buffalo, NY.

Introduction: Neoadjuvant chemoradiotherapy (NCR) is routinely used in the management of locally advanced esophageal adenocarcinoma (EA). Identifying patients with residual disease is critical, since surgery is potentially the only curative option in these patients. There is conflicting data regarding the PET characteristics, being able to predict pathologic response, following NCR in EA as existing studies include squamous histology, have had limited numbers and non-standardized PET imaging. Methods: Patient records were reviewed from a prospective collected database covering 2005-2012. Inclusion criteria included patients undergoing esophagectomy for locally advanced EA post NCR with two standardized PET studies at our institution (pre and post NCR) for review. Data collected included clinical, pathologic, imaging and treatment characteristics. Quantitative and qualitative PET data was collected including SUV measurements and pattern of uptake. PET studies and all pathology slides were re-reviewed by a single nuclear medicine physician (JG) and a single pathologist (KK) respectively, blinded to the clinical data. Results: 77 patients met the inclusion criteria. 22 patients (28.6%) had a pathologic complete response (pCR) versus 55 patients with residual disease (pRD). The two groups were similar in terms of age, gender, race, comorbid conditions, ECOG status, tumor grade, chemotherapy and radiation regimen and days between the 2 PET CTs. Mean pre SUV was higher in tumors with a pCR (14.45) vs. pRD (11.23, P=0.05). Delta SUV was significantly higher in those with a pCR vs pRD (10.25 vs. 6.61, p=0.03) as was relative Delta SUV (p=0.03). Utilizing the Youden's index, a relative delta SUV value of less than 45% was significantly associated with residual disease with a positive predictive value of 91.7% (73%-99%, p<0.05). Conclusions: To our knowledge, this is the largest series examining the role of PET characteristics in EA undergoing NCR and demonstrates that relative Delta SUV of less than 45% reliably predicts patients who have residual disease.

81

The Usefulness of Neoadjuvant Chemoradiation Therapy for Locally Advanced Esophageal Cancer with Multiple Lymph Nodes Metastasis H. Okumura,* Y. Uchikado, I. Omoto, Y. Kita, K. Sasaki, M. Matsumoto, T. Owaki, T. Arigami, Y. Uenosono, S. Ishigami, S. Natsugoe. Kagoshima University, Kagoshima, Japan.

Introduction The prognosis of esophageal cancer (EC) patients with multiple lymph nodes metastasis was quite poor. In this study, we examined the neoadjuvant chemoradiation therapy (CRT) effect on the EC patients with more than 4 lymph nodes metastasis and compared the outcome with the patients with less than 3 lymph nodes metastasis without CRT in order to explore the new treatment strategy for the locally advanced EC. Patients and methods The present study was prospective trial and involved consecutive 50 patients with T3-4 tumor without organ metastasis. Among them, 20 patients had more than 4 lymph nodes metastasis that underwent CRT plus operation (CRT group), and other 30 patients had less than 3 lymph nodes metastasis underwent only operation (Surgery group). Finally, clinical outcome of both groups was compared. CRT consisted of 5-fluorouracil plus cisplatin and 40 Gy of radiation. The histological criteria for the response of CRT were as follows: Grade 1: tumor is present in more than 1/3 of the whole lesion. Grade 2: tumor is present in less than 1/3 of the whole lesion. Grade 3: No viable tumor cells are observed. Results Among 50 patients surgical treatment was performed in 48 patients except for two patients with bone or liver metastasis in CRT group. According to histological effects of primary tumors, in CRT group, the number of patient with Grades 1, 2 and 3 was 8, 2 and 8, respectively. Eight patients became ypN0, therefore mean LN metastatic number was changed from 7 to 3 throughout CRT. There were 4 patients with relapse disease in CRT group,

and 8 patients in Surgery group. The 3-year survival rate was 71% in the CRT group and 72% in the Surgery group (P = 0.97). According to the histological effect in the CRT group, 3-year survival was 50% for Grade 1, 100% for Grade 2 and 80% for Grade 3 (P = 0.05). This prospective trial did not demonstrate a statistically significant survival difference between the CRT group and the Surgery group. Conclusion The neoadjuvant CRT was beneficial for the patients of locally advanced EC with more than 4 lymph nodes metastasis.

82

Resource Utilization in Esophagectomy: When Higher Costs are Associated with Worse Outcomes D.E. Abbott,* S.G. Gaitonde, D.J. Hanseman, K. Wima, J.M. Sutton, G. Wilson, J.J. Sussman, M. Edwards, S.A. Ahmad, S.A. Shah. Surgery, University of Cincinnati, Cincinnati, OH.

INTRODUCTION: Esophagectomy is a complex, morbid operation that requires significant devotion of resources. However, factors that influence the extent of cost and care for this high acuity intervention are unclear. We sought to determine which clinical variables contribute to increased resource utilization. METHODS: 6,737 patients undergoing total esophagectomy or esophagogastrectomy from 2009-2012 were identified from the University Healthsystems Consortium (UHC). A UHC specific severity of illness (SOI) index was used. Chi-square, generalized linear and logistic regression models were used to determine patient factors associated with resource utilization, including mortality, length of stay (LOS), readmission rate, cost and discharge disposition. RESULTS: Older age (>70 vs. <70 years old) and higher severity of illness (SOI) were significant predictors of increased use of health care resource. Older patients undergoing esophagectomy cost 7.4% more than younger patients (\$25,859 vs \$24,084, p<.001) and had a longer median LOS (11 vs 10 days, p<.001). Furthermore, older patients were more likely to be discharged with home health or to a rehabilitation/SNF locale (OR 1.5; 95% CI 1.3-1.7 and OR 4.9; 95% CI 4.1-5.7, respectively). Older patients were readmitted at the same rate as younger patients (17.7% vs. 17.4%, p=0.74) but had a significantly higher rate of perioperative mortality (OR 2.1; 95% CI 1.7-2.7). Similarly, patients with higher SOI cost 51% more (\$25,266 vs 17,399, p<.001), had longer median LOS (11 vs. 8 days, p<.001) and were discharged with home health or to rehabilitation/SNF at a higher rate (OR 1.8; 95% CI 1.6-2.1 and OR 5.9; 95% CI 4.2-8.3, respectively). Higher SOI patients, however, were more likely to be readmitted (17.9% vs 14.4%, p<.001) and suffer a postoperative death (OR 13.9; 95% CI 4.5-43.6). CONCLUSION: Older patients and those with a higher severity of illness utilize more resources, with higher perioperative mortality and readmission rates. As health care costs are increasingly scrutinized, future efforts should examine patient-center scenarios in which reduction of adverse outcomes can help lower health care utilization.

83

Impact of Inflammation-metaplasia-adenocarcinoma Sequence and Inflammatory Microenvironment in Esophageal Carcinogenesis using Surgical Rat Models T. Miyashita,^{1*} H. Tajima,¹ I. Makino,¹ H. Nakagawara,¹ H. Kitagawa,¹ F.A. Shah,² M.D. Duncan,² J.W. Harmon,² T. Ohta.¹ I. Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan; 2. Department of Surgery, Johns Hopkins University, Baltimore, MD.

The incidence of esophageal adenocarinoma continues to rise in the Western world. Prior studies have suggested that gastroduodenal content reflux from gastroesophageal reflux disease (GERD) induces the inflammation mediated progression from hyperplasia to metaplasia, and to adenocarcinoma. We proved inflammation-metaplasia-adenocarcinoma sequence with the use of an established surgical rat model without carcinogen. We also found that duodenal contents reflux plays an important role in the inflammation induced transformation of esophageal mucosa to adenocarcinoma than acid reflux in esophageal carcinogensis. Chronic inflammation has been demonstrated to correlate with tumor onset and progression. An inflammatory microenvironment ensues during tumor growth as a result of the secretion of inflammatory mediators (cytokines, chemokines, growth factors, reactive oxygen and nitrogen species, prostaglandins) by the tumor and/or stromal cells. Recently, we confirmed that macrophages (M1 phenotype macrophage) infiltrate the esophagus and pStat3 pathway activated in stromal cells and neighborhood epithelium at the early inflammatory stage of esophageal carcinogenesis. M2 phenotype macrophages infiltrate following infiltration of M1 macrophage and contribute to tumor

development. Thus the inflammatory microenvironment is formed. Furthermore, regulatory T cell (Treg) was induced by tumor or M2 phenotype macrophages relating to process of carcinogenesis(Figure). We introduces an esophagus carcinogenic process in clinically relevant surgical rat models.



84

Changing Patterns in Presentation and Therapy of Esophagogastric Junction Cancers in the U.S R.E. Schwarz,^{1*} D.D. Smith,² R. Nelson.² 1. IUH Goshen Center for Cancer Care, Goshen, IN; 2. City of Hope Cancer Center, Duarte, CA.

Background: Esophagogastric junction cancer (EGJC) has recently been included within the esophageal cancer (EC) AJCC TNM staging criteria. Trends in clinical presentation, therapeutic approach and outcomes are of interest. Methods: We identified EGJCs from the U.S. population SEER database and examined incidence, demographic, therapeutic and outcomes information. Siewert classification-related EGJC subtype-associated findings were also examined Results: EGIC age-adjusted incidence rates (x10e-5) have increased from 3.3 in 1973 to 7.5 in 2009. While the incidence rate for females has remained around 2, rates in males have increased from 6 to 13. Among 30,710 EGJC patients diagnosed between 1992 and 2009, potentially curative resection increased from 31% to 36% and radiation increased from 32% to 41% (p<0.0001). For resected EGJCs, significant trends over time include: increased total LN count (mean: 15.5 vs. 12.3), fewer positive LNs (3.1 vs. 4), smaller tumor size (29% vs. 36% >5 cm), lower T category (39% vs. 29% T1/2), lower N category (42% vs. 35% N0), lower stage group (29% vs. 38% stage 3/4), increased preoperative radiation (26% vs. 3%), decreased 90-day mortality (6.5 vs. 14.1%), longer overall survival (OS, median: 2.9 vs. 1.7 years) and longer disease-specific survival (median: 3.9 vs. 2.0 years) (all at p<0.0001). Multivariate predictors of OS include TNM categories, age, ethnicity, radiation, and total LN count (all at p<0.0001). There were significant differences in stage-for-stage OS between EC subtypes based on histology and primary tumor location, and in DSS between EGJC subtypes (Siewert I, II or III) as well. Conclusions: EGJC incidence rates, diagnosis and treatment have undergone significant changes within the U.S. population. The regional dissection extent remains an area of importance as it is associated with OS. Comparisons of various survival outcomes do not support using the same staging criteria for EGJC as for EC.

85

Surgical Outcomes of Patients with Locally Advanced Non-small Cell Lung Cancer E. Lushaj, W. Abi Jaoude, R. Macke, J. Maloney.* University of Wisconsin, Madison, WI.

Background: Controversy continues regarding the optimal therapy for stage IIIa non-small cell lung cancer (NSCLCa). Survival is improved in patients undergoing multimodality therapy that includes surgery. Surgery in locally advanced stages is presumed to have greater potential morbidity.

The goal of this study was to assess the impact of locally advanced disease on operative outcomes based on STS criteria. Methods: We retrospectively reviewed prospectively collected institutional STS data. 74 consecutive patients with stage IIIa NSCLCa were treated surgically between 08/2006 and 11/2012. The cohort was divided into patients having surgery as their initial intervention followed by adjuvant therapy, and patients having neoadjuvant therapy followed by surgery. Demographics, post-treatment survival, complications and survival rates were assessed. Results: Mean age at hosnital admission was 64 years. Video-Assisted Thoracoscopic Surgery (VATS) was performed in 17.5% (n=13) of patients. Seventy three percent (73%; n=54) of patients had surgery as the initial treatment. 27% (n=20) had neoadjuvant therapy prior to surgery. Length of hospital stay (LOS) of patients having neoadjuvant therapy was significantly higher (p=0.04; mean=5±3.4 days; median=5 days) compared to LOS of patients having only surgery (mean=3.7±3davs: median=3 davs). No difference was found in prolonged (>5 days) air leak (15% of patients having neoadjuvant therapy vs. 9.2% of patients having only surgery; p=0.46), reoperation rate (15% vs. 4% in neoadjuvant and surgery group respectively; p=0.11), pneumonia (0% of patients in each group) or UTI rates (5% vs. 1.8% in neoadjuvant and surgery group respectively; p=0.45). 30-day readmission rate was 9% (n=5) for surgery and 10% (n=2) for neoadjuvant groups (p=0.89). 30 day survival was 100% in both groups. Conclusions: Pulmonary resection as an initial therapy or following neoadjuvant radiation and chemotherapy is a safe for patients with stage IIIa NSCLCa. Though LOS was increased in the neoadjuvant group compared to initial surgical therapy, locally advanced disease does not confer increased risk of morbidity or mortality in our study population.

86

FDG PET/CT versus CT in Predicting Histopathological Response to Epidermal Growth Factor Receptor: Tyrosine-kinase Inhibitor (EGFR-TKI) Treatment in Resectable Non-small Cell Lung Cancer T. Aukema,^{1*} M. Van Gool,¹ E. Schaake,¹ I. Kappers,¹ H. Codrington,² R. Valdes Olmos,¹ J. Teertstra,¹ R. Van Pel,¹ S. Burgers,¹ H. Van Tinteren,¹ H. Klomp.¹ J. Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; 2. Haga Hospital, The Haque, Netherlands.

Introduction: The purpose of this study was to prospectively evaluate diagnostic computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography/CT (FDG-PET) for identification of histopathologic response to neoadjuvant erlotinib, an epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) in patients with resectable non-small cell lung cancer (NSCLC). Patients & Methods: This study was designed as an open-label phase II trial, performed in four hospitals in the Netherlands. Patients received preoperative erlotinib 150 mg once daily for 3 weeks. CT and FDG-PET/CT were performed at baseline and after 3 weeks of treatment. CT was assessed according to the RECIST criteria 1.1 and Hounsfield Units were measured. FDG-PET/CT, tumour FDG uptake and changes were measured by standardized uptake values (SUV). Patients were divided in three groups based on the histopathologic response according to percentage of necrosis (>90% [CpR]; 90%-50% [PpR]; <50%). Radiologic and metabolic responses were compared to the histopathological response. Results: Relative change in tumour diameter on CT was not significantly associated with histopathologic response. Relative change was similar in the three groups determined by histopathologic evaluation with means close to 0% (p=0.29). Relative change in Hounsfield Units on CT was inconsistent among the three groups (p=0.3715). Relative change in SUVmax on FDG-PET/CT showed significantly more SUVmax decrease in the histopathologic response group versus the no pathologic response group (p=0.0132). The ROC curve for FDG PET/CT was 0.69 (95% CI: 0.51-0.87) with optimal cutpoint at 28%. The ROC curve of CT was 0.53 (95% CI: 0.34-0.71) with optimal threshold of 35%. Conclusion: FDG-PET/CT has an advantage over CT as a predictive tool to identify histopathologic response after 3 weeks of EGFR TKI treatment in patients with resectable NSCLC.

87

Initial Experience of Thoracoscopic Evacuation and Tunneled Pleural Catheters for Palliation of Malignant Pleural Effusion J. Corona-Cruz, ¹* A. Herrera-Gomez, ¹ K.S. Martin-Tellez, ¹ E.O. Macedo-Perez, ² M. Blake-Cerda, ² E. Jimenez-Fuentes, ¹ H. Martinez-Said, ¹ E. Bargallo-Rocha, ¹ O.G. Arrieta-Rodriguez. ² 1. Surgical Oncology Department-Instituto Nacional de Cancerologia (INCan) Mexico, Mexico City, Mexico; 2. Thoracic Oncology Clinic-Instituto Nacional de Cancerologia (INCan) Mexico, Mexico, City, Mexico.

Introduction Malignant pleural effusion diminishes quality of life and requires multiple admissions and interventions. We review our experience with tunneled catheters and report our rates of palliative efficacy Methods Retrospective chart review of patients with malignant pleural effusion treated by a thoracoscopic evacuation and tunneled pleural catheter installation from January 2012 to June 2013. Palliation was considered successful when the patient required no additional effusion-directed drainage procedures Results We included 29 patients in the final analysis, 14 male (48.3%) and 15 female (51.7%). Mean age 53.9 years (range 20-78). Common primary cancer were lung (9 cases 31%), breast (7 cases 24.1%), ovarian (2 cases 6.9% and lymphoma (2 cases 6.9%), among others. In 24 patients (82.8%) there was a previous procedure for palliation of effusion (median 1.62, range 1-6). A trapped lung was identified preoperatively in 21 patients (72.4%). Average surgical time was 57.52 minutes (range 15-130), median blood loss was 52.76 milliliters (range 5-400). There were no trans-operative complications. Mean duration of postoperative chest tube was 2.59 days (range 0-8); mean postoperative stay was 4.55 days (range 1-25). There were no postoperative complications in 23 patients (86.3%), 3 patients developed an atelectasis (10.3%) and 1 patient (3.4%) a wound failure. There were 2 deaths (6.8%) during the first 30 days of postoperative follow-up, none directly related with the catheter (one pulmonary thromboembolic event and one hemorrhagic cerebral vascular event). After a median follow-up of 22 weeks (range 1-67) a total of 21 patients still alive (72.4%) with a median duration of tunneled catheter in situ of 29.14 days (range 2-93) Moreover, successful palliation was achieved in 28 patients (96.6%) Conclusions Despite the high variability on practice for palliation of malignant pleural effusion, in our study we found that thoracoscopic evacuation with the use of tunneled pleural catheters is a safe procedure, associated with a short hospital stay, a low rate of catheter-related complications and with a high rate of palliation

88

Experience with Primary and Metastatic Adenoid Cystic Carcinoma B. Sepesi,* W.L. Hofstetter, G.L. Walsh, D. Rice, R.J. Mehran, A. Vaporciyan, J. Roth, S.G. Swisher. *Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, TX.*

Adenoid cystic carcinoma (ACC) is a rare malignancy. Primary intrathoracic ACC arises in the tracheobronchial tree, whereas pulmonary metastases commonly develop from head and neck (H&N) ACC. The aim of this study was to evaluate outcomes of primary and metastatic ACC encountered on our thoracic surgery service. Departmental database was searched for ACC resections from 1999-2013. Fourteen patients with 1° tracheobronchial ACC and 24 patients with pulmonary metastases from H&N ACC were identified. Studied variables included type and completeness of resection, outcomes included overall survival (OS) and recurrence rate. Kaplan Meier method was used to estimate OS. Surgical resections in 14 patients (6 female, 8 male, median age 47 years) with 1° tracheobronchial ACC included: trachea (N=6), carina (N=3). carinal pneumonectomy (N=1), left pneumonectomy (N=3), and sleeve lobectomy (N=1). R0 resection was achieved in 50% (7/14) patients. Adjuvant radiation was used in 93% (N=13) patients. At median follow up 28 months, estimated 5-year survival was 88%, with 14% (2/14) distant recurrence rate. Pulmonary metastases from H&N ACC (N=24, 16 female, 8 male, median age 52 years) developed at median 73 months from primary diagnosis. Total of 73 wedge (median 2) resections was performed. The majority 62% (15/24) of metastases presented bilaterally; R0 resection was achieved in 92% of primary metastases (22/24). Six patients underwent 2nd and two 3rd metastasectomy. Recurrence of metastases occurred in 70% (17/24) of patients; 58% (14/24) was pulmonary at median 16.4 months. The median OS after 1st metastasectomy was 100 months. Estimated OS from the time of 1st metastasectomy was 88% at 5-years, 35% at 10 years, and 17% at 15 years. Despite the high rate of R1 resection, good outcomes with low recurrence rate can be achieved in 1° tracheobronchial ACC. On the contrary, despite the initial R0 resection

of metastatic ACC many patients experience pulmonary metastases recurrence. Metastasectomy may potentially benefit patients with prolonged initial disease free interval. Due to the relatively indolent nature of ACC patients experience prolonged survival even with metastatic disease.

89

Utility of the Proximal Margin Frozen Section for Resection of Gastric Adenocarcinoma: A 7-institution Study of the U.S. Gastric Cancer Collaborative M.H. Squires, ¹* D.A. Kooby,¹ T. Pawlik,⁷ S.M. Weber,³ G.A. Poultsides,² C.R. Schmidt,⁴ K.I. Votanopoulos,⁶ R.C. Fields,⁵ A. Ejaz,⁷ A.W. Acher,³ D.J. Worhunsky,² N. Saunders,⁴ D.S. Swords,⁶ L.X. Jin,⁵ C.S. Cho,³ M. Bloomston,⁴ E. Winslow,³ M.C. Russell,¹ K. Cardona,¹ C.A. Staley,¹ S.K. Maithel.¹ *1. Division of Surgical Oncology, WInship Cancer Institute, Emory University, Atlanta, GA; 2. Stanford University Medical Center, Palo Alto, CA; 3. University of Wisconsin School of Medicine and Public Health, Madison, WI; 4. The Ohio State University Comprehensive Cancer Center – The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH; 5. Washington University in St. Louis, St. Louis, MO; 6. Wake Forest University, Winston Salem, NC; 7. The Johns Hopkins University, School of Medicine, Baltimore, MD.*

Background: The proximal gastric margin dictates the extent of resection for gastric adenocarcinoma (GAC). The value of achieving negative margins by additional gastric resection after a positive proximal margin frozen section (FS) is unknown. Methods: The U.S. Gastric Cancer Collaborative includes all patients who underwent resection of GAC at 7 institutions by oncologic surgeons from 2000-2012. Intraoperative proximal margin FS data were classified as R0 or R1 based on final permanent section (PS); positive distal margins were excluded. The primary aim was to evaluate the impact on local recurrence (LR) of converting a positive proximal margin FS to an R0 final margin by additional resection. Secondary endpoints were recurrence-free (RFS) and overall survival (OS). Results: Of 860 patients, 520 had a proximal margin FS; 67 were positive. Of these 67, 48 were converted to R0 on PS by additional resection. R0 proximal margin was achieved in 447 patients (86%), R1 in 25 (5%), and R1 converted to R0 in 48 (9%). Median follow-up was 28 months. Although LR was decreased in the converted R1 to R0 group compared to the R1 group (10% vs 32%, p=0.01), when accounting for other pathologic variables on multivariate (MV) analysis, R1 to R0 conversion was not associated with decreased LR. Median RFS was similar between the R1 to R0 and R1 cohort (37 vs 31 months; p=0.6) compared to 110 months for the R0 group. Median OS was similar between the R1 to R0 conversion and R1 groups (36 vs 26 months; p=0.14) compared to 50 months for the R0 group. On MV analysis, increasing T-stage and positive lymph nodes were associated with worse OS; R1 to R0 conversion of the proximal margin was not associated with improved OS (p=0.5; Table). Conclusion: Conversion of a positive intraoperative proximal margin frozen section during gastric cancer resection does not decrease local recurrence or improve recurrence-free or overall survival. This may guide decisions regarding the extent of resection.

	Multivariate	Regression	Analysi	s for	Overall	Surviva
--	--------------	------------	---------	-------	---------	---------

Variable	HR	95% CI	p-value
Proximal Tumor	0.9	0.6-1.3	0.6
T-stage	1.4	1.2-1.6	< 0.001
Poor Grade	1.2	0.8-1.8	0.3
Signet Ring	1.2	0.8-1.6	0.4
LN Positive	1.5	1.03-2.1	0.04
Final Proximal Margin R0 R1 R1-R0 Conversion	Ref 1.7 1.3	0.9-2.9 0.6-2.9	0.09 0.5
Tumor Size	1.03	0.99-1.1	0.2

90

Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers D. Park,* C. Yoon, N. Thomas, G.Y. Ku, Y.Y. Janjigian, D.P. Kelsen, D.H. Ilson, K.A. Goodman, L.H. Tang, V.E. Strong, D.G. Coit, S.S. Yoon. *Memorial Sloan-Kettering Cancer Center, New York, NY.*

Introduction: Circulating angiogenic and growth factors in patients with gastric and gastroesophageal junction (GEJ) cancers may promote tumor progression and metastasis and may also represent targets for therapy. Methods: Serum levels of ligands from four targetable pathways - vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF2), epidermal growth factor (EGF), hepatocyte growth factor (HGF) - were measured before surgery, and levels were correlated to clinicopathologic characteristics and outcomes. Results: For 147 patients who underwent potentially curative resection for gastric and GEJ adenocarcinoma, median age was 67, 59% of patients were male, and 75% were Caucasian. Tumor location was lower in 35%, middle in 24%, upper in 19%, GEJ in 19%, and diffuse in 3%. VEGF-A levels were higher in patients with R1 resection than R0 resection (p=.037). High EGF level were associated with poorly-differentiated tumors (p=0.02). High FGF2 levels were found in patients with Lauren diffuse type tumors (p=.017) and tumors with 7 or more metastatic nodes (N3) (p<.042). High HGF levels were correlated with advanced stage tumors (p=.012). At a median follow-up of 35 months, 46 patients (31%) had died. High VEGF and HGF levels were associated with decreased overall survival (p=0.009 and 0.005, respectively). As shown in Figure 1, an adjusted total value (ATV) of all factors was better than any single factor in stratifying patients into good and poor prognosis groups (5- year overall survival 84.1% vs. 53.9%, p=0.005). By multivariate analysis, serum VEGF-A and ATV were significant independent prognostic factors (along with T and N status) for overall survival (p=.028 and p=.013, respectively). Conclusions: In patients undergoing resection for gastric and GEJ cancer, high levels of angiogenic and growth factors are associated with unfavorable tumor characteristics and poorer overall survival. Thus levels of these factors can help delineate tumor biology, stratify prognosis, and possibly direct targeted therapies.



91

Clinical Significance and HER2 Expression of Circulating Tumor Cells in Patients with Gastric Cancer Y. Uenosono,* T. Arigami, S. Yanagita, D. Matsushita, N. Haraguchi, T. Hagihara, T. Kozono, S. Ishigami, S. Natsugoe. *Kagoshima University, Kagoshima, Japan*.

Introduction Our hypothesis is that circulating tumor cells (CTCs) in patients with gastric cancer are associated with the prognosis and the recurrence. In this study, we evaluated CTCs in gastric cancer and clarified the clinical impact of CTCs. Furthermore, primary tumors and CTCs were confirmed the HER2 expression. Methods A total of 265 consecutive patients with gastric cancer were enrolled. Fourteen patients were excluded in analysis because 12 patients had another cancer and 2 patients refused the treatment. Two hundred fifty one patients were divided into two groups. One hundred forty eight patients with gastrectomy were included in Resection Group, and 103 patients without gastrectomy were in Non-resectable Group. Peripheral blood samples were collected before gastrectomy or chemotherapy. The CellSearch system was used for the isolation and enumeration of CTCs. Clinical samples of 36 patients with un-resectable gastric cancer were examined the expression of HER2 in primary tumor and CTCs. Results CTCs were detected in 16 patients (10.8 %) of Resection Group and 62 patients (60.2 %) of Non-resectable Group. The overall survival rate of all patients was significantly lower in patients with than without CTCs (p<0.0001). In Resection Group, relapse-free and overall survival in patients with CTC was significantly lower than patients without CTC
(p< 0.0001). It is worth mentioning that expression of CTC was an independent factor for determining overall survival of gastric cancer in multivariate analysis (p=0.024). In Non-resectable Group, overall survival rate was significantly lower in patients with than without CTCs (p=0.0044). Twenty percent of all patients were pathological HER2 positive. CTCs were found in 25 patients, and HER2 positive expression on CTCs was found in 10 patients. Conclusion The evaluation of CTCs in peripheral blood may be a useful tool for predicting tumor progression, prognosis, and the effect of chemotherapy in patients with gastric cancer. Her2 expression of CTCs may be extended the adaptation of Trastuzumab for gastric cancer.

CellSearch evaluation of HER2/neu expression in



92

Neoadjuvant FOLFIRINOX Combined with Aggressive Surgical Resection Allows Potentially Curative Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer M. Bloomston,* M. Blazer, J. Onesti, C.R. Schmidt, P. Muscarella, T. Bekaii-Saab. Surgical Oncology, Ohio State University Wexner Medical Center, Columbus, OH.

Background:Since its first report to improve survival in metastatic pancreatic cancer, we have used neoadjuvant FOLFIRINOX for borderline resectable (BR) and locally advanced (LA) pancreas cancer with planned major vascular resection. Herein we report our early experience with this approach. Methods: Non-metastatic pancreatic cancers not meeting strict NCCN guidelines for resectable disease were treated with 2 months of modified FOLFIRI-NOX. If tolerance and response were favorable, mFOLFIRINOX was continued until maximum response followed by chemoradiation for those still BR or LA. Surgery was offered if complete resection was feasible +/- arterial or venous resection. Response rates, resection rates, and outcomes were followed. Kaplan-Meier PFS curves were compared by log rank analysis based on resection status. Results: Since January 2011, 43 patients (18 BR and 25 LA) have been treated (Table). BR tumors were more commonly in the head of the pancreas compared to LA (89% vs 36%, p<0.001). Patients received an average of 4.9 cycles of mFOLFIRINOX and 56% received chemoradiation. Ultimately 67% were explored and 49% were resected. Failure to resect was due to metastases in 4, LA in 11, and medical/toxicity in 3. One patient was lost to followup and 3 are yet to be restaged. Major vascular resection was required in 19% (venous 1, arterial 3) and negative margins achieved in 90% of those resected. There were no postoperative deaths. Final pathology showed nodal metastases in less than half with complete pathologic responses in 2. Early follow-up shows median PFS 18.4 months in those resected vs 9.2 months for not resected (p<0.05). Median OS has not been reached in either group. Conclusion: Neoadjuvant mFOLFIRINOX is a promising and effective treatment regimen for nonmetastatic yet not clearly resectable pancreatic cancer. The modified regimen was associated with acceptable tolerance and led to a high resection rate and downstaging. Even in those with locally advanced unresectable cancer, potentially curative resection was achieved in some with aggressive surgery after neoadjuvant mFOLFIRINOX.

	Total (N=43)	BR (N=18)	LA (N=25)
Mean age	62.3	62.2	62.6
Location (Head)	25 (58%)	16 (89%)	9 (36%)
FOLFIRINOX cycles Mean (range)	4.9 (1-14)	4.4 (1-8)	5.3 (1-14)
Chemoradiation	24 (56%)	8 (44%)	16 (64%)
Explored	29 (67%)	15 (83%)	14 (56%)
Resected	21 (49%)	11 (61%)	10 (40%)
Vascular resection	4/21 (19%)	1/11 (9%)	3/10 (30%)
Node positive	9/21 (43%)	5/11 (45%)	4/10 (40%)
R0 resection	19/21 (90%)	9/11 (82%)	10/10 (100%)

93

The Impact of Post-operative Complications on the Administration of Adjuvant Therapy following Pancreaticoduodenectomy for Adenocarcinoma M. Weiss,* W. Wu, J. He, J. Cameron, K. Soares, N. Ahuja, M. Makary, J. Herman, L. Zheng, D. Laheru, M. Choti, T. Pawlik, C. Wolfgang. *Surgery, Johns Hopkins Hospital, Baltimore, MD.*

Background: The relationship of post-operative complications and administration of adjuvant chemoradiation therapy following pancreaticoduodenectomy (PD) for adenocarcinoma is poorly defined. Methods: A retrospective review of all patients undergoing PD at our institution between 1995 and 2010 was performed. Clinicopathological data including Clavien-Dindo complication grade, time to adjuvant therapy (TTA), and survival was analyzed. Results: 1144 patients underwent PD for adenocarcinoma between 1995 and 2010. The overall complication rate was 49.1% and clinically significant complications (≥3b) occurred in 4.2%. 621 patients (54.3%) received adjuvant chemoradiation therapy. The median TTA was 60 days. Neither the presence (p=0.98) nor grade of complication (p=0.430) delayed TTA. On multivariate analysis, only age >68 (p<0.001) and length of stay >9 days (p=0.002) correlated with no adjuvant therapy. Patients with post-operative complications more frequently received single modality adjuvant therapy (31.4%) rather than combined chemoradiation (17.1%, p<0.001). Patients without a complication had a longer median survival compared to patients with complications (19.5 vs 16.1 months, p=0.001). Patients without complications who received adjuvant chemoradiation had longer survival than patients with complications who received no adjuvant (22.4 vs 10.7 months, p<0.001). Multivariate analysis demonstrated that complications (HR 1.19, p=0.013) and adjuvant chemoradiation (HR 0.67, p<0.001) are related to survival. Conclusion: Complications and no chemoradiation therapy are common following PD for adenocarcinoma. Post-operative complications do not delay TTA but reduce the likelihood of multimodality adjuvant therapy. Identifying patients at increased risk for complications and those unlikely to receive adjuvant chemoradiation warrants further investigation, as they may benefit from a neoadjuvant approach.



Defining the Learning Curve for Team-based Laparoscopic Pancreaticoduodenectomy P.J. Speicher,* D.P. Nussbaum, R.R. White,

B.M. Clary, T.N. Pappas, D.S. Tyler, A. Perez. Duke University Medical Center, Durham, NC.

Introduction: The purpose of this study was to define the learning curve for laparoscopic pancreaticoduodenectomy (LPD) using paired surgical teams consisting of an advanced laparoscopic and advanced oncologic surgeon. Methods: All patients undergoing pancreaticoduodenectomy (PD) without vein resection at a single institution were retrospectively analyzed. LPD was first introduced as a hybrid procedure, with the resection performed laparoscopically followed by open reconstruction. After 18 months, a transition was made to total laparoscopic pancreaticoduodenectomy (TLPD). All procedures were performed by a paired team of a surgical oncologist and a fellowship-trained minimally invasive surgeon. Five surgeons participated in this pilot program. Cases were compared with Fisher's exact test, Kruskal-Wallis ANOVA, and linear regression. Results: Between March 2010 and June 2013, 140 PDs were performed, of which 56 (40%) were attempted laparoscopically. The first 31 cases were undertaken as planned hybrid procedures; however, seven of these cases (23%) required premature conversion to open pancreaticoduodenectomy (OPD) prior to completion of the resection. Following these 23 hybrid procedures, 25 TLPDs were performed. None required conversion to OPD. For the first 10 LPDs, mean operative time was 480 minutes (vs. 417 in pre-LPD era, p=.018). Following these initial procedures, there was a significant reduction in operative time (67 min, p=0.01) (Figure). After 50 LPDs, operative times and EBL were consistently lower than those for OPD. Complication rates were similar across 10-patient cohorts. In addition to improvements in EBL and operative time, LPD was associated with increased node retrieval (14.5 vs. 9, p=.008) and shorter length of stay (8.5 vs. 12 days, p=0.04). There were no significant differences in margin status, type C leak, surgical site infection, reoperation, or readmission. Conclusions: In building a LPD program, the initial 10 cases appear to represent the biggest hurdle. For an experienced teaching center using a staged and team-based approach, LPD appears to offer meaningful reductions in operative time, blood loss, and hospital length of stay within 50 cases



Operative times for patients undergoing laparoscopic pancreatoduodenectomy shown in successive 10-patient cohorts, stratified by learning curve.

95

A 13 Gene Expression Signature Predicts Survival of Patients with Pancreatic Cancer and Identifies New Genes of Interest

T. Newhook,^{1*} J.M. Lindberg,¹ S.J. Adair,¹ W. Xin,² E. Blais,³ J.K. Lee,² J.A. Papin,³ J. Parsons,⁴ T. Bauer.¹ I. University of Virginia, Department of Surgery, Charlottesville, VA; 2. University of Virginia, Department of Public Health Science, Charlottesville, VA; 3. University of Virginia, Department of Biomedical Engineering, Charlottesville, VA; 4. University of Virginia, Department of Microbiology, Immunology, and Cancer Biology, Charlottesville, VA.

Background: Pancreatic cancer patients at all stages of disease are currently offered systemic chemotherapy that can greatly impact quality of life. Currently, prognostication is based upon a crude clinical staging system. Thus, there is a need for a prognostic test for pancreatic cancer that can help physicians and patients make treatment decisions that can greatly affect outcome and quality of life. Methods: Pancreatic cancers from 15 patients (AJCC stage I-IV) were harvested and grown orthotopically in mice. Gene expression profiling was performed on these 15 early-passage tumors and we identified a 13-gene signature that correlated with patient survival. This 13-gene signature was then externally validated on 102 pancreatic cancer patients. Results: Patients with a high risk score had a significantly higher risk of death compared to patients with low risk score (HR 2.33, [95% CI: 1.38-3.95], p=0.002; Fig. 1a) When the 13-gene score was combined with lymph node status the risk score further discriminated survival time (p<0.001, Fig. 1b). Patients with a high risk gene signature score had poor survival independent of nodal status, however nodal status increased the predictability for survival in patients with a low risk gene signature score (low-risk N1 vs. low-risk N0: HR=1.9, [95% CI=0.95 - 3.77], p=0.07; Fig. 1b). While AJCC stage correlated with patient survival (p=0.03), the 13-gene score was superior at predicting survival, making this a clinically useful tool. Of the 13 genes comprising the predictive model, 4 have previously been shown to be important in pancreatic cancer (ELAV1/HuR, MDM2, MS4A3, TGFA), another 4 are unreported in pancreatic cancer, but reported in other cancers, and 5 have not previously been reported in any cancer. Conclusions: We have identified a thirteen-gene signature that predicts survival for patients with pancreatic cancer and could prove useful for physicians and patients in making treatment decisions. This risk score should be evaluated prospectively in future clinical trials. Current investigation of the new genes identified in our model may lead to novel targets for therapy.



96

Modeling Pancreatic Tumor Behavior: Differences in Gene Expression, Surface Receptor Activity, and Drug Response between Patient-derived Orthotopic Xenografts and Cell Lines J. Lindberg,* T. Newhook, D.M. Walters, S.J. Adair, E. Blais, J.A. Papin, J. Parsons, T. Bauer. University of Virginia, Charlottesville, VA.

Objectives: Established pancreatic ductal adenocarcinoma (PDAC) cell lines are used extensively in cancer research. We hypothesized that orthotopic patient-derived xenograft (PDX) tumors would more closely model patient PDAC tumor genetic behavior than established cell lines. We sought to compare the gene expression profiles (GEP), receptor tyrosine kinase activity (RTK), and response to drug therapy of PDAC cell lines and PDX tumors. Methods: Affymetrix GeneChip arrays were used to generate GEPs from normal pancreatic tissue (n=18), human PDAC tissue (n=51), PDX tumors (n=12), established PDAC cell lines (MPanc96, BxPC3, L3.6p1, Panc-1), and all NCI 60 cell lines, which were compared using hierarchical clustering analysis. RTK profiles from PDX cell line and tumor lysates were generated with R&D systems RTK arrays. Response to drug therapy with anti-EGFR (panitumumab) and anti-HER2 (trastuzumab) agents was assessed using CyQuant proliferation assays and sequential volumetric MRI. Results: Clustering analysis demonstrated differences in genome-wide gene expression patterns. Xenografts clustered most similarly to patient tumor and normal pancreatic tissue, while 3 of 4 established PDAC cell lines were most similar to non-pancreatic NCI 60 cells. PDX tumors and cell lines exhibited differences in baseline activation of surface receptors with Insulin-R, IGFR-1, and c-Met receptors often active

in culture but not tumor lysates. Combination anti-EGFR/anti-HER2 therapy failed to inhibit cell proliferation *in vitro*, however, *in vivo* this combination produced an 88% reduction in PDX tumor growth rate relative to control treatment in our most responsive xenograft. **Conclusions:** High-passage, established PDAC cell lines should be used with caution in preclinical studies as their GEPs are dissimilar to human PDAC tumors. Discordant baseline pRTK profiles reflect mircoenvironmental differences between PDX tumpact cell lines that impact drug response. Preclinical studies of agents that impact cell-microenvironment interactions should be conducted using orthotopic PDX models.



Figure 1 A: Dendrogram demonstrating the hierarchical clustering of a representative sample of gene expression profiles (GEP) from normal pancreas, PDX tumors, established PDAC cell lines and NCI 60 cell lines where samples with similar GEPs are clustered in closer proximity on the dendrogram. B: Heat map depicting the relative phosphorylation of RTKs from 3 PDX tumors, 3 PDX cell lines, and 4 established cell lines determined by RXD systems PRTK array. Red boxes indicate phosphorylation 3x background, green boxes = 2-3x background, blue boxes 1-2x background, and white boxes = - 1x background. C: Left panel line graft demonstrates the change in cell number of PDX 738 cells exposed to increasing concentrations of panitmumab trastuzumab for table to the cells after a 5-day CyOuant profileration assay. The right panel line graft depicts the relative change in tumor volume over time of orthotopic PDX 738 tumors exposed to control or drug treatment with panitmumab (200µ, intraperitoneal injection, twice weekly) and then panitmumab + trastuzumab (200µ, intraperitoneal injection, twice weekly) and then panitmumab + trastuzumab (200µ, intraperitoneal injection, twice weekly) and then panitmumab + trastuzumab (200µ), intraperitoneal injection, twice weekly) and then panitmumab + trastuzumab (200µ), intraperitoneal line than the set the set of volumetric MRI.

97

CCR2 Blockade Enhances Anti-tumor Immune Responses in Patients with Pancreatic Cancer D. Sanford,* B. Belt, R. Panni, T. Nywening, A. Wang-Gillam, P. Goedegebuure, D. Linehan. Surgery, Washington University, St. Louis, MO.

Introduction: Pancreatic ductal adenocarcinoma(PDAC) is characterized by a uniquely dense stroma where macrophages(MAC) are predominant. These protumor MAC suppress anti-tumor immunity as well as promote angiogenesis, chemoresistance, tumor invasion, and metastasis. Inflammatory monocytes(IM; CCR2+) are produced and stored in the bone marrow(BM), and depend on CCL2 for mobilization from the BM to both the primary tumor and premetastatic sites where these cells become protumor MAC. We have previously shown that IM recruitment from the BM depends on CCL2 production by PDAC, peripheral blood(PB) monocyte count predicts survival in PDAC patients, and CCR2 inhibition(CCR2i) decreases tumor growth and metastasis in murine PDAC models. We hypothesize that CCR2i will enhance antitumor immunity and chemotherapeutic responses in patients with borderline resectable and locally advanced PDAC (LAPDAC). Methods: We are testing a novel CCR2i(PF-04136309) in combination with FOLFIRINOX(FX) in patients with LAPDAC as part of a phase 1B/2 clinical trial(NCT#01413022). Patients are treated with either FX alone(n=6) or FX in combination with CCR2i(FX&CCR2i) (n=6+32[Phase 2 expansion cohort]). Presented here are the results of the Phase1b correlative studies on evaluable patients from the FX(n=5) and FX&CCR2i groups(n=5). PB, BM, tumor biopsies, and CT scans were taken pre and post treatment. Flow cytometry and qRT-PCR were performed on the blood, bone marrow, and tumors of patients. Results: The addition of CCR2i to FX prevented the recruitment of IM from the BM to the PB of PDAC patients. This was characterized by increased IM in the BM(Fig A) and decreased IM in the PB(Fig B) of patients treated with FX&CCR2i compared to FX alone. Patients treated with FX&CCR2i had a shift in the immune gene profile of tumors from a protumor(TH2) to an anti-tumor(TH1) immune response not observed with FX alone(Fig C). Also, 3 of the first 5 evaluable patients who received FX&CCR2i had partial radiologic responses by RECIST criteria, and underwent resection, Conclusions: This preliminary evidence suggests that CCR2i may enhance anti-tumor immunity and improve chemotherapeutic responses in PDAC patients.



98

Optimal Staging of Pancreatic Neuroendocrine Tumors: Mandatory Grading using Ki67 Index and Mitotic Rate Increases the Prognostic Accuracy of Disease-free Survival and Overall Survival P. Philips,^{1*} J.P. Wright,² D.A. Kooby,³ S.K. Maithel,³ C. Cho,⁴ M.H. Squires,³ A. Parikh,² N. Merchant,² S.M. Weber,⁴ E. Winslow,⁴ D.E. Abbott,⁶ A. Syed,⁶ H.J. Kim,⁵ C.R. Scoggins,¹ K.M. McMasters,¹ R.C. Martin.¹ I. Surgery, Surgical Oncology, University of Louisville, Louisville, KY; 2. Vanderbilt University Medical Center, Nashville, TN; 3. Emory University, Atlanta, GA; 4. University of Wisconsin, Madison, WI; 5. University of North Carolina, Chapel Hill, NC; 6. University of Cincinnati, Cincinnati, OH.

INTRODUCTION:Ki-67 proliferative index(Ki-67 index) is suggested to be an important prognostic variable for grading Pancreatic NeuroEndocrineTumors(PNETs). New WHO Grading system requires mitotic rate & Ki67 for PNETs; but the 7th AJCC staging system does not & between American & European staging for PNET is NOT universally accepted. METH-ODS:A multi-institutional prospective database review of 5 institutions from 2002-2010 was performed to determine the effect of Ki-67 index in predicting Disease-free survival(DFS) & Overall Survival(OS). Grading was based on mitotic activity(<2 mitoses/10 HPF, 2-20/10 HPF & >20/10 HPF) & Ki-67 index(<3% per 10HPF, 3-20% & >20%). Final grade was selected based on higher grade of either variable. RESULTS: 395 patients were identified. Ki67 & Mitotic rate was similar, except for 58 patients had discordant grades. Univariate analysis for OS, Ki67, mitotic rate, final grade, PNI, positive lymph nodes & margin status was significant. However on Multivariate analysis Final Grade(G2: p=0.01, HR 1.2; G3: p=0.002, HR 2.8), Ki67(3-20%: p=0.03, HR 1.2; >20%: p=0.007,HR 2.4), Mitotic rate(2-20/10hpf: p=0.04, HR 1.1; >20/10HPF: p=0.02, HR 2.1) and Lymph node status(p=0.05, HR1.17) were significant. For DFS, in univariate analysis, Ki67, mitotic rate, final grade, T stage, positive lymph nodes and margin status were significant. However on Multivariate analyses, only Final grade (Grade 2: p=0.05, HR 1.4; Grade 3: p=0.009, HR 2.3), Ki67 (3-20%: p=0.05, HR 1.3; >20%: p=0.01, HR 2.3) and Mitotic rate (2-20/10HPF: p=0.04, HR 1.4; >20/10HPF: p=0.009, HR 2.2)) and Margin status(p=0.03, HR 1.09) significantly predicted DFS. For OS, Ki 67 was a better model than Mitotic rate, whereas the opposite was true for DFS. Overall combined Final Grade was the Best model based on HZ for both OS and DFS. CONCLUSION:Ki67 is a POWERFUL prognostic factor for OS and DFS and should be included in all PNET pathology reviews. The addition of Mitotic rate allows for more robust prognostic information. In cases with Discrepancy, worse grade predicted by Ki67 or Mitotic rate should be used



Survival Curves (Overall Survival and Disease free Survival) for PNET based on Final Grade (i.e. worse grade between Ki67 proliferation index and Mitotic rate)

Radio-guided Thoracoscopic Resection for Small Lung Nodules J. Corona-Cruz,^{1*} A. Herrera-Gomez,¹ A. Cruz-Rodriguez,¹ K.S. Martin-Tellez,¹ C.E. Rojas-Marin,³ E.A. Lara-Garcia,³ E. Jimenez-Fuentes,¹ V. Gomez-Argumosa,² H. Martinez-Said.¹ *1. Surgical Oncology* Department-Instituto Nacional de Cancerologia (INCan) Mexico, Mexico City, Mexico; 2. Nuclear Medicine Department-Instituto Nacional de Cancerologia (INCan) Mexico, Mexico City, Mexico; 3. Interventional Radiology-Instituto Nacional de Cancerologia (INCan) Mexico, Mexico, City, Mexico.

Introduction Thoracoscopic resection of lung nodules is a widespread practice when suspicious of malignancy. Minimally invasive approaches are easy when the nodule is peripherally located and the diameter is >2 cm. However when they are located deep in the parenchyma or small in size, the lack of palpation becomes a limiting factor for localization and increases the rates of conversion to open thoracotomy. Methods We describe a procedure using tc99malbumin for preoperative marking of the nodule, via a CT-guided puncture, and intra-operative identification with portable gamma-probe. Results To date we have performed 14 resections with this technique, mean surgical time is 46 minutes, with a blood loss of 35.6 ml in average. Complications associated with the resection were no reported, however 1 patient developed a pneumothorax during the marking procedure and 1 patient an intra-parenchymatous bleeding, both asymptomatic and none of these patients required additional procedures after the marking. The success rate of identification was 100%. Conclusions Radio-guided surgery is a safety procedure, associated with a high rate of success, is recommended for lung nodules located >1.5 cm intraparenchymatous or when size is <1 cm

V2

Minimally Invasive Esophagectomy with Cervical Anastomosis M. Kukar,* S.N. Hochwald. *Roswell Park Cancer Institute, Surgical Oncology, Buffalo, NY.*

Purpose: This video demonstrates the steps involved in minimally invasive esophagectomy with cervical anastomosis. This technique is routinely employed in patients with esophageal cancer requiring surgical treatment. Methods: The patient is placed in left lateral decubitus position and the dissection is begun in right chest. The esophagus is mobilized past the thoracic inlet carefully preserving the recurrent laryngeal nerve. A penrose drain, looped around the esophagus is placed at the highest level of dissection and a 24 F Blake drain is placed and chest ports are closed. A 6 cm cervical incision is made along the anterior border of sternocleidomastoid muscle and the penrose drain placed through the chest is identified. The abdominal portion of the procedure involves mobilizing the stomach, carefully preserving the right gastroepiploic vessels and construction of gastric conduit. The gastric conduit is brought into the neck and side to side stapled esophagogastrostomy is done. A 16 F T tube is used as a feeding jejunostomy and abdominal ports are closed. Cervical incision is closed with a 7 F Jackson Pratt drain.

V3

The Inframammary Approach to Nipple Sparing Mastectomy A.J. Swistel.* *Weil Cornell Medical College, New York, NY.*

As more patients opt for bilateral mastectomy for early stage disease or high risk based on genetic or familial susceptibility, the nipple sparing technique has become more popular. The most common surgical approach is to utilize the peri-areolar skin sparing incision through the mid chest. Although this has been relatively successful, it does compromise a portion of the blood supply to the nipple areolar complex (NAC) with potential skin loss and necrosis. Traction injury is also higher because of retraction of the NAC skin during the procedure. The infra-mammary approach allows for less injury to the NAC and provides the optimum amount of vascular supply to the areolar skin.All anatomic guidelines for a total mastectomy result in the removal of breast tissue to the clavicle, medial sternal border, latissimus muscle and inferior rectus fascia. The NAC is assessed for margins. This approach results in an improved potential survival of the NAC, as well as better cosmetic outcome without compromising the basic requirements of a total mastectomy. Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients with Melanoma J.W. Jakub,* T.E. Grotz, R.C. Hernandez Irizarry. *Division of Gastroenterologic and General*

Surgery, Mayo Clinic, Rochester, MN.

Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection (SAFE-MILND, NCT01500304) is a multi-center, phase 1 clinical trial to determine the safety and feasibility of MILND for patients with melanoma. As part of the training to participate in this trial a high quality video of the procedure was produced, which includes both live video footage of the case and professional animation. Participating surgeons completed special training, including being provided a DVD of the procedure, attending didactic lectures and participating in a cadaveric, hands on lab. The 1st patient enrolled in June 2012 and the study is scheduled to close Sept 2014. Our video of this innovative technique will be shown. MILND is a novel approach to inguinal lymph node staging and treatment, but very little experience exists. This study is an innovative approach to the development of technological training of surgeons to characterize the learning curve, assure the rapid assimilation of a new procedure and obtain patient outcome data in an abbreviated time frame. It is common to incorporate new surgical technologies without mandating prior training of surgeons on the new procedure. Many randomized studies comparing a novel procedure to an established technique do not provide formal training of the new operation. This lack of quality control likely decreases the chance that the new procedure will fare better, mostly because of the learning curve inherent with any new procedure. Our trial is innovative by mandating the surgeons participating be formally trained and objectively measured prior to enrolling patients. We will need to assure the oncologic community that MILND is at least as good as an open lymphadenectomy, but with less morbidity. The hypotheses for this study are 1) minimally invasive groin dissection is a safe procedure 2) a structured educational training program is a feasible and effective method to train practicing surgeons in this novel procedure and 3) precourse generic laparoscopic technical skills correlate with minimally invasive groin dissection performance in a clinical setting, including operative oncologic standards and safety metrics.

V5

Video Documentation of the Minimally Invasive Open Technique for Pelvic Lymphadenectomy in Patients with Metastatic

Melanoma A.J. Spillane, R.L. Read.* Melanoma Institute Australia, North Sydney, NSW, Australia.

Metastatic melanoma to the groin is managed by either inguinal (IL) or ilioinguinal (I-IL) dissection. Controversy exists regarding the extent of surgery with some surgeons preferring to offer only IL unless there is clear evidence of pelvic disease. A randomized trial is currently being initiated to try to give a better evidence base for this decision. Many surgeons lack confidence in the technique of pelvic lymphadenectomy. Both IL and I-IL can have significant morbidity with wound complications occurring in approximately thirty percent of patients. The main focus of this video is to demonstrate a minimally invasive technique for pelvic lymphadenectomy utilizing a retroperitoneal approach through a skin crease and muscle splitting incision in the right iliac fossa. The IL dissection is performed through a second vertical incision over the sartorius muscle below the inguinal ligament. These incisions maintain skin cover over the groin crease as well as the femoral artery and vein and provide excellent exposure. Most of the footage in this video was recorded using a laparoscopic camera to enable the camera to get closer to the operation and to facilitate a unique view. The video was recorded from a single operative case (right I-IL dissection) in a patient who had known inguinal and pelvic metastatic melanoma after nodal observation, including ultrasound surveillance, for a sentinel node positive right leg melanoma. The procedure took ninety minutes to complete.

V6

Pushing the Limits of Local Excision for Rectal Cancer: Transanal Minimally Invasive Surgery (TAMIS) for a Mid-rectal Cancer with Post-endoscopic Mucosal Resection Structure R.A. Smith,²

A. Artinyan.^{1*} 1. Baylor College of Medicine, Houston, TX; 2. Scott and White Hospital - Round Rock, Round Rock, TX.

Background: Transanal Minimally Invasive Surgery (TAMIS) is an evolving technique for the local excision of early rectal cancers1, particularly for

mid-rectal lesions. We demonstrate TAMIS for a mid-rectal cancer and partial rectal stricture that resulted from multiple previous attempts at endoscopic mucosal resection (EMR). Methods: The patient is an 85 y/o male with multiple medical comorbidities whom colonoscopy demonstrated a large sessile polyp of the mid-rectum, with biopsy demonstrating multifocal high-grade dysplasia and intramucosal adenocarcinoma. EMR was performed on 3 separate occasions, each time with residual adenocarcinoma and positive margins. Endoscopic ultrasound was consistent with uT1N0 lesion. The patient was referred to surgical oncology and rigid proctoscopy demonstrated a 2-3cm scar and partial rectal stricture at 6-7cm from the anal verge. The patient underwent TAMIS with a disposable transanal access port, using our previously published stepwise technique.2 Results: TAMIS was performed uneventfully without any perioperative complications. A stepwise approach to excision and repair is described consisting of 1) identification of margins, 2) full thickness incision, 3) circumferential dissection, 3) suture repair, along with technical tips and pitfalls. Intraoperatively, a partial rectal stricture was again noted and resected along with the rectal lesion. The patient did well and was discharged on postoperative day #1. On outpatient follow-up, the patient was symptom free with no fevers, pain, bleeding, fecal incontinence, or genitourinary functional deficits. Final pathology revealed mucosa with ulceration and microfocal residual carcinoma with negative margins. He remains disease free 18 months from his procedure. Conclusions: TAMIS of rectal lesions with post-EMR stricture is technically challenging, but can be accomplished safely in well-selected patients.

V7

Modified Surgical Technique for Pancreaticoduodenectomy following Coronary Artery Bypass Grafting using an in situ Right Gastroepiploic Artery S. Fukuhara,^{1*} M.M. Montgomery,¹ N. Ikoma,² R. Miyata.³ 1. Department of Surgery, Beth Israel Medical Center, New York, NY; 2. University of Texas Health Science Center at Houston, Houston, TX; 3. International Goodwill Hospital, Yokohama, Kanagawa, Japan.

This video demonstrates pylorus preserving pancreaticoduodenectomy (PPPD) in a 66-year-old female with an ampullary tumor who had undergone coronary artery bypass grafting using right gastroepiploic artery (RGEA) 10 years ago. The procedure began with exploration of abdominal cavity through median celiotomy. The RGEA conduit was found at the left of ligamentum teres reaching the pericardial cavity. There was no evidence of peripyloric lymph node enlargement. Clamp test of the RGEA did not cause any remarkable changes on hemodynamics. Dissection of the adhesions surrounding the

RGEA followed by division of the duodenum was preceded in order to mobilize and keep it from being in the main resection field. The duodenum was divided 2cm distal to the pylorus. Pancreaticoduodenal arcade was also testclamped before division to assure that perfusion of RGEA conduit is maintained after ligation of superior mesenteric artery system. Satisfactory mobilization of RGEA conduit was gained after division of the pancreaticoduodenal arcade. The RGEA conduit was kept wrapped with papaverine soaked gauze during this procedure. The standard processes of PPPD followed the preservation and mobilization of the RGEA. Pathological examination showed moderately differentiated adenocarcinoma (pT2 N0 stage IB). Postoperative course was uneventful. At present, 5 years after the surgical procedure, the patient remains well. The key to the success of this procedure is to gain curative oncological resection and preserve the conduit. Preoperative assessment of the function of the conduit and its gentle manipulation in its entirety of procedure are crucial. Adequate oncological curability while preserving the RGEA may be achievable considering the negligible incidence of subpyloric nodal metastasis in earlier-stage ampullary adenocarcinoma. By contrast, locally advanced disease may be associated with significantly higher nodal involvement and extensive resection with sacrifice of the RGEA conduit might be needed. Therefore, additional strategies for salvage revascularization of coronary artery should be considered.

V8

Totally Laparoscopic Pancreaticoduodenectomy for Pancreatic Head Cancer with Involvement of the SMV- PV Confluence *Z.* Awad.* Surgery, University of Florida, Jacksonville, FL.

Laparoscopic pancreaticoduodenectomy is a technically demanding pro-

cedure. In this video we demonstrate the technical aspects of performing the procedure. 50 year old male with ascending cholangitis, ERCP was unsuccessful, PTC was done for bilary decompression. EUS: pancreatic head ade-nocarcinoma. The procedure was done using 5 trocars. Extensive lymphadenectomy was done. The Uncinate process was skeletonized off the SMA. The SMV- portal vein confluence was involved wit the cancer and it was transsected using laparoscopic linear stapler with negative margin. All the anastomosis were done using laparoscopic intracorporeal suturing. Oprative time 8 hours 20 minutes, hospital stay 5 days. Final pathology T3 N1 (one lymph node out of 40 was positive). Conclusion: Laparoscopic pancreatic duadenectomy can be performed safely in selected cases of pancreatic head cancer with vascular involvement. Skilled laparoscopic skills are necessary to execute such procedures safely.

ABSTRACTS

Accepted for POSTER PRESENTATIONS

67th Annual Cancer Symposium Society of Surgical Oncology March 12–15, 2014 Phoenix, Arizona Survival after Breast Conserving Surgery with Whole Breast or Partial Breast Irradiation in Women with Early Stage Breast Cancer: A SEER Database Analysis S. Grover,² S. Nurkic,² S.L. Showalter.^{1*} 1. Surgery, University of Virginia, Charlottesville, VA; 2. University of Pennsylvania, Philadelphia, PA.

Background: Randomized clinical trials have demonstrated equivalency in survival outcomes for early stage breast cancer treated with either mastectomy or breast conserving surgery (BCS) with adjuvant radiation. Recent state level population-based data confirm comparable survival between these two treatments. Using a national level population database, Surveillance Epidemiology and End Research (SEER), we sought to evaluate national survival outcomes among patients with early stage breast cancer treated with mastectomy, BCS with whole breast irradiation (BCS+WBI), or BCS with partial breast irradiation (BCS+PBI). Methods: Inquiry of the SEER database identified 150,171 women 50 years of age or older, diagnosed with a new unilateral, node negative, invasive breast cancer 3 cm or less in size, from 1995-2009. All eligible women were treated with mastectomy, BCS+WBI or BCS+PBI. Kaplan-Meier estimates and Cox proportional hazard models were used to compare overall survival (OS) and cancer-specific survival (CSS) among the three treatment groups. Results: OS was significantly improved among women treated with BCS+WBI or BCS+PBI, compared to mastectomy. This relationship was maintained after adjusting for age, race, tumor size, hormone receptor status, and year of diagnosis. Adjusted hazard ratios (aHR) for OS in BCS+WBI and BCS+PBI compared to mastectomy were 0.73 (aHR 95%CI= 0.71-0.76) and 0.68 (aHR 95%CI=0.58-0.79), respectively. CSS was also significantly improved among women treated with BCS+WBI or BCS+PBI compared to mastectomy alone, HR 0.60 (HR 95%CI=0.58-0.79) and HR 0.50 (HR 95%CI=0.37-0.67). A significant CSS benefit was maintained in the BCS+WBI group after adjusting for patient age, race, tumor size, hormone receptor status and year of diagnosis, aHR 0.80 (aHR 95%CI= 0.76-0.85). Conclusion: BCS with adjuvant radiation was associated with improved OS and CSS. These population-based data support both BCS+WBI and BCS+PBI as safe and effective treatment strategies for patients with early stage breast cancer.



P2

The Effects of TNM Stage on Surveillance after Curative-intent Treatment for Breast Carcinoma D. Wu, ¹* E.S. Allam, ¹ K.S. Virgo,² J.A. Margenthaler, ³ L. Chen, ³ F.E. Johnson. ¹ *1. Saint Louis University School of Medicine, Saint Louis, MO; 2. American Cancer Society, Atlanta, GA; 3. Washington University School of Medicine, Saint Louis, MO*

Introduction: An increasing survival rate has resulted in about 3 million women who are breast cancer survivors in the United States and essentially all are candidates for surveillance. Based on clinical trials comparing low and high intensity surveillance, the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) have published recommendations encouraging low intensity strategies, primarily consisting of office visit and mammogram, unless clinical evaluation suggests otherwise. We aimed to determine whether ASCO experts carry out surveillance

differently for patients with breast cancer of different TNM stages. Methods: We created a web-based survey instrument describing 4 patient vignettes with TNM stages 0 to IIIA. Respondents were asked how often they would recommend 12 specific diagnostic modalities for each vignette during post-treatment vears 1-5. A link to the survey was e-mailed to 3.245 members of ASCO who had identified themselves as having breast cancer as a major clinical focus. Statistical analysis utilized repeated measures analysis of variance to generate mean, standard deviation, median, and range, Results: 1,012 of the 3,245 ASCO members surveyed responded to the survey (31%). There were 915 (90%) evaluable responses. Office visit was the most frequently recommended surveillance modality and complete blood count (CBC) was second. Responders also commonly recommended liver function tests and mammogram. There was statistically significant variation in recommended surveillance intensity for all 12 modalities according to TNM stage and post-treatment year. Several modalities not recommended by ASCO guidelines, including CBC, were frequently recommended by physicians. Conclusions: ASCO guidelines were first published in 1999, but our results indicate there is still significant variability in the recommended use of all surveillance modalities by ASCO experts. The frequency of recommended modalities varied with the initial TNM stage of the described patients, but ASCO guidelines do not stratify according to TNM stage. Our results suggest both overuse and underuse of surveillance modalities.

	Frequen	cy of recommende	d use of mammo	grams: mean ± SE)
Year	Stage 0	Stage IIA	Stage IIB	Stage IIIA	P-Value
1	1.3 ± 1.7	1.8 ± 1.9	1.9 ± 1.7	2.9 ± 2.7	< 0.0001
2	1.1 ± 1.5	1.6 ± 1.7	1.7 ± 1.6	2.2 ± 1.9	< 0.0001
3	1.0 ± 1.5	1.4 ± 1.6	1.4 ± 1.6	1.8 ± 1.7	< 0.0001
4	0.9 ± 1.5	1.3 ± 1.6	1.4 ± 1.5	1.7 ± 1.7	< 0.0001
5	0.9 ± 1.6	1.2 ± 1.5	1.3 ± 1.5	1.6 ± 1.6	<0.0001
	Frequenc	y of recommended	use of CBC: me	dian and (min, ma	x)
Year	Stage 0	Stage IIA	Stage IIB	Stage IIIA	
1	1 (0, 12)	1 (0, 12)	2 (0, 12)	2 (0, 12)	
2	1 (0, 12)	1 (0, 12)	1 (0, 12)	2 (0, 12)	
3	1 (0, 12)	1 (0, 12)	1 (0, 12)	2 (0, 12)	
4	1 (0, 12)	1 (0, 12)	1 (0, 12)	2 (0, 12)	
5	1 (0, 12)	1 (0, 12)	1 (0, 12)	2 (0, 12)	

The number in each cell is the number of times a particular modality is recommended in a particular post-treatment year. These data present all values from all evaluable responses for all vignettes.

P3

Sphingosine-1-phosphate Signaling Exacerbates Obesity-related Breast Cancer Progression M. Nagahashi,* A. Yamada, T. Aoyagi, W. Huang, J. Allegood, S. Milstien, S. Spiegel, K. Takabe. *Virginia Commonwealth University, Richmond, VA*.

INTRODUCTION: Although obesity is an established independent prognostic factor for breast cancer patients, the underlying mechanisms are poorly understood. The pleiotropic bioactive lipid mediator sphingosine-1phosphate (S1P) has emerged as a key regulatory molecule in cancer progression and inflammation. S1P produced by SphK1 in cancer cells is exported out of the cells by S1P transporters, and exerts its functions by binding to S1P receptors. In this study, we examined the role of S1P signaling in obesity-related breast cancer progression and evaluated the effects of the S1P receptor modulator FTY720/fingolimod. METHODS: Two syngeneic breast cancer mouse models were used: 4T1-luc2 cells in BALB/c mice and E0771 cells in C57Bl/6 mice, both inoculated into mammary fat pads of mice fed with normal or high fat diets. FTY720 was given daily by gavage. Protein expression was determined by immunoblotting and mRNA by qPCR. S1P and FTY720 levels were measured by mass spectrometry (LC-ESI-MS/MS). RESULTS: We found that breast tumors in obese animals were significantly larger, and expressed higher levels of SphK1 and S1P transporters, such as ABCC1 and Spns2, compared to animals on a normal diet. The levels of S1P, not only in the tumor tissue, but also in the tumor interstitial fluid and serum were higher in obese mice than in lean mice, which appears to be a consequence of higher production of S1P by SphK1 in the tumor and its microenvironment. FTY720 administration decreased S1P levels not only in the circulation, but also in the tumor and tumor interstitial fluid. FTY720 treatment also suppressed tumor progression significantly in both mouse models. Interestingly, however, it was more efficacious in the obese mice than the lean mice. CONCLUSIONS: Our data suggest that S1P signaling worsens obesity-related breast cancer progression. Targeting the S1P signaling with FTY720 may be useful for treating breast cancer in individuals with obesity. MN is a Japan Society for the Promotion of Science Postdoctoral Fellow. This work was supported by NIH R37GM043880 and R01CA61774 to SS, and R01CA160688 and Susan G. Komen IIR12222224 to KT.

P4

Preoperative Prediction of Cosmetic Results after Breast Conserving Surgery E.L. Vos, ^{1*} A.H. Koning, ² I. Obdeijn, ¹ V.V. Verschuer, ¹ C. Verhoef, ¹ P.J. Van der Spek, ² M.B. Menke-Pluijmers, ³ L.B. Koppert. ¹ *I. Erasmus MC-Cancer Institute, Rotterdam, Netherlands; 2. Erasmus MC, Rotterdam, Netherlands; 3. Albert Schweitzer Hospital, Dordrecht, Netherlands.*

Background: Cosmetic result plays an important role in the choice for mastectomy or breast conserving surgery (BCS) in breast cancer treatment and is associated with quality of life. Preoperative tumor volume as compared to breast volume (TV/BV ratio) was tested as predictor for cosmetic result. Methods: Data was collected prospectively of women treated for invasive breast cancer with (oncoplastic) BCS in our cancer institute and from whom preoperative magnetic resonance imaging (MRI) was available. Using a CAVE-like virtual reality system, the I-Space, tumor and breast volumes were measured in a three-dimensional projection of the preoperative MRI. Cosmetic result was assessed on a linear scale by 9-item patient questionnaire, 11-item panel evaluation of photographs, and breast retraction assessment (BRA). Quality of life was assessed by the EORTC OLO-C30 and BR23. Results: A total of 67 women with 69 breast cancers were included. Intraobserver and interobserver correlation coefficients for tumor and breast volume as measured in I-Space were all >0.95. Median time between date of BCS and date of inclusion was 33 months (range 6-66). Excellent/good cosmetic result in contrast to moderate/bad cosmetic result was reported in 55 (79.7%) of the patient questionnaire, 49 (71.0%) of the panel evaluation and 43 (62.3%) of the BRA. Increasing TV/BV ratio correlated with a decrease in all three cosmetic result assessments (Figure 1). After linear regression analyses adjusted for excision volume and radiological tumor size, TV/BV ratio was a significant independent predictor for panel evaluation of cosmetic result (P=0.028) as were lower medial and lower lateral tumor location in the breast (P=0.036 and P=0.015) and specimen weight (P=0.008). A preoperative prediction model including TV/BV ratio and tumor location had good accuracy in predicting panel evaluation of cosmetic result (AUC=0.83). Conclusion: TV/BV ratio can be precisely measured in I-Space with preoperative MRI. TV/BV ratio is an independent predictor for cosmetic result as determined by a panel and TV/BV ratio can be used in a preoperative prediction tool to aid in surgical treatment decision making and informing patients.



P5

A Comparison of Complication Rates and Local Recurrence in Early Stage Breast Cancer Patients Treated with Brachytherapy versus Whole Breast Irradiation N. Ajkay,^{1*} A.E. Collett,¹ E.V. Bloomquist,¹ E.J. Gracely,² T.G. Frazier,¹ A.V. Barrio.¹ *1. Compre-*

hensive Breast Center, The Bryn Mawr Hospital, Bryn Mawr, PA; 2. School of Public Health, Drexel University College of Medicine & Drexel University, Philadelphia, PA.

INTRODUCTION: The adoption of breast brachytherapy into clinical practice for early stage breast cancer has increased over the last several years. Studies evaluating complication rates following treatment with brachytherapy have shown conflicting results. We compared local toxicity and in breast tumor recurrence (IBTR) in patients treated with brachytherapy to those treated with whole breast irradiation (WBI). METHODS: An IRB approved retrospective chart review identified 417 early stage breast cancer patients treated with lumpectomy and radiation between 2004 and 2010. We compared 271 women treated with balloon-based brachytherapy to 146 women treated with WBI. Long-term complications and IBTR rates were assessed using Kaplan-Meier curves with log-rank test. RESULTS: Median follow-up was 4.6 years. The WBI cohort was younger (p<0.001), had larger tumors (p<0.001), had more node positive patients (p<0.001), and was more likely to receive systemic therapy (p=0.01). Five-year incidence of infectious skin complications (9.7% vs 11.0%, p=0.84), abscess (1.1% vs 0%, p=0.4), telangiectasia (8.0% vs 5.3%, p=0.35) and breast pain (14.2% vs 9.4%, p=0.2) were similar between the two groups. The brachytherapy cohort had a higher 5-year rate of seroma (47.8% vs 18.5%, p<0.001), and fat necrosis (39.5% vs 24.4%, p<0.001). Fat necrosis was detected more often as a palpable mass in the brachytherapy group compared to WBI group (54.3% vs 34.4%, p=0.06). Brachytherapy patients trended towards more frequent biopsies as a result of fat necrosis to rule out a recurrence (11.2% vs 6.7%, p=0.13). Five-year IBTR rates were similar between the brachytherapy and WBI cohorts (6.2% vs 4.6%, p=0.41). CONCLUSIONS: Patients treated with brachytherapy had more local toxicity, particularly seroma and fat necrosis, with similar rates of IBTR compared to the WBI cohort. The increased rate of fat necrosis in brachytherapy patients led to more biopsies to rule out recurrence. Patients should be counseled on the possible increased rate of long-term complications associated with brachytherapy treatment.





P6

The Clinical Benefit and Safety of Boosting the HER2 Peptide Vaccine (GP2+GM-CSF) in the Adjuvant Setting to Prevent Breast Cancer Recurrence E. Schneble,^{1*} J.S. Berry,¹ A.F. Trappey,¹ D.F. Hale,¹ T.J. Vreeland,¹ A. Sears,² G.T. Clifton,¹ S. Ponniah,³ M. Papamichael,¹ S. Perez,¹ G.E. Peoples,¹ E. Mittendorf.² I. San Antonio Military Medical Center, San Antonio, TX; 2. MD Anderson Cancer Center, Houston, TX; 3. Uniformed Services University of Health Sciences, Bethesda, MD.

Background: GP2 is an HLA-A2+-restricted immunogenic peptide from the HER2 protein that stimulates CD8+ T cells to recognize and kill HER2 expressing tumor cells. Here we present the clinical efficacy and safety of boosters in a prospective, randomized, placebo-controlled phase II trial of GP2+GM-CSF for prevention of breast cancer (BrCa) recurrence. Methods: HLA-A2+, clinically disease-free, high risk BrCa patients (pts) enrolled in our GP2 vaccine trial who completed the primary vaccine series (PVS) more than 6 months prior were offered a series of 4 booster vaccinations every 6 months (500 mcg GP2 peptide + GM-CSF). Boosters were added after trial initiation. The primary endpoint of the trial is disease free survival. Secondary endpoints are local and systemic toxicity including delayed urticarial reactions (DUR) defined as hypersensitivity reactions generally occurring 9-10 days post-inoculation. Results: A total of 170 pts have enrolled (88 HLA-A2+ controls and 82 vaccinated pts). To assess the benefit of boosters, we have only included pts completing the PVS. Therefore, 13 pts who have not completed the PVS, 1 pt declared ineligible, 4 pts with early recurrence prior to PVS completion, and 1 pt who developed a secondary malignancy were excluded leaving 63 evaluable pts. At 39 mos median f/u, the recurrence rate is 5.0%. Of these 63 pts, 46 have been boosted (B) and 17 were not (NB). There are no differences between B and NB with respect to age, grade, nodal status, tumor size, ER/PR status, and HER2 expression. The safety profile of the booster inoculations was similar to that seen in the PVS. DURs occurred in 6.5% during booster inoculations versus 4.8% during the PVS, p=0.51. The recurrence rate was reduced by 62.7% with booster inoculations (NB, 11.8%, vs. B, 4.4%, p=0.29). Conclusions: The GP2 vaccine is safe overall, and the current 5% recurrence rate is half that expected in this population. The boosters have not added toxicity but have been associated with a trend towards decreased disease recurrence. This data suggests that boosting CD8-eliciting, peptide vaccines will optimize their clinical benefit.

P7

Surgeon Bias in Sentinel Lymph Node Dissection: Do Tumor Characteristics Influence Decision Making? K.A. Robinson,* B.A. Pockaj, N. Wasif, K. Kaufman, R.J. Gray. *General Surgery, Mayo Clinic Hospital, Phoenix, AZ.*

Introduction Determining which lymph nodes are considered sentinel lymph nodes (SLNs) in breast cancer staging involves some subjective interpretation by the operating surgeon. We hypothesized that patient and tumor characteristics considered "higher risk" may influence the number of SLNs harvested. Methods A single institution prospectively collected database was queried for all clinically node-negative breast cancer patients undergoing SLN surgery from January 2002 to June 2013. Mean SLN counts were compared by clinical factors known to influence risk of metastases or false-negative SLN biopsy. Results 2,394 SLN biopsy procedures were performed. The mean and median number of SLNs per patient for the entire cohort was 2.6 and 2 respectively. The mean number of SLNs removed per patient was significantly greater for younger patients with mean SLN count for those ≤ 50 years being 2.88 compared to 2.56 for those \ge 50 years (p<0.0001). This difference persisted when the age threshold was set at 60 years or at 70 years (p<0.0001 for each). Fewer SLNs were removed in smaller tumors with the mean SLN count for patients with a tumor ≤ 1 cm being 2.51 compared to 2.63 for those with tumors >1 cm (p=0.002). Patients with tumor grades 2 or 3 had more SLNs removed than those with a grade 1 tumor: 2.64 vs. 2.52 (p= 0.03). Patient receipt of neoadjuvant therapy was associated with more SLNs being removed (2.96 vs. 2.61 for no neoadjuvant therapy, p=0.005). Estrogen receptor status (2.60 vs. 2.64, p=0.63) and ductal carcinoma in-situ vs. invasive cancer (2.46 vs. 2.58 (p=0.17) did not influence number of SLNs removed. Conclusion The number of SLNs removed in breast cancer staging varies significantly based on risk factors for SLN metastases or false negative SLN biopsy. With the exception of patient age, these factors would not be expected to influence SLN mapping itself. Thus the pre-test probability of SLN metastases and risk of false negative SLN biopsy appears to influence surgeons to retrieve a greater number of SLNs. Across broad populations this has the potential to bias the staging of breast cancer patients.

P8

Deviation from the Standard of Care for Early Breast Cancer in the Elderly: What are the Consequences? S. Sun, C. Hollenbeak, A.M. Leung.* *Surgery, Penn State Hershey Medical Center, Hershey, PA.*

Introduction: Operative lymph node sampling and adjuvant radiation are standards of care in the treatment of early breast cancer. In the elderly populations, however, these standards are often not strictly adhered to due to either clinician biases of patient health and longevity or patient refusal of treatment. We hypothesized forgoing the standard of care for elderly patients would have a negative impact on survival. Methods: Using the SEER database we identified 53,619 women over the age of 55 with Stage I breast cancer undergoing partial mastectomy. These groups were then examined for adjuvant radiation and lymph node sampling. Patients were further stratified by age, race, hormone receptor status, and other demographics. Univariate and multivariate

analyses were performed and survival was analyzed using the Kaplan-Meier method. Results: As patients aged they were significantly less likely to receive the standards of care of radiation and lymph node sampling both on univariate and multivariate analysis. When we examined survival for those who had adjuvant radiation versus no adjuvant radiation we found those with adjuvant radiation had a 15.8 percentage point increase in survival (p=.005). Survival for those who had lymph node sampling versus no lymph node sampling was 27.1% increased (p=0.05). However, when propensity score was done to address selection bias and covariate imbalance we found the survival improvement for the radiation group decreased to 0.9% and was no longer statistically significant (p=0.617). The same held true for lymph node sampling when matched by propensity score as the survival advantage for those with sampling was only 0.2% after matching (p=0.522) (Figure 1). Conclusions: Although as patients age they are less likely to receive the standard of care in early breast cancer, results from this large population study show that when matched for other factors survival is not affected.



Overall Survival for Early Breast Cancer Patients not receiving radiation and lymph node sampling is equivalent with propensity score matching.

P9

SFRP2 Regulates Angiogenesis via the FZD5 Receptor J. Samples,^{1*} C. Patterson,² D. Glatt,³ R.J. Mumper,³ S. Snyder,¹ E. Hilliard,¹ S. Siamakpour-Reihani,¹ D. Ketelsen,¹ N. Klauber-DeMore.¹ *1. University of North Carolina at Chapel Hill, Chapel Hill, NC; 2. UNC McAllister Heart Institute, Chapel Hill, NC; 3. Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC.*

Introduction: Secreted frizzled related protein-2 (SFRP2) is a secreted protein highly expressed in breast cancer endothelium. We previously reported that antagonism of SFRP2 inhibits triple negative breast cancer growth. We have shown that that SFRP2 stimulates angiogenesis via activation of calcineurin, which results in nuclear translocation of NFATc3, a transcription factor involved in angiogenesis. We hypothesized that frizzled 5 (FZD5) is the receptor that the ligand SFRP2 binds to stimulate angiogenesis. Methods: FZD5 was silenced in endothelial cells with shRNA and compared to sham-transfected endothelial cells. Matrigel tube assay was used to quantify angiogenic branches after treatment with or without recombinant SFRP2 (10nM) in sh-FZD5 transfected cells or sham-transfected cells. NFATc3 activation: Sham transfected or sh-FZD5 transfected cells were treated with control media or SFRP2 7nM for 1 hour, nuclear lysates were extracted and subjected to Western blot. SFRP2/FZD5 binding affinity: The dissociation constant (Kd) between SFRP2 and FZD5 was determined using a microplate solid phase protein binding assay. Results: Western blot showed successful silencing of FZD5 in sh-FZD5 transfected cells. Matrigel tube assay. Sham-transfected cells had 476 ± 6 branch points; and sham cells treated with SFRP2 had 665 branch points \pm 23 (p=0.001). sh-FZD5 transfected cells had 101 \pm 14 branch points, which did not increase with the addition of SFRP2 (98 branchpoints \pm 6, p=NS). NFATc3 activation: Western blot showed that nuclear NFATc3 was increased in SFRP2 treated sham-transfected cells compared to untreated sham-transfected cells. However, nuclear localization of NFATc3 did not increase in the

sh-FZD5-transfected cells with or without SFRP2 treatment (Fig. 1). SFRP2/ FZD5 binding affinity: SFRP2 and FZD5 bound with high affinity, with a Kd value of 0.084 nM. Conclusion: We report that FZD5 is a high affinity receptor of SFRP2, and interference with FZD5 expression abolishes SFRP2 stimulated NFATc3 activation and angiogenesis. We propose a previously unknown function of this molecule: the ability to mediate SFRP2 stimulated calcineurin/ NFAT activation to induce angiogenesis via binding to the FZD5 receptor.



Fig. 1. FZD5 is required for SFRP2 stimulated NFATc3 activation. Sham transfected or sh-FZD5 transfected cells were treated with control media or SFRP2 7nM for 1 hour, nuclear lysates were extracted and subjected to Western blot. Western blot showed that nuclear NFATc3 was increased in the SFRP2 treated sham-transfected endothelial cells compared to untreated sham-transfected cells. However, nuclear localization of NFATc3 did not increase in the shFZD5-transfected cells with or without SFRP2 treatment.

P10

The Impact of Routine Sentinel Lymph Node Biopsy of Internal Mammary (IM) Lymph Nodes on the Risk of Recurrence in the IM Chain K.C. Aalders,^{1*} E. Postma,¹ P. Van Oort,¹ E. Madsen,² M. Smidt,⁴ L. Strobbe,³ T. Van Dalen.¹ *1. Diakonessenhuis, Utrecht, Utrecht, Netherlands; 2. St. Antonius, Nieuwegein, Utrecht, Netherlands; 3. Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands; 4. Maastricht Universitair Medisch Centrum, Maastricht, Limburg, Netherlands.*

Introduction: Preoperative lymphoscintigraphy frequently identifies internal mammary sentinel lymph nodes (IM SLNs) in addition to axillary SLNs in breast cancer patients. Following peritumoral tracer injection IM SLNs are observed in up to 25% of the patients, whereas uptake is seen in less than 5% following periareolar injections. We studied the impact of identifying and retrieving IM SLNs on the incidence of regional parasternal recurrences. Methods: Two patient cohorts that underwent treatment for cT1-2N0 breast cancer in two different hospitals after the introduction of the SLN procedure in 1999 were evaluated. In one hospital (cohort A; n= 1431) the SLN procedure was done following peritumoral radioactive tracer injections and IM SLNs were surgically removed when visualized. The presence of metastases in IM SLNs was an indication for subsequent radiotherapy to the IM chain. In the other hospital (cohort B; n=1002) the radiotracer was injected periareolarly and lymphatic drainage to the IM lymph nodes was ignored. Results: In cohort A IM SLNs were visualized in 20.5% of the patients and IM metastases were detected in 4.3%. In cohort B, parasternal lymphatic drainage was not documented, and IM SLNs were not retrieved. After a median follow-up of 5 years, 2 patients developed a regional recurrence in the parasternal lymph nodes in cohort A. One of them did not have an IM SLN at the time of initial treatment. In cohort B, 14 patients developed a regional recurrence in the IM chain. The cumulative 5-year regional IM recurrence rate was 0.1% in cohort A and 1.4% in cohort B (P<0.001). Overall, the cumulative 5 year ipsilateral locoregional recurrence rate was 2.0% and 3.9% respectively (P=0.011). Conclusions: Retrieving IM SLNs and adjusting treatment accordingly impacts the risk of recurrence in the IM chain. The absolute incidence of regional recurrence in the IM lymph nodes remains very low and should be reason to question the pursuit of IM SLNs.

P11

Breast Cancer Characteristics with and without Chemoprevention in Patients with Atypical Breast Lesions S. Coopey,¹* E. Mazzola,² C.E. Cauley,¹ F. Polubriaginof,¹ J.E. Garber,² A.J. Guidi,³ B.L. Smith,¹ M. Gadd,¹ M. Specht,¹ C.A. Roche,¹ K.S. Hughes.¹ *1. Massachusetts General Hospital, Boston, MA; 2. Dana Farber Cancer Institute, Boston, MA; 3. Newton Wellesley Hospital, Newton, MA.*

Background: Chemoprevention significantly reduces breast cancer risk in patients with atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), and lobular carcinoma in situ (LCIS). The objective of our study was to determine if there is a difference in cancers which develop in patients taking and not taking chemoprevention for atypical breast lesions. Methods: Natural language processing was used to review and parse 76.333 breast pathology reports from a single healthcare system from 1987-2010. This identified 2938 women with atypical breast lesions. Subsequent pathology reports were reviewed to identify those who developed invasive cancer and ductal carcinoma in situ (DCIS). Cancer details were obtained. Cancers that developed with and without chemoprevention were compared. Use of chemoprevention (tamoxifen, raloxifene, or exemestane) was determined by chart review; follow-up documentation that medication was taken was required. Estrogen receptor (ER) was considered positive if $\geq 1\%$ of tumor nuclei stained. Results: We identified 2938 women with atypical breast lesions (1198 ADH, 827 ALH, 568 LCIS, 345 severe ADH). 263/2938 (9.0%) patients developed cancer at a mean follow-up of 67 months. 164/263 (62.4%) cancers were invasive and 99/263 (37.6%) were DCIS. 184/1472 (12.5%) patients not treated with chemoprevention and 24/466 (5.2%) patients treated with chemoprevention developed cancer (p<0.001). There was no significant difference in the proportions of cancer subtypes which developed in those taking and not taking chemoprevention (p=0.21) and no difference in invasive tumor sizes between groups (p=0.081) [Table 1]. We found no significant difference in the proportions of ER positive cancers in the chemoprevention and no chemoprevention groups (p=0.92). Cancers that developed in patients taking chemoprevention had a higher rate of lymph node positivity (p=0.0012), although this represented few patients (n=15). Conclusion: The vast majority of breast cancers which developed in patients previously diagnosed with atypical breast lesions were estrogen receptor positive, regardless of whether or not they took chemoprevention.

Comparison of breast cancers that developed with and without chemoprevention

	No Chemoprevention (n=184)	Chemoprevention (n=24)	p-value
Type of Cancer DCIS IDC ILC/mixed Other Invasive	67 (36.4%) 79 (42.9%) 35 (19.0%) 3 (1.6%)	9 (37.5%) 8 (33.3%) 5 (20.8%) 2 (8.3%)	0.21
Estrogen Receptor +	151/159 (95.0%)	21/22 (95.5%)	0.92
Tumor Size (cm)	0.9 (range: 0.1-7)	1.3 (range: 0.1-10)	0.081
Lymph node +	19/112 (17.0%)	8/15 (53.3%)	0.0012

Chemoprevention status known for 208/263 (79.1%) patents who developed cancer. ER status known for 181/263 (68.8%) cancers.

P12

Incidence of Chronic Pain after Continuous Local Anesthetic in Comparison to Standard Systemic Pain Treatment after Axillary Lymphadenectomy or Primary Reconstruction with a Tissue Expander in Breast Carcinoma Patients: A Prospective Randomized Study N. Besic,* B. Strazisar. Institute of Oncology, Ljubljana, Slovenia.

Background and Objectives: Continuous wound infusion of local anesthetic reduces acute postoperative pain and consumption of opioids compared to the standard intravenous piritramide analgesia after breast cancer surgery. Our aim was to evaluate if continuous wound infusion of a local anesthetic into the surgical wound reduces incidence of chronic pain compared to standard analgesia after axillary lymphadenectomy or primary breast reconstruction. Methods: Altogether 120 patients were enrolled: 60 (mean age 60 y.) after axillary lymphadenectomy and 60 (mean age 48 y.) after primary breast reconstruction with a tissue expander. Half of the patients from each group had for two days postoperative wound infusion of local anesthetic. The other half had standard analgesia: a continuous intravenous infusion with piritramide (30 mg), metoclopramide (20 mg) and metamizole (2.5 g) until the next morning. The nursing staff was instructed to maintain the lowest rate of drip infusion, which relieved the patient of her pain. From the first post-operative day, all patients received analgesics in the form of tablets. All patients completed a questionnaire on pain three months after surgical procedure and were seen by a pain management team six months after surgical procedure. Results: Chronic pain was reported three months after axillary lymphadenectomy by 17% and 50% of patients from local anesthetic and standard analgesia group (p=0.01), respectively. A neuropathic chronic pain was diagnosed six months after lymphadenectomy in 20% and 40% of patients from local anesthetic and standard analgesia group (p=0.09), respectively. Three months after primary breast reconstruction with a tissue expander, chronic pain was reported by 17% and 50% of patients from local anesthetic and standard analgesia group (p=0.01). Conclusions: Wound infusion of a local anesthetic reduces chronic pain in comparison to standard analgesia after axillary lymphadenectomy or primary breast reconstruction with a tissue expander in breast carcinoma patients.

P13

Measuring the Impact of ACOSOG Z0011 on Breast Cancer Surgery in a Community Health System: When, Where, and How Practice has Changed G. Wright,^{1*} H. Sobel,² M. Mater,¹ G.M. Knoll,¹ L.D. Oostendorp,³ M.K. Melnik,³ M.H. Chung.³ 1. GRMEP/MSU General Surgery Residency Program, Grand Rapids, MI; 2. Michigan State University College of Human Medicine, Grand Rapids, MI; 3. Spectrum Health Medical Group, Grand Rapids, MI.

Introduction: The ACOSOG Z0011 trial has been lauded as a practicechanging trial by demonstrating lack of a survival benefit in performing axillary lymph node dissection (ALND) in patients with sub-clinical sentinel lymph node (SLN) metastases. To date, no studies have measured the direct impact of the results on patient care in the post-Z0011 era. Methods: A retrospective chart review was performed for patients with invasive breast cancer who underwent lumpectomy and SLN biopsy. The time period was November 1, 2008 to June 30, 2013, 28 months before and after the publication of the Z0011 trial. Data from seven hospitals were obtained and analyzed in 14 month time periods. The primary outcome measures were the rate of completion ALND and performance of intraoperative SLN analysis in patients meeting the Z0011 criteria. Significance was assessed for p<0.05. Results: A total of 1125 lumpectomies with SLN biopsies were performed. There were 180 subjects meeting the inclusion criteria, 70 of which were in the post-Z0011 era. Performance of ALND (p<0.0001) and intraoperative SLN analysis (p<0.0001) steadily declined during each time period (Fig. 1). Despite these reductions, the rates of ALND and intraoperative SLN analysis were still 29% and 45%, respectively, in the latest time period. On multivariate analysis, patients more likely to undergo ALND on multivariate analysis included those with extracapsular extension in the SLN (OR 11.7, 95% CI 2.5-54.8) and those who underwent re-excision lumpectomy (OR 10.2, 95% CI 2.3-46.3) or completion mastectomy (OR 12.9, 95% CI 1.8-94.5) for close/positive margins. Neither surgeon specialization nor hospital size impacted treatment. On subgroup analysis of patients with ALND, only 13/121 (11%) were upstaged to \ge N2 and 72/121 (60%) had zero additional positive lymph nodes identified. Conclusion: The results of ACOSOG Z0011 have indeed proved to be practice-changing in a community hospital setting. Future efforts should focus on quality monitoring to improve on the delivery of care to patients with sub-clinical SLN metastases who may benefit from avoiding the morbidity of unnecessary ALND.



P14

The Value of Screening Breast MRI in an At Risk Population E. Bloomquist,* N. Ajkay, T.G. Frazier, A.V. Barrio. *The Bryn Mawr Hospital, Bryn Mawr, PA*.

Background: In 2007, the American Cancer Society published guidelines for screening breast magnetic resonance imaging (MRI) in patients at high risk for breast cancer. However, the low specificity of MRI may result in unnecessary biopsies and elevated healthcare costs. The aim of our study was to assess the value of screening MRI in a high risk population. Methods: Following IRB approval, a retrospective chart review identified 152 high risk patients who underwent one or more screening MRIs (mean 2.4, range 1-8) between January 2006 and December 2012. MRIs were ordered in asymptomatic women with a personal history or family history (Tyrer-Cuzick lifetime risk > 15%) of breast cancer, atypical hyperplasia (AH), lobular carcinoma in situ (LCIS), or dense breasts. Patients with a BRCA mutation were excluded. Results: In total, 372 screening MRIs and 745 screening mammograms were performed in 152 high risk women. Personal history (45%) and family history (30%) were the most common reasons for screening with MRI. Of 372 MRIs, 39 (10.5%) biopsies were recommended in 28 patients. Cancer was detected in 4/39 (10.3%) MRI biopsies and in 4/152 (2.6%) MRI screened patients. Three cancers were detected by MRI alone (2 breast, 1 axillary) for a cancer detection rate of 0.8% (3/372). All 3 cancers were detected in women with a personal history of breast cancer as their only risk factor. Of 745 screening mammograms performed in the same cohort, 31 (4.1%) biopsies were recommended in 25 patients. Cancer was detected in 12/31 (38.7%) mammogramgenerated biopsies and in 12/152 (7.9%) patients, for a cancer detection rate of 1.6%. Over the 6 year study period, the cost to detect one cancer with MRI screening was \$ 98,020.79. Conclusions: Screening with breast MRI led to a substantial number of biopsies and resulted in detection of occult malignancy in a limited number of patients with a personal history of breast cancer. The cost to detect one cancer with screening MRI was significant in this population. Further refinement of the ACS guidelines for screening with MRI in high risk patients may be needed to avoid unnecessary healthcare expenditures.

Table 1. Medicare reimbursement rates and cost to detect one cancer with screening MRI in a high risk population

Imaging	Medicare Reimbursement	N	Cost
Breast MRI	\$626.02	372	\$232,879.44
MRI Biopsy	\$1,207.06	28	\$33,797.68
Ultrasound guided biopsy	\$1,024.35	10	\$10,243.50
Stereotactic biopsy	\$945.76	1	\$945.76
6 month F/U MRI	\$626.02	12	\$7,512.24
Pathologic analysis of core biopsy	\$222.69	39	\$8,683.74
Total cost for screening MRI			\$294,062.36
Total cost per cancer (n=3)			\$98,020.79

MRI magnetic resonance imaging

The Clinical Value of the 21-gene Recurrence Score (RS) Assay for High-grade Tumors is Questionable M. Gage,^{2*} M. Rosman,¹ C. Mylander,¹ E.M. Giblin,¹ L. Tafra.¹ *1. Breast Surgery, Anne Arundel, Annapolis, MD; 2. Walter Reed National Military Medical Center,*

Bethesda, MD.

Introduction: Controversy exists over the ability of Oncotype Dx (ODX) to add benefit over routine pathological analysis. Although published results show high grade and RS have equal hazard ratios, high tumor grade is not routinely considered an exclusion criterion for ODX testing. Our purpose was to determine if ODX testing on high grade tumors has significant clinical utility. Methods: Three pathologists using the same staining and computer-aided slide reading methodology from 4/08 to 7/13 evaluated 226 samples that underwent ODX testing; the retrospectively analyzed data included RS, tumor type, tubular formation, nuclear pleomorphism, mitotic count, and ER, PR, HER2 and Ki67 status. Results: Of the 226 samples, 37 (16.4%) have a Nottingham Grade (NG) of 8 or 9 (high grade). When evaluated separately, the high grade group and the rest of the cohort showed no statistical difference in mean age and tumor size. However, mean Ki67 is significantly higher $(59\% \pm 9\% \text{ vs.})$ $19\% \pm 4\%$). The vast majority of patients with high grade tumors (n=31, 83.8%) have a RS of 26 or above (the threshold for the chemo-sensitive group in the TAILORx trial). The distribution of RS is shown in the Table. Of the 27 with a NG of 9, only one has a RS below 26, it is 25. Additionally, 5% (n=11) have low ER (<20%); a group previously shown to have high RS (30 and above in this sample). To determine the potential impact of excluding from ODX testing the group of high-grade-or-low-ER patients we examined our breast center's population of invasive, sentinel lymph node negative, hormone positive cancer patients. It contains 20.4% high-grade-or-low-ER patients, while 16.8% in this study are in that group. Conclusion: ODX testing has limited clinical utility in patients with high grade tumors, because of their strong concordance with a high RS. In view of equal hazard ratios of RS and high grade, as evaluated by a multivariate Cox model (using age, several pathologic variables, and RS)(Piak et al. NEJM '04), the decision to give or withhold chemotherapy based solely on ODX testing is not supported. Further studies may confirm the limited clinical value of ODX testing in these patients.

Distribution of Oncotype DX Recurrence Score in Study

	≤10	11-17	18-25	26-30	≥31	Total
NG 3-7	47	75	48	9	10	189
NG 8	0	2	3	1	4	10
NG 9	0	0	1	6	20	27
Total	47	77	52	16	34	226

NG: Nottingham Grade Score. A NG of 8 or 9 defines high grade tumor.

P16

Pathologic Nodal Stage (pN) is Superior to Lymph Node Ratio (LNR) as a Predictor of Recurrence and Survival in Persistently Node-positive Breast Cancer following Neoadjuvant Chemotherapy (NAC) J. Steiman,* A. Soran, K. McGuire, P. McAuliffe, E. Diego, M. Bonaventura, R. Johnson, G. Ahrendt. *Magee-Womens Hospital of UPMC, Pittsburgh, PA.*

Introduction: Axillary node status predicts survival in breast cancer. The current classification system (pN) is determined in part by an absolute number of positive lymph nodes (LN). Some authors have reported LNR to more accurately predict recurrence and survival versus pN, but this has not been evaluated in the NAC setting. It has also been reported that fewer lymph nodes are retrieved after axillary lymph node dissection (ALND) following NAC. A decrease in the number of lymph nodes identified by ALND in this cohort of patients is presumably the effect of chemotherapy on their "normal" lymph nodes, making them unidentifiable during pathologic exam. As such, NAC may falsely elevate the LNR while having no effect on the number of positive nodes. Therefore, pN may not be the best predictor of diseasefree or overall survival (OS). We sought to compare the utility of LNR versus pN in predicting recurrence and OS after NAC. Methods: A retrospective review was completed through the Cancer Registry. Patients (pts) who underwent NAC with documented node-positive breast cancer were evaluated from 2005-10. LNR was calculated by dividing all positive nodes by total LN retrieved. Pts were then divided into 3 groups according to their LNR (1-20%, 21-60%, >61%), in keeping with previous reports. Overall recurrence (OR), loco regional recurrence (LRR), distant recurrence (DR) and OS were analyzed. Results: A total of 252 pts with clinically node positive disease received NAC. Pts who had a complete axillary response or only sentinel lymph node biopsy were excluded from analysis. Two hundred seven pts who had ALND of >6 nodes were then analyzed. Average LN retrieved was 16 +/- 4. Average pN was 5 +/- 5. On univariate analysis, LNR was predictive of LRR and DR, but not OR or OS. In contrast, pN was predictive of OR, LRR, DR and OS. Conclusions: In our cohort of pts who received NAC and had persistently positive LN, pN was superior to LNR in predicting OR and OS. This calls into question the utility of calculating LNR in pts who have undergone NAC.

-						
	omnaricon	ot I		<u>ы</u>	to.	nN
_	UIIIDalisuli	01	_ N	11	w	DIN

		LNR				pN		
	1-20%	21-60%	>61%		NI	N2	N3	
Pts (n)	103	74	30		114	62	31	
OR	25 (24%)	22 (30%)	14 (47%)	p=0.06	25 (22)%	19 (31%)	17 (55%)	p=0.002
NR*	78 (76%)	53 (72%)	16 (53%)		89 (78%)	43 (69%)	15 (48%)	
LRR	8 (8%)	2 (3%)	1 (3%)	p=0.02	8 (7%)	2 (3%)	1 (3%)	p=0.002
DR	17 (17%)	19 (26%)	13 (43%)		17 (15%)	17 (27%)	15 (48%)	
OS	77 (75%)	49 (66%)	18 (60%)	p=0.22	87 (76%)	41 (66%)	16 (52%)	p=0.02

*NR= no recurrence

P17

Time to Fixation Significantly Impacts Prognostic Factor Testing A. Rickles,* E. Tillett, K. McCarthy, B. Turner, M. Jackson, P. Tang, R. Farkas, D.G. Hicks, K.A. Skinner. *University of Rochester; Rochester, NY.*

Background: Accurate prognostic factor testing is essential for the appropriate use of targeted therapies in breast cancer. Based on bench studies showing that estrogen receptor (ER) staining diminishes with increasing specimen ischemic time, guidelines for specimen processing currently recommend a time to fixation (TTF, time from specimen extraction to specimen fixation) of < 60minutes (min). This study sought to evaluate whether TTF impacts prognostic factor testing in the clinical setting. Methods: All breast cancer biopsies and resections from a single institution between 2008-2013 were reviewed. ER, progesterone receptor (PR), Human Epidermal Growth Factor Receptor 2 (Her2) status and TTF were recorded. Core biopsies were assigned a TTF of 10 min. Critical Time Analysis was performed to identify the earliest time at which the fraction of + cases significantly changes. The fraction of positive (+) specimens (ER,PR: Allred>2, Her2: IHC 3+ or FISH ratio >2.2) was then compared between TTF above and below the critical time value using Chi-Square test. The effect of increasing TTF on the fraction of + cases was determined by linear correlation. Results: Out of 736 breast cancer specimens, the mean TTF was 53.8 min (SD=37.8 min). 453 (61.5%) cases had a TTF <60min and 283 (38.5%) had TTF >60min. The critical time points for ER, PR and Her2 were 55, 45, and 25 min, respectively. 83.5% of specimens with TTF less than 55 min were ER+ compared to 73.2% of those with longer TTF (p=0.001). 74.7% of specimens with TTF less than 45 min were PR+ compared to 66.5% of those with longer TTF (p=0.016). 20.0% of specimens with TTF less than 25min were Her2+ compared to 8.9% of those with longer TTF (p=0.004). All 3 prognostic factors had a negative correlation with TTF (ER: Pearson's Correlation Coefficient (rho) = -0.945, p=0.004, Figure 1; PR: rho = -0.846, p=0.016; Her2: rho = -0.720, p=0.068). Conclusion: This is the first clinical study to demonstrate that ER, PR, and Her2 staining decreases with increasing TTF, with significant changes seen as early as 25 minutes. Minimizing TTF is critical for accurate prognostic factor testing and appropriate therapeutic decisions in breast cancer.



P18

Risk of Breast Cancer in Women Observed after Core Biopsy Diagnosis of Atypical Ductal Hyperplasia N. Ganesan, T.B. Bevers, J. Ying, R. Coyne, D. Lane, C. Albarracin, I. Bedrosian.* University of Texas, MD Anderson Cancer Center, Houston, TX.

Background: Surgical excision remains standard practice to rule out occult carcinoma after a diagnosis of atypical ductal hyperplasia (ADH) on core biopsy. We hypothesized that multidisciplinary team review could identify women with ADH at low risk for occult carcinoma who could be observed and whose outcomes would be similar to those undergoing excision. Methods: Our prospective departmental registry was reviewed to capture the management and outcomes of patients with ADH. Breast cancer (BrCa) events were classified as index site (site of ADH biopsy), ipsilateral breast unrelated to index site or contralateral breast. Patients were excluded from analysis if they had no followup, had ADH based on excisional biopsy or had been upstaged to carcinoma following diagnostic excision. Results: We identified 125 women who had been observed and 50 who had undergone excision with benign findings. Thirteen percent had a prior BrCa history and 24% took chemoprevention. There were no significant differences in age, race, prior BrCa history, use of chemoprevention and median follow-up between the 2 groups. With a median follow-up of 3 years, 14 BrCa events were noted in 13 patients. 5-year probability of any BrCa event for the cohort was 20%. Six BrCa events, including 1 bilateral, (12%) were reported in the surgery group and 7 (5.6%) in the observed group (p=0.14). Index site events were the same in both groups (2% vs 0.8%, p=0.49) as were ipsilateral cancers outside of the index site (4% vs 4.8%) p=1.00). All the contralateral cancers were in the surgical group (8 vs 0%, p< 0.01). Prior BrCa history was the only variable significantly associated with any subsequent BrCa event. When follow-up time was taken into account, Cox proportional hazards regression analysis showed that this association remained significant even after adjusting for all significant variables (HR 12.5 [95%CI 3.3-42.5]). Conclusion: Observation is appropriate in select women with core biopsy diagnosis of ADH. Index site failures are rare and are superseded by risks of cancer elsewhere in the breast. Outcomes are similar among women managed with observation or with excision of ADH.

P19

Breast Cancer Molecular Subtype Predicts Lymphovascular Invasion (LVI) and Lymph Node Involvement S. Ugras,* M. Stempel, S. Patil, M. Morrow. *Memorial Sloan-Kettering Cancer Center, New York, NY.*

Introduction: The ACOSOG Z11 trial demonstrated that axillary dissection (ALND) is not necessary for local control or survival in women with T1/2 cN0 cancer undergoing breast conserving therapy. There is concern about applying these results to triple negative (TN) breast cancers secondary to their poor prognosis and increased rate of in-breast recurrence. We sought to examine the frequency of LVI and nodal metastases in TN breast cancer to determine whether ALND can be safely avoided in this subgroup. Methods: Data were obtained from a registered database of patients with invasive breast cancer treated at our institution from January 1998 to December 2010. 11,496 tumors were classifiable into molecular subtype by immunohistochemical analysis: hormone receptor (HR)+/HER-2+, HR+/HER-2-, HR-/HER-2+, and TN(HR-/HER-2-). Multivariate logistic regression analysis (MVA) was used to determine the associations between LVL nodal metastases (any amount of tumor), and involvement of 4 or more nodes with subtype. Results: There were differences in age, tumor size, LVI, nuclear grade, extensive intraductal component and nodal involvement among subtype (Table 1). On MVA controlling for age, tumor size and grade, subtype was a significant predictor of LVI (p<.0001). Relative to TN tumors, HR+/HER-2+, HR+/HER-2-, and HR-/HER-2+ tumors had higher odds of demonstrating LVI of 2.4 (odds ratio, 2.4; 95% confidence interval 1.9-3.1), 2.0 (2.0;1.6-2.4), and 1.7 (1.7;1.3-2.3), respectively. On MVA adjusting for patient age, tumor size, grade and LVI, TN tumors had the lowest odds of having any lymph nodes involved (p<.0001). HR-/HER+ tumors had higher odds of having 4 or more nodes involved than HR+ and TN tumors. Conclusions: LVI and any nodal metastases were least frequent in TN breast cancers compared with the other subgroups, despite the uniformly worse prognosis and increased rate of local recurrence in these tumors. This suggests that TN breast cancers do not spread via lymphatics and that ALND may be avoided in TN patients meeting ACOSOG Z0011 eligibility criteria. Molecular subtype may be a better predictor of prognosis and guide to adjuvant therapy than nodal involvement.

Tumor and Patient Characteristics	by	Subtype
-----------------------------------	----	---------

	HR+/HER-2+	HR+/HER-2-	HR-/HER-2+	TN	P value
N	915 (8%)	8440 (73%)	621 (5%)	1520 (13%)	
Age (mean, range)	51.0 (21-89)	58.0 (23-96)	54.0 (25-90)	56.5 (19-95)	<.0001
Tumor size (mean (cm))	1.6	1.6	1.7	1.7	<.0001
LVI (%)	43%	28%	41%	32%	<.0001
High nuclear grade (%)	64%	28%	89%	87%	<.0001
EIC >25% (%)	29%	17%	58%	13%	<.0001
Any + Nodes (%)	50%	41%	53%	41%	0.0008
4 or more + nodes (%)	16%	9%	22%	13%	<.0001

P20

Can Completion Axillary Node Dissection be Omitted for Mastectomy Patients with Tumor Positive Sentinel Nodes? S.M. Sharpe,²* K. Yao,¹ E. Wang,¹ E. Liederbach,¹ C. Pesce,¹ D.J. Winchester.¹ *1. NorthShore University HealthSystem, Evanston, IL; 2. University of Chicago, Chicago, IL.*

Background Randomized clinical trials have established equivalent survival for axillary dissection (AD) and sentinel node biopsy (SNB) alone for women with cT1-2cN0M0 breast cancer treated with breast conservation therapy. We hypothesize no survival difference exists for women treated with mastectomy and AD or SNB with limited axillary disease. Methods A retrospective review of the National Cancer Data Base from 1998-2005 was conducted of clinically node-negative patients with pT1-2pN1M0 breast cancer who underwent mastectomy and did not receive neoadjuvant therapy. After controlling for age, adjuvant therapy, grade, race, insurance status and treatment facility type, the 5-year overall survival (OS) was compared between patients who had \leq 3 nodes examined (SNB) versus \geq 10 nodes examined (AD) using the Kaplan-Meier method and Cox regression analysis. Results Of the 83,913 patients analyzed who met study criteria, 6,358 (7.6%) had SNB and 77,555 (92.4%) had AD. The median ages were 60 and 56 years of age for those having SNB and AD, respectively. SNB was associated with a worse OS (HR 1.18; 95% CI 1.06, 1.31; p=0.0027) than AD when examining the entire group of patients with 1-3 positive nodes. However, there was no difference in survival with an AD or a SNB in patients with pT1-2N1M0 disease who received chemotherapy and had 1 positive node (HR=1.06; p=0.65) or 2 positive nodes (HR=1.4; p=0.089). Nor was there a survival difference in patients with pT1N1M0 disease who received hormone therapy alone and had only one positive node. Conclusions Overall survival following mastectomy and nodal sampling varies according to disease burden and treatment. Axillary dissection can be omitted in patients with pT1-2N1M0 disease with two or fewer positive nodes if treated

with chemotherapy. It can also be omitted for patients with pT1N1M0 disease with single node involvement if treated with hormonal therapy alone.

P21

Neutrophil Elastase Uptake by Breast Cancer Increases Anti-tumor Adaptive Immune Response by Upregulation of HLA Class I Molecules A. Chawla,* A. Philips, N. Qiao, P. Sukhumalchandra, C. Kerros, J. Molldrem, G. Alatrash, E. Mittendorf. Surgical Oncology, MD Anderson Cancer Center, Houston, TX.

Introduction: Neutrophil elastase (NE) is an inflammatory mediator that is taken up by breast cancer cells. We have previously shown that NE uptake increases susceptibility to lysis by cytotoxic T lymphocytes (CTL) targeting the tumor antigens PR1 and cyclin E. This study was undertaken to determine if NE uptake has a more ubiquitous effect on adaptive immunity through regulation of HLA class I expression. Methods: Healthy donor HLA-A2+ peripheral blood mononuclear cells (PBMC) were used to generate antigen specific CTL by stimulation with IL7, IL2, and dendritic cells pulsed with E75, a HER2derived epitope we are currently investigating as a vaccine in clinical trials. Calcein-AM cytotoxicity assays were performed to evaluate E75-specific lysis of MDA-MB-231 breast cancer cells maintained in standard media ± NE (10µg/mL). NE uptake was confirmed using flow cytometry. HLA-A2 expression was determined by staining with anti-HLA-A2 antibody (bb7.2) and assessed using flow cytometry. Cells were maintained with NE ± protease inhibitors elafin or phenylmethanesulfonyl fluoride (PMSF) to determine if the effects of NE on HLA expression required enzymatic activity. Results: NE uptake resulted in increased lysis by E75-specific CTLs (Fig 1, *p<0.05). NE uptake also led to a concentration- and time-dependent increase in HLA-A2 surface expression. At a 12-hour time point, the MFI for cells in NE-supplemented media was 7341 ± 867 vs. 5144 ± 272 for cells in standard media, p<0.05. NE co-incubation with elafin or PMSF resulted in a 3-fold decrease in protease activity (p<0.05) and abrogated the effect of NE on surface HLA-A2 expression (MFI: 8687 ± 419 vs. 5490 ± 530 for NE vs. NE+elafin; 8569 ± 395 vs. 4644 ± 564 for NE vs. NE+PMSF; p<0.05). MCF-7 cells, which took up NE poorly, exhibited no change in HLA-A2 expression ± NE (MFI: 722 ± 69 vs. 693 ± 75 , p=0.69). Conclusions: NE uptake leads to increased lysis by antigen-specific CTL in part by increasing HLA class I expression. These results show an important link between innate and adaptive immune responses that could be exploited to improve anti-tumor immunotherapy.

Figure 1: E75-Specific CTL Lysis of MDA-MB-231 Cells



E75-specific CTL were used in calcein-AM cytotoxicity assays at various effector to target ratios (E:T) versus MDA-MB-231 cells maintained in low serum media \pm NE supplementation (10ug/mL). Uptake of NE by MDA-MB-231 cells resulted in increased E75-specific lysis. E75-specific lysis was confirmed using T2 cells pulsed with E75 peptide or irrelavent PR1 peptide (data not shown). Assays were performed in triplicate; results are compiled from 3 separate experiments, (*p<0.05).

P22

Invasive Breast Cancer with and without Ductal Carcinoma in situ: Do Outcomes Differ? M. Ruszczyk,¹* C. Hong,¹ H. Hwang,² S.E. McCann,¹ P. Schedin,³ P. Starostik,⁴ P. Masso-Welch,⁵ C. Ambrosone,¹ S. Kumar.⁶ *1. Roswell Park Cancer Institute, Department of Cancer Prevention, Buffalo, NY; 2. University of Texas, Southwestern Medical Center, Dallas, TX; 3. University of Colorado, Department of Medicine, Denver, CO; 4. Roswell Park Cancer Institute, Department of Clinical Diagnostics, Buffalo, NY; 5. University at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY; 6. Roswell Park Cancer Institute, Department of Surgical Oncology, Buffalo, NY.*

Invasive carcinoma in the absence of concomitant ductal carcinoma in situ (DCIS) may reflect a biologically more aggressive breast tumor than invasive carcinoma with DCIS. The objective of this study was to compare clinical characteristics and survival endpoints for invasive cancer with and without a DCIS component. From 1522 consecutive patients treated surgically for invasive ductal carcinoma between July 1997 and December 2005, we identified 1386 women who met study criteria and had pathology available. We compared clinical characteristics and survival outcomes between patients with a DCIS component (mixed IDC/DCIS) and without concomitant DCIS (pure IDC). Local recurrence, distant metastasis, breast cancer specific survival and overall survival were examined using clinical characteristics and treatment information. Survival analyses were performed by creating Kaplan-Meier curves and constructing proportional hazards models for hazard ratios (HRs). Models were adjusted for age at diagnosis, tumor size, grade, lymph node status, lymphovascular invasion, estrogen receptor (ER) status, and surgical margin status. IDC from 238 (19%) patients were considered pure IDC. Pure IDC was associated with older age, larger tumor size, higher grade and negative ER status. Mean follow-up time for recurrence and death was 80.2 (SD, 37.2) and 103.0 (SD, 38.1) months, respectively. Patients with pure IDC were less likely to experience a local recurrence, even after adjustment for clinical variables (HR 0.32; 95% confidence interval (CI) 0.11-0.90). Distant metastasis and death from breast cancer were less likely to occur among patients with pure IDC; however, estimates were not statistically significant (HR 0.79; 95% CI 0.48-1.30 and HR 0.78; 95% CI 0.47-1.29, respectively). There was no difference observed between patients with mixed IDC/DCIS and pure IDC in overall survival (HR 0.99; 95% CI 0.70-1.38). Recurrence was higher among patients with mixed IDC/DCIS, even after adjustment for surgical margin status. Patients with pure IDC may represent a unique group who are less likely to recur. Although patients with pure IDC have poorer pathologic features, survival is unchanged



Figure 1 Kaplan-Meier curve of (A) local recurrence, n=1,334 (B) metastasis, n=1,354 (B) breast cancer specific survival, n=1,358 and (C) overall survival, n=1,382 in patients with mixed IDC/DCIS and pure IDC "adjusted for age at diagnosis, tumor size, grade LN status, presence of LM, ER status, and surgical margins IDC, invasive ductal cancinoma DCIS, ductal cancinoma in stu

P23

Predicting Occult Malignancy or High-risk Lesion in Contralateral Prophylactic Mastectomy L.M. Erdahl,* T.J. Hieken, T.L. Hoskin, A.C. Degnim, J.C. Boughey. *Mayo Clinic, Rochester, MN*.

INTRODUCTION The increase in rates of contralateral prophylactic mastectomy (CPM) for patients with unilateral breast cancer has prompted criticism that surgeons fail to adequately counsel patients. Identifying risk factors for contralateral high risk lesion (HRL) or occult malignancy (OM) can aid individual risk assessment. Our aim was to evaluate the frequency and predictors of HRL or OM identified in CPM specimens. METHODS We identified breast cancer patients undergoing CPM from 10/2008 to 06/2013 from a prospective breast surgery database. Logistic regression was used to assess potential risk factors for the outcome of occult finding in CPM. RESULTS We identified 740 women with unilateral cancer undergoing concurrent therapeutic mastectomy and CPM with no prior history of cancer in the CPM breast. Clinically occult HRL or OM was identified in 108 (14.6%) CPM specimens: HRL in 78 specimens (10.5%) and OM in 30 specimens (4.1%), invasive in 17 (2.3%) and in situ only in 13 (1.8%). In univariate analysis, age, estrogen receptor (ER) positivity, progesterone receptor (PR) positivity, and invasive lobular carcinoma (ILC) in the index breast were significantly associated with an occult CPM finding. Patients treated with neoadjuvant chemotherapy (NAC) were less likely to have occult findings (7% vs 17%, p=0.0006). Age, ILC, and PR positivity remained significant on multivariate analysis. The adjusted effects for these variables were: age, OR 1.35 (95% CI: 1.10-1.66) per 10-year increase; ILC vs other histology, OR 2.71 (95% CI: 1.50-4.81); and PR positive, OR 1.81 (95% CI: 1.01-3.40). There remained a trend for NAC with OR 0.49 (95% CI: 0.22-1.04). There was no significant association of contralateral presentation, HER2neu status, or clinical stage with occult finding on CPM. CONCLUSION Although invasive cancer is infrequently identified in CPM specimens, the rate of either HRL or OM was 14.6%. We identified older age and index breast cancer characteristics of ILC and PR positivity as predictive factors for HRL or OM in the CPM. These findings can assist with counseling patients regarding the risk of contralateral cancer and improve selection of patients for CPM.

Univariate Analysis: Factors Associated with Occult Finding in Contralateral Prophylactic Mastectomy

Factor	N	Occult Finding in CPM N(%)	p-value
Age			0.02
<50	325	36 (11.1%)	
≥50	415	72 (17.3%)	
Contralateral preoperative diagnosis			< 0.0001
DCIS	158	23 (14.6%)	
IDC	428	47 (11.0%)	
ILC	71	23 (32.4%)	
IMC	38	7 (18.4%)	
Recurrence	32	8 (25%)	
Other malignancy	13	0	-
Neoadjuvant therapy			0.0006
No	551	94 (17.1%)	
Yes	189	14 (7.4%)	
Contralateral presentation			0.41
Screening MMG or MRI	374	59 (15.8%)	
Symptomatic*	346	46 (13.3%)	
Other	15	1 (6.7%)	
Missing	5	2	
Contralateral ER status			
Negative	177	15 (8.5%)	
Positive	530	86 (16.2%)	
Missing	33	7	
Contralateral PR status		15.	
Negative	303	28 (9.2%)	
Positive	404	73 (18.1%)	
Missing	33	7	
Contralateral Her2 status			0.10
Negative	427	66 (15.5%)	
Positive	89	8 (9.0%)	
DCIS	158	23	
Missing	66	11	
Contralateral Clinical T stage			0.94
TO	3	1 (33.3%)	0.51
Tis	163	26 (16.0%)	
TI	240	36 (15%)	
T2	209	28 (13.4%)	
T3	81	12 (14.8%)	
T4	17	2(11.8%)	
Missing	27	3	
Contralateral Clinical N stage			0.12
NO/NX	574		
N1-N3	165	90 (15.7%)	
Missing	1	18 (10.9%)	

*Symptomatic presentation combined the categories palpable abnormality, palpable axillary mass, nipple discharge, focal breast pain, skin abnormality, and Paget's disease.

P24

Impact of Axillary Ultrasound (AUS) on Axillary Dissection in Breast Conserving Surgery (BCS) C. Reyna,* A. Frelick, J.V. Kiluk, N. Khakpour, C. Laronga, M. Lee. *H. Lee Moffitt Cancer Center*, *Tampa, FL*.

Introduction: The American College of Surgeons Oncology Group (ACoSOG) Z0011 trial has revolutionized management of the clinically negative axilla. Increasing use of preoperative AUS for clinically node-negative disease and subsequent FNA may drive axillary lymph node dissection (ALND) in patients (pts) undergoing BCS who fit the ACoSOG Z0011 criteria. We hypothesize that incorporation of preoperative AUS does not lead to excessive ALND in this select population. Methods: After IRB approval, a singleinstitution retrospective review of female breast cancer pts receiving AUS from 2004-2012 was performed; pts with clinical T1 and T2 tumors undergoing BCS were included. Preoperative chemotherapy and recurrent breast cancer cases were excluded. Four pts refused axillary staging after AUS and were excluded. Clinical, radiologic, and pathologic data were collected and analyzed. Results: Of 903 preoperative AUS pts, 121 of the 141 pts (86%) with BCS had no palpable axillary nodes at presentation; 48/121 pts (40%) had an abnormal AUS and 15/48 (31%) had a positive FNA. Fourteen of 15 pts had ALND with 10/14 (71%) having \geq 3 positive nodes. In contrast, 6/33 pts (18%) with abnormal AUS and FNA negative had a positive sentinel lymph node (SLN); only 1 pt (17%) had ALND (≤2 positive nodes). Of the 73 normal AUS, 16 pts (22%) had a positive SLN; 9/16 (56%) had ALND, of which 1 pt (11%) had ≥ 3 positive nodes. In all, 24 pts had ALND; 13 SLN positive did not. In the overall population, AUS plus FNA had sensitivity of 56%, specificity of 100%, and negative predictive value (NPV) of 84%. When evaluating for total nodal disease ≥ 3, AUS plus FNA had a sensitivity of 91%, specificity of 94%, NPV of 99%, and PPV of 71%. Conclusions: Since the publication of ACoSOG Z0011, preoperative AUS/FNA in clinically node-negative BCS pts has raised concerns about unnecessary ALND. Our data demonstrates a high NPV of AUS/FNA for axillary metastasis and remarkable sensitivity of AUS/FNA for operative axillary disease. This supports the practice of considering abnormal AUS/FNA as clinically node-positive despite a normal physical exam, and it should be considered even in patients planning BCS.

Figure 1. Consort Diagram of the Impact of Axillary Ultrasound (AUS) on Axillary Dissection in Breast Conserving Surgery (BCS)



P25

Study to Assess the Feasibility of Tumor Xenograft in Mice as a Valid Preclinical Model of Breast Cancer I.T. Rubio,^{1*} A. Esgueva,¹ B. Morancho,² J. Arribas.³ 1. Hospital Universitario Vall de Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; 2. Vall de Hebron Institute of Oncology, Barcelona, Spain; 3. Vall de Hebron Institute of Oncology, Catalan Institute for Research and Advanced Studies (ICREA), Barcelona, Spain.

Background. Despite recent advances, up to 30% of breast cancer (BC) patients will relapse. Preclinical assays based on breast cancer xenografts (BCx) are the most convincing model for conducting drug development. The objective of the study was to assess the rate of success establishing BCx and to analyze the effectiveness of anti-IL-6 therapy on the growth of BCx from surgical specimens. Methods. Patients with a diagnosis of invasive BC who underwent surgery signed an inform consent. After surgery, isolation of breast cancer cells was performed from some samples. Purified BC cells or tumor pieces were orthotopically injected into the humanized mammary fat pad of NOD-SCID mice. Posteriorly, mice were treated with anti-IL6 neutralizing antibodies. The Ethics Committee approved the study. Results. One hundred and fourteen samples from primary BC were grafted into the mice. Fifteen BC xenografts were established (13.3%). Tumor take rate was correlated with the status of hormone receptors and Her2 expression. Eight of 19 (42%) of triple negative (TN) tumors were successfully engrafted, 1 of 5 (20%) nonluminal Her2 positive, 3 of 36 (8.3%) Luminal Her2 positive, 3 of 43 (6.9%) luminal B Her2 negative tumors. No luminal A tumors were successfully grafted. BCx maintain the features of the original patient tumors. Two HER2 positive and two TN BCx were treated with siltuximab, a monoclonal antibody, to determine the effectiveness of anti-IL6 therapies. Siltuximab inhibited the growth of one HER2-positive tumor. Unexpectedly, the HER2-positive tumor that did not respond to the anti-IL6 antibody expressed high levels of the cytokine indicating that expression of IL6 is not a marker of sensitivity to this treatment. Analysis of CD44hi/CD24lo cells, indicated that the antibody

acts on the tumor initiating cell population. Conclusion. BCx is a valid preclinical model of breast cancer and represents a tool for testing new agents. Our results show that anti-IL6 antibodies may be a therapeutic option in some breast cancers. However, makers of response should be identified in the future since expression of IL-6 does not seem to correlate with effectiveness of the drug.

P26

Screening Patients at Increased Risk for Breast Cancer: Does Digital Breast Tomosynthesis Make a Difference? H. Schmidt,* C. Weltz, A. Cohen, N. Patel, E. Sonnenblick, J. Szabo, L. Margolies, E. Port. *Mount Sinai, New York, NY.*

Introduction: Technical innovations to improve mammography's sensitivity and specificity have included digital breast tomosynthesis (DBT). DBT has been shown to decrease findings related to tissue overlap, thereby reducing false positives and improving detection of cancer. Optimal screening regimens for patients at increased risk for breast cancer remain to be defined. We investigated the utility of DBT in patients at increased risk for breast cancer. Methods: DBT was performed in combination with Full Field Digital Mammography (FFDM) on 2005 patients presenting over one year. 324 patients at increased risk of breast cancer (BRCA mutation, 1st degree relative with breast cancer, or previous biopsy showing LCIS or atypia) were identified. 30/324 (9%) had more than one risk factor. FFDM was performed and management recommendations were prospectively recorded blinded to DBT results. Change in recommendation based on DBT was then determined and recorded. Results: For 324 high risk patients mean age was 52 (range 25-88). 191 (59%) had dense breasts. Tomosynthesis affected interpretation and changed management in 39/324 (12%). The most common change was elimination of recommendation for further imaging in 28/39 (72%) patients. In 9/39 (23%) DBT detected findings not seen on FFDM that led to additional mammographic views or ultrasound, and in 2/39 (5%) DBT resulted in decreased imaging for one breast, but increased for the other. Findings on DBT led to image guided biopsy in 4 cases yielding 2 with fibrocystic changes, 1 papilloma, and 1 radial scar. Of the 324 patients, 8 (2%) were diagnosed with breast cancer. All cancers were seen on both FFDM and DBT with the exception of one case diagnosed by ultrasound only. There was no individual risk group where change in management based on DBT was significantly higher; age and breast density also did not affect change in management. Conclusion: In a population of patients at increased risk for breast cancer, DBT decreased the need for additional imaging. Further evaluation of DBT relative to other imaging modalities may define the role of this technology in the screening regimens for high risk patients.

P27

Breast Surgery Training and Tendency to Operate: A National Survey N. Wilson, ^{1*} F. Wilson, ² K. Murayama, ³ K. Armstrong, ⁴ B.J. Czerniecki. ¹ *1. Department of Endocrine and Oncologic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA; 2. Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania, Philadelphia, PA; 3. Department of Surgery at Abington Memorial Hospital, Abington, PA; 4. Department of Medicine at the*

Memorial Hospital, Abington, FA, 4. Department of Meatcine at the Massachusetts General Hospital, Boston, MA.

Background: Surgical practice variation may lead to adverse outcomes. It is unclear whether post-graduate training in breast surgery affects practice patterns. Methods: National, web-based survey. Participants were board-certified US surgeons. The survey consisted of 25 clinical case-scenarios which were ambiguous with regards to the appropriateness of surgical intervention. Surgeons rated their likelihood to recommend surgery on a five-point Likert scale. We defined tendency to operate (TTO) as the mean of the responses. There were 3 breast-relevant scenarios. Fellowship training status was by self-report. Results: Of 907 total respondents, 64 (7.1%) reported receiving fellowship training in breast surgery or surgical oncology. There were 102 practicing breast surgeons, of whom 26 (25%) were fellowship trained. There were no differences between fellowship-trained and non-fellowship-trained breast surgeons in terms of gender (p=0.23), race (p=0.56) or ethnicity (p=0.27), but fellowship-trained breast surgeons were significantly younger, mean (SD) age 45.8 (1.8) vs. 53.4 (1.1) years, p=0.0004. Regarding the breast scenarios, breast surgeons had significantly lower TTO scores versus non-breast surgeons, mean (SD) TTO 2.10 (0.08) vs. 2.95 (0.03), p<0.0001. Fellowship-trained breast surgeons had a similar TTO to non-fellowship trained breast surgeons,

mean TTO 2.27 (0.17) vs. 2.04 (0.09), p=0.24. TTO in non-breast cases did not differ between breast surgeons and non-breast surgeons, mean TTO 3.11 (0.05) vs. 3.14 (0.02), p=0.50. In multivariable analysis, working with residents, working in small private practice, and higher TTO in non-breast cases were associated with higher TTO in breast cases. Malpractice concerns, surgical volume, and fellowship training were not associated with TTO. Conclusions: Breast surgeons are significantly less likely to operate on ambiguous breast cases than surgeons who don't perform as much breast surgery, despite having similar operative tendencies for non-breast cases. This effect does not appear to be mediated by fellowship training. Our research suggests that greater specialization, even after surgical training is completed, may act to decrease practice variation.

P28

Identification of BRCA Gene Mutation Carriers through Systematic Family History Screening in Mammography Populations A. Hendrix,* L. Robinson, M. Pritzlaff, R. Gabordi, R. Rao, A. Leitch, X. Xie, S. Pass, P. Read, D. Euhus. Surgical Oncology, UT Southwest-

ern, Dallas, TX Introduction: Historically, BRCA gene mutation carriers are identified when physicians recognize high-risk family histories and refer patients for genetic counseling. Even with special training and software tools, this approach is inefficient. An alternative approach is to automate genetic screening and referral processes at just a few points of service rather than across the entire primary care system. Methods: A validated family history screening tool was incorporated into the mammography intake processes at three sites: two County Hospitals primarily serving uninsured/underinsured women and one University Hospital primarily serving affluent insured women. Results: Between October 1, 2011 and June 30, 2013, 57,996 women underwent family history screen in the County Hospitals and 34,131 in the University Hospital. 2,650(4.6%) of the screened County hospital population met criteria for referral to Cancer Genetics as compared to 1,557 (4.6%) in the screened University hospital population. Only 15% of the County hospital patients whose screening forms met criteria for genetic counseling referral were found to be ineligible when interviewed by a patient navigator. Ultimately, 446 patients were tested for BRCA gene mutations in the county hospital with a 4.9% positivity rate, and 115 patients in the University hospital with 15.6% positivity rate. Barriers to mutation carrier identification included refusal to schedule a Genetic counseling appointment (22% for County patients and 17% for the University patients) and failure to attend a counseling appointment (50% for the County patients and 15% for the University patients). Conclusion: Systematic family history screening is feasible and reasonably accurate in uninsured/underinsured mam-

P29

mography populations, but unresolved barriers to accessing genetic counsel-

ing services significantly hampers identification of mutation carriers.

Breast Reconstruction is not Associated with Reduced Overall or Breast Cancer Specific Survival: Long-term Follow-up of a Retrospective Population-based Cohort J. Platt, ¹* N.N. Baxter,³

J. McLaughlin,¹ J. Semple.² 1. University of Toronto, Toronto, ON, Canada; 2. Women's College Hospital, Toronto, ON, Canada; 3. St. Michael's Hospital, Toronto, ON, Canada.

Introduction: Many women with breast cancer require mastectomy and may consider breast reconstruction (BR) as an option to restore the breast mound. Concern that BR has a negative impact on survival has not been thoroughly evaluated using long-term follow-up data. Randomized study design may not be feasible or ethical. Methods: A retrospective cohort study using population-based data from Ontario Cancer Registry (OCR). We selected records of women who underwent BR within 5 years after mastectomy for invasive breast cancer from OCR (1980 to 1990). We analyzed the records of an age, cancer histology matched cohort from OCR who did not undergo BR to form the control group. We obtained patient demographic and oncologic information including pathology. To account for our timevarying exposure, an extended Cox proportional hazards model was used to compare overall and breast cancer specific survival (OS, BCS) after adjusting for age, tumor size, lymph node status and hospital. Secondary analysis examined differences in OS across 3 periods (< 10, 10 - 19, 20 - 30 yrs from diagnosis) using Kaplan-Meier curves. Results: 758 matched pairs formed our cohort, with a median age of 44 years (interquartile range, IQR

39 to 51). Median time to BR was 1.5 years (IQR 0.9 - 2.4) and follow-up was 23.4 years (IQR 1.1 - 33.0). BR participants had lower nodal disease status compared to controls (44% vs. 36% with N0, p = 0.004), but did not differ on tumor size (p = 0.067). Fewer BR patients died overall or from breast cancer compared to controls (OS: 44.5% vs. 56.7%, p < 0.0001; BCS: 31.8% vs. 42.6%, p = 0.0002; respectively). BR was associated with a 15% reduced risk of breast cancer death, after adjustment (OS: hazard ratio 0.85, 95% CI 0.73 to 0.97; BCS: hazard ratio 0.82, 0.69 to 0.97). Among 879 (58%) women surviving > 20 years, there was no difference in OS (Log Rank p = 0.45). Conclusion: In a large cohort of women with breast cancer followed over 20 years, there is no evidence that BR is associated with reduced overall or breast cancer specific survival compared to mastectomy alone.

Events overall, 10 & 20 years from breast cancer diagnosis, breast reconstruction and mastectomy alone

	Death from any cause	Death due to breast cancer	Metastasis
	n (%)	n (%)	n (%)
10 year			
BR	178 (23.5)	163 (21.5)	94 (12.4)
Control	220 (29.0)	198 (26.1)	133 (17.5)
20 year			
BR	277 (36.5)	226 (29.8)	96 (12.7)
Control	354 (46.7)	296 (39.1)	135 (17.8)
Overall			
BR	345 (45.5)	241 (31.8)	96 (12.7)
Control	430 (56.7)	323 (42.6)	135 (17.8)

BR, Breast reconstruction Control, mastectomy alone

P30

The Association of Health Literacy with Screening Mammography L. Wikholm, ¹* I. Komenaka, ¹ J. Nodora, ² C. Hsu, ³ M. Bouton, ¹

L. WRIGHI, J. Kolmana, J. Foorota, C. Hisa, In Zoana, M. Martinez, A. Klemens,¹ B. Weiss,⁴ I. Maricopa Medical Center, Phoenix, AZ; 2. University of California San Diego, San Diego, CA; 3. Cleveland Clinics, Cleveland, OH; 4. University of Arizona, Tucson, AZ.

Background: Patient compliance with screening mammography, starting at either 40 years or 50 years, is suboptimal. The current study was performed to determine factors which affect use of screening mammography in an underinsured population. Methods: From January 2010 to April 2013, every female patient at least 40 years of age seen at a Breast Clinic was included. Use of screening mammography was determined from the medical records. Health literacy was assessed using the Newest Vital Sign (NVS) validated screening instrument. Multivariate analysis was performed to determine factors associated with use of screening mammography. Results: A total of 1664 patients were included. The population was racially and ethnically diverse (NHW 23%, AA 11%, Hispanic 61%). Ninety percent of patients were insured by Medicaid or uninsured. Health literacy assessment found that 80% of patients had low health literacy and 20% had adequate health literacy. Only 22% of those with a high school education had adequate health literacy. Of the 1664 patients, only 31% had undergone screening mammography. The rate of mammography screening among women 40-49 years of age was 35% and the rate among women 50 years of age and older was 27%. Univariate analysis found that Hispanic ethnicity and being uninsured were associated with not undergoing screening, while younger age, NHW race, English as primary language, family history of breast cancer, more years of education, adequate health literacy, current employment, non-smokers, and higher income were associated with greater use of screening mammography. After adjustment for all of the aforementioned variables in multivariate logistic regression analysis, only three factors were associated with poor compliance with screening mammography: low health literacy (OR=0.27; 95% CI 0.19 - 0.37; p < 0.0001), smoking (OR=0.64; 95% CI 0.47 - 0.85; p = 0.0019) and being uninsured (OR=0.66; 95% CI 0.51 -0.85; p = 0.0011). Conclusions: Health literacy was the strongest predictor of use of screening mammography. Tailored interventions not only to increase awareness of screening, but also of the availability and coverage of screening may have the potential to improve mammography screening rates.

Correlated Intrinsic Breast Cancer Subtypes and Expression of CD47 in BM and PB Predicts Poor Prognosis M. Nagahara,^{1*} K. Sugihara,¹ M. Mori.² 1. Department of Surgical Oncology, Tokyo Medical and Dental University, Tokyo, Japan; 2. Osaka University, Osaka, Japan.

Introduction: The intrinsic breast cancer subtypes have shown the prognostic features. Focused on CD47 expression in bone marrow (BM) and peripheral blood (PB) we found the correlation between breast cancer subtypes and CD47 expression in BM and PB, which may indicate important implications for prognostic factor. Experimental Design: Quantitative real-time PCR was used to evaluate CD47 mRNA expression in BM and in PB from 452 cases of breast cancer. ER, PR, and Her2 scores were obtained from immunohistochemistry (IHC) staining and Her2 FISH analysis conducted for Her2 score 2+. Results: According to ER, PR, and Her2 statuses, the groups of Her2 enriched (ER- and PR- and Her2 3+) and triple negative(ER- and PR- and Her2-) were divided (n=38 and 72). In Her2 enriched patients with high CD47 expression in BM and PB, survival was significantly poorer compared to patients with low CD47 expression (DFS in BM: P=0.003, DFS in PB: P=0.001, OS in BM: P=0.03, OS in PB: P=0.003). Furthermore, high CD47 expression group in Her2 enriched of multivariate analysis showed significance as an independent variable for poorer prognosis in DFS (BM: P = 0.002, PB: P = 0.01) and in OS (BM: P=0.02, PB: P=0.008). On the other hand, in triple negative patients with high CD47 expression in BM, survival was significantly poorer compared to patients with low CD47 expression group (DFS in BM: P=0.002, OS in BM: P=0.02). Conclusions: Overexpression of CD47 in BM correlated with the recurrence in Her2 enriched and triple negative subtypes. CD47 high expression may indicate the potential capacity to relapse after surgical operation. It can be inferred from the association between CD47 and cancer stem cells that ITC would elude the immune system by taking advantage of activation and initiation of CD47's signal transduction cascade, resulting in inhibition of phagocytosis. CD47 high expression might represent a dormant state in BM and PB. CD47 is a useful prognostic biomarker for predicting survival of Her2 enriched and triple negative subtype in breast cancer and could be used as an index of therapeutic effect marker.



Kaplan-Meire curves of disease free survival (DFS) and overall survival (OS) in BM.

P32

Lobular Carcinoma in situ (LCIS): What Happens after Chemoprevention (CP)? S. Koslow,* A. Park, S. Muhsen, R. Sakr, T. King. Breast Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.

Background: LCIS is both a risk factor and non-obligate precursor of estrogen receptor positive (ER+) breast cancer (BC). Current CP options reduce the risk of BC in women with LCIS, yet these strategies fail in some women. We sought to identify factors associated with failure of CP in LCIS pts and to describe the features of BC that develop after CP use. Methods: From a prospective database of 1317 pts in surveillance for a diagnosis of LCIS (11/1980-7/13), we identified pts who took CP (tamoxifen or raloxifene) for \geq 6 months. Comparisons were made between CP pts who did and did not develop BC. Tumor characteristics were compared between CP pts and those in surveillance only. Results: Among 1317 pts with LCIS, 70(5%) chose risk reducing surgery and were excluded. Of 1247 pts in surveillance, 1190(95%) had $\ge 6 \mod 6$ follow-up and 192 pts(16%) took CP. Among CP pts, median age at LCIS diagnosis was 51yrs, 46% were postmenopausal, 41% had a family history (FH) of BC. 85/192(44%) pts completed 5yrs of CP, 64(33%) pts remain on CP, 30(16%) pts stopped CP, and 13(7%) pts were lost to follow-up. At a median followup of 67 mos(range 6-380 mos), 11/192(6%) CP pts developed 13 BC; compared to 147/1190(12%) pts not taking CP. Among CP pts, median time from LCIS to BC was 82 mos(range 9-194 mos). 3/11(27%) CP pts developed BC after 5yrs of CP, 4 were still on CP and 4 stopped prior to 5yrs of CP. Among pts that completed or stopped CP, BC diagnosis occurred at a median of 46 mos(range 3-104 mos) after CP. There was no significant difference in age at LCIS, menopausal status, FH of BC, number of biopsies, BIRADS breast density, or length of CP use between CP patients who did and did not develop BC. BC characteristics of CP pts and those not taking CP are shown in the table. Conclusions: Despite the efficacy of CP in reducing the risk of ER+ breast cancer, the uptake of CP in women with LCIS remains low. We were unable to identify factors associated with failure of CP, however we do demonstrate that failure of CP in LCIS pts is not associated with the development of more aggressive ER negative BC. These data should be considered when counseling LCIS pts on the risks and benefits of CP.

Patholog	tic Characteristics	Surveillance only (n=157 cancers)	Surveillance+Cl (n=13 cancers)	p-value	
III and and	DCIS	51 (32%)	6 (46%)	264	
Histology	Invasive (IDC, ILC, special types)	106 (68%)	7 (54%)	.304	
Cancer ipsilat	eral to breast with LCIS	93 (59%)	6 (46%)	.358	
Mean tumor size [®] (cm)		1.1 (.1-12)	0.65 (.2-1.1)	.353	
	pN0	79 (75%)	6 (86%)		
Nodal Status*	pN1, pN2, pN3	21 (20%)	0	.596	
	pNX	6 (6%)	1 (14%)		
	ER/PR+	92 (87%)	6 (86%)		
Hormone-receptor Status*	ER/PR-	6 (6%)	0	1.00	
	Unknown	8 (8%)	1 (14%)		

*Based on invasive cancer only

P33

Measuring Effects of System Changes on Breast Cancer Outcome Variability W.C. Dooley,* C. Wilson, D. Luu, D. Zhao. University of Oklahoma, Oklahoma City, OK.

Introduction: Previous reports have shown breast cancer outcome differences based on whether the surgical provider was a surgical oncologist or a general surgeon. Our breast program instituted a series of measures to achieve identical rates of NCCN guideline compliance and research protocol enrollment to address these discrepancies in outcomes. Methods: We have performed an IRB approved retrospective analysis of prospectively collected data on all breast cancer cases at our institution from 2000-2013. Using all electronically available diagnostic, treatment and outcome data we have looked at the effects of system changes to address differential outcomes between surgical providers. Results: Standardized work-up and treatment indices (SWI and STI) were compared for two over-lapping intervals: 2000-2008 and 2004-2013. Each interval had long enough average follow-up to have statistically relevant and comparable data. As can be seen in the table the system changes, which nearly equalized NCCN guideline compliance and enrollment rates in clinical trials, had their most dramatic effect on STI or the stage specific survival outcomes using a standardized index. Effects on SWI (or work up index) showed much smaller changes between the two time periods between surgical oncologist and general surgeon. Surgical oncology was less likely to employ pre-operative MRI and more likely to use systemic staging radiographic exams on the basis of clinical exam findings and in patients with poorer prognostic markers. Surgical oncology had lower rates of up-staging within a year of diagnosis. Conclusions: More accurate staging prior to treatment remains as a major distinguishing characteristic between surgical oncologic care and general surgeon care for breast cancer patients. Developing methods to decrease this difference could substantially address disparities in breast cancer treatment outcomes.

	2000 - 2008		2008-2013	
	Surg Onc	Gen Surg	Surg Onc	Gen Surg
SWI	0.786	1.212*	0.883	1.194*
STI	0.716	0.999*	0.860	0.860
SWI/STI ratio	1.094	1.213*	1.027	1.041

* shows significant differences (p<0.02) between SO and GS

P34

Effects of Eribulin on Cell Growth and Phosphoinositide-3-kinase (PI3K) Pathway Activity with and without Everolimus in Triplenegative and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Breast Cancer D. Luyimbazi,* T. Luu, Q. Xing, J. Yan, D. Tully, E. Han, R. Yip, J. Yim. *City of Hope National Medical Center*, *Duarte*, CA.

INTRODUCTION: Patients with triple-negative breast cancer have high levels of Akt expression and activation of the PI3K pathway. Eribulin is a microtubule-targeting agent with benefits in treating refractory triple negative disease. Our objective was to evaluate its efficacy in inhibiting PI3K pathway activity and cell growth both alone and in combination with mammalian target of rapamycin (mTOR) inhibitor Everolimus. METHODS: Multiple breast cancer cell lines were used to assess the effect Eribulin has on growth. IC50 values for each cell line were calculated using MTT assay. Western blots were used to evaluate the expression of phosphorylated Akt-Ser473 (pAkt) and S6K1 after MDA468 and SKBR3 cell lines were treated with both agents for 24 hours. MDA468 and BT549 breast cancer cell lines were used to assess growth inhibition after 72 hour treatment with Eribulin alone and in combination with Everolimus. Combination indices (CI) generated by Chou-Talalay plots were used to quantify synergy. RESULTS: Both MDA468 and SKBR3 cells treated with Eribulin in varying concentrations showed inhibition of pAkt expression. Standard dilutions of Eribulin in combination with log dilutions of Everolimus resulted in marked synergistic growth inhibition (CI<<1) in both MDA468 and BT549 cells. Western blot analysis for MDA468 cells treated with the combination of Erubulin and Everolimus showed a dose related suppression of pAkt along with complete inhibition of pS6K1, while Everolimus alone increased pAkt. CONCLUSION: Our study shows dose related inhibition of Akt activation as well as inhibition of cell growth in triple negative breast cancer and HER2 cell lines treated with Eribulin alone or combined with Everolimus. We also show reversal of the pAkt feedback response seen with mTOR inactivation, and a significant synergistic growth inhibition with combination treatment. These findings point to a potential role for Eribulin and Everolimus in the treatment of refractory triple-negative breast cancer.

BT549 cells treated with a combination of Everolimus and Eribulin

	0 nM	1 nM	10 nM	100 nM	1000 nM	10,000 nM
0 nM	0.837 +/- 0.044	0.491+/- 0.077	0.395 +/- 0.022	0.345 +/- 0.005	0.262 +/- 0.030	0.230 +/- 0.017
0.1 nM	0.769 +/- 0.034	0.427+/- 0.063 CI = 0.293				
0.2 nM	0.778 +/- 0.016		0.284 +/- 0.091 CI = 0.117			
0.4 nM	0.737+/- 0.035			0.24 +/- 0.042 CI = 0.183		
0.8 nM	0.49+/- 0.037				0.163 +/- 0.03 CI = 0.19	
1.6 nM	0.234+/- 0.018					0.063 +/- 0.01 CI = 0.109

CI: Combination Indices

Top Concentrations: Everolimus in log dilutions Side Concentrations: Eribulin in standard serial dilutions.

P35

Outcomes with and without Axillary Node Dissection (ALND) for Node-positive Mastectomy Patients C. Laronga, ^{1*} R. Snow,² C. Johns,² W. Sun,¹ W. Fulp,¹ J.V. Kiluk,¹ M. Lee.¹ *1. Moffitt Cancer*

Center, Tampa, FL; 2. USF Morsani College of Medicine, Tampa, FL. Background: The ACoSOG-Z0011 trial identified women with sentinel lymph node biopsy (SLN) positive breast cancer having breast conservation and demonstrated no difference in survival or local-regional recurrence between SLN+ALND vs. SLN alone. We hypothesize that the outcome is the same in SLN only and SLN+ALND for SLN-positive women treated with mastectomy. Methods: An IRB-approved retrospective review of women with SLN (N1) disease at mastectomy from January 1, 1995 to November 1, 2012 was performed. Neoadjuvant therapy and noninvasive breast cancer cases were excluded. Demographic, co-morbidity, tumor type/size, receptor status, surgery type, adjuvant treatment, recurrence, and survival data were collected.

Statistical analyses via Exact Chi square Test with Monte Carlo estimation, Kaplan-Meier curves, and log-rank tests were used to compare SLN alone vs. SLN+ALND cohorts. Results: Of 528 pts reviewed, 192 with positive SLN (N1) disease and mastectomy were identified. 32 (16.6%) received SLN alone; 160 (83.4%) received SLN+ALND. Median age was 53.6years (range: 21-86), (SLN: 55.8yrs, ALND: 53.2yrs; p=0.11). There were no differences between the SLN and SLN+ALND cohorts in co-morbid conditions, histology, receptor status, or mean number of nodes retrieved in SLN (SLN and SLN+ALND; 2.91: p=0.81). The mean number of positive nodes retrieved was significantly different (SLN: 1.09, SLN+ALND: 1.64; p=0.001). Of pts undergoing ALND, the median number of nodes retrieved was 15 (range 4-42) and the median number with metastases was 0 (range 0-20). Rates of chest wall radiation and chemotherapy were not significantly different between the cohorts (p=0.93, p=0.15). At median follow-up of 44 months (range: 0-150), there were no statistically significant differences in local, regional, or distant recurrence (p=0.24), or in overall survival (p=0.16) between SLN alone and SLN+ALND. Conclusions: In patients with clinically node-negative invasive breast cancer undergoing mastectomy, the extent of axillary surgery had no impact on survival or recurrence. These data suggest that the findings of the ACoSOG-Z0011 trial can be extended into the mastectomy population.

P36

Surgical Site Infections after Mastectomy and Breast Reconstructive Surgery A. Kirane,* P. Sreeramoju, D. Euhus, J. Huth, A. Leitch, R. Wooldridge, R. Rao. *UT Southwestern, Dallas, TX.*

Surgical site infections(SSI) are a significant source of postoperative morbidity and cost; data regarding the incidence of SSI following mastectomy and breast reconstruction is highly variable and series dependent. In response to a cluster SSI after breast reconstructive surgery in our population, an epidemiologic investigation was performed to identify risk factors for SSI. All female patients who underwent mastectomy with or without reconstruction. from 2010 to 2013, were identified. Patients who underwent primary procedure without reconstruction, or reconstruction surgery without implantation of prosthesis were followed for 30 days from date of surgery for development of SSI. Patients who underwent any breast reconstruction involving implantation of prosthesis were followed for 1 year(or until January 31, 2013) for development of SSI. Definitions from CDC-NHSN were used. A total of 1,311 eligible procedures were performed during the study period. The incidence of SSI was 5.1% (49/963) in patients undergoing mastectomy alone, 13.3% (2/15) in patients undergoing mastectomy with delayed reconstruction and 35.6% (32/90) in patients undergoing mastectomy with immediate reconstruction. Of 108 patients undergoing reconstructive surgery, 40 (37%) had muscle flap; 31 (29%) had biologic matrix implanted. A third of these patients (36, 33.3%) developed SSI. Use of muscle flap was significantly associated with development of SSI (18/40 vs. 18/68; Unadjusted OR 1.7, 95% CI 1.007, 2.87, P<0.05) . Use of any implant was not associated with development of SSI. History of diabetes, smoking, hypertension or prior admission to the hospital was not significantly associated. Preliminary data show a trend for association of higher BMI (P=0.08). Our population demonstrated an unusually high rate of SSI during this time period. In this series, the greatest incidence of SSI was encountered in patients undergoing immediate breast reconstruction or reconstruction with muscle flap. Further investigation of operative factors specific to this finding may elucidate opportunities to reduce SSI events.

P37

Incidence Patterns of Breast Cancer among Women 35 and Younger at Diagnosis R.A. Greenup,* K. Arbeev, I. Akushevich, A. Mackey, L. Tolnitch, E.S. Hwang. *Duke University Medical Center*,

Durham, NC. INTRODUCTION: Recent attention to young women with breast cancer has called into question an increasing incidence of breast cancer in this population. We sought to determine whether an observable increase in the incidence of breast cancer exists among women ≤35 when compared to women in older age groups. METHODS: The SEER database was queried to determine whether age-adjusted breast cancer incidence rates changed among women ≤35 years old when compared to women ages 36-50 and 51-60. The SEER registry consists of 18 cancer registries covering distinct geographic U.S. regions. Initiation of data collection varied among sites: nine registries began in 1973-1975,

four in 1992, and five in 2000. Patient demographics, clinicopathologic fea-

tures, and geographic region were evaluated for age-adjusted breast cancer incidence rates. RESULTS: A total of 1,157,757 breast cancers were reported to the SEER registry between 1973-2009. 28,769 (2.5%) women were diagnosed at ≤35, 267,410 (23%) women between ages 36-50, and 269,546 (23%) women between ages 51-60. Age-adjusted incidence rates were 14.3, 162.6, and 323.8 per 100,000 respectively. Overall, the incidence rates of breast cancer for the youngest group did not change, although 5 SEER sites including Connecticut, Hawaii, Iowa, San Jose/Monterey (California) and Louisiana had a significant increase. The proportion of ER(+) breast cancers increased within all age groups; however, the greatest increase occurred among women ≤35 (p<0.0001). There was no difference in age-adjusted incidence rates among women diagnosed ≤35 based on race/ethnicity. CONCLUSIONS: The diagnosis of breast cancer among women ≤35 significantly increased over the study period in several SEER registries, although no clear pattern between incidence and geographic distribution emerged. This increase among young women was predominantly driven by an increase in the incidence of ER+ tumors and was independent of race. Since the higher incidence seen in some registries is unlikely to be associated with mammographic screening in this young age group, other endogenous or exogenous factors must explain this observation.



P38

Triple-negative Breast Cancer is not Associated with Increased Nodal Metastases A. Gangi,* J. Mirocha, T. Leong, A.E. Giuliano. *Surgery, Cedars Sinai Medical Center; Los Angeles, CA.*

Introduction: Axillary lymph node metastases are a prognostic indicator for breast cancer. Studies suggest that breast cancer subtypes are associated with the presence of lymph node (LN) metastases. The purpose of this study was to determine if patients with triple negative breast cancer (TNBC) have a higher risk of LN metastases than those with non-TNBC. Methods: Prospective database review identified 3,289 female patients with invasive breast cancer treated with mastectomy or breast conserving surgery (BCS) between January 2000 and May 2012. Patients who received neoadjuvant therapy were excluded. Patients who underwent sentinel node biopsy (SNB) and/or axillary lymph node dissection (ALND) and those with complete information regarding age at diagnosis, tumor size, grade, stage, histologic subtype, presence of lymphovascular invasion (LVI), estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2) status were included in the final analysis. Results: A total of 2,967 patients met inclusion criteria. BCS was performed in 1,889 and mastectomy in 1,078 patients. Breakdown by subtype included 2,201 (74%) patients with Luminal A, 344 (12%) with Luminal B, 144 (5%) with HER2, and 278 (9%) with TNBC. SNB was performed in 1,094 (37%), ALND in 756 (25%), and 1,117 (38%) patients had both. LN metastases were detected in 1050 (35%) patients. The LN positivity rate varied across subtypes with 734/2,201 (33%) in Luminal A, 143/344 (42%) in Luminal B, 108/278 (39%) in TNBC, and 65/144 (45%) in HER-2 (p=0.0007). On multivariable analysis, there was no difference in LN positivity among subtypes (p=0.24). Only age <50 (HR 1.5, CI 1.3-1.8), grade 2 or 3 tumors (HR 1.8, CI 1.4-2.5), size > 2cm (HR 3.2, CI 2.7-3.9), and LVI (HR 3.9, CI 2.4-6.3) were significant predictors of LN positivity. Four or more involved nodes were seen most commonly in the HER2 (28/144; 19%) and Luminal B (47/344; 14%) subtypes, but not TNBC (26/278; 9%) or Luminal A (199/2201; 9%) (p<0.0001). Conclusions: Predictors of LN metastases include younger age, higher grade, larger size, and presence of LVI. Patients with TNBC are not more likely to have lymph node metastases than those with non-TNBC.

Multivariable Analysis of Predictors of Lymph Node Positivity

Variable	OR	95% CI	P-Value
Age < 50 vs 50-79	1.52	1.29 - 1.83	< 0.0001
Age ≥ 80 vs 50-79	1.05	0.74 - 1.48	0.79
Grade 2 vs. Grade 1	1.71	1.33 - 2.19	< 0.0001
Grade 3 vs. Grade 1	1.87	1.43 - 2.45	< 0.0001
LVI	3.88	2.41 - 6.27	< 0.0001
T2 vs. T1	3.24	2.71 - 3.86	< 0.0001
T3 vs. T1	11.15	7.90 - 15.73	< 0.0001
TNBC vs. Luminal A	0.79	0.58 - 1.06	0.12
TNBC vs. Luminal B	0.72	0.50 - 1.03	0.07
TNBC vs. Her2	0.68	0.44 -1.06	0.09

P39

Use of Gail Model to Predict Breast Cancer Risk in Mexican Population: Analysis of a Prospective Cohort of 1,000 Patients H. Medina-Franco,* A. Garza-Gangemi, U.E. Clemente-Gutierrez, P. Gaonauwiene, Surgery, National Institute of Medical Sciences and Nutrition

Luviano. Surgery, National Institute of Medical Sciences and Nutrition, Mexico City, Mexico.

Background. Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer related death in females in Mexico as in other Western Countries. The most widely used model for breast cancer risk assessment is the Gail Model (GM), which is currently the most validated tool, however considering it was mainly done for western populations, its validation in an international context is required. The validation of the GM has never been done for a Latin American country. Methods: In 2002 a cohort of 1000 female patients were recruited in a tertiary referral center in Mexico City. An assessment of individual breast cancer risk was performed for these patients. At that moment, the mean calculated absolute risk utilizing the GM at 5 years was 1.18%. These patients were followed for 10 years and those who developed breast cancer were identified retrospectively from the medical charts at the institute. Results: Thirty-three patients were lost to follow up. Twenty-four out of nine hundred sixty seven individuals developed invasive breast cancer (2.48%). The mean age of these individuals at the time of cancer diagnosis was 63. By the fiveyear mark, twelve of these patients had developed invasive breast cancer, exactly to the predicted GM risk calculated in 2002. Conclusions: Despite the limitation of a small sample, our results suggest that the GM is a well-fitting model for breast cancer risk assessment for a Mexican population.

P40

Dose-dependent Effects of Autophagy on Ductal Carcinoma in situ (DCIS) D.D. Brown, P. McAuliffe.* *Surgery, University of Pittsburgh, Pittsburgh, PA.*

INTRODUCTION: If left untreated, most DCIS will not progress to invasive cancer. However, current clinic-pathologic features cannot reliably predict aggressive versus indolent course. Therefore, many patients with DCIS are over-treated. Refining our understanding of DCIS will allow better selection of risk-appropriate therapy for patients. Autophagy is a central growth regulator in the breast, both physiologically, as in post-weaning involution, and pathologically, in invasive breast cancer, but its role in in situ lesions has not been extensively evaluated. Autophagy is a cytoprotective process whereby cells utilize their own non-essential proteins, organelles and subcellular membranes to conserve nutrients. We hypothesize that autophagy plays a crucial role in DCIS proliferation and survival. METHODS: Human DCIS cell lines SUM225 and MCF10DCIS.COM were treated for 24 or 72 hours with escalating doses of rapamycin, an autophagy promoter, or chloroquine, an autophagy inhibitor. Proliferation was detected with automated cell imaging, MTT and sulpharhodamine B (SRB) assay. Cell death was determined using CellTox green. All were done in triplicate. Activation of autophagy and mTOR pathways was identified on Western blot. SOSTM1 immunocytochemistry was used to visualize autophagosome accumulation. RESULTS: In both cell lines, proliferation decreased with induction of autophagy by rapamycin; cell death did not increase with increasing dose. In contrast, cellular proliferation was promoted at low doses and inhibited at high doses of the autophagy inhibitor, chloroquine (see Figure), with an associated dose-dependent increase in cell death (p<0.05, ANOVA). In addition, autophagy induction resulted in a decrease in phosphorylated P70 S6 kinase, indicating inhibition of the mTOR kinase signaling pathway in conjunction with autophagy inhibition. SQSTM1 immuno-cytochemistry demonstrated marked inhibition of autophagosome-lysosome fusion in response to chloroquine. CONCLUSION: Modulating autophagy affects DCIS cellular proliferation and survival. Future mechanistic studies in DCIS cell cultures derived directly from fresh patient specimens may reveal a new therapeutic target in the treatment of DCIS.



Figure: Rapamycin (top) or chloroquine (bottom) sensitivity of DCIS cell lines, SUM225 (left) and MCF10DCIS.COM (right), treated at 10-fold dilutions. Cell proliferation measured at 72 hours using SRB assay is displayed as mean ± standard deviation of three independent experiments.

P41

Which Patients Benefit from Post-mastectomy Radiation Therapy in the Setting of T3 Node-negative Breast Cancer? L. Elmore,

A. Deshpande, J.A. Margenthaler.* Surgery, Washington University School of Medicine, St. Louis, MO.

Background: We investigated the predictors of adjuvant radiation therapy for patients undergoing mastectomy for a T3 node-negative invasive breast cancer. Further analyses were conducted to determine whether survival outcomes varied according to receipt of adjuvant radiation. Methods: Characteristics associated with post-mastectomy radiation therapy among women with T3 breast cancers but negative axillary lymph nodes were identified from the 1988-2009 Surveillance, Epidemiology, and End Results (SEER) database. The primary outcome was breast cancer-specific mortality. Predictors associated with receipt of adjuvant radiation were ascertained through bivariate analysis. Cox models were used to calculate adjusted hazard ratios (aHR) and 95% confidence intervals (CI). Results: We identified 5181 patients with T3, nodenegative invasive breast cancers who underwent mastectomy between 1988 and 2009. Of those identified, 3125 (60.3%) did not receive adjuvant radiation therapy, 2053 (39.6%) received adjuvant radiation therapy, and 3 (0.06%) had adjuvant radiation therapy status unknown. Factors that were predictive of the receipt of adjuvant radiation therapy included younger age at diagnosis, positive marital status, grade 3 tumors, and increasing tumor size (p<0.001 for each). Receipt of post-mastectomy adjuvant radiation therapy resulted in lower breast cancer-specific mortality (22.6% versus 43.5%, p<0.0001) and patients were less likely to die during the follow-up period (aHR=0.696, 95% CI: 0.624-0.776) compared to patients who did not receive post-mastectomy adjuvant radiation therapy. Conclusion: Analysis of the SEER database indicated that several patient and tumor characteristics predict a higher likelihood of receiving post-mastectomy adjuvant radiation therapy in the setting of T3, node-negative disease. Further, receipt of radiation resulted in over 30% reduction in breast cancer-specific mortality for this sub-group of patients.

P42

Addressing Psychosocial Needs of Partners of Breast Cancer Patients: A Pilot Program using Social Workers to Improve Communication and Psychosocial Support R. Kauffmann,* C. Bitz, K. Clark, M. Loscalzo, L. Kruper, C. Vito. *City of Hope National Medical Center, Duarte, CA.*

INTRO: Psychosocial (PsySoc) distress in caregivers is a well-described entity, but most studies are in patients with chronic conditions or terminal illnesses. PsySoc needs of caregivers of patients with early- stage operable breast cancer has not previously been studied. However, some caregivers experience more distress than patients themselves, and emotional support is a predictor of PsySoc well-being in both patients and caregivers. METHODS: We developed a program for newly-diagnosed breast cancer patients and their primary caregiver (partner). Both were screened for common stressors. The couple was then paired with two social workers trained in communication and gender differences, who educated them in communication-based problem solving. Program satisfaction surveys were administered at the conclusion of the visit, along with appropriately triaged referrals to supportive service teams to address identified stressors. RESULTS: Eighty-six patients and eighty-two partners returned surveys. Compared to partners, patients were more likely to report feeling anxious or fearful (59% vs. 38%, p= 0.014), report difficulty in managing their emotions (46% vs. 11%, p= 0.003), experience distress over being unable to take care of themselves (37% vs. 6% p= 0.000), and report substance use by themselves or in their environment (9% vs. 2%, p= 0.049). Interestingly, there was no difference between patients and partners in feeling unsupported by their partner (6% vs. 5%, p= 0.85), or in feeling down or depressed (29% vs. 30%, p= 0.96). CONCLUSIONS: Both patients and partners experience significant distress after a breast cancer diagnosis. We found that partners are equally likely to feel unsupported by their partner (patient) and feel down or depressed. The magnitude of this distress was similar between groups. Further study is needed to learn about both patients' and partners' significant distress over lack of support and depression. Partner-focused PsySoc interventions should be initiated in all cancer centers in order to address the emotional needs of both breast cancer patients and their partners.

P43

Pathological Features of Local Recurrences after Breast Conserving Surgery for Ductal Carcinoma in situ J. Kam, ^{1*} P. Drury, ¹ J. Fong, ² J.P. Collins, ² A.K. Rose, ³ G. Mann. ¹ *1. The Breast Service, The Royal Melbourne and Royal Women's Hospital, Melbourne, VIC, Aus-*

tralia; 2. Department of Surgery, The Royal Melbourne Hospital, Melbourne, VIC, Australia; 3. Department of Radiology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.

Background: Accurate identification of ductal carcinoma in situ (DCIS) that will recur, either as invasive breast cancer (IBC) or in situ disease is highly desirable but currently not possible. Most reports of local recurrence (LR) after treatment for DCIS have not examined the pathological features of the recurrences. We used a large cohort of patients treated for DCIS in a single program to investigate the characteristics of LR to compare and correlate features of the original DCIS and those of recurrences. Methods: A retrospective review of prospectively collected data of women diagnosed with DCIS through screening mammography between the years 1994-2008. Follow-up on all patients was sought, including information on local and distant recurrences. Results: 431 women were diagnosed with DCIS, underwent wide local excision and had >6 months follow-up. 88 of 431 (20.4%) developed a LR. Of these recurrences, 41 of 88 (46.5%) were IBC and 47 of 88 (53.4%) were DCIS. Significant predictors of LR were high nuclear grade (p=0.006), comedonecrosis (p=0.021), calcification (p=0.045) and positive surgical margins (p=0.046). High-grade DCIS recurred significantly more often as invasive disease than low or intermediate-grade DCIS (27/215, 12.6% vs.14/216, 6.5%, p=0.03). All invasive cancers from patients with originally low and intermediate-grade DCIS were node-negative, whereas 6 of 21 (28.6%) high-grade index DCIS cases developed node-positive disease. All low-grade DCIS developed Luminal A IBC. Recurrences after intermediate-grade DCIS were Luminal A, Luminal B and HER2-like IBC, while those after high-grade DCIS were Luminal A, Luminal B, HER2-like and Basal-like IBC. Initial ER status was a significant predictor of ER status in invasive recurrence (p=0.01). Conclusion: While some histological characteristics are associated with LR rate, no standard features can identify a large group of patients at minimal risk of recurrence. Type and features of recurrence is influenced by initial nuclear grade and ER status. Biomarkers or gene expression analysis is needed to more accurately identify lesions that may recur and present as potentially more lethal disease.

P44

Modified Core Wash Cytology: A Reliable Same Day Biopsy Result in the One-Stop-Shop Breast Clinic J. Bulte,^{1*} C.A. Wauters,² L.E. Duijm,² J.H. De Wilt,¹ L. Strobbe.² 1. Surgical Oncology, UMC St Radboud, Nijmegen, Netherlands; 2. Canisius Wilhelmina hospital, Nijmegen, Gelderland, Netherlands.

Background: International breast cancer guidelines require women with suspicious breast lesions be diagnosed expediently. For a definitive diagnosis a biopsy is often required. Besides Fine Needle Aspiration (FNA) and Core Needle biopsy (CNB), hybrid techniques including Core Wash Cytology (CWC) are available to establish a same-day diagnosis in these cases. CWC combines the speed of cytology with the superior diagnostic power of CNB. A washing of the otherwise regular CNB specimen is evaluated as a cytological specimen, yielding a provisional diagnosis. The CNB specimen is subsequently processed and analyzed. Literature reports of test characteristics for CWC vary substantially. Materials & methods: All CWC procedures performed on Ultrasound guided CNB specimens in our clinic between May 2009 and May 2012 were reviewed, correlating CWC results with the result of the CNB specimen, the post-operative pathology report and/or follow-up through the automated Dutch national pathology database 'PALGA'. Results: 1,253 CWC procedures were performed during the study period. Of the evaluated lesions 849 (68%) were malignant and 404 (32%) lesions were benign. 80% of CWC procedures yielded a conclusive diagnosis: this percentage was higher amongst malignant lesions and lower for benign lesions. Low grade carcinoma and lobular histology type were associated with more inconclusive results. The sensitivity of a conclusive CWC result was 98.3%, specificity 90.4%. Conclusion: In the largest series currently available we demonstrate CWC can be used as an adjunct to regular CNB provide a reliable provisional diagnosis of a breast lesion within the hour. Increasing numbers of inconclusive results in benign lesions means the technique is especially well suited for high risk populations.



P45

Predictive Value of Axillary Nodal Imaging following Neoadjuvant Chemotherapy J. Steiman,* K. McGuire, A. Soran, P. McAuliffe, E. Diego, M. Bonaventura, R. Johnson, G. Ahrendt. *Magee-Womens Hospital of UPMC, Pittsburgh, PA.*

Introduction: Despite their common use in determining residual in-breast disease after neoadjuvant chemotherapy (NAC), neither MRI nor ultrasound (US) has been recommended to radiographically assess nodal response following treatment. Recent studies have demonstrated accuracy of sentinel lymph node biopsy (SLNB) after NAC for patients (pts) who present with a clinically positive axilla. As a result, preoperative imaging that could predict residual axillary disease would be helpful for operative planning, Methods: A retrospective review was completed using our institutional Cancer Registry. Clinicopathologic data was collected from pts who presented with clinically node positive disease and underwent NAC from 2005 - 2010. Those who had a post-NAC breast MRI and/or axillary US were evaluated. Axillary imaging response was determined by the official radiology dictation. A positive result was defined as a node >1 cm and/or a cortex >2mm. Nodal involvement was confirmed pathologically after surgery. Results: Of 252 pts with clinically node positive disease treated with NAC, 151 had breast MRI, 99 had axillary US, and 45 had both. No significant difference in sensitivity or specificity between MRI and US is identified (Table 1). The positive (PPV) and negative (NPV) predictive values of MRI for axillary evaluation following NAC is 90% and 23%, respectively. The PPV and NPV of US is 95% and 21%, respectively. In pts with concordant results on both MRI and US, comparable predictive values are obtained. Within the MRI group, a subset analysis by phenotype demonstrates that triple negative (TN) breast cancer has the highest sensitivity (83%) and luminal cancers have the highest PPV (100%). Conclusions: This study demonstrates that imaging of the node positive axilla after NAC cannot reliably predict pathologic nodal status. The predictive value of MRI and axillary US for residual axillary disease following NAC is equivalent. Because of high false negative rates (low NPV), preoperative imaging is not a good predictor of complete axillary response to NAC. However, the high PPV suggests it may be helpful for determining the utility of SLNB following NAC, especially in luminal tumors.

Imaging modality

	Total MRI n=151	Luminal * n=76	Her2+ * n=35	TN * n=30	Axillary + US n=99	MRI +US n=45
True positive	55(36%)	20 (26%)	9 (26%)	20 (67%)	40 (40%)	17 (38%)
True negative	21 (14%)	7 (9%)	10 (29%)	4 (13%)	12 (12%)	7 (16%)
False positive	6 (4%)	0 (0%)	3 (9%)	2 (7%)	2 (2%)	0 (0%)
False negative	69 (46%)	49 (65%)	13 (37%)	4 (13%)	45 (45%)	21(47%)
Sensitivity	44%	29%	43%	83%	47%	45%
Specificity	78%	100%	77%	67%	86%	100%
PPV	90%	100%	75%	91%	95%	100%
NPV	23%	13%	43%	50%	21%	25%

*Ten patients with an unknown receptor status were excluded from the subtype analysis

P46

Combined Efficacy Analyses from Three Phase 3 Trials of (99mTc) Tilmanocept for Sentinel Lymph Node Biopsy cN0 Breast Cancer, Melanoma, and Head and Neck Cancer Patients A. Wallace,^{1*} J. Kim,² A. Agrawal.³ 1. UC San Diego Moores Cancer Center, La Jolla, CA; 2. University Hospitals Seidman Medical Center, Cleveland, OH; 3. The Ohio State University Wexner Medical Center, Columbus, OH

INTRODUCTION: CD206 receptor-targeted [99mTc]tilmanocept has been evaluated in three Phase 3, prospective, multi-institutional, open-label, single arm trials for the identification of sentinel lymph nodes (SLNs) in clinically N0 breast cancer, melanoma, and head and neck cancer patients (ClinicalTrials.gov identifiers NCT00671918, NCT01106040, and NCT00911326). In the two breast cancer and melanoma trials in which [99mTc]tilmanocept was used in comparison to blue dye, lymph nodes were removed if they were hot, blue, palpable, or discretionarily "suspicious." In the single head and neck cancer trial, patients with intraoral or cutaneous squamous cell carcinoma (SCC) underwent SLN biopsy with [99mTc]tilmanocept alone, and elective neck dissection to remove regional non-SLNs. All excised lymph nodes from the studies, regardless of identification method, were subjected to histopathology analy-ses. METHODS: Patient data were integrated for the three [99mTc]tilmanocept Phase 3 trials. The primary endpoint was Per Patient Sensitivity of ^mTc]tilmanocept (identification of pathology-positive SLNs). Secondary endpoints included other pathology analyses of negative predictive value (NPV) and overall accuracy, SLN localization rate (% of patients with a SLN identified by [99mTc]tilmanocept), and degree of localization (DL, # of SLNs per patient). RESULTS: 384 out of 390 patients injected with [^{99m}Tc]tilmanocept in the Phase 3 trials had complete data for the integrated analyses, and 100 of these (34 melanoma, 27 breast cancer, 39 intraoral SCC) had pathology-positive lymph nodes identified. Table 1 summarizes the per patient integrated results. No differences were observed between tumor types, except for DL. CONCLUSIONS: High sensitivity, NPV, and accuracy indicate that [^{9m}Tc]tilmanocept accurately identifies SLNs and is likely to be predictive of pathological staging. High patient localization rates demonstrate the effectiveness and consistency of the agent.

Per Patient Analyses of Integrated Phase 3 $[^{99m}\mbox{Tc}]\mbox{Tilmanocept Trial Results}$

	Pooled Analysis	Weighted Least Squares Meta-Analysis
Sensitivity (combined)	98.0% (95% CI: 93.0%, 99.8%)	99.8% (95% CI: 98.8%, 100%)
Melanoma (n=34 pN+)	100%	100%
Breast Cancer (n=27 pN+)	96.3%	99.9%
Head and Neck SCC (n=39 pN+)	97.4%	n/a*
Negative Predictive Value (combined)	≥99%	≥99%
Overall Accuracy (combined)	≥99%	≥99%
Localization Rate (combined)	≥97%	≥99%
Melanoma (n=153)	98.0%	99.9%
Breast Cancer (n=148)	98.7%	99.9%
Head and Neck SCC (n=83)	97.6%	n/a*
Degree of Localization (combined)	2.6	2.2
Melanoma (n=153)	2.4	2.3
Breast Cancer (n=148)	2.2	2.1
Head and Neck SCC (n=83)	3.9	n/a*

Abbreviations: CI = confidence interval, SCC = squamous cell carcinoma, n/a = not applicable.

*Intraoral and cutaneous SCC were only tested in 1 trial, so a metaanalysis between trials is not applicable.

P47

False Negative Rate of Combined Mammography and Ultrasound for Women with Palpable Breast Masses C.H. Chan,* S.B. Coopey, P.E. Freer, K.S. Hughes. *Massachusetts General Hospital, Boston, MA*.

Introduction: Mammography and ultrasound are often used concurrently for patients with breast masses. While mammography by itself has a false negative rate of approximately 15%, the addition of breast ultrasound may decrease this rate among patients with palpable breast masses. There are currently no outcome data regarding the use of Combined Reporting of Ultrasound and Mammography (CRUM) for breast masses. Methods: We retrospectively reviewed female patients presenting with a breast mass in a prospectively entered database at a single institution by a single surgeon from June 2010 to July 2013. We identified a patient cohort with CRUM and tissue diagnosis. False negative and false positive rates were calculated. Results: We identified 1240 female breast mass patients in our database; 954 (77%) patients had CRUM (Table 1). 98 patients were found to have cancer. While 96% of patients with combined Breast Imaging-Reporting and Data System (BIRADS) score of 4-5 had tissue diagnosis, 9% and 33% of patients with BIRADS 1-2 and 3, respectively, also underwent biopsy due to patients' insistence or worrisome clinical features. 40% of patients without tissue diagnosis had follow-up imaging; none developed cancers. 2/686 (0.3%) patients with BIRADS 1-2 and 2/54 (3.7%) patients with BIRADS 3 had either ductal carcinoma in-situ or invasive cancers. 112/176 (64%) patients with BIRADS 4 had no malignancy. In terms of cancers, 2/98 (2%) cancers had negative CRUM (BIRADS 1-2); and 2/98 (2%) cancers were BIRADS 3. Conclusions: In the modern era of combined imaging for breast masses, the false negative rate for CRUM is approximately 2% not the 15% often quoted.

Table 1: Summary of our patient cohort

BIRADS	No of patients (%)*	No of patients biopsied (%)**	No of cancers (%)***	False Negative (%)*	False Positive (%)**
Total	954	284 (30%)	98 (35%)		
1-2	686 (72%)§	60 (8.7%)	2 (3.3%)	2 (0.3%)	N/A
1	432 (45%)	37 (8.6%)	2 (5.4%)	2 (0.5%)	N/A
2	254 (27%)	23 (9.1%)	0 (0%)	0 (0%)	N/A
3	54 (5.7%)	18 (33%)	2 (11%)	2 (3.7%)	N/A
4	183 (19%)	176 (96%)	64 (36%)	N/A	112 (64%)
5	31 (3.2%)	30 (97%)	30 (100%)	N/A	0 (0%)

* Percent of total number of patients in cohort (N=954)

** Percent of number of patients in each BI-RADS category

§ 40% of patients without tissue diagnosis had follow-up imaging; none developed cancers

P48

Predictors of Use of Adjuvant Chemotherapy and Overall Survival Outcomes in Elderly Breast Cancer Patients P. Kanumuri,*

D.R. Lannin, M. DiGiovanna, B. Killelea, N.R. Horowitz, M. Abu-Khalaf, A.B. Chagpar. Yale University School of Medicine, New Haven, CT.

Introduction: The average age of breast cancer incidence is steadily on the rise. There are limited data on the utilization and benefits of adjuvant chemotherapy [CT] in breast cancer patients older than 70 years of age. We sought to determine factors influencing the decision to administer CT in this population, along with outcomes in terms of overall survival [OS] using data from the National Cancer Database [NCDB]. Methods: Patients > 70 years of age with Stage I - III breast cancer, who underwent surgical treatment for their breast cancer were identified from the NCDB [1985 - 2010]. Univariate and multivariate analyses of predictors of CT use and survival were performed using SPSS. Results: Of the 434,660 patients > 70 years of age with surgically resected stage I-III breast cancer for whom data was available regarding receipt of chemotherapy, 56,574 [13%] received treatment. Clinicopathologic variables associated with the receipt of chemotherapy on multivariate analysis are shown in the table below. On univariate analysis, overall survival was significantly lower in patients who received versus those who did not receive CT [67.3 (Mean) months (M); 95% CI, 66.9-67.7 vs 69.6 M; 95%CI, 69.4-69.8; p<0.001]. On multivariate analysis controlling for age, sex, race, Charlson-Deyo Score, region, urban-rural location, insurance, facility type, tumor size, tumor grade, node positivity, and surgery type, chemotherapy remained a predictor of worse overall survival [OR: 1.091; 95%CI, 1.08 -1.10; p<0.001]. Conclusions: Use of adjuvant chemotherapy appears to be associated with worse overall survival in the elderly with surgically treated, non-metastatic breast cancer, independent of tumor size, tumor grade, lymph node status and comorbidities. While these data do not control for the type of chemotherapy offered, nor compliance with the prescribed regimen, they offer a note of caution for use of chemotherapy in the elderly.

Factors Associated with Adjuvant Chemotherapy Use in Elderly Breast Cancer Patients - Multivariate Logistic Regression

Factors		Odds Ratio (95%CI)	P value
Age*		0.82 (0.813-0.818	< 0.001
Race	Caucasian	Referent	
	African American	1.11 (1.06-1.16)	< 0.001
Charlson/Deyo Score	0	Referent	
	1	0.85 (0.82-0.88)	< 0.001
	>=2	0.55 (0.51-0.59)	< 0.001
Facility Type	Community Cancer Program	Referent	
	Comprehensive Community Cancer Program	0.94 (0.90-0.97)	< 0.001
	Academic Research Program	0.89 (0.85-0.92)	< 0.001
	Others	0.72 (0.63-0.81)	< 0.001
Tumor Size	T1	Referent	
	T2	2.31 (2.24-2.38)	< 0.001
	T3	3.30 (3.14-3.47)	< 0.001
Tumor Grade	Low	Referent	
	Intermediate	2.15 (2.06-2.24)	< 0.001
	High	5.86 (5.61-6.12)	< 0.001
Nodes	Negative	Referent	
	Positive	3.53 (3.43-3.63)	< 0.001
Surgery Type	Partial Mastectomy	Referent	
	Total Mastectomy	1.30 (1.27-1.34)	< 0.001

* Continuous variable

P49

Breast Cancer Outcomes according to Mammographic Screening Status J. Fong,² H. Farrugia,³ A. Soon,² G.B. Mann.^{1*} 1. The Royal Womens Hospital, Parkville, VIC, Australia; 2. The University of Melbourne, Melbourne, VIC, Australia; 3. The Victorian Cancer Registry, Melbourne, VIC, Australia.

Background: The value of population-based mammographic screening has been the subject of debate over recent years. We aimed to investigate the impact of mammographic screening by examining all cases of breast cancer diagnosed over a 13 year period in a defined area of Melbourne, Australia, and comparing those women who had undergone screening with those who had not. Methods : All women diagnosed with breast cancer between 1994 and 2006 were identified. Demographic and pathology details were recorded. Vital status was determined from the National Death Registry. BreastScreen Victoria records were cross-referenced to identify patients known to the screening program, and to identify cancers were screen-detected or interval cancer. Cancers in Non-

^{***} Percent of number of patients biopsied

screened and Screened women were compared, and Screen-detected and Interval cancers were also analysed. Results: 5579 women residing in the catchment area of NorthWestern BreastScreen were diagnosed with invasive cancer between 1994 and 2006. 3408 were diagnosed in non-screened women and 2171 in women undergoing screening. 404 of these were interval cancers. Cancers in Non-screened women were larger - 24.7% were >30mm compared with 9.8% in the Screened population. Non-screened cancers were more likely to be high grade (42.7% vs 28%) and node positive. 5year overall survival after diagnosis was 91% vs 81% for Non-screened. Size, grade and nodal status was significantly better for Screen-detected, but not significantly different between Interval and Non-screened groups. Breast Cancer Specific Survival was similar for Interval and Non-screened cancers. Conclusion: Breast cancer outcomes after diagnosis are better for patients within a screening program. Those diagnosed outside a program are similar to interval cancers diagnosed within a program. Figure 1: Breast cancer specific survival for Screened and Non-Screened population (1a), and according to screen=-detected vs interval (1b)

P50

Lymph Node Ratio is a Prognostic Indicator of Overall Survival for Non-metastatic Breast Cancer Patients after Neoadjuvant Chemotherapy M. Miller,* R. Ottesen, J. Niland, L. Kruper, S. Chen,

C. Vito. City of Hope National Medical Center, Duarte, CA.

Background Neoadjuvant chemotherapy (NAC) is utilized for more advanced breast cancers to decrease tumor burden. Other than "y" notation, current AJCC staging does not take into account NAC downstaging in the pathologic stage. NAC decreases the total number of lymph nodes (LN)s harvested limiting the value of current staging which is based only on total positive LNs. Lymph node ratio (LNR) may provide more useful predictive information of overall survival (OS) in a NAC setting. Methods A retrospective review of institutional data collected for the National Comprehensive Cancer Network database was performed, identifying women diagnosed between 1997-2009 with primary, unilateral, LN positive breast cancer, excluding those with Stage IV disease. Patient demographics, tumor characteristics, and survival data were analyzed. The LNR was calculated from pathologic reports at definitive resection (total positive/total harvested). Patients were divided into 3 strata ($\geq 0-0.1$). 0.1-0.5, and >0.5). Kaplan-Meier curves were constructed to compare OS and evaluated using the log-rank test. A Cox proportional hazard model was constructed for multivariable analysis to control for potential confounders. Results The cohort had 168 women with primary, unilateral, LN positive breast cancer. OS was significantly improved in the lower LNR groups (p=0.014). In multivariable analysis, after adjusting for age at and year of diagnosis, T stage, her2neu and hormone receptor status, patients with LNR of >0 to 0.10, patients with a LNR of >0.10 to 0.50 (HR=4.04 95% CI: 1.33-12.23) and >0.50 (HR=3.95 95% CI: 1.20-12.99) had significantly higher hazard of death with increasing LNR. AJCC staging N1-3, in same model, was not predictive of OS (p=0.48). Conclusions In the post NAC setting, LNR is a statistically significant prognostic indicator of OS in operable breast cancer patients and provides better prognosis prediction than standard N-stage criteria. Further study is merited.



Increasing Mastectomy Rates: A Review of the Tennessee Breast Cancer Registry C.M. Kiernan,¹* L. Du,¹ M. Whiteside,² C.C. Solorzano,¹ M.A. Hooks.¹ *1. General Surgery, Vanderbilt Univeristy, Nashville, TN; 2. Tenesseee State Department of Health, Nashville, TN.*

Background and Objectives Current surgical approaches for in situ and early stage invasive breast cancer include partial mastectomy or total mastectomy. Previous studies have suggested that total mastectomy rates are rising while SEER data analysis has not confirmed this. We therefore sought to determine the trend of total mastectomy rates in the state of Tennessee and explore patient and tumor factors that may influence the surgical choice. Methods: Registry analysis was carried out for women diagnosed with in situ or invasive breast cancer between 2000 and 2009 using the Tennessee Cancer Registry. Type and rate of surgical treatment was examined over time. Factors influencing the probability of total mastectomy were analyzed using univariate and multivariate logistic regression. Results: A total of 39,640 women with breast cancer were analyzed. There were 6,969 (18%) in situ and 32,671 (82%) invasive carcinomas. Overall, 51% and 49% of women underwent partial or total mastectomy, respectively. The rate of total mastectomy decreased from 2000 to 2006 (52% to 45%, p<0.0001) however from 2006 to 2009 the rate increased significantly to 50%. (p<0.0001) On multivariate analysis, age at diagnosis (p<0.0001), race when compared to white (black OR 0.64, CI 0.59-0.71, Asian OR 1.03 CI 0.72-1.50 p<0.0001), year of surgery (p <0.0001), tumor size (p<0.0001), invasiveness (in situ vs. invasive, OR 1.56, CI 1.35-1.80, p <0.0001), ER positive (OR 0.76 CI 0.68-0.85, p<0.0001), PR positive (OR 1.35 CI 1.22-1.49 p<0.0001) grade (OR 1.06 CI 1.01-1.11 p =0.01), and stage (OR 1.73, CI 1.64-1.82, p<0.001), were found to be significant predictors of total mastectomy. Conclusion: The rate of total mastectomy in Tennessee declined until 2006 however since that time it has been increasing. Multiple patient and tumor factors are associated with the preferential use of total mastectomy. Further studies are needed to determine the etiology of these trends.

P52

Characterizing Breast Cancer in Women with African Ancestry: Triple-negative Tumors, Androgen Receptor and ALDH1 Expression E. Proctor,^{1*} E. Jiagge,¹ J. Bensenhaver,¹ K. Kidwell,¹ B. Awuah,² K. Toy,¹ B. Salem,¹ J.K. Oppong,² I. Kyei,² M. Ohene-Yeboah,² M. Wicha,¹ S. Merajver,¹ C. Kleer,¹ L.A. Newman.¹ *1. University of Michigan Health System, Ann Arbor, MI; 2. Komfo Anoyke Teaching Hospital, Kumasi, Ghana.*

Introduction: Androgen Receptor (AR) is the most commonly expressed nuclear hormone receptor in breast cancer and may be a marker of response to targeted anti-androgen therapy, a particularly attractive option in the setting of triple negative breast cancer (TNBC). Gene expression studies suggest that AR-positivity may distinguish a luminal/AR TNBC subtype from mesenchymal, stem cell-like, and basal-like subtypes. Furthermore, frequency of TNBC is 2-3 times higher in African American and African compared to White American and European breast cancer patients, yet little is known regarding the distribution of TNBC subtypes in the high-risk African-ancestry populations. We sought to characterize AR expression and TNBC patterns among a series of breast cancers from Ghana, Africa. Methods: Invasive breast cancer specimens from 147 pts treated at a single teaching hospital in Ghana were studied at a comprehensive cancer center in the United States and analyzed for estrogen receptor (ER), progesterone receptor (PR), HER2/neu, ALDH1 and AR expression via immunohistochemistry. Results: Median patient age was 45 (range, 28-76yrs). Only 31 cases (21%) were ER-positive, and 14 (10%) were HER2positive; 89 tumors (61%) were TNBC. For the entire group, 44% were ARpositive and 45% were ALDH1-positive. ER/PR-positive tumors were more likely to be AR-positive compared to ER/PR-negative tumors (87% versus 26%; p<0.0001) but there was no association between ALDH1 and AR expression. Among the TNBC cases, 45% were ALDH1-positive and 24% were ARpositive. Within the subset of TNBC tumors, ALDH1-positive lesions were more likely to be AR-positive compared to ALDH1-negative lesions (36% versus 14%; p=0.019). Conclusions: We confirmed the results of others showing that the majority of African breast cancers are triple-negative. We also found that AR expression is lower than that reported in other populations. Surprisingly, a marker of mammary stem cell expression was found to correlate with AR expression among triple negative tumors in this series, suggesting that patterns of TNBC subtypes may differ in populations with substantial African ancestry.

P53

Cannula-assisted Flap Elevation (CAFE): A Novel Technique for Developing Flaps during Skin-Sparing Mastectomies (SSMs) M.D. Grant.* Baylor Charles A. Sammons Cancer Center and Baylor University Medical Canter, Dallas, TX.

One of the most challenging procedures in breast surgery is the SSM. Various techniques and incisions have evolved that characterize this procedure: however what is common in all of them is the smaller the incision, the more difficult it is to develop skin flaps. Here we report a procedure which incorporates the use of liposuction cannulas (without suction) to create skin flaps. Briefly, the plan for mastectomy incision would be the same as for any procedure, but small "access incisions" are made along incision lines, with enough room for the cannula. The skin incision is made with a scalpel and hemostasis is done with cautery. A plane is started with a hemostat and blunt-spreading technique is used to find the plane in fascia. The cannula is inserted in this opening and passed radially towards the periphery of the breast parallel to skin surface in a back and forth motion. Multiple small channels are created in the plane, but no fat removed. At least 2 quadrants of breast can be accessed through each incision. This same technique is repeated from different angles until the entire superficial plane has been perforated with multiple intersecting channels. After this first step, the rest of the planned surgery is done as normal. In over a year, 100+ mastectomies have been performed using this procedure. Postoperatively, no problems were experienced with flap viability. The main side effect of the CAFE technique was more bruising than normal, but this resolved rapidly. The results for use of this technique were consistently impressive. The learning curve for this procedure is very short, especially for those who perform SSMs using scissors. Residents and fellows became proficient with the CAFE technique in a relatively short amount of time. Plastic surgeons were pleased with the cosmetic outcomes of their reconstructions that follow this type of mastectomy. Patients were extremely satisfied with their reconstructions as well. Incorporating the use of liposuction cannulas makes the creation of flaps for SSM a relatively simple and rapid method. It is especially useful to assist in developing skin flaps with even the smallest of skin incisions.



Figure 1. CAFE technique for flap development. A. "Access incisions" are made along incision lines, which are large enough to accommodate the cannula (arrow). B. A hemostat is used to get the appropriate plane started in the superficial fascia. C. A cannula is inserted in the opening and passed radially towards the periphery of the breast parallel to the skin surface in a back and forth motion (arrow). D. At least 2 quadrants of the breast can be accessed through each incision using the back and forth motion (arrows). E. This technique is repeated circumferentially from different angles until the entire superficial plane has been perforated with multiple intersecting channels. Ovals represent completed areas of the breast skin flaps that have been subcutaneously perforated with cannulas before flap elevation (M= medial, S= superior, L= lateral, and I= inferior). F. A pair of Cooley scissors is used to finish this part of the procedure. G. A skin hook can be used to assist in counter tension if necessary.

P54

Predictive Factors of Response to Neoadjuvant Chemotherapy in Hormone Receptor Positive Breast Cancer L. Lai,* R. Ottesen, J. Niland. Surgery, City of Hope, Duarte, CA.

Background: Previously reported low response rates of hormone receptor positive (HR+) breast cancer to neoadjuvant chemotherapy have limited the use of this treatment algorithm. Our objective was to identify clinical and treatment factors that may predict for response to neoadjuvant chemotherapy in HR+ breast cancer patients. Methods: An institutionally approved prospective breast cancer database incorporating the NCCN Breast Cancer Outcomes Project data dictionary was used to identify patients with cancers that expressed estrogen receptor (ER) and/or progesterone receptor (PgR) who received neoadjuvant chemotherapy from 1997 – 2012. Only patients who underwent surgical resection were included. Response to neoadjuvant chemotherapy was confirmed by pathological findings. Logistic regression analyses were performed to identify demographic, clinical and treatment factors predictive of response to neoadjuvant chemotherapy. Results: Of the 2,473 patients in the database, 153 with HR+ breast cancer patients were treated with neoadjuvant chemother apy followed by definitive surgical resection. The mean age of the patients was 49 years. 54 (35%) patients demonstrated response with downstaging of disease. Complete pathological response was identified in 12 (7.8%) patients. Using a multivariable logistic regression model, ER (p=0.0456), clinical stage (p=0.0018) and LVI (p=0.0220) were associated with response to neoadjuvant chemotherapy. Patients with disease that did not express ER (OR=4.86 95%CI 1.03 – 22.91), with Stage II disease (OR=2.37 95%CI 1.09-5.18), with cancers that lacked lymphovascular invasion (OR=2.95 95%CI 1.17-7.45) were more likely to respond. Age, menopausal status, race/ethnicity, HER2 receptor status, and grade were not predictive of response. Conclusions: The use of preoperative chemotherapy in HR+ breast cancer is associated with encouraging response rates. In patients with ER-PgR+ cancers, node negative disease, and no lymphovascular invasion, preoperative chemotherapy is more likely to result in disease downstaging and complete pathological response.

P55

Cytotoxic T Lymphocyte Infiltration of Normal and Benign Breast Lobules Diminishes with Age and Epithelial Abnormality R.D. Brahmbhatt,^{1*} D.W. Visscher,¹ T.L. Hoskin,¹ D.C. Radisky,² L.M. Murphy,¹ M.L. Stallings Mann,² E.E. Miller,² L.C. Hartmann,¹ M.H. Frost,¹ A.C. Degnim.¹ *1. Mayo Clinic, Rochester, MN; 2. Mayo Clinic, Jacksonville, FL.*

Introduction: CD8+ tumor infiltrating lymphocytes have a predominantly cytotoxic phenotype and a hypothetical role in tumor immunosurveillance. Here we investigate whether cytotoxic T lymphocyte (CTL) density varies in nonmalignant breast lobules according to confirmed breast cancer risk factors: age and histologic features of fibrocystic change/epithelial proliferation and involution. Methods: Archived breast tissue samples were obtained from 81 women: 54 with benign breast disease (BBD) and 27 normal women without clinical breast disease from the Komen Tissue Bank at Indiana University (KTB). Up to 10 representative lobules in each sample were characterized by H&E for fibrocystic changes/degree of epithelial proliferation (normal, nonproliferative, proliferative) and involution (none, partial, complete). Consecutive sections were immunostained for CD8+ CTLs. Using digital image analysis, quantitative CTL density (cells/mm2) was obtained on a per lobule basis and analyzed by linear mixed effects regression. Results: Among 81 women (age 37-70), 756 lobules were evaluated: 236 KTB and 520 BBD. The majority of lobules were normal (419, 55%); 190 (25%) had nonproliferative fibrocystic changes, and 141 (19%) had epithelial proliferation. Among normal lobules, 32 (8%) had no involution, 131 (31%) had partial involution, and 256 (61%) had complete involution. CTL density was higher in women younger than 55 years (152 cells/mm2) compared to women 55 years and older (108 cells/mm2; p = 0.04). Mean CTL density decreased with increasingly abnormal epithelial proliferation: 143 cells/ mm2 in normal lobules, 120 cells/ mm2 in nonproliferative fibrocystic lobules, and 88 cells/ mm2 in lobules with epithelial proliferation (Figure, p <0.0001, also significant after adjusting for age). CTL density did not vary with involution status, even when adjusted for age. Conclusions: CTL infiltration of breast lobules decreases with age and with increasing degrees of epithelial abnormality, features associated with breast cancer risk. These findings raise questions about a possible role of CTLs in tumor immunosurveillance and in early steps of carcinogenesis.



Phosphatidylinositol 3-kinase (PI3-kinase) Pathway Aberrations are Frequently Seen in Triple-negative Breast Cancer B. Pockaj,^{1*} A.E. McCullough,¹ H.E. Cunliffe,³ K.S. Anderson,¹ L.G. Gonzalez,² M.L. Alvarez,¹ M.T. Barrett.¹ *1. Mayo Clinic, Phoenix, AZ; 2. Arizona State University, Tempe, AZ; 3. Translational Genomics Research Institute, Phoenix, AZ*.

Background: Triple negative breast cancer (TNBC) has limited therapeutic options. Activating mutation or focal amplification of the PIK3CA gene is the most common oncogenic event found in breast cancer including TNBC. The emergence of PI3-kinase pathway inhibitors has led to their potential use in the treatment of breast cancer, including in the context of Androgen Receptor (AR) positive status. Methods: Paraffin samples from 18 patients with TNBC were obtained from an IRB approved, annotated biorepository. Pure tumor populations were flow sorted from each block using DNA content-based flow cytometry. Array-based comparative genomic hybridization (aCGH) was performed to evaluate genomic amplifications and deletions. Multiple genes in the PI3-kinase pathway (PIK3A, PTEN, AKT1, AKT2) were analyzed and compared with clinical data. AR status was determined by IHC. Results: Average age of the 18 TNBC cases was 51 years (range 34-77 years). Mean tumor size was 3.0 cm (range 0.7-6.5 cm) and 8 patients were lymph node positive. 7 patients were AR+. A total of 7 patients developed a systemic recurrence. 15/18 patients (83%) had an aberration in a PI3-kinase pathway gene by aCGH. There was no difference in patients who were AR+(6/7) compared to those who were AR- (9/11). More than one aberration was seen in 8 patients (53%) and no difference between those who were AR+ or AR-. There were also no differences between patients based upon systemic recurrence. Heterozygous PTEN deletion was the most common abnormality found occurring in 9 patients (50%) and 4 patients were homozygous for the PTEN deletion. Abnormalities in PIK3CA, AKT1, and AKT2 were less common. Conclusions: Aberrations in the PI3-kinase pathway were very common in our TNBC cohort. The presence of alterations in the PI3-kinase pathway in the presence of AR positivity suggests that dual therapy with an AR inhibitor and PI3-kinase pathway inhibitor could potentially be a biomarker-driven therapeutic approach in TNBC. Evaluation of larger datasets including DNA sequence analysis of PI3K pathway genes and functional assays will be performed to verify these results.

P57

Papilloma on Core Biopsy: Excision versus Observation

F. Nakhlis,¹* N. Ahmadiyeh,² S. Lester,¹ S. Raza,¹ P. Lotfi,¹ J. Brock,¹ M. Golshan.¹ *1. Dana Farber/Brigham and Women's Cancer Center, Boston, MA; 2. UCSF School of Medicine, San Francisco, CA.*

INTRODUCTION: Intraductal papillomas (IP) are commonly seen breast lesions with variable clinical presentation. For a palpable lesion and/or evidence of cellular atypia and/or pathologic nipple discharge (PND), an excision is warranted to rule out adjacent carcinoma, while for asymptomatic IPs lacking atypia current data for excision vs. observation are controversial. We reviewed outcomes of IPs diagnosed at our institution. METHODS: With IRB approval a retrospective review was done of consecutive patients with IPs seen on core biopsy (CBx) between 2005 and 2013. Those with PND were excluded. All patients had an excision, with sub-specialty breast pathology review of CBx and excision specimens. The rate of upgrade to invasive cancer or DCIS on excision was recorded. Differences between atypia and no-atypia groups (Table 1) were determined by two tailed t test and by Fisher's exact test. RESULTS: We identified 97 patients (age range 31-83 years) with IP's on CBx. Among 52 patients with atypical IPs, DCIS was seen in 11 (upgrade 21%). In 45 patients with IPs without atypia 3 cancers were seen (upgrade 6.7 %): 2 had palpable lesions and were found to have DCIS; 1 invasive cancer (grade 2, 1.9 cm) was found in a non-palpable mammographically detected BIRADS 4C lesion, whose CBx result was discordant. If the 2 palpable lesions are excluded the upgrade rate for IPs without atypia is 2.2%. Since all 3 upgraded lesions were discordant and thus would have been excised, in our limited series of IPs without atypia no concordant lesions would have been upgraded. CON-CLUSIONS: This series shows a low upgrade rate for IP without atypia seen on CBx in the absence of a palpable mass and radiographic/pathologic discordance, suggesting that close mammographic surveillance for such patients may be appropriate and that a surgical biopsy may not be necessary. Further prospective studies to better estimate the upgrade rate for IPs without atypia may be helpful to better counsel such patients.

Table 1

Atypia	Yes	No	p valu
Pts, N	52	45	
Mean age	56	51	0.02
No palpable mass	46 (88%)	35 (78%)	NS
BIRADS 4	51 (98%)	43 (96%)	NS
Concordant (agreement between radiographic appearance and pathology)	40 (77%)	24 (53%)	0.02
Mean number of cores	5.2	5.2	NS

P58

Wait Times for Breast Cancer Surgery, 2003-2010: A Report from the National Cancer Database E. Liederbach,^{1*} C. Pesce,¹ S. Sharpe,² M. Sisco,¹ D.J. Winchester,¹ K. Yao.¹ *1. Surgery, Northshore University Healthsystem, Evanston, IL; 2. University of Chicago, Chicago, IL.*

Background: There are few multicenter studies that have examined wait times for breast surgery and no benchmarks exist. We hypothesized that wait times have increased and these increases are related to certain patient and facility factors. Methods: Using the NCDB, we analyzed time from diagnosis to surgery for 666,803 non-neoadjuvant AJCC stage 0-III breast cancer patients treated in 2003-2010. Chi-square and logistic regression models were used to examine factors associated with longer wait times. Results: Sixty-seven percent of patients underwent a lumpectomy (LP), 23% a mastectomy (MA), and 10% a mastectomy with reconstruction (MR). The median time from diagnosis to surgery was 25 days for LP, 27 days for MA, and 35 days for MR. The median time from diagnosis to operation increased from 2003 to 2010 (Figure 1, p<.001). In a multivariate analysis the following variables were independent predictors of a longer wait time across all procedures: increasing age, African American race, Medicaid insurance, low educational status, greater Charlson-Deyo co-morbidity score, academic/research facilities, and facilities located in the Northeast and Atlantic regions. Academic/research facilities had longer relative wait times than community centers for LP (OR=1.75 95% CI: 1.7-1.8), MA (OR=2.0 95% CI: 1.9-2.1) and MR (OR=1.50 95% CI: 1.3-1.6) and wait times for facilities in the Northeast were over two times longer (OR=2.16-2.58, 95%CI: 1.9-2.8) for all mastectomies. The largest discrepancies were noted for MR; median wait time was 42 days for African Americans compared to 35 days for Caucasians, 44 days for Medicaid patients compared to 33 days for private insurance, 39 days for facilities located in the Northeast compared to 28 days for facilities in the Midwest, and 38 days for academic/research facilities compared to 32 days for community facilities. Conclusions: Wait times have increased for all surgical procedures. Facility and socioeconomic factors are associated with longer wait times across all breast operation types. These findings can be used as benchmarks to determine timely delivery of care.



Median Days from Diagnosis to First Breast Operation

P59

Increase in Contralateral Prophylactic Mastectomy Rates is Associated with Increased Use of Immediate Reconstruction

J.C. Boughey,* T.J. Hieken, A.C. Degnim, J.W. Jakub, T.L. Hoskin. *Mayo Clinic, Rochester, MN.*

Background: Contralateral prophylactic mastectomy (CPM) rates have been increasing nationally. Reasons for this are not fully elucidated and immediate breast reconstruction (IBR) has been proposed as a factor. This study's goal was to evaluate 5 year trends in CPM rates and IBR at a tertiary referral center. Methods: With IRB approval we evaluated the selected surgical procedures for women with newly diagnosed unilateral Stage 0-III breast cancer (without a prior breast cancer history) from 10/08 to 6/13. Proportions were compared across years using chi-square tests for linear trend. Results: We identified 2886 patients. Median age was 60 yrs (range 24-93). The stage distribution was 0 (25%), I (45%), II (23%), and III (7%). Surgical procedure was lumpectomy in 49% and mastectomy in 51%. Of the 1473 patients undergoing therapeutic mastectomy, 706 (48%) additionally underwent CPM and 615 (42%) underwent IBR. Therapeutic mastectomy rates did not change significantly over the study period (p=0.46), but use of IBR increased from 30% in 2008 to 58% in 2013 (p<0.0001). CPM rates increased significantly from 38% in 2008 to 52% in 2013 (p=0.01). The choice of IBR was significantly associated with the choice of CPM; 57% of patients who elected CPM opted for IBR compared to 27% choosing IBR in the unilateral mastectomy (UM) group (p<0.0001). Within the therapeutic mastectomy subset, rates of therapeutic unilateral mastectomy (UM) decreased from 2008 to 2013 (62.5% to 48%) with the major decrease in UM without IBR, from 52% in 2008 to 27% in 2013 (p<0.0001). Despite the overall decrease in UM, rates of UM with IBR increased from 11% in 2008 to 21% in 2013 (p<0.001). The increase in CPM was entirely due to an increase in CPM with IBR from 19% to 38%, p<0.0001, while CPM without IBR rates decreased from 19% to 15%, p=0.16. Conclusion: CPM rates increased significantly over the past 5 years, driven by an increase in the choice of CPM with IBR. Use of IBR may influence patients' decisions to pursue CPM. Further work to evaluate these trends nationally and to better understand the patient decision-making process regarding CPM is warranted.



P60

The Impact of Total Skin-sparing Mastectomy Incision Type on Reconstructive Complications following Radiation Therapy A. Warren Peled,* C. Ligh, F. Wang, H. Sbitany, R.D. Foster, B. Fowble, L.J. Esserman. University of California, San Francisco, San Francisco, CA.

Introduction Postoperative ischemic complications after total skin-sparing mastectomy (TSSM) and expander-implant reconstruction can negatively impact outcomes, particularly in the setting of post-mastectomy radiation therapy (PMRT). The goal of this study is to determine if rates of ischemic complications after PMRT are impacted by TSSM incision. Methods We queried a prospectively-collected database of patients undergoing TSSM and immediate 2-stage expander-implant reconstruction. Our hypothesis was that, in the setting of PMRT, patients with inframmary (IMF) incisions would be more likely to develop ischemic complications than those without incisions on the dependent portion of the breast. We divided our patient cohort into two groups, those with IMF incisions and those with other TSSM incisions and then analyzed the proportion that received PMRT. Results Of 756 cases of TSSM and immediate expander-implant reconstruction during the six-year period included in the analysis, 469 (62%) had IMF incisions and 287 (38%) had other incisions. Overall, rates of TSSM incision breakdown (2.6% vs. 4%, p = 0.4) and mastectomy skin flap necrosis (6.4% vs. 8.7%, p=0.3) were equivalent amongst incision types. A subgroup of 91 patients (12%) received PMRT, 62 (68.1%) with IMF incisions and 29 (31.9%) with other TSSM incisions. Mean followup was 3.1 years (range 0.8 - 6.6 years). Rates of mastectomy skin flap necrosis (3.2% vs. 6.9%, p = 0.4) following PMRT were not significantly higher in the IMF group. However, breakdown of the TSSM incision after PMRT was twice as likely in the IMF group vs. others (21% vs. 10.3%, p = 0.2) and was more likely to lead to subsequent implant removal when incisional breakdown occurred (77% vs 0%, p = 0.03), despite attempts at implant salvage. Conclusions In the setting of PMRT, TSSM incision type may impact the development of incisional breakdown and implant loss, with higher rates of complications seen with IMF incisions. Multiple factors, including preoperative breast size, degree of breast ptosis, and likelihood of PMRT, should be considered in determining optimal TSSM incision and reconstructive choice.

P61

Second-look Axillary Ultrasound after Breast MRI for Enhanced Preoperative Nodal Staging in Newly Diagnosed Breast Cancer Patients T.J. Hieken,^{1*} K.N. Jones,² J.C. Boughey,¹ S.S. Shah,³ K.N. Glazebrook.² 1. Surgery, Mayo Clinic, Rochester, MN; 2. Radiology, Mayo Clinic, Rochester, MN; 3. Pathology, Mayo Clinic, Rochester, MN.

Background: Concomitant with widespread adoption of axillary ultrasound (AUS) with ultrasound-guided needle biopsy (USNB) of suspicious lymph nodes (LN) for preoperative nodal staging of breast cancer patients, utilization of breast MRI, which includes axillary imaging, has increased. Little is known about the added value of MRI imaging of the axilla in this context. We undertook this study to assess the role of breast MRI in preoperative axillary nodal staging. Methods: We studied 988 consecutive invasive breast cancers in patients undergoing primary operation including axillary surgery, without neoadjuvant therapy, from 2010-2011 from our prospective institutional breast surgery database. Results: 505 patients (51%) underwent MRI of which 168 (33%) demonstrated suspicious findings in the axilla. Abnormal axillary MRI findings included cortical thickening, edema, enhancement, hilar effacement, and/or altered nodal shape and size. 114 patients (68%) with abnormal axillary imaging on MRI had findings concordant with a prior abnormal AUS. 54 patients (32%) had suspicious LNs on MRI either without a preceding AUS (31 cases) or after an initially negative AUS (23 cases). Second-look AUS was performed in 35 of these cases and was abnormal in 3 (9%). The 35 second-look AUSs included 27 performed in patients with no prior AUS (of which 1 AUS was abnormal) and 8 repeat AUSs after a pre-MRI negative AUS (of which 2 were abnormal). All 3 patients with abnormal second-look AUSs were confirmed LN+ on preoperative USNB. Of the 54 cases with MRI-detected suspicious LNs, 20 (37%) were node positive at operation with a pN stage of N0 (63%), N0i+ (5%), N1mic (4%), N1 (20%), N2 (6%), and N3 (2%). Extranodal extension was seen in 7 of 20 LN+ patients (35%). Conclusions: Second-look AUS, when performed subsequent to suspicious axillary MRI findings, identified LN metastasis preoperatively in 9% of patients. When MRI is done to evaluate the breast in newly diagnosed breast cancer patients, axillary findings can enhance the accuracy of preoperative nodal staging. We recommend second-look AUS when MRI demonstrates suspicious axillary LN find-

		Pathology :	P value	
	N	Node negative	Node Positive	
Breast MRI Axillary Imaging Normal Abnormal	505 337 168	255 (76%) 71 (42%)	82 (24%) 97 (58%)	<0.0001
MRI abnormal, second look AUS Normal Abnormal	29 26 3	18 (69%) 0 (0%)	8 (31%) 3 (100%)	
MRI abnormal, no second look AUS	25	16 (64%)	9 (36%)	
MRI abnormal, concordant with preceding abnormal AUS	114	37 (32%)	77 (68%)	

ings.

P62

Validation of Intraoperative Radiation Therapy Dose for Breast Cancer using Radiochromic Film V.V. Villescas,^{1*} R. Rudolph,¹ A. Pederson,² C.I. Price,² P.C. DeNitto,¹ C. Frazier,² J. Duttenhaver.² 1. Department of Surgery, Memorial Health University Medical Center, Savannah, GA; 2. Memorial Health University Medical Center -Department of Radiation Oncology, Savannah, GA.

BACKROUND: Intraoperative Radiation Therapy (IORT) is a novel single session procedure that applies partial breast irradiation at the low photon energy of 50 kv, reducing regional tissue damage and increasing convenience of treatment. The purpose of this study was to quantify dose absorbed within the partial mastectomy cavity and surrounding tissue. STUDY DESIGN: This prospectively collected data was retrospectively reviewed to evaluate actual dose absorbed versus the intent of 20 Gy per treatment. Skin exposure to radiation was also evaluated above and below the applicator site using radiochromic film. RESULTS: A total of 78 patients have been treated with IORT since inception of the program in October of 2012. The first 11 patients were treated before the use of radiochromic film for in vitro measurement of dose absorbed by the tumor bed, and thus were ineligible for evaluation. Of the 67 remaining patients, one was excluded from analysis as a result of surgeon oversight in placing radiochromic film within the breast cavity. Another was excluded due to mechanical malfunction, resulting in less than one minute of radiation therapy. The measured dose of radiation absorbed by the breast cavity in the remaining 65 patients was 19.08 ± 3.08 Gy, and the superior and inferior skin exposure was measured to be 2.36 ± 1.29 Gy and 2.22 ± 0.93 Gy, respectively. A final patient was excluded after being administered a radiation dose 4 standard deviations below the mean. Recalculating the data with this final patient excluded, the measured radiation mean within the breast cavity was $19.54 \pm$ 1.58 Gy, with skin measurements of 2.29 ± 1.28 Gy and 2.23 ± 0.89 Gy superiorly and inferiorly respectively. CONCLUSIONS: In our cohort, it appears that IORT delivers the prescribed 20 Gy to the partial mastectomy cavity, while virtually eliminating tissue toxicity to surrounding skin with levels of radiation less than those currently accepted in conventional whole breast irradiation. The use of radiochromic film has been shown to be a practical, reproducible, and cost effective method of ensuring minimal tissue damage and establishing a permanent record of intracavity and skin dose delivery.

P63

The Rise and Fall of Accelerated Partial Breast Irradiation (APBI): What Happened? R. Jimenez,^{1*} T. Boyd,¹ L. Hollander,² R.J. Piorkowski.¹ *1. Hartford Hospital, Hartford, CT; 2. University of Connecticut Medical School, Farmington, CT.*

Introduction: APBI is offered as an alternative to whole breast radiation for selected patients with early breast cancer who choose breast conservation. While initially adopted with enthusiasm, we have recently observed decreased utilization of APBI. Possible influencing factors include decreasing rates of breast conservation and/or physician reaction to the publication of practice guidelines in 2009. Our goal in this study was to evaluate our clinical experience with APBI over the past 9 years and identify possible causes for the current loss in case volume. Methods: Analysis of prospective database of patients with Stage 0. I or II breast cancer treated with APBI via brachytherapy between 2004 and 2012. APBI cases were classified as suitable, cautionary or unsuitable based on the 2009 ASTRO consensus guidelines. Tumor Registry data for the study period was also reviewed. Results: 259 patients received APBI, most having stage I (74%) or stage 0 (22%) breast cancer. Distribution by guidelines was 40% suitable, 51% cautionary, 9% unsuitable. Since 2004 the number of APBI cases per year rose to a peak of 57 in 2009 (19% of stage I cancers that year), declining thereafter to a nadir of 22 in 2012 (5% of stage I cancers that year, P<0.001 compared to 2009). Loss of case volume over the past 3 years was not correlated to changes in breast conservation cases (270±17 cases/year), loss of breast surgeons (6±1 surgeons/year), or poor clinical results (cancer recurrence rate 3.1%). The initial drop in APBI cases occurred in 2010 following the appearance of ASTRO guidelines in 2009. After publication of the guidelines less unsuitable cases received APBI (12% vs. 4%, P<0.036), but there was no difference in the proportion of suitable and cautionary cases before and after 2009. Conclusions: Decreased utilization of APBI followed the publication of the ASTRO guidelines, although a cause-and-effect relationship was not demonstrated. A reduction in unsuitable cases treated after 2009 does not explain the global loss of referrals. Other factors for future analysis include decreasing surgeon remuneration and negative effects of terminology such as cautionary or unsuitable within the guidelines.



APBI cases per year.

P64

Rapid Processing Algorithm for CTC Enumeration and RNA Isolation in Breast Cancer J. Wecsler,* W. Zhu, N. Mineyev, V. Punj, D. Tripathy, A. Ring, S. Sener, J.E. Lang. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.

Introduction: We are performing an ongoing study of gene expression profiling of circulating tumor cells (CTCs) in Stage II-III breast cancer patients. We have developed a method for isolating CTCs that uses immunomagnetic separation followed by fluorescence activated cell sorting (IE/FACS) and a rapid processing algorithm. We hypothesized that pre-analytical variables such as time to CTC testing may influence CTC enumeration results. Methods: IE/FACS was performed with magnetic beads coated with monoclonal antibody (mAb) to the epithelial cell adhesion marker (EpCAM) followed by FACS with positive selection by EpCAM and thioflavin and negative selection for CD45. Our protocol requires a 20 mL peripheral blood draw to be processed for CTC testing in less than 20 minutes. CTC positive status was defined as 1 or more detectable CTC. We assayed healthy control subjects during initial assay set-up and serially as cross-sectional validation that the assay shows no CTCs in healthy subjects. Results: To date we have enrolled 14 patients and

10 healthy controls. All negative control subjects had no detectable CTCs. The median patient age was 57.8 years. 12/14 (85.7%) patients had CTCs. The median number of CTCs isolated was 6 (range 0-65) with a mean of 0.85 CTCs per mL of blood. CTCs were identified in 8/10 (80%) ER positive, 8 of 9 (88.9%) PR positive, 2/2 (100%) HER2 positive, and 3/3 (100%) triple negative patients. 8/14 (57.1%) patients were node positive; no association between CTC and nodal status was present. Similarly, no association between tumor size and CTC status was found. Historical controls using a commercially available CTC enumeration strategy found 30-40% of Stage II-III patients to be CTC positive with processing generally performed within 72 hours. Conclusion: The time interval between blood draw and CTC processing assays involving cell surface markers may impact the rate of CTC detection. Using a rapid processing algorithm we were able to double the number of CTCs isolated for future RNA profiling. This strategy may increase the probability of isolating non-degraded nucleic acids for Next Generation Sequencing to study the biomarker CTCs in breast cancer.

P65

Does the Type of Surgery after Neoadjuvant Therapy for T3/T4 Breast Cancer Impact Survival? J. Al-Azhri,* T. Koru-Sengul, F. Miao, S.L. Tannenbaum, M. Byrne, H. Alghamdi, C. Saclarides, D. Franceschi, E. Avisar. Surgery, University of Miami Miller School of Medicine. Miami, FL.

Introduction: Our purpose was to study the impact of type of surgery on survival of women with T3/T4 breast cancer treated with neoadjuvant therapy. Methods: Population-based Florida Cancer Data Registry was screened for women diagnosed with T3/T4 breast cancer and received neoadjuvant therapy followed by either breast conserving surgery (BCS) or mastectomy. A multivariable Cox regression was used to identify significant predictors of overall survival. Variables including sociodemographics characteristics, clinicopathological characteristics, type of surgery and type of neoadjuvant therapy were all entered in the model. Adjusted hazard ratios (HR) and 95% confidence intervals (95%CI) were calculated. Type-I error rate was set to 5%. Statistical analyses were done in SAS v9.3. Results: Out of 712 patients, 72 (10%) had BCS and 640 (90%) had mastectomy post neoadjuvant therapy. After adjusting for aforementioned characteristics, neoadjuvant chemotherapy+hormonal therapy was associated with a better prognosis than chemotherapy alone (HR=1.94; 95%CI:1.25,3.01; p=0.003) or hormonal therapy alone (HR=2.34; 95%CI:1.02, 5.36; p=0.044). Hispanics (HR=0.48; 95%CI:0.27, 0.88; p=0.018), middle-high SES (HR=0.66; 95%CI:0.45,0.97; p=0.034) compared to lowest, medicare (HR=1.69; 95%CI:1.08,2.65; p=0.023) and uninsured (HR=1.70; 95%CI:1.11,2.60; p=0.016) compared to private insurance, poorlydifferentiated (HR=2.59; 95%CI:1.22,5.54; p=0.014) and undifferentiated (HR=3.55; 95%CI:1.42,8.87; p=0.007) compared to well-differentiated grade, and distant SEER stage (HR=3.92; 95%CI:1.65,9.30; p=0.002) were significant predictors of overall survival. Survival between patients with BCS vs. mastectomy did not differ significantly (HR=0.74; 95%CI:0.45,1.21; p=0.229). Conclusion: The type of breast surgery after neoadjuvant therapy for T3/T4 breast cancer does not impact survival. Predictors of survival include tumor grade and stage, type of neoadjuvant therapy, ethnicity, SES and health insurance. In-depth studies are needed to help understand the mechanism by which these factors impact the overall survival.

P66

Cox-2 Expression in High-grade Breast Cancer: Evidence for Prognostic Significance in the Subset of Triple-negative Breast Cancer B. Chikman, R. Lavy,* A. Kapiev, A. Halevy. *Assaf Harofeh Medical center i, Tel Aviv, Israel.*

Background Cox2 is a key enzyme responsible for prostaglandin production and is frequently overexpressed in breast cancer. Experimental studies showed that COX2-expression stimulates angiogenesis, cell proliferation, inhibits apoptosis, and promotes development of cancer metastases. Almost all clinical studies found predominance of Cox-2 expression in high grade breast cancer compared to grade I-II. The aim of our study was to evaluate the significance of Cox-2 expression in group of patients with high grade breast cancer. Materials and methods Three hundred and three patients (median age 55; range 25-95 years) were included in the study. The mean follow-up period was 65.2 months. COX2 expression was evaluated immunohistochemically using score system, based on the sum of staining intensity and percentage of positive cells. Results 129 out of 303 patients (42.6%) were Cox-2 negative and 174 (57.4%) Cox-2 positive. There was no correlation between any clinicopathological pattern and Cox-2 expression. There was no difference in Cox-2 expression according to ER/PR status and Her2 overexpression. In group of patients with triple-negative breast cancer the 5-year disease-free survival rate was 58.3% for the group of patients with Cox-2 expression as compared to 83.9% for patients without Cox-2 expression (p=0.042). In other intrinsic subtypes of high grade breast cancers Cox-2 expression did not provide prognostic significance. 5-year DFS in patients with Cox-2 positive and Cox-2 negative tumors were : Luminal A type 86.9% versus 83.3% (p=0.587), Her2-negative type 52.6% versus 50.0% (p=0.894) and Luminal type B 83.3% versus 60.9% (p=0.116), correspondently. Conclusion We found no correlation between Cox-2 expression in high grade breast cancer and primary tumor characteristics, hormonal receptor status and Her2 expression . Cox-2 expression is associated with poor disease free survival in triple-negative breast cancer Efficacy of Cox-2 inhibitors combination with standard regimens of chemotherapy needs further evaluation

P67

Limits of Real-time 2D and 3D Ultrasound (US) for Volumetric Analysis: A Prospective Study S.J. Gonzalez,^{1*} B. Mooney,¹ B. Robert,² J.V. Kiluk,¹ N. Khakpour,¹ C. Laronga,¹ M. Lee.¹ I. Surgical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; 2. Virginia Baptist Hospital, Lynchburg, VA.

Introduction: US allows real-time imaging and has great potential for intraoperative soft tissue assessment in breast and abdominal surgeries. We evaluated the volumetric limits of 2-dimensional (2D) and 3-dimensional (3D) US compared to MRI. Methods This is an IRB-approved, prospective clinical trial evaluating US-to-MRI volumetric correlation, 2D and 3D US images of pre- and postneoadjuvant breast cancer tumors were obtained. Cases with skin involvement, incomplete or poor images were excluded. The US-to-MRI volumetric discrepancies were calculated by non-parametric Wilcoxon Signed-Rank test. Expected inter-observer variability (IOV) of <14% was evaluated as Relative Paired Difference (RPD) and the clinical relevance of this variability was analyzed using the volumetric Standard Error of the Mean (SEM); values <5cm3 were considered clinically usable. Subgroup analyses of size, age and treatment status were performed. Results: Forty-two patients enrolled; 133/170 US were evaluable with 65 2D and 68 3D US images paired to MRI. In tumors ≤20cm3, both probes showed high correlation to MRI with RPD within IOV, SEM <0.6cm3 and p>0.09. Lesions 20-40cm3 had significantly different US-to-MRI volumes (p<0.05 for both US); the discrepancy was within IOV for 2D (RPD:13%) but not 3D US (RPD:27%); however, this was small and reproducible in both probes (SEM:1.47cm3 for 2D and SEM:2.28cm3 for 3D), suggesting some clinical utility. Tumors >40cm3 had significantly different US-to-MRI volumes (p=0.02 for 2D and p<0.001 for 3D); RPD values were within IOV (RPD<13.3%) but SEM exceeded clinical utility limits (8.3cm3 for 2D and 9.9cm3 for 3D US). Age <40 had no effect on US-to-MRI correlation but post-treatment status showed a high US-to-MRI volume correlation (p=0.17 for 2D and p=0.21 for 3D US) with measurements within IOV and acceptable variability for clinical use (SEM=0.4cm3 for 2D and 4.2cm3 for 3D US). Conclusion: Post-neoadjuvant tumors and those <20cm3 showed high US-to-MRI correlation even after IOV correction. Tumors</p> 20-40cm3 may also be amenable to US volumetrics. Future studies of clinical and intraoperative volumetric applications of 2D and 3D US are needed





Conservative Surgery and Intraoperative Radiation Therapy in Early Breast Cancer A. Maffuz-Aziz,* J. Huerta-Bahena, C.A. Dominguez-Reyes, A.R. Espejo-Fonseca, E. Ruvalcaba-Lim, S.A. Rodríguez-Cuevas. *Instituto de Enfermedades de la Mama FUCAM, Mexico, Distrito Federal, Mexico.*

Introduction: Partial breast irradiation can be effective in preventing local recurrence in patients with early breast cancer treated with conservative surgery. When applied intraoperatively is feasible to provide all local treatment in one intervention. Methods: This is a prospective study of patients with early breast invasive ductal carcinoma treated with conservative surgery and intraoperative radiotherapy with 50kV X-ray system, receiving a dose between 20-22Gy to the surgical bed. All patients underwent additional MRI or 3-D mammography to rule out multifocal disease. We analyzed the characteristics of the tumor, lymph node involvement, molecular subtype, adjuvant treatment and follow-up to assess the incidence of local relapse. Results: 131 patients were included, the average age was 58.8 years (44-79 years old), average tumor size of 1.44cm (0.4 to 3.2cm), negative surgical margin was considered as no tumor cells in the inked margin, 26 patients had at least one positive node, 20% had lymphovascular invasion, 68% were luminal A, 18.7% luminal B, 2.5 % HER2 +, 9.8% and triple negative. In 14 patients an onclopastic procedure were performed and two patients were treated with bilateral conservative surgery and intraoperative radiotherapy. Adjuvant hormonal therapy was received by 53% of the patients, chemotherapy in 10 %, chemotherapy + hormonal therapy in 19%, 16% required adjuvant whole breast radiotherapy because of adverse prognostic factors for local recurrence and 2% required total mastectomy for a positive surgical margins. At a median follow up of 18 months, no patient had local or regional relapse. Fourteen patients had complications, of which 12 were minor (infection, seroma or dehiscence) resolved in office and 2 mayor requiring reoperation for debridement of the wound and another patient present severe infection treated with intravenous antibiotics. Conclusions : Intraoperative radiation therapy after conservative surgery is a safe procedure with low morbidity and provides the all local treatment in one intervention in selected cases, is necessary a longer period of surveillance to assess local recurrence.

P69

Perceptions of Contralateral Breast Cancer Risk: A Prospective Longitudinal Survey P. Portschy,¹* A. Abbott,¹ E.E. Burke,¹ R. Nzara,¹ K.M. Kuntz,² T.M. Tuttle.¹ *1. Department of Surgery, University of Minnesota, Minneapolis, MN; 2. Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN.*

Introduction: An increasing proportion of breast cancer patients undergo contralateral prophylactic mastectomy (CPM) to reduce their risk of contralateral breast cancer (CBC). Our aim was to evaluate the perceived risk of CBC among breast cancer patients and determine if this perceived risk changes over time. Methods: We conducted a prospective longitudinal study of women with newly diagnosed unilateral breast cancer. Patients completed a standardized survey before and approximately 2 years after treatment. Survey questions used open-ended responses or 5-point Likert scale scoring (5 = very likely, 1 = not at all likely). Results: A total of 74 women completed the pre-treatment survey, and 43 completed the post-treatment survey. Baseline characteristics were not significantly different between responders and non-responders of the follow-up survey. The mean time between surveys was 2.4 years. The mean estimated 10-year risk of CBC on the pre-treatment survey was 35.7% and 13.8% on the post-treatment survey. (p = 0.0005). On the Likert scale, the perceived risk of CBC significantly decreased from 2.8 to 2.0 (p = 0.0001). Moreover, the perceived risks of developing cancer in the same breast and elsewhere in the body significantly decreased between surveys. Overall, 26% of women underwent CPM. For both CPM and non-CPM patients, the perceived risk of CBC significantly decreased from pre- to post-treatment surveys. As compared with non-CPM patients, CPM patients had a significantly lower perceived 10-year risk of CBC (5.8% vs. 17.3%, p=0.046) on post-treatment surveys. Conclusion: Although women substantially overestimated their risk of CBC before treatment, the perceived risk significantly attenuated over time for both CPM and non-CPM patients. These data emphasize the importance of early physician counseling to provide women with accurate information before treatment.

P70

National Trends in Mastectomy Rates from 1998 to 2010 M.A. Lautner,* C. Parker, H.Y. Lin, Y. Shen, H. Kuerer, S.F. Shaitelman, G. Babiera, I. Bedrosian. *UT MD Anderson Cancer Center, Houston, TX.*

INTRODUCTION Although breast conserving therapy (BCT) has been established as an appropriate alternative to mastectomy, uncertainty remains about the direction of recent trends in BCT versus mastectomy. We hypothesized that the discrepancies in mastectomy trends noted across the literature reflect differences in cohort characteristics and practice patterns. MATERI-ALS AND METHODS Using information in the National Cancer Database (NCDB) from 1998 through 2010, we evaluated women who either underwent a mastectomy or BCT. We conducted a retrospective review of the patient demographics, tumor characteristics and type of institution associated with undergoing BCT versus mastectomy and the trend of mastectomy rates over time. Logistic regression analysis was used to assess the multivariate relationship between these variables and the probability of undergoing a mastectomy. RESULTS We identified 1,687,192 women who had a mastectomy or BCT for stage 0-4 breast cancer. The mastectomy rate decreased from 53% in 1998 to 44% in 2006 (p<0.001). Thereafter, the mastectomy rate stabilized at approximately 46% through 2010. Mastectomy rates increased with increasing stage of disease and with hormone receptor negative tumors (p<0.001). After adjusting for disease characteristics, other factors associated with the use of mastectomy include lower income, less education, no health insurance and rural residence (all p<0.001). Mastectomy rates also varied depending on the type of institution delivering care; Community Cancer Programs had a higher rate of mastectomy (50%) than Comprehensive Community Cancer Programs (47%) and Academic/Research Programs (46%) (p<0.0001). Facility location affected rates of mastectomy, with the highest rates seen in the West (60%) and South (59%) and lowest rates in the Northeast (34%) (p<0.001). Institutional and geographic variations in mastectomy rates persisted even after adjusting for socio-economic variables. CONCLUSION Data from this comprehensive population based registry shows declining rates of mastectomy over the last decade. However, differences in mastectomy rates remain across socio-economic demographics, hospital practice type and geographic location.

P71

A Novel Animal Model for Locally Advanced Breast Cancer J. De Andrade,* M. Bogachek, J. Park, M.V. Kulak, P.M. Spanheimer, T.B. Bair, A. Olivier, R.J. Weigel. *University of Iowa, Iowa City, IA.*

INTRODUCTION: Locally advanced breast cancer (LABC) has a distinct clinical presentation that poses challenges for surgical care. Patients who fail neoadjuvant chemotherapy progress to local complications with skin erosion, superinfection and lymphedema. Most cell line and animal models are not adequate to study LABC. METHODS: A new cell line (IOWA-1) was derived from tumor cells of a patient with LABC that was unresponsive to neoadjuvant chemotherapy. A second cell line was developed from xenografting IOWA-1 cells in nude mice (IOWA-1T). Primary tumor and cell lines were characterized by IHC, expression array profile, short tandem repeat (STR) profile, sequencing of 50 common oncogenic genes and growth as xenografts. RESULTS: STR profile authenticated the cell line as derived from a human female, most closely associated with BT20 breast cancer cells. The primary tumor and derived xenografts were characterized by IHC as weakly ER+ (<5%), PR- and HER2 non-amplified. Expression array profile of IOWA-1T compared to MCF-7 and BT549 cell lines indicate that IOWA-1T was more closely related to basal breast cancer (Fig. 1A). Comparing the expression pattern for genes known to differentiate luminal vs. basal breast cancer lines, IOWA-1T had reduced expression of the luminal target genes FOXA1, GATA3, RET, FGFR4, MUC1, and KRT18 and overexpressed the basal target genes CALD1, SFRP1 and KRT14. IOWA-1T harbors a homozygous R248Q mutation of TP53. Nude mice flank injected with 6x10⁶ IOWA-1T cells developed palpable tumors in 9.6 ± 1.6 days, compared to 49 ± 13 days for parallel experiments done with BT20 cells (p<0.002). Tumor xenografts became locally advanced, growing to >2 cm in 21.6±2 days characterized with skin erosions that necessitated euthanasia (Fig. 1B). CONCLUSIONS: IOWA-1T is a novel breast cancer line with an expression pattern consistent with basal breast cancer. The cells rapidly form large, skin-eroding xenografts in nude mice and can be used as a LABC animal model. Since the line was derived from a chemotherapy-insensitive tumor, IOWA-1T may be useful as a model to investigate novel therapeutic drugs that may be effective in cases where conventional chemotherapy is ineffective.



P72

Outcomes following Breast Conservation Therapy in Women 80 Years of Age or Older M.D. Fana,* M.S. Jawad, A.V. Pietron, M. Wallace, H. Ye, N. Dekhne, I. Grills, P. Chen. *Departments of Surgery and Radiation Oncology, Beaumont Health System, Royal Oak, MI.*

Departments of Surgery, Division of Breast Surgery1, and Radiation Oncology2, Beaumont Cancer Institute, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan Purpose: To evaluate clinical outcomes following breast conservation therapy (BCT) with whole breast irradiation (WBI) or partial breast irradiation (PBI) in women ≥ 80 vrs old. Materials and Methods: 157 women \geq age 80 were treated with BCT from 9/91-5/12 at a single institution. BCT included surgery and adjuvant radiation therapy. WBI (n=81) was delivered via standard fractionation (50-61Gy, 25-33 fx) or hypofractionation (42.56Gy, 16 fx). 39 patients had a lumpectomy cavity boost with median dose 16 Gy (8-16). APBI (n=76) was delivered via low dose rate (n=23) or high dose rate (n=25) brachytherapy or 3D-conformal RT (n=28). Clinical outcomes were retrospectively analyzed, including ipsilateral breast tumor recurrence (IBTR), regional recurrence (RR), contralateral breast tumor recurrence (CBTR), distant metastases (DM), cause-specific survival (CSS), and overall survival (OS). Results: Median follow-up was 4.4yrs (0.1-16.7), with slightly longer in the APBI group (5.6 v 3.7yrs, p<0.001). Patient characteristics are in Table 1. WBI patients were more likely to have larger tumors (median 13 v 10mm, p=0.042), T2 disease (29 v 8%, p=0.007), LN+ disease (N1/2 15 v 1%, p=0.004), positive final margins (13 v 0%, p=0.012), and receive chemo (9 v 0%, p=0.02). There were no differences in histology, tumor grade, lymph nodes removed, or ER/PR/Her2 status. 59% of ER+ patients received hormone therapy. Clinical outcomes were similar between the two groups. Few events were noted at 5 years, with no RR or other failures. 5% of patients in the WBI group had CBTR at 5 years, compared to 0% in the APBI group (p=0.07). OS and CSS at 5 years were 81% and 95% overall, and not significantly different between APBI and WBI (OS 78 v 86%, p=0.521; CSS 95 v 97%, p=0.64). Conclusion: Breast cancer outcomes for women ≥80 yrs. were excellent, with a 5-year CSS of 95%. Both APBI and WBI appear to be reasonable treatment options. Further analysis with comparison to a matched cohort treated with surgery alone is under way.

Table 1. Patient Outcomes

	All Patients	APBI (n=76)	WB1(s=81)	P value
Age (ym)	83.15	83.16	\$10	
Mean	83	83.0	82.0	0.982
Modian	80.07	70.03	10.07	0.002
Range	80-91	30-72	100-97	
Follow ap (yrs)		1.01	1.05	
Mean	4,95	6.04	7.90	-0.000
Median	4.35	3.33	5.75	<0.001
Range	0.06-15.70	0.05-14.29	0.42-15.79	
Tumor Size (mm)	0000			
Mean	13.85	11.18	16.56	10.000
Mofian	11.0	10.0	13.0	0.003
Easter	1-90	2-32	1.99	
T Space				
To	13 (8.3%)	6(7.9%)	7(8.8%)	
Th	112(71.9%)	64 (84,2%)	-8K (56PE)	10000
10	29(18.5%)	6 (7.9%)	23 (28.8%)	0.007
	1(0.6%)	0.09%3	1 (1.9%)	1000
0	6 (29,6%)	0.09%)	1(1.3%)	
14				
N Path Stage	122 (785)		54 (66.2%)	
NO	7 (1.3%)	68 (89.5%)	0.055	
No (i+)	2 (1.3%)	2 (2.6%)	2(2.9%)	
Ni Mic	7 (4.7%)	0 (0%)	6/2.457	0.004
NI	6/3 8/3	1(1.9%)	6.73.453	
N2	012.8%)	5 (6.6%)	12 (1943)	
Na	19(11:4)	1. Set 19785	13(10%)	
Histology				
DCIS	12(7,6%)	0(7595)	0(7,4%)	
IDC .	125 (79.6%)	59(77.8%)	00 (81.5%)	
B.C.	8 (5.1%)	3 (3.9%)	5 (6.2%)	0.355
Both IDC & ILC	3(1.9%)	1 (1.9%)	2(2.5%)	100.000
Other (Modellary, Colloid, Tubular)	9 (5.8%)	7 (9.9%)	2(2.5%)	
Owk				
	53 (34.9%)	26 (35.1%)	27 (34.6%)	
	72 (47.4%)	37 (50%)	35 (44.9%)	0.639
	.27 (37.8%)	11 (14.9%)	16 (20.5%)	
III III				
Fina Margin	10 (6.6%)	0.0%)	10 (13.2%)	
Postor	121(80.9%)	68 (39.5%)	55(72.4%)	
Negative (>+2mm)	15 (9.9%)	7(9.2%)	8(10.5%)	0.012
Close (0.1-1.9mm invasive)	3(29)	1(1.2%)	2(2.6%)	
Close (0.1-1.90at non invasive)		1.1442.44	- 14-1-17	
Chemo	117(9079)	21/95/923	46 (83,672)	
No	5/1953	0.055	5 (9 (5))	0.020
Yes	5(5,45)	1/4/50	4/7 251	
Uskaowa	5 (2000)	714147	4(1)(4)	
Hormone	50 (A) A1)	77.000.0003	26 (22 20)	
No	77 (40.4.6)	201000.201	20 C/0.7 W/	0.101
Yes	20(32%)	29 (42.0%)	47 (00.5%)	0.104
Unknown	11 (7.5%)	0 (8.8%)	5 (0.4%)	
ER				
Prairing	134 (85.4%)	00 (88.0%)	68 (84%)	0.488
Negative	18(7.5%)	8 (20.5%)	10 (12.9%)	
PR III				
Position	106 (67.5%)	50 (55.8%)	56 (69.1%)	0.286
Nanotice	-43 (27.4%)	22 (28.9%)	21 (25.9%)	0.280
Negarite			-	-
Resident	6-(3.9%)	3(4%)	3 (3.8%)	1,000
Positive	120 (77.4%)	52(69.3%)	68 (85%)	1,000
Negative				

P73

Detrimental Association of Blood-product Transfusions on Survival of Breast Cancer Patients D. Franceschi,¹* D. Yakoub,¹ L. Koniaris,² A.S. Livingstone,¹ T. Koru-Sengul,¹ D.J. Lee,¹ F. Miao,¹ S.L. Tannenbaum,¹ M. Byrne.¹ *1. University of Miami, Miami, FL; 2. Indiana University, Bloomington, IN.*

Background: Transfusion of blood products is associated with worse survival for certain cancer patients. This effect has not been clearly defined in patients with breast cancer. Methods: Florida cancer registry data linked to the Florida Agency for Health Care Administration (AHCA) database were examined for breast cancer patients (1996-2009). Data were corrected for potential confounders related to blood transfusions, including age, gender, race, treatment, and comorbid conditions. Results: Overall 208,461 breast cancer patients were identified; 26,392 (12%) had transfusion of at least 1 unit of blood products. Patients receiving blood transfusion were older (66 versus 62 years, p< 0.0001), with more advanced stage disease. Transfused patients had reduced overall median survival of 94 months versus 162 months for non-transfused patients (p< 0.0001). Of 184,635 patients who received breast surgery with therapeutic intent, 1,271 (0.06%) received blood perioperatively, while 21,521 (11%) received blood at some other point during treatment. Median survival was 153 months for patients who did not receive peri-operative blood versus 54 months for those who did. Survival was adversely affected by blood product independent of surgical treatment, race, timing of transfusion, or stage except for patients with metastatic disease (Table). The amount of transfusions received was inversely correlated with survival. Multivariate analysis correcting for co-morbidities demonstrated blood transfusion to be an independent predictor of mortality (HR=1.36; CI 1.32-1.41; p<0.001). Conclusions: While blood transfusion is a relatively unusual event in the management of breast cancer patients, it is a significant independent risk factor for breast cancer patient mortality. This suggests that blood transfusions should be avoided in the management of breast cancer when possible.

Median Survival in Months

		Stage			Race		Surgery	
	In Situ	Local	Regional	Mets	Caucasian	Black	No	Yes
Overall Survival	NR	164	131	16	145	118	53	153
Transfusion								
No	NR	NR	152	15	163	144	60	NR
Yes	142	118	89	22	97	68	46	101
n valua	< 0.001	< 0.001	< 0.001	NC	< 0.001	< 0.001	< 0.001	< 0.001

Note: NR = Not Reached; Mets = metastatic

Thickness of Lumpectomy Shaved Cavity Margins Impacts Re-Excision Rates B. Wexelman,* R. Tang, M. Gadd, K.S. Hughes, M. Specht, B.L. Smith, S.B. Coopey. *Surgical Oncology, Massachusetts*

General Hospital, Boston, MA. Introduction: Shaved cavity margins (SCM) are often taken at the time of breast cancer lumpectomy to decrease rates of positive margins and minimize volume of resection. The optimal thickness of these "shaved" margins is not well established, and there is considerable variability in surgical practice. We sought to determine the optimal thickness of SCMs and the impact of SCM thickness on rates of re-excision, mastectomy, and local recurrence. Methods: We performed a retrospective review of all newly diagnosed breast cancer patients who underwent lumpectomy with complete SCM (4-6 individual shaved margins, or 2 hemispheric shaved margins) at our institution from 2004-2006. We excluded patients who had an excisional biopsy for diagnosis. Pathology reports were reviewed to determine the thickness of each shaved margin, and mean thickness of all SCM was calculated for each patient. Local recurrence, defined as in-breast recurrence, was recorded. Mean SCM thickness was correlated with re-excision, completion mastectomy, and local recurrence rates. Statistical significance was evaluated using chi-square tests between thickness groups. Results: 437 patients underwent lumpectomy with complete SCM, with median follow-up of 77.8 months. The mean shaved margin thickness was 6.4mm, range 2-25mm. Patients were grouped by mean SCM thickness into four groups: 1.0-3.9mm, 4.0-6.9mm, 7.0-9.9mm, and greater than 10.0mm. Thicker shaves were associated with significantly decreased re-excision rates (p=0.046) [Table 1]. Mean SCM \geq 10mm achieved the lowest re-excision rate of 19.2%, while SCM < 7mm and <4mm had re-excision rates that were twice as high (38.6%, 39.3%). We found no correlation between SCM thickness and ultimate success of breast conserving surgery. While there was a trend toward lower local recurrence rates with SCM \ge 7mm, this did not reach statistical significance. Conclusions: Shaved margin thickness has an inverse relationship with re-excision rates. Optimal shave thickness to avoid re-excision was 10mm in our cohort of patients.

Shaved Margin thickness and rates of re-excision, mastectomy and local recurrence

Mean Shaved Margin Thickness (mm)	N (%)	Re-excision Performed (%)	Completion Mastectomy (%)	In-Breast Recurrence (% of Successful BCS)
1.0- 3.9	70 (16.0%)	27 (38.6%)	7 (10.0%)	5 (7.9%)
4.0-6.9	214 (49.0%)	84 (39.3%)	29 (13.6%)	14 (7.6%)
7.0-9.9	101 (23.1%)	33 (32.7%)	13 (12.9%)	3 (3.4%)
10.0+	52 (11.9%)	10(19.2%)	7 (13.5%)	3 (6.7%)
Total	437 (100%)	154 (35.2%)	56 (12.8%)	25 (6.6%)
p value		0.046	0.892	0.588

P75

Pleomorphic Invasive Lobular Carcinoma: Characterizing a Lobular Carcinoma Variant A.S. Ojo,¹* A. Sharma,² B. Taback,¹

S.M. Feldman,¹ A. Preya.¹ 1. Columbia University Medical Center, New York, NY; 2. New York University, New York, NY.

INTRODUCTION: Pleomorphic invasive lobular carcinoma (PILC) is a subtype characterized by nuclear atypia and irregularity in contrast to the cytologic uniformity of classic invasive lobular carcinoma (ILC). It is considered a more aggressive based on limited reports in the literature with small series. We aim to further characterize this variant from a larger series at a single institution. METHOD: Following exclusion of PILC on core biopsy only, presence of ductal carcinoma on final pathology, and stage 4 disease not undergoing surgery, 81 of 124 patients with PILC were identified from a retrospective chart review from 1998 to 2012. We investigated age, nodal status, ER/PR status, HER2/neu expression, multifocal cases, nuclear grade, lymphovascular invasion (LVI) and imaging in order to characterize the disease. We analyzed the 5 year overall survival and disease free survival in the 36 cases with followup information available (1998-2008). RESULTS: The median age was 60 years (range 29-90) with median follow-up 38 months (range 0-120). 23 patients (28%) had stage 1 disease, 42 (52%) stage 2 and 16 (20%) stage 3. 39 patients (48%) had nodal metastasis. Multifocal disease was present in 12 cases(15%). 62 (77%) had moderately differentiated tumors, 16 (20%) poor, 1 (1%) well be modified.

differentiated, 2 (2%) unknown grade. LVI was present in 23 (28%) cases. HER2/neu overexpression was present in 9 patients (11%). 71 cases (88%) were ER positive, 64(79%) PR positive, and 4 (3.4%) were triple negative. Of note 49 patients (60%) had associated LCIS on surgical excision. Of 56 patients with mammographic findings 29 (52%) demonstrated a mass and 10 (18%) exhibited architectural distortion. The most common sonographic finding was a mass, noted in 39 (76%) of 51 cases. 5 year overall survival was 94% and 5 year recurrence free survival was 80% in the 36 patients assessed. CONCLU-SION: In addition to histopathology thought to confer poor prognosis, our series has a high percentage of early stage disease and almost half had nodal disease, which suggests PILC is an aggressive variant of ILC. Further investigation may determine whether overall survival is affected and if therapy should

P76

Impact of Tumor Histology on the Performance of Preoperative Axillary Imaging for Staging of Breast Cancer Patients J.R. Bergquist,^{1*} J.C. Boughey,¹ K.N. Glazebrook,² S.C. Dupont,¹ A.R. Shah,¹ S.S. Shah,³ T.J. Hieken.¹ I. Surgery, Mayo Clinic, Rochester, MN; 2. Radiology, Mayo Clinic, Rochester, MN; 3. Pathology, Mayo Clinic, Rochester, MN.

Introduction: Preoperative staging of the axilla with ultrasound (AUS) and US-guided needle biopsy (USNB) of suspicious lymph nodes (LN) can identify patients with significant nodal disease, triage patients to axillary LN dissection (ALND) and guide the use of neoadjuvant systemic therapy. While overall performance characteristics have been described, little is known of the influence of tumor histology on the utility of preoperative axillary imaging. We examined whether preoperative AUS was equally useful across breast cancer histologic subtypes. Methods: With IRB approval we identified 1510 consecutive new invasive breast cancers in 1455 patients undergoing operation including axillary surgery at our institution from 1/2010 to 7/2013 using our prospective institutional database. DCIS and neoadjuvant therapy patients were excluded. We reviewed preoperative imaging and surgical pathology. Results: 1375 patients (91%) had a preoperative AUS of which 401 (29%) had abnormal findings. USNB was performed in 374 of which 124 were USNB+ and the remainder negative. At operation 386 patients (28%) were node positive. The sensitivity and specificity of AUS for infiltrating ductal (IDC), infiltrating lobular (ILC) and mixed mammary (MMC) carcinoma were 55% and 79%, 45% and 83%, and 50% and 77%, respectively and 17% and 85% for special types. 52% of all node positive patients had an abnormal AUS and 32% were diagnosed preoperatively by USNB+: 34% of IDC, 24% of ILC, 33% of MMC, and 17% of special types (p=0.35). Patients with special type tumors had a significantly lower nodal positivity rate (9.8%) and smaller metastases. Patients with >2 positive LNs were USNB+ in 65% of IDC, 50% of ILC and 58% of MMC cases (p=0.83). Conclusions: Despite their differing histologies and growth patterns, AUS with USNB performed comparably for IDC, ILC and MMC. The majority of IDC, ILC and MMC patients with significant nodal disease were proven LN+ preoperatively, helping tailor operative management and patient expectations appropriately and efficiently. Given the low yield of USNB in special tumor types, routine USNB may not be warranted in this patient population.

Performance Characteristics of AUS with USNB for Various Breast Cancer Histologies

	IDC	ILC	MMC	Special Types	All Patients
Number of patients	1000	187	127	61	1375
Number of patients pN+	261 (26.0%)	71 (38.0%)	48 (37.8%)	6 (9.8%)	386 (27.9%)
AUS Findings Negative Suspicious	702 298	135 52	85 42	52 9	974 401
Number USNB	277	49	41	7	374
Number USNB+	90	17	16	1	124
Proportion (%) pN+ patients with suspicious axillary imaging	143/261 (55%)	143/261 (55%)	24/48 (50%)	1/6 (17%)	200/386 (52%)
Proportion (%) pN+ patients detected preoperatively	90/261 (35%)	17/71 (24%)	16/48 (33%)	1/6 (17%)	124/386 (32%)
Size of largest LN met, mm AUS Negative AUS Suspicious/USNB- AUS Suspicious/USNB+	4.2±0.7, 2.5 4.9±1.2, 2.5 17.0±0.8, 14	5.9±1.4, 3 7.9±2.4, 4 17.9±2.1, 14	4.6±1.4, 3 4.0±2.5, 2 13.8±1.7, 14	0.7±0.2, 0.6	4.5±0.6, 2.5 5.4±1, 3 16.8±0.7, 14
P value	p<0.0001	p<0.0001	p=0.0008	p.0.0001	p<0.0001
piN+ patients, number of +LINS, mean, median	1.6±0.4, 1	2.6±1, 1	2.6±1, 1	1, 1	1.8±0.3, 1
AUS Suspicious/USNB- AUS Suspicious/USNB+ P value	5.2±0.4, 3 p<0.0001	7.3±1.5, 3 p=0.03	7.3±1.5, 3 p=0.03	2, 2	5.4±0.7, 3 p<0.0001
pN Stage N1/N2/N3 AUS Negative AUS Suspicious/USNB- AUS Suspicious/USNB+ P Value*	65/185 (35%) 26/185 (14%) 88/185 (48%) p<0.0001	25/52 (48%) 8/52 (15%) 17/52 (33%) p<0.0001	15/34 (44%) 3/34 (9%) 15/34 (44%) p<0.0001	0 (0%) 0 (0%) 1/1 (100%)	105/272 (39%) 9/272 (3%) 121/272 (45%) p<0.0001
pN Stage N2/N3 AUS Negative AUS Suspicious/USNB- AUS Suspicious/USNB+ P Value**	7/50 (14%) 5/50 (10%) 36/50 (72%) p<0.0001	5/15 (33%) 3/15 (20% 7/15 (47%) p=0.0003	4/13 (31%) 2/13 (15%) 7/13 (54%) p=0.0013	0 (0%) 0 (0%) 0 (%)	16/974 (2%) 10/250 (4%) 50/124 (40%) p<0.0001

Abbreviations: AUS=axillary ultrasound, USNB=ultrasound-guided needle biopsy, pN+=pathology node positive at operation, *Versus N0, N0(i+),N1mi, **Versus N0, N0(i+),N1mi,N1

P77

Alteration of Fatty Acid Profile by MR Spectroscopy in the Peritumoral Adipose Tissue of Breast Cancer Patients J.L. Gnerlich,^{1*} G. Iordanescu,² P.N. Venkatasubramanian,² M.M. Smith,² B.K. Martz,² A.M. Wyrwicz,² K. Yao.² *1. Surgery, University of Chicago Medical Center, Chicago, IL; 2. NorthShore University HealthSystem, Evanston, IL.*

Background: Altered enzyme activity in the peritumoral stroma of breast cancer patients may lead to differences in fat metabolism. We hypothesized that a change in the peritumoral fatty acid profile would support the release of exogenous fatty acids to potentially serve as an energy source for the tumor. Methods: In a pilot study, tissue from mastectomies (n=6) was collected from sites adjacent to the tumor (peritumoral adipose [PA]) and distant to the tumor (DA) for comparison of fatty acid composition using MR spectroscopy (MRS). Peak integrals of fatty acid functional groups were measured and fractions of saturated (fS), mono-unsaturated (fM), and poly-unsaturated (fP) fatty acids were calculated. Ratios of fM/fS and fP/fS were compared between PA and DA depots. Corresponding ROC (receiver operating characteristic) curves were used to calculate positive predictive (PPV) and negative predictive values (NPV). Results: Mean tumor size was 2.6 cm and 4 patients had node-positive tumors. PA had elevated fM (PA: 0.44±0.04 vs. DA: 0.36±0.06) and decreased fS (PA: 0.28±0.03, vs. DA: 0.35±0.06) compared with DA tissue, which resulted in significant elevations in fM/fS (PA: 1.62±0.31 vs. DA: 1.08±0.30, p=0.013) and fP/fS (PA: 1.02±0.15 vs. DA: 0.87±0.15, p=0.024) in the PA tissue, suggesting that PA tissue had increased levels of mono-unsaturated and poly-unsaturated fatty acids and reduced levels of saturated fatty acids. MRS-derived fatty acid measures were compared against two prognostic indicators of breast cancer: tumor size and node status. AROC analysis revealed that peritumoral adipose fM and fM/fS predicted nodal status with a PPV of 0.94 (95% CI: 0.890.99) for fM and 0.78 (95% CI: 0.65–0.94) for fM/fS. In contrast, peritumoral fP had NPV for nodal status with 0.96 (95% CI: 0.92–0.99). Fatty acid profile did not correlate with tumor size. Conclusion: Alterations in lipid metabolism occur in the peritumoral adipose tissue of breast cancer patients. Peritumoral fatty acid composition might represent unique changes in the tumor microenvironment that support breast cancer progression and may be used as a prognosticator with MR.

Fatty Acid Profiles in Breast Cancer

Adipose Tissue Site	fM	fP	fS	fM/fS	fP/fS
Peritumoral Adipose Tissue	0.44±0.04	0.28±0.03	0.28±0.03	1.62±0.31	1.02±0.15
Distant Adipose Tissue	0.36±0.06	0.29±0.02	0.35±0.06	1.08±0.30	0.87±0.15

fM: mono-unsaturated fatty acids

fP: poly-unsaturated fatty acids

fS: saturated fatty acids

P78

Impact of Z0011 on the Surgical Management of the Axilla in Patients with Breast Cancer T. Kenny, M. Hunsinger, J. Dove, A. Morgan, A. Plank, N. Woll, J. Blansfield, M. Shabahang.* *General* Surgery, Geisinger Medical Center, Danville, PA.

Background: The American College of Surgeons Oncology Group Z0011 trial redefined the standard of care for breast cancer patients with positive sentinel lymph nodes (SLN). Z0011 illustrated that axillary lymph node dissection (ALND) is not necessary for all breast conservation patients. This study aimed to evaluate changes in the surgical management of the axilla in breast cancer patients at a tertiary care center before and after Z0011. Methods: Patients who met Z0011 criteria were identified and sorted into pre- and post-Z0011 cohorts. Similar patients who underwent mastectomy were analyzed for comparison. Results: This analysis included 494 patients that had breast cancer surgery from July 2008 to February 2013. Of these, 255 were pre-Z0011 and 239 were post. Pre-Z0011, 152 (60%) had breast conservation surgery (BCS). Fourteen patients had T1/2 tumors and 1-2 positive sentinel lymph nodes (SLN) without extracapsular extension. ALND was performed in 10 of these patients (71%). Post-Z0011, 147 patients (61.5%) underwent BCS. Sixteen patients had T1/2 tumors with 1-2 positive SLN, two had extracapsular extension. In the 14 patients without extracapsular extension, only 1 received ALND (7%). The decrease in the rate of axillary dissection from 71% to 7% was statistically significant (p=0.001). In the mastectomy subgroup, 103 patients were in the pre-Z0011 era and if Z0011 criteria were extrapolated to this population 28 met criteria. Of these, 23 patients underwent ALND compared with 5 that did not. Post-Z0011, 92 patients had mastectomy and 14 of these met the extrapolated criteria. Five of these patients underwent ALND compared with 9 who did not. Comparing the pre and post mastectomy groups there was a statistically significant reduction of ALND from 82% to 36% (p<0.005). Conclusion: This study demonstrates that the results of the Z0011 trial significantly altered the management of the axilla in breast cancer patients with positive sentinel lymph nodes. Even though these treatment recommendations were to apply only to patients with breast conservation surgery, they have clearly affected the management of the axilla in all breast cancer patients.

P79

Long-term Results of Excision of Ductal Carcinoma in situ followed by Radiofrequency Ablation to Extend Intraoperative Margins K. Gallagher,* R. Betzold, E. Tummel, L. Adkins, M. McCarthy, S. Korourian, M. Hardee, R. Henry-Tillman, D. Ochoa, V. Klimberg. University of Arkansas for Medical Sciences, Little Rock, AR.

Excision followed by radiofrequency ablation (eRFA) is an intraoperative method which utilizes heat to create an additional tumor-free zone around the lumpectomy cavity in breast cancer patients similar to partial breast irradiation. We hypothesize that eRFA after lumpectomy for ductal carcinoma in-situ (DCIS) could reduce the need for re-excision for close margins while maintaining local control. Methods: This prospective phase II institutional review board (IRB)-approved study was conducted from February 2004 to April 2013. A standard lumpectomy was performed and the RFA probe was deployed 1 cm circumferentially into the lumpectomy cavity. The cavity was heated to 100 °C for 15 minutes. Validated doppler sonography was used intraoperatively to monitor the ablation zone and assess the adequacy of ablation. Results: 46 patients were accrued to the trial. Age: 65 ± 9 years. Stage: Tis. Tumor size: 9 ± 9 mm. Grade 2 ± 0.8 . Number with negative margins: 37. Number with close margins: 4. Number with focally positive margins: 4. Number with gross positive margins: 0. Number with close or positive margins spared surgery: 6/8 spared. Mean follow-up: 46 ± 32. Median followup: 48 ± 32 months. Number of in site recurrences: 1. Number of elsewhere recurrences: 1. Conclusion: Long-term follow up suggests that eRFA may reduce the need for re-excision for close or focally positive margins in patients with DCIS. eRFA may be beneficial for patients that desire a single operation for DCIS.

P80

Impact of Obesity on Breast Cancer Surgical Decision Making G. Porter,^{1*} L. Helyer,² T. Topp,² V. Calverley,² A. Hilchie-Pye.² I. Canadian Partnership Against Cancer and Dalhousie University/QEII Health Sciences Centre, Halifax, NS, Canada; 2. Dalhousie University/QE II Health Sciences Centre, Halifax, NS, Canada.

BACKGROUND: The association between obesity and both breast cancer risk and prognosis has been well-investigated. However, little is known about the impact of obesity on surgical decision-making, specifically related to the use of breast conservation surgery (BCS) vs. mastectomy. We hypothesized that obesity may be associated with an increased use of BCS.. METH-ODS: This cohort study involved patients with invasive breast cancer or ductal carcinoma in situ diagnosed on core needle biopsy who preoperatively were considered candidates for BCS. Body mass index (BMI), identified at the time of hospital admission for surgery, was categorized according to National Institutes of Health criteria: normal/underweight (NW; BMI < 25 kg/m2), overweight (OW; BMI = 25-29.9 kg/m2), obese (OB; BMI = 30-34.9 kg/m2), and severely obese (SOB;BMI \ge 35 kg/m2). The use of BCS, controlling for age, tumor size, bra cup size, and detection method (screening vs. clinical), was compared among the BMI groups. RESULTS: The study cohort consisted of 315 patients; 149 (47.3%) NW, 83(26.3%) were OW, 48 (15.2%) were OB, and 35 (11.1%) were SOB. A significant association with increasing BMI was observed with both larger bra cup size (p=0.001), and larger tumors (p=0.002), although no differences in age or detection method were identified between the BMI groups. Overall, 257 (81.6%) underwent BCS while 58 (18.4%) underwent mastectomy. On univariate analysis, no significant differences in use of BCS was identified among NW, OW, OB, and SOB groups (80.5%, 83.1%, 84.4%, 77.1%; respectively, p=0.71). Controlling for age, tumor size, bra cup size, and detection method (screening vs. clinical), no significant association between use of BCS and any of the weight groups was identified (p=0.50). CONCLUSIONS: Although eligibility for BCS among overweight and obese patients involves larger tumors, the decision to perform or undergo BCS among eligible women does not appear to be associated with presence or extent of obesity.

P81

A Cosmesis Outcome Sub-study in a Prospective, Randomized Trial Comparing Radioguided Seed Localization to Wire Localization for Nonpalpable, Invasive and in situ Breast Cancers E. Parvez,^{1*} S.D. Cornacchi,² N. Hodgson,³ A. Thoma,² I. Kong,³ G. Foster,⁴ J. Cheng,⁴ C.H. Goldsmith,⁴ D. Dao,⁴ P.J. Lovrics.² *1. Department of* Surgery, McMaster University, Hamilton, ON, Canada; 2. Department of Surgery, St. Joseph's Healthcare, Hamilton, ON, Canada; 3. Department of Surgical Oncology and Oncology, Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, Hamilton, ON, Canada; 4. Department of Clinical Epidemiology and Biostatistics and Biostatistics Unit, McMaster University and St. Joseph's Healthcare, Hamilton, ON, Canada.

INTRODUCTION: The goal of breast conserving surgery is to obtain negative margins while achieving an acceptable cosmetic result. Radioguided seed localization (RSL) is purported to have benefits over wire local-

ization (WL) for intraoperative identification of nonpalpable tumours including more precise localization, smaller specimen volumes and improved incision placement. The primary study objective was to compare the cosmetic result of WL to RSL. METHODS: Patients enrolled in a multicentered, randomized trial comparing WL to RSL were invited to participate in the cosmesis study. Frontal photographs were taken 1 and 3 years post-surgery. The European Organization for Research and Treatment of Cancer (EORTC) Cosmetic Rating System was used to evaluate cosmesis. Breast size and shape, areola location and shape, scar appearance and overall cosmesis were assessed by the patient and a panel of 5 raters. Panel members were blinded to group allocation. RESULTS: Seventy-three patients (n=38 WL, n=35 RSL) enrolled into the sub-study between June 2007 and January 2010. Assessment was completed by 57 (73%) and 64 (82%) patients at 1 and 3 years, respectively. There was no difference between groups in patient or tumor characteristics, rate of positive margins, rate of reoperation or specimen volume. Panel inter-observer agreement was moderate for overall cosmesis (kappa statistic=0.55). The majority of patients rated their overall cosmetic outcome as "excellent" or "good" (76% WL, 80% RSL). Patient and panel ratings on all cosmetic outcomes were similar between RSL and WL. Multivariable regression analysis for overall cosmesis found larger specimen volume (p=0.044) and reoperation (p=0.015) to be predictors of worse panel rating. Reoperation was also predictive of worse patient rating (p=0.011). CONCLUSION: This is the first study to compare the aesthetic result of WL to RSL. Within the limitations of a cosmetic evaluation in a relatively small sample, outcomes were similar after WL and RSL. The comparable outcomes may reflect similar reoperation rates and volumes of excision between groups.

P82

The Significance of Core Needle Biopsies with Ductal Carcinoma in situ Suspicious for Microinvasive Carcinoma J.P. Namm,^{1*} J. Mueller,² M. Kocherginsky,³ S. Kulkarni.¹ I. Department of Surgery,

University of Chicago, Chicago, IL; 2. Department of Pathology, University of Chicago, Chicago, IL; 3. Department of Health Studies, University of Chicago, Chicago, IL.

Background: Sentinel lymph node biopsy (SLNB) is a staging procedure used to guide adjuvant treatment planning in patients with invasive breast cancer; however, in a patient with ductal carcinoma in situ (DCIS), invasion cannot always be ruled out in core needle biopsy (CNB) specimens. Although some have advocated SLNB in this setting, the incidence of upstaging to invasive cancer and presence of axillary nodal metastasis is unknown. With 2% or less of T1mi cases associated with macrometastatic nodal involvement, the clinical utility of SLNB in DCIS without definite microinvasion is unclear. Methods: From 2000 to 2012, the institutional pathology database was queried for patients with CNB showing DCIS suspicious for microinvasion (Smic) or definite microinvasion (Mic). We analyzed histology, imaging, nodal status, core needle size, and the use of myoepithelial immunohistochemistry (IHC) markers to identify microinvasion. Results: We identified 79 women, 60 with Smic and 19 with Mic on CNB. In the Smic group, 33% were upstaged to infiltrating ductal carcinoma (IDC) after surgical excision. There were 42 SLNB performed for Smic with 38 of those done at the initial surgery. All cases of Mic underwent a SLNB. The SLNB was positive in 3 of 42 (7%) and 2 of 19 (11%) for Smic and Mic respectively (p=0.64). When N1mic was excluded, the incidence of macroscopic nodal disease was 1 of 42 (2.4%) for Smic and 1 of 19 (5.3%) for Mic (p=0.53). Of those with Smic, upstaging to IDC was associated with a lesion size \ge 14 mm on imaging, smaller CNB needle size (11, 12 and 14-gauge compared to 9-gauge), and the diagnosis of Smic based on IHC. Conclusion: In patients with Smic on CNB, those with tumors ≥ 14 mm, the use of smaller gauge biopsy needles, and Smic based on myoepithelial IHC may be at higher risk for IDC. The incidence of macroscopic nodal disease after SLNB is extremely low. Therefore, reserving the use of SLNB only after a definitive diagnosis of IDC may prevent overtreatment.

Risk Factors for IDC in Smic Patients n = 60				
DCIS grade		1.000		
High	15/45 (33)			
Low or Intermediate	5/14 (36)			
Necrosis		0.307		
Y	18/49 (37)			
N	2/11 (18)			
Calcifications		1.000		
Y	18/54 (33)			
N	2/6 (33)			
Mass on US		0.146		
Y	9/19 (47)			
N	11/41 (27)			
Biopsy guidance		0.164		
Stereotactic	12/39 (31)			
US	7/16 (44)			
MR	0/4(0)			
Manual	1/1(100)			
Size		0.018		
> 14 mm	6/8 (75)	102.000		
$\leq 14 \text{ mm}$	2/13 (15)			
Biopsy needle		0.006		
9 gauge	0/14(0)			
11, 12, or 14 gauge	9/22 (41)			
Myoepithelial IHC		0.009		
Y	11/19 (58)	01005		
N	9/41 (22)			

† Fisher's exact test

P83

Is Sentinel Lymph Node Biopsy Justified In Patients Undergoing Mastectomy for DCIS? S. Mohammed, ^{1*} R. Fernandez, ² J. Salmans Lacross, ¹ B. Lassinger, ¹ E. Bonefas, ¹ K. Liscum, ¹ E.J. Silberfein. ¹ *1. Department of Surgery, Baylor College of Medicine, Houston, TX; 2. Feinberg School of Medicine, Northwestern University, Chicago, IL.*

Introduction: The rate of sentinel lymph node biopsy (SLNB) positivity in ductal carcinoma in situ (DCIS) is low and debate regarding the clinical value of SLNB in these patients continues. The purpose of this study is to assess the rate of positive SLNB in patients undergoing mastectomy for DCIS and correlate this with preoperative factors. Methods: A retrospective consecutive cohort study of 109 patients treated with mastectomy and SNLB for DCIS from 2003 to 2011 was performed. Demographic, clinical, operative and pathologic data were analyzed utilizing descriptive statistics and chi-square analysis for comparison of proportions. Results: The mean age at diagnosis was 54.9 years. In 65.7% of the biopsy specimens comedo necrosis was present in greater than 50% of the sample and 40.7% had histologic grade 3 disease. Intraoperatively, the sentinel lymph node contained metastatic disease in 8 patients (7.3%), all of whom underwent concomitant complete axillary dissection. Two of these patients had evidence of further disease in the axilla on final pathology. Five additional patients had either micrometastatic disease (n=3, 2.8%) or isolated tumor cells (n=2, 1.8%) in the sentinel node on final pathology, one of whom subsequently underwent complete axillary dissection without additional axillary disease. Of the 13 patients with axillary disease, comedo necrosis and grade 3 histology were present 46% (n=6) and 23% of the time (n=3) respectively but did not predict positivity (p=0.33 and 0.84). Patients with positive sentinel node were significantly more likely to have invasive disease on final breast pathology (64.3% vs 11.5%, p<0.001) than their DCIS counterparts with negative sentinel nodes. Conclusions: Despite the relatively high incidence of invasive disease after mastectomy for DCIS, the incidence of metastatic disease found on SLNB remains low. With recent trials failing to show survival advantage of axillary dissection for invasive disease, the need for SLNB in DCIS must weigh the potential benefit against the added morbidity of this procedure. Further multidisciplinary study is warranted to evaluate the value of SLNB for DCIS.
Complex Sclerosing Lesions: Excision or Observation after Core Biopsy A. Mongiu, S. Lester, M. Golshan, F. Nakhlis.* *Brigham and Womens Hospital, Boston, MA.*

Background: Complex sclerosing lesion (CSL) of the breast is an uncommon histopathologic entity of unclear biologic potential. When seen on core biopsy with other high risk lesions, such as atypical ductal hyperplasia (ADH), CSL is routinely excised. However, the management of isolated CSLs is controversial. An upgrade rate of up to 10 % on excision of CSL has been reported. We sought to determine the rate of upgrade to DCIS and/or invasive cancer on excision of CSL and to learn about the risk of future breast cancer development when CSL is not excised, seen at our institution. Methods: WIth IRB approval, our core biopsy database was queried for CSL. Between 2005 and 2013 65 CSL lesions were identified, 47 of them were pure CSL. Of these 23 had an excision, while 24 have been followed (Table 1). Results: In the excision group, 2 DCIS lesions (both found in pts with cellular atypia on core biopsy) and 1 invasive cancer (a 0.4 cm tubular carcinoma, not associated with CSL) representing a 13% upgrade rate. Of note, both patients with CSL and atypia in whom DCIS was found would have been referred for excision due to the presence of atypia, while the patient with invasive cancer had a BIRADS 5 discordant lesion warranting an excision on radiographic basis. In the group followed with imaging (mean follow up of 2.3 years) 1 pt developed ipsilateral invasive cancer 4.5 cm from the CSL site 5 years later. Conclusion: In our series of exisions for pure CSL on core biopsy, we realized an upgrade rate of 13%. However, all 3 of these pts would have been referred for excision due to histologic (atypia) or radiographic (BIRADS 5 and discordant) indications and therefore would not have been missed. Based on this we recommend considering observation for CSL found on core biopsy of BIRADS 4 concordant lesions. We also found a very low risk of future breast cancer development for CSL managed by observation. Further studies to address the upgrade rate for pure CSL would be helpful.

Table 1

	Excised (n=23)	Not excised (n=24)	P value
Mean age at diagnosis	46.5	49	0.74
Mean core biopsy gauge	13	12	0.75
Mean number of cores	6.7	5.4	0.04
Concordant (pathology report explains imaging findings) (%)	10 (43.5%)	17	0.06

P85

Comparing Seed versus Needle Localization: Is there a Difference? A. Condren,* L. Margolies, D. Garcia, J. Szabo, N. Patel, E. Sonnenblick, J. Machac, Z. Zhang, H. Schmidt, A. Cohen, E. Port. *Surgery, Mount Sinai Hospital, New York, NY.*

Introduction: Seed Localization(SL) is a novel technique for localizing non-palpable breast lesions, and offers an alternative to needle localization(NL). SL de-couples the localization process from surgery, and therefore is associated with shorter patient experience on the day of surgery and can optimize surgical scheduling. We compared outcomes of single site SL vs NL. We also sought to determine whether there was a significant learning curve for performing the procedure by comparing endpoints from SL cases earlier in our experience with later cases. Methods: A retrospective review of a prospective database identified all patients undergoing SL or NL for single, nonpalpable breast lesions between May 2012 and August 2013. Operative, pathology, and radiology reports were reviewed. Lesions requiring more than one seed or needle (ie bracketing) were excluded. Excisions for both benign and malignant lesions were included. Results: 113 patients were identified who underwent SL and 99 patients were identified who underwent NL. As expected mean volume of excision was greater for malignant lesions compared to benign(35 vs 25 cm3, p=0.001), however there was no difference comparing SL and NL volumes excised for either benign or malignant lesions(23.4 vs 23.4cm3, p=0.99; 35.4 vs 30.6cm3, p=0.14). There was no significant difference in the operative time comparing SL with NL (26.6 vs. 27.6 minutes, p=0.51). Reexcision rate for positive margins in patients with malignant lesions excised using SL was (12/58, 21%), and was the same as that for patients who underwent NL (10/48, 21%). When comparing operative time and specimen volume of our first 25 SL cases to our last 25 cases to see if performance improved, there were no significant differences noted for either volume (28.3 vs 28.6cm3, p=0.95) or operative time(23.0 vs 25.8 minutes, p=0.19). No complications related to SL or NL occurred, and target retrieval was 100% for both SL and NL. Conclusions: SL is as effective and accurate as NL when excising nonpalpable breast lesions. SL should be an integral part of the armamentarium for surgical excisions, and can be advantageous for optimizing surgical scheduling and patient satisfaction.

P86

Factors Associated with Surgical Treatment of Second Primary Breast Cancers A.E. Voci,* L. Reparez, W. Fry, A. Arrington. University of South Carolina School of Medicine Palmetto Health Richland, Columbia, SC.

INTRODUCTION: Given improvements in treatments, more survivors are faced with the challenge of a second primary breast cancer (2BC). Though many may wish for lumpectomy, 2BC treatment remains a dilemma due to prior therapies. We hypothesize that mastectomy rates are high and reconstruction rates will be low even in contralateral disease; there will also be a number of demographic differences between the treatment groups. METH-ODS: SEER was queried to identify patients age>18 with a 2BC from 1998-2010 without metastatic disease. Ipsilateral 2BC (IL-2BC) and contralateral 2BC (CL-2BC) were analyzed separately; treatment groups were divided into lumpectomy, mastectomy, and mastectomy/reconstruction.RESULTS: 4375 patients had CL-2BC while 765 had IL-2BC. Lumpectomy rates were 33%(n=1443) in CL-2BC and 31%(n=234) in IL-2BC; mastectomy rates were 67%(n=2932) in CL-2BC and 69%(n=527) in IL-2BC. Mastectomy/reconstruction rates were 20% CL-2BC and 22% IL-2BC. Younger patients (age<50) were more likely to undergo mastectomy (73.3% CL-2BC, 77.6% IL-2BC) compared to older patients (58.6% CL-2BC, 55.4% IL-2BC; p>0.001). Older patients (age>80) were statistically more likely to undergo lumpectomy (41.3% CL-2BC, 44.6% IL-2BC, p<0.001). Mastectomy/reconstruction patients were significantly younger than mastectomy alone (53yrs vs 63yrs, p<0.001). White race and marital status were significant factors on univariate and multivariate analysis for mastectomy/reconstruction in CL-2BC (11.7%, p=0.025 and 14.3%, p<0.001) and IL-2BC (15.2% p<0.001 and 19.2% p<0.001) respectively. Of lumpectomies, 66.1% CL-2BC and 61.7% IL-2BC underwent radiation. In all 2BC, mastectomy patients had a better overall survival than lumpectomy (log-rank p=0.028). CONCLUSIONS: With advancements in treatments, women will be faced with the dilemma of a 2BC. Therapies for the initial cancer must be taken into account when determining treatment recommendations for a 2BC. We found that older age, single marital status, and non-Caucasian women elected for lumpectomies more often in both CL-2BC and IL-2BC. Nonetheless, 2BC must be treated aggressively given that opting for less treatment results in measurably higher mortality.

P87

Nipple-sparing Mastectomy following Prior Whole Breast Radiation or Neoadjuvant Chemotherapy A. Saigal,¹* B. Taback,² A. Preya,² S.M. Feldman.² 1. New York University Langone Medical Center, New York, NY; 2. Columbia University Medical Center, New York, NY.

Introduction: Nipple-sparing mastectomies (NSM) are being performed more frequently for both risk reduction and breast cancer treatment. Selection criteria for NSM include tumor size, tumor distance from nipple, degree of ptosis, and breast size. However, NSM in patients who have had prior breast cancer treatment with either breast radiation or neoadjuvant chemotherapy has not been evaluated. Methods: We reviewed our mastectomy database from April 2007 to April 2013 for patients undergoing NSM. Thirty-one patients were identified that had NSM following prior breast radiation or neoadjuvant chemotherapy. Endpoints assessed included mean follow-up post-NSM, nipple-areola complex (NAC) complications, wound infections, cosmesis and recurrence. Patients with severe post-radiation skin changes were excluded from NSM. Results: Of the 31 patients, 20 (65%) underwent neoadjuvant chemotherapy prior to NSM and 11 (35%) had prior whole breast radiation following breast conservation surgery for previous breast cancer. The average age was 45. Three of 31 (9.6%) developed NAC complications, partial necrosis of the NAC in 2 patients and complete loss in one. One patient developed a postoperative wound infection requiring removal of the tissue expander however the NAC was viable. One patient had bilateral NAC excisions due to positive margins. All patients had immediate reconstruction with no delay in adjuvant treatment. Mean length of follow up was 16 months. There have been no local

treatment. Mean length of follow up was 16 months. There have been no local recurrences and only one patient was found to have distant metastasis following surgery. Conclusions: In this study, our rate of NAC loss (3%) and partial NAC necrosis (6%) is comparable to published rates of 5% and 2-20%, respectively reported in the literature analyzing NSM in patients without any prior breast cancer treatment. Our results demonstrate that NSM can be safely and effectively performed in these subsets of patients and that prior breast radiation and neoadjuvant chemotherapy should not be considered a contraindication to NSM. Further analysis with long term follow-up is needed to determine the efficacy of NSM as a safe oncologic surgical intervention.

P88

Nodal Upstaging in Sentinel Lymph Node-positive Breast Cancer after Axillary Node Dissection (ALND) C. Laronga, ^{1*} C. Johns,² R. Snow,² W. Sun, ¹ W. Fulp, ¹ J.V. Kiluk, ¹ M. Lee. ¹ *1. Moffitt cancer center, Tampa, FL; 2. USF Morsani College of Medicine, Tampa, FL.*

Introduction: Nodal burden remains the most important prognostic factor and determines the course of adjuvant breast cancer treatment. ALND is performed following positive sentinel lymph node biopsy (SLNB) because additional nodal disease may alter treatment recommendations. We hypothesize that ALND-resultant upstaging from N1 to N2/N3 disease is low with little impact on recommended adjuvant therapy plans. Methods: An IRB approved, retrospective chart review of clinically node-negative breast cancer pts with positive SLNB (pN1 disease) for invasive breast cancer from January 1995 to November 2012 was conducted. Women electing ALND comprised our study cohort. Neoadjuvant chemotherapy and non-invasive/micro-invasive cases were excluded. Descriptive statistics evaluated demographics, histology, type of surgery, number of positive SLN, ALND pathology and TNM stage. Results: A total of 262 pts with positive SLNB and ALND were identified. Median age was 54yrs (range: 21-96) with median invasive tumor size of 2cm (range: 0.2-10). The median number of SLN excised was 2 (1-10) and the median number of positive SLN was 1 (1-10). The median number of lymph nodes resected at ALND was 15 (4-43). Prior to ALND, 251/262(95.8%) patients were staged as N1 (1-3 positive SLN), 10/262 (3.8%) as N2 (4-9 positive SLN), and 1/262 (0.4%) as N3 (≥ 10 positive SLN). After ALND, 213/251 (84.9%) pts remained N1 on final TNM stage, 24/251 (9.6%) were upstaged to N2 and 14/251 (5.5%) were upstaged to N3. Frequency of nodal upstaging increased with larger tumor size (see table). Overall 38/251 (15.1%) pts had an upstaging in the nodal status and 21/251 (8.4%) had a change in TNM stage. Conclusion: Nodal burden remains the most prognostic outcome factor for invasive breast cancer. Nodal upstaging and stage migration of SLNB positive (N1) disease after ALND are infrequent; this is an important consideration when contemplating completion ALND in a clinically node-negative patient.

T stage	SLNB N1	SLNB+CALND N1-> N1	SLNB+CALND N1-> N2 or N3
T1	123	112 (91.1%)	11 (8.9%)
T2	116	94 (81.0%)	22 (18.9%)
T3	11	6(54.5%)	5(45.5%)
T4	1	1 (100%)	

P89

Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single Institution Experience T. Barbie, C.X. Ma, J.A. Margenthaler.* Surgery, Washington University School of Medicine, St. Louis, MO.

Background: In postmenopausal women with hormone receptor positive (HR+) breast cancer, neoadjuvant endocrine therapy (ET) provides effective down-staging of tumor for improved surgical outcome and offers the advantage of assessing tumor endocrine responsiveness for individualized adjuvant treatment planning. While approximately 60% of breast cancer in premenopausal women is HR+, the role of neoadjuvant ET in this population is not defined. Methods: Retrospective review of our prospectively maintained database from 2003 to 2012 identified 18 premenopausal women with 20 dif-

ferent tumors treated with neoadjuvant ET. All patients were required to have estrogen receptor Allred scores of 6 or greater for eligibility. Data collected included patient and tumor characteristics, surgical, systemic, and radiation treatment received, and outcomes. Descriptive statistics were utilized for data summary. Results: The average age of the 18 patients was 46 years. Patients were treated with a combination of gonadotropin releasing hormone agonist with either an aromatase inhibitor (n=16) or tamoxifen (n=2); 5 patients underwent oophorectomy during the systemic therapy course. The average duration of ET was 4.25 months. Of the 20 tumors, 16 (80%) were grade 1 and 4 (20%) were grade 2. At 4-6 weeks post-initiation of ET, 15 (75%) tumors demonstrated a partial clinical response by examination and/or Ki-67 suppression, while 5 (25%) did not; the 5 non-responders were switched to neoadjuvant chemotherapy. Of the 15 tumors completing neoadjuvant ET, all were noted to have some partial clinical response (4 had non-palpable tumors at the time of surgical resection; 11 had >30% reduction in size by pre-surgical imaging measurements). Negative surgical margins were obtained in 14 of 15 (93%) patients; breast-conserving therapy was performed on 5 and mastectomy was performed on 10. Conclusions: As with all neoadjuvant systemic interventions, we identified responders and non-responders to ET, emphasizing the heterogeneity of HR+ breast cancers. In addition to improving surgical outcomes overall, this approach helps identify the highly-endocrine sensitive tumors.

P90

Clinical and Demographic Factors Influencing Survival in Patients with Inflammatory Breast Cancer K. Mahendraraj,* J.A. Di Como, R.S. Chamberlain. St. Barnabas Medical Center, Livingston, NJ.

Introduction: Inflammatory breast cancer (IBC) is a rare type of breast cancer presents with characteristic inflammatory symptoms and well described histologic findings. IBC accounts for less than 6% of invasive breast cancers diagnosed annually. This study represents the largest series of IBC patients vet reported and sought to analyze demographics and clinical outcomes of IBC which may influence clinical outcomes and decision making. Methods: Data on 716,303 patients with IBC and infiltrating ductal carcinoma (DC) was abstracted from the Surveillance Epidemiology and End Result (SEER) database (1973-2010). There were 708,480 cases of DC and 7,823 cases of IBC. Standard statistical analyses were performed. Results: Both IBC and DC are most common among Caucasian women, however IBC presents earlier in life (p<0.001). 13.8% of all IBC cases occurred in African Americans (AA) compared to 9.1% of DC (p<0.001). Significantly more IBC was poorly differentiated and had distant metastases at the time of diagnosis, and almost twice as many IBC was >4 cm at diagnosis compared to DC (p<0.001). IBC was ER/PR positive in only 33.1% and 39.6% of patients, compared to DC (54.5% and 45.8%, p<0.001). Primary treatment for DC patients was surgery while combination surgery and radiotherapy was mainly used in IBC (p<0.001). IBC mean survival (6.1 years) was significantly lower than DC (16 years, p<0.001). IBC had a higher overall mortality than DC (76.5% vs 37.7%). Multivariate analysis identified age over 80 (OR10.5), AA race (OR1.2), metastasis (OR4.5), poor grade (OR1.8) and size over 4 cm (OR2.0) as independently associated with increased mortality for IBC, p<0.005. Conclusion: IBC is a rare but aggressive form of breast cancer that is typically higher grade, larger size and diagnosed at a later stage compared to DC. IBC is proportionately far more prevalent in AA than is DC. IBC is significantly less likely to express ER and PR, and is associated with worse survival. Clinical awareness of the prognosis of IBC, particularly factors negatively impacting survival, should permit selection of more appropriate treatment regimens with different radicality.

11.1.1.1	0 "	I du de Derrit	1.0
Variables	Overall	Infiltrating Ductal	Inflammatory
N (%)	/16,303	708,480 (98.9)	7,823 (1.1)
Age, (Mean ± SD)	60.8 ± 14.2	60.9 ± 14.2	57.9±14.0
Conder N(%)	10.4 ± 0	10.0 ± 0*	0.1 ± 0.1*
Female	71 0771 (99 2)	712 983 (99 2)*	7 788 (99 6)*
Male	5,532 (0.8)	5,497 (0.8)	35 (0.4)
Race N(%)	0,002 (0.0)	5,157 (6.6)	55 (0.1)
Caucasian	546.421 (76.3)	540,979 (76.4)*	5.442 (69.6)
African American	65,700 (9,2)	64,620 (9,1)	1,080 (13.8)*
Hispanic	52,979 (7.4)	52,056 (7.3)	923 (11.8)
Other	48,369 (6.8)	48,009 (6.8)	360 (4.6)
Unknown	2,834 (0.4)	2,816 (0.4)	18 (0.2)
Grade N(%)			
Well Diff.	97,454 (13.6)	97,362 (13.7)	92 (1.2)
Moderately Diff.	237,942 (33.2)	236,748 (33.4)	1,194 (15.3)
Poorly Diff.	229,370 (32.0)	225,672 (31.9)	3,698 (47.3)*
Undifferentiated	12,319 (1.7)	11,961 (1.7)	358 (4.6)
Unknown	139,218 (19.4)	136,737 (19.3)	2,481 (31.7)
stage N(%)	122.052.00.0	122 012 (61 12	26 (0.5)
Decianzed	432,953 (60.4)	432,917 (61.1)	36 (0.5)
Distont	41.614 (5.8)	230,319 (32.5)	7 000 (00 7)*
Unstand	41,014 (3.8)	10 720 (1.5)	118 (1.5)
Fumor Size N(%)	10,647 (1.5)	10,729 (1.3)	118(1.5)
Microscopic	488 (0.1)	486 (0.1)	2 (0.03)
Inder 2 cm	340 704 (47.6)	340 521 (48 1)	183 (2.3)
to 4 cm	206 348 (28.8)	205 889 (29 1)	459 (5.9)
Over 4 cm	61.054 (8.5)	59 904 (8 5)	1.150 (14.7)*
Inknown	107 709 (15.0)	101 680 (14.4)	6.029 (77.1)
Lymph Node Involvement N(%)	1011101 (1010)	1011000 (1 111)	0,022 (1111)
Yes	215,346 (30,1)	210,562 (29.7)	4,784 (61.2)*
No	403,969 (56.4)	402,984 (56.9)	985 (12.6)
Unknown	96,988 (13.5)	94,934 (13.4)	2,054 (26.3)
ER Status N(%)			
ER(+)	387,797 (75.4)	385,211 (54.5)*	2,586 (33.1)
ER(-)	124,233 (24.2)	121,680 (17.2)	2,553 (32.6)
Borderline	2,047 (0.4)	2,018 (0.3)	29 (0.4)
PR Status N(%)			
PR(+)	326,352 (64.5)	324,323 (45.8)*	2,009 (39.6)
PR(-)	175,986 (34.8)	172,968 (24.4)	3,018 (59.5)
Borderline	3,999 (0.8)	3,954 (0.6)	45 (0.9)
Freatment N(%)	26051 (2.0)		1.000 (10.011
No Treatment	26,954 (3.8)	25,564 (3.6)	1,390 (17.8)*
Surgery Only	3/3,500 (52.1)	3/1,213 (52.4)*	2,287 (29.2)
Radiation Only	7,856 (1.1)	7,137 (1.0)	719 (9.2)
Dom	288,096 (40.2)	285,054 (40.2)	3,042 (38.9)
Unknown	19,897 (2.8)	19,312 (2.8)	385 (4.9)
No Treatment	68+01	71+01	24+01
Surgery Only	157+01	157+01	61+03*
Radiation Only	54+01	57+01	29+02
Both	18.8 ± 0.1	189±01	83+0.2*
Overall Mortality N(%)	10.0 = 0.1	10.7 = 0.1	0.2 ±0.2
Alive	446,209 (62,3)	444,374 (62,7)	1,835 (23.5)
Dead	270,094 (37,7)	264,106 (37,7)	5,988 (76.5)*
Cancer Specific Mortality N(9	6)		
Alive	446,209 (79,6)	444,374 (80,2)	1,835 (29.6)
Dead	114,233 (20.4)	109,855 (19.8)	4,368 (70.4)*
Survival (Cumulative %)			
-year		96	77
2-year		91	57
Sugar		74	26*

Abbreviations: N = number; 50 = standard deviation; EK = Estrogen Receptor; FK = Progesterone Recepto Diff = Differentiated. *represents statistically significant difference between inflammatory and infiltrating ductal cancer for given variable, defined as p=0.001

P91

Sentinel Node Biopsy after Neoadjuvant Chemotherapy for Breast Cancer: Intraoperative Injection of Radiocolloid H. Vu,*

P. Williams, R. Shoemaker, M. Fratkin, W. Wan, H. Bear. Surgery, VCU, Richmond, VA.

Introduction. Preoperative radio-colloid injection is painful for breast cancer patients undergoing sentinel node biopsy (SNB). This study sought to determine the sentinel node identification rate (SNIDR) with radiocolloid injection pre- or intra-operative in patients who have received neoadjuvant chemotherapy (NAC). Methods. A retrospective comparison of sentinel node identification rate between intraoperative radiocolloid injection (IRCI) and preoperative radiocolloid injection (PRCI) after NAC was performed. All injections used 1mCi 0.5 ml of filtered (0.22 micron) Tc-99m sulfur colloid. All surgeons included injections into the retroareolar tissue. The SNIDR was tested for noninferiority test by a two-proportion z-test. The difference between demographics, SNIDR, tumor response rate, pathologic T stage (pT), clinical N stage (cN), and incidence of positive sentinel nodes was evaluated by Fisher's exact test. The number of sentinel nodes removed was analyzed by two-sample t-test. Results. 134 SNBs were performed after NAC in the six-year study period: 96 received PRCI of radiocolloid and 38 received IRCI. There were more African-Americans (P = 0.0159) and more pT3 cancers (P = 0.0286) in the IRCI group. The SNIDR was similar for the two groups: 88.5% for the PRCI group and 81.6% for the IRCI group. By two-proportion z-test and by Fisher's exact test the SNIDR of the two methods did not differ and remained equivalent for both groups when analyzed by tumor response rate, pT, and cN. The mean number of lymph nodes removed was higher in the IRCI group: 3.39 nodes versus 2.46 nodes (P = 0.0192). The number of lymph nodes removed did not differ when analyzed by cN or pN. The incidence of positive SNB was higher for the IRCI group: 58.1% versus 30.6%, (P = 0.0095). When analyzed by pT, the positive SNB rate was higher for T1 cancer in the IRCI group: 61.5% versus 27.3%, (P = 0.0441). Conclusion. The timing of SNB for patients requiring NAC remained controversial. The SNIDR appear similar whether the injection of radiocolloid was preoperative or intraoperative. IRCI would reduce the pain experienced by breast cancer patients undergoing axillary SNB.



P92

Preoperative MRI: Much Ado about Nothing? P. Li,* S. Cate, J. Rescigno, M. Chadha, A. Gillego, S. Boolbol. *Beth Israel Medical Center, New York, NY.*

Preoperative MRI has been used to identify mammographically occult lesions and to determine extent of disease. However, the role of preoperative MRI in breast cancer remains controversial. We previously found that preoperative MRI does not increase total mastectomy (TM) rate. In this study we sought to identify a specific subgroup of patients in which preoperative MRI may be useful. Methods: In this IRB approved study, we conducted a retrospective review of 257 breast cancer patients who underwent preoperative MRI from 2010-2012. We evaluated whether additional imaging and biopsies were recommended after MRI and whether it influenced the final surgical plan and decreased re-excision rate after partial mastectomy (PM). We collected data on several clinical factors and tested these for significant associations with both upgrading to TM and with the need for post-MRI imaging and biopsy using crosstab analysis and Fisher's Exact test. Age as a continuous variable was also evaluated using binary logistic regression. Results: In our study cohort, additional imaging and biopsies were performed in 62% (n=158) and 32% (n=83) of patients respectively. Of those biopsies prompted by MRI, 39% revealed cancer. However, only 3% of patients upgraded to TM. Preoperative MRI did not decrease re-excision rates. We did not find any statistically significant differences in patients who were upgraded to TM by clinical factors such as age, menopausal status, mammographic breast density, ER/PR, HER2/neu status, or pathologic T stage; though there was a trend towards upgrade to TM in those who required additional imaging (P=0.16). We found no clinical factors associated with the need for additional biopsies. Conclusion: We did not find a specific subgroup of patients in which preoperative MRI influenced management. Although preoperative MRI slightly increased the rate of TM, it does lead to numerous additional imaging studies and biopsies. These biopsies may be helpful in guiding PM, but we did not see a decreased re-excision rate after PM. Given these results, we are no longer using preoperative MRI routinely at our institution. Additional studies will be needed to determine strict indications for the use of MRI in the preoperative setting.

P93

The Impact of Calcium Ionophore on Dendritic Cell Cytokine Production and Induction of Th1 and Th17 Responses J. Terhune,* B.J. Czerniecki. University of Pennsylvania, Philadelphia, PA.

Calcium ionophore (CI) is known to rapidly mature human monocytes into mature dendritic cells (DCs) with typical expression of co-stimulatory cell surface markers and enhanced T cell sensitization efficiency. We sought to investigate the role CI has on the production of cytokines from DCs in type-17 polarizing conditions and the subsequent impact on induction of Th17 versus Th1 immune responses. Human monocytes were cultured with pharmacologic agents to become mature, polarized dendritic cells (DCs); supernatant was collected

for quantitative measurement of cytokine production and the DCs were analyzed for cell surface markers of maturity. The mature DCs were used to stimulate purified human CD4+ T cells; T cell cytokine production was measured and T cells were analyzed by flow cytometry for the presence of the same cytokines intracellularly. Dendritic cells with receiving no maturation agents are referred to as immature DCs (iDCs) and upon co-culture with T cells did not induce any significant cytokine production. Interferon-y (IFN-y) & lipopolysaccharide (LPS)-matured DCs produce high levels of the cytokines IL-12, IL-23, and IL-6 with modest IL-1ß and polarize CD4+ T cells into both Th1 and Th17 phenotypes. The combinations ATP & lipotechoic acid (LTA) or prostaglandin E2(PGE2) & LPS resulted in less IL-12 and IL-23 production, similar levels of IL-6, high levels of IL-1ß and polarize Th17 responses. The addition of calcium ionophore to Th17 maturation conditions led to decreased levels of IL-1ß and IL-6 and enhanced levels of IL-23. CI-matured DCs induced CD4+ T cells into predominantly Th1 responses with high levels of IFN-y and minimal IL-17 production even when DCs were matured in type-17 polarizing conditions. Th1 responses occurred despite minimal or undetectable IL-12 production by CI-matured DCs. The addition of calcium ionophore to DC maturation protocols that induce Th17 immune responses resulted in less IL-17 production by the CD4+ T cells and instead resulted in immune responses characteristic of Th1 cells. We believe these results suggest that calcium signaling in DCs limits these cells' ability to induce type-17 T cell responses.





P94

Assessing Axillary Lymph Node Positivity in Microinvasive and T1a Breast Cancer E. Stavrou, ^{1*} K.M. Hirshfield,² I. Adelaja,² T.J. Kearney,² L. Kirstein.² 1. Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ; 2. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

Introduction. Sentinel lymph node biopsy (SLNBx) is used to assess the axillary status in breast cancer patients. The role of SLNBx in microinvasive (Tmic) and T1a breast cancer has not been well studied. It has been suggested that smaller breast cancers yield fewer positive SLNBx results. This study examines the rate of SLN positivity in patients with Tmic or T1a breast cancer that underwent axillary evaluation. Methods. An IRB approved retrospective chart review of patients diagnosed with Tmic or T1a breast cancer from 1987-2013 was performed. Patient and tumor characteristics were observed, including age at diagnosis, tumor size, hormone receptor status and tumor histology. Only patients with Tmic or T1a tumors who underwent axillary evaluation were considered. Axillary nodal status was examined. Results. Of 133 patients with Tmic (n=19) or T1a tumors (n=114) that underwent SLNBx or ALND, 8 patients (6%) had positive results. All 8 patients with a positive node had a T1a breast cancer. None of the patients with Tmic breast cancer had a positive node. For axillary evaluation, 10 of 133 patients underwent ALND; none had positive nodes. 123 patients had a SLNBx. Two of the 8 node positive patients (25%) had 2 positive nodes and 6 patients (75%) had 1 positive node. There was no statistically significant correlation of positive nodal status with any tumor or patient characteristics. Conclusions. This study found that SLNBx positivity is very low in patients with Tmic and T1a breast cancer. No tumor or patient characteristic correlated with SLN positivity. None of the patients with Tmic breast cancer had positive nodes, although fewer Tmic patients were studied. These data suggest that for Tmic breast cancer, consideration can be made to omit SLNBx. At this time SLNBx biopsy is still beneficial for patients with T1a breast cancer. Larger studies need to be performed to determine if there is a subset of T1a patients for which SLNBx may be omitted.

Sentinel Lymph Node Biopsy Results for T1a and Tmic patients

	T	Tla		Tmic	
Number of Patients	SLNBx +	SLNBx -	SLNBx +	SLNBX -	
Total	8	106	0	19	
Micrometastasis	2	NA	0	NA	
Macrometastasis	6	NA	0	NA	

P95

Boost Radiation Treatment for Anal Cancer Decreases the Risk for Lifetime Colostomy: Analysis from the National Cancer Data Base (NCDB) C.N. Budde,^{1*} N. Nabavizadeh,¹ J. Kim,² K.C. Lu,¹ K.G. Billingsley,¹ C.R. Thomas,¹ D.O. Herzig,¹ V.L. Tsikitis.¹ *1. Surgery, Oregon Health and Science University, Portland, OR; 2. Portland State University, Portland, OR.*

Introduction Treatment for anal canal cancer has evolved from abdominoperineal resection to a combined chemoradiotherapy (CRT) approach, which allows for sphincter preservation. An additional boost dose of radiation is often used for patients (pts) with advanced local disease (T3, 4, and N+), and/or persistent disease following standard CRT. The specific aim was to determine the relationship between boost radiation treatment (RT) and future colostomy construction rate. Methods All pts with de-novo anal cancer from the NCDB were examined (53,523 pts). After excluding pts with anal margin cancer, missing data points, and/or those who did not receive standard CRT, 1025 pts were analyzed. Variables included age, gender, race, primary tumor size, clinical nodal status, TNM stage, boost radiation, and colostomy construction. We assessed which pts received boost RT after standard CRT. A logistic regression model assessing the relationship between boost RT and colostomy construction was developed. Results A cohort of 1025 pts met inclusion criteria. Four hundred and fifty patients received CRT without boost RT; 575 patients received CRT with boost RT. The two groups were similar in age, gender, race, tumor size, nodal status, and TNM stage, (p-values all = NS). Statistically significant variables for colostomy construction were age (p=0.05), tumor size (p<0.001), negative nodal status (p<0.001) and boost RT (p=0.002), while gender, race, and TNM stage did not reach statistical significance. On logistic regression model, when controlling for age, tumor size, and nodal status, colostomy construction is less likely to occur with an RT boost (Odds Ratio 0.63 with boost RT, 95% CI 0.47-0.85, p=0.003). Conclusions Boost RT has been administered to pts regardless of their demographics and stage of disease. When controlling for age, tumor size and nodal status, those who received boost RT, were less likely to require future colostomy. Due to inherent limitations in the retrospective nature of this hypothesis-generating observation, the role of boost RT may warrant validation as part of prospective clinical trial.

P96

Diagnostic Performance of Multi-detector Row CT for Assessment of Lymph Node Metastasis in Patients with Distal Rectal Cancer H. Kobayashi,* K. Sugihara. *Center for Minimally Invasive Surgery, Tokyo Medical and Dental University, Tokyo, Japan.*

INTRODUCTION: The accurate preoperative diagnosis of depth of tumor invasion and nodal status in distal rectal cancer is important, because neoad-juvant chemotherapy or lateral pelvic lymph node dissection is indicated in patients with T3-T4 tumor or nodal involvement. The aim of this study was to determine the optimal cut-off value for predicting lymph node metastasis in patients with distal rectal cancer using multi-detector row computed tomography (MDCT). METHODS: 77 patients who had undergone surgery for distal rectal cancer for depth of tumor invasion and mesorectal and lateral pelvic lymph node metastases was evaluated. The optimal cut-off value was determined by receiver operating characteristic curve analysis. RESULTS: The sensitivity and specificity of MDCT for depth of tumor invasion, mesorec

tal lymph node metastasis, and lateral pelvic lymph node metastasis were: 0.92, 0.59; 0.37, 0.90; and 0.78, 0.97, respectively. The optimal cut-off values of the lengths of the major and minor axes for predicting mesorectal lymph node metastasis were 6.5 mm and 5.7 mm, respectively. The areas under the curve (AUCs) were 0.82 and 0.88, respectively. For predicting lateral lymph node metastasis, the optimal cut-off values were 9 mm for the major axis and 6 mm for the minor axis were; both AUCs were 1. CONCLUSIONS: Using MDCT, the optimal cut-off value of the length of the minor axis for predicting mesorecetal and lateral pelvic lymph node metastases in patients with distal rectal cancer is 6 mm. The accuracy of MDCT was satisfactory for predicting lateral pelvic lymph node metastasis.

P97

Optimization of Regional Adoptive Cell Therapy for Liver Metastases through Prevention of Myeloid Derived Suppressor Cell Expansion and Blockade of PDL-1 Mediated T Cell Suppression R.A. Burga,^{1*} M. Thorn,¹ E. Santos,¹ G.R. Point,¹ A. Ayala,² R. DeMatteo,³ N. Espat,¹ R.P. Junghans,¹ S.C. Katz.¹ *I. Surgical Immunotherapy, Roger Williams Medical Center, Providence, RI; 2. Brown University School of Medicine, Providence, RI; 3. Memorial Sloan-Kettering Cancer Center, New York, NY.*

Introduction: Myeloid-derived suppressor cells (MDSC) possess the ability to suppress genetically-modified "designer" T cells (dTc), which presents an obstacle for this form of adoptive cell therapy. It has been demonstrated that granulocyte-macrophage colony-stimulating factor (GM-CSF) drives MDSC expansion while PDL-1 on the surface of MDSC engages PD-1 on dTc to mediate suppression. We hypothesized that combined neutralization of GM-CSF and PDL-1 would enhance dTc anti-tumor efficacy in a murine model of liver metastases (LM). Methods: CEA+ MC38 colorectal tumor cells were transduced to express luciferase and injected into the spleens of C57BL/6 mice to establish LM. Mice were treated with anti-CEA dTc 7 days after tumor injection, and in vivo blockade was performed with PDL-1 and GM-CSF-neutralizing antibodies. Luciferin was administered prior to bioimaging. Results: Treatment with anti-GM-CSF reduced LM-induced expansion of MDSC to baseline levels (79.9% vs 43.1% CD11b+Gr1+, p=0.006). In vitro, anti-PDL-1 antibody abrogated MDSC-mediated dTc suppression (dTc+MDSC: 12.2% proliferation vs dTc+MDSC+anti-PDL1: 38.5% proliferation, p=0.002). Bioluminescence imaging of mice with established LM revealed a delay in tumor progression following regionally infused dTc therapy in tandem with administration of anti-GM-CSF and anti-PDL-1 antibodies (Figure 1). A reduction in tumor burden was found in livers harvested 11-days post tumor injection by flow cytometry analysis (2.4-fold decrease in CD66e+ cells, p=0.1). Combined GM-CSF and PDL-1 blockade prolonged survival in animals with LM treated with regional dTc compared to dTc alone (p=0.03, Figure 1). Conclusion: We demonstrated that prevention of MDSC expansion with anti-GM-CSF antibody as well as interference with their suppressive function with anti-PDL-1 antibody augmented regional dTc administration and may represent a clinical strategy for improved treatment of LM. Work supported by the Society of Surgical Oncology Clinical Investigator Award with an educational grant from Genentech.





Soluble LIGHT (TNFSF14) Enhances the Expression of Dendritic Cell Costimulatory Molecules B7-H2 and B7-2 for Immunotherapy J.F. Calata, ¹* S. Jayaraman,² B.S. Prabhakar,² A.V. Maker.² I. University of Illinois at Chicago Metropolitan Group Hospitals, Chicago, IL; 2. University of Illinois at Chicago, Chicago, IL.

Background: Dendritic cells (DC) play a critical role in the initiation of the immune response. For optimal T cell activation, DC must present tumor antigens in an MHC-restricted fashion and simultaneously provide co-stimulatory signals. In the absence of a co-stimulatory signal, the antigen-specific T-cell can become anergic. LIGHT is a TNF family immunostimulatory determinant that we have found in the tumor microenvironment to be associated with improved survival. We hypothesized that LIGHT could increase the expression of T-cell co-stimulatory molecules on DC. Methods: Bone marrow cells were harvested from 6-8 week old BALB/c mice and cultured in complete media with Flt3 ligand. On day 6, DC were exposed to soluble LIGHT or LPS, a known DC activator. On Day 8, cultured bone marrow cells were stained with fluorochrome conjugated monoclonal antibodies against CD11c (DC marker), B7-2 (CD86, a T-cell co-stimulatory molecule that binds to CD28), and B7-H2 (CD275, a T-cell co-stimulatory molecule that binds ICOS), and analyzed by flow cytometry. Results: DC cultured with Flt3 ligand displayed a baseline level of B7-2 expression (42.9%). At increasing concentrations of soluble LIGHT (100 ng/ml, 500 ng/ml, and 1000 ng/ml), B7-2 expression increased to 60% (p=0.0001), 84% (p=0.0001), and 92% (p=0.012), respectively. B7-H2 expression on DC similarly increased from a baseline expression of 18% to 26% (p=0.034), 45% (p=0.005), and 54% (p=0.022). LIGHT alone at 1000 ng/mL concentration increased the expression of co-stimulatory molecules to a level comparable to DC stimulated with the known DC stimulant, LPS. Conclusions: Soluble LIGHT substantially increased the expression of the T-cell co-stimulatory molecules B7-2 and B7-H2 on bone marrow derived DC. Techniques to increase co-stimulatory signals on dendritic cells are a promising strategy in cancer immunotherapy. These results introduce LIGHT administration as a potential cancer treatment modality that warrants further investigation.



P99

Did Modern Treatment of Rectal Cancer Make the Change for the Mucinous Subtype? N. Hugen,¹* C.J. Van de Velde,² M.A. Elferink,³ J.H. De Wilt,¹ I.D. Nagtegaal.¹ *1. Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; 2. Leiden University Medical Center, Leiden, Netherlands; 3. Comprehensive Cancer Centre the Netherlands, Utrecht, Netherlands.*

BACKGROUND Introduction of preoperative radiotherapy has improved outcome in rectal cancer (RC) patients, but it is unclear whether benefits are applicable to all histological subtypes. Rectal mucinous adenocarcinoma (MC) has been associated with impaired prognosis compared with nonmucinous adenocarcinoma (AC). This study analyses overall survival (OS) of MC in RC patients over time and evaluates efficacy of preoperative radiotherapy in MC. METHODS Two patient populations were selected. From the nationwide population-based cancer registry data on 51,200 RC patients diagnosed between 1989 and 2010 was retrieved and 5-year OS rates were calculated. In addition, 1530 patients were selected from the prospective randomized multicentre TMEtrial, that investigated the value of short-term preoperative radiotherapy compared with TME-surgery alone. RESULTS Results from the population-based study showed that 5-year OS in AC patients improved from 41.9% in 1989-1994 to 55.3% in 2006-2010 (p<0.0001), compared with 34.2% and 53.5% in MC patients (p<0.0001). In the TME-trial in the surgery alone group we found a higher rate of positive circumferential resection margin (CRM) in MC versus AC (35.3% versus 18.6%; P=0.004) with a higher rate of local recurrence (25.5% vs 11.4% after 10 years; P=0.002). Local recurrence rates and OS were not different between MC and AC patients treated with short term radiotherapy when the CRM was negative (local recurrence: 8.2% vs 3.3%; P=0.102 and 10-year OS 56.6% vs 52.8%; P=0.406). When the CRM was positive and patients underwent short-term radiotherapy prior to surgery, there was a higher rate of local recurrence in MC patients (37.5% vs 14.1% after 10 years; P=0.001). Consequently, there was a lower 5-year OS in MC patients in this group (14.3% vs 40.4%; P=0.001). CONCLUSIONS From 2000 onwards prognosis of rectal MC is no longer different from AC. Results from a prospective radiomized trial demonstrated equal benefit from properative radiotherapy and showed that a higher frequency of positive CRM in rectal MC might be responsible for a poor outcome. Preoperative imaging and quality of surgery is essential in predicting prognosis in MC patients.

P101

Surveillance for Local Recurrence of Rectal Cancer is Futile M.E. Gross,^{1*} M.C. Mone,¹ C.K. Whiting,¹ E.M. Mecham,² H.J. Hansen,¹ W. Peche,¹ C.L. Scaife.¹ *1. Surgery, University of Utah, Salt Lake City, UT; 2. University of Texas Medical Branch, Galveston, TX.*

National Comprehensive Cancer Network (NCCN) guidelines recommend routine proctoscopy every 6 months for 5 years after low anterior resection for rectal adenocarcinoma. There are no studies to support this recommendation, which was based on high local recurrence rates prior to total mesorectal excision (TME). The purpose of this study was to determine the value of rectal surveillance after TME. This is a single-center, retrospective review of stages I-III rectal adenocarcinoma patients who underwent TME (2004-2011). The primary endpoint was cancer recurrence. The methods of identifying each recurrence as well as the number of procedures for rectal surveillance were collected. The study included 108 patients who underwent TME with at least one year of postoperative follow-up. Of these, 53 (49%) had stage III rectal cancer, 38 (35%) had stage II, and 17 (16%) had stage I disease. The average age was 57.8±12.2, with the majority being male (67%). The mean length of follow up was 4.1 years (1 - 9.4 years). There were 16 recurrences, 15%, (1 local, 15 distant). The majority of recurrences were stage III patients (75%), and occurred between 0.7-4.2 years. The local recurrence, at 1.3 years, was found by CEA, followed by a mass biopsy. A total of 20 anoscopies, 43 rigid proctoscopies, and 489 flexible sigmoidoscopies were performed. The majority of patients (56%) had 4 or more procedures. The total charges for these procedures were estimated to be \$150,000, or \$600 dollars per patient per year. Local rectal surveillance was unnecessary, as it added no information relative to recurrence in 108 patients. The only local recurrence was identified with CEA screening. As TME is now the standard surgical approach, with concomitant neoadiuvant chemoradiation for advanced disease, the rates of local recurrence have dropped significantly. Routine rectal surveillance did not add accuracy to CEA, imaging studies, and standard colonoscopic screening of rectal cancer patients. This retrospective review challenges the NCCN guideline recommendations of the use of an invasive, expensive, and uncomfortable procedure in the clinic for rectal surveillance, and we feel that the NCCN guideline should be reconsidered.

P102

Increasing Trends in Positron Emission Tomography (PET) Utilization after Colon Cancer Diagnosis C. Bailey,* C. Hu, Y. You, H. Kaur, R. Ernst, G.J. Chang. University of Texas, MD Anderson Cancer, Houston, TX.

Background: Current colon cancer surveillance guidelines do not routinely include PET imaging however, the utilization of PET scans has been increasing. The primary aim of this study is to evaluate the trends in PET utilization during the first 2 years after colon cancer diagnosis or surgical resection among elderly patients. Methods: A retrospective cohort study of patients ≥ 65 years old with colon cancer who underwent surgical resection or received chemotherapy in the Surveillance, Epidemiology, and End Results-linked Medicare database (July 2001 to December 2009, Medicare Part A/B only) was performed. All patients had at least 2 years of follow-up. PET utilization was assessed using the test for trends and multivariate logistic regression for patient, tumor and treatment characteristics. Results: Of 43,924 patients diagnosed with colon cancer, 8,160 (18.6%) underwent PET scan within 2 years after colon cancer

diagnosis or resection. The utilization rate steadily increased from 9.1% in 2001 to 23.6% in 2009 (P<0.001). A total of 15,555 PET scans were performed and 4,661 patients (57.1%) had 1 PET scan, 1,750 (21.5%) had 2 PET scans and 1,749 (21.4%) had >2 PET scans. The majority of PET scans (n=3,005) were performed within 2 months after colon cancer diagnosis or resection (Table). Among patients who underwent resection, 51% (n=19,993) underwent imaging (PET/CT, CT, or MRI) ≤3 months prior to surgical resection and 18.0% (n=1,977) of these patients were reimaged with PET scan within 2 months after resection. In multivariate analysis, year of diagnosis, stage and chemotherapy were significantly associated with increased PET utilization. Conclusion: The utilization of PET scans after colon cancer diagnosis among patients with either localized or metastatic disease has steadily increased since 2001. The majority of PET scans are being performed within 2 months after diagnosis or resection. As clinicians are obtaining PET imaging despite lack of support for their use in guidelines, further study is needed to understand the clinical value and effectiveness of PET scans and the reasons for this departure from guideline based care.

PET utilization rate and time to first PET scan

	PE	Т
Year of diagnosis	N	%
2001	241	9.0
2002	663	11.0
2003	804	13.0
2004	982	18.0
2005	1,065	20.6
2006	1,147	23.4
2007	1,103	23.4
2008	1,151	25.1
2009	1.004	23.6
Time to first PET scan (months)		
<2	3,005	36.8
3-6	1,473	18.1
7-12	1,662	20.4
>12	2,020	24.7

P103

Identifying Predictors of One-year All-cause Mortality after Colon Cancer Surgery in Patients 65-years of Age and Older: The Potential of Billing Claims J. Braun,^{1*} S. Krotneva,¹ H. Alabbas,² A. Ramjaun,² T. Eguale,³ A. Meguerditchian.¹ *I. Surgical Oncology, McGill* University, Montreal, QC, Canada; 2. Clinical Health and Informatics Group, McGill University, Montreal, QC, Canada; 3. Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Background: Although elderly patients are at increased risk of short-term postoperative morbidity and mortality, many elderly patients are physiologically fit for operation. This study aims to quantify one-year all-cause postoperative mortality and identify patients at risk based on health service utilization in the year before surgery as a surrogate for physiologic condition. Methods: A historical prospective cohort of colon cancer patients aged ≥ 65 years was assembled from hospitalization data provided by a single universal healthcare insurance provider between 2000 to 2006. Kaplan-Meier and Cox multivariate survival were employed to determine independent predictors and hazard ratios (HR) of postoperative one-year all-cause mortality. Results: 3789 patients underwent colonic resection for cancer (2000-2006). 1731 (45.7%) were male while 2058 (54.3%) were female. Overall 30 day, 90 day and one year all-cause mortality were 5.0%, 8.6% and 19.2% respectively. Multivariate analysis demonstrated that patient age at surgery, receipt of health care for cardiovascular disease (HR = 1.4) or dementia (HR = 1.9) and type of admission (emergency vs. elective) (HR = 2.1) independently predicted one-year postoperative mortality (all P < .05). Relative risk of mortality was decreased in those who underwent a physical exam by a general practitioner in the year prior to operation (HR = 0.7). Higher mean income as defined by residential area income, reduced mortality at a relative rate of 0.94 per \$10,000 increase in the first postoperative year (all P < .05). Conclusion: Mortality after colon resection in the postoperative year is high in the elderly population (19 %). Age, use of medical resources for geriatric comorbidities, and lack of continuity of care were strong predictors of mortality. Although the

ability to identify such risk factors through billing claims remains to be refined, a potential to prospectively identify patients at highest risk of decreased survival exists.

Figure 1: Kaplan-Meyer curves showing the percentage of patients surviving for one year after colon cancer surgery by type of admission to surgical hospitalization (P<.0001)

With Number of Subjects at Risk



P104

A Phase II Multicenter Single-arm Trial of Adjuvant Chemotherapy with S-1 after Curative Resection of Colorectal Liver Metastasis (N-SOG 01 Trial) K. Uehara,¹* A. Maeda,² E. Sakamoto,³ K. Hiramatsu,⁴ E. Takeuchi,⁵ K. Sakaguchi,⁶ Y. Tojima,⁷ T. Ebata,¹ M. Nagino. *1. Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; 2. Ogaki Municipal Hospital, Ogaki, Gifu, Japan; 3. Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; 4. Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan; 5. Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Aichi, Japan; 6. Chubu Rosai Hospital, Nagoya, Aichi, Japan; 7. Chukyo Hospital, Nagoya, Aichi, Japan.*

Background: This phase II trial was designed to evaluate the safety and efficacy of adjuvant chemotherapy with S-1 in patients with curatively resected liver metastasis from colorectal cancer. The primary endpoint was 3-year disease-free survival (DFS). Methods: We enrolled 62 patients from 19 Japanese hospitals between October 2008 and August 2010. Patients who underwent curative resection of liver metastasis from colorectal cancer received S-1 monotherapy (on days 1 to 28, followed by 14-day rest, 8 cycles) as adjuvant chemotherapy. We report the safety and survival at 3-year. The mean duration of follow-up was 40.5 (5.4-57.2) months. Results: Among 62 patients, 60 patients were eligible for analysis. The most frequent grade >3 hematologic toxicity involved neutropenia in 3 patients (5.0%). Non-hematologic toxicities of grade >3 were fatigue in 6.7% of patients. Grade 4 enteritis occurred in one patient, but resolved promptly after withdrawal of S-1 therapy. The completion rate of the 8 scheduled cycles of chemotherapy was 58.3%. The most common reason for withdrawal of treatment was the detection of early relapse in 16 patients (64%). When the 16 patients who had recurrence during adjuvant treatment were excluded from analysis, 79.5% of the remaining 44 patients completed the scheduled treatment. Early recurrence within 1 year after curative liver resection occurred in 21 patients (35%). The most common site was the remnant liver in 14 patients. The 3-year DFS and overall survival were 43.6% and 78.1%, respectively. Univariate analysis showed that time from primary resection to liver resection (p=0.008), location of primary tumor (p=0.009), and lymph node metastasis at primary site (p=0.002) were significant prognostic indicators of DFS. Conclusion: Orally administered S-1 after curative liver resection had an acceptable toxicity profile and a high rate of completion of the therapy. Additionally, 3-y DFS was comparable to the previous reports. A randomized trial comparing adjuvant S-1 to FOLFOX in colorectal liver metastases is anticipated. (UMIN number, 000001498.)

Table. Univartiate risk analysis for disease-dree survival (n=60)

Variables	n (%)	3y-DFS (%)	p value
Timing of metastasis			0.061
Synchronous	26 (43.3)	34.1	
Metachronous	34 (56.7)	57.5	
Time from primary resection to liver resection			0.008
<24 month	39 (65.0)	35.7	
>24 month	21 (35.0)	69.6	
Location of primary tumor			0.009
Colon	40 (66.7)	59.1	
Rectum	20 (33.3)	25.0	
Lymph node metastasis at primary site			0.002
Present	37 (61.7)	31.1	
Absent	23 (38.3)	73.4	

P105

Effects of Hyperthermia versus Drug Dose on Toxicity and Pharmacodynamics of Oxaliplatin-based Intraoperative Chemoperfusion: Results of a Phase II Trial L. De Smet,² A. Izmer,³ F. Vanhaecke,³ J. Remon,² C. Vervaet,² W. Ceelen.^{1*} 1. GI Surgery, UZ Gent, Ghent, Belgium; 2. Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium; 3. Departement of Analytical Chemistry, Ghent University, Ghent, Belgium.

Background: cytoreductive surgery (CRS) followed by hyperthermic intraoperative chemoperfusion (IC) benefits selected patients with carcinomatosis. There are to date no clinical studies that have compared hyperthermic with normothermic IC using oxaliplatin (OX). Methods: patients underwent CRS and were treated with OX at 37°C, 90 min, 200 mg/m2 (group 1), 37°C, 30 min, 460 mg/m2 (group 2), or 41°C, 30 min, 460 mg/m2 (group 3). The amount of platinum (Pt) in the perfusate and blood was determined by inductively coupled plasma-mass spectrometry (ICP-MS), and platinum tissue penetration in healthy abdominal wall was analysed by laser ablation ICP-MS (LA-ICP-MS). Postoperatively, morbidity and mortality were also evaluated. This trial was registered with ClinicalTrials.gov, NCT01575730. Results: no significant differences in pharmacokinetic parameters (Cmax, AUCt=7days) were observed between groups 2 and 3. Also, no effects of hyperthermia were observed on Pt tissue penetration. Increased postoperative and systemic toxicity was, however, observed in the group treated under hyperthermic conditions. Among patients treated under normothermic conditions, short high dose treatment (group 2) resulted in a significantly higher Cmax while the AUC(t=7days) was similar for both groups resulting in a similar systemic toxicity. Also, tissue Pt penetration was much higher in the short high dose group. Conclusions: addition of hyperthermia does not enhance tissue penetration of OX used as IC, but increases postoperative and systemic complications. Short, high dose OX IC results in a similar AUC over 7 days, but enhanced tissue Pt penetration compared to a long, lower dose IC.

P106

Rectal Cancer Treatment and Complications in Patients with IBD S. Van Rooijen,* S.L. Bosch, H.J. Braam, G.M. Bökkerink, I.D. Nagtegaal, J.H. De Wilt. *Radboud University Nijmegen Medical Centre*, *Nijmegen, Gelderland, Netherlands.*

Background IBD patients have an increased risk of developing colorectal cancer (CRC). For sporadic rectal cancer (RC), neoadjuvant therapy followed by total mesorectal excision (TME), is standard of care. Data on the effects of this treatment for IBD related RC are rare, since IBD patients are usually excluded from neo-adjuvant trials. Methods All IBD-RC patients between 1990 and 2010 were selected using a Dutch nationwide search in the Dutch Pathology Database (PALGA). Surgical complications were scored according the Clavien-Dindo scale. Results from patients with IBD were compared with data from the Dutch surgical colorectal audit containing all colorectal cancer patients treated in the Netherlands. Results 180 patients from 36 hospitals were identified (84 Ulcerative Colitis (UC), 72 Crohn's Disease (CD), 7 indeterminate colitis). 112(61.9%) were males and 67(37%) females with mean age of RC diagnosis of 59.9 years (± 13.8). The mean duration of IBD before development of RC was 16 years(± 12.4). Neoadjuvant therapy was used in 66(36.5%) patients, 29(16.1%) received short course radiotherapy(RT), 10(5.6%) long course RT, 23(12.8%) chemoradiation therapy (CRT). 158(87.8%) patients underwent resection of the tumor. Diagnosis of RC was known preoperatively in 137(86.2%) patients (CD 80% and UC 92.7%; p< 0.001). Stage distribution was: 1 patient stage0(0.9%), 27 stageI(23.9%), 41 stageII(36.3%), 30 stageIII(26.5%), and 14 stageIV(12.4%). 16(19%) patients had a positive circumferential resection margin(CRM), 4(9.8%) UC and 10(25.6%) CD patients(p<0.001). 48% of the patients developed one or several complications after rectal surgery. Local recurrence risk was increased in patients with CD(27.1%) compared to patients with UC(16.2%, p=0.05). The 5 year overall survival rates per stage were: stage184.6%, stageII62.5%, stageII139.3% and stageIV7.1%, which is comparable to the general population. Conclusions Rectal cancer is often not recognized in patients with IBD who undergo surgery. This leads to a high number of R1 resections and an increased local recurrence rate, especially in patients with CD. The complication rate after TME surgery in IBD patients seems comparable with sporadic RC patients.

P107

Patients with Complete Pathological Response to Preoperative Chemoradiation Surgically Treated with Local Excision have a Low Systemic Relapse Risk P. Luna-Perez,* R. Maria de Lourdes, G. Marcos, R. Saul, R. Erika. Surgical Oncology, Hospital de Oncologia CMN SXXI, Mexico City, Mexico.

Background. Management of distal rectal cancer remains a significant challenge. Neoadjuvant chemoradiation (CRT) has been considered the preferred treatment option for stages II and III distal rectal cancer. Optimal surgical treatment strategy remains controversial and highly dependent on accurate disease staging, tumor location, distance from anal verge and response to CRT Objective. To compare local excision vs. Total mesorectal excision (TME) in terms of patterns of recurrence in those patients with pathological complete response pCR after CRT Materials and methods. Between 1996 and 2011, 1080 patients with rectal adenocarcinoma were treated with CRT. All patients received neoadjuvant 5-FU-based chemotherapy and 50.4 Gy of external beam radiation (RT). Seventy-four (6.8%) achieved pCR. Results. There were 39 males and 35 females with a mean age of 58 years. Mean distance from distal tumor margin to the anal verge was 4.4 Cm. Endorectal ultrasound evaluation before neodjuvant chemoradiation was: uT3,N(-) = 30 and uT2-3, N(+) = 44. Median duration of RT was 5 weeks. Median time for surgery was 11 weeks. Surgery performed was: low anterior resection, 40; abdominoperineal resection, 10; trans-anal local excision, 24. At median follow-up of 82 months, local recurrence was observed in 1 patient treated with local excision, conversely in those treated with TME was $\hat{0}$ (p= 0.15). Distant recurrences were observed in 2 patients treated with local excision, conversely was observed in 9 patients treated with TME (p=0.03) Conclusion. Local excision after pathological complete response (pCR) for rectal cancer patients treated with CRT offers very low rate of local recurrences similar to the obtained with radical surgery with TME. Furthermore, low rate of distant recurrences was observed.

P108

Incorporation of Diagnostic Laparoscopy in the Management Algorithm for Patients with Peritoneal Metastases: A Multi-institutional Analysis P. Tabrizian,^{1*} T.T. Jayakrishnan,² A.J. Zacharias,² S. Aycart,¹ F.M. Johnston,² U. Sarpel,¹ D.M. Labow,¹ K.K. Turaga.² *1. Surgical Oncology, Mount Sinai Medical Center NY, New York, NY; 2. Medical College of Wisconsin, Milwaukee, WI.*

Introduction Patients with peritoneal metastases (PM) derive therapeutic benefit from cytoreductive surgery and HIPEC (CRS+HIPEC) when a complete cytoreduction (CC) is achieved. Diagnostic laparoscopy (DL), which can predict CC, is often considered unfeasible in patients with PM due to a hostile abdomen, re-operative surgery, incomplete assessment or for fear of port site recurrence. We hypothesized that DL can be successfully incorporated into the management of patients with PM. Methods Retrospective review of prospectively maintained databases from two high volume institutions was performed between 2007-2013. Data on tumor and host characteristics, operative detail, and survival outcomes were analyzed. Results DL was successfully completed in 158 of 166 (95%) patients with PM, of which 134(81%) had previously undergone cytoreductive or primary tumor surgery. The technique for entry was the Hasson in 66%, optical trocar in 30% and Veress needle in 4%. Serosal injury from DL occurred in 1 patient (0.6%). Predominant histology included appendiceal (47%) and colorectal primaries (28%). Exclusion from cytoreduction by DL occurred in 35 (22.4%). Among those excluded, 8 (of 35, 22.9%) subsequently underwent CRS+HIPEC after receiving systemic chemotherapy. Overall survival (from laparoscopy) for those that underwent CRS+HIPEC at the original operation was 34 vs. 36 months that underwent a delayed CRS+HIPEC (p=0.64). Histology or PCI adjusted analysis revealed no significant difference. Overall survival for those that were excluded by laparoscopy was 13 months (p=0.006) compared to the other groups. There were no cases of port site recurrence in the study period. Conclusion Diagnostic laparoscopy can be safely incorporated in the management of patients with peritoneal metastases, and can be especially beneficial in excluding patients from attempted incomplete cytoreduction.

P109

Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Colon Tumor Vaccine in Combination with Epigenetic Therapy in a Preclinical Model of Colon Cancer K.C. Soares,* B. Ladle, E. Jaffee, N. Azad, N. Ahuja, C. Gamper, L. Zheng. Johns Hopkins School of Medicine, Baltimore, MD.

Introduction: Our phase I human clinical trials utilizing a GM-CSF secreting allogeneic colon tumor vaccine (GVAX) have been shown to be safe in inducing anti-tumor immune response in colorectal cancer (CRC) patients. We found that treating CRC cells in vitro with hypomethylating agents led to enhanced expression of cancer/testis antigens. Building upon our experience with DNA hypomethylating agents and GVAX in preclinical and clinical studies, we hypothesized that demethylation treatment can improve the antigenicity of CRC vaccines and enhance the trafficking of immune effector cells into the tumor microenvironment. Methods: Mice were orthotopically transplanted with 2 x 10⁶ CT26-HA tumor cells to form liver metastases by a hemisplenectomy technique. Following tumor transplantation, mice were treated subcutaneously with a mouse GM-CSF secreting CRC tumor vaccine (mouse GVAX) in combination with decitabine (DAC). GVAX was given subcutaneously to mice on day 11 following tumor transplantation, together with a single low dose of cyclophosphamide on day 10. DAC was administered intraperitoneally for five consecutive days at a dose of 0.14 mg/kg at varying time periods in relation to vaccine therapy (Figure 1A). Results: DAC pretreatment plus GVAX demonstrates a reduction in percentage of mice disease free at 25 days compared to DAC alone, GVAX followed by DAC and no treatment controls. In mice that rejected tumor, tumor infiltrating lymphocytes from DAC+GVAX treated mice have increased IFNy production compared to single modality treatment (P<0.001) (Figure 1B). DAC pretreatment or concurrent treatment with GVAX increases IFNy production from splenocytes following ex vivo co-culture with tumor targets (P=0.03). DAC pretreatment also increases a CT26 MHC Class I-restricted epitope (AH-1) specific immune response compared to vaccine alone (P=0.003). Conclusions: Combinatorial treatment with DAC followed by GVAX results in increased antigen specific responses in a preclinical model of CRC. Our study provides strong rationale that combining epigenetic and GVAX will improve vaccine induced CRC responses.



Figure 1. Decitabine (DAC), administered in combination with a whole cell CT20HA GM-CSF vaccine (GVAX) and cyclophosphamide prevents tumor formation in mice challenged with CT20HA Inver metastases. A) Experimental design for the administration of cyclophosphamide, GVAX given subscituationacously and DAC. B) In anice that rejected tumor, tumor infiltrating lymphocytes from DAC+GVAX treated mice have increased IFNy production compared to single modality treatment (p=0.001)

30-year Review of Surgical Resection and Intraoperative Radiation Therapy for Locally Advanced Rectosigmoid and Rectal Carcinoma Z. Fong,* D.M. Furfaro, P.C. Shellito, D.L. Berger, J. Szymonifka, J. Wo, T.S. Hong, J.C. Cusack Jr.. *Massachusetts General Hospital, Boston, MA.*

It has been proposed that surgical resection with intraoperative radiation therapy (IORT) may improve local control rates for locally advanced rectosigmoid or rectal adenocarcinoma (LARSA). We retrospectively evaluated patients with LARSA treated with surgical resection and IORT. We evaluated the impact of combined treatment on overall survival (OS), disease-free survival (DFS) and local control (LC). The prognostic impact of resection margins was assessed. Between 1979 and 2010, 438 patients with LARSA were referred for consideration of IORT. Of those, 110 patients received IORT for primary LA disease. The average age was 60 ± 14years old; 49 (45%) were female and 61 (55%) were male. Preoperative radiation therapy was delivered to 94.5% of patients, and 19.1% received post-operative radiation. Neoadjuvant chemotherapy was given to 72.7% of patients, and 41.8% received adjuvant chemotherapy. The median cone size, radiation dose and beam energy delivered were 6 cm, 12.5 Gy and 9 MeV respectively. The resection margins achieved, measured as R0, R0.5 (margins within 1 mm), R1 and R2 were 60%, 10%, 21.8%, and 0.3%, respectively. The overall 5-year DFS, LC, and OS were 45.2%, 79.6%, and 57.0%, respectively. Patients with R0 margins had an improved OS (HR 0.48, 95% CI 0.28-0.82, p=0.008), and DFS (HR 0.48, 95% CI 0.28-0.81, p<0.006) when compared to R0.5, R1 and R2 margins. Patients with R0.5 margins showed worse OS when compared to R0 resections (HR 3.66, 95% CI 1.46-9.18, p=0.006), and were in fact no different when compared to R1 resections (HR 1.74, 95% CI 0.66-0.458, p=0.261). The overall radiation-associated morbidity was 17.3%. Improved OS (HR 0.73, 95% CI 0.54-0.99, p=0.040) was observed in the most recently treated cohort when compared to the earlier treatment cohorts. Optimal DFS, LC and OS were achieved when IORT was performed in conjunction with a margin negative surgical resection of LARSA. The outcome of patients who were found to have surgical resection margins ≤1 mm was prognostically similar to that of patients with positive resection margins, and was not significantly improved by IORT.

P111

Transduction of a KRAS V12 Oncogene into a Caco-2 Cell Line Establishes a Gene Expression Profile known to be Associated with KRAS Mutation in Colorectal Cancers O.S. Chow,^{1*} R. Pelossof,¹ C. Chen,¹ Z. Chen,² J. Garcia-Aguilar.¹ *1. Memorial Sloan Kettering Cancer Center, New York, NY; 2. City of Hope, Duarte, CA.*

Background: KRAS mutation in rectal cancer is associated with response to neoadjuvant therapy as well as overall prognosis. We previously identified a profile of 61 differentially expressed genes when comparing KRAS wildtype to KRAS mutant rectal cancer tissue. This signature was validated in colorectal samples of The Cancer Genome Atlas, as well as in an independent cohort of colon cancer resection samples. Many genes in our differential expression profile are known to be involved with cell proliferation and regulation of the extra-cellular matrix. We hypothesized that transduction of a KRAS V12 mutant oncogene into a KRAS wild-type colon cancer cell line would recapitulate our expression profile. Methods: A retroviral KRAS V12 vector was created by subcloning GFP and KRAS V12 into pQCXIP. This vector was transduced into Caco-2, a colon cancer derived cell line that is normally KRAS wild-type. Cells with the mutant oncogene were isolated using fluorescenceactivated cell sorting. Total RNA was extracted from the two cell lines at four time points, and quantitative real-time PCR was used to compare the expression of 6 genes of interest (DUSP6, HOXB6, HOXB8, LOX, COL1A1, and SPARC). Results: Comparing KRAS wild-type with KRAS V12 Caco-2 cells, qRT-PCR revealed DUSP6, HOXB6, HOXB8, and LOX were differentially expressed at all four time points with the same directionality as predicted by our profile (Figure 1). Conclusions: KRAS mutant CRCs have a unique profile of differential expression compared with KRAS wild-type, which we have previously validated. Transduction of a KRAS V12 oncogene establishes a subset of this profile in a KRAS wild-type colon cancer cell line. This in vitro finding shows that KRAS mutation drives a distinct gene expression profile involving genes known to modulate cell proliferation and regulation of extracellular matrix. This expression profile may help elucidate the mechanisms by which KRAS mutation affects response to neoadjuvant therapies and prognosis.



Figure 1 (A) Subset of 6 differentially expressed genes (FDR <0.15) previously identified comparing KRAS mutant and wild-type colorectal cancers using microarray. (B) Relative abundance of mRNA for 6 genes at day 5 (one representative time point shown for simplicity) in Caco-2 KRAS V12 compared with Caco-2 KRAS wild-type. Same directionality of differential expression observed in DUSP6, HOX86, HOX86, LOX.

P112

The Impact of Fondaprinux on the Prophylaxis of Venous Thromboembolism: The Efficacy, Safety and Prognosis after Resection for Colorectal Cancer Y. Yamaoka,¹* M. Ikeda,¹ M. Ikenaga,² N. Haraguchi,¹ M. Miyake,¹ K. Yamamoto,¹ T. Asaoka,¹ K. Nishikawa,¹ A. Miyamoto,¹ M. Miyazaki,¹ M. Hirao,¹ S. Nakamori,¹ M. Sekimoto.¹ *1. Surgery, Osaka National Hospital, Osaka, Japan; 2. Osaka Rosai Hospital, Sakai, Japan.*

Background: Colorectal cancer (CRC) surgery is a risk factor for venous thromboembolism (VTE). The aim of this study is to examine the efficacy, safety and impact on survival of fondaparinux (FPX) combined with intermittent pneumatic compression (IPC) after resection for CRC. Patients and Methods: We reviewed 953 patients with CRC who underwent colorectal resection between April 2006 and March 2013. Patients were divided into 2 groups, the IPC group (n=591) and the FPX group (n=362). The IPC group was treated with IPC alone as a control. The FPX group was treated with IPC and received subcutaneous injections of FPX (2.5mg) once daily for 4 days. The incidence of VTE, postoperative bleeding, postoperative complications, and prognosis were compared. Results: No statistical difference was found in age, sex, prevalence of arteriosclerotic disease, ASA-PS, operating time, tumor location, and disease stage between the two groups. Body mass index (FPX:23.0 kg/m2, IPC:22.4 kg/m2) and the rate of laparoscopic surgery (FPX:59.4%, IPC:34.7%) were higher in the FPX group. Blood loss was less in the FPX group (FPX:67.4ml, IPC:109.5ml). Symptomatic VTE was found only one patient (0.1%) in the IPC group, who died on post-operative day 14. The incidence of major bleeding was 0.55% in the FPX group and 0.51% in the IPC group (p=0.93), and the incidence of minor bleeding was 9.4% and 3.4%, respectively (p=0.0001). The incidence of postoperative complications (Clavien-Dindo classification≧3a) (FPX:9.4%, IPC:9.0%) was similar. There was no significant difference in overall survival rate in stage 0, I, II, and IV. However, in stage III 3-year overall survival rate was significantly better in the FPX group than IPC group (FPX:93.3%, IPC:81.1%, p=0.0061). Conclusions: The use of FPX increases the incidence of minor bleeding, but not major bleeding. Postoperative anticoagulation with FPX may inhibit cancer cell metastasis in high risk patients. VTE prophylaxis with FPX was safe, and effective, randomized prospective study investigating the efficacy of FPX on prognosis in curatively resected CRC patients needs to be warranted.

P113

Analysis of Cancer-related Genes in Mucinous Appendiceal Neoplasms using High Resolution, Targeted Amplicon Sequencing S. Downs-Canner, W.A. LaFramboise, R. Pai, P. Petrosko, M. Belsky, M.P. Holtzman, A.H. Zureikat, S.A. Ahrendt, J. Pingpank, H.J. Zeh, D.L. Bartlett, M.A. Choudry.* Surgery/ Surgical Oncology, University of Pittsburgh, Pittsburgh, PA.

Introduction: We sequenced 7405 exon domains of 409 cancer genes in mucinous appendiceal neoplasms (MAN) to identify diagnostic and prognostic biomarker candidates and prospective therapeutic targets. Methods: Genomic DNA from primary tumors (MAN), corresponding metastases (pseudomyxoma peritonei; PMP), and matched blood samples (PBMCs) from four patients with MAN/PMP underwent amplicon sequencing of 409 tumor suppressors and oncogenes. Tumors were macro-dissected to minimize cellular hetero-geneity (>70% tumor cells) and amplicon sequencing was performed at high

depth (average base depth>150X) and coverage (99% of targets). Results: We identified shared, non-synonymous, single base variants (SNVs) present in every tumor and/or every metastatic specimen that were not found in the normal reference genome. Fourteen SNVs were present in all MAN, 13 SNVs were common to all PMP, and 9 SNVs were present in both MAN and PMP specimens. We identified 5 germline SNVs that were common to all MAN, PMP and PBMC samples. Copy number variation (CNV) analysis using exonspecific base depth comparison (p<0.002; 1.5<CNV<-1.5) revealed 94 genes with significant gains or losses (losses=86) in MAN and 98 genes with significant CNV in PMP (losses=89). MAN and PMP samples were remarkable for highly similar CNV profiles (94 in common). The aberrant genes containing SNV and/or CNV were broadly classified into five functional protein categories including chromatin remodeling; extracellular matrix; cellular transport/scaffolding; stem cell signaling, cellular oncogenic signaling; and transcription factors. There was a cluster of gene deletions in both MAN and PMP samples specific to DNA damage-response enzymes. (Table) Top canonical pathways associated with these genomic changes were NF-kappaB and PTEN signaling (p<0.0001). Conclusions: We identified several candidate cancer genes potentially associated with malignant transformation in MAN/PMP that may comprise diagnostic, prognostic and/or predictive disease biomarkers. The finding that these genes cluster in essential oncogenic signaling pathways suggests that they may represent efficacious targets for therapy.

Candidate Cancer Genes

Categories	SNVs	CNVs
Chromatin Remodeling Proteins	ARID1A, NSD1, SETD2, MLL2, TRRAP, ATR, KAT6B	SMARCA4, WHSC1 (NSD2), EP400, KAT6A, BRD3, ASXL1, BAP1
Extracellular Matrix Proteins	FN1, ITGA9, ADAMTS2, FLT4 (VEGFR-C), GPR124 (TEM5)	COL1A1, ITGB2, LPHN3, GNA11, GNAS
Cellular Transport, Structural and Scaffold Proteins	TPR, NUP214, AKAP9, PDE4DIP, LAMP1	SEPT9, FZR1
Stem Cell Signaling Proteins	NOTCH1, TCF3, NFE2L2	EPHB1/4/6, STK36, TLX1, POU5F1 (OCT4)
Cellular Oncogenic Receptors and Signaling Proteins	EGFR, PLCG1, CARD11, LIFR, CD79A	ALK, LTK, AXL, NTRK1, RET, FGFR1/3/4, IGFR2, TNFRSF14, INS-IGF2, NDE1, NUMA1, MPL, AKT2, PIK3CD, PLCG1, TSC2, RPS6KA2 (RSK3), SRC, LCK, HRAS, BCL3, IKBKE, PLEKHG5, MALT1, NFKB2, JAK3
Transcription Factors	FOXP4, GATA3, ARNT, PML, AR	CREBBP, CRTC1, PER1, PML, PAX5/7, CIC, ETV4, HNF1A, MLLT10, MEN1
DNA Damage Response Enzymes		PIM1, CDK6, SMUG1, MUTYH, RECQL4, ERCC2, PMS2, SDHB, MTRR

P114

Body Mass Index x Visceral Fat Area/Subcutaneus Fat Area Ratio: A New Fat Parameter Associated with Severe Postoperative Complications after Colorectal Surgery M.M. Buijs,^{1*} J.W. Spliethoff,² R. Bezooijen,¹ I. Grossmann,¹ M. Brusse-Keizer,¹ C.H. Slump,² J.M. Klaase.¹ 1. Medisch Spectrum Twente, Enschede, Netherlands; 2. University of Twente, Enschede, Netherlands.

Introduction: Obesity is considered an important risk factor for postoperative complications after colorectal surgery but evidence in literature is still weak. Visceral fat is strongly related to the metabolic syndrome as opposed to BMI. This study investigates whether BMI multiplied by VFA/SFA ratio is a valueble new fat parameter related to postoperative complications after colorectal cancer surgery. Methods: A retrospective chart review was conducted in 100 randomly selected patients who were surgically treated for colorectal cancer. VFA/SFA was determined using 20 consecutive CT-slices cranial to the iliac crest. BMI, VFA/SFA and BMI*VFA/SFA were used as obesity measures and tested in relation to severe complications. Results: Eighty-five patients fullfilled the inclusion criteria, 43 males (50,6%), 42 females (49,4%) with mean age of 69 years. Post-operative complications occurred in 33 patients (38,8%) of which 14 (16,5%) were severe according to the Clavien-Dindo classification (IIIA or higher). Eleven patients needed reintervention, in 7 because of anastomotic leakage, in 2 because of fascial dehiscence, in one case because of iatrogenic ureter injury and in one case because of abdominal abcess. Three patients died of surgery related complications. According to BMI 33 (38,8%) patients were overweight (BMI>25) and 22 (25,9%) other patients were obese (BMI >30). Only BMI*VFA/SFA and hypertension were found to have a significant relation to the development of severe complications. All variables significantly associated with severe complications and a raised BMI, VFA/SFA

or BMI*VFA/SFA in univariate analysis were entered into multivariate analysis using logistic regression . Three explanatory models were developed of which BMI*VFA/SFA was best correlated to severe complications (OR 1,06; 95% CI: 1,01-1,12). Conclusion: BMI*VFA/SFA is a fat parameter associated with severe postoperative complications in colorectal cancer patients. Prognostic significance of BMI*VFA/SFA should be further determined in a prospective study with a larger population.

P115

The iRGD Peptide Potentiates Tumor Penetration of Intraperitoneal Chemotherapy K.N. Sugahara,¹* T. Tambet,¹ P. Scodeller,¹ V. Kotamraju,¹ A.M. Lowy,² E. Ruoslahti,¹ *I. Sanford-Burnham Medical Research Institute, La Jolla, CA; 2. University of California, San Diego, La Jolla, CA.*

INTRODUCTION: Intraperitoneal (IP) chemotherapy for peritoneal metastasis is limited by poor drug penetration into tumor tissue. iRGD, a tumorspecific, tissue-penetrating peptide, facilitates intratumoral distribution of attached drugs, and even free drugs co-injected with iRGD, through transvascular and local penetration (Cancer Cell 16:510-520, 2009; Science 328:1031-1035, 2010). Here, we examined the ability of iRGD to potentiate IP chemotherapy in murine models of peritoneal carcinomatosis. METHODS: Fluorescent dextran or doxorubicin (DOX) was co-injected with iRGD into the abdominal cavity of mice with peritoneal carcinomatosis. Intratumoral accumulation of dextran and DOX was evaluated with imaging, microscopy, and/or spectrophotometry. The anti-tumor effects of iRGD/DOX IP combination therapy were examined in long-term treatment studies. RESULTS: Fluorescein-labeled iRGD efficiently accumulated into disseminated peritoneal tumors of colon, gastric and ovarian cancer in mice. Co-injection of iRGD and fluorescent dextran into the peritoneum resulted in tumor-specific accumulation of dextran. The accumulation occurred via local penetration as dextran entry into subcutaneous tumors that were only accessible through the circulation was minimal. Intraperitoneally injected CRGDC, a tumor-targeting peptide with no tissue-penetrating properties, only labeled the surface of peritoneal tumors, and failed to enhance the entry of co-injected dextran into the tumors. iRGD enhanced the accumulation of free DOX into peritoneal tumors by 5 fold, and significantly potentiated the anti-tumor activities of DOX in a long-term treatment study. No enhanced systemic toxicity was observed in the iRGD/DOX treated mice. iRGD also facilitated penetration of biological nanoparticles into freshly excised human peritoneal tumor explants suggesting clinical relevance of the iRGD drug delivery system. CONCLUSION: iRGD significantly enhanced intratumoral accumulation and anti-tumor activities of free DOX in mice with peritoneal tumors. The iRGD system provides a simple way to potentiate IP chemotherapy and deserves further investigation as a possible companion to cytoreductive surgery and IP chemotherapy.

P116

Pretreatment Serum CEA Level may Predict Molecular Profiling of Colorectal Cancer P. Thirunavukarasu, ^{1*} M. Alaeddine,² A. Yeh,² A. Karunamurthy,² A.H. Zureikat.² *1. Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY; 2. University of Pittsburgh, Pittsburgh, PA*.

Introduction: Elevated pretreatment serum CEA level in colorectal cancer (CRC) is known to portend a poorer long-term prognosis. The molecular mechanism behind CEA's biological aggressiveness is unknown. We aimed to study if elevated serum CEA was related to some of the well-established carcinogenic pathways for which molecular testing is commonly done. Methods: We identified consecutive CRC patients who had routine molecular testing at our institution between February 2012 and July 2012 and stratified them according to the pretreatment serum CEA level as 'C0' (normal, ≤5ng/ml) or 'C1' (elevated, >5ng/ml). Differences in occurrences of KRAS, MSI, BRAF and MMR mutations in C0 and C1 cohorts were analyzed using Chi-Square method and correlation using Pearson product moment method. Results: Among 154 consecutive cases, information on molecular testing on KRAS, BRAF, MMR and MSI status was available in 150, 145, 152 and 150 patients respectively. KRAS mutations were identified in 50 (33.3%) and its prevalence was significantly higher in C1 than C0 patients (54.5% vs 25.7% P = .002). MMR mutations were seen in 23 (15.1%) patients, and all of them were C0 (P=.001). No significant difference was observed in BRAF mutations in C0 compared to C1 (11.3% vs. 4.65%, P=0.3). Microsatellite instability (MSI) was identified in 24 patients (16%), of which 21 patients had MMR mutations. All patients with MSIwere C0 (P=.001). In our dataset, there was no C1 patient who tested positive for MMR wild type or microsatellite stability. Conclusion: KRAS mutations were twice as more common among C1 compared to C0 patients. All (100%) MSI-unstable and MMR mutated patients were found to have normal levels of pretreatment CEA, making CEA an unreliable prognostic indicator in this group of patients. If the above findings are consistently demonstrated in larger studies, high CEA levels could be used as a surrogate test to exclude MMR mutations and microsatellite instability.

P117

Antero-posterior Perineal Approach for Sphincter Preservation in Ultra Low Rectal Cancer: Oncologic and Functional Outcome W.M. Gawad,* O. Mansour, M. Lotief, M. Sakr. Surgical Oncology, National Cancer Institute-Cairo University, Cairo, Egypt.

Background: The perineal dissection through an Antero-Posterior perineal entry has been introduced to minimize the oncological drawbacks encountered with ultra-Low rectal tumours resection (2-5 cm) from anal verge as Circumferential Resection Margin (CRM) involvement, inadvertent intraoperative bowel perforation with subsequent increase in local recurrence rate & low overall survival. This approach confers better access to low seated rectal tumours enabling sphincter saving and bowel continuity with better life qualityt.Methods:Between 2008 and 2012, 35 consecutive patients with low rectal tumous (3-5 cm) from anal verge, underwent ultra Low Anterior Resection with concomitant Antero-Posterior perineal entery, compared to 45 patients with conventional Low Anterior Resection .All patients received neoadjuvant Chemoradiation with R0 Resection.Patients data was prospectively collected from our Colorectal data base. Rates of CRM involvement, bowel perforation and wound infection were compared. Continence was subjectively evaluated according to Kirwan Scale. The sphincter preservation and Colo-Anal Anastomosis (CAA) in the antero-posterior approach was achieved through either hand sewn in 10 patients or double stapling technique in 25 patients with protective ileostomy in 15 patientsResults: The Rates of CRM involvement, bowel perforation and wound infection in such perineal approach versus conventional resection were 3.5% vs 10% (P=0.04), 5% vs 21.1% (P=0.521) and 11% vs 31% (P=0.518) respectively. Operative time was lower with the perineal entry than with conventional surgery(220.3 & 300min) respectively (P=0.04). Continence to stool & flatus was achieved in 48 patients (88%) Kirwan scale I, while 7 patients (12%) had control to stools only .Conclusion: This technique facilitates addressing ultra- low rectal tumours, with increased chances for sphincter preservation & bowel continuity concomitant with superior oncologic outcome compared to the conventional techniques suggesting its significance as a valid approach for low seated rectal tumours. .

P118

Cost Differential among Systemic Therapies for Colon Cancer H. Nadeem, T.T. Jayakrishnan,* T.C. Gamblin, K.K. Turaga. *Medical College of Wisconsin, Milwaukee, WI.*

Introduction According to the National Cancer Institute (NCI), national cancer care expenditures were an estimated \$124.6 billion in 2010, of which a significant portion is attributed to chemotherapy costs. The National Comprehensive Cancer Network (NCCN) has outlined recommendations for the treatment of various cancers that incorporates alternative chemotherapeutic strategies presumed to be of similar effectiveness. In the evolving economic climate with resource constraints, we hypothesized that there is a significant cost differential between possibly therapeutically equivalent systemic therapy regimens for colon cancer. Methods Details of the chemotherapy regimens and dosages outlined in NCCN guidelines (2013) were acquired for colon cancer. Baseline costs (in US dollars US\$) were calculated based on the payment allowance for Medicare part-B drugs database (2013). Dosage amounts were calculated for an average American patient and additional costs (treatment time, pumps) were also added to the total regimen cost. The total costs were calculated for a treatment period of 6 months. Results A total of 25 regimens (advanced/metastatic and adjuvant) were studied. The median cost for systemic treatment of advanced/metastatic colon cancer for a 6-month period was \$34,840 (IQR \$9,420 - \$68,840, n=20 regimens) (Table 1). The median cost for adjuvant treatment alone was \$13,870 (Range \$2,600- \$33,230, n=5). The cost differential for a single patient between FOLFOX and Folfiri+ziv-Aflibercept was \$ 4.2 million for metastatic colon cancer. The addition of novel anti-

Table 1. Demonstrating	the cost differential	among	systemic	therapy
regimens for metastatic	colon cancer			

REGIMEN	COST (\$US)
5-FU BASED	
Roswell Park regimen	,770
Simplified Bi-Weekly infusional 5-FU	3,421
Simplified Weekly infusional 5-FU	8,381
Capecitabine	33,229
Capecitabine+Bevacizumab	69,392
IRINOTECAN BASED	
Irinotecan	2,790
IROX	8,560
Folfiri	10,286
Folfoxiri	17,340
Folfiri+Bevacizumab	47,369
Folfiri+Panitumumab	68,782
Folfiri+Cetuximab	75,216
Folfiri+ziv-aflibercept	4,248,806
OXALIPLATIN BASED	
Folfox	11,728
CapeOX	32,833
mFolfox6+Bevacizumab	36,450
CapeOX+Bevacizumab	68,896
mFolfox6 + Panitumumab	70,223
OTHERS	
Panitumumab	58,495
Cetuximab	64,930

5-FU – 5- Flurorouracil, Roswell Park regimen – Leucovorin & 5-FU, IROX – Irinotecan & Oxaliplatin, Folfiri – Flurorouracil, Ironetecan & Leucovorin, Folfox – Flurorouracil, Leucovorin & Oxaliplatin, CapeOX – Capecitabine & Oxaliplatin,

P119

What is the Best Surgical Strategy for Low or Mid-rectal Cancer (LMRC) with Synchronous Liver Metastases (SLM)? J. Hetu,* A. Dupr, S. Chabaud, Y. Chen, P. Peyrat, M. Rivoire. *Centre Léon-Bérard, Lyon, France.*

Objectives LMRC with SLM is a challenging situation. Optimal treatment strategy is still discussed. Methods Retrospective analysis of a prospective database of patients surgically treated for SLM from LMRC between 1991/01 and 2013/01. Patients' demographic data, operative morbidity, overall survival (OS) and disease-free survival (DFS) were analyzed. Combined surgery (CS) and sequential surgery (SS) were compared. Results Among 110 patients surgically treated for SLM from rectal cancer, 47 had LMRC with SLM at diagnosis. 25 patients had combined rectal and hepatic surgery (CS group), and 22 patients had sequential surgery, that is liver-first surgery (2 patients) or rectal surgery first (20 patients) (SS group). All had received an induction chemotherapy (n=28) and/or neoadjuvant chemoradiotherapy(n=44). There was no difference between groups in terms of age, sex and hepatic extent of disease. Median number of SLM was higher in the SS group than in the CS group (6 vs 3), as well as rate of major hepatectomy (72% vs 56%) and resected liver weight (785g vs 695g). Median number of procedures was 2 (1-4) in CS group and 3 (2-4) in SS group. Cumulative incidence of complications (at least one complication in all surgeries) was identical in both groups (76% CS vs 63.6% SS, p=0.524), but there was a significantly higher incidence of major complications in the SS group (16.0% CS vs 40.9% SS, p= 0.033). No perioperative death occured. With a median follow-up of 73.3 months, median OS and DFS were respectively 56.5 months and 18.4 months. 3- and 5-year OS was 64% and 46%. One- and 3-year survival was 72.3% and 23.6%. There was no difference between groups. Conclusion Combined surgery appears to be a good option with acceptable morbidity when treating patients with low or mid rectal cancer and synchronous liver metastases. This approach allows optimal metastatic disease treatment with integration of rectal cancer radiotherapy while limiting the number of surgeries.

Identification of a Novel Biomarker Related to Lymph Node Metastasis in Colorectal Cancer through Gene Expression Analysis H. Baba,¹* T. Ishikawa,² N. Iwata,¹ H. Takahashi,¹ A. Kikuchi,¹ S. Okazaki,¹ M. Ishiguro,¹ H. Kobayashi,¹ S. Iida,¹ H. Uetake,² K. Sugihara.¹ I. Department of Surgical Oncology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan; 2. Department of Translational Oncology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.

Background Progression of Molecular Biology have developed identification of biomarkers for personalized cancer treatment. But there are few biomarkers used by clinical practice. Lymph node metastasis in colorectal cancer (CRC) is poor prognostic factor. Purpose This study aimed to identify genes related to lymph node metastasis in colorectal cancer through gene expression analysis and to investigate the possibility of the candidate gene as a prognostic biomarker. Methods mRNAs were extracted from 156 stage I-III CRCs by laser microdissection, which were resected at our institution from 2005 to 2009. We compared the expression profiles of mRNA expression in cancer cells of CRC patients with (Stage I+II,N=98) and without (Stage III,N=58) lymph node metastasis by oligonucleotide microarray analysis. We defined the gene which had highly expressed in integration analysis of copy number and gene expression as candidate gene. Then we analyzed protein expression level of the candidate gene by immunohistochemistry (IHC) using the same 156 colorectal cancer tissue and finally evaluated the correlation between the candidate gene expression and clinicopathological parameters. Results Special AT-rich sequence-binding protein 1 (SATB1) was extracted from integrated microarray analysis (Fold change > 2, P < 0.05). The high expression of SATB1 protein was significantly related to lymph node metastasis in CRC (P<0.001). The high expression of SATB1 was also associated with short OS (P=0.038) and RFS (P=0.024). Conclusion This study suggested that SATB1 may play an important role in lymph node metastasis of CRC. SATB1 would be a predictive biomarker of lymph node metastasis and recurrence after surgery of CRC. Further investigasion is important.



SATB1 protein expression

P121

Does Chemotherapy/Biologics beyond Second Line Affect Colon Cancer? Specific and Overall Survival in Metastatic Colon Cancer: An Analysis of 5,129 Patients N. Hanna,¹* C. Woods,² Z. Zheng,² E. Onukwugha,² B.S. Seal,³ C. Mullins.² *1. Surgery, University of Maryland, Baltimore, MD; 2. University of Maryland School of Pharmacy, Baltimore, MD; 3. Bayer Healthcare Pharmaceuticals, wayne, NJ.*

Background: The purpose of this study was to investigate whether additional chemotherapy/biologic treatments after second line affect colon cancer-specific and overall survival in patients with metastatic colon cancer (mCC). Methods: Patients aged 66 to 105 years old diagnosed with mCC between 2003 and 2007 were selected for analysis from the Surveillance, Epidemiology and End Results SEER-Medicare data to determine the association between chemotherapy/biologic treatment lines and survival. We examined the survival benefits using Cox proportional-hazards regressions with inverse probability weighting method to adjust for the probability of receiving treatment lines. Results: Patients with no chemotherapy/biologic treatment had an adjusted median survival time of 6.8 months. Each chemotherapy/biologic treatment line received was associated with longer adjusted median survival times: 11.9 months, 23.2 months and 26.4 months for receipt of 1st-line treatment only, 2nd-line treatment and subsequent treatment, respectively. Colon cancer-specific mortality hazard ratios (HRs) were 0.637, 0.391 and 0.350 (p<0.001 for each) for 1st-line, 2nd-line and subsequent treatments, respectively. Overall mortality hazard ratios were 0.604, 0.398 and 0.364 (p<0.001 for each) for 1stline, 2nd-line and subsequent treatments, respectively. Compared to receiving only first-line treatment, proceeding to second-line treatment was associated with longer colon cancer-specific survival (HR=0.614, p<0.001) and longer overall survival (HR=0.659, p<0.001). Patients with a low-graded tumor had longer colon cancer-specific and overall survival (HR=0.746, p<0.001; HR=0.762, p<0.001, respectively) and lived 5.6 months longer. Conclusions: Among mCC patients who survived at least 3 months from diagnosis, each of the 1st and 2nd chemotherapy/biologic treatment lines was independently associated with significantly longer survival. Additional treatment after the 2nd line showed neither benefit nor harm. Similar significant survival differences were seen in patients who survived at least 6 and 9 months from diagnosis.



Five-year adjusted survival curves by chemotherapy/biologic treatment line in a cohort of patients with metastatic colon cancer using Cox regression and inverse probability weighting to adjust for treatments received.

P122

FTY720, a Sphingosine-1-phosphate Signaling Modulater, as a Novel Therapy for Colon Cancer Peritoneal Carcinomatosis T. Aoyagi,* A. Yamada, M. Nagahashi, W. Huang, K.P. Terracina, D. Avini, S. Milstien, S. Spiegel, K. Takabe. *Virginia Commonwealth University, Richmond, VA*.

Introduction: Median survival of colon cancer peritoneal carcinomatosis (PC) remain dismal with only 6 months. Current treatment, 5-fluorouracil (5-FU) in combination with other drugs, is not effective for PC. Tumor associated macrophages produce Tumor Necrosis Factor-alpha(TNFa) that progress PC and cause cachexia. Sphingosine-1-phosphate (S1P), a bioactive lipid mediator produced by Sphingosine kinase (SphK1), is now known to play important roles in cancer progression by binding to S1P receptor-1 (S1PR1). We have recently published that S1P link inflammation and cancer in colitis-associated colon cancer and FTY720, a functional antagonist of S1PR1, suppress its progression. Here we demonstrate that FTY720 significantly suppress progression and prolong survival of colon cancer PC by decreasing both tumor associated and peritoneal macrophages, decreased TNFa levels, and prevent cachexia. Methods: PC was generated by ip of CT26-luc cells or HCT116-luc cells into mice. Tumor growth was measured live by a bioluminescence imaging system. Gene and protein expressions were analyzed by RT-qPCR, and immunohistochemistry. Angiogenesis and lymphangiogenesis were determined by microvessel density. Four cell lines were used for in vitro studies and cell viability were determined by WST-8 assay. Results: SphK1, S1PR1, TNF-alpha and IL-6 levels are remarkably elevated in PC nodules compared from peritoneum. FTY720 suppress the growth and number of PC nodules and decrease Ki67 index and increase apoptosis in both PC models. FTY720 significantly

decrease SphK1 and S1PR1 levels, and angiogenesis and lymphangiogenesis are suppressed. FTY720 significantly decreased tumor associated macrophages as well as peritoneal macrophages. TNFa levels are significantly decreased in the tumor, ascites, and serum by FTY720, which maintained body weight compared to the vehicle group that developed cachexia. Combination therapy with FTY720 and 5-FU synergistically suppressed survival of 4 cell-lines, and significantly prolonged survival in vivo. Conclusion: FTY720 can be a novel treatment modality and may provide better quality of life in advanced PC patients.

P123

Extended versus Segmental Resection for Colon Cancer of the Splenic Flexure: Short and Long-term Outcomes N. Okkabaz,* H. Kessler, D. Dietz, F.H. Remzi, E. Gorgun. Department of Colorectal

Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH.

Background: Defining the best surgical approach for colon cancers located in the splenic flexure remains controversial. Our aim in this study was to compare short/long term outcomes and oncological results after extended resection for splenic flexure cancer with those of segmental colectomy. Methods: All patients who underwent colectomy for splenic flexure cancer between 1995 and 2010 were retrieved from an institutional review board approved, prospectively maintained cancer database. Palliative resections and patients with synchronous colon cancer were excluded. Patients who underwent limited resection with ligation of the left colic artery and left branch of the middle colic artery (group A) were compared to those who underwent extended resection, including main colic arterial ligation (group B). Perioperative variables and both short/long term and oncologic outcomes were compared between the groups. Results: 114 patients [77(67.5%) male; mean age: 66±14] underwent colon resection for splenic flexure cancer during the study period. There were 29 (25.4%) patients in group A and 85 (74.6%) patients in group B. Group A patients were older, had more cardiac disease and a higher ASA class (p<0.05). Intraoperative parameters including operative time, blood loss, rate of transfusion and adjacent organ involvement were similar between the groups. More laparoscopic resections were performed in group A (p<0.05). Postoperative complications and short-term outcomes were similar between the groups. Tumor stage and rates of both positive resection margins and lymphovascular invasion were similar. The median number of harvested lymph nodes was higher in group B [16(6-43) vs. 34(7-303); p<0.001]. Local, distant and overall recurrence rates were comparable between the groups. Conclusion: Segmental or limited colonic resection that respects lymphovascular anatomy may be offered with acceptable oncologic outcomes to carefully-selected patients with colon cancer located in the splenic flexure.

Preoperative	and Postoperati	ve Character	istics Based or	Resection Type

	Group A (n=29)	Group B (n=85)	р
Age	71.8±14.1	64.5±13.8	0.016
Gender (female)	28 (75.7)	57 (74.0)	0.850
ASA Class 2 3 4	4 (13.8) 16 (55.2) 9 (31.0)	28 (32.9) 49 (57.6) 8 (9.4)	0.008
Operation approach Laparoscopic Conventional	11 (37.9) 18 (62.1)	12 (14.1) 73 (85.9)	0.006
Multivisceral resection Abdominal wall Stomach Distal pancreas Spleen Diaphragm Total	0 0 1 (3.4) 1 (3.4) 0 2 (6.9)	3 (3.6) 5 (5.9) 2 (2.4) 3 (3.5) 1 (1.2) 10 (11.8)	0.568 0.327 >0.999 >0.999 >0.999 0.728
Operation time (min.)	153.0±63.3	148.5±56.3	0.725
Estimated blood loss (ml)	250 (50-1700)	300 (20-2000)	0.343
Intraoperative transfusion (ml)	0 (0-1480)	0 (0-1800)	0.224
Postoperative complications	18 (62.1)	40 (47.1)	0.163
Length of stay	8 (0-33)	7 (4-46)	0.519
Stage (TNM) I II III IV	6 (20.7) 16 (55.2) 5 (17.2) 2 (6.9)	17 (20.0) 43 (50.6) 25 (29.4) 0	0.106
Recurrence Local Distant Total	0 3 (10,3) 3 (10,3)	5 (5,9) 12 (14,1) 13 (15,3)	0,327 0,757 0,758

ASA: American Society of Anesthesiology

P124

The Impact of Sarcopenia on Survival in Locally Advanced Rectal Cancer A. Gamenthaler,* E. Siegel, W. Clark, X. Zhao, A. Chen, K. Maddox, D. Shibata. Surgical Oncology, Moffitt Cancer Center, Tampa, FL.

INTRODUCTION: The association between sarcopenia (or muscle loss) and worse oncologic outcomes has been documented in several different cancers and is thought to be a potential marker of a diminished host response to tumor. We sought to examine the impact of radiologically-defined sarcopenia on outcomes of RC patients treated by neoadjuvant chemoradiation (NCR) and radical resection. METHODS: Between 1998-2010, we identified 90 patients with Stage II/III RC treated by NCR and radical surgery. Sarcopenia was assessed using 3 CT-based measures derived at the L4-L5 level including mean psoas density (MPD; Hounsfield Units), total psoas area (TPA; mm2) and muscle mass index (MMI=TPA/height2; mm2/m2). Clinicopathologic data (age, gender, pretreatment and final tumor stage, treatment response and CEA level) were collected. Associations were analyzed by Wilcoxon Rank Sum while the Kaplan-Meier method, log-rank test, and Cox proportional hazards models were used to evaluate overall survival (OS) and disease-free survival (DFS). RESULTS: Our population consisted of 50 males and 40 females with a median age at diagnosis of 61 (range 35-87). By univariate analyses, only age >61 was associated with the presence of sarcopenia by all 3 measures [MPD (p=0.0003). MMI (p=0.0001), and TPA (p=0.0008)]. Female gender was associated with increased muscle loss by MMI (p<0.0001) and TPA (p<0.0001). By Cox multivariate analysis, MPD (range 14.5-77.3 HU) was independently associated with a worse OS (AHR=0.94; 95% CI, 0.88-0.99; p=0.04) and marginally associated with DFS (AHR= 0.95; 95% CI, 0.89-1.00; p= 0.056) when controlling for age, gender and pathologic response. This translates to a 28.5% reduction in risk of death with every 5 HU decrease in MPD. CONCLUSIONS: We have demonstrated that pre-treatment sarcopenia as measured by MPD is associated with worse OS and possibly DFS in patients with RC treated by NCR and radical surgery. Larger scale studies of sarcopenia and RC are warranted. Strategies targeting reversal of processes associated with muscle loss may play a potential future role in the multidisciplinary management of rectal cancer.

P125

Neoadjuvant Chemotherapy with Bevacizumab may Improve Outcome following Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Colorectal Carcinomatosis W. Ceelen,* P. Pattyn. *GI Surgery, UZ Gent, Ghent, Belgium.*

Objective: In selected patients with PC from colorectal origin, CRS and HIPEC may improve survival. At present, it is unclear whether neoadjuvant chemotherapy with or without targeted agents is indicated in this patient population. We aimed to define prognostic factors after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal peritoneal carcinomatosis (PC). Methods Selected PC patients from colorectal origin without extra-abdominal disease were treated with cytoreductive surgery and HIPEC using oxaliplatin (200-460 mg/m2) or mitomycin C (35 mg/m2). Postoperative outcome and long term survival were prospectively recorded. The impact of clinical variables on overall survival (OS) was assessed using univariate analysis and Cox multivariate regression. Statistical significance was assumed whenever the probability of a type I error was ≤ 0.05. Results Between October 2002 and May 2012, 166 patients were treated with CRS and HIPEC. Neoadjuvant chemotherapy alone was administered to 21%, and neoadjuvant chemotherapy with bevacizumab to 16% of patients. Postoperative mortality and major morbidity were 2.4% and 35%, respectively. Half of the patients received adjuvant chemotherapy. After a median follow-up of 18 months, OS was 27 months (95% CI 20.8-33.2). On univariate analysis, OS was associated with extent of disease (P<0.001), neoadjuvant chemotherapy with bevacizumab (P=0.021), completeness of cytoreduction (CC) (P<0.001), and adjuvant chemotherapy (P=0.04) but not with primary site, synchronous presentation, or chemoperfusion drug. In multivariate Cox regression, independent predictors of OS were CC (HR 0.29, P<0.001) and neoadjuvant therapy containing bevacizumab (HR 0.31, P=0.019). Conclusions Long term outcome after CRS and HIPEC for colorectal cancer is associated with CC and neoadjuvant therapy containing bevacizumab. This regimen merits prospective study in patients with resectable PC from colorectal origin.

Robotic Extended Resections for Locally Advanced Anorectal Cancer C.N. Clarke,^{1*} A.K. Agarwal,² Y. You,¹ B. Bednarski,¹ M.A. Rodriguez-Bigas,¹ J.M. Skibber,¹ S. Nguyen,¹ E. Schlette,¹ G.J. Chang.¹ I. Surgical Oncology, MD Anderson Cancer Center, Houston, TX; 2. University of Texas Medical School at Houston, Houston, TX.

Purpose: The robotic interface offers potential for expanding the therapeutic window of minimally invasive surgery (MIS) for patients with locally advanced anorectal cancer. This study evaluates the technical feasibility, safety, and short-term oncologic effectiveness of robotic extended resection for advanced anorectal cancer. Methods: We conducted a retrospective study of a prospective consecutive database of patients who underwent robotic resection for anorectal cancers from 1/09 to 9/13 at a tertiary cancer center. Patients who underwent robotic extended pelvic resection of extra-regional lymph nodes, en-bloc resection of involved adjacent organs or had a secondary additional procedure were identified. Operative parameters, pathologic findings, and perioperative outcomes were analyzed. Results: Among a total of 30 patients who met criteria, extra-regional lymph node dissection (LND) was performed in 11 (9 lateral pelvic, 2 aorto-caval) en-bloc resections in 12 (3 partial vaginectomy, 2 prostatectomy, 3 small bowel, 2 coccygectomy, 1 bladder). 7 patients required additional procedures for associated pathology (6 oophorectomy, 1 uterine myomectomy). Median tumor location was 4 cm (interquartile range [IQR] 2-7) from the anal verge. Median BMI was 25.83 kg/m2 (IQR: 23.6- 28.9). Twenty-four (80.6%) received neoadjuvant chemoradiation. There were no conversions. Median blood loss was 175 mL (IQR: 100-325). Resection was R0 in all cases (radial margin median 11 mm, IQR: 4-18) with no patients having an incomplete mesorectal resection. Median number of examined lymph nodes was 21 (IQR 19-28). Eight of 11 patients who underwent extra-regional LND, had confirmed residual lymph node metastases. Median hospital stay was 4 (IQR: 3-5) days. Postoperative morbidity developed in 10 patients (33.3%), 4 pelvic abscess, 3 ileus, 1 bowel obstruction, 1 acsites, 1 bleed requiring reoperation. Conclusions: MIS for locally advanced anorectal cancer can be safely performed using the surgical robot to include extended lymph node dissection or en-bloc multivisceral resection. It is technically feasible with acceptable morbidity and short term oncologic outcomes. Further study of long term outcomes are ongoing.

P127

Nodal Involvement and Impact of Adequate Staging in Older Patients with Resectable Colon Cancer: A Population-based Analysis H. Khan,^{1*} A. Olszewski,² P. Somasundar.¹ I. Surgery, Roger Williams Medical Center, Providence, RI; 2. Memorial Hospital of Providence, Pawtucket, RI.

Background: The variation in nodal involvement between age groups has not been thoroughly studied in colon cancer, but it may affect strategies for extent of resection in geriatric patients (pts). The objective of our study was to compare nodal involvement in resectable colon cancer pts, with a focus on surgical staging practices in the elderly. Methods: We extracted data from the Surveillance, Epidemiology and End Results registry on 183,055 pts diagnosed with stage I-III colon adenocarcinoma between 2000 and 2010. Proportions of pts undergoing colon resection, pts with adequate staging with ≥12 lymph nodes examined (LNE, n=99,308) and with node-positive (N+) cancers were compared in age groups using chi-squared test. Relative risk (RR) of N+ cancer was compared in a multivariable log-linear model, and relative survival in a flexible parametric model, reporting excess hazard ratios (HR) with 95% confidence intervals (CI). Results: While the rates of colon resection were similar in all age groups, older pts were significantly less likely to have ≥12 LNE (P<0.0001, Table). When adequately staged, older pts had a significantly lower proportion of N+ cancers (P<0.0001), even after adjusting for multiple other variables. Survival was better in pts with ≥12 LNE, with no significant difference in the benefit between the age groups (P=0.25 for interaction). Conclusions: When adequately staged, older pts are less likely to have N+ colon cancer, which may help them avoid the recommendation for adjuvant chemotherapy. Since the survival benefit of ≥12 LNE is similar in every age group, the guidelines for extent of resection and pathological examination should be diligently adhered to in all pts undergoing curative surgery, regardless of age.

Age Group	N	Colon resection (%)	≥12 LNE after colon resection(%)	Node positive cancer (≥12 LNE) (%)	Relative risk of N+ cancer (≥12 LNE), 95% CI	Excess mortality for pts with ≥12LNE, HR (95% CI)
20-49 y	13,071	94%	70%	47%	1	0.71 (0.64-0.79)
50-64 y	45,481	92%	62%	41%	0.95 (0.92-0.97)	0.71 (0.67-0.75)
65-74 y	48,034	93%	57%	37%	0.85 (0.83-0.88)	0.69 (0.65-0.73)
75-84 y	53,705	93%	56%	35%	0.80 (0.78-0.82)	0.65 (0.61-0.68)
≥85 y	22,764	91%	55%	34%	0.74 (0.71-0.76)	0.62 (0.58-0.67)

P128

Intralymphatic (IL) Infusion of Type 1 Polarized Dendritic Cells (aDC1) for the Treatment of Colorectal Cancer (CRC) M. Radomski,* H.J. Zeh, A.H. Zureikat, J. Pingpank, J. Heather, E. Wieckowski, L. Butterfield, P. Kalinski, D.L. Bartlett. University of Pittsburgh, Pittsburgh, PA.

INTRODUCTION: The overall efficacy of dendritic cell-based vaccines has been disappointing. We hypothesize this is secondary to the delivery route of the cell-based vaccine and inadequate polarization of DC's. Here, we describe a pilot study evaluating the feasibility of a semi-continuous IL infusion of a type 1 polarized DC (aDC1). Secondary endpoints consisted of overall survival (OS), as well as circulating immune reactivity to tumor antigens. METH-ODS:Patients were divided into three treatment arms and injected with aDC1's (prepared with IL-1 β , TNF- α , IFN α , poly-I:C and IFN γ) loaded with autologous tumor (UV irradiated) and heterologous helper antigens (KLH protein or PADRE peptide) at a dose of $2x10^6$ cells per course (4 courses). Routes of delivery were varied in each treatment arm. Arm A received 4 daily injections per course via intradermal delivery, arm B received a single intranodal injection per course, and arm C received a semi-continuous IL infusion via an implanted subcutaneous port over 4 days. Blood samples were collected pre and post-treatment and analyzed for immune reactivity against survivin and CEA. RESULTS: Nine patients with stage IV CRC underwent R0 resection. Six patients received IL ports. Average port patency was 1.36(±0.48) months. Only 4 patients (44%) successfully received 2 concurrent courses of IL vaccine. No patients received more than 2 concurrent courses of IL vaccine without having the port replaced due to catheter thrombosis. Of the 9 patients, 2 are still alive (66mo and 43mo after initial treatment date). Overall survival of the cohort was 25(±19) months. One patient with recurrent carcinomatosis is still alive without evidence of disease at 66mo. We detected an increase in antisurvivin responses (IFNy ELISPOT) following vaccination, especially in patients demonstrating prolonged OS, while no increase in anti-CEA responses were detected. CONCLUSIONS: Our study shows that prolonged IL delivery via an implantable port is not a feasible route for delivery of DC's due to loss of port patency. In 4 patients studied to date, immunological assays show a correlation between level of anti-survivin response and OS



Morbidity and Mortality following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Diabetes R.W. Randle, ¹* K.R. Swett, ² J.H. Stewart, ¹ P. Shen, ¹ E.A. Levine, ¹ K.I. Votanopoulos, ¹ *I. General Surgery, Wake Forest Uniyearsity School of Medicing, Winter Schem, NC: 2. Piostatistics, Wake*

versity School of Medicine, Winston-Salem, NC; 2. Biostatistics, Wake Forest University School of Medicine, Winston-Salem, NC. BACKGROUND: Patients with diabetes suffering from peritoneal sur-

face disease (PSD) represent a challenging group to treat due to the effects of both processes on multiple organ systems. The impact of diabetes on outcomes following cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) remains undefined. METHODS: A retrospective analysis of a prospective database of 1065 CRS-HIPEC procedures was conducted. Patient demographics, comorbidities, type of primary, hospitalization, morbidity, mortality, and distribution of complications were reviewed. RESULTS: CRS-HIPEC was performed in 91 diabetic and 844 non-diabetic patients from 1991 to 2013 for PSD originating from 452 (48%) appendiceal and 220 (24%) colorectal primaries. Patients with diabetes were older (p=0.005) and more likely to have lung disease (p<0.001), heart disease (p=0.009), higher BMI (p<0.001), and worse performance status (p=0.011) than non-diabetic patients. Diabetics and nondiabetics spent 6.8 and 3.1 (p=0.009) days in the ICU and 18.1 and 13.9 (p=0.074) days in the hospital, respectively. Thirty-day major morbidity was 48.9% and 43.2% (p=0.522) while 90-day major morbidity was 51.1% and 45.8% (p=0.526) in diabetics and non-diabetics, respectively. Despite similar major morbidity rates, diabetics had more infectious (p<0.001) and thrombotic complications (p=0.046), arrhythmias (p=0.007), renal insufficiency (p=0.002) and respiratory failure (p=0.002) than non-diabetics. Mortality was significantly worse for diabetic patients at 30-days (8.8% vs. 2.7%, p=0.007) and at 90-days (13.2% vs. 5.2%, p=0.008) and was predominantly attributed to older age (p=0.002), infectious complications (p=0.003), and enteric leak (p=0.007). CONCLUSION: Diabetes predicts a specific complication pattern associated with increased ICU stay and worse mortality in patients undergoing CRS-HIPEC. Diabetic patients deemed to be appropriate candidates for CRS-HIPEC, should be treated with caution.

P130

Trends and Predictors of Resection of the Primary Tumor for Patients with Stage IV Colorectal Cancer: Operating Despite Guidelines M. Shapiro,¹* N.U. Rashid,² E.E. Whang,¹ V.A. Boosalis,⁴ Q. Huang,⁵ C.H. Yoon,³ M.S. Saund,⁶ J.S. Gold.¹ *I. VA Boston Healthcare Surgical Service, Boston, MA; 2. Dana-Farber Cancer Institute, Boston, MA; 3. Brigham and Women's Hospital Department of Surgery, Boston, MA; 4. VA Boston Healthcare Medicine Service, Boston, MA; 5. VA Boston Healthcare Pathology Service, Boston, MA; 6. Harvard Vanguard Medical Associates, Boston, MA.*

Introduction: Approximately 20% of colorectal cancer patients have unresectable distant metastatic disease at diagnosis. Only a small percentage of these patients develop symptoms necessitating surgical intervention. Current guidelines recommend that patients with unresectable metastases receive chemotherapy without resection of the primary tumor. Our goal was to examine the trends and predictors of surgical resection in this group using a population-based database. Methods: Cases of colorectal cancer diagnosed with synchronous metastatic disease between 1988 and 2010 were identified using the SEER registry. Cases prior to 1988 were excluded as information regarding surgery was incompletely coded. Associations between surgical resection and available clinicopathological variables were sought using univariate and multivariate logistic regression. Results: 80,716 patients with Stage IV colorectal cancer diagnosed between 1988 and 2010 were identified. Of these, 68% underwent resection of the primary tumor. There was a trend toward the decreased use of surgical resection over time (Figure, p<0.001), however, in the most recent time period (2008-2010, n=13,120) 53% of patients with stage IV tumors who did not undergo resection of metastatic disease still had resection of the primary tumor. Variables associated with an increased rate of resection in this period were younger age (p<0.001), female gender (p=0.002), married status (p<0.001), private insurance status (p<0.001), earlier year of diagnosis (p<0.001), geographical region (highest in Southeast, p<0.001), right sided cancers (p<0.001), smaller tumor size (p<0.001), higher grade (p<0.001), and normal CEA (p<0.001). Race and urban location were not associated with the rate of surgery. Gender (p=0.015), marital status (p=0.001), insurance status (p=0.018), region (p<0.001), tumor site (p<0.001), grade (p=0.025), and CEA (p<0.001) were independent predictors in the multivariate analysis. Conclusions: Despite recommendations, surgical resection of the primary site is still common practice for patients with synchronous Stage IV colorectal cancer.



P131

Increased Incidence of Early Onset Colorectal Cancer in Arizona R.M. DiGiovanni,* E. Ohlson, V. Nfonsam. *Department of Surgical Oncology, The University of Arizona, Tucson, AZ.*

Introduction: Colorectal cancer (CRC) is the second leading cause of cancer related deaths in the United States. In the last three decades overall incidence of colorectal cancer in the United States has been declining. However, recent studies using the SEER database have shown an increasing incidence in younger age demographics. These studies were done using the SEER Cancer Database which Arizona does not participate in. The aim of this study is to investigate and analyze the incidence of CRC in Arizona, using the Arizona Cancer Registry. Methods: We performed a retrospective analysis of patients with colorectal cancer reported in the Arizona Cancer Registry from 1995-2010. Data obtained included age at diagnosis, gender, race, location of tumor, grade of tumor and stage of disease. The data was organized into 5-year increments from 0 to 4 years old to 85+ years old for incidence of colon, rectal, and overall CRC. Statistical analysis was performed using SPSS. Results 39.623 cases of colorectal cancer were reported to the Arizona Cancer Registry from 1995-2010. There were 53.1% males and the average age at diagnosis was 69.5 years. There was a 3.1% decrease in the average age of diagnosis, 70.8 years to 68.1 years. Of the 39,623 cases 92% were >50 years. Overall, there was a 30% decrease in the incidence of CRC. However, there was a 22% increase incidence in patients aged 10-50. There was a 15% and 41% increase in the incidence of colon and rectal cancer respectively during that time frame. The most significant increase in overall CRC was seen in patients age 10-29, with a 102% increase. A 225% increase incidence of rectal cancer was seen in patients aged 30-34. For colon cancer, a 110% increase incidence was seen in patients 10-29. Conclusion: Overall, there is a decreasing incidence of colorectal cancer in Arizona. However there is increasing incidence of early onset CRC mirroring the national trend. We also saw a shift in mean age of diagnosis from 70.8 to 68.1. Rigorous screening and early detection have led to the overall decrease in the incidence of CRC. Increase in early onset CRC is likely multifactorial and further studies are necessary to better understand this trend.





Perforated Colon Cancer Increases the Risk of Metastases in Early Stage I and II Colon Cancer C.J. Wai,¹* T. Li,² E.R. Sigurdson,² J.M. Farma.² 1. Surgical Oncology, Hartford HealthCare Medical Group, Hartford, CT; 2. Fox Chase Cancer Center, Philadelphia, PA.

Introduction: Early stage colon cancer patients have a 5-year overall survival (OS) of up to 90% with poorer survival for those with later stage disease. There is a subset of early stage patients who will develop metastases. The aim of our study was to evaluate factors predictive of developing metastases in patients with early stage colon cancer. Methods: An IRB approved study was performed on stage I and II colon cancer patients operated on from 2005-2011 at our tertiary referral center. We compared age, gender, race, stage, location and surgical pathologic characteristics in patients that developed metastases to those that did not. Results: There were 94 patients identified with 43 males and 51 females (Table 1). The median age at diagnosis was 64.9 years (range 22-89). There were 34 stage I and 60 stage II patients. Seven developed metastases. All were stage II patients. Mean time to developing metastases was 17.4 months (range 5-58). Stage II patients were more likely than stage I patients to develop metastases (p = 0.038). Patients with T4 disease were more likely to develop metastases than T3 (p = 0.03) and T1/T2 (p = 0.0005). Patients with perforated cancer were more likely to develop metastases (p=0.027). The median number of lymph nodes excised in those with metastases was 17 and 12 in those who did not develop metastases (p=0.04). Metastases were located in the liver (2), abdominal wall (1), peritoneum (1), pelvic organs (2) and lymph nodes (1). Three-year OS was 91%. For those without metastases, the 3 year OS was 93% compared to an OS of 62% in those who developed metastases (p=0.001). Pathologic grade, histology, lymphovascular invasion and chemotherapy were not factors associated with developing metastases. On multivariate analysis, patients with perforated cancer were still more likely to develop metastases (p = 0.05). Conclusions: Patients with early stage I and II colon cancer have a high survival rate. However, a subset is more likely to develop metastases, such as those with perforated and thicker tumors. These patients should be treated aggressively with closer surveillance as they portend a subset of patients with a higher risk of recurrence.

Table 1. Early stage colon cancer patient characteristics.

Characteristics	N
Median Age at Diagnosis	64.9 years
Gender Male	43 (45.7%)
Female	51 (54.3%)
Race Caucasian	82 (87.2%)
African American	9 (9.6%)
Other	3 (3.2%)
Location of Primary Tumor	
Right	37 (39.4%)
Transverse	10 (10.6%)
Left	6 (6.4%)
Sigmoid	41 (43.6%)
Pathologic Stage	
I	34 (36.2%)
П	60 (63.8%)
T Stage	
T1	18 (19.1%)
T2	16 (17%)
Т3	51 (54.3%)
T4	9 (9.6%)
Median Lymph Nodes Collected	
Patients with Metastases	17
Patients without Metastases	12
Site of Recurrence	
Lymph Node	1 (14.3%)
Liver	2 (28.6%)
Abdominal Wall	1 (14.3%)
Carcinomatosis	1 (14.3%)
Pelvic	2 (28.6%)

P133

Appendiceal Carcinoid Tumors in Children: A Population-based Outcomes Study Involving 766 Patients from the Surveillance, Epidemiology, and End Results (SEER) Database (1973-2010) K. Mahendraraj,* R.S. Chamberlain. *St. Barnabas Medical Center, Liv*ingston, NJ.

Introduction: Carcinoid tumors of the appendix (CT) is a rare disease in children, although it is the most common pediatric gastrointestinal neoplasm. Typically diagnosed incidentally following appendectomy for appendicitis, few studies compare clinical outcomes between pediatric (PP) and adult carcinoid patients (AP). This study examines a large cohort of adult and pediatric CT patients to identify differences in presentation and factors which affect clinical outcomes and may guide therapeutic decision making. Methods: Data on 766 patients with CT was abstracted from the Surveillance Epidemiology and End Result (SEER) database (1973-2010). PP was defined as age <20 and AP as ≥20. Standard statistical analyses were performed. Results: PP comprised 10.6% (n=81), and AP 89.4% (n=685) of the study cohort. Mean age was 15.3 in the PP and 45.6 among AP. CT in both PP and AP was significantly more common in Caucasians (81.6% and 85.2%, p<0.05), and females (76.5% and 66%, p<0.05). PP had more locoregional disease (92.6% vs 85.8) and less lymph node involvement (9.9% vs 18.2%) than AP. Surgery was the primary treatment for both groups, however PP were treated with less aggressive surgical therapy for similar disease stage and presentation (29.8% received appendectomies and ileocecectomies vs 14.5% of AP). Conversely, 7.4% of PP had hemicolectomy vs. 17.8% of AP. PP had significantly better mean overall survival (36.7 years vs 27.3 years, p<0.05) and lower overall mortality (2.5% vs 23.9%; p<0.001). PP also had better 5- and 10-year survival (100% and 98%) than AP (84% and 78%); p<0.05. Conclusions: CT is a rare tumor in children which occurs most commonly in Caucasians and females. Surgery is the primary treatment modality in both AP and PP. AP present with more advanced disease and undergo more aggressive surgery. Compared to adults, CT in the pediatric population has better long term survival and excellent prognosis with surgical treatment.

Table 1.Demographics	and Clinical Profile	of 766 Adult and Pediatric Pat	ients with Malignant
Appendiceal Carcinoid Tun	nors from the Surveil	lance Epidemiology and End	Result (SEER) Database
Variables	Overall	Pediatric population	Adult population
N (%)	766	81 (10.6)	685 (89.4)
Age, (Mean ± SD)	42.4±18.3	15.3±2.9	45.6±16.6
Mean Survival (years)	28.3±0.6	36.7±0.7*	27.3±0.7*
Gender			
Males	252 (32.9)	19 (23.5)	233 (34.0)
Females	514 (67.1)	62 (76.5)	452 (66.0)
Female: Male ratio	2.03:1	3.3:1*	1.94:1
Race N(%)	9		
Caucasian	625 (81.6)	69 (85.2)	556 (81.2)
Hispanic	58 (7.6)	6 (7.4)	52 (7.6)
African American	57 (7.4)	2 (2.5)	55 (8.0)
Other	17 (2.2)	3 (3.7)	14 (2.0)
Unknown	9(1.2)	1 (1,2)	8 (1.2)
Stage N(%)			
Localized	442 (57.7)	54 (66.7)	388 (56.6)
Regional	221 (28.9)	21 (25.9)	200 (29.2)
Distant	72 (9,4)	0	72 (10.5)
Unstaged	31 (4.0)	6(7.4)	25 (3.6)
Tumor Size N(%)	()	1	20 (010)
Under 2 cm	263 (34.3)	27 (33.3)	236 (34.5)
2 cm and over	107 (14.0)	4 (4,9)	103 (15.0)
Unknown	396 (51.7)	50 (61.7)	346 (50.5)
Lymph Node Involvement N	(%)		
Yes	133 (17.4)	8 (9,9)	125 (18.2)
No	315 (41.1)	27 (33 3)	288 (42.0)
Unknown	318 (41.5)	46 (56.8)	272 (39.7)
Treatment N (%)	510(11.5)	10 (50.0)	212 (07.17)
Neither	20 (2.6)	4 (4,9)	16 (2.3)
Surgery Only	738 (96.3)	77 (95.1)*	661 (96.5)
Radiation Only	0	0	0
Both	2 (0.3)	0	2 (0.3)
Unknown	6 (0.8)	0	6 (0.9)
Type of Surgery N(%)			
No surgery	13 (1.7)	4 (4.9)	9 (1.3)
Appendectomy	73 (9.5)	8 (9.9)	65 (9.5)
lleocecetomy	145 (18.9)	16 (19.8)*	34 (5.0)
Hemicolectomy	128 (16.7)	6 (7.4)	122 (17.8)*
Total colectomy or more	13 (1.7)	7 (8.6)	12 (1.7)
Colectomy, NOS	36 (4.7)	2 (2.5)	34 (5.0)
Data Unavailable	358 (46.7)	44 (54.3)	314 (45.8)
Overall Survival N(%)			
Alive	600 (78.3)	79 (97.5)*	521 (76.1)
Dead	166 (21.7)	2 (2.5)	164 (23.9)
Cancer-Specific Survival N	%)		
Alive	600 (78.3)	79 (97.5)*	521 (76.1)
Cancer Death	49 (6.4)	2 (2.5)	47 (6.9)
Cumulative Survival (%)			
1-year		100	93
5-year		100	84
10-year		98*	78*
Abbraviations: N = number: SI	= etandard deviation	Diff = Differentiated #rennes	ante statistically significant

difference between pediatric and adult patients for given variable, defined as p<0.05

P134

Disparities in Stage of Presentation and Treatment of Colorectal Cancer among Hispanic and Non-Hispanic White Patients R.A. Rodriguez,* M. Gonzales, B. Fahy, A. Kinney, A. Rajput. Univer-

sity of New Mexico, Albuquerque, NM.

Background: Although incidence rates for colorectal cancer (CRC) for Hispanics are similar to non-Hispanic whites (NHW) in New Mexico, the cause-specific mortality is higher among the Hispanic population. Hispanics have also been shown to be less likely to be current with colorectal cancer screening guidelines as compared to NHW. The purpose of this study was to determine if there was a difference between Hispanics and NHW in Stage at presentation and if the care provided was concordant with NCCN guidelines at our NCI Designated Cancer Center. Methods: A prospective data base of all patients who presented with colorectal cancer between June 2009 and July 2013 was queried. A total of 197 patients were identified. Data was extracted that included: demographics, stage of CRC at first diagnosis, treatments given, and pathology results. Frequencies of stage at presentation and NCCN guideline concordance (meeting the 12 lymph node metric, receipt of adjuvant therapy for Stage III disease and radiation therapy for locally advanced rectal cancer) were recorded. Results: Table 1 shows the results. There were 107 (55 %) males. There was not a statistical difference in the stage of presentation for Hispanics and NHW for patients with colon cancer. Hispanic patients with rectal cancer, however, presented with more advanced stage of disease as compared to NHW (p<0.05). There was no statistically significant difference in concordance with NCCN guidelines for the 3 metrics analyzed. Conclusions: Hispanics and NHW with colon cancer presented with similar stage of disease and were concordant with NCCN guideline metrics. Hispanics with rectal cancer, however, presented at a more advanced stage of disease as compare to NHW patients.

The reason for this disparity remains to be elucidated. Future studies to include outreach, education, screening and molecular profiling of these disparate populations are planned.

Distribution by Ethnicity, Stage at Presentation and Treatment.

	Colon (Stage)			1	Rectal (Stage)			12 LN		Adj Chemo	XRT Rectal	
	I	II	III	IV	I	II	III	IV	Colon	Rectal	Stage III	Cancer
Hispanic	21.8%	27.3%	23.6%	27.3%	6.4%	19.4%	61.3%	12.9%	91%	85%	85%	86%
NHW	17.4%	26.1%	26.1%	30.4%	34.5%	13.8%	41.4%	10.3%	91%	91%	85%	72%
Other	18.8%	25%	31.2%	25%	25%	25%	43.8%	6.2%	93%	67%	89%	69%

P135

Predictors of Postoperative Complications in Seniors Undergoing Colon Cancer Surgery H. Alabbas, ¹* S. Krotneva, ³ A. Ramjaun, ³ T. Eguale, ² A. Meguerditchian. ¹ *1. Department of Surgery, McGill Univerity, Montreal, QC, Canada; 2. Brigham and Women's Hospital and*

Harvard Medical School, Boston, MA; 3. Clinical and Health Informatics Research Group, McGill University, Montreal, QC, Canada.

Introduction: The postoperative complication rate in seniors undergoing colon cancer surgery is nearly double that of the general population. While colon cancer incidence is high in seniors, there is a lack of an effective, accurate and time sensitive risk-profiling tools in seniors who may experience severe postoperative complications (SPCs). The aim of this study was to identify predictors of SPCs in seniors undergoing colon cancer surgery. Methods: A historical prospective cohort of colon cancer patients aged ≥ 65 years was assembled from administrative claims and hospitalization data provided by Quebec's universal healthcare insurance provider between 2000 to 2006. The incidence and grades of SPCs were assessed using Clavien's classification (grades III-V). A multivariate Cox model was employed to evaluate patient and various patient-related predictors of SPCs and to account for clustering of patients within surgeons. Results: 3789 patients (median age of 76) were included with 54.3% being female. Emergency admissions were encountered in 24.2%. SPCs were experienced by 29% of the cohort (median time to first complication of 6 days), with 17.3%, 12.6%, and 5% experiencing grade III, IV, and V complications, respectively. The incidence of emergency room visits and hospital readmissions were 17.8% and 11.3%, respectively. The multivariate analysis indicated that the following factors were associated with SPCs included: male (HR=1.28, 1.13-1.45), age ≥ 85 years (HR=1.25, 1.03-1.52), ≥ 10 different medications prescribed within 6 months preceding surgery (HR=1.24, 1.03-1.49) receipt of care for either renal insufficiency or cardiovascular disease (HR=1.43, 1.02-1.99) and emergency admissions (HR=1.39, 1.22-1.59). Conclusion: Recently prescribed medications, receipt of care for renal insufficiency or cardiovascular disease and emergency admissions, which can be identified through administrative databases, were associated with SPCs. These can potentially be tracked through administrative claims electronically to provide a risk assessment prior to the surgical intervention.

Factors associated with any post-operative complication (III-V) within 30 days of surgery in colon cancer patients (N=3789).

Factors	No. of patients	% with complication			tivaria HR 9	α α 05%0	ox model T P		
No. of unique drugs									
<5	367	26.6	1.00	Refe	rence	1.00	F	Refer	ence
5-9	412	27.5	1.030	0.89 1.18	0.712	0.99	0.85	1.15	0.892
≥10	320	35.0	1.391	.19 1.61	< 0.0001	1.24	1.03	1.49	0.026
Geriatric Comorbidities									
Urinary Incontinence	16	29.1	0.990	0.60 1.62	0.962	1.01	0.62	1.66	0.966
Anemia	560	30.1	1.080	0.96 1.22	0.138	0.99	0.88	1.12	0.909
Arthritis	257	27.8	0.940	0.82 1.08	0.387	0.90	0.78	1.04	0.141
Depression	190	31.6	1.120	0.95 1.30	0.171	1.09	0.92	1.28	0.328
Osteoporosis	134	25.5	0.850	0.71 1.02	0.851	0.93	0.76	1.13	0.443
Cardiovascular disease	446	35.1	1.441	.27 1.62	< 0.0001	1.25	1.10	1.43	0.001
Dementia	39	31.2	1.150	0.84 1.59	0.379	1.02	0.74	1.42	0.893
Diabetes	247	33.0	1.211	.05 1.39	0.009	1.08	0.93	1.25	0.342
Renal Insufficiency	38	46.3	1.781	.29 2.46	0.001	1.43	1.02	1.99	0.036
Respiratory Illnesses	109	33.7	1.221	.00 1.48	0.051	0.94	0.75	1.16	0.549
Health Service Utilization									
Fall-related ER visits	55	34.4	1.270	0.97 1.66	0.089	1.24	0.94	1.64	0.129
Hospital admissions									
0	689	27.7	1.00	Refe	rence	1.00	F	Refer	ence
1	280	30.7	1.130	0.98 1.30	0.085	1.06	0.91	1.22	0.473
≥2	130	33.4	1.271	.05 1.53	0.014	1.10	0.90	1.36	0.357
Type of admission									
Elective	769	26.8	1.00	Refe	rence	1.00	F	Refer	ence
Emergency	330	36.0	1.441	.27 1.64	< 0.0001	1.39	1.22	1.59	< 0.0001

CI, confidence interval; HR, hazard ratio; P, p-value; ER, Emergency R o o m :

 α Adjusted for clustering of patients within physicians (N=390), year of surgery, rural residence and mean income in residence. The median cluster size was 6 patients, range: 1-53.

P136

Biochemical Cure following Reoperations for Medullary Thyroid Carcinoma: A Meta-analysis K.J. Rowland,* L.X. Jin, J.F. Moley. Surgery, Washington University in St Louis School of Medicine, St Louis, MO.

INTRODUCTION: Despite meticulous surgical techniques, calcitonin levels remain detectable in 40% to 66% of patients following initial surgery for medullary thyroid carcinoma (MTC) and the optimal surgical management for persistent or recurrent disease remains controversial. Reoperative approaches range from targeted removal of detectable disease to comprehensive compartment-oriented lymph node clearance. Previous studies have suggested that biochemical cure, defined by normalization of postoperative calcitonin measurements, can be used to predict disease free survival. To date, the surgical approach to reoperations for MTC varies widely and the reported rate of biochemical cure ranges from 0% to up to 45%. METHODS: A review of clinical case series with a proportional meta-analysis of postoperative calcitonin clearance following reoperation for MTC was performed. Studies were obtained from the following sources: PubMed, EMBASE, SCOPUS, and Cochrane Library. RESULTS: 27 articles capturing 984 patients met inclusion criteria and were included in the final metaanalysis. Overall, normalization of calcitonin following reoperation for MTC was achieved in 16.2% of patients (95% CI 14.0% to 18.5%). When stratified by operative procedure (see figure), targeted selective lymph node removal procedures had a normalization of calcitonin in 10.5% of patients (95% CI 6.4% to 14.7%), while compartment-oriented procedures had a higher rate of normalization of calcitonin at 18.6% of patients (95% CI 15.9% to 21.3%). Regardless of operative procedure, the percentage of patients with a 50% or greater decrease in calcitonin following reoperation for MTC was 65.7% (95% CI 55.1% to 76.3%). CONCLUSIONS: Our results indicate that while calcitonin reduction of 50% or greater is achievable through either compartment-oriented or selective reoperation approaches, the rate of calcitonin normalization and biochemical cure following reoperation for MTC is enhanced through use of a meticulous compartment-oriented lymph node dissection. Compartment-oriented node dissection should be the procedure of choice in reoperative MTC patients in whom the goal is disease free survival.

Figure: Proportional meta-analysis of calcitonin normalization following reoperative surgery for medullary thyroid carcinoma, stratified by non-compartment oriented or compartment-oriented procedure.



P137

Referral Patterns and Results of Genetic Testing for Adrenal and Extra-adrenal Pheochromocytoma D. Press,* S. Aliyev, R. Rahbari, R. Chagpar, J. Moline, H.E. Taskin, E. Aksoy, O. Birsen, A. Hamrahian, J. Mitchell, A. Siperstein, C. Eng, E. Berber. *Cleveland Clinic, Cleveland, OH.*

Introduction: An increasing number and higher rates of genetic mutations associated with pheochromocytoma and paraganglioma (PGL) have been identified, making genetic testing integral for optimal treatment. The aim of this study is to analyze patterns of referral and results of genetic testing in pheochromocytoma and PGL in a single institution. Methods: One hundred fifty six patients with pheochromocytoma or PGL who underwent surgery at a single institution by various subspecialties over 8 years were retrospectively reviewed. Clinical presentation, patterns of referral to genetic counseling, and results of genetic testing were analyzed. Results: At presentation, 12 (10%) of pheochromocytoma and 1 (3%) of PGL patients had known familial disease. Of pheochromocytoma patients, 41 (33%) met criteria for genetic testing (age <45, bilateral, multifocal, suspicious family history) and 26 of these (63%) were referred to genetics. Half (13 patients) were seen by genetics and a mutation was identified in 3 (23%). Of pheochromocytoma patients (n=85) not filling these criteria, 32 (38%) were referred to genetics at the time of diagnosis (17/32) or via a follow-up letter (15/32). Eleven patients (34%) were compliant with their appointment and none of these patients tested positive for mutations. Half of patients with PGL (n=15) were referred to genetics, and 11 (73%) attended the appointment. Two of these patients (18%) tested positive for an SDHB mutation, while the results are pending in another patient. Eighty-two percent of pheochromocytoma patients managed by endocrine surgery (46/56) were recommended genetic counseling compared to 14% of those treated by other specialties (10/70) (p<0.001). Among PGL patients, 73% of those treated by endocrine surgery (8/11) were referred to genetics versus 37% of those treated by other specialties (7/19) (p=0.05). Conclusions: A significant number of patients with pheochromocytoma and PGL do not undergo genetic testing due to patient incompliance and inconsistent physician referral across different subspecialties. Benefits of routine genetic testing are unproven within the limitations of the study.

P138

Increased Thyroid Malignancy Rates Associated with AUS/FLUS Utilization: A Single Surgical Center Experience B. Wang,* A. Madiedo, P. Mascaro, A. Marcadis, J.I. Lew. University of Miami Leonard M. Miller School of Medicine, Miami, FL.

Introduction: The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) includes atypia or follicular lesion of undetermined significance (AUS/FLUS) as an additional indeterminate classification to improve diagnostic accuracy of thyroid fine needle aspiration (FNA). This study evaluates

the impact of the BSRTC before and after its implementation at a single surgical referral center. Methods: A retrospective review of prospectively collected data of 1115 consecutive patients with index thyroid nodules who underwent FNA and thyroidectomy was performed. Records of these patients during pre-BSRTC (n=837) and post-BRSTC (n=278) periods were compared. FNA cytology distribution was compared before and after BSRTC. Analysis of FNA diagnosis, malignancy within each category, AUS/FLUS utilization rates after BSRTC was performed using Student-T, Z and Pearson's Chi-Square tests. A P-value <0.05 was considered significant. Results: In this surgical series, distribution of pre-BSRTC cytology included: insufficient, n=21(3%); benign, n=279(33%); indeterminate, n=291(35%); suspicious for malignancy, n=87(10%); malignant, n=159(19%), and for post-BRSTC cytology: insufficient, n=8(3%); benign, n=76(27%); AUS/FLUS, n=80(29%); follicular/Hürthle neoplasm, n=15(5%); suspicious for malignancy, n=35(13%); malignant, n=64(23%). Overall, there was a significantly higher malignancy rate in the post-BSRTC compared to pre-BSRTC period (55% vs. 41%, p=0.001), respectively. AUS/FLUS was identified in 29% of post-BRSTC surgical patients with a high malignancy rate of 46%. There was a significant increase of malignancy rate in post-BSRTC III and IV (46% and 54%, respectively) categories compared to the pre-BSRTC indeterminate (27%) category (p<0.05 for both). Only 19% of patients with AUS/FLUS cytology underwent repeat FNA in 6 months, whereas the remaining 81% chose to directly undergo surgical resection. Conclusion: At this institution, pre-to post-BRSTC period correlation reveals a significant overall increase of malignancy among thyroidectomy patients. More frequent AUS/FLUS utilization was associated with higher than expected malignancy rates after BSRTC adoption.

P139

Can Surgeon Volume Mitigate Complications following Total Thyroidectomy? A. Hauch,¹* Z. Al-Qurayshi,¹ D. Slakey,¹ G. Randolph,² E. Kandil.¹ 1. Surgery, Tulane University School of Medicine, New Orleans, LA; 2. Harvard School of Medicine, Boston, MA

Background: The extent of thyroid removal in cases of benign conditions or indeterminate nodules is still a matter of much debate. However, there has been an increase in the use of total thyroidectomy for management of benign thyroid diseases over the last fifteen years in US. We sought to compare the rates of complications between total/bilateral vs. unilateral thyroidectomy and whether surgeon experience had an effect. Methods: Cross-sectional analysis was performed using ICD-9 procedure codes included in the Nationwide Inpatient Sample (NIS) from 2003-2009 to identify all adult patients who underwent total/bilateral and unilateral thyroidectomy for benign or malignant conditions. Adjusted logistic regression models were used to control for confounders and to test for interaction between surgeon volume and risk of complications. Results: 62,722 procedures were included in this analysis. The majority of cases consisted of total/bilateral thyroidectomy in 57.9%, which was performed typically for benign disease. Overall there was a significant difference between the risks of complication following total/bilateral compared to unilateral thyroidectomy (20.4% vs. 10.8%: p<0.0001). High volume surgeons (performing >100 thyroid operations/year) performed only 4.96% of the procedures and 62.56% of them were total thyroidectomies. Low volume surgeons (performing <10 thyroid operations/year) were more likely to have postoperative complications following total/bilateral thyroidectomy compared to high volume surgeons (OR: 1.53, 95% CI: 1.12, 2.11), however, there was no difference when comparing unilateral thyroidectomy among the different surgeon strata. Mean charges were significantly higher for total thyroidectomy (\$21,198 vs. \$16,410: p<0.001). Conclusion: Higher surgeon volume is associated with improved patient outcomes following total thyroidectomy. However, higher risk of complication associated with total/bilateral thyroidectomy compared to unilateral thyroidectomy is evident even among high volume surgeons. Thyroid surgeons should be mindful of the inherent risk of a total thyroidectomy.

Complication Risk by Surgeon Volume

Surgeon Volume	Unilateral Complication Rate (%)	Total/Bilateral Complication Rate (%)	OR: (95% CI)	p-value
Overall	10.8	20.4	2.14: (1.98, 2.32)	< 0.0001
Low	11.8	24.1	2.34: (2.12, 2.58)	< 0.0001
Intermediate	9.9	18.8	1.92: (1.70, 2.16)	< 0.0001
High	7.6	14.5	1.90: (1.65, 2.19)	< 0.0001

P140

ESS Improves Preoperative Diagnosis of Indeterminate Thyroid Nodules J.E. Rosen, N.J. Giordano,* H. Suh, E. Rodriguez-Diaz, O.M. A'Amar, I.J. Bigio, S.L. Lee. Boston University, Boston, MA.

Introduction: Thyroid nodules are common. The current gold standard, fine-needle aspiration biopsy (FNAB), yields 10-25% indeterminate results necessitating surgery for diagnosis. Elastic scattering spectroscopy (ESS) is a minimally invasive optical-biopsy technique, mediated by a fiberoptic probe. We hypothesized that by combining ESS with FNAB, we could improve the treatment of indeterminate thyroid nodules. Methods: We built a miniaturized ESS-integrated biopsy syringe that can fit through a 23-gauge biopsy needle and assessed the potential of ESS to pre-operatively differentiate benign from malignant thyroid nodules. An IRB approved protocol was conducted on patients undergoing ultrasound-guided FNAB of thyroid nodules. Cells and ESS data were collected from within the thyroid nodule. Post-surgical pathology was our gold standard for indeterminate cytology. Results: 140 patients were enrolled in the study, and 135 patients had usable data. All patients tolerated the procedure well; additional time to perform ESS measurements required less than 20 seconds. The average enrolled patient was an African American female in her early 50's. Cytology resulted in 5 patients with malignant, 94 with benign, 32 with indeterminate and 4 with insufficient nodules. 35 patients underwent surgery, and 8 had histopathology-confirmed malignancy. Of the patients that underwent surgery, 17 had indeterminate thyroid nodules and only 3 of those patients had malignant pathology. Visual inspection revealed that an ESS waveform signature could discriminate benign from malignant disease. Analysis of spectra through an automated algorithm confirmed this finding. Preliminary results show a NPV of 0.99, a sensitivity of 0.92 and a specificity of 0.85. Conclusion: ESS can reduce the number of indeterminate nodules that require surgical treatment. With the collection of further data, an algorithm using cytology and ESS data could potentially be used as an in-situ real time minimally invasive adjunct to conventional FNA cytology to improve diagnosis and prevent unnecessary surgery.

Demograp	ohics (n = 135)
Characteristic	Result
Gender	Female = 117, Male = 18
Age	Avg = 53 (Range = 22 - 84)
Race	White = 49 Black = 52 Asian = 8 Hispanic = 22 Other = 4
Cytology	Malignant = 5 Benign = 94 Indeterminate = 32 Insufficient = 4
Histopathology	Malignant = 8 Benign = 27 No Surgery Yet = 100

P141

Preoperative Modified 4D-CT Reduces Unnecessary Opposite Side Exploration in Patients with Primary Hyperparathyroidism S. Singla,* P. Thirunavukarasu, M. Kukar, T. Platz, S. Kumar,

W.G. Cance. Roswell Park Cancer Center, Buffalo, NY.

Background: 4DCT with volume rendering is a sensitive imaging modality for disease localization in primary hyperparathyroidism. Our aim was to determine whether the use of 4DCT reduces unnecessary opposite side exploration. Methods: We performed a retrospective review of 196 consecutive patients with primary hyperparathyroidism between 2010 and 2013. All patients

underwent 4DCT with volume rendering. Comparison was made to US and Sestamibi for preoperative localization, intra-operative correlation and pathology. Results: US, Sestamibi and 4DCT results were available in 176 (89.8%), 181 (92.3%) and 196 (100%) patients, respectively, and 163 patients had all three tests available. The US, Sestamibi and 4DCT were non-diagnostic in 50%, 43.1% and 6.1%, respectively. Among patients who had any diagnostic test, we calculated a usefulness rate based on its use in guiding non-unnecessary exploration, and a failure rate based on wrong side or unnecessary exploration, by correlating the results of investigations with final pathology results. The usefulness rate of US, Sestamibi and 4DCT were 48.3%, 53.5% and 92.3%, respectively for the entire cohort, and 46.6%, 54.6% and 93.1%, in patients who had all the three tests. The failure rates of US, Sestamibi and 4DCT were 3.4%, 5.8% and 2.7%, respectively for the entire cohort and 3.8%, 5.3% and 2.6%, for patients with all the three tests. In patients with all the three tests available, the 4DCT scan was non diagnostic in 1 patient (0.6%), while US and Sestamibi were concordant in only 55 (33.7%) patients. In patients undergoing parathyroid surgery in re-operative necks (n=18), 4DCT was non-diagnostic in only 1 patient. In 12 patients where 4DCT was non diagnostic, US and Sestamibi were concordant in only 1 patient, while in 5 patients who had unnecessary side exploration as guided by 4DCT, sestamibi and US were nondiagnostic in all. Conclusions: Modified 4DCT scan is superior to US and Sestamibi in diagnostic accuracy and reduces unnecessary opposite side exploration in primary hyperparathyroidism. The concordant use of US and Sestamibi for preoperative localization may be safely replaced by 4DCT alone.

P142

Histone Deacetylase Inhibitors Induce NF-kB Activity in Medullary Thyroid Cancer Y.R. Somnay,* X. Yu, S. Miyamoto, H. Chen. Surgery, University of Wisconsin, Madison, WI.

INTRODUCTION: Histone deacetylase inhibitors (HDACi) reduce medullary thyroid cancer (MTC) growth and invasion, but have failed to prolong long term survival (NCT01013597). Notably, Nuclear factor kappa B (NFkB) can be induced by genotoxic stress, driving tumorigenicity and extrinsic chemoresistance. Here, we examine the effect of HDACi treatment on NFkB activity and its modulation by targeted suppression of specific NFkB pathway intermediaries in MTC. METHODS: Two MTC cell lines (TT, MZ) were transfected w/ a luciferase-fused NFkB binding site or a mutant-kB (neg. control), and exposed to 1µM suberovlanilide hydroxamic acid (SAHA), 6mM valproic acid (VPA), or 4nM of the new HDACi Thailandepsin (TDPA) for up to 48hrs before luciferase reading. NFkB inhibitors were tested concomitantly w/ HDACis (5mM PrC-210, 10µM KU5593, 1-5µM Withaferin A (WA), or 5-20nM bortezomib). RESULTS: SAHA, VPA and TDPA dose dependently decreased TT and MZ cell growth and increased NFkB-dependent luciferase reporter activity over 48hrs. Activity peaked at 12hrs, w/ fold increases of 42±6, 33±3 and 23±2 w/ SAHA, VPA and TDPA treatments respectively in MZ cells, and 428±4, 215±4, and 361±6 w/ SAHA, VPA and TDPA treatments respectively in TT cells (p<0.01, compared with non-treated induction). Wild type fold changes were significant w/ respect to mutants (p<0.01), except for among untreated cells (MZ, p=1.0; TT, p=0.08) underscoring the specificity of NFkB activity targeting and detection. HDACi-induced NFkB luciferase activity in the face of WA, PRC210, K5933 and Bortezomib was dose dependently reduced in MZ cells. While SAHA and VPA activated NFkB the most, WA(5µM), Prc210, KU5933 and Bortezomib(5nM and 20nM) significantly reduced NFkB activity (p<0.05). Since PRC210, a ROS scavenger, and K5933, an ATM kinase blocker, deter NFkB activity specifically upstream genotoxic stimuli and not cytokine signals, HDACis may induce NFkB by oxidative stress. CONCLU-SION: HDACis activate NFkB in MTC in vitro. Inhibition of HDAC-induced NFkB activity can be attained by targeting cytokine-induced pathway intermediates or reducing genotoxic stress. Thus, NFkB inhibition may potentiate HDACi induced cytotoxicity in MTC.

P143

A Preoperative Diagnosis of Papillary Thyroid Cancer: Incidence and Implications C.D. Adkisson,* N.P. Ohori, M.J. Armstrong, K.L. McCoy, M.T. Stang, G.M. Howell, S.P. Hodak, S.O. LeBeau, Y.E. Nikiforov, S.E. Carty, L. Yip. *Endocrine Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA*.

Introduction: The aim of this study is to determine the incidence of patients with histologic PTC who were successfully identified preoperatively by current diagnostic modalities, and to evaluate if a preoperative PTC diagnosis has prognostic implications. Methods: We performed a retrospective single institution review of 1088 consecutive patients with histologic PTC from 2007-2012. Patients with incidentally identified microPTC (≤1 cm) were excluded. Successful preoperative PTC diagnosis was defined by a fine needle aspiration biopsy (FNAB) cytology classified as "Positive for PTC," or the presence of BRAF V600E mutation or RET/PTC rearrangement after prospective mutation testing (MT) of cytologically indeterminate FNAB specimens. Results: A preoperative PTC diagnosis occurred in 50% of patients, and was diagnosed by cytology in 32% and by positive MT in 18%. When PTC was known preoperatively, patients were more likely to have a smaller primary tumor (1.8 v. 2.0 cm, p=.03), extrathyroidal extension (ETE, 38% v. 10%, p<.001), central compartment lymph node metastasis (CLNM, 47% v. 20%, p<.001), and tall-cell variant PTC (15% v. 4%, p<.001). TNM stage III/IV disease was more common in patients diagnosed preoperatively with a trend towards significance (28% v. 21%, p=.05), yet no differences in distant metastasis or recurrence were observed. Patients with microPTC identified preoperatively were more likely to have ETE (21% v. 4%, p<.001) or CLNM (46% v. 5%, p<.001) compared to those who had a postoperative cancer diagnosis. ETE (34% v. 16%, p<.001) was more common in patients diagnosed by cytology compared to those diagnosed by MT, but patients in both groups were equally likely to have CLNM (p=0.5) and TNM stage III/IV disease (p=.6). Conclusion: A successful preoperative diagnosis of PTC occurred in only half of patients with histologic PTC. The use of routine preoperative adjunctive mutation testing successfully increased this likelihood by 40%. A preoperative diagnosis was associated with PTC with aggressive histopathologic features thus regardless of tumor size, at a minimum, total thyroidectomy should be considered in patients with a preoperative PTC diagnosis.

P144

Outcomes after Subtotal Parathyroidectomy for Primary Hyperparathyroidism due to Hyperplasia: Significance of Whole versus Partial Gland Remnant M. Rajaei, ^{1*} S.C. Oltmann,² D.F. Schneider,² R.S. Sippel,² H. Chen.² *1. Wisconsin Institute for Medical Research, Madison, WI; 2. University of Wisconsin, Department of Surgery, Madison, WI.*

Introduction: Primary hyperparathyroidism (PHPT) due to multi-gland hyperplasia has been traditionally managed by subtotal parathyroidectomy (PTX), with a partial gland left in situ, roughly the size of a normal gland. However, smaller, hyperplastic glands may be encountered at time of surgery, and it is unclear if leaving an entire, intact gland is an equivalent alternative. This study sought to evaluate the rates of permanent hypoparathyroidism and cure of PHPT with in patients with 4-gland hyperplasia that were left with either a whole or partial gland remnant after subtotal PTX. Methods: We reviewed the outcomes of PHPT patients with hyperplasia who underwent PTX at an academic institution. Surgeon intra-operative judgment determined remnant size (whole vs. partial gland), and patients were assigned one of these two categories. Results: Between 2002 and 2013, 189 patients underwent PTX for PHPT hyperplasia. 92 patients (49%) had a subtotal PTX with whole gland remnant while 97 (51%) had a partial gland remnant. Mean age was 58±1 years. 81.5% were female. Patients with a whole gland remnant had higher pre-operative serum phosphate (3.9±0.6 vs. 3.0±0.1, p=0.047) and PTH levels (87±5 vs. 100±7, p=0.047), and lower t- scores versus patients selected for partial gland remnant (-2.2±0.14 vs. -1.7±0.2, p=0.048). A family history for hyperparathyroidism (17.5% vs. 4.4%, p=0.004) was more prevalent in the partial gland remnant group. Both groups had similar pre-operative serum calcium, creatinine, alkaline phosphatase, and vitamin D levels. Only two patients were noted to develop permanent hypocalcemia. Overall cure rate was 98.4%. However, a mean long term follow up of 21 ± 1.5 months revealed a recurrence rate of 5.3%. Disease persistence and recurrence rates were similar in patients with whole versus partial gland remnant. Conclusion: PHPT due hyperplasia can potentially be managed with subtotal PTX, leaving an intact gland as remnant without increased rates of disease persistence or recurrence. Older patients and those with smaller diseased glands may be the best candidates for this approach.

Robotic Thyroidectomy for Cancer in the United States: Patterns of Use and Short-term Outcomes M. Abdelgadir Adam,¹* P.J. Speicher,¹ S. Reed,² S. Roman,¹ J.A. Sosa.³ *1. Department of Surgery, Duke University Medical Center, Durham NC, NC; 2. Duke Clinical Research Institute, Durham NC, NC; 3. Department of Surgery & Duke Clinical Research Institute, Durham, NC.*

Introduction There are few studies analyzing adequacy of resection or utilization of robotic thyroidectomy in the U.S. Our aims were to determine patterns of use and short-term outcomes from robotic vs. open thyroidectomy for thyroid cancer. Methods Patients with thyroid cancer who underwent thyroidectomy in the National Cancer Database (2010-11) were included. Patients who underwent robotic surgery were compared to those who had open thyroidectomy. Descriptive statistics were used to analyze patterns of use, patient characteristics, and outcomes. Logistic regression was employed for factors associated with use of robotic surgery. Results 68252 patients with thyroid cancer underwent thyroidectomy; 225 had robotic surgery, and 57629 had open surgery. Compared to the open group, the robotic group was younger (47 vs. 51 yrs, p=.0002), and had more Asian (8% vs. 4%, p=.006) and privately insured patients (77% vs. 68%, p=.01). Robotic thyroid surgery use increased by 30% from 2010 to 2011 (p=.07). Robotic cases were reported from 93 centers, with just 4 centers performing one third of cases. There was significant regional variation, with 25% of cases reported from the Mid-Atlantic region; just 3% were done in New England (p<.0001). In the robotic group, 39% had tumors <1cm, and 8% had tumors >4cm, but tumor size was similar to the open group (p=.9). Total thyroidectomy was performed in 61% of patients in the robotic group vs. 80% in the open group (p<.0001). The rate of conversion to open surgery was 4%. Patients were more likely to undergo robotic surgery if they were at an academic institution (OR 6.1) or <45 yrs (OR 2.2). After multivariate analysis, there were no differences in tumor margin status, number of lymph nodes removed, length of stay, or 30-day readmission rates between the two groups. Conclusion Use of robotic thyroid surgery for cancer is limited to a few high-volume institutions. While the overall number of cases remains small, robotic thyroid surgery appears to have short-term outcomes comparable to open thyroidectomy. Larger multi-institutional studies should be undertaken to determine thyroidectomy-specific complications and long-term outcomes.

P146

Patients Rely on Physicians to Inform Them about New Genetic Tests for Hereditary Cancer Syndromes M.A. Romero Arenas,* T.A. Rich, E.G. Grubbs, N.L. Busaidy, G. Cote, M.I. Hu, R.F. Gagel, P.W. Gidley, C. Jimenez, M.E. Kupferman, S.K. Peterson, D.L. Urbauer, S.G. Waguespack, A.K. Ying, N.D. Perrier. *The University of Anderson MD Anderson Cancer Center, Houston, TX.*

Introduction: New genetic tests may benefit former patients or their families; however no guidelines exist regarding physicians' duty to inform patients about new genetic tests, and research on this topic is limited. To evaluate feasibility of disseminating information and patient expectations, we surveyed patients' response to a notification about new genetic tests. Methods: We identified adult patients treated at a single institution from 1950 to 2010 for medullary thyroid cancer, pheochromocytoma, or paraganglioma. Patients were included if their history suggested high risk for a hereditary syndrome and never had a genetic test or had negative results on an outdated panel. We first sent an informational letter describing new genetic tests, benefits, and risks. Then we sent a questionnaire assessing attitudes toward the letter, the physicians' role in informing patients about new developments, and whether patients took action based on the letter. Descriptive statistics were calculated. Results: Ninety-seven of 312 eligible patients (31%) completed the questionnaire. Most respondents had a history of medullary thyroid cancer (n=71, 73%). After receiving the letter, 29% (n=28) discussed genetic testing with their doctor and 8% (n=8) pursued it. Of those who never had genetic testing (n=62), 71% indicated they would consider obtaining it. Nearly all respondents (97%) indicated that physicians should make an effort to inform patients about new developments that may improve their or their family's health. 71% also thought patients should contact their doctor regarding new developments. Most patients understood the letter (84%) and were glad it was sent (84%); 11% felt the letter was upsetting. Conclusions: Patients believe it is important for physicians to inform them of potentially beneficial medical developments, such as new genetic tests. Physician-initiated letters to introduce new information appear inadequate alone in motivating patients to seek services. Further research is needed regarding the physicians' and patients' roles and responsibilities in disseminating and obtaining information about new genetic tests, including clinical and ethical implications.

P147

Adrenocortical Carcinoma in Adults and Children: A Populationbased Outcomes Study Involving 1,623 Patients K. Mahendraraj,* K. Sidhu, R.S. Chamberlain. *St. Barnabas Medical Center, Livingston, NJ.*

Introduction: Adrenocortical carcinoma (ACC) is a rare endocrine tumor that is typically aggressive in adult patients (AP), yet follows an unpredictable course in pediatric patients (PP) that has been little studied. This study examines a large cohort of adult and pediatric ACC patients to identify disease factors which affect clinical outcomes and that can be used to risk stratify patients from treatment and clinical trial accrual. Methods: Data on 1,623 patients with ACC was abstracted from the Surveillance Epidemiology and End Result (SEER) database (1973-2010). PP was defined as age <20 and AP as ≥20. Subgroups of PP were created as '<5', '5-9' and '10-19'. Standard statistical analyses were performed. Results: PP comprised 6.2% (n=101) of ACC (n=1,623) while AP made up 93.8% (n=1,522). 2.8% were aged <5, 0.9% were 5-9, and 2.5% were 10-19. Mean age was 7.8 in PP and 55 in AP. Most ACC occurred in Caucasian females and presented with size >4 cm (p<0.001). PP<5 had less metastatic disease (7.1%; p<0.001) and lymph node (LN) involvement (2.9%) compared to other groups. Age 10-19 had the highest rates of metastasis and LN positivity. Mean overall survival (OS) was highest for PP<5 (25.7;p<0.001). The most common therapy for both PP and AP was surgery (77% and 66.4%). Surgical resection improved OS in both PP<10 and AP (30.6 and 13.6 years);p<0.001. PP<5 had lower overall mortality (13%) as well as better 2- and 5-year survival (90% and 90%) than all other groups; p<0.001. PP age 10-19 had the highest overall mortality (72.5%) and lowest 2and 5-year survival (21% and 21%). Multivariate analysis identified age >10 (OR 46.6), distant disease (OR 13.7) and undifferentiated grade (OR 6.0) as independently associated with increased mortality, p<0.05. Conclusions: ACC is a rare tumor commonly presenting in adult females and Caucasians with size >4 cm. PP age 10-19 and AP present with more advanced disease than PP<10. Surgical resection significantly improves OS in all groups, particularly PP<5. Older age and advanced disease are associated with increased mortality. PP<5 have the greatest OS and lowest mortality while PP age 10-19 have the worst outcomes.

	1		Padiate'-		Adult
	Overall	<5 years	5.9 years	10-19 years	>20 years
N (%)	1.623	46 (2.8)	15 (0.9)	40 (2.5)	1 522 (93.8)
Age. (Mean + SD)	52+18.7	15+13	72+17	15 3+2 6	55+15.2
Mean Survival (years)	84+04	25 7+2 0*	13 3+4 4	8 3+2 5	7.6+0.4
Gender	0.11011	a providence	TPIPETIA	010 - MIC	110.011
Male	710 (43.7)	15 (32.6)	6 (40.0)	13 (32.5)	676 (44.4)
Female	913 (56.3)	31 (67.4)	9 (60.0)	27 (67.5)	846 (55.6)
Race N (%)	1 515 (5615) 1	21 (0//11)	7 (0010)	ar (orie)	010 (0010)
Caucasian	1.257	28 (60.9)	11 (73.3)	31 (77.5)	1,187 (78.0)
African American	111 (6.8)	3 (6.5)	1 (6.7)	1 (2.5)	106 (7.0)
Hispanic	152 (9.4)	14 (30.4)*	2 (13.3)	7(17.5)	129 (8.5)
Other	98 (6.0)	1(2.2)	1(67)	1(2.5)	95 (6.2)
Unknown	5(0.3)	0 (0.0)	0(0.0)	0(0.0)	5 (0,3)
Stage N (%)	- (0.0)	0 (010)	0 (5/0)	0 (310)	- (0.0)
Localized	415 (40.8)	21 (75.0)*	3 (21.4)	8 (30.8)	383 (40.4)
Regional	192 (18.9)	3 (10,7)	4 (28.6)	2 (7.7)	183 (19.3)
Distant	341 (33.5)	2 (7.1)	6 (42.9)*	15 (57.7)*	318 (33.5)
Unstaged	69 (6.8)	2 (7.1)	1(7.1)	1 (3.8)	65 (6.8)
Tumor Size N (%)	1 07 (010) 1		1	. (0.0)	1 01 (0.07
Microscopic	1 (0.1)	0(0.0)	0 (0.0)	0(0.0)	1 (0.1)
< 2 cm	19(1.5)	1 (2.9)	0 (0.0)	1 (4.5)	17(1.5)
2-4 cm	51 (4.1)	3 (8.6)	0 (0.0)	0 (0.0)	48 (4.1)
>4 cm	1,168	31 (88.6)	10 (100.0)	21 (95.5)	1,106 (94.4)
Lymph Node Involvement ?	N (%)				1
Yes	134 (13.1)	1 (2.9)	1 (12.5)	5 (25.0)	127 (13.2)
No	892 (86.9)	34 (97.1)	7 (87.5)	15 (5.0)	836 (86.8)
Treatment N (%)	1				1
Neither	324 (20.0)	2 (4.3)	2 (13.3)	9 (22.5)	311 (20.4)
Surgery Only	1.089	43 (93.5)*	12 (80.0)	23 (57.5)	1.011 (66.4)
Radiation Only	54 (3.3)	0(0.0)	0 (0.0)	2 (5.0)	52 (3.4)
Both	111 (6.8)	0 (0.0)	1 (6.7)	5 (12.5)	105 (6.9)
Unknown	45 (2.8)	1 (2.2)	0 (0.0)	1 (2.5)	43 (2.8)
Survival by treatment (year	s± SD)				
No treatment	2.0±0.4	4.5	3.3	0.4±0.2	2.0±0.4
Surgery only	14.6±0.7	30.64	2.1*	5.7±1.8	13.6±0.8
Radiation only	1.0±0.3			0.7±0.2	1.1±0.3
Both surgery and radiation	7.9±1.6	7.84	0.0	15.5±7.9	6.9±1.4
Overall Mortality N (%)					
Alive	498 (30.7)	40 (87.0)*	5 (33.3)	11 (27.5)	442 (29.0)
Dead	1,125	6 (13.0)	10 (66.7)	29 (72.5)	1.080 (71.0)*
Cancer Specific Mortality N	N (%)				
Alive	498 (37.8)	40 (90.9)*	5 (35.7)	11 (27.5)	442 (36.3)
Cancer Death	819 (62.2)	4 (9.1)	9 (64.3)	29 (72.5)	777 (63.7)*
Cumulative Survival (%)					
1- year		93*	60	58	60*
2- year	1	90	53	21	48
S. wear		90*	45	21	33#

pediatric patients and adult patients for given variable, defined as p<0.05

Loss of SMAD4 Results in Clinically Meaningful Differences in Overall Survival in Resected Gastrointestinal Neuroendocrine Tumors C.L. Roland,* Y. Kang, D. Chatterjee, J. Estrella, A. Rashid, J.E. Lee, J.C. Yao, J.B. Fleming. *MD Anderson Cancer Center, Houston, TX.*

Background: Studies by comparative genomic hybridization have demonstrated that the 18q chromosomal region is frequently lost in gastrointestinal neuroendocrine tumors (GI-NET). However, the impact of DPC/SMAD4 loss, which is located 18q21, in the pathogenesis of GI-NET remains controversial. In this study, we sought to determine the protein expression of SMAD4 in GI-NET and the impact on oncologic outcomes. Methods: To investigate the role of SMAD4 in GI-NET, a tissue microarray consisting of 33 GI-NET was constructed and analyzed by immunohistochemistry for SMAD4 expression. SMAD4 expression was classified as negative, SMAD4-low (≤10% cells +) or SMAD4-high (>10% cells+). Staining results were correlated clinicopathologic features and overall survival. Results: Of the 33 tumors examined, 93% were low- or intermediate-grade and 7% high-grade. 35% of GI-NET were negative for SMAD4, 45% were SMAD4-low and 15% SMAD4-high. Expression of Chromogranin was observed in 91% of all tumors, synaptophysin in 94%, CDX2 in 64%, and CK19 in 55%. We were unable to identify any association between loss of SMAD4 and stage or tumor grade. There was an inverse correlation between loss of SMAD4 and CK19 expression, whereby 75% of SMAD4-neg tumors expressed CK19 and only 32% of SMAD4+ expressed CK19 (p=0.01). At a median follow-up of 123 months, median overall survival was 203 months. Survival differences related to SMAD4 status resulted in clinically meaningful, although statistically non-significant, differences in overall survival (SMAD4-low: 132 months vs. SMAD4-high: 203 months, p=0.058; Fig 1). Conclusions: Differences in SMAD4 expression result in clinically important differences in overall survival, although this cohort may be underpowered to detect a statistically-significant difference. Future studies with larger patient populations may be critical to evaluate the importance of SMAD4 in the pathogenesis of GI-NET.



P149

The Effect of Thyroiditis on the Yield of Central Compartment Lymph Nodes in Patients with Papillary Thyroid Cancer V. Lai,* T.W. Yen, S. Misustin, D. Evans, T.S. Wang. *Medical College of Wisconsin, Milwaukee, WI.*

Background: In patients undergoing thyroidectomy and central compartment neck dissection (CND) for papillary thyroid cancer (PTC), visualization of enlarged central compartment lymph nodes (LN) may lead to more extensive CND. We sought to determine the effect of patient age and the presence of thyroiditis on the number of malignant and total LN resected in patients undergoing CND for PTC. Methods: This is a retrospective review of a prospective database of patients with a preoperative diagnosis or suspicion of PTC who had a total thyroidectomy and CND between 4/09-6/13 who were noted to have thyroiditis on final pathology. Patients were categorized by age (18-29, 30-39, 40-49, 50-59, and >60 years) and compared to a control group of patients matched by age, gender, and tumor size. Results: In the cohort of 79 patients with thyroiditis, 66 (84%) were female and median age was 57 (range, 18-72) years. Overall, patients with thyroiditis had a higher median number of LN removed than those without thyroiditis (11 vs. 7; p=0.001); the median number of malignant LN was similar (0 vs. 1; p=0.095), resulting in a lower ratio of malignant:total LN (0 vs. 0.2; p=0.005). By age group, thyroiditis patients aged 18-29 and 40-49 years had statistically more LN removed; the ratio of malignant:total LN was lower in thyroiditis patients ages 18-29 and >60 (Table). For patients with or without thyroiditis, there was no difference between the age groups in the median number of LN removed (total or malignant) or in rates of recurrent laryngeal nerve injury or long-term hypoparathyroidism. Conclusions: Patients with thyroiditis and PTC who undergo CND have a greater number of LN removed but a lower proportion of metastatic LN, compared to those who do not have thyroiditis. The higher number of LN removed in the thyroiditis group may be attributed to a locoregional inflammatory process created by the thyroiditis. Although we have shown no difference in long-term complication rates, surgeons performing CND in patients with PTC and suspected thyroiditis should be aware that enlarged lymph nodes more likely represent an inflammatory, and not malignant, process.

Age (years)		Total lymph nodes removed (median, range)	Malignant lymph nodes removed (median, range)	Ratio of malignant:total lymph nodes
18-29	Thyroiditis (n=9)	17 (5-31)	1 (0-15)	0.05
(n-16)	No Thyroiditis (n=7)	7 (4-7)*	6 (0-7)	0.86**
30-39	Thyroiditis (n=21)	15 (4-48)	2 (0-15)	0.11
(n=40)	No Thyroiditis (n=19)	11 (2-18)	3 (0-17)	0.18
40-49	Thyroiditis (n=15)	10 (6-22)	1 (0-5)	0.05
(n=29)	No Thyroiditis (n=14)	7.5 (1-17)***	1 (0-5)	0.20
50-59	Thyroiditis (n=20)	11.5 (0-25)	0 (0-10)	0
(n=39)	No Thyroiditis (n=19)	7 (1-26)	0 (0-21)	0
>60	Thyroiditis (n=14)	10 (1-50)	0 (0-25)	0
(n=27)	No Thyroiditis (n=13)	6 (1-23)	2 (0-8)	0.22****

P150

Discordance of Histological Grade between Primary and Metastatic Neuroendocrine Carcinoma T. Adesoye,* M.A. Daleo, S.M. Weber, E. Winslow, A.G. Loeffler, C. Cho. *Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI.*

Introduction. The prognosis and management of neuroendocrine carcinoma is largely driven by histological grade as assessed by mitotic activity or Ki67 expression. We reviewed our institutional experience to determine if the histological grade of neuroendocrine carcinoma changes between primary and metastatic tumors. Methods. We reviewed our institutional database to identify patients with metastatic neuroendocrine carcinoma. Specimens were independently reviewed and primary and metastatic tumors were categorized as low, intermediate, or high grade as determined by mitotic count or Ki-67 immunohistochemical staining. Results. We identified 18 patients with metastatic neuroendocrine carcinoma treated at our institution between 1997 and 2013 for whom complete pathological review of primary and metastatic tumors was possible. Primary lesions were found in the small intestine (n=9), pancreas (n=6), ampulla (n=1), stomach (n=1) and rectum (n=1). Metastatic lesions were hepatic (n=17) or peritoneal (n=1). Timing of metastasis was synchronous in 13 cases and metachronous in 5 cases. Histological grade was concordant between primary and metastatic tumors in 7 cases, and discordant in 11 cases. Among the discordant cases, 7 had a higher metastatic grade than primary grade, and 4 had a lower metastatic grade than primary grade. Metachronous presentation was associated with a higher likelihood of grade discordance (p=0.036); in this series, the histological grade of all metachronous metastases differed from that of primary tumors. Conclusions. There is a high prevalence of histological grade discordance between primary and metastatic foci of neuroendocrine carcinoma, particularly among patients with metachronous metastatic presentation. Given the importance of histological grade in disease prognostication and treatment planning, this finding may be informative in the management of patients with metastatic neuroendocrine carcinoma.

Surgeon and Staff Radiation Exposure During Radioguided Parathyroidectomy at a High Volume Institution S.C. Oltmann,*

A. Brekke, J.D. Macatangay, D.F. Schneider, H. Chen, R.S. Sippel. Surgery, University of Wisconsin, Madison, WI.

Introduction Radioguided parathyroidectomy (RGP) requires patient injection with technetium-99m (Tc-99m) sestamibi the day of procedure. Emitted gamma rays are detected during surgery to aid dissection, and confirm resected tissue is parathyroid tissue. Source (the patient) proximity and exposure duration are key determinants of exposure levels. The aim of this study is to quantify surgeon and staff radiation exposure during RGP. Methods Faculty surgeons and first assistants wore chest radiation safety badges to measure surface and deep dose exposure during RGP procedures at a high volume endocrine surgery practice. Area monitors were also used to measure personnel potential exposure. Patients were given 9-11 mCi of Tc-99m intravenously 1 to 2 hours prior surgery. Data was prospectively collected. To correct for duration of exposure and case volume, ratios were calculated per provider based on exposure in mrem. Institutional safety requirements has 100 mrem/yr as indicator for radiation training and monitoring, and 375 mrem/month (4500/yr) as maximum allowed exposure. Results 120 RGP were performed over 6 months. Badges were worn in 82 cases (68%), and involved 3 faculty and 4 trainee assistants. Primary hyperparathyroidism was the diagnosis for 95%. 10.7±0.2 mCi was given 115±16 minutes prior surgery. Directed RGP was performed in 64%, 36% required bilateral exploration. Median case volume per provider was 13 cases (6 to 45), with median exposure of 18hrs (9 to 70). Provider deep dose exposure (DDE) was 22±10 mrem, and surface dose exposure (SDE) was 23±10 mrem. Corrected for exposure duration, DDE was 0.6±0.2 mrem/hr and SDE 0.7±0.2 mrem/hr Corrected for case volume DDE was 0.8+0.2 mrem/case and SDE 0.9±0.2 mrem/case. Anesthesia exposure was minimal, while mayo stand exposure ranged from one to two thirds that of the operating surgeon and assistants. Based on institutional guidelines and above data, performing 63 to 143 RPG/yr warrants training and monitoring. >2800 RGP/yr would reach maximum allowable radiation exposure. Conclusion Surgeon and staff radiation exposure during RGP is minimal. High volume centers may warrant monitoring.

P152

Incidental Cancer in Surgically Treated Benign Goiter D. Farquhar,* H. Wachtel, I. Cerullo, E. Bartlett, G.C. Karakousis, R.R. Kelz, D.L. Fraker. *Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.*

Introduction: Rates of incidentally found cancer in benign goiter range from 10-35%. We analyzed our population of goiter patients undergoing surgery to determine the incidence of undetected thyroid cancer and to identify risk factors predictive of malignancy. Methods: A retrospective chart review was performed of consecutive patients undergoing thyroidectomy or lobectomy for goiter (2006-2012). Patients with preoperative fine needle aspiration (FNA) with pathology Bethesda level III-VI (FLUS, follicular neoplasm, suspicious, or positive for malignancy) were excluded. Thyroid cancer includes all histologic subtypes. Micropapillary carcinomas are reported separately (papillary tumors <1 cm). Clinical and histopathologic variables were collected pre- and intra-operatively. Univariate analysis was performed using the ranksum test. Student's t-test or Fisher's exact test as appropriate, and a multivariate logistic regression model was developed. Results: Of 362 patients undergoing surgery for goiter, 290 patients met inclusion criteria. Incidence of thyroid cancer was 12% (n=35). Distribution of cancers by pathology was 80% (n=28) papillary carcinoma, 20% (n=7) follicular carcinoma, and 6% (n=2) thyroid lymphoma (two patients had multiple cancers). Among cases of papillary cancer, the most common subtype was follicular variant (n=26, 93%). An additional 20% (n=58) had micropapillary tumors. Thyroid cancer patients were younger (mean 49.7 vs. 55.1 years, p=0.014) and more likely to be male (31 vs. 17%, p=0.038) than non-cancer patients. In all patients under the age of 45, the incidence of cancer was 22% (n=67); in males it was 33% (n=6). Patients with nodules identified by a healthcare provider (17 vs. 7%, p=0.042), or incidentally (11 vs. 1%, p=0.002) were more likely to have thyroid cancer. On multivariate analysis, younger age (OR=.96; p=0.009) and male gender (OR=2.9, p=0.011) remained significant. Conclusion: The incidence of thyroid cancer in male patients under the age of 45 undergoing thyroid surgery for goiter was quite high (33%). This association should influence the decision to refer for surgical intervention and the discussion regarding potential surgical findings.

Table I: Characteristics of patients with goiter presenting for thyroid surgery with or

	Total goiter population (290)	Goiter only (255)	Goiter with thyroid cancer (35)	P-value
Age, years (n=289)				
Mean (SD)	54.4 (13.3)	55.1 (13.1)	49.7 (14.2)	0.014
Gender				0.038
Female	236 (81%)	212 (83%)	24 (69%)	
Male	54 (19%)	43 (17%)	11 (31%)	
Ethnicity (n=287)				0.833
Caucasian	181 (63%)	159 (63%)	22 (65%)	
Non-Caucasian	106 (37%)	94 (37%)	13 (35%)	
Onset of condition, years (n=278)				
Mean (SD)	5.97 (10.2)	5.66 (9.3)	8.11 (14.8)	0.182
Median (IQR)	2 (6)	2 (6)	1 (15)	0.353
Symptoms (n=286)				
Pressure	209 (73%)	185 (74%)	24 (69%)	0.521
Dysphagia	96 (34%)	82 (33%)	14 (40%)	0.390
Hoarseness	14 (5%)	10 (4%)	4 (12%)	0.077
Weight gain	2 (1%)	2 (1%)	0 (0%)	1.000
Hair loss	1 (0.5%)	0 (0%)	1 (0.5%)	0.122
Cold intolerance	2 (1%)	2 (1%)	(0%)	1.000
Weight loss	35 (12%)	29 (12%)	6 (17%)	0.345
Anxiety	3 (1%)	2 (1%)	1 (1%)	0.325
Sweating	7 (2%)	6 (2%)	1 (3%)	1.000
Other	15 (5%)	13 (5%)	2 (6%)	1.000
No symptoms	48 (17%)	40 (16%)	8 (24%)	0.305
Unspecified	1 (0.5%)	1 (0.5%)	0 (0%)	1.000
Malaise/fatigue	26 (9)	23 (9%)	3 (9%)	1.000
Shortness of breath	35 (12%)	29 (11%)	6 (18%)	0.345
Nodule identified by (n=87)				
Patient	8 (3%)	5 (2%)	3 (9%)	0.059
Healthcare provider	24 (8%)	18 (7%)	6 (17%)	0.042
Family member	1 (0.5%)	1 (0.5%)	0 (0%)	1.000
Incidental	6 (2%)	2 (1%)	4 (11%)	0.002
No mention	48 (17%)	45 (18%)	3 (9%)	0.228
Risk factors (n=12)				
Radiation exposure	9 (3%)	8 (3%)	1 (3%)	1.000
Family history	3 (1%)	3 (1%)	0 (0%)	1.000
Prior surgery (n=290)				
Previous neck surgery	24 (8%)	23 (9%)	1 (3%)	0.207

P153

Spectrum of Gene Mutations in Primary Hürthle Cell Thyroid Carcinoma with and without Distant Metastases R. Petric, ¹ B. Krhin, ¹ V. Dolzan, ² N. Besic, ^{1*} 1. Institute of Oncology, Ljubljana, Slovenia; 2. Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Background and Objectives: Hürthle cell thyroid carcinoma (HCTC) is a rare type of thyroid cancer which represents 3 to 10 % of all thyroid cancers. Patients with Hürthle cell thyroid cancer have worse prognosis than patients with follicular thyroid carcinoma. The aim of our study was to test which mutations are present in primary tumor of patients with and without metastatic HCTC. In this manner, we would like to establish which biological drugs could be potentially used in the treatment of metastatic HCTC. Methods: Altogether six patients (4 females, 2 males; median age 68 y; range 47-48 y) were included in our study. Three patients had distant metastases (median age 76 y.), while three patients had no metastases (median age 47 y.). Genomic DNA was extracted from paraffin embedded samples of primary tumors. Commercially available cancer panel primers, ion library kit and ion sequencer were used in order to analyze a large number of target mutations. The library of PCR amplicons covering 739 different mutations in 46 target genes was constructed using multiplex PCR approach. The libraries were used for template preparation and sequenced on the sequencer. Results: All the primary tumors harbored mutations in APC, FGFR3, and PDGFRA genes. In primary tumors of patients with distant metastases we found mutations in the following genes: EGFR (all 3 of 3 samples), ATM (2 of 3), FGFR2 (2 of 3), RET (2 of 3), C-KIT (1 of 3), VEGF (1 of 3), MET (1 of 3), NRAS (1 of 3), PIK3CA (1 of 3), PTEN (1 of 3) and p53 (1 of 3). In primary tumors of patients without metastases we found mutations in the following genes: EGFR (2 of 3), ATM (1 of 3), FGFR2 (3 of 3), RET (2 of 3), C-KIT (1 of 3), VEGF (1 of 3), PIK3CA (1 of 3) and p53 (1 of 3). Conclusion: In our patients with distant metastases of HCTC the following genes need to be further investigated as potential targets for the treatment with targeted therapy: APC, FGFR3, PDGFRA, EGFR, ATM, FGFR2, RET, C-KIT, VEGF, MET, NRAS, PIK3CA, PTEN and p53 gene.

Is There a Survival Benefit with Total Thyroidectomy for Hurthle Cell Carcinoma? A 10-year Study S. Anantha Sathyanarayana,^{1*}

G. Deutsch,¹ M. Beg,¹ S. Dubner,² A. Kadison,¹ L. Sznyter,² C. Conte.¹ *1. Surgery, Hofstra- NSLIJ School of Medicine, Manhasset, NY; 2. Hofstra- NSLIJ School of Medicine, New Hyde Park, NY.*

Introduction: Hurthle cell carcinoma (HCC) is known to be an aggressive thyroid cancer seen in 3% of thyroid carcinomas. While the standard surgical treatment is still total thyroidectomy, many patients undergo thyroid lobectomy. Previous studies have reported unclear survival benefit with partial thyroidectomy for HCC. The objective of our study was to analyze long term survival in HCC patients undergoing partial or total thyroidectomy. Methods: A retrospective analysis from 2000-2010 from a tertiary care hospital tumor registry was performed. Patient demographics, tumor characteristics including tumor size, type of surgery - thyroid lobectomy (TL) versus total thyroidectomy (TT) and post operative radioiodine therapy (RI) were collected. Kaplan Meir survival curves were plotted for survival analysis among the groups. Multivariate Cox Proportional Hazards Regression was performed for risk factor analysis. Results: Our sample consists of 106 patients with 80% Caucasians, 67% females (n=71) and 33% males (n=35), ranging between 35-85 years of age (mean=60). 53.7% (n=57) patients underwent TL and 46.3% (n=49) underwent TT. 80 %(n=39) patients from TT group had RI compared to 53% from TL group. The tumors were larger in the TT group $(3.3 \text{ cm} \pm 1.9)$ vs.2.9 cm ± 1.9 ; p = 0.35).5-year and 10- year survival analysis showed 96 % vs. 84% (p<0.46) and 93% vs.81%(p <0.54) for TL vs. TT respectively(Figure 1) .No statistically significant long term survival benefit was observed among post TT patients receiving RI (85% for RI vs 80% for no RI at 5 years and 80% at 10 years irrespective of radioiodine therapy; p=0.71). Multivariate analysis demonstrated age at diagnosis >60 years with HR 12.0(1.3-112.2 p=0.03), tumor size >4 cm with HR 18.45(2.0-169.3 p= 0.01) and extrathyroidal extension with HR 2.8 (0.4-17.7; p=0.28) as risk factors for mortality. Conclusion: Thyroid lobectomy appears to be a comparable surgical option for patients with HCC. Radioactive iodine therapy after total thyroidectomy did not demonstrate any survival benefit. Patient age at diagnosis and tumor size was statistically significant risk factors for mortality.



Figure 1: 5-year and 10-year Kaplan Meir survival curves

P155

Long-term Survival of Papillary Carcinoma of Thyroid is not Dependent on Histological Subtype S. Anantha Sathyanarayana,^{1*} G. Deutsch,¹ M. Beg,¹ S. Dubner,² A. Kadison,¹ L. Sznyter,² C. Conte.¹ I. Surgery, Hofstra- NSLIJ School of Medicine, Manhasset, NY; 2. Hofstra- NSLIJ School of Medicine, New Hyde Park, NY.

Introduction: Papillary carcinoma of thyroid is differentiated into histological distinct subtypes with different prognostic significance. Given the paucity of evidence, we conducted this study to evaluate the long-term survival of various subtypes of papillary carcinoma. Methods: Retrospective analysis of 1963 patients from 2000-2010 from a tertiary care hospital tumor registry was performed. Patient demographics, tumor characteristics including tumor size, type of surgery, histological subtype and postoperative radioiodine therapy (RI) were collected. We subdivided our patient population into 3 groupspapillary carcinoma (PC), papillary carcinoma- follicular variant (PC-FV) and a third composed of other rare subtypes. Standard methods of survival analysis (Kaplan-Meier survival curves, log-rank test) were performed to compare the two groups. Multivariate Cox Proportional Hazards Regression was performed for risk factor analysis. Results: Out of total patients (PC= 1248, PC-FV= 637, others- 78), 77% were females, with an average age of 50 years (range 11-92). The tumor characteristics for all 3 groups are shown in Table 1. Total thyroidectomy was performed in 88% patients in the PC group and 64% patients in the PC-FV group. 55% patients from PC group and 47% patients from PC-FV group received postoperative radioiodine therapy. 5-year survival for PC, PC-FV and other groups was 96,1%, 97,1% and 94,8% respectively (p =0.32) with 10-year survival of 90.9%, 92% and 87.1% respectively (p = 0.58). On multivariate analysis, age >50 years (PC-HR 8.9; 95% CI 2.9-26.1 and PC-FV-2.7; 95% CI 0.7-11.4) and advanced stage (Stage 4 compared to Stage 1 PC- HR 8.3 95% CI 1.8-38.5 and PC-FV-HR 19.0 95% CI 1.3- 281.8) of the disease were significant risk factors predicting mortality. Conclusion: .Despite various histological subtypes of papillary carcinoma, the long-term survival appear to be the same amongst groups. Despite the discrepancy in tumor size, node positive disease and extent of surgical therapy, the long-term overall survival amongst both PC and PC-FV was similar.

Demographics	PC n=1248 (63.6%)	PC-FV n=637 (32.4%)	Others n= 78 (4.0%)	p value
Age at diagnosis (years ± SD)	48.1±14.9	51.1±14.9	50.6±15.9	<0.0001
Gender				
Female (%)	938 (75.2)	512 (80.4)	59 (75.6)	< 0.038
Male (%)	310 (24.8)	125 (19.6)	19 (24.4)	
T stage (%)				
X	12(1)	8(1)	0	< 0.0001
0	7(0.5)	1 (0.1)	0	
1	684 (56)	318 (52)	48 (69)	
2	212 (17)	171 (28)	8 (11)	
3	241 (19)	102(16)	13 (18)	
4	73 (6)	17 (3)	1(1)	
Lymph nodes metastasis(%)				
Yes	391 (31)	71 (11)	13 (17)	<0.0001
No	549 (44)	368 (58)	34 (44)	
Unknown	286 (23)	178 (28)	23 (29)	
AJCC Stage (%)				
1	652 (65)	307 (66)	34 (68)	< 0.0001
2	64 (7)	76 (16)	4 (8)	
3	215 (22)	61 (12)	9 (18)	
4	63 (6)	19 (4)	3 (6)	
Thyroid lobectomy	151 (12)	231 (36)		<0.0001
Total thyroidectomy	1097 (88)	406 (64)		<0.0001
Radioactive Iodine				
Yes	683 (55)	299 (47)		
No	530 (43)	327 (51)		<0.0008
Unknown	35 (3)	11(2)		

Figure 1: Patient demographics and tumor characteristics.

P156

Pediatric Thyroid Microcarcinoma J. Lerner,* M. Goldfarb. *Surgery, University of Southern California Keck School of Medicine, Los Angeles, CA.*

Background The incidence of thyroid microcarcinomas (TMCs) is increasing in the general population and its characteristics are well documented in older individuals. However, the incidence pattern and features of TMCs in the pediatric population has not been well described. Methods All pediatric patients \leq 19 years of age with differentiated thyroid carcinoma (DTC) were identified from the SEER registry from 1988-2009. Patients were divided into 2 groups based on tumor size: TMCs and tumors > 1cm. Demographic, tumor, and treatment characteristics as well as overall (OS) and disease specific survival (DSS) were compared between the 2 groups. Results Of 1831 pediatric DTC patients, 8.4% (n=154) had a TMC; the incidence decreased during the last decade (6.5% vs 14.5%, p < 0.001). Compared to patients with DTC > 1cm, multivariate

regression showed that TMCs occurred more commonly in Whites (OR: 2.16, CI: 1.02-4.56, p=0.044), exhibited no extrathyroidal extension (OR: 0.048, CI: 0.01-0.34, p=0.003), and patients underwent a partial thyroidectomy (OR: 0.45, CI: 0.26-0.75, p=0.002) with no radioiodine therapy (OR: 0.57, CI 0.36-0.90, p=0.016). There was no difference in OS (TMC: 253.58 months, DTC >1cm: 257.82m) or DSS (TMC: 256.38m, DTC >1cm: 260.60m) between the two groups. Of the 154 patients with TMCs, there were 2 deaths from disease and 2 from other causes. Predictors of death from any cause were a non-primary cancer (p=0.04) and distant metastases (p < 0.001) whereas risk factors for TMC-specific death were follicular/Hurthle-type histology (p=0.04) and distant metastases (p=0.014). Conclusions TMCs make up a small percentage of pediatric DTCs and unlike in older individuals, the incidence is decreasing. In this age group, TMCs rarely exhibit aggressive tumor features and patients tend to undergo less extensive treatment. Although small tumor size does not appear to influence OS or DSS, TMCs that present with distant metastases, non-papillary histology, or as a subsequent neoplasm warrant close follow-up due to possible increased risk of death.

P157

Healthcare Utilization in the Pre-diagnostic Period for Neuroendocrine Tumors J. Hallet, ¹* C. Law,² S. Singh.² 1. Division of General Surgery, University of Toronto, Toronto, ON, Canada; 2. Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, ON, Canada.

Background: Despite being a rare malignancy, incidence of Neuroendocrine Tumors (NET) has increased. NET diagnosis (NETD) is often delayed, but limited data is available regarding the NET peri-diagnostic period. We sought to define the pre-diagnostic healthcare utilization for NET. Methods: We conducted a retrospective cohort study using the Ontario Cancer Database and ICD 9 and 10 codes to identify NETs in Ontario from 1994 to 2009. Patient demographics, physician encounters, and radiology imaging at 2-year, 1-year and 60-day prior to NETD were abstracted. We used the Andersen Behavioral Model framework to structure the results. Results: We retrieved 4 926 NET cases. Predisposing and enabling factors included age (mean 59.9 ±14.9 years old), gender (49.7% males), income (41.7% 4th/5th quintiles), and Health Community. Evaluated needs were 69% chronic comorbidities, 33.5% psycho-social issues, 57.1% major symptoms, 20.3% metastases at diagnosis, and 63.9% requiring surgery 60 days before NETD. 60.3%, 52.3% and 35.3% patients diagnosed with NET visited the Emergency Room respectively within 2-year, 1-year and 60-day. 99.7%, 99.5% and 97.6% consulted a physician at the same time points, with General Practitioner (median 14 visits/patient within 2 years of NETD), General Surgery and Gastroenterology being the most common. At the same time points, 83.1%, 78%, and 65.4% underwent radiology imaging, most commonly CT scan, X-ray and ultrasound. Number of physician encounters and radiology imaging per patient differed based on Health Community (p<0.01 at all time points). Conclusion: This population-based study defined that NET patients have a high level of healthcare utilization in the pre-diagnostic period. High burden of symptoms, comorbidities, and psychosocial issues highlighted a strong need for coordinated healthcare. This situation translated into numerous physician encounters and multiple imaging studies before NETD. Defining Health Community characteristics, physicians' attitudes, health policies and individual perceived need for healthcare will complete the model, and help identify how to improve the efficiency of the NET diagnostic process.



Figure 1. Framework for Pre-diagnostic Healthcare Utilization in NET using population-based data (n=4 926).

P158

Serum Cytokine and Neutrophil: Lymphocyte Ratio Changes in Patients Receiving Hepatic Artery Genetically Modified T Cell Infusions for Metastatic Carcinoma A. Saied Calvino,* L. Licata, R.A. Burga, M. Thorn, E. McCormack, B.F. Stainken, E.O. Assanah, R.P. Junghans, N. Espat, S.C. Katz. Roger Williams Medical Center; Providence, RI.

Introduction: We recently completed the phase I Hepatic Immunotherapy for Metastases (HITM) trial testing the safety of genetically modified "designer" T cells (dTc) hepatic artery infusions (HAI) for patients with incurable CEA+ liver metastases (LM). IL6 and IL17 are markers of inflammation and neutrophil expansion. High neutrophil:lymphocyte ratios (N:L) predict poor outcome in several malignancies. In contrast, IFNy is associated with anti-tumor immunity. We hypothesized that N:L and IFNy would be associated with responses to dTc HAI. Methods: Eight patients with unresectable, progressing LM were enrolled and six completed the protocol. The first three patients received anti-CEA dTc as an intrapatient dose escalation. The last three patients received 3 dTc doses (1e10) with low dose IL2 infusions. DTc HAI were given every 2 weeks and serum cytokines measured by ELISA. Results: The mean N:L for all patients was 13.9 (range 4.8-38.1). Four patients demonstrated increased N:L after treatment with a mean N:L fold change of 1.9. The mean peak IL6 level was 133.8 pg/ml (range 24.0-288.0) while the mean peak IL17 value was 436.4 pg/ml (range 0-1346.0). The patient with the highest peak N:L (88.9) had peak IL6 and IL 17 levels of 120 pg/ml and 1204.6 pg/ml. Increased N:L and IL6 levels showed a trend toward a positive correlation (r=0.77, p=0.10) and patients with high N:L (>20) demonstrated elevated IL6 levels (202.8±48.5 vs 64.8±35.2, p=0.08). IL2 levels correlated with IFNy (r=0.89, p=0.03) but not N:L (r=0.54, p=0.29). Increasing N:L was weakly associated with rising CEA level (r=0.67, p=0.18) while elevated IFNy level significantly correlated with a decrease in CEA in response to HAI dTc (r=-0.94, p=0.02). Conclusions: N:L increased in most patients following dTc HAI in association with elevated IL6, which may reflect inflammation in response to treatment or disease progression. Elevated IFNy levels correlated with serum IL2 concentrations and a decrease in serum CEA, indicating that serum IFNy may be a surrogate of IL2 activity and response to dTc HAI. Sponsored by SSO Clinical Investigator Award



P159

Central Hepatectomy for Centrally Located Liver Malignancies: A Safe Alternative to Extended Hemihepatectomy M.D. Kluger,¹* S. Lee,² A. Laurent,² D. Azoulay,² D. Cherqui.² *1. Surgery, New York-Presbyterian Hospital-College of Physicians and Surgeons, New York, NY; 2. Service de Chirurgie Digestive et Hépatobiliaire, Hopital Henri Mondor, Creteil, France.*

Introduction: Centrally located liver tumors (segments 4, 5 & 8) may require extensive resections due to their close relationship to major vascular and hilar structures and their deep location. Traditionally, these centrally located tumors are resected by hemi- or extended- hemihepatectomies (EH) because of technical ease relative to central hepatectomy (CH). The objective was to

compare the perioperative and long-term outcomes among patients undergoing CH and EH for malignant tumors of the liver. Methods: A 2 EH:1 CH casecontrol cohort was generated with propensity score matching on tumor size, location and pathology from a prospective database. Clinicopathological data were analyzed using chi-square, t-test and Kaplan-Meir methodologies were appropriate. Results: 49 CH patients were matched to 98 EH patients. There were no significant differences in demographics or tumor characteristics among the 98 EH and 49 CH, and underlying liver disease was present in 28% and 42% (p<0.09), respectively. There were no significant differences in mean operative and clamping time between EH and CH: 246 vs. 254 minutes and 31 vs. 34 minutes, respectively. Mean blood loss was 741 mL (EH) and 527 mL (CH) (p<0.1), with a mean 1 unit transfusion in each group. Clavien grade 2-5 complications occurred in 46% of EH and 31% of CH (p=0.08). R0 margins were achieved in 68% of EH and 88% of CH (p<0.01). Overall and recurrencefree survival did not differ by hepatectomy type (log-rank 0.14 and 0.18 respectively) Conclusion: CH is technically safe and not time consuming in patients with centrally located tumors that may otherwise require EH. Parenchymal preservation is critical in the presence of liver disease to minimize the risk of liver failure, or when recurrence may incur repeat resections. CH has the advantage of preserving parenchyma without oncological compromise, or increased blood loss or bile leaks despite two-planes of parenchymal transection.

P160

Novel Evaluation for Hepatic Functional Reserve after Liver Resection for Liver Tumors in Combination with 99mGSA Scintigraphy and 3D-CT M. Taniguchi,* H. Furukawa. Division of Gastroenterologic and General Surgery, Asahikawa Medical University, Asahikawa, Japan.

Background and Aim It is important to develop accurate diagnostic tools that can predict the risk of poor hepatic functional reserve (PHFR) after liver resections. In this study, the role of preoperative technetium -99m -diethylenetriaminepentaacetic acid-galactosyl human serum albumin (99m-Tc-GSA) liver scintigraphy and CT volumetric measurement of the liver in the preoperative risk assessment for PHFR was evaluated. Patients and method Sixtyfour patients who were scheduled for liver resection more than sectionectomy because of liver tumors were enrolled in this study. Indocyanine green clearance, 99m-Tc-GSA studies, and remnant liver volume calculated by CT were performed preoperatively. 99m-Tc-GSA studies and conventional liver function tests were estimated on 14 and 28 days after liver resection. In 99m-Tc-GSA studies, the receptor index [ratio of liver to heart-plus-liver radioactivity at 15 minutes (LHL15), ratio of liver to heart radioactivity at 15 minutes (HH15)] and functional liver volume were calculated. The correlations among preoperative tests, postoperative liver function, and PHFR were evaluated. Result Significant correlations were observed between postoperative 99m-Tc-GSA studies and conventional liver function tests. Preoperative functional liver volume times remnant liver volume (FLV×RLV) showed better correlation with postoperative 99m-Tc-GSA studies, conventional liver function tests, and PHFR than preoperative LHL15, HH15, FLV, or RLV alone. According to multivariate analysis, FLV×RLV was the only significant independent predictor of PHFR. No patients with FLV×RLV above 200 manifested PHFR. Using a FLV×RLV of 160, it was possible to predict postoperative PHFR at a sensitivity of 92%, specificity of 83%. Conclusion Preoperative measurement of 99m-Tc-GSA and the remnant liver volume on CT proved valuable in assessing the risk of liver failure after liver resection.

P161

Local Treatment of Breast Cancer Liver Metastases E. Sadot,* L. Ser Yee, E. Petre, C. Sofocleous, C. Hudis, M. Gönen, T. Kingham, P. Allen, S. Solomon, Y. Fong, R. DeMatteo, W. Jarnagin, M. D'Angel-

ica. Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Background Approximately 5% of patients with breast cancer develop liver metastases as the only sign of disseminated disease. Well selected patients are candidates for local treatment of their breast cancer liver metastases (BCLM) with surgery or ablation. The aim of this study was to analyze prognostic factors associated with survival in patients undergoing liver resection or ablation for BCLM. Methods A review of metastatic breast cancer patients undergoing liver resection and/or ablation for BCLM at a single institution from 1993 to 2013 was performed. Survival was calculated from the time of either liver resection or ablation. Analysis of factors associated with outcome was per-

formed with standard Kaplan-Meier and Cox-Regression methods. Results Seventy patients underwent local treatment for their BCLM; 52 patients had liver resections of which 4 had concomitant ablations and 18 patients had ablations as the sole treatment. The average age was 53±12.3 years at the time of BCLM treatment. The primary breast tumor was stage I in 28% of patients and the median recurrence-free interval (RFI) from breast surgery to diagnosis of BCLM was 4.86 years (range: 0.2-20.5). Most BCLM were solitary (62%), unilobar (70%), and smaller than 5cm (74%). Median follow-up was 36.2 months (range: 2-129). Overall 5-year survival was 37%, median overall survival was 49.6 months (range: 2-129), and median recurrence-free survival was 18.4 months (range: 1-118). Multivariate analysis identified 2 independent prognostic factors associated with improved overall survival: absence of adjuvant chemotherapy after breast surgery and RFI of more than 2 years. There were no significant prognostic factors associated with recurrence-free survival after liver-directed treatment of BCLM. (Table 1) Conclusions Liver-directed therapies (resection, ablation) are appropriate and may lead to prolonged survival in carefully selected patients. Absence of chemotherapy treatment after resection of the primary, likely a surrogate for early stage disease, and RFI of more than 2 years were the only independent predictors of outcome.

Prognostic factors for Overall Survival and Recurrence-free interval in patients with Breast cancer liver metastases

Variable	Category	No. of patients	Median survival	p	Multivariate analysis (p-value; OR; Confidence interval)	Recurrence free interval (after liver directed treatment of BCLM)	P
Demographics		Total N+70			1.000		
Age (years)	<50 vs. >50	27 vs. 43	41.354.5 vs. 59.1±13.8	0.75		21.918.1 vs. 28.618.2	0.
Breast Cancer				_			-
Primary tamor, T	T1/2 vs. T3/4	59 15.6	57.8±10.5 vs. 41.4±7.4	0.25		28.515.2 vs. 14.314.9	0.3
Primary namor, N	N0 v N1	29 vs. 40	49.6±10.9 vs. 41.4±10.5	0.15		17.815.5 vs. 31.113.5	0.6
AJCC stage (7th edition)	1 vs. 2, 3, 4	19.15.48	110.710 15. 49.6110.1	0.053		25.4±7.7 vs. 28.5±6.4	0.2
ER status	negative vs. Positive	12 vs. 42	57.8±17.9 vs. 57.9±13.1	0.77		19.3±7.5 vs. 31.1±3.2	0.5
PR status.	negative vs. Positive	22 vs. 32	57.8±10.3 vs. 58.5±16.9	0.27		28.519.7 vs. 30.217.6	0.9
HER2 status	negative vs. Positive	23 vs. 19	41.7±1.3 vs. 59.1±12.4	0.84		21.9:8.2 vs. 27.5:17.2	1.2
Adjuvant chemotherapy after breast surgery	Without vs. with	14 15. 56	87.2±20.1 vs. 43.0±5.0	0.07	0.02; 3.7; 1.2 - 11.4	\$1.6±25.5 vs. 25.4±6.1	0.
Adjavant hormonal therapy after breast surgery	Without vs. With	31 vs. 36	43.0±10.6 vs. 49.6±11.0	0.75	-	19.3±2.2 vs. 39.8±18.8	0.2
Adjuvant radiotherapy after breast surgery	Without vs. with	25 15.45	57.9±20.8 vs. 43.2±10.3	0.99		31.112.4 vs. 21.215.9	0.8
Liver metastases							-
Number	Solitary vs. multiple	40 vs. 25	60.0115.8 vs. 57.8115.9	0.18		31.3±3.3 vs. 18.7±7.5	0.8
Site	Unilobar vs. Bilobar	48 vs. 21	49.6111.5 vs. 57.8119.5	0.99	-	30.254.2 vs. 21.252.9	0.8
Largest size	«3 vs. >5cm	52 vs. 18	49.619.1 vs. 21.9122.0	0.89		31.1±2.8 vs. 21.2±2.9	0.0
Consulative size	<5 vs. >5cm	43 vs. 25	493.6±10.2 vs. 58.5+21.4	0.82		31.112.5 vs. 25.416.8	10
Grade/ differentiation	Grade 1 vs. 2-3	4 vs. 17	NR	0.27		NR	10.
Presentation	Synchronous vs. metachronous	7 vs. 63	32.315.8 vs. 49.6110.0	0.84		10.7±4.7 vs. 28.6±6.3	0.2
Vascular invasion	negative vs. Positive	3411.7	43.0±13.7 vs. 58.5±0.9	0.62		33.1±12.3 vs. 21.8±2.9	1.8
Capatar invasion	negative vs. Positive	34 vs. 15	58.5±10.9 vs. 36.4±7.4	0.52		33.1±15.3 vs. 27.5+5.1	0.5
Recurrence free interval (from time of liver surgery/ablation to cancer recurrence)	<2 yr 16. >2 yr	37 10.31	32.3±1.8 vs. 73.3±5.5	10.001	<0.001; 3.9; 1.9-8	NA	N
Time from breast cancer diagnosis to Liver resection/ablation	<5 yr vs. >5 yr	35.55.34	41,314.2 vs. 58,516.9	0.09		27.516.1 vs. 31.1113.6	0.4
Swpry				_			
Liver resection	Minor vs. Major	28 vs. 24	43.0±16.4 vs. 58.5±17.5	0.89		45.0±16.4 vs. 18.1±2.5	12
Margins	negative vs. Positive	44 15.8	41.1 ±13.9 vs. 58.5±12.5	0.69	-	25.4±6.4 vs. 21.9±6.4	0.5

NR - not reached

NA - not applicabe

P162

Radiofrequency Ablation as First-line Therapy of Non-operable Hepatocellular Carcinoma: Results from 1,168 Patients H. Tran Cao, ¹* V. Albino,² M. Leongito,² V. Granata,² R. Palaia,² S.A. Curley,¹ F. Izzo.² *1. The University of Texas M.D. Anderson Cancer Center, Houston, TX; 2. Istituto Tumori de Napoli, G Pascale Foundation, Naples, Iceland.*

INTRODUCTION: Radiofrequency ablation (RFA) provides a viable therapeutic alternative to surgery in the treatment of hepatocellular carcinoma (HCC) in the setting of unresectable disease or poor patient physiology, including cirrhosis. Our study evaluates the short- and long-term outcomes of RFA when utilized as first-line therapy in patients with non-operable HCC. METH-ODS: In this dual-institutional retrospective review of prospectively maintained HCC databases, with institutional review board approval, all patients who received RFA as primary treatment for HCC from 1995 to 2008 were identified. Patient demographic and clinicopathologic characteristics were reviewed. Short-term peri-procedural outcomes were measured. Long-term outcomes, including disease-free and overall survival, were analyzed. RESULTS: 1,168 patients with 2,116 lesions were treated with RFA during the study period. Median age of the cohort was 58, with 57% of patients being male. 51.2% of patients had Child's class A, 40.5% Child's class B, and 8.3% Child's class C cirrhosis. 62.8% of RFAs were performed percutaneously (pRFA) and 37.2% via an open approach (oRFA). Patients undergoing pRFA had fewer and smaller tumors than oRFA (median number of tumors 2 vs. 3, median size 2.7 vs. 4.0cm). Overall procedural complication and mortality rates were 5.5% and 1.5%, respectively. Causes of death included liver failure and hemorrhagic sequelae. With a median follow-up time of 5 years, overall recurrence rate was 11%, whereas 49% of patients had developed new liver or extrahepatic lesions. 5-year disease-free survival (DFS) was higher in the pRFA group compared to their oRFA counterparts (44.8% vs. 24.1%); likewise, 5-year overall survival (OS) was higher in the pRFA group (57.5% vs. 47.0%). CONCLU-SIONS: RFA is a safe and effective local treatment option for patients with non-operable HCC lesions. It can provide long-term local control and may achieve long-term survival, especially when transplant livers are not readily available.

P163

Defining the Benefit of Adjuvant Therapy following Resection for Intrahepatic Cholangiocarcinoma H. In,¹* S. Sharpe, ¹ M.S. Baker,² R.R. Weichselbaum, ¹ M.S. Talamonti,² M.C. Posner.¹ *I. Surgery, University of Chicago, Chicago, IL; 2. NorthShore University HealthSys tems, Evanston, IL.*

Background The role of adjuvant treatment following resection of intrahepatic cholangiocarcinoma has not been well-defined. Methods The National Cancer Data Base (NCDB) was used to identify patients from 1985 to 2011 diagnosed with non-metastatic intrahepatic cholangiocarcinoma who underwent surgical resection. Kaplan-Meier and Cox regression analyses evaluated differences in overall survival between patients who did and did not receive adjuvant therapy post-resection. Results Of the 1,674 patients who underwent resection for cholangiocarcinoma, 1,191 (71.2%) had an R0 resection, 432 (25.8%) had an R1 resection and 51 (3.1%) had an R2 resection. In R0 resection patients, 194 (16.3%) patients received chemotherapy and 159 (13.4%) received chemoradiation. In R1 or R2 resection, 89 (18.4%) received chemotherapy and 157 (32.5%) received chemoradiation. By multivariate regression, patients who were younger, had positive lymph nodes, had positive margins and diagnosed in more recent years were more likely to receive adjuvant therapy. The median overall survival after an R0 resection was 33.0 months (95% CI 30.3, 36.2), 17.0 months (95% CI 15.4, 20.0) after R1 resection and 7.7 months (95% CI 3.8, 12.9) after R2 resection. Cox regression analysis identified older age, higher Charlson score, lymph node positivity, higher tumor grade and positive margins as factors associated with decreased median overall survival. All patients, regardless of completeness of resection, had an overall survival benefit after adjusting for the above prognostic factors when they received chemotherapy (R0 resection: HR=0.68, p=0.002; R1/R2 resection: HR=0.65, p=0.006), however the benefit of chemoradiation therapy was limited to those with R1/2 resection (R0 resection: p=0.29; R1/2 resection: HR=0.61, p<0.0001). Conclusion Positive lymph nodes, positive margins and high tumor grade are critical determinants of survival after resection for intrahepatic cholangiocarcinoma. Adjuvant chemotherapy had an overall survival benefit regardless of resection status. However, only those patients with positive margin resection benefitted from the addition of postoperative radiation therapy.

Benefit of adjuvant therapy according to margin status (adjusted model)

	R0 resection patients (n=1191)		R1/R2 resection patier (n=483)	
	HR	p-value	HR	p-value
No adjuvant therapy (n=1075)	ref		ref	
Chemotherapy (n=283)	0.68	0.002	0.65	0.006
Chemoradiation (n=316)	0.88	0.293	0.61	<.0001

P164

Non-invasive Radiofrequency Field-induced Hyperthermia Inhibits Homologous Recombination Mediated Repair of Gemcitabine Stalled Replication Forks M. Raoof,^{1*} C. Zhu,² B. Cisneros,² H. Liu,² S. Corr,² L. Wilson,² S.A. Curley.² 1. University of Arizona, Tucson, AZ; 2. MD Anderson Cancer Center, Houston, TX.

Background: Hepatocellular carcinoma is a worldwide problem with rapidly rising incidence in the U.S. At diagnosis more than 75% of patients are not amenable to curative therapy. Conventional chemotherapy is highly toxic and resistance develops rapidly. Here we investigate the effect of non-invasive radiofrequency field (RF) induced-hyperthermia on repair of gemcitabine stalled-replication forks in the DNA of liver cancer cells and tumors in vivo. Methods: Human liver cancer cell lines (Hep3B, SNU449 and HepG2) were evaluated. Reproductive viability was measured by clonogenic assay. Thermoability of homologous recombination proteins was determined by western blotting and immunocytochemistry. Orthotopic mouse liver tumor models were generated in CB17 SCID mice. All RF exposures were at 13.56MHz, 600W using an external capacitatively coupled RF generator. Results: We observed lack of localization of Mre11 exonuclease and downstream Rad51 recombinase to the gemcitabine-stalled replication fork after mild hyperthermia. This was consistent with degradation of Mre11. This resulted in a G2 arrest consistent with inhibition of post-replication recombination repair. Clonogenic assays demonstrated synergy between hyperthermia and gemcitabine. This was confirmed to be due to Mre11 by using an inhibitor of Mre11 exonuclease (mirin) and by knocking-down mre11 expression using shMre11. The findings were further confirmed in two different orthotopic models (generated from Hep3B and HepG2 cell lines) Conclusion: Hyperthermia sensitizes liver cancer cells and tumors to gemcitabine at 12-25% of the current clinically relevant dose. This sensitization is mediated through inhibition of repair of gemcitabine-stalled replication fork through an mre11 dependent homologous recombination pathway. This physical thermal therapy combined with nontoxic doses of chemotherapy may enhance treatment efficacy in this highly lethal cancer.

P165

Impact of Volume on Outcomes in Liver Surgery: Hospital Volume may Outweigh Surgeon Volume M. Porembka,* D.M. Rubin, M. Gönen, M. D'Angelica, P. Allen, T. Kingham, W. Jarnagin, Y. Fong. Memorial Sloan Kettering Cancer Center, New York, NY.

Background: Favorable outcomes have been associated with institutions and surgeons that perform a high-volume of complex surgical procedures. However, there are limited data describing the impact of institutional volume on liver surgery outcomes performed by high- and low-volume surgeons. We used a statewide database to investigate the association between surgeon caseload, hospital volume, and outcome. Methods: Patients undergoing elective liver resection for malignancy between 1994 and 2000 were identified from the New York State Statewide Planning and Research Cooperative System (SPARCS) database. The SPARCS data system collects patient level data on patient characteristics, diagnoses, treatments, and charges for every hospital discharge in New York State. Centers with 3 or more liver surgeons were selected for analysis. Surgeons and institutions were considered high-volume if they performed greater than 15 and 30 cases per year, respectively. Outcomes including 30-day mortality were compared between high- and low-volume surgeons and institutions. Multivariate analysis was conducted to identify factors associated with improved outcome. Results: 2549 elective liver resections were performed at 35 institutions by 50 individual surgeons. A trend toward improved outcome was observed with high-volume centers (HVC, n=2) compared to low-volume centers (LVC, n=33) (mortality: 3.6% vs. 4.5%). Outcomes by high-volume surgeons (HVS, n=9) and low-volume surgeons (LVS, n=41) were comparable (mortality: 4.0% vs. 4.0%). LVS operating at HVC had a significantly lower mortality than HVS operating at LVC (3.4% vs. 5.3%; p<0.05). Multivariate analysis revealed extent of hepatic resection (p<0.01), presence of comorbid condition (p<0.01), patient age (p<0.05), and hospital volume (p<0.05) were significantly associated with mortality. Surgeon volume was not associated with outcome (p>0.05). Conclusion: In this study, hospital volume was a significant predictor of mortality in hepatectomy performed for cancer while individual surgeon volume was not. Consideration should be given to referral patterns that favor performance of hepatic surgery in HVC over HVS in LVC.

P166

Preoperative CA 19-9 Kinetics as a Prognostic Variable in Radiographically Resectable Pancreatic Adenocarcinoma E. Brown,* R. Canter, R. Bold. Department of Surgery, University of California, Davis. Sacramento. CA.

Introduction: Cancer antigen 19-9 (CA 19-9) is a well-studied marker of tumor burden in pancreatic cancer. Serial levels during chemotherapy correlate with treatment response and survival; a decrease following surgical resection is also correlated with survival. However, very little is known about the kinetics of CA 19-9 in the absence of therapy. We hypothesize that CA 19-9 kinetics in the preoperative period in the absence of any therapy predicts both resectable rates at time of surgery as well as survival. Methods: Retrospective review of an institutional database of patients with pancreatic adenocarcinoma identified 72 patients with two separate pre-operative CA 19-9 levels prior to planned pancreaticoduodenectomy. Primary outcome measures were resectability and overall survival. Univariate analysis was performed using Chi-squared analysis. Survival analysis was performed with Kaplan-Meier estimates. Results: Sixty-four percent of patients had resectable disease (46 of 72 patients). Unresectable patients had a higher absolute change in CA 19-9 than patients with resectable disease (median: 93 U/ml vs. -38 U/ml). A predictive threshold of >50 U/ml identified 58% of patients with unresectable disease, while only 26% of patients who were resectable exceeded this threshold (p=0.008). Unresectable patients also had a higher rate of change in CA 19-9 than patients with resectable disease (median: 4 U/ml vs. -1 U/ml/day). When a predictive threshold of >10 U/ml/day for rate of change in CA 19-9 was used, only 1% of resectable patients exceeded this threshold, while 35% of unresectable patients had a rate ≥ 10 U/ml/day (p=0.004). Survival analysis of the entire group revealed that a change in CA 19-9 <50 U/ml and a rate of change of CA 19-9 <10 U/ml/day each predicted improved survival (p=0.01, p<0.001); however, for patients with resectable disease, CA 19-9 changes did not predict survival. Conclusions: Preoperative change in CA 19-9 and the rate of change are useful tools to predict resectable disease for pancreatic cancer. These variables also predict overall survival; however, it does not predict survival for those with resectable disease.

P167

Non-neoplastic Liver Fibrosis Staged by the Modified Ishak Method Predicts Two-year Recurrence for Patients with Early Hepatitis-B Associated Hepatocellular Carcinoma S. Blank, Q. Wang, M. Fiel, H.S. Kadri, W. Luan, A. Zhu, P. Deaderick, S. Hiotis.* *Mount Sinai Medical Center, New York, NY.*

Hepatocellular carcinoma (HCC) associated with hepatitis B (HBV) infection is a leading cause of cancer-related mortality world-wide, and there is a need to identify factors in early HCC associated with poor outcomes. Ishak fibrosis stage has been found to be an important prognostic indicator for HBV-HCC, and the aim of this analysis was to investigate the role of Ishak fibrosis stage in prognosis among early tumors (<= 2cm in greatest diameter). Data were obtained for patients with HBV-associated HCC treated by primary hepatic resection at a single Western institution between 1988 and 2013. A dedicated liver pathologist blinded to patient outcomes performed a histologic assessment of all liver resection specimens and evaluated fibrosis according to the modified Ishak method (fibrosis stages 0-6) in addition to other histopathologic variables. Other data were obtained via medical record review. Cox proportional hazards regressions adjusted for vascular invasion and histologic differentiation were used to compare disease-free survival and short-term recurrence in these groups. Fifty-three resection patients with a maximal tumor diameter <= 2cm were available for analysis. Median survival for these patients was 50.7 months, and median disease-free survival was 30.0 months. Within five years of resection there were 4 deaths and 21 recurrences, and 14 recurrences occurred within two years of resection. Adjusted Hazard Ratios (HR) and 95% confidence intervals for recurrence-free survival (time to recurrence or death) showed that each increase in stage of fibrosis was associated with a 40% increased risk of recurrence or death overall [HR=1.40 (1.02-1.94)] and a 65% increased risk of recurrence within two years [HR=1.65 (1.06-2.57)]. Results indicate that even among early HBV-HCC, increased fibrosis and cirrhosis are associated with higher risk of early recurrence. The significant impact of liver fibrosis on HCC progression is established early on and is independent of tumor differentiation and vascular invasion.

P168

Does Pancreatic Intraepithelial Neoplasia Predict Recurrence of Pancreatic Adenocarcinoma or Development of a Second Primary in the Remnant Gland? T. Nguyen,* J. Steve, A.H. Zureikat,

A.D. Singhi, H.J. Zeh. University of Pittsburgh Medical Center, Pittsburgh, PA.

Introduction: Pancreatic intraepithelial neoplasias (PanINs) are well established as a precursor lesion to pancreatic cancer. While PanINs at the transection margin have not been shown to affect the dismal survival outcomes

for pancreatic cancer, it is not known whether the presence or grade of PanINs in the gland may predispose patients who do achieve long-term survival to having a localized recurrence or a second primary mass in the remnant pancreas. Methods: After IRB approval was obtained, a retrospective chart review of patients with long term survival (defined as more than two years) from pancreatic ductal adenocarinoma (PDA) who underwent a margin negative pancreatic resection between 2007 and 2010 was performed. Results: One hundred and seven patients at a multi-site single academic institution were identified as having more than a two-year survival from a pancreaticoduodenectomy or distal pancreatectomy for PDA. Forty-six patients had PanIN-3, 31 patients had PanIN-2, 10 patients had PanIN-1A or -1B, 2 patients had no PanINs and PanIN status in the resected gland was not noted for 18 patients. There was no statistically significant difference in overall survival or time to localized recurrence based on PanIN grade. Five patients developed a second mass in the remnant pancreas with an average time to progression of 35.6 months (range 16.7 - 59.2 mo). Four patients have had resection of the remnant pancreas and one has undergone chemotherapy treatment with plans for re-resection. All five patients were alive at last follow-up. Of these five patients, three patients had PanIN-3 in their original resected pancreatic specimen, one patient had PanIN-2 and one patient had PanIN-1B. Conclusion: For patients with a resected pancreatic ductal adenocarcinoma, the presence or grade of PanIN lesions in the surgical specimen does not affect outcome or time to localized recurrence.

P169

The Positive Postoperative CEA is an Independent Predictor of Recurrence for Patients who underwent Curative-intent Treatment for Colorectal Liver Metastases R. Araujo,* M. Gönen, P. Allen, L. Blumgart, R. DeMatteo, W. Jarnagin, M. D'Angelica, Y. Fong. *Memorial Sloan-Kettering Cancer Center, New York, NY.*

INTRODUCTION: The importance of CEA for monitoring recurrence for Colorectal Liver Metastases (CRLM) after resection continues to be debated. The objective of this study is to assess the postoperative CEA as independent predictor of recurrence for patients with CRLM after hepatectomy with curative-intent treatment. METHODS: Patients were identified from a prospectively maintained CRLM database and studied retrospectively. Patients who had extrahepatic disease, initially unresectable CRLM, received intra-arterial chemotherapy, exclusive tumor ablation or previous metastasectomies were excluded. All patients in this study received adjuvant systemic chemotherapy for CRLM including 5-fluourouracil, oxaliplatin or irinotecan. Post-operative CEA is defined as the first CEA assessment performed within the first six months after operation. Univariate and Cox regression models were developed to determine factors independently associated with recurrence in two years. RESULTS: Between 1997 and 2007, 318 consecutive patients were studied and 168 patients (52.8%) experienced recurrence in two years. Among the postoperative CEA cutoffs tested and identified as independent predictors, a postoperative CEA \ge 15 ng/ml obtained the highest HZ (1.87 – 95% C.I. 1.09 – 3.2; p=0.023) and it was chosen to be included in the survival analysis in the multivariate model. The postoperative CEA \geq 15 ng/ml presented specificity of 96% and positive predictive value of 81.8% for recurrence. On multivariate analysis, age \geq 70 years, positive lymph node at primary tumor resection, disease free interval ≤ 12 months, number of lesions > 1, largest lesion ≥ 5 cm, presence of positive margins, and postoperative CEA ≥ 15 ng/ml were independent predictors of recurrence in two years. Kaplan-Meier curves of recurrence in two years were made according to Clinical Risk Score (CRS high [3-5] and low [0-2]), postoperative CEA \ge 15 ng/ml or lower and combining them (FIGURE). DISCUSSION: This study suggests that the postoperative CEA is a worthwhile test for predicting recurrence in two years, and being independently associated with recurrence.



Resistance to PI3K Inhibition in Pancreatic Cancer is Mediated through the ErbB Pathway C. Tignanelli,* R.J. Torphy, J. Stratford, R.A. Moffitt, R. Reuther, S.G. Herrera Loeza, G.L. Johnson, J. Yeh. University of North Carolina, Chapel Hill, NC.

KRAS mutational activation plays a critical role in tumorigenesis, but exactly which downstream KRAS effector pathway is critical for this role remains less clear. One of the most studied downstream pathways is the phosphatidylinositol-3-kinase (PI3K) pathway which mediates cellular growth and survival. We evaluated the effect of BKM120 (a pan-class 1 PI3K inhibitor), currently in Phase I/II clinical trials, using cell lines and patient derived xenograft (PDX) models and assessed potential mechanisms of BKM120 resistance. Kinome reprogramming has been found as a mechanism of resistance to MEK inhibition in triple negative breast cancer. We hypothesized that kinome reprogramming may play a role in resistance to PI3K inhibition in pancreatic cancer. A panel of 10 pancreatic cancer cell lines were evaluated for response to BKM120 using a cell viability assay. A pancreatic cancer PDX mouse model, where actual tumors from patients are directly engrafted into mice, was used to assess BKM120 response in vivo. PDX were treated with vehicle or BKM120 (40mg/kg) daily for 28 days. Kinome reprogramming was evaluated using multiplexed inhibitor bead/mass spectrometry assays and receptor tyrosine kinase arrays. Combination indices were calculated using Compusyn. 20% tumor growth inhibition was observed in PDX (p=0.017) treated with BKM120 with corresponding decrease in pAKT levels. Because this effect was not impressive, we evaluated the kinome response to BKM120 treatment. We found upregulation of ErbB1, ErbB2 and ErbB3 in both cell lines and PDX tumors in response to BKM120 treatment, suggesting that the ErbB pathway may play a role in BKM120 resistance. We therefore evaluated BKM120 and dacomitinib (a pan-ErbB inhibitor currently in Phase III clinical trials) treatment in combination. We found that combined treatment with BKM120 and dacomitinib was significantly synergistic across all cell lines with a mean combination index of 0.24 (0.002 - 0.49). Our results suggest that resistance to PI3K inhibition in pancreatic cancer is mediated through the ErbB pathway. Pan-ErbB and PI3K inhibition may be more effective than single agent alone and should be considered in clinical trials.

P171

Defining the Role of Adjuvant External Beam Radiotherapy on Resected Adenocarcinoma of the Ampulla of Vater J.T. Miura,* A. Amini, T.T. Jayakrishnan, S. Tsai, K.K. Christians, F. Johnston, T.C. Gamblin, K.K. Turaga. *Medical College of Wisconsin, Milwaukee, WI*.

Introduction: The role of adjuvant radiotherapy in the treatment of ampullary carcinoma remains unclear. We hypothesized that adjuvant radiotherapy (RT) does not improve survival following resection for adenocarcinoma of the ampulla of Vater (AC). Methods: The Surveillance, Epidemiology, and End Results database was queried for all patients with nonmetastatic AC who underwent surgery (S) from 2004-2010. Propensity score (PS) modeling was applied to create balanced cohorts of patients that would be equally likely to receive radiation based on age, T-stage, N-stage, nature of surgery and grade of the tumor. Cox proportional hazards models were used to compare survival. Results: Of 1,287 patients identified, 329 (25.6%) patients received adjuvant RT. Unadjusted median overall survival for patients receiving adjuvant RT compared to surgery alone was 27 vs. 36 months (p=0.14). Patients receiving adjuvant RT versus S alone were younger (63 vs. 69 years, p<0.001), had more advanced tumors (69 vs. 53% T3/T4 tumors, p<0.001), and more frequent lymph node metastasis (73 vs. 40%, p<0.001). Multivariate analysis demonstrated that adjuvant radiation was not associated with improvement in overall survival (HR 0.88; 95% CI: 0.73-1.07, p= 0.2) or disease specific survival (HR 0.92; 95%CI: 0.73-1.16, p=0.42). In PS matched cohorts, adjuvant RT failed to improve both overall survival (27 vs. 29 months, p=0.58) and disease specific survival (36 vs. 40 months, p=0.92) when compared to surgery alone. Adjuvant RT, in PSmatched multivariate models, was not associated with improved overall survival (Multivariate HR 0.84; 95% CI: 0.65-1.07, p=0.16). Conclusion: Adjuvant RT does not confer a survival benefit for patients with ampullary tumors. The lack of disease specific survival benefit suggests that it may also not be beneficial to prevent local recurrences and related mortality. Currently in practice adjuvant RT is administered for high risk ampullary adenocarcinoma, without proven benefit.

Table: Multivariate analysis of prognostic variables for overall survival

Variable	HR	95% CI	P
Age	1.01	1.01-1.02	<0.01
Adjuvant XRT	0.88	0.73-1.07	0.20
Primary Tumor (T Stage)			
T1	Ref	-	-
T2	0.97	0.71-1.33	0.86
Т3	1.49	1.09-2.01	0.01
Т4	1.67	1.22-2.28	<0.01
Lymph Node Status,			
NO	Ref		-
N1	2.17	1.78-2.64	<0.01
Tumor Grade			
Well differentiated	Ref	-	-
Moderate differentiated	1.37	1.00-1.88	0.05
Poorly differentiated	1.61	1.16-2.23	<0.01
Surgery			
Limited	Ref	-	-
Radical	1.02	0.86-1.22	0.82

Molecular MR Imaging of Collagen to Diagnose Liver Fibrosis D.K. DePeralta,* C. Farrar, H. Day, L.Y. Gregory, K.K. Tanabe, P. Caravan, B.C. Fuchs. *Massachusetts General Hospital, Boston, MA*.

Introduction: The gold standard in diagnosing liver fibrosis remains biopsy despite its limitations, which include sampling error, and complications related to the invasiveness of the procedure. The goal of this study was to utilize a peptide probe targeted to type I collagen linked to gadolinium (Gd) with the goal of using magnetic resonance imaging (MRI) to non-invasively diagnose biljary fibrosis in a rodent model. Methods: Male CD Rats underwent bile duct ligation (BDL) or sham laparotomy. To assess liver fibrosis at different stages, rats were MR imaged on post operative day 4, 10, or 18 on a 1.5T clinical MRI system with a custom-built volume coil. A series of T1-weighted and T1-mapping images were acquired prior to and for one hour after injection of the collagen-targeted contrast agent, EP-3533. Following imaging, animals were euthanized and liver tissue was removed for hydroxyproline analysis (total collagen), Gd concentration (probe uptake) and Sirius red staining to determine an Ishak fibrosis score. Results: BDL in rats led to fibrous expansion of the bile ducts, which was evident after 4 days, and more dramatic after 10 days. By 18 days, the liver was cirrhotic as indicated by histology as well as markedly increased serum bilirubin levels. Injection of EP-3533 increased the relaxation rate enhancement ($\Delta R1$ where $\Delta R1 = 1/T1$ post - 1/T1 pre) of the liver and a significant difference was seen between sham controls and BDL rats at post operative day 18. These findings consistently correlated with measurements of Gd uptake, which was increased in animals that underwent BDL with a significant difference observed at post operative day 18. Conclusion: We have developed a non-invasive, collagen-enhanced MRI technique for the diagnosis of biliary fibrosis, and validated it in a rodent model. This technique may also be more broadly applicable to other forms of fibrosis, and may be especially useful in patients when biopsy is not feasible, as well as in clinical trials to monitor the efficacy of anti-fibrotic therapies over time.

P173

Survival Benefit of Adjuvant Therapy for Resectable Pancreatic Cancer (PC) Patients Treated with Neoadjuvant Therapy K. Duelge, A.N. Krepline, A. Mahmoud, B. George, P.S. Ritch, B.A. Erickson, E.J. Quebbeman, K.K. Turaga, F. Johnston, T.C. Gamblin, K.K. Christians, D. Evans, S. Tsai.* Surgery, Medical College of Wisconsin, Milwaukee, WI.

Background: Adjuvant therapy has been shown to offer a survival benefit to patients (pts) with PC as compared to surgery alone. For pts who receive neoadjuvant therapy and then surgery, the benefit of adjuvant therapy is unknown. Methods: We identified all pts with PC who completed all intended neoadjuvant therapy and surgery from 2008-2013. Data regarding demographics, neoadjuvant treatment history, surgical outcomes, pathologic, and survival data were abstracted from electronic medical records. Results: We identified 67 pts; 42 (63%) received additional postop adjuvant therapy and 25 (37%) did not. Pts who did not receive adjuvant therapy were more likely to be age 75 or older (10 [71.4%] of 14 vs. 13 [25.0%] of 52, p =0.002), have a higher Charlson Comorbidity Index (mean 3.56 vs. 2.46, p = 0.003), and require more days in hospital during neoadjuvant therapy (2.75 vs. 7.12 days, p = 0.22). Pts were also less likely to receive adjuvant if they were discharged to a skilled nursing facility (SNF) after surgery (p = 0.001). The receipt of adjuvant therapy was associated with node positive disease status; 18 (42.9%) of 42 vs. 5 (20.0%) of 25, p = 0.04. Overall median survival for the entire cohort was 36.5 months. The median survival for node positive pts who received adjuvant vs. no adjuvant therapy was 26.2 vs. 10.3 months, (log rank p = 0.08) respectively. Median survival for node negative pts who received adjuvant therapy was 31.4 months and was not met by the pts who did not receive adjuvant (p = 0.54). Conclusion: As expected, a significant proportion of pts who receive neoadiuvant therapy and surgery do not receive adjuvant therapy. As shown for the experience with surgery alone, older age and greater comorbidities are associated with failure to receive adjuvant therapy. Node positive disease after neoadjuvant therapy is a powerful predictor of poor outcome especially in the absence of additional systemic therapy. Our translational research laboratory is focusing on this patient population where novel approaches to systemic therapy are needed.



P174

Squamous Cell Carcinoma of the Pancreas: A Population-based Clinical Outcomes Study with 357 Patients K. Mahendraraj,* J.A. Di Como, R.S. Chamberlain. St. Barnabas Medical Center, Livingston, NJ.

Introduction: Squamous cell carcinoma of the pancreas (SCP) is a very rare and aggressive exocrine pancreatic neoplasm. Clinical information relating to SCP is scant and is derived primarily from small retrospective studies. This study sought to examine a large cohort of SCP in order to determine demographic, clinical, and pathologic factors characteristic of SCP patients, and to compare SCP clinical outcomes to pancreatic ductal adenocarcinoma (PDAC). Methods: Demographic and clinical data on 174,515 patients with pancreatic cancer were abstracted from the SEER database (1973-2010). 347 SCP and 102,735 PDAC formed the study groups. Standard statistical analyses were performed. Results: SCP comprised 0.3% and PDAC made up 58.9% of all pancreatic cancers identified. The mean age of the SCP and PDAC patients was similar (68.7±12 vs. 68.2±12). Both SCP and PDAC was more common in Caucasians (73.7% and 74.6% (PDAC)) and in the head of the pancreas (44.3% and 50.9% (PDAC)). SCP were more often poorly differentiated, > 4cm, and presented with distant disease compared to PDAC, p<0.05. The majority of SCP and PDAC patients were not treated with surgery or radiation therapy (67.5% and 68.8). SCP mean survival was significantly lower than PDAC (0.74 vs 0.85 years), however SCP patients benefited more from both surgery (3.8 years) and a combination surgery and radiotherapy (3.8 years) than PDAC patients (2.2 years and 3.0 years),p<0.001. Multivariate analysis identified age over 65 (OR 1.4), pancreatic ductal origin (OR 1.5), metastatic disease (OR 2.3), and poor grade (OR 2.3) as associated with mortality for SCP, p<0.005. Conclusions: Pancreatic SCP is a rare malignancy that presents with poorer grade, larger tumor size, with a higher rate of metastatic disease than PDAC. Despite these aggressive features, SCP patients amenable to surgical or combined surgery/radiation therapy derive greater survival advantage than similarly treated PDAC. Surgical resection should be considered in all SCP patients with resectable disease. Older age, pancreatic ductal origin and advanced stage or grade are associated with increased mortality among the cohort studied.

 Table 1.Demographics and Clinical Profile of 102,735 patients with Pancreatic Ductal Adenocarcinoma and 357 patients with Squamous Cell Carcinoma of the Pancreas from the Surveillance Epidemiology and End Result (SEER) Database (1973-2010).

Variables	Overall	Squamous Cell Carcinoma of Pancreas	Pancreatic Ducta Adenocarcinoma
N (%)	103,092	357 (0.3)	102,735 (99.7)
Age, (Mean ± SD)	68.2±11.7	68.7±11.8	68.2±11.7
Mean Survival (years)	0.85±0.01	0.74±0.14*	0.85±0.01
Gender			
Male	50,356 (48.8)	156 (43.7)	50,200 (48.9)
Female	52,736 (51.2)	201 (56.3)	52,535 (51.1)
RaceN(%)			
Caucasian	76,899 (74.6)	263 (73.7)	76,636 (74.6)
Hispanic	7,490 (7.3)	14 (3.9)	7,476 (7.3)
African American	12,084 (11.7)	49 (13.7)	12,035 (11.7)
Other	6,421 (6.2)	31 (8.7)	6,390 (6.2)
Unknown	198 (0.2)	0	198 (0.2)
Location			
Head of pancreas	52,404 (50.8)	158 (44.3)*	52,246 (50.9)
Body of pancreas	10,303 (10.0)	42 (11.8)	10,261 10.0)
Tail of pancreas	10,645 (10.3)	39 (10.9)	10,606 (10.3)
Pancreatic Duct/ Islets	664 (0.6)	1 (0.3)	663 (0.6)
Pancreas, unspecified	29,076 (28.2)	117 (32.8)	28,959 (28.2)
Grade N(%)			
Well Differentiated	6,156 (6.0)	15 (4.2)	6,141 (6.0)
Moderately Diff.	17,185 (16.7)	39 (10.9)	17,146 (16.7)
Poorly Diff.	18,811 (18.2)	114 (31.9)*	18,697 (18.2)
Undifferentiated	1,008 (1.0)	5(1.4)	1,003 (1.0)
Unknown	69,932 (58,1)	184 (51.5)	59,748 (58,2)
Stage N(%)			
Localized	7.463 (7.2)	22 (6.2)	7.441 (7.2)
Regional	28,923 (28,1)	80 (22.4)	28,843 (28,1)
Distant	59,545 (57,8)	213 (59.7)	59.332 (57.8)
Unstaged	7,161 (6.9)	42 (11.8)	7,119(6.9)
Tumor Size N(%)			
Microscopic	336(0.3)	0	336(0.3)
Under 2 cm	2.816(2.7)	4(1.1)	2.812 (2.7)
2 to 4 cm	27.912 (27.1)	47 (13.2)	27.865 (27.1)*
Over 4 cm	22,833 (22.1)	98 (27.5)*	22,735 (22.1)
Unknown	49 195 (47.7)	208 (58 3)	48 987 (47 7)
Treatment N(%)	47,175 (47.1)	200 (50.5)	40,507 (41.1)
No treatment	70 942 (68 8)	241 (67.5)	70 701 (68 8)
Surgery only	9,783 (9,5)	31 (8.7)	9,752 (9.5)
Radiation only	13,578 (13,2)	59 (16.5)	13,519 (13.2)
Both surgery and radiation	5.031 (4.9)	8(2.2)	5.023 (4.9)
Unknown	3,758 (3,6)	18 (5.0)	3,740 (3,6)
Survival by treatment (years+SI))	10 (010)	217.10 (2.0)
No treatment		0.36±0.06	0.50±0.01
Surgery only		3.84+1.42*	2.18+0.07
Radiation only		0.54±0.06	0.94±0.02
Both surgery and radiation	2	3.76+2.18*	2 97+0.02
Cumulative Survival (%)		0110-0110	#177.00.07
Lavor		13	20
i-year	-	10	e.v
2-year	1	6	7
-			

P175

Short and Long-term Outcomes for Transarterial Radioembolization with Yttrium-90 Microspheres for Hepatocellular Carcinoma H.F. Schoellhammer, ^{1*} P.H. Ituarte, ¹ Y. Chen, ² J. Park, ³ H. Marx, ⁴ J. Kessler, ⁴ G. Singh, ¹ J.J. Park, ⁴ J. Kim. ¹ I. Division of Surgical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA; 2. Department of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA; 3. Department of Diagnostic Radiology, City of Hope Comprehensive Cancer Center, Duarte, CA; 4. Division of Interventional Radiology, City of Hope Comprehensive Cancer Center, Duarte, CA.

Introduction: Selective internal radioembolization treatment (SIRT) with yttrium-90 (Y-90) microspheres has been shown to be safe and efficacious for unresectable hepatocellular carcinoma (HCC). Our goals were to report our clinical experiences and survival outcomes with SIRT at a non-transplant comprehensive cancer center. Methods: Patients with unresectable HCC who underwent SIRT from 2007-2012 were reviewed. Patient demographics were evaluated and complications graded with Common Terminology Criteria for Adverse Events. Kaplan-Meier (KM) survival curves were constructed and compared with the log-rank test. Predictors for survival in KM models were tested with multivariable Cox proportional hazards analysis. Results: During the study period 53 patients (n=37, male) underwent 89 SIRT treatments. Mean age was 68 (range 16-86); mean follow-up time from first treatment was 12.7 months. Overall, 24 patients received one treatment, and 29 patients received \geq 2, with 95% outpatient treatments. SIRT was well tolerated; fatigue, upper quadrant abdominal pain, and nausea were the most common adverse effects (55% of patients), all resolving over 1-2 weeks. Serious complications included pancreatitis (n=1, Grade 3), radiation pneumonitis (n=1, Grade 5), and hepatic decompensation (n=2, Grade 1 and 3). Median overall survival (OS) for the cohort was 13.4 months. Twenty-four patients previously underwent other liverdirected therapies; however, no difference in OS was seen compared with patients receiving SIRT de novo (15.4 vs. 12.4 months, respectively; p=NS). Patients undergoing \geq 2 SIRT had significantly longer OS than those undergoing 1 treatment (18.8 vs. 5.7 months, respectively; p=0.015). On multivariable analysis, receipt of \geq 2 SIRT significantly predicted OS at 3 years (HR 0.43, 95% CI 0.22-0.87, p=0.018). Conclusion: Patients with unresectable HCC can be safely and effectively treated with Y-90 microspheres SIRT in a non-transplant center. Our experience verifies the safe application of SIRT and suggests that patients who undergo multiple SIRT treatments may have biology of disease or treatment response that results in prolonged survival.

P176

Differential Hepatic MicroRNA Expression in an Animal Model of Intrahepatic Cholangiocarcinoma J. Rose,¹* E. Nearing,¹ Y. Li,² C. Ni,² J. Nelson,² K. Kowdley,¹ F. Rocha.¹ *1. Virginia Mason Medical Center, Seattle, WA; 2. Benaroya Research Institute, Seattle, WA.*

Introduction: Intrahepatic cholangiocarcinoma (IHC) is a rare, often difficult to treat primary malignancy of the liver with a median survival of 6-12 months for unresectable disease. MicroRNA (miR) is a class of non-coding RNA molecules known to regulate oncogenic gene transcription. We aimed to identify differentially expressed miRs in a drug-induced rat model of IHC. Methods: Fischer rats were administered 300 mg/L of thioacetamide in drinking water ad libitum to induce IHC. Tumor-bearing and control livers were harvested at 22 weeks and next generation RNA sequencing was utilized to compare hepatic miR profiles between thioacetamide treated rats and age-matched controls in triplicate. Resultant miR counts were normalized using Kernel Density Estimation. MiRs with a greater than twofold change and a read count of at least 4 per million were considered for further analysis. Results: All thioacetamide treated animals developed IHC by 22 weeks confirmed with histology. At a median read depth of 6.6 million per sample, 547 unique miRs were detected between all samples. Based on cut-off criteria, 112 microRNAs were included for analysis with a median fold change of 2.5 (See Figure). Of these, mir-200, mir-215, mir-130, and mir-181 were amongst the most significantly overexpressed in tumor tissue; while let-7 and mir-29 were amongst the most underexpressed when compared to control livers (FDR <0.05). These six miRs have previously been demonstrated to regulate genes associated with the development of human hepatobiliary cancer and disease. The most abundant miR in IHC was mir-21, however its expression was less than 2 fold compared to normal liver. Conclusion: Mir-200, mir-215, mir-130, mir-181, let-7, and mir-29 are differentially expressed in a drug-induced rat model of IHC. This model may serve to study miR gene targets for design of novel therapeutic strategies in IHC.



Fold Change of Tumor vs. Control

Volcano plot depicting distribution of fold change between tumor and control groups.

Impact of Repeat Resection for Borderline Colorectal Liver Metastases A. Saiura,* Y. Inoue. *Cancer Institue Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.*

Backgrond: Liver resection is the only treatment of potential cure, however, recurrence rate is extremely high especially in patients of borderline resectable colorectal liver metastases (CLMs). Although repeat resection is the only curative therapy, the outcome after repeat resection is unclear. This study analyzed the impact of repeat resection for borderline resectable CLMs. METHODS: Between 1999 and 2008, a total of 274 patients underwent hepatic resection for CLMs and 251 were liver limited CLMs. In this study, 5 nodules or >5cm is defined as borderline CLMs (BL-CLMs). Of 251 patients, the number of non BL-CLMs and BL-CLMs were 251 and 97. Predictors of survival were analyzed focusing on BL-CLMs. RESULTS: After median follow up of 50 months, 5-year overall and recurrence free survival after liver resection were 41%, 13% in the BL-CLMs, which were significantly poorer compared with the non BL-CLMs (68%,p=0.0003, 32%, p<0.00001), respectively. Among 97 patients with BL-CLMs, 86 (88%) developed recurrence. Repeat resection underwent in 36 (37%) patients including 35 patients with repeat liver resections (2nd;n=24, 3rd; n=8, 4th; n=3) and one patient with pulmonary resectoion. In 86 patients with recurrence, 5-year survival is significantly improved in repeat resection group compared with non-resection group (55% vs. 12%, p<0.001). The recurrence free survival in patients with repeat resection is the similar compared with those of non resectable recurrence (4 months vs. 5 months, p=0.873). Univariate and multivariable analysis revealed the repeat resection was the only favorable prognostic factor (55% vs 35%, p=0.035). Five or more nodules (p=0.013) and positive resection margin at liver resection (p=0.029) were identified as a poor prognostic factor for recurrent free survival in univariate analysis. Thirty seven patients (38%) survived more than 5 years, 18 of 37 (48%) underwent single or multiple repeat resections. CONCLUSION: Recurrence rate after liver resection for BL-CLMs with numerous metastases is especially high. Repeat resection plays a key role for a long term survival and cure.

Overall Survival after primary hepatectomy in patients with BL-CLM and recurrence according to presence or absence of repeat resection (n=86).



P178

Sarcopenia in Preoperative Therapy for Resectable Pancreatic Cancer: Does It Matter? A. Cooper, ¹* D.R. Fogelman, ¹ H.M. Holmes, ¹ R. Slack, ¹A. Balachandran, ¹N. Garg, ¹M.Q. Petzel, ¹N. Parker, ¹ D. Evans, ² G. Varadhachary, ¹R.A. Wolff, ¹C. Crane, ¹J.E. Lee, ¹ T.A. Aloia, ¹J. Vauthey, ¹C. Conrad, ¹J.B. Fleming, ¹M.H. Katz. ¹I. Surgical Oncology, MD Anderson Cancer Center, Houston, TX; 2. Medical College of Wisconsin, Milwaukee, WI.

Background: Sarcopenia (loss of muscle mass) predicts perioperative complications and delayed recovery after cancer surgery, and poor survival following de novo pancreatectomy in patients with pancreatic adenocarci-

noma. However, the association between sarcopenia and outcomes following treatment with neoadjuvant therapy is unknown. We sought to characterize changes in body composition of pancreatic cancer patients treated with preoperative chemoradiation to determine the prevalence and impact of baseline and treatment-associated sarcopenia when neoadjuvant therapy is employed. Methods: We examined the pretreatment and preoperative CT scans of all 90 patients with potentially resectable pancreatic cancer enrolled on a previously-reported phase II trial of neoadiuvant gemcitabine-based chemoradiation. We computed normalized cross-sectional areas (CSA) of skeletal muscle (SKM), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) at the L3 vertebral level. Sarcopenia was defined using gender-specific norms and evaluated in the context of prospectively-acquired clinical data. Results: At enrollment, 46 (52%) patients were sarcopenic, 53 (59%) were overweight or obese, and 21 (24%) were both. After neoadjuvant therapy (median 4.2 months), CSA (cm²/m²) decreased for each compartment [SKM 47.6 vs. 46.3 (p=0.004), VAT 45.1 vs. 41.2 (p=0.01), and SAT 53.0 vs. 15.9 (p<0.001)] and 9 (23%) patients without baseline sarcopenia developed sarcopenia. Neither pretreatment nor preoperative sarcopenia were associated with either successful pancreatectomy or progression free or overall survival (all p>0.05). Conclusion: From this first study of changes in body composition of patients receiving preoperative therapy for pancreas cancer, we conclude that sarcopenia is prevalent at baseline and that neoadjuvant chemoradiation is associated with a further decline in skeletal muscle mass. However, sarcopenia alone may not portend a poor prognosis when nonoperative therapy is delivered prior to pancreatectomy. Further studies of anthropometric changes that occur during curative therapy for pancreatic cancer are needed to develop perioperative strategies and optimize outcomes.

P179

Should Some Patients with Locally Advanced Pancreatic Cancer be Considered for Surgery? A. Amini,* A.N. Krepline, A. Mahmoud, B. George, P.S. Ritch, B.A. Erickson, J.P. Thomas, E.J. Quebbeman, F. Johnston, K.K. Turaga, T.C. Gamblin, K.K. Christians, D. Evans, S. Tsai. *Medical College of Wisconsin, Milwaukee, WI*.

Introduction: A favorable response to induction therapy may allow a subset of patients with locally advanced pancreatic cancer (LAPC) to be considered for resection. We sought to assess our early experience with such patients who traditionally would not have been considered for surgery. Methods: We identified all patients (pts) with LAPC who were well enough to receive either chemotherapy or chemoradiation from 2008-2012. Criteria for LAPC included encasement of the celiac axis (CA) or SMA, lack of a venous target for SMV-PV reconstruction, or invasion of adjacent structures (other). Demographics, treatment data, and survival outcomes were abstracted. Results: We identified 31 pts with LAPC due to arterial encasement (CA [n=12, 39%], SMA [n=12, 39%], both CA and SMA [n=2, 6%]), lack of venous target (n=2, 6%), or other (n=3, 10%). Chemotherapy and chemoradiation was given to 28 (90%) pts; 8 (26%) had gemcitabine monotherapy, 6 (18%) had gemcitabine-based combinations, and 14 (44%) had 5-fluorouracil-based therapy. Three pts (10%) received only chemoradiation. Of the 31 pts, 12 (39%) developed disease progression; 10 (32%) local and 2 (6%) distant. Of the remaining 19 (61%) pts, 1 refused surgery, 3 (15%) had metastases at laparoscopy, and 15 (48%) were resected. Operations included pancreaticoduodenectomy (n=6, 33%), distal pancreatectomy (n=7, 39%), central pancreatectomy (n=1, 7%), and total pancreatectomy (n=1, 7%). Vascular resections were performed in 9 (60%) of the 15 pts (6 arterial, 1 venous, and 2 arterial and venous). R0 resections were achieved in 14 (93%) of the 15 pts; 1 pt had an R1 resection. No demographic or chemotherapeutic regimen was associated with surgical resection. Pts with CA encasement were more likely to undergo resection than pts with SMA encasement (OR 7.00, P=0.057). Median survival was significantly greater in pts who completed all therapy including surgery (45 mo vs. 14 mo; P<.005) (Fig 1). Conclusions: Induction therapy may identify a subset of pts with LAPC in whom a complete resection of the primary tumor is both technically possible and of potential oncologic benefit. The survival duration for this subset of patients is quite favorable.



Figure 1. Overall Survival

Effect of Adjuvant Chemotherapy with S-1 or Uracil-Tegafur compared to Surgery Alone for Patients Undergoing Curative Resection of Biliary Tract Cancer O. Itano,* M. Shinoda, M. Kitago, Y. Abe, T. Hibi, H. Yagi, M. Ishii, Y. Kitagawa. Department of Surgery, keio University School of Medicine, Tokyo, Japan.

Introduction: Although the surgical resection rate of advanced biliary tract cancer (BTC) has increased, it has not achieved satisfactory improvements in survival. These findings indicate the limitations of surgical resection and emphasize the need for adjuvant treatment. The purpose of this study is to evaluate the effect of postoperative adjuvant chemotherapy with S-1 or uracil-tegafur (UFT) versus surgery alone on 2-year survival and disease-free survival (DFS) for resected BTC patients. Methods: Between January 1995 and April 2013, a total of 117 patients with carcinomas of gallbladder (Stage III/IV) (n=22), or bile duct (n=95) undergoing resection with curative intent were analyzed retrospectively and compared among surgery alone (n=63), UFT (n=41) (400 mg/m2/day) and S-1 (n=13) (80 mg/m(2), days 1-28, given orally twice daily for 4 weeks, followed by a 2-week rest, repeated every 6 weeks) groups.. Results: Compared of clinicopathological characteristics among three groups, there were no differences in patient's factors. As to tumor factors, there were no differences in T factor and Stage, however the number of lymph node metastasis is more in adjuvant groups than those in surgery alone group. Toxicity was generally mild in both adjuvant groups. UFT was administered for 3-36 months (mean 18 months) and no grade 3 or 4 toxicity was diarrhea (2.4%), and leucopenia (2.4%). S-1 was administered for 2-19 months (mean 11 months) and grade 3 or 4 toxicities were diarrhea (7.7 %) and skin rash (7.7%). There were no treatment-related deaths. The 2-year survival and DFS rates in patients of the UFT group (51.2% and 48.8%) and the survival rate in the S-1 group (59.3%) were not statistically different from those in the surgery alone group (39.7% and 33.3%, respectively). However, the 2-year DFS rate was significantly better in the TS-1 group (69.2 %) than that in the surgery alone group (33.3%) (p=0.047). Conclusion: Postoperative adjuvant therapy with S-1 improved the short-term DFS of resected BTC patients in this retrospective study.

P181

Improved Detection of Liver Metastases with Breath-hold MRI Sequences compared to Standard MRI F.A. Adeshuko,¹* S.G. Nour,² J. Li,² M.H. Squires,¹ S.K. Maithel,¹ K. Cardona,¹ M.C. Russell,¹ D.A. Kooby.¹ *I. Surgical Oncology, Emory University, Atlanta, GA; 2. Radiology and Imaging Sciences, Emory University, Atlanta, GA.*

INTRODUCTION: Standard Magnetic Resonance Imaging (MRI) may not reliably identify subtle liver metastases. High resolution MRI with controlled breath suspension under general anesthesia (breath-hold) is employed for precise targeted ablation of liver metastases. We assessed the value of breathhold MRI for the detection of additional subtle metastatic liver lesions not seen on pre-procedural imaging. METHODS: Patients with known liver metastases detected on standard MRI not deemed appropriate for resection were referred for MRI-guided ablation with breath-hold technique. Prior to planned ablation, preliminary imaging was performed during suspended breathing to obtain TSE T1, TSE T2, and VIBE images with EOVIST contrast in 3 planes. Pre-procedure standard MRI findings were compared with breath-hold MRI results for number of hepatic lesions detected. RESULTS: Between 2011-2013, 37 patients with liver metastases underwent both standard and breath-hold MRI. Median age was 61 and 22 were men. 15 patients (41%) had colorectal cancer (CRC) and 10 patients (27%) had neuroendocrine tumor (NET) primary pathology; a total of 98 liver lesions were detected on standard MRI in all 37 patients. Additional hepatic metastases not seen on standard MRI were found in 13 patients (35%) with similar frequency among the most common pathologies studied [CRC: 6 of 15 (40%) vs NET: 5 of 10 (50%)]. Among these 13 patients, an average of 5 additional hepatic metastases per patient were detected. CON-CLUSION: Utilizing MRI controlled breath suspension under general anesthesia enables detection of additional liver metastases not visible on standard MRI imaging in up to 35% of patients. This technique may allow earlier detection of occult liver metastases and potential intervention at the time of imaging. Further studies on the recurrence rate and overall survival of patients undergoing breath-hold MRI compared to standard MR imaging are needed.

P182

The Impact of Pancreaticojejunostomy versus Pancreaticogastrostomy Reconstruction on Pancreatic Fistula after Pancreaticoduodenectomy: Meta-analysis of Randomized Controlled Trials F.S. Zih, ¹* J. Hallet, ¹ R. Deobald, ¹ A.S. Scheer, ¹ N. Coburn, ² P. Karanicolas.² 1. Division of General Surgery, University of Toronto, Toronto, ON, Canada; 2. Division of Surgical Oncology, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, ON, Canada.

Introduction: Pancreatic fistula (PF) remains a common source of morbidity following pancreaticoduodenectomy (PD). Despite numerous prospective studies, the optimal conduit for pancreatic remnant reconstruction is controversial; we sought to compare the impact of pancreaticojejunostomy (PJ) with pancreaticogastrostomy (PG) on PF. Methods: We systematically searched Medline, EMBASE, Scopus, Web of Science, Cochrane Central and the grey literature for randomized controlled trials (RCTs) comparing PJ and PG after PD. Two reviewers independently selected the studies, extracted data, and assessed the risk of bias using the Cochrane Risk of Bias tool. Primary outcome was clinically significant PF, defined as International Study Group on Pancreatic Fistula (ISGPF) grades B and C, or based on authors' definition. Secondary outcomes included bile leak, delayed gastric emptying (DGE), overall morbidity and mortality. We pooled results from the studies using a random-effects model, evaluated the degree of heterogeneity, and explored potential explanations for heterogeneity. Results: From 2212 citations, we identified 6 RCTs including 1010 patients. All studies presented moderate risk of bias. Patients who underwent PG experienced significantly less PF (Relative Risk (RR)=0.65, 95% Confidence Interval (CI) 0.47-0.92), and bile leak (RR=0.19, 0.04-0.88). Delayed gastric emptying, overall post-operative morbidity, and mortality did not differ between the groups. When assessing PF, moderate heterogeneity was present (I2 35%). When considering only the subgroup with soft pancreas/small pancreatic duct the summary risk ratio was slightly lower (RR=0.61, 0.38-0.97). Conclusion: PG reconstruction decreases the rate of PF when compared to PJ. Surgeons should consider reconstructing the pancreatic remnant following PD with PG, particularly in patients at high risk of PF

	PG	1	PJ			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Bassi, 2005	9	79	13	83	18.0%	0.73 [0.33, 1.61]	
Duffas, 2005	13	81	11	68	20.9%	0.99 [0.48, 2.07]	-+-
Fernandez-Cruz 2008	2	53	10	55	5.2%	0.21 [0.05, 0.90]	
Topal 2013	13	162	33	167	31.0%	0.41 [0.22, 0.74]	-8-
Wellner 2012	6	59	7	57	10.7%	0.83 [0.30, 2.31]	
Yeo, 1995	9	73	8	73	14.1%	1.13 [0.46, 2.75]	-
Total (95% CI)		507		503	100.0%	0.65 [0.47, 0.92]	•
Total events	52		82				
Heterogeneity: Chi ² = 7	.64, df =	5 (P =	0.18); I ²	= 35%			has de la de
Test for overall effect: Z	= 2.47 (8	P = 0.0	1)				0.01 0.1 1 10

Figure 1. Impact of PG compared to PJ on proportion of patients presenting a PF, by study (Risk Ratios, 95% Confidence Interval).

Prognostic Factors and Long-term Outcomes of Resected Pancreatic Adenocarcinoma: A Comparison between Two Decades P. Serrano Aybar,^{1*} P.T. Kim,¹ K. Leung,¹ S.P. Cleary,¹ P.D. Greig,¹ C. Moulton,¹ S. Gallinger,¹ A.C. Wei.² *1. University of Toronto, Toronto, ON, Canada; 2. Princess Margaret Cancer Centre, Toronto, ON, Canada.*

Background: There have been improvements in short and long-term survival rates for patients with resected pancreatic adenocarcinoma over time The main objective of this study was to evaluate differences in long-term survival in a cohort of patients with resected pancreatic adenocarcinoma. Methods: This is a retrospective cohort study of patients who underwent pancreatic resection for pancreatic adenocarcinoma over 2 decades at a high volume academic centre. Univariate and multivariate analysis using Cox proportional hazards model were performed to evaluate prognostic factors associated with long-term survival. Time trend analyses were performed to evaluate differences between decades. Results: There were 489 patients identified, 179 patients during the early (1991-2000) and 310 during the recent decade (2001-2010). Main differences between early and recent decade were: node-positive disease rate (59% vs. 69%), number of lymph nodes collected (median 7 vs. 17), perioperative mortality (6.7% vs. 1.6%) and percentage of patients receiving adjuvant therapy (33% vs. 68%), respectively. There were no differences in sex distribution, age, margin positivity rate or tumor grade. In the multivariate analysis, node, margin status, tumor grade, adjuvant therapy and decade of resection were independently associated with overall survival for the entire cohort. Patients who received adjuvant therapy had better median overall survival: 17 [95% confidence interval (CI): 14-22] vs. 26 months (95% CI: 24-31). Median overall survival for the early and recent decade were 16 months (95% CI: 14-20) and 27 months (95% CI: 24-30, P<0.001), respectively. Conclusions: Factors associated with improved long-term survival remain comparable over time: low tumor grade, node and margin negative disease. Short and long-term survival for patients with resected pancreatic adenocarcinoma has improved in the recent decade. This is due to decreased perioperative mortality and increase use of adjuvant therapy.

P184

Robotic Assisted Pancreaticoduodenectomy may be Associated with an Increased Likelihood of Receiving Adjuvant Chemotherapy M. Khreiss,* M. Shakir, B.A. Boone, M.S. Zenati, D.L. Bartlett, A.H. Zureikat, H.J. Zeh, M.E. Hogg. UPMC, Pittsburgh, PA.

Introduction: One of the potential advantages to the minimally invasive approach to the pancreaticoduodenectomy is improved time to recovery and decreased physiologic stress. Multiple prospective randomized trials have shown that adjuvant chemotherapy (AC) after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma (PDA) improves survival compared to surgery alone. However, data from the National Cancer Database shows only 16-32% utilization of AC at teaching hospitals. We hypothesized that patients who undergo robotic pancreaticoduodenectomy (RPD) have a higher chance of receiving AC, completing AC, and faster time to AC than those who undergo open pancreaticoduodenectomy (OPD). Methods We retrospectively reviewed the records of all patients who underwent RPD for PDA between 2009-2012. We compared these results to our cancer registry data of OPD performed for PDA between 2005-2008. Results: 236 patients with PDA were analyzed: 47 underwent RPD and 189 underwent OPD. There was no statistical difference between groups in terms of: age, sex, stage, clinical trial participation, R0/R1 resections, or 30/90 day peri-operative mortality. However, RPD patients were more likely to receive AC than ODP patients (81.8 vs 50.8 %, p<0.001). Only 6.5% of RPD did NOT receive chemotherapy (neoadjuvant chemotherapy [NAC] and AC) compared to 30.2% in OPD (p=0.001). More RPD than OPD patients underwent NAC (46.8 vs. 19.1%, p <0.001). In addition, in the RPD group, there was a trend in patients who received NAC to faster AC than those who did not (57 vs 71.5 days, p=0.067). There was also no difference in time to AC (63 vs 69 days, p=0.356), and no difference in utilization of XRT (23.4 vs 35.1%, p=0.164). Conclusion Patients undergoing minimally invasive robotic pancreaticoduodenectomy were more likely to receive adjuvant chemotherapy than a historical control cohort undergoing open pancreaticoduodenectomy.

P186

Does Preoperative Transperitoneal Biopsy Affect Long-term Outcome of Patients with Resectable Hilar Cholangiocarcinoma? A. Shah,* A. Kengo, V. Zaydfudim, C. Lohse, P. Funk, J.K. Heimbach, C.B. Rosen, D.M. Nagorney. *Department of Surgery, Mayo Clinic, Rochester, MN.*

Introduction: Hilar cholangiocarcinoma is an uncommon hepatobiliary malignancy with an overall poor prognosis. Complete resection provides the only potential for cure. Although several clinicopathological factors have correlated with survival, the impact of various preoperative interventions has not been widely evaluated. We previously showed that preoperative transperitoneal biopsy of cholangiocarcinoma by FNA was associated with a greater frequency of peritoneal metastases in patients undergoing liver transplantation. Whether similar findings occurred in patients undergoing non-transplant resection is unknown. We sought to determine if preoperative transperitoneal biopsy in patients undergoing resection would affect their long term outcome and patterns of recurrence. Method: A retrospective chart review of 89 patients with resected hilar cholangiocarcinoma from 1993-2013 was performed. Data review included perioperative imaging, pathology findings of transperitoneal biopsies, and operative pathology. The primary endpoint of the study was diseasefree survival. Survival was estimated using Kaplan Meier method. Result: Preoperative transperitoneal biopsy was performed in 50 of 89 patients with resected cholangiocarcinoma. FNA biopsy was positive in 30 (62.5%) patients and negative in 18 (37.5%) patients. Two patients had a non-diagnostic result. An R0 resection was performed in 85 of 89 patients. Disease recurred overall in 21 of 50 patients after preoperative biopsy. Among patients with a biopsy +, biopsy -, and no biopsy recurrence rates were 53%, 28%, and 49% respectively. Five year recurrence free survival for biopsy +, biopsy -, and no biopsy was 36%, 24%, and 41% respectively (P =0.52). (See Figure). Conclusion: Transperitoneal biopsy does not impact long-term outcome in patients undergoing resection of hilar cholangiocarcinoma. However, difference in recurrence rates between biopsy positive and biopsy negative patients warrants broader study for corroboration and impact on survival.



P187

Erlotinib Sensitizes Hepatocellular Cancer Cells to TRAIL-induced Cell Death V. Dudeja,* R. Chugh, S. Banerjee, V. Sangwan, O. Alsaied, S. Vickers, A. Saluja. *University of Minnesota, Minneapolis, MN*.

Introduction: TRAIL (Tumor Necrosis Factor-Related Apoptosis Inducing Ligand) is emerging as a promising anti-cancer therapy by virtue of its strong anti-tumor activity in wide range of cancer cells. Unfortunately, Hepatocellular cancer is resistant to TRAIL. Development of strategies to overcome this resistance will lead to emergence of novel therapies for this difficult to treat malignancy. EGFR dependent signaling pathways are up-regulated in multiple cancer cells and induce resistance to chemotherapy and apoptosis. In this study we evaluated whether erlotinib, an inhibitor of EGFR signaling, sensitizes hepatocellular cancer cells to TRAIL induced cell death. Methods: Hepatocellular cancer cell line HUH-7, which is very resistant to TRAIL was treated with TRAIL(0-40ng/ml), Erlotinib(0-25 μ M) or a combination of the two and the effect on the viability and caspase-3 and 8 activation was measured. The effect of the combination therapy was also evaluated in Capan-1 pancreatic cancer cell line and HT29 colorectal cancer cell line to ascertain whether these effects are limited to the hepatocellular cancer only or are observed in other malignancies as well. Results: Combination of Erlotinib and TRAIL was markedly more effective in killing hepatocellular cancer cells when compared with either drug alone (Table). Similarly, combination therapy led to higher level of caspase-3 activation as compared to either drug alone (Table). Analogous results were observed in colon cancer and pancreatic cancer cell lines. Conclusion: Erlotinib sensitizes cancer cells to TRAIL induced apoptosis and cell death. Combination of Erlotinib and TRAIL has immense potential to emerge as novel therapeutic strategy for cancer.

Effect of TRAIL, Erlotinib or combination of the two on the viability and caspase-3 in hepatocellular and pancreatic cancer cell lines.

HU	H-7	Capan-1		
Viability (% of Control) 48h	Caspase-3 (% of Control) 48h	Caspase-3 (% of Control) 48h	Caspase-3 (% of Control) 48h	
100±0	100±0	100±0	100±0	
80±7	168±24	92±11	150±13	
93±5	173±34	91±13	170±12	
50+4*	1057±110*	37+17*	250+17*	

* p<0.05, Data expressed as mean±SEM

P188

The Safety and Efficacy of Minimally Invasive Approaches to Liver Resection: A Meta-analysis N.R. Jackson,* A. Hauch, T. Hu, J. Buell, E. Kandil. *Tulane University School of Medicine, New Orleans, LA*.

Introduction Minimally invasive surgical approaches for liver surgery are gaining popularity. The aim of this study is to compare the safety and efficacy of conventional laparotomy with that of robotic and laparoscopic approaches to liver resection. Methods Two independent reviewers conducted a systematic review on publications in PubMed and EMBASE identified from the following keyword searches: robotic liver, laparoscopic hepatic, and open hepatectomy. Clinical trials and observational studies in an adult population were included. Searches were limited to comparative articles of laparoscopic hepatectomy with either conventional or robotic liver approaches. Outcomes included total operative time, estimated blood loss, length of hospitalization, resection margins, postoperative complications and perioperative mortality. Outcome comparisons were calculated using random effects models to pool estimates of mean net differences or of the relative risk between group outcomes. Results Eight hundred thirty-three abstracts were identified by our search criteria. Forty-nine manuscripts met the inclusion criteria and were included in analysis. Of the 3155 patients represented in this analysis, 1582 (50.1%) underwent a laparoscopic approach, 1572 (49.8%) an open approach, and 60 (1.9%) a robotic approach. There was no difference in total operative times, surgical margins, or perioperative mortality rates between groups. Across all outcome measures, laparoscopic and robotic approaches showed no difference. As compared with the minimally invasive groups, patients undergoing laparotomy had a greater estimated blood loss (pooled mean net change: 152.0mL, 95% CI: 103.3, 200.8), a longer length of hospital stay (pooled mean difference: 2.22d, 95%CI 1.78, 2.66), and a higher total complication rate (OR: 0.51, 95%CI: 0.42, 0.57). Conclusion This meta-analysis suggests that minimally invasive approaches to liver resection are as safe as conventional laparotomy, affording less estimated blood loss, shorter lengths of hospitalization, and lower complication rates. There was no proven advantage of robotic approaches compared to laparoscopic approaches.



LH vs OH total operative complications. LH, laparoscopic hepatectomy; OH, open hepatectomy

P189

Adherence to BCLC Guidelines and Impact on Overall Survival J. Mathew, S. Slipak, A. Kotru, J. Blansfield, N. Woll, M. Shabahang.* *Geisinger Health System, Danville, PA.*

Background: Multiple studies exist that validate the prognostic value of the Barcelona Clinic Liver Cancer (BCLC) staging. However, none have established a survival benefit. The aim of this study was to evaluate the adherence to the BCLC guidelines at a rural tertiary care center, and to determine the effect of following the treatment recommendations on overall survival. Methods: A retrospective chart review was conducted for 97 patients newly diagnosed with hepatocellular carcinoma (HCC) from 2000 to 2012. The treatment choice was compared with the BCLC guidelines and percentage adherence calculated. Overall survival was estimated using the Kaplan-Meier method and the log rank test was used to test the difference between the two groups. Cox regression tests were used to determine independent effects of stage, treatment aggressiveness, and guideline adherence on survival. A p-value <0.05 was considered statistically significant. Results: Of 97 patients, 75% (n=73) were male. Median overall survival was 12.9 months. In 59.8% (n=58) of the patients, treatment was adherent to stage specific guidelines proposed by the BCLC classification. There was no significant difference in overall survival between the adherent and non-adherent groups (11.2 vs 14.1 months, p<0.98). However on stage specific survival analysis, we noted a significant survival benefit for adherence to the guidelines for early stage HCC (27.9 vs 14.1 months, p<0.05), but a decrease in survival for adherence in the end stage (20 days vs 9.3 months, p<0.01). On univariate analysis, more aggressive treatment was associated with increased survival (hazard ratio [HR], 0.4; 95% confidence interval [CI], 0.22 to 0.87; p = 0.018). Multivariate analysis revealed that adherence did not independently affect survival when stage and aggressiveness of treatment were included in the model (HR, 1.3; 95% CI, 0.76 to 2.2, p = 0.34). Conclusions: Although the BCLC guidelines serve as a practical guide to the management of patients with HCC, they are not universally practiced. These results indicate that survival of patients with hepatocellular cancer is determined by stage and aggressiveness of treatment, not adherence to BCLC guidelines.

P190

Pretreatment Neutrophil/Lymphocyte Ratio versus Platelet/Lymphocyte Ratio as a Predictor of Survival in Pancreatic Cancer

Patients B. Azab,* M. Shariff, N. Shah, W.K. Von Waagner, A. Alam, A. Picon, S.W. Bloom. *Staten Island University Hospital, Staten Island, NY.*

Background: The aim of our study was to assess the predictive value of pretreatment platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR) in terms of survival in pancreatic cancer patients. Methods: A retrospective study of a prospectively maintained database of 367 pancreatic cancer patients treated between January 2004 and December 2011. Exclusion criteria included those with hemoproliferative disorders, leukopenia

(WBC<4k/cc), leukocytosis (WBC>12k/cc) and unavailable blood count before surgery or chemotherapy. Those patients expired within 60 days of blood count draw were also excluded. Survival status was obtained from our cancer registry and social security death index. Results: Total of 157 patients were qualified for the study. The average follow-up period was 14 months (range 80-3 month). There were 57 patients underwent pancreatectomy and 86 received chemotherapy. According to Kaplan Meier survival curves, the patients in the highest 4th NLR quartiles had worse survival compared to lower NLR quartiles(p=0.029), whereas the highest PLR quartile did not (p=0.356) (Figure 1). Conclusion: Pretreatment NLR is a significant predictor of mortality in pancreatic cancer patients, whereas pretreatment PLR was not.



Figure 1: Kaplan Meier curves of the survival among the pancreatic cancer patients according to their pretreatment neutrophil / lymphocyte ratio (NLR) and platelet / lymphocyte ratio (PLR) quartiles.

P191

Post-treatment Serum CEA Levels May Determine Response to Yttrium-90 Microspheres in Patients with Refractory Hepatic-only mCRC R. Aimaq,* G. Singh, Y. Chen, L. Lai. *City of Hope, Duarte, CA*.

Introduction: Yttrium-90 (Y-90) is a radioisotope that can be used to treat tumors while sparing surrounding healthy tissues. In particular, Y-90 resin microspheres is FDA approved for selective internal radiation therapy (SIRT) of unresectable hepatic metastatic colorectal cancer (mCRC). The purpose of this study was to evaluate our institutional experience using Y-90 SIRT in the mCRC patient population. Methods: Patients with liver-only mCRC who received Y-90 SIRT from 2008 - 2012 were identified from a prospectively maintained database. Demographic, treatment and outcome variables were analyzed. Overall survival (OS) was calculated using the Kaplan-Meier method and differences compared using the log rank test. Chi-square and multivariate analysis were used to evaluate prognostic factors. Results: In the study period, 19 patients with hepatic only mCRC refractory to systemic therapy and ablative techniques underwent Y-90 SIRT. These patients were mostly male (n = 11) with predominantly bilobar (n = 9) or right lobe disease (n = 8) and had failed a median of two regimens of systemic chemotherapy (range 1-4) and liver-directed therapies. Fifteen patients underwent one treatment; four were treated twice. The most common complication was transient nausea and abdominal pain (63%). Post-procedure CT at 2 months demonstrated stable disease

in 5/22 (23%) and progression in 17/22 (77.3%). OS in the patients with stable disease compared with patients with progression was 18 vs. 10 months (p=0.06). On multivariate analysis age, sex, race, prior treatment, and baseline serum CEA levels were not predictive of response; however, initial post-treatment CEA levels were significantly lower in the stable disease group compared with the group who progressed (p=0.02). Conclusions: Patients with refractory hepatic mCRC may be treated with Y-90 SIRT with minimal morbidity. The treatment may confer a possible survival advantage in those patients who have stable disease on post-treatment imaging. Post-treatment CEA levels were and assist in the determination of treatment benefit.

P192

Survival after Resection For Pancreatic Cancer at a High Volume, Academic, Community-based Hospital does not Differ from Outcomes Seen in University Hospitals and Specialty Cancer Centers C. Anderson, P. Santoro, R.Z. Abdel-Misih, N.J. Petrelli, J.J. Bennett.* Surgical Oncology, Helen F. Graham Cancer Center, Newark, DE.

Introduction: Outcomes in pancreatic cancer treatment in community-based settings remain understudied. The aim of our study is to evaluate survival after resection for pancreatic ductal-adenocarcinoma (PDAC) in a high-volume, community-based teaching hospital. Most of the literature on pancreatic cancer outcomes is derived from University based medical centers and specialty cancer centers. Since most cancer care in the country is provided through community hospitals, it is imperative to evaluate outcomes in this setting. Methods: The study was designed as a retrospective review of medical records for patients who underwent curative surgical resection for PDAC between 2006 and 2012. Patient and tumor characteristics were evaluated. Overall survival was determined using Kaplan-Meier analysis. Data was compared to the pancreatic cancer nomogram, derived from a high volume, specialty cancer center. Results: Between 2006 and 2012, 295 patients were brought to the operating room for resection of various pancreatic neoplasms, 118 had PDAC, and 69 underwent successful resection. These patients are the focus of the study. Median overall survival was 19 (±4) months. Median N-stage specific survival was: $N0 = 25 (\pm 5.6)$ months, $N1 = 18 (\pm 3.5)$ months. Median survival stratified by margin resection status: $Margin(-) = 24 (\pm 3.5) months$, Margin(+) =11 (±2.8) months (p=0.07). For our patient population, the pancreas cancer nomogram predicted survival rates of 64%, 30% and 16% at 1, 2 and 3 years. The actual survival for our patient population was 55%, 35% and 23% at 1, 2 and 3 years, respectively, with a 5 year overall survival of 17%. Conclusion: Post-resection survival outcomes for pancreatic adenocarcinoma treated at a high volume community cancer center are similar to data published from University hospitals and specialty cancer centers. In an era where performance metrics for complex surgeries are being scrutinized, this study shows that specialized community hospitals can provide comparable outcomes and patients don't need to travel far to obtain optimal care.

P193

A Single Institution Experience with Irreversible Electroporation for Pancreatic Cancer B. Bates,¹ J. Ouellette,¹ S. Kauffman,² M. Hellan.^{1*} 1. Wright State University, Dayton, OH; 2. Miami Valley Hospital, Dayton, OH.

Background: Irreversible electroporation (IRE) is an ablative technique in which short, high-voltage pulses are applied to tissues to permeabilize the cell membranes. As no thermal energy is created it can be used close to vital structures. Here we report our initial experience with this novel technique in a series of unresectable pancreatic cancer. Methods: We performed a retrospective data review of all IRE cases performed at out institution for pancreatic cancer from July 2011 to September 2013. These patients were evaluated for peri-operative morbidity, mortality and oncologic outcome. A total of 7 open pancreatic cases were performed. Results: Seven patients (4 women and 3 men) underwent IRE with a median age of 68 years (51 to 76 years) and a median BMI of 34 (22 to 40). One patient underwent margin accentuation with IRE in combination with a distal pancreatectomy. One patient was treated for a recurrence at the root of the SMA one year after a Whipple followed by CHT and CRT. The remaining five patients were found unresectable at time of surgery and ablation of the tumor was performed instead. In one of the patients the final pathology was benign, the other four received perioperative CHT or CRT. We encountered no intra-operative complications with a median blood loss of 100 ml (50 - 1500 ml). The overall 30-day mortality was 0%. Median length of
stay was 8 days (3-31). Procedure related complications included one gastric hematoma and one gastric outlet obstruction due to post-ablation edema. Two patients died of disease at 6 and 12 months after IRE ablation, the remaining patients are alive with no evidence of disease progression (1 - 21 months). Conclusion: Our comprehensive early experience suggests that IRE for unresectable pancreatic cancer is safe and feasible. Other small series have suggested a survival benefit. A randomized trial including IRE in the treatment regimen for pancreatic cancer should strongly be considered to truly understand the possible benefits of the novel technique.

P194

Efficacy and Cost-effectiveness of Robotic Hepatectomy J.G. Sham,* M.K. Richards, R. Yeung, J. Park. University of Washington, Seattle, WA.

Introduction Robot-assisted surgery is increasingly utilized in many specialties and becoming the standard for select procedures. However, its use in hepatobiliary surgery has only recently been explored at a handful of institutions. Concerns around safety, as well as a perceived increase in cost, are often cited as barriers to adopting this technology. Methods Between May 2011 and March 2013, forty-six laparoscopic robot-assisted hepatectomies were performed at a single institution. Clinical data from the surgical procedures and postoperative outcomes were reviewed retrospectively. For cost analysis, 41 patients who underwent open hepatectomy during the same fiscal year were selected as controls. Results Of the 46 robotic hepatectomies, 16 (35%) were performed for metastatic colorectal cancer and 15 (33%) for hepatocellular carcinoma. Median patient age was 57 and 48% were female. Thirty-two (70%) patients had undergone prior abdominal surgery and median BMI was 26. Median largest tumor size was 3.5cm and a median of 2 hepatic segments were resected. Median operative time was 229 minutes with a median blood loss of 250ml. Four (8.7%) patients required intraoperative blood transfusion and three (6.5%) were converted to an open procedure. Median length of stay was 3 days. All-cause 30-day mortality was 0%. For patients in whom 1-2 hepatic segments were removed, direct costs were 34% lower compared to open controls (p=0.04). No difference in direct costs was observed in patients undergoing more extensive liver resection (\geq 3 segments). Conclusions Our institution's preliminary experience demonstrates that hepatectomy can be safely and effectively performed via robotic approach. Operative length, blood loss, conversion rate, intraoperative transfusion rate, complication rate, and mortality for these cases are equivalent or superior to those reported in open and robotic series from other institutions. Direct costs are not higher in robotic hepatectomy, particularly in smaller resections, likely due to the decreased length of stay. As surgeons gain more experience with this technology, further studies are needed to effectively compare its outcomes with traditional surgical approaches.

P195

Outcomes of Microwave Ablation for Colorectal Cancer Liver Metastases O.S. Eng,^{1*} S. Narayanan,¹ A. Tsang,¹ D. Moore,¹ C. Chen,¹ C.J. Gannon,² D.A. August,¹ D.R. Carpizo,¹ L.G. Melstrom.¹ I. Rutgers Cancer Institute of New Jersey, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ; 2. Advanced Surgical Associates of New Jersey, Capital Health Management, Pennington, NJ.

Introduction: The surgical management of colorectal cancer liver metastases continues to evolve to optimize oncologic outcomes while maximizing parenchymal preservation. Although long term results after hepatectomy and radiofrequency ablation are well reported, follow-up data after microwave ablation are limited. This study investigates outcomes and patterns of recurrence in patients who underwent intraoperative microwave ablation of colorectal cancer liver metastases. Methods: Thirty-three consecutive patients who underwent intraoperative microwave ablation with or without concomitant hepatectomy of colorectal cancer metastases from 2009-2013 at our tertiary care center were identified. Clinical and pathologic variables were recorded and analyzed. Perioperative and long-term data were reviewed to determine outcomes. Results: In the patient cohort, 73% (24) were male, and the median age was 61 (range 42-89). A total of 49 tumors were treated with ablation, with 70% (34) of ablations in conjunction with a concomitant hepatectomy. Most tumors were ≤3 cm (42, 86%). Median preoperative CEA was 4 ng/mL (range 0.7-9.6). Nearly all patients received either preoperative (32, 97%) and/or postoperative (30, 90%) chemotherapy. Median length of stay was 6 days (range 1-32). Median Clavien-Dindo classification was 1 (range 0-5). Fourteen (42%) of patients had no complications. Median follow-up was 301 days (range 13-1035), with 45% (15) of patients presenting with a recurrence. Median time to first recurrence was 259 days (range 64-956). In those patients, 13% (2) presented with an isolated local recurrence in the liver. The majority of recurrences included either a local and distant component (12, 80%) or distant disease alone (2, 7%). On univariate analyses, there were no perioperative variables to predict local recurrence alone. Conclusion: Intraoperative microwave ablation is a safe and effective modality for use in the treatment of colorectal cancer liver metastases. Recurrences in these patients most often included distant disease. Therefore, microwave ablation alone or in conjunction with hepatectomy is a reasonable approach for the management of metastatic colorectal cancer to the liver.

P196

Depth of Invasion is Predictive of Sentinel Lymph Node Status and Overall Survival in Merkel Cell Cancer F. Smith,* B. Yue, S. Marzban, B. Walls, R. Jackson, C.A. Puleo, T. Padhya, C.W. Cruse,

R.J. Gonzalez, A.A. Sarnaik, J.L. Messina, V.K. Sondak, J.S. Zager. H. Lee Moffitt Cancer Center, Tampa, FL.

Introduction: Unlike melanoma, the impact of primary tumor depth in predicting the risk of a positive sentinel lymph node biopsy (SNLB) and survival in Merkel Cell Cancer (MCC) is not well characterized. We sought to identify factors associated with SLNB status, disease-specific survival (DSS) and overall survival (OS) in patients (pts) with MCC. Methods: An IRB-approved retrospective review of pts with MCC treated between 1988 and 2012 at a single center. Pts. were categorized into 5 groups based on nodal status: 1) SLNB negative, 2) SLNB positive, 3) SLNB not done, 4) MCC of unknown primary origin (MCCUP), and 5) primary MCC with synchronous clinically evident regional nodal disease (MCC + RLN). Logistic regression, proportion hazard models, and competing risk regression methods were used to analyze factors associated with SLN status and survival. Results: 391 pts were identified. 274 (70%) were male and median age was 75 years (range 13-96). Median tumor diameter was 1.5 cm (range 0.2-12.5 cm) and median tumor depth was 4.8 mm (range 0.3-45.0 mm). 194 pts had SLNB performed; the rate of SLN positivity was 31% (61 pts). Age, gender and presence of lymphovascular invasion were not associated with SLN positivity. Increasing tumor diameter and depth were associated with an increased risk of SLN positivity (p=0.024 and 0.016, respectively) Table 1. Presence of immunosuppression, increasing tumor diameter and tumor depth were associated with overall survival (p=<.01, <.001 and <.001 respectively). Primary location was associated with OS (p=0.032); truncal primary had a 1.92 fold- increased risk vs. head and neck. The DSS differed by patient group (p=0.021), being best in pts with negative SLNB and worst in pts with MCC + RLN at presentation. SLNB positive and SLNB not done patients had the worst DSS and OS. Pts with negative SLNB fared marginally better than patients with a positive SLNB (85 months vs. 59.5 months, p=0.062). Conclusions: Increasing tumor depth and diameter are independently associated with the probability of positive SLN and worse OS in MCC. Additional data is required to analyze the impact of tumor depth in the staging of MCC.

Table 1. Clinicopathological features vs. Risk of Positive Sentinel Lymph Node Biopsy and Overall Survival in Merkel Cell

Variable	F	Risk of Posi SLNB(n=1	itive 94)	Overall Survival (n=388)		urvival 8)	Disease Specific Survival (n=388)		
	OR	95% CI	p value	HR	95% CI	p value	HR	95%CI	p value
Gender (M vs F)	1.5	0.7	0.27	0.8	0.6-1.2	0.27	2.1	1.2-3.8	0.014
Age (per 10 year increase)	1.2	0.96-1.6	0.26	1.6	1.3-1.9	<.001	1.4	1.1-1.4	<.01
Presence of immunosuppression(n=349)	1.2	0.47-2.92	0.74	1.8	1.2-2.7	<.01	1.3	.7-2.5	0.41
Tumor diameter (cm) (n=120, 193,193)	1.4	1.05-1.89	0.024	1.2	1.1-1.3	<.001	1.2	1.1-1.3	<.001
Tumor depth (mm) (n=139,209,209)	1.1	1.02	0.16	1.1	1.0-1.1	<.001	1.1	1.1-1.1	<.001
Location of Primary			0.033			0.032			0.58
Head and Neck	1			1			1		
Lower Extremity	2.9	1.3-6.7		0.9	0.5-1.5		0.9	0.4-1.8	0.77
Unknown	N/A	N/A	N/A	0.7	0.4-1.3		0.5	0.2-1.3	0.16
Trunk	2.8	0.9-8.0		1.9	1.2-3.2	· · · · · ·	1.4	0.7-2.7	0.34
Upper Extremity	1.2	0.5-2.5		0.9	0.6-1.3		1	0.5-1.5	0.64
Nodal Group* (n=356)									
Negative SLN (n=130)	N/A	N/A	N/A	1		0.0049	1		0.02
Positive SLN(n+61)	N/A	N/A	N/A	1.5	0.9-2.4	-	2.03	1.0-4.2	0.058
SLNB Not done	N/A	N/A	N/A	1.9	1.3-2.9		2.29	1.2-4.3	0.01
MCCUP (n=46)	N/A	N/A	N/A	0.8	0.4-1.8		1.28	0.4-4.0	0.67
MCCKP + RI N (n=29)	N/A	NI/A	NIA	0.2	12.32		3.00	15.65	< 01

Patients with distant metastatic disease were removed from the association testing between nodal status and OS or DSS. \P Sample size for the Risk of Positive SLNB, OS and DSS respectively.

Hazard ratios for LVI on DSS were unable to be estimated because no patient without LVI died of MCC, and this suggests strong prognosis effect of LVI.

P197

The Effect of the AJCC 7th Edition Definition of T1 Melanoma on Utilization of Sentinel Lymph Biopsy for Thin Melanoma T.J. Hieken,^{1*} T.E. Grotz,¹ N.I. Comfere,² J.W. Inselman,³ E.B. Habermann.³ I. Mayo Clinic, Department of Surgery, Rochester, MN; 2. Mayo Clinic, Departments of Dermatology and Pathology, Rochester, MN; 3. Mayo Clinic, Department of Health Sciences Research, Rochester, MN.

Introduction: Practice guidelines suggest that sentinel lymph node biopsy (SLNB) be offered to select patients with "high risk" thin melanomas. While the majority have an excellent prognosis and low prevalence of LN metastasis, 25% of melanoma deaths are attributable to T1 tumors. Earlier guidelines recommend consideration of SLNB for T1b patients. The AJCC 7th edition staging, implemented in 2010, changed the definition of T1 melanoma to reflect mitogenicity rather than level of invasion, based on prognostic models, not the likelihood of occult LN metastasis. We assessed the effect of this 2010 staging change on SLNB rates for T1 melanoma patients. Methods: Using Surveillance, Epidemiology, and End Results (SEER) Registry 2004-2010 data, we identified 32,527 cases of T1 melanoma and compared pre-2010 (N=27,170) with 2010 (N=5,357) data on a year to year basis. Logistic regression models were used to analyze SLNB rates in 2004-2009 vs 2010 T1 melanoma patients. Results: 40.9% of 2004-2009 T1b melanoma patients (prior to staging change) vs 33.3% of 2010 T1b patients (after staging change) had a SLNB, while the overall SLNB rate for T1 patients increased from 12.1% in 2004 to 14.4% in 2010 (p<0.001 for both). SLNB was performed for 38.3% of 2004-2009 melanomas ≥ 0.7 mm vs 39.3% post-staging change (p=0.556). T stage, tumor thickness, level, ulceration, SEER registry and patient age were associated with the performance of SLNB, all p<0.001. The proportion of SLN+ T1 patients was 6.1% pre-2010 and 7.8% in 2010, p=0.12. The rate of completion LN dissection for SLN+ patients declined from 59.6% pre-2010 to 46.7% in 2010, p=0.07. Conclusions: Overall SLNB rates for T1 melanoma patients increased from 2004 to 2010 along with SLN positivity rates, while performance of SLNB for T1b patients decreased. This may be a function of T-stage reclassification, as SLNB rates were stable for patients with melanomas ≥0.7mm. These data suggest that mitotic rate may not be the best predictive marker for occult LN disease. Improved definition of and treatment guidelines for "high-risk" T1 melanoma patients most likely to benefit from lymph node surgery are needed.

SLNB	for	T1	Melanoma	Patients	Before	and	After	the	AJCC	7th
Edition	ı Re	clas	sification							

	Pre 2010 (AJCC 6th)	2010 (AJCC 7th)	P value
T1 Melanoma Cases, (N=32,527)	27,170	5,357	
T1 (listed only as T1), N, % of all T1 Tla Patients, N, % of all T1 Tlb Patients, N, % of all T1 T1 NOS (listed as T1 NOS), N, % of all T1	1,645 (6.1%) 19,050 (70.1%) 4,373 (16.1%) 2,102 (7.7%)	133 (2.5%) 2,615 (48.8%) 1,199 (22.4%) 1,410 (26.3%)	<0.001
SLNB performed T1, N, %	3,640 (13.4%)	770 (14.4%)	0.056
SLNB performed T1a, N, %	1,443 (7.6%)	228 (8.7%)	0.0398
SLNB performed T1b, N, %	1,787 (40.9%)	399 (33.3%)	< 0.001
Thickness of T1 Melanoma Cases, N, % ≥0.7 mm <0.7 mm Missing/Unknown	4,779 (17.6%) 20,227 (74.4%) 2,164 (8.0%)	919 (17.2%) 3,872 (72.3%) 566 (10.6%)	<0.001
SLNB performed by thickness, N, % SLNB performed ≥0.7 mm SLNB performed <0.7 mm	1,828 (38.3%) 1,562 (7.7%)	361 (39.3%) 340 (8.8%)	0.5562 0.0252
Mean number of SLNs removed (mean, SD)	3.2 (4.8)	3.1 (5.1)	0.9309
SLN Status: N (%) SLN-negative SLN-positive Unknown	3,291 (90.4%) 223 (6.1%) 126 (3.5%)	690 (89.6%) 60 (7.8%) 20 (2.6%)	0.1208
Number of Positive Nodes, SLN+ cases (mean, SD)	1.4 (1.3)	1.6 (2.3)	0.6359
Completion LND performed for SLN+ patients, N (%)	133 (59.6%)	28 (46.7%)	0.0716

Abbreviations: SLNB = sentinel lymph node biopsy, SLN = sentinel lymph node, SLN+ = sentinel lymph node positive

P198

CXCL10 Expression by Melanoma Cells is Associated with Metastatic Ability and Tumor Cell Adhesion S.C. Wightman,¹* A. Uppal,¹ S.M. Lim,¹ G. Oshima,¹ S. Ganai,² T.E. Darga,¹ N.N. Khodarev,¹ M.C. Posner,¹ R.R. Weichselbaum.¹ *1. University of Chicago, Chicago, IL; 2. Southern Illinois University, Springfield, IL.*

Introduction: Oligometastasis is a state of limited metastasis with the potential for cure by surgery or radiotherapy. We designed a syngeneic mouse melanoma model with stable tumor clones representing oligo- (<5 lesions) and polymetastatic (>30 lesions) pulmonary disease. After evaluating transcriptomic and proteomic differences between oligo- and polymetastatic tumor cells, we found CXCL10 consistently elevated in polymetastatic tumor clones. To understand potential functions of CXCL10 in the metastatic phenotype we generated stable knockdowns (KDs) of this chemokine in oligo- and polymetastatic clones of B16 murine melanoma. Methods: Stable CXCL10 KDs of oligo- and polymetastatic B16F1 clones (P2M5B and P2M3C respectively) were generated by lentiviral transfection. CXCL10 expression was assessed by Western blot and ELISA (R&D Systems, MN). Cell adhesion was measured in 96-well plates coated by Matrigel and assayed by Cell Titer-Blue. Results: The oligoand polymetastatic CXCL10 KDs demonstrated more than 10-fold suppression of CXCL10 expression by Western analysis relative to controls. Secretion of CXCL10 was suppressed 4.60-fold (p=0.0005) and 1.35-fold (p=0.0003) in P2M5B and P2M3C KDs respectively by ELISA. The oligometastatic parental clone P2M5B had reduced adhesion compared with the polymetastatic P2M3C clone (1.49-fold p = 0.00006); this indicates that adhesion may be responsible for oligo- versus polymetastatic development of metastases. Suppression of CXCL10 led to a 1.33-fold (p=0.04) and 1.27-fold (p=0.001) decrease in adhesion of P2M5B and P2M3C KDs respectively when compared to the non-targeting vector. Conclusion: Our data indicate that colonization of the lung microenviroment by melanoma cells is associated with matrix adhesion properties of tumors. Our data also demonstrate for the first time that CXCL10 plays an important role in the regulation of tumor cell adhesion to cellular matrix, and therefore may act as previously unrecognized regulator of melanoma metastases development.

P199

Does Increasing Wait Time to Surgery for Cutaneous Melanoma Increase the Risk for Nodal Metastases? B. Giles, ¹ N. Wasif,² B. Rawal, ¹ S. Bagaria. ^{1*} *1. Mayo Clinic, Jacksonville, FL; 2. Mayo Clinic, Scottsdale, AZ.*

Introduction There are no standardized recommendations for how long a patient can wait from time of diagnosis to definitive surgery for cutaneous melanoma without increasing the risk of nodal metastases. In this study we investigate the impact of wait-time to surgery for cutaneous melanoma on the risk for sentinel node metastasis. Methods A retrospective review of a singleinstitutional database was performed to identify patients diagnosed with clinically node negative cutaneous melanoma undergoing sentinel node biopsy between 1995 and 2013. Wait-time to surgery was calculated from the date of diagnosis to date of definitive surgery. The primary outcome measured was the presence of sentinel nodal metastasis. Results Our study population consisted of 1,037 patients with cutaneous melanoma. Median age was 63 years. There were 487 (47%) T1 lesions, 317 (31%) T2 lesions, 163 T3 (16%) lesions, and 70 (7%) T4 lesions. Sentinel node metastases were found in 116 (11%) of all cases and in 39 (8%) T1, 229 (9%) T2, 31 (19%) T3, and 19 (27%) T4 lesions. The number of cases with wait-times of 1-14, 15-42, and > 42 days were 115 (11%), 685 (66%), 237 (23%), respectively. The mean wait-time for those with negative sentinel nodes was similar to those with positive sentinel nodes (34 vs. 32 days, respectively). The rate of sentinel node metastasis did not differ for wait-times of 1-14, 15-42, and > 42 days (12%, 11%, 11%, respectively; p=0.94). Patients were then stratified into low-risk melanomas (T1 and T2 lesions) and high-risk melanomas (T3 and T4 lesions). Once again, no difference in the rate of sentinel node metastases was seen for wait-times of 1-14, 15-42, and > 42 days for low-risk melanomas (10%, 8%, and 8%, respectively; p=0.80) and high-risk melanomas (21%, 22%, and 19%, respectively; p=0.91). Conclusion When compared to a wait-time of < 2 weeks, wait-times of 6 weeks for sentinel node surgery are not associated with an increased incidence of sentinel node metastasis in patients with cutaneous melanoma. These data can provide reassurance to patients and their referring physicians without immediate access to a melanoma center.

Ipilimumab Combined with Isolated Limb Perfusion (ILP) for Extremity Melanoma M. Kim,* C. Wilfong, A.B. Blum, J.A. Alosi, D. Fisher, J. Skitzki. *Roswell Park Cancer Institute, Buffalo, NY.*

Background: Ipilimumab (IPI) an anti-CTLA-4 antibody has shown significant activity against metastatic melanoma. T cell CTLA-4 receptors inhibit immune activation and systemic IPI promotes anti-tumor immunity. The combination of systemic IPI prior to regional therapy was explored with a novel mouse model of ILP. Methods: Female C57BL/6 mice were injected with 1 × 106 B16-OVA cells subcutaneously in the leg. After 5 days of tumor establishment, 3 doses of IPI (100 µg intraperitoneal) were delivered over 7 days. In the ILP group, tumor bearing legs were perfused with 90 µg melphalan for 30 minutes through the superficial femoral artery using a non-oxygenated circuit. Using immunohistochemistry and flow cytometry, CD8+ and OVA-specific CD8+ T cells within the tumor microenvironment were analyzed at 1, 7, and 14 days following ILP. Tumor growth was measured every other day. Result: Administration of IPI by itself had no effect on tumor growth compared to controls. ILP treatment significantly delayed tumor growth with no additive effect when combined with IPI. Local and systemic toxicity was not increased after ILP with the addition of IPI. However, increased numbers of CD8+ T cells were seen in tumors treated with IPI compared to untreated controls at 1 and 7 days (p<0.05). Antigen-specific tumor infiltrating cells were also noted to be increased with both IPI and IPI+ILP treatments (p < 0.05vs. untreated control and ILP alone respectively). At 2 weeks post limb perfusion, the IPI+ILP mice continued to trend towards increased tumor infiltrating CD8+ and OVA-specific cells compared to ILP alone. Conclusion: The addition of IPI to ILP produced equal inhibition of tumor growth with no added toxicity. Importantly, tumor infiltrating CD8+ and OVA-specific cells were increased and were indicative of a brisk immune response that may be exploited during regional therapies to enhance local, regional, and systemic anti-tumor responses.



P201

Yield of Radiologic Studies for Identifying Distant Disease in Clinical Stage IIB and IIC Melanoma C.V. Angeles,* D. De Blasi, M.S. Brady, C.E. Ariyan, D.G. Coit. Surgical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Introduction: The diagnostic value of radiologic studies for patients with newly diagnosed stage II melanoma is unknown. This study sought to determine the yield of radiologic imaging at presentation in the highest risk patients with Stage IIB or Stage IIC melanoma. Methods: Clinical stage IIB/C (cIIB, cIIC) patients diagnosed between 1998-2008 were identified from a prospective single institution database. Patients were included if radiologic studies were completed within 3 months of diagnosis in image naïve patients prior to sentinel lymph node biopsy (SLNB). Studies included were CT or MRI of the brain, CXR, CT or MRI of the neck, chest, abdomen, or pelvis, PET scan, or bone scan. Results: A total of 495 patients were included in the analysis: 300 stage cIIB and 195 stage cIIC. Median follow-up was 55 months. Among stage cIIB patients, imaging studies resulted in indeterminate findings in 30% and true positive (TP) in 0.7%. Among stage cIIC patients, imaging studies resulted in indeterminate findings in 27.7%, TP in 9.2%, and FP in 4.1%. The true positive findings are 4 non-melanoma cancers and 16 melanoma metastases. Median recurrence free survival (RFS) for all patients with negative and indeterminate findings was 88 and 36 months, respectively (p<0.001). Of patients

who subsequently underwent SLNB (299/495), those with indeterminate imaging findings were more likely to have a positive SLN than those with negative studies (45% vs 32%, Z-score -2.1, p=0.03). Conclusion: Radiological studies obtained during initial staging workup for clinical stage IIB and IIC melanoma patients generate indeterminate findings in 29% of patients and identify true positive disease in only 4%. Patients with indeterminate findings are more likely to have a positive SLN and worse RFS than patients with negative studies.

	Image Result 						
SLNB	Negative (%)	Indeterminate (%)	True Positive (%)	False Positive (%)			
Negative	134 (42)	49 (34)	4 (20)	4 (50)			
Positive	63 (20)	40 (28)	4 (20)	1(13)			
Not Done	126 (39)	55 (38)	12 (60)	3 (38)			
Total	323 (100)	144 (100)	20 (100)	8 (100)			

P202

Necessity of Completion Pelvic Lymph Node Dissection after Positive Inguinal Sentinel Lymph Node Biopsy in Cutaneous Melanoma K. Carpenter, M.R. Forster,* T. Sarantou, J.C. Salo, J.S. Hill, R.L. White, Jr. Department of Surgical Oncology, Carolinas Medical

Center, Levine Cancer Institute, Charlotte, NC.

Introduction: In patients with melanoma metastatic to an inguinal sentinel lymph node (SLN), the decision to complete a pelvic lymph node dissection including external iliac and obturator nodes in addition to an inguinal dissection, is controversial. We reviewed our experience with inguinal SLN's to evaluate the role of pelvic lymph node dissection in an attempt to identify those patients at risk for iliac recurrence. Methods: We retrospectively reviewed patients at our institution that underwent inguinal SLN biopsy for melanoma between 1996 and 2012. Patients were evaluated for tumor characteristics, SLN status, surgical treatment, and recurrence patterns. Results: 301 patients underwent inguinal SLN biopsy from 310 groins: 188 (63%) were women, the median Breslow depth of primary tumors was 1.4mm, and 58 (19%) were ulcerated. Fifty-nine patients (20%) had metastatic melanoma identified in a SLN, and their median Breslow depth was 2.1mm. Fiftythree SLN positive patients (90%) underwent further lymph node dissection; all of these were inguinal dissections without pelvic lymph node dissection. Over a median follow up of 38.4 months, 46 of the 301 patients (15%) developed recurrent melanoma, with a median time to recurrence of 17.2 months. Fifteen patients recurred in an iliac lymph node, 7 of whom (47%) previously had a positive inguinal SLN. Only 1 of the 7 met current guidelines for pelvic lymph node dissection. Thirteen of 15 patients (87%) who went on to recur in an iliac node, had eventual distant metastases, and 11 of them (73%) have died of their disease. The median time from development of iliac disease to the development of distant metastases was 3.1 months. Conclusions: Only one of 15 patients that developed iliac nodal recurrent melanoma met current guidelines for pelvic lymph node dissection. Also, nearly 90% of patients who recurred in their iliac nodes ultimately recurred distantly, and have had a 73% mortality, supporting the idea that iliac metastasis could be considered distant metastatic disease rather than regional disease, and would therefore not benefit from prophylactic pelvic lymph node dissection.

P203

Therapy With Hedgehog Inhibitors for Locally Advanced or Metastatic Basal Cell Carcinoma R.I. Neves,* B. Anderson, J. Drabick. *Penn State Hershey Cancer Institute, Hershey, PA*.

Basal cell carcinoma (BCC) may occasionally progress to an advanced state that is no longer amenable to surgery, radiation therapy or, more rarely, may spread to distant sites. Genetic studies have shown that almost all BCC's contain aberrant Hedgehog signaling pathway activation and uncontrolled proliferation of basal cells. Vismodegib is an inhibitor of the Hedgehog pathway that binds to and inhibits SMO, a transmembrane protein involved in Hedgehog signal transduction. We present a series of patients from a single institution with locally advanced BCC (LABCC) or metastatic BCC (MBCC) that were treated with Vismodegib in a 16-month period. From April 2012 to August 2013 twenty adult patients with LABCC or MBCC not candidates for surgery or radiation therapy received Vismodegib 150 mg daily until disease progression, unacceptable side effects or discontinuation of the treatment. When applicable, objective response rate was assessed by RECIST 1.0 and defined as decrease of 30% or more in the externally visible or radiographic dimension

or complete resolution of ulceration present at baseline. Progressive disease was defined as increase of 20% or more in the externally visible or radiographic dimension, new ulceration, or new lesion. Patients who had a response underwent tumor biopsy during treatment and pathological evaluation was used to determine whether the response was partial or complete. The most common side effects from treatment were loss of taste, cramps, hair loss, weight loss and fatigue. Patients with LABCC (n=19) had objective response rate above 80%. As of the data-cutoff point 13 patients had complete response confirmed by absence of residual BCC on biopsy and had not disease progression. The only MBCC to the axillary lymph nodes (n=1) had only clinical objective response by assessment of cessation of pain, weeping and shrinkage of axillary wound by 2 months of treatment. The totality of patients with LABCC had tumor shrinkage. Visible reductions in tumor size and improvement in appearance were noted for the majority of patients. Conclusions: Vismodegib is a new treatment alternative and associated with tumor responses in patients with LABCC or MBCC.



Multiple BCC's involving face, scalp and trunk. Complete response after 6 months of treatment

P204

Prognosis of Acral Lentiginous Melanoma compared to Sun Induced Melanomas: An Analysis of 1,039 Cases H. Martinez Said,^{1*} M. Cuellar-Hubbe,¹ V. Villavicencio-Valencia,¹ X. Sanchez-Galvez,¹ J. Torres-Pelayo,¹ J. De la Garza-Salazar,¹ C.M. Balch.² *1. Skin Cancer* & Soft Tissue Tumors, Instituto Nacional de Cancerologia, Mexico City, Distrito Federal, Mexico; 2. University of Texas Southwestern Medical Center, Dallas, TX.

Introduction: Of the four major histologic subtypes of cutaneous melanoma, Acral Lentiginous Melanoma (ALM) is the most frequent in Latin America and Asia. Some studies indicate that ALM has a worse prognosis when compared with other subtypes. This study report the analysis of ALM compared with sun-induced melanomas. Methods: Review of Melanoma prospectively revised database from 1982 to 2012. All patients with subungueal, palmar or plantar melanoma and histologically confirmed was recorded as ALM. The other subtypes were clinically and pathologically identified. A total of 1,603 patients were diagnosed with melanoma and includes this database. Of this 1,039 patients were ALM or Sun-induced melanoma with available information for analysis of Breslow thickness, pathologic determination of ulceration, localization, histologic subtypes, age, gender, nodal status, presence of distant metastases and follow up. Results: A total of 555 ALM and 484 sun-induced melanomas (SIM) were identified. The median age was 63.8 and 56 years respectively (p=0.01). The 66.7% of ALM patients were older than 60 years while only 47.9% of SIM (p=0.0001). The median Breslow thickness was 5.79 mm for ALM patients and 4.23 mm for SIM (p=0.0001). The distribution according to Breslow thickness was 16.04% (T1), 15.86%(T2), 23.06% (T3) and 45.05% (T4) of ALM versus 29.55% (T1), 20.45% (T2), 20.25% (T3) and 29.75% (T4), reflecting thicker melanomas in ALM patients (p=0.0001). Most of the ALM was ulcerated more than SIM (70.27% vs 41.2% p=0.000). The stage distribution is showed in table 1. We do not find significant differences in terms of gender distribution (p=0.281) or sentinel node biopsy result (p=0.79). The median survival time was 55 months versus 82 months for ALM and SIM respectively (p=0.0001). The 5 and 10 years overall survival (OS) was 46.8% and 27.3% for ALM and 57.9% and 45.4% for SIM (p=0.000). No differences were found in median survival or OS when ALM and SIM were stratified by disease stage. Conclusion: ALM have more aggressive features, clinically and pathologically, that results in lower survival rates compared to sun-induced melanomas.

Prognostic variables distribution in ALM and Sun-induced Melanoma

Variable	General (n=1,039)	ALM (n=555)	Sun-induced (n=484)	p=
Median Age	60.24	63.84	56	0.01
Male	417(40.13%)	233 (41.90%)	184 (38.02%)	0.1
Female	622 (59.87%)	322 (58.02%)	300 (61.98%)	
Median Breslow Thickness	5.06 mm	5.79 mm	4.23 mm	0.0001
T1	232 (22.3%)	89 (16.4%)	143 (29.55%)	
T2	187 (18%)	88 (15.86%)	99 (20.45%)	
T3	226 (21.8%)	128 (23.06%)	98 (20.25%)	
T4	394 (37.9%)	250 (45.05%)	144 (29.75%)	0.0001
Ulceration	589 (56.7%)	390 (70.27%)	199 (41.12%)	0.0001
Stage IA	165 (16.0%)	56 (10.13%)	109 (22.71%)	
Stage IB	97 (9.4%)	40 (7.23%)	57 (11.88%)	
Stage IIA	106 (10.3%)	54 (9.76%)	52 (10.83%)	
Stage IIB	142 (13.7%)	73 (13.2%)	69 (14.38%)	
Stage IIC	127 (12.3%)	81 (14.65%)	46 (9.58%)	
Stage IIIA	39 (3.8%)	21 (3.8%)	18 (3.75%)	
Stage IIIB	108 (10.5%)	63 (11.39%)	45 (9.38%)	
Stage IIIC	165 (16%)	117 (21.16%)	48 (10%)	
Stage IV	78 (7.6%)	46 (8.32%)	32 (6.67%)	0.0001
SNB Positive	143 (34.20)	87 (37.34%)	56 (30.27%)	
SNB Negative	275 (65.8%)	146 (62.66%)	129 (69.73%)	0.79

P205

Type I Polarized Dendritic Cell-based Vaccine Combined with Small Molecule BRAF Inhibitor PLX4720 Effectively Treats Melanoma in a Mouse Model J. Cintolo-Gonazelz, ^{1*} R. Somasundaram,² S. Xu,¹ B.J. Czerniecki.² *1. Surgery, University of Pennsylvania, Philadelphia, PA; 2. Wistar Institute, Philadelphia, PA.*

Introduction: We previously presented a Type I Polarized dendritic cell (DC)based vaccine capable of eliciting an antigen-specific CD8+ T cell response to BRAF V600E and preventing tumor formation in mice challenged with B16V600E+ melanoma. We have subsequently tested the ability of our vaccine to treat established B16 tumors in conjunction with a BRAF inhibitor (PLX4720). Methods: Our DC1 vaccine was prepared from bone marrow precursors matured to a DC1 phenotype. Cohorts of 10 C57Bl/6 mice were injected with 5x10^4 B16 cells transfected with lentiviral vector to express the BRAF V600E mutation. On day 15, when tumors were palpable, treatment was initiated with DC1s pulsed either with affinity modified BRAF peptide or OVA control peptide with or without PLX4720. Another group received no treatment. Vaccinations were administered via intradermal injection twice weekly. Tumors were measured with a digital caliper and volume was calculated using the formula: (1 x w^2)/2. Antigen specific CD8+ responses were assessed by IFNy ELISA and differences determined by two-tailed t test. Group survival was compared with the log rank test; differences in tumor growth were determined by comparing tumor doubling times. Results: CD8+ T cells isolated from mice vaccinated with DC1s pulsed with either BRAF or Ova peptide demonstrated increased antigen specific IFN-y secretion (P<0.05). Mice treated with DC1s-pulsed with mutated BRAF peptide with and without PLX4720 demonstrated improved survival compared to control mice who received no treatment (p=0.0002 and p=0.0008, respectively) or treatment with PLX4720 alone (p=0.0006 and p=0.0177), respectively). Mice vaccinated with DC1s pulsed with ova combined with PLX4720 did not show survival benefit compared to PLX4720 alone (p=0.3302). Addition of the DC1 BRAF vaccine to PLX4720 decreased tumor burden over time, causing a significant slowing of tumor doubling time (p=0.0199). Conclusions: Treating mice with established B16V600E+ melanomas with BRAF-pulsed DC1s in combination with PLX4720 prolongs survival and slows tumor growth superior to those treated with PLX4720 alone.



Tumor growth over time for mice receiving no treatment or PLX4720 only compared with mice receiving DC1 vaccine targeting BRAF V600E with and without PLX4720.

Sentinel Node Biopsy is Indicated for Thick Clinically Node-negative Melanoma M. Yamamoto,^{1*} J.Y. Wong,¹ K.J. Fisher,¹ J. Koscso,² M. Konstantinovic,² N. Govsyeyev,² J.L. Messina,¹ A.A. Sarnaik,¹ C.W. Cruse,¹ C.A. Puleo,¹ R.J. Gonzalez,¹ V.K. Sondak,¹ J.S. Zager.¹ *I. H Lee Moffitt Comprehensive Cancer Center, Tampa, FL; 2. University of South Florida, Tampa, FL.*

Introduction: Sentinel lymph node biopsy (SLNB) is considered standard of care and a useful staging procedure for intermediate thickness melanoma. Since the ASCO guidelines do not definitively recommend SLNB for thick melanoma, we sought to determine if there is a prognostic survival benefit to SLNB in these pts. Methods: From 1999 to 2012, 571 pts with melanoma whose primary tumors were ≥4mm in Breslow depth were evaluated from a single institution. Pts who presented with distant disease were excluded from this study. Associations between survival and clinicopathologic characteristics were explored using stratified Kaplan Meier curves and log rank p-values. Results: Of 571 pts, 401(70.2%) were male and median age was 66. The median Breslow depth was 6.2 mm (range 4-25) with the predominant histology being nodular type (45.5%). 412 pts (72%) underwent SLNB and 46 (8%) underwent a complete node dissection due to clinically positive nodal disease at presentation. An additional 113 pts (20%) did not have a SLNB (i.e. medical comorbidities, patient preference, failure to map on lymphoscintigraphy). A positive SLN was seen in 161 of 412 pts (39.1%). Nineteen pts presented with nodal recurrence in the mapped basin despite a negative SLNB (false negative rate [FNR] 10.6%). The median overall (OS) and disease-specific survival (DSS) for the entire cohort was 42.5 and 62.1 months, respectively. The median DSS for pts with a negative SLN was 82.4 months, 41.2 for positive SLN and 26.8 for those with clinically positive nodal disease at presentation (p<0.0001). Recurrence-free survival (RFS) showed a similar survival benefit for SLN negative pts, with a median survival of 32.4 months versus 14.3 for SLN positive and 6.8 for those with clinical positive disease (p<0.0001). Conclusions: With an acceptable low FNR, pts with thick melanoma and negative SLNB have significantly prolonged DSS and RFS over those with a positive SLNB. Identifying nodal disease at an occult stage is associated with a significantly increased survival advantage over those pts with clinically positive nodes. Based on these data, we consider SLNB to be indicated for pts with thick clinically node negative melanoma.



P207 Tanning Beds: How Harmful are they in Young Patients with Melanoma? C. Farley, Y. Alimi, S. Perez, W. Knechtle, A. Hestley, G.W. Carlson, M.C. Russell, K. Delman, M. Rizzo.* *Emory University, Atlanta, GA.*

BACKGROUND: An increase in the incidence of melanoma has been observed over the past decade, particularly in young women ages 19-35 years. Recent data has shown a link between tanning bed use and melanoma risk. This study sought to determine the incidence and frequency of tanning bed use among young patients diagnosed with melanoma at a single institution. METHODS:A retrospective case-control design analyzed the incidence and frequency of tanning bed use among melanoma patients ages 18-50 years and diagnosed between 1991 to 2011 compared to controls (randomly selected general surgery patients ages 18-50 years). A telephone survey investigated family history of skin cancer and/or melanoma, hair color, eye color, skin type, tanning bed use (absolute and frequency), and patient awareness of risks and/or dangers associated with tanning bed use. RESULTS: 611 melanoma cases were identified. 267 (44%) completed the telephone survey as did 96 controls. Of these 363 subjects, 192 were female. Females were 4.2 times more likely to have used a tanning bed than males (OR 4.18; 95% CI, 2.69-6.51). Melanoma patients were 2.5 times more likely to have used a tanning bed than controls (OR 2.48; 95% CI, 1.51-4.07). Melanoma patients were more likely to have natural light color hair and blue-green eyes than controls. Of 171 tanning bed users, 75% were younger than 25 years of age at first use. Among the tanning bed users, 90% were aware of a danger or risk associated with tanning bed use as shown in the Table. CONCLUSION: Melanoma diagnosed between the ages of 18-50 is associated with increased tanning bed use. In this study population, tanning beds were most commonly used at a young age and, more specifically, by females reinforcing the need to advocate for legislation to restrict access to tanning beds.

	Total (n=363)	Melanoma (n=267)	Controls (n=96)	p-value
FAMILY HISTORY OF SKIN CANCER OR MELANOMA				0.0002
Yes	111	96 (36%)	15 (16%)	
No	250	169 (63%)	81 (84%)	
Unknown	2	2(1%)	0 (0%)	
NATURAL HAIR COLOR				< 0.0001
Blonde/Red/Light brown	174	149 (56%)	25 (26%)	
Brown/Black	189	118 (44%)	71 (74%)	
EYE COLOR				< 0.0001
Blue/Green/Hazel	250	204 (76%)	46 (25%)	-
Brown/Black	113	63 (23%)	50 (49%)	
SKIN RESPONSE TO SUN EXPOSURE				< 0.0001
Never burn	42	16 (6%)	26 (27%)	
Some redness	125	96 (36%)	29 (30%)	
Burn	147	115 (43%)	32 (33%)	
Burn with blisters	49	40 (15%)	9 (9%)	
TANNING BED USE				0.0003
Never used	192	126 (47%)	66 (69%)	
Ever used	171	141 (53%)	30 (31%)	
AGE AT FIRST USE				0.1732
≤25 years old	132	106 (75%)	26 (86%)	
≥25 years old	39	35 (25%)	4 (14%)	
FREQUENCY (times/year)				0.4528
1-10	104	84 (59%)	20 (67%)	
>10	67	57 (41%)	10 (33%)	
TANNING BED USERS AWARE OF RISKS				0.2462
Yes	156	127 (90%)	29 (97%)	
No	15	14 (10%)	1 (3%)	

P208

Evaluating Sentinel Lymph Node Biopsy in Thin (<1mm) Melanoma W. Lancaster,* K. Armeson, E. Hill, J. Kaifi, E. Kimchi, K. Staveley-O'Carroll, D. Cole, E.R. Camp. Surgery, Medical University of South Carolina, Charleston, SC.

Introduction: The role of sentinel lymph node biopsy (SLNB) in T1(<1mm) melanomas remains controversial. Numerous relatively small retrospective studies have identified factors associated with SLN metastasis, but there is a lack of consensus as to when biopsy should be pursued. The purpose of this study is to assess the role of sentinel node biopsy in T1 melanoma patients using a large population database to identify high risk patients and assess the prognostic value of the procedure. Methods:Using the Surveillance Epidemiology and End Results (SEER) database, T1 melanoma patients who underwent SLNB from 2004-2009 were identified. Clinicopathologic data based on the 2002 TNM staging system and overall survival (OS) were compared among patients with positive(+)

and negative(-) SLNs. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for tumor specific factors, adjusted for demographic factors. Results: Of the T1 melanoma patients identified, 8867 (14.3%) underwent SLNB. The overall SLNB(+) rate was 3.6%. The SLNB(+) rate for patients with ulceration was 9%, associated with a 5-fold increased likelihood of positive biopsy (95% CI: 2.9 - 9.8, p<0.001). Rates of nodal positivity for CL 4-5 and thickness >0.75mm were 4.8% and 4.1%, respectively. For melanomas with both CL 4-5 and ulceration, the SLNB(+) rate was 14.8%, associated with a 14-fold increased odds of a SLNB(+) versus having neither high risk feature (95% CI: 8.4 -23.0,p<0.001). Survival distributions stratified by SLNB status were significantly different (p<0.001; log-rank test). 5-year OS was 91.2% for SLNB(-) patients (95% CI: 90.2% - 92.2%) and 75.6% for SLNB(+) patients (95% CI: 69.2% - 82.6%). Conclusions: The present study represents the largest series of T1 melanoma patients studied and demonstrates the strong prognostic value of SLNB in this population. Although the overall sentinel node positivity rate was low, high risk factors such as ulceration, CL 4-5, and increased thickness were associated with a significantly increased rate of nodal spread. Ulceration is the factor most strongly associated with nodal positivity. Mitotic rate should be critically assessed in the future.



P209

Intratumoral Immune Environment in Patients with Advanced or Metastatic Melanoma before and after Ipilimumab C.V. Angeles,¹* D. Gyorki,² M. Pulitzer,¹ C.E. Ariyan.¹ *1. Surgical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY; 2. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.*

Introduction: While ipilimumab (IPI) has a clinical benefit in patients with advanced or metastatic melanoma, the response rate is low. Efforts to identify biomarkers of response have identified an increase in HLA-DR expression in the blood and an inflammatory gene signature in the tumor, but there is little understanding about the routine changes within the tumor. This study sought to identify changes in immune infiltrate and alterations in antigen expression in tumors removed after treatment with IPI. Methods: From a prospective single institution database, patients with matched pre- and post-IPI tumor specimens were selected. Tumors were de-identified and labeled immunohistochemically for immune markers as well as tumor antigens. Slides were analyzed and quantified for staining (0-3) and intratumoral location in a blinded fashion by a melanoma dermatopathologist. Results: Thirteen patients were identified with matched pre- and post-IS, respectively). At the start of IPI treatment, patients were either stage IIIB or stage IV. Median time between start of IPI treatment and surgery was

61wk(range 12-123wk). 77% of patients showed clinical benefit with partial response or stable disease at 24wk. There were no complete responders. The causes for surgery were progressing disease (46.7%), only remaining site of disease (26.7%) or symptoms (26.7%). All patients but one had T-cell infiltration in tumor prior to IPI treatment. Post treatment, 71.4% of patients had an increase in CD8. Only 6.7% of patients had an increase in HLA-DR. The majority of patients had a decrease or stable expression of tumor antigens S-100 and HMB-45. The 5-year overall survival was 51%. Conclusion: In this small cohort of selected patients, we saw a survival benefit with ipilimumab even in patients with isolating progressing lesions. Contrary to previous data, we did not see a marked post-treatment increase in HLA-DR. The intratumoral immune environment did demonstrate an increase in CD8, but no other striking changes. These observations underscore the importance of considering additional immune therapy as well as surgery for patients with advanced melanoma.

Marker	Increase (% of patients)	Decrease (% of patients)	Unchanged (% of patients)
CD4	26.7	20	60
CD8	71.4	0	28.6
FoxP3	10	33.3	26.7
CD8/FoxP3	33.3	26.7	40
CD25	26.7	13.3	60
CD45RO	46.7	26.7	26.7
HLA-DR	6.7	20	66.7
S-100	13.3	53.3	33.3
HMB-45	20	26.7	53.3

P210

Expansion of Pharmacologically Activated Melanoma-specific Lymphocytes in Alternate Gamma Chain Cytokines: Gene Expression Variances between T Cells and T Cell Subsets Exposed to IL-2 versus IL-7/15 C.K. Zoon,^{1*} E. Seitelman,² L. Graham,² C.I. Dumur,³ H. Bear.² 1. General Surgery, Virginia Commonwealth University, Richmond, VA; 2. Virginia Commonwealth University - Department of Surgical Oncology, Richmond, VA; 3. Virginia Commonwealth University -Department of Pathology, Richmond, VA.

Introduction: We have previously demonstrated that culturing tumor-sensitized T cells in interleukin (IL)-7/15 after activation in bryostatin/ionomycin (B/I) surpassed T cells cultured in IL-2 in both expansion and anti-tumor activity. Our present study sought to determine whether B/I-activated T cells exposed to IL-7/15 exhibited gene expression patterns that were distinct from \hat{T} cells cultured in IL-2. Methods: Lymphocytes were harvested from the lymph nodes of Pmel-1 mice whose footpads were previously injected with B16-GMCSF melanoma cells. Sensitized lymphocytes were then activated with B/I, washed and cultured in IL-2 or IL-7/15 for 1, 3 or 6 days. Lymphocytes were either directly analyzed by microarray or by real time quantitative polymerase chain reaction (RT-QPCR), or sorted into T cell subsets and analyzed for gene expression. Results: We demonstrated a significant difference in the gene expression patterns for T cells cultured in IL-7/15 vs. IL-2, starting at day 3 of culture and remaining consistent on day 6. Interestingly, we found that even when divided into T cell subsets, the central memory (TCM), effector memory (TEM) and effector (TE) T cells cultured in the same cytokine more closely resembled each other than their identical subset phenotype exposed to a different cytokine regimen. Conclusions: Our study suggests that the global changes in gene expression seen between unsorted T cells grown in IL-2 or IL-7/15 do not merely reflect the difference in frequency of TCM cells vs. TEM cells vs. TE cells that are enriched when cultured, but rather reflect that the genetic expression of those T cell subsets, when exposed to different cytokines, are fundamentally different, independent of T cell differentiation markers.



The Immunologic Profile of Cutaneous Squamous Cell Carcinoma D.J. Cucher,^{1*} D. Bradley-Dunlop,³ R.S. Krouse.² 1. University of Arizona Department of Surgery, Tucson, AZ; 2. Southern Arizona Veterans Administration Health Care System, Tucson, AZ; 3. University of Arizona Department of Immunobiology, Tucson, AZ.

Background: Immunocompromised (IC) state may contribute to the increased development of cutaneous squamous cell carcinoma (CSCC). This may be related to changes in dermal immunologic cell presence and activity. This study is an initial evaluation of the immunologic difference of CSCC arising in IC and non-IC patients. Methods: Twenty cases of CSCC were included in this study (10 IC and 10 non-IC). Internal controls were from adjacent normal skin, and patients matched by site of tumor and age. IC state was due to medications or disease. Mononuclear cell populations were characterized by quantitative immunohistochemistry (IHC). Markers included: CD4 and CD8 (T cell markers), CD1a (antigen presenting cell marker), CD207 (Langerhans cell marker), CD 83 (dendritic cell activation markers), and Granzyme B (activated cytotoxic T cell marker). Statistical analysis was via a paired student ttest. Results: CSCC in IC patients had an average size of 1.9cm vs 1.5cm in non-IC patients. Tumors in the IC group invaded deeper (6 mm vs 3mm). 7 of 10 tumors in the IC group were moderately to poorly differentiated, 3 were well differentiated. 6 of 10 tumors in the non-IC group were well differentiated, 4 moderately differentiated. Tumor tissue trended towards increased CD4 (p=0.056) and CD8 (p=0.0489) T cell counts compared to normal skin in both groups (Fig. 1). The CD4:CD8 ratio in IC tumor was almost half of that in non-IC tumor. CD1a dendritic cells were modestly increased in tumor and adjacent skin of non-IC patients, and CD207 Langerhans cells in the tumors of both groups were decreased. CD83 was minimal and correlated with the absence of Granzyme B staining in all tissue groups. Conclusion: CSCC in IC individuals are larger, invade more deeply, and are less well differentiated compared to non-IC tumors. IHC suggests a lack of T cell anti-tumor function at the tumor site in both groups that may contribute to tumor progression. The immunologic differences in CSSC versus normal skin may be intensified in IC patients. Further study is needed to determine the entirety of immunologic changes in IC versus non-IC patients. This may lead to the development of local preventative measures for potentially aggressive SCC.



P212

Isolated Limb Infusion with Melphalan and Actinomycin D for Melanoma: A Meta-analysis for Response and Toxicity H.M. Kroon,* A.M. Huismans, P.C. Kam, J.F. Thompson. *Melanoma Institute Australia, North Sydney, NSW, Australia.*

Introduction: Isolated limb infusion (ILI) has been developed as a simplified and minimally invasive alternative to isolated limb perfusion (ILP) to treat irresectable limb melanoma. An increasing number of centers around the world have reported their results using this procedure. For the current study we conducted this, to date, first ILI meta-analysis. Methods: A literature search was carried out according to the guidelines for diagnostic meta-analysis in order to select eligible papers reporting limb toxicity and response rates following ILI using melphalan and actinomycin D for irresectable limb melanoma. A total of 576 patients from 7 publications could be included. Results: Regional toxicity following ILI was low: no visible effect of the treatment or slight erythema and/or oedema was seen in 79% of the patients while considerable erythema and/or oedema with blistering was experienced by 19%. In 2% a threatened or actual compartment syndrome was seen while no procedure-related amputation has been reported. A complete response was seen in 33% of the patients and a partial response in 40%, resulting in an overall response of 73%. Stable disease and progressive disease was seen in respectively 14% and 13% of the patients. Conclusion: This first meta-analysis of ILI using melphalan and actinomycin D shows that regional toxicity was generally low. The procedure resulted in a satisfactory overall response rate of 73%. When comparing ILI and ILP one should bear in mind that ILI is usually applied to significantly older patients and patients suffering from higher stages of disease, which both have been shown to decrease the chance of a favorable response.

P213

miR-21 Inhibition Slows Disease Progression and Improves Survival in a Murine Metastatic Melanoma Xenograft Model

E. Paulus,* M.D. Fleming, C.H. Yang, L. Pfeffer. University of Tennessee Health Science Center, Memphis, TN.

Background: Advanced melanoma is an aggressive malignancy with a dismal prognosis. Interferon (IFN) is a biological agent that regulates cell proliferation and apoptosis. IFN also induces the expression of microRNA (miR)-21, which plays an important role in the oncogenic process. This study examines the role of miR-21 on human melanoma growth, invasion, metastatic potential, and sensitivity to IFN. Methods: Human melanoma cell line SK-MEL 188 was cultured and transduced with an antagomir-21 lentivirus (miR-21 KD) or an empty vector (EV) lentivirus, and subjected to various in vitro and in vivo biological assays. Results: Knockdown of miR-21 reduced SK-MEL 188 cell proliferation in vivo. The proliferation of SK-MEL 188 cells for the combination of miR-21 KD and IFN (mean cell count ratio 0.24) was reduced (p=0.006) when compared to EV and IFN (mean cell count ratio 0.52). When cell invasion was measured by transwell migration assays, the mean number of migrating cells (MMC) of miR-21 KD was decreased when compared to EV (p=0.035). Immunocompromised mice were injected via tail vein with EV and miR-21 KD SK-MEL 188 cells expressing luciferase for bioluminescence imaging. At 14 days, mice injected with EV-transduced cells had a statistically higher average

bioluminescence compared to mice with miR-21 KD. Mice injected with EV cells (n=7) had a median survival of 14 days, whereas mice injected with miR-21 KD (n=7) had a median survival of 21 days (p=0.037). Upon necropsy, mice injected with EV exhibited large melanocytic tumors in the liver and lungs, whereas mice injected with miR-21 KD exhibited smaller, often non-melanocytic nodules. Conclusion: These results indicate that miR-21 KD enhances the sensitivity of SK-MEL 188 cells to basal and IFN-induced inhibition of cell proliferation and migration. A significant increase in the median survival was found in mice injected with miR-21 KD cells. This study identifies a linkage between miR-21 and the metastatic behavior of human melanoma cells.

Kaplan-Meier Analysis of Survival Data



Mice injected with EV cells (n=7) had a median survival of 14 days, whereas mice injected with miR-21 KD (n=7) had a median survival of 21 days (p=0.037).

P214

Do Tumor-infiltrating Lymphocytes in Melanoma Metastasectomy Specimens Change after Ipilimumab Treatment? J. Ozao-Choy,^{1*} R.R. Turner,² T. Ly,¹ O. Hamid,³ H. Torisu-Itakura,¹ D.L. Morton,¹ M.B. Faries.¹ 1. John Wayne Cancer Institute, Santa Monica, CA; 2. St. John's Hospital Center, Santa Monica, CA; 3. Angeles Clinic, Santa Monica, CA.

Background: Ipilimumab is now an FDA-approved treatment for patients with metastatic melanoma. We examined whether tumor-infiltrating lymphocytes (TIL) in metastasectomy specimens differ before and after treatment with ipilimumab. Methods: Our cancer center's database was queried for patients who had metastasectomy before and after ipilimumab treatment; paired specimens from the same patients were sought. Nine pairs of paraffin-embedded metastasectomy specimens were stained by immunohistochemistry for CD3+, CD8+ and CD4+ TIL. A blinded pathologist selected three separate areas of the tumor edge and within the tumor with the most immune infiltrate to photograph and to perform semi-quantitative assessments on the specimens. An image analysis of the percent area of staining was also performed with Image J. Both analyses were then analyzed by paired t-test. Results: The semi-quantitative pathology assessments of CD8+ TIL of the entire specimens showed an increase which approached a statistically significant difference (p=0.08); however, there were no differences in CD3+ or CD4+ TIL. The mean percent area of staining of CD3+, CD8+, CD4+ TIL at the tumor edge all decreased after treatment while the mean CD8+ TIL within the tumor increased; however, these changes were not statistically significant (Table 1). When a ratio of within tumor to edge (W:E) percent area was analyzed, the mean CD8+ TIL W:E ratio increased from 0.54 to 0.85 (p=0.05). Conclusions: This is the first study, to our knowledge, to evaluate paired whole metastasectomy specimens rather than biopsies from the same patients before and after ipilimumab treatment as well as the first to assess the location of TILs. Interestingly, all patients had significant numbers of TIL in their pre-ipilimumab specimens mostly concentrated at the periphery of the tumor. After treatment, the W:E ratio of CD8+TIL appears to increase suggesting that ipilimumab enables a redistribution of CD8+ TIL from the edge to the center of the tumor. Further studies will be necessary to evaluate how this redistribution effect occurs and possible use as a prognostic factor to predict response and survival.

TIL % area before and after ipilimumab treatment

TIL	Pre-ipilimumab mean % area	Post-ipilimumab mean % area	p-value
CD3+ Edge	11.0	7.4	0.10
CD8+ Edge	7.5	5.5	0.20
CD4+ Edge	10.5	7.1	0.21
CD3+ Within	5.3	4.0	0.35
CD8+ Within	4.2	4.4	0.89
CD4+ Within	6.4	5.8	0.55
CD3+ W:E ratio	0.55	0.58	0.84
CD8+ W:E ratio	0.54	0.85	0.05 **
CD4+ W:E ratio	0.72	0.70	0.87

**statistically significant

P215

Immunotherapeutic Intra-arterial Adoptive Transfer In a Murine Model C. Wilfong,* A.B. Blum, M. Kim, D. Fisher, J. Skitzki. *Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY.*

Background: Adoptive transfer of CD8 T cells by the standard intravenous (IV) route is a promising treatment for metastatic melanoma. We hypothesize that intra-arterial (IA) adoptive transfer avoids cell trapping within the pulmonic and splenic vasculatures, resulting in greater delivery of adoptively transferred cells to the tumor and improved anti-tumor effect. Methods: Female C57BL/6 mice were injected with 1×106 B16-OVA cells s.g. in the distal thigh. 1x106 activated, OVA-specific OT1 cells were labeled using two different fluorescent cell labels (CFSE or CTO). After 7 days of tumor growth, mice were injected IA with 1x107 CTO cells via common femoral artery and IV with 1x107 CFSE cells via tail vein. Trafficking of adoptively transferred cells was examined by flow cytometry at 1 and 24 hours post injection in liver, spleen, lymph nodes, lungs, and tumor. Tumor growth studies were performed via IV and IA injection of 5x106 OT1 cells with caliper measurements every 2 days. Results: At 1 hour, there were significantly more CFSE versus CTO labeled OT1 cells within the lymph nodes and tumors. There was no significant difference observed in the remaining tissues. At 24 hours there were significantly more CTO versus CSFE labeled cells within all tissues. Tumor growth studies showed no significant differences. Tumor sections 1 hour following adoptive transfer demonstrated no significant difference between the ratio of CSFE and CTO cells; however, at 24 hours there were significantly more CTO cells within the tumors. CTO cells accounted for 75% of the adoptively transferred cells seen within the tumor tissue at 24 hours (p < 0.05). Conclusion: After 24 hours the amount of adoptively transferred OT1 cells using the IA route was greater in the tumor than using the IV route. Despite non-significant differences in tumor growth data between IV and IA groups, flow cytometry data suggests that intra-arterial delivery of adoptively transferred cells may result in a greater number reaching the tumor, which may translate to improved long-term outcomes.



P216

Merkel Cell Carcinoma: What Makes a Difference? J. Tseng,* B. Dhungel, M. Sarff, J. Mills, B.S. Diggs, R. Weerasinghe, J. Fortino, J. Vetto. *Oregon Health and Science University, Portland, OR.*

Introduction: Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine tumor that occurs on sun-damaged skin, may spread via lymphatics, and can therefore be staged with sentinel lymph node biopsy (SLNB). MCC is radioand chemo-sensitive, although the role of adjuvant therapy is still unclear. We examined the impact of different treatments on the outcome of MCC. Methods: We performed a retrospective review of state cancer registry data from California, Oregon and Washington of patients diagnosed with pathologically confirmed primary skin MCC between 1988 and 2012 (n = 4,038). Data was analyzed using Cox-regression and Kaplan-Meier methods. Results: Mean tumor size was 27.7 mm. Head and neck primaries were the most frequent (47%), followed by extremity (37%) and truncal (9%). Male gender, age > 60years, and tumor size > 21 mm were predictors of lower overall survival. Patients with positive nodes or no documented nodal evaluation had worse 5year disease-specific survival compared to patients who were node negative. No nodal evaluation had decreased survival (Hazard Ratio = 1.72, 95% CI [1.38, 2.15]) compared to lymph node evaluation by SLNB. Completion lymph node dissection conferred improved survival in patients with a positive SLNB. In clinically node negative patients who had a positive SLNB, radiation and chemotherapy did not affect survival. Conclusions: Negative prognostic factors for MCC include male gender, age > 60 years, tumor size >21 mm, and positive nodal status. Lymph node evaluation is an important component to MCC treatment. The role of adjuvant radiation and chemotherapy needs further evaluation.

P217

Clinical Significance of Ornithine Decarboxylase Activity in Melanoma K.A. Brueske, Y. Zhang, G. Peng, E.C. Hsueh.* Surgery, Saint Louis University, St. Louis, MO.

We have observed variable expression of ornithine decarboxylase (ODC), a key enzyme for polyamine synthesis, in human melanoma cell lines and tissues. Inhibition of ODC had negative growth and migration effect on human melanoma cells in vitro. We evaluated the expression of ODC and its regulatory molecules in human melanoma specimens and the clinical significance of their expression. Snap-frozen tumor specimens from 29 metastatic melanoma patients were evaluated. Total RNA was extracted and reverse transcribed into cDNA using random hexamers primer. Quantitative real-time PCR was performed using TaqMan Gene Expression Assay (Applied Biosystems) with the probe and primer set for ODC, antizyme-1 (AZ-1), antizyme-2 (AZ-2), antizyme-3 (AZ-3) and antizyme inhibitor (AZI). All experiments were repeated three times. GAPDH was used as an internal control. Clinical variables and follow-up disease status were obtained under a Saint Louis University IRBapproved protocol. Disease-free and overall survival was calculated from time of diagnosis to the time of recurrence or death, respectively. Log-rank test was used for survival analysis. Spearman test was used for correlation between laboratory and clinical variables. P< 0.05 was considered to be statically significant. Variable expressions of ODC, AZI, AZ-1, AZ-2, and AZ-3 were observed in human melanoma tissues. There was an inverse correlation between ODC expression and AZ-1 expression, p < 0.05. However, there was no correlation between any of the antizyme isoform expression and the expression level of AZI, the antizyme inhibitor. On log-rank analysis comparing the marker expressions and clinical variables, significant correlation of AZ-3 expression and disease-free survival was noted (P=0.0075). There was a trend for significant correlation between AZ-3 and Breslow thickness (P=0.1). No significant correlation between the marker expressions and overall survival was observed. Significant correlation of disease-free survival with antizyme-3 was observed in this small cohort of metastatic melanoma patients. Validation of this finding is on-going in a larger dataset. Antizyme-3 may be a promising target for melanoma treatment and surveillance.

P218

Prognostic Significance of Sentinel Lymph Node and Non-sentinel Lymph Node Status in the Elderly Melanoma Patient T.E. Grotz,* C. Puig, T.J. Hieken. Surgery, Mayo Clinic, Rochester, MN.

Background: Despite evidence-based guidelines supporting sentinel lymph node (SLN) biopsy and completion lymphadenectomy (CLND), national data suggests compliance is suboptimal. Advanced age is one of the most commonly cited reasons for failure to comply with standard guidelines. We therefore investigated the prognostic significance of SLN and non-SLN status in the elderly population Methods: Single institutional retrospective review of patients \geq 65 with melanoma who underwent SLN biopsy. Wilcoxon tests were used to compare continuous variables and chi-square or Fisher's exact tests were used to compare categorical variables between groups. Univariable and multivariable Cox regressions were used for analysis of time-to-event variables. Results: 169 elderly patients underwent SLN biopsy. The median age was 76 (65-97) years; 134 (80%) had an ECOG performance status of zero. 31 (18%) one, and 3 (2%) two. Lymphatic mapping failed in 3 (1.8%) patients all with head and neck primaries. 63 (38%) patients had a positive SLN and 53 (84%) underwent CLND. Reasons for omission of CLND included patient refusal in 4 (40%), surgeon recommendation in 4 (40%) and postoperative complication in 1 (10%). Additional nodal disease was identified on CLND in 9 patients (17%) with a positive SLN. 5 patients (5%) with a negative SLN had a regional nodal basin recurrence after median follow-up of 82 months. SLN+ patients were younger (p < 0.0001), had thicker (p = 0.005) and more often ulcerated (p = 0.003) melanomas. In univariate analysis male sex (p = 0.04), Breslow depth (p < 0.001), ulceration (p < 0.02), positive SLN (p < 0.001) and positive non-SLN on CLND (p = 0.03) were all associated with poor disease-specific survival as well as disease-free survival. In multivariable analysis the presence of microsatellites (p = 0.02) and a positive SLN (p = 0.02) were associated with worse disease-specific survival. Conclusions: Lymphatic mapping and SLN biopsy with CLND for SLN+ patients provide important prognostic information. Lymphatic mapping failure in the elderly was uncommon. Age alone should not be a contraindication to SLN biopsy and CLND for SLN+ disease.



Kaplan Meier curves demonstrating disease-specific survival for elderly melanoma patients with positive (n = 63) and negative (n = 106) sentinel lymph node (p < 0.001) as well as positive (n = 9) and negative (n = 44) non-sentinel lymph nodes (p = 0.026).

P219

Generation of Induced Pluripotent Stem Cells from Tumor-infiltrating Lymphocytes H. Saito, ¹ K. Okita, ² N. Fusaki, ³ M.S. Sabel, ¹ A. Chang, ¹ F. Ito. ^{1*} *1. University of Michigan, Ann Arbor, MI; 2. Kyoto University, Kyoto, Japan; 3. Keio University, Tokyo, Japan.*

Human induced pluripotent stem cells (iPSCs) derived from somatic cells of patients hold great promise for autologous cell therapies. One of the possible applications of iPSCs is to use them as a cell source for producing autologous lymphocytes for cell-based therapy against cancer. Tumor-infiltrating lymphocytes (TILs) were found to have tumor-reactive T cells and have been used for adoptive cell therapy for metastatic melanoma. The objective in this study is to generate iPSCs from TILs and assess their pluripotency. Under the approved protocol by the Institutional Review Board and the Human Pluripotent Stem Cell Research Oversight Committee, we obtained tumor from a patient who provided informed consent for tissue procurement and generation of iPSCs. TILs were reprogrammed by Sendai virus (SeV) vector encoding four pluripotency transcription factors (Oct3/4, Klf4, Sox2 and c-Myc). TILderived iPSCs (TIL-iPSCs) were characterized by their pluripotency. Within 3 weeks of infection with SeV to deliver pluripotency transcription factors, we identified colonies that resembled embryonic stem cells (ESCs) among the T cell derivatives. TIL-iPSCs displayed typical stem cell morphology and had a normal karyotype. Alkaline phosphatase and immunofluorescence staining with stem cell surface marker, OCT3/4, SSEA3, SSEA 4, TRA1-81 and TRA1-60 proteins suggested pluripotency of colonies. RT-PCR analyses revealed that TIL-iPSCs expressed pluripotent stem cell markers such as NANOG, OCT3/4 at levels comparable to those in ESCs. T cell receptor (TCR) gene rearrangement analysis in TIL-iPSCs confirmed that they originated from mature T cells and retained diversity of TCR gene rearrangement. In conclusion, human iPSCs with diverse TCR gene rearrangement can be generated from TILs efficiently by SeV encoding four pluripotency transcription factors. Future work will explore their differentiation potential to T cells for cancer immunotherapy. We acknowledge Dr. Mamoru Hasegawa in DNAVEC Corporation for kindly providing Sendai virus vectors.

Sentinel Lymph Node Biopsy is Less Frequently Performed in Melanoma Patients with a Low Socioeconomic Status A.M. Huismans,¹ M. Niebling,¹* K. Wevers,¹ M. Schuurman,² H.J. Hoekstra.¹ 1. University Medical Center Groningen, Groningen, Netherlands; 2. Comprehensive Cancer Centre the Netherlands, Groningen, Netherlands.

Background: Sentinel lymph node biopsy (SLNB) is recommended for patients with a cutaneous invasive melanoma AJCC stage Ib and II. In the US, whether a SLNB is performed depends on patient factors including high socioeconomic status and possession of a private health care insurance. We analyzed whether socioeconomic status and other patient and tumor characteristics influenced the chance of having a SLNB performed in a country where every patient has equal access to healthcare. Material and Methods: Patients diagnosed with a cutaneous invasive melanoma of ≥1mm between 2004 and 2011 from the northeastern part of the Netherlands were selected from the Netherlands Cancer Registry. An estimate of the socioeconomic status (SES) was defined by income, employment, and level of education. Patients were equally divided over five groups based on SES score. Regression analysis was performed to assess the association of patient and tumor characteristics and SLNB use. Results: SLNB was performed in 1009 of the 2413 included patients (42%) The frequency of performing SLNB increased from 24% in 2004 to 55% in 2011 (P<0.001). Patients were less likely to undergo SLNB if they had a low SES (p=0.03), a melanoma located in the head and neck area (p<0.001) or when they were older than 55 years (p=0.001). SLNB use was more likely when the diagnosis of melanoma was made in a university hospital (p=0.045) or when the Breslow thickness was 2.01-4.0 mm (p=0.03). Conclusions: The use of SLNB has increased significantly between 2004 and 2011. However, although SLNB is a worldwide accepted staging procedure for patients with invasive cutaneous melanoma, in 2011 it was still only performed in 55% of the Dutch patients with a melanoma ≥1mm. SLNB was less frequently performed in patients with melanoma in the head and neck region, patients older than 55 years and in patients with low socioeconomic status. The final MSLT-I results should reveal whether this also has impact on the survival of these subgroups of patients.





The use of SLNB in patients with melanoma ≥1mm Breslow Thickness from 2004-2011 in the Northeastern part of the Netherlands

P221

Intralesional BCG as Adjuvant Therapy for Melanoma D.D. Kirchoff,* D.L. Morton, L.J. Foshag, J. Lee, M. Sim, M.B. Faries. John Wayne Cancer Institute, Santa Monica, CA.

Background: Bacille Calmette-Guerin(BCG) is a potent immune stimulant which was demonstrated in the 1960s to cause regression of melanoma. Intralesional (IL) application of BCG can help control locally advanced disease that is difficult to treat by surgical excision or other modalities such as limb perfusion. Here we report the largest series of ILBCG in melanoma as well as factors associated with relatively favorable outcomes using this treatment. Methods: A prospectively maintained melanoma database was queried for all patients treated with ILBCG. Stage/extent of disease, demographic data, and outcome (overall and melanoma-specific survival) were analyzed to assess treatment patterns and efficacy of ILBCG in a general melanoma population. Results: 593 patients received ILBCG. At the time of ILBCG 93 patients were Stage I or II, 326 were Stage III and 172 were Stage IV. Five-year overall survival (OS) and melanoma-specific survival (MSS) for the entire cohort were 51.0% and 54.5%, respectively with median survivals not yet reached. MSS for patients with Stage I/II. Stage III, and Stage IV at time of ILBCG were 64.7%, 56.1%, and 46.2%, respectively. Surprisingly, patients older than 60 exhibited improved post-BCG outcomes relative to younger patients (p=0.012). On multivariable analysis, stage of disease and female sex carried significant survival advantages. Unexpectedly, patients with head and neck sites of disease had significant survival advantage relative to truncal lesions (p=0.026) and equivalent to extremity melanoma. Conclusions: ILBCG remains a valuable therapy for superficially accessible metastatic melanoma. Patients with head and neck sites of disease and older patients, both of which are normally adverse prognostic groups, enjoyed significantly improved outcomes and may be particularly good candidates for this therapy. Ongoing research will investigate mechanisms of action for this inexpensive and non-toxic therapy.

P222

Cervical Sentinel Node Melanoma Metastases: When is Parotidectomy Indicated? E.A. Arena,* D.L. Morton, S. Steen, V. Stager, J. Albright, J.H. Howard, M. Sim, M.B. Faries. *John Wayne Cancer Institute, Santa Monica, CA.*

Introduction: Current standard of care in head and neck (H&N) melanoma includes completion lymph node dissection (CLND) for patients with cervical sentinel node (SN) metastases. Although superficial parotidectomy is indicated for parotid SN metastases, it is unclear whether a parotidectomy is required in the setting of cervical SN metastases alone. Methods: We performed a retrospective review of our prospectively maintained melanoma database. We queried for patients with H&N melanoma, age at diagnosis, sex, primary tumor site, Breslow, histologic subtype, ulceration, procedure type, location of SN, lymph node (LN) positivity, size of SN metastasis, and disease recurrence. Patients with parotid SN metastases were excluded. Results: We identified 70 patients with H&N melanoma who underwent CLND for cervical SN positivity. Five underwent initial parotidectomy at the time of CLND and 65 did not. Parotid LN metastases were found in two of the five undergoing initial parotidectomy. Of those without initial parotidectomy, six (9%) developed subsequent parotid LN metastases and were treated with parotidectomy. Compared to patients without parotid involvement (n=62), patients with parotid LN metastases (n=8) were significantly more likely to have anterior scalp primary lesions (Fisher's exact test p<0.0001) and thicker primary lesions (t test p=0.02, mean Breslow with parotid involvement 4.05mm, without 2.55mm). Cervical SN location did not predict parotid involvement. No significant differences were identified in histologic subtype, ulceration, or size of SN metastases. However, parotid LN metastases were identified even in patients with isolated tumor cells in cervical sentinel nodes. Conclusions: The rate of parotid nodal involvement with a positive cervical SN is similar to that of involvement of non-sentinel nodes in other areas. Pending the results of ongoing clinical trials, parotidectomy should be considered at the time of CLND in patients with cervical SN metastases, particularly patients with anterior scalp lesions and thicker primary tumors.

P223

Small Bowel Metastasectomy for Adoptive Immunotherapy in Metastatic Melanoma: A Single Institution Experience

S.M. Inchauste, M.M. Alvarez-Downing, S.M. Atay, S. Steinberg, G.Q. Phan, R.M. Sherry, R.E. Royal, S.A. Rosenberg, M.S. Hughes, P. Pandalai.* *Surgery, National Cancer Institute, Bethesda, MD.*

Introduction: Prolonged survival has been demonstrated in select patients (PT) with metastatic melanoma (MM) receiving adoptive cell therapy (ACT). Procurement of tumor infiltrating lymphocytes (TIL) for ACT requires metastasectomy. Prior studies have demonstrated benefit in PT with MM undergoing thoracic or hepatic metastasectomy for TIL procurement. Small bowel is the most common gastrointestinal site of MM (SBM) and caries a poor prognosis with median survival of 6 to 8 months (m). We evaluate the outcome of PT with SBM who underwent resection in preparation for TIL therapy. Methods: A retrospective analysis of a prospective database identified 102 PT with

SBM from 2,313 PT treated for MM from December 1989 to June 2011. Results: The incidence of SBM was 4%. At initial diagnosis, AJCC stage was I (23%), II (27%), III (25%), and IV (25%), 11% classified as M1c. Mean time to development of SBM was 48m (0.5-346m). Eighty-two (80%) presented with symptoms of fatigue (59%), pain (40%), obstruction (23%) and acute GI bleeding (3%). The 102 PT underwent 125 operations. Eighty (78%) underwent single segmental small bowel resection (SBR), 22% required multiple SBR, and 17% required multi-visceral resection. Following resection 21% had no evidence of disease (NED) and 79% had residual disease (RD). Postoperative morbidity and mortality was 19% and 2% respectively. Sixty-one (60%) went on to receive ACT. Median overall survival (OS) for all PT having surgery was 12.3 m. PT resected to NED had a median OS of 5.5 years, vs. 10.0 m in PT with RD (p < 0.0001). Median OS was superior for those PT with \leq 3 lesions resected vs. \geq 4 lesions resected, 13.1 m vs. 9.4 m respectively (p = 0.049). Actuarial 1-Y, 3-Y and 5-Y OS from resection was 52%, 21% and 17%. Overall comparison of actuarial 1-Y, 3-Y and 5-Y OS for PT NED vs. RD was significant (85%, 68% and 60% vs. 42%, 10% and 7%). Conclusions: Prolonged OS can be achieved in a select group of PT who undergo resection of SBM in preparation for immunotherapy.

P224

Melanoma and Sarcoidosis: An Unusual and (or) Confounding Relationship? R. Tuttle,* N. Khushalani, S. Singla, J. Skitzki, V. Francescutti, J. Kane. *Roswell Park Cancer Institute, Buffalo, NY.*

Introduction: Sarcoidosis is a very rare inflammatory disease (<40 cases per 100,000) of unknown etiology, primarily involving the lungs/lymph nodes. We observed a higher than expected incidence of sarcoidosis in our melanoma patients. Methods: Retrospective review of all melanoma patients at our institution from 2003-2013 who also had an ICD-9 diagnosis of sarcoidosis. Patient, tumor, treatment, and follow-up information were collected/analyzed. Results: Out of 3912 melanoma patients, 21 also had a diagnosis of sarcoidosis (calculated incidence 537 cases per 100,000). All patients were Caucasian and 48% were male. Melanoma stage at diagnosis: I-43%, II-24%, III-29%, and unknown-4%. The relationship of sarcoidosis diagnosis to melanoma diagnosis: 33% prior to, 14% synchronous diagnoses, and 48% subsequent. For patients diagnosed with melanoma first, the median time to the sarcoidosis diagnosis was 22.8 months. The site of sarcoidosis was 48% lymph node only 14% lung only, 14% lymph node and lung, and 14% unknown. Sarcoidosis was symptomatic in 29% of patients; 10% received steroids. Eleven patients with sarcoidosis diagnosed simultaneously or subsequently to melanoma were found on surveillance imaging. Melanoma immunotherapy was administered to 9 patients; 4 prior to the sarcoidosis diagnosis (3 received Interferon and 1 Ipilimumab). During melanoma follow-up, sarcoidosis led to an initial incorrect diagnosis of recurrent melanoma in 48%. This resulted in 12 additional procedures (10 mediastinal biopsies, 2 lung/endobronchial biopsies) to make the correct diagnosis. A diagnosis of metastatic melanoma was delayed in 1 patient due to the presence of known sarcoidosis. Conclusions: The incidence of sarcoidosis in melanoma appears to be significantly higher than for the general population. Lung and lymph node involvement confounded melanoma surveillance, leading to additional workup for "false positive" findings or a delay in the diagnosis of metastatic disease. The etiology of this unusual relationship requires further investigation.

P225

Quality Assurance in Melanoma Surgery: Benchmarks for Surgical Audit R.L. Read,* A.J. Spillane. *Melanoma Institute Australia, North Sydney, NSW, Australia.*

Purpose Surgical outcomes in melanoma surgery need to be assessed on the basis of both oncological outcome and surgical complications. Currently there is no meaningful data on complication rates for common procedures or validation of quality assurance parameters in melanoma surgery. These procedures include wide excision (WE), sentinel node biopsy (SNB) and regional lymph node dissection (RLND). There is only minimal data available whereby individual surgeons can audit their practice. Methods Surgical performance indicators were determined from a review of the literature and expert opinion. Audit data has been collected against these parameters since 2008 and is presented in a quarterly 'parameters' meeting. Key performance indicators (KPI) include death, unplanned intensive care unit admission, DVT/PE, return to theatre and readmission to hospital for complications. Melanoma surgery specific performance indicators (MSSPI) were developed and assessed. Proposed standards for MSSPIs were determined. For wide excision primary closure (WE-PC) wound infection and dehiscence should occur in <2% of cases, for wide excision skin graft (WE-SG) failure of >20% of the grafted area should occur in <5% of cases and for wide excision flap repair (WE-flap) flap necrosis should occur in <5% of cases. In SNB procedures wound infection and seroma requiring intervention should occur in <5% of cases and the procedure should aim to remove all the sentinel nodes identified on the lymphoscintigram. In RLND cases involving the neck (≥ four levels), axilla, inguinal and ilioinguinal fields at least 20, 10, 7 and 11 lymph nodes should be retrieved >90% of the time respectively. The rates of would complications requiring intervention in the neck, axilla and groin should be <5, <10 and <30% respectively. Results Complications classified as KPIs were uncommon. MSSPI targets were generally achieved though for WE-SG the benchmark was exceeded in 2011. Data for 2011 and 2012 are shown in the table below. Conclusion The data presented provide a standard by which melanoma surgeons can audit their surgical performance with the ultimate aim of improving patient outcomes.

KPI	Mean total cases/year	2011 (%)	2012 (%)
Death	1653	0	0
Unplanned ICU admission		< 0.1	< 0.1
DVT/PE		< 0.1	< 0.1
Return to theatre		0.4	0.2
Readmission for complication		1.1	0.6
MSSPI	Mean cases/year	2011 (%)	2012 (%)
WE-PC dehiscence	886	0.8	0.5
WE-SG loss >20% area	158	11.6	3.5
WE-flap necrosis	442	0.8	0.2
SNB site infection or seroma	322	3.3	1.3
RLND wounds requiring intervention	196	10.1	6.0
RLND node count <90% threshold	196	2.5	0.4

P226

Factors Associated with Sentinel Node Positivity in Patients with Thick Cutaneous Melanoma (\geq 4mm) M. Yamamoto,^{1*} J.Y. Wong,¹ K.J. Fisher,¹ J. Koscso,² M. Konstantinovic,² N. Govsyeyev,² J.L. Messina,¹ A.A. Sarnaik,¹ C.W. Cruse,¹ C.A. Puleo,¹ R.J. Gonzalez,¹ V.K. Sondak,¹ J.S. Zager.¹ I. H Lee Moffitt Comprehensive Cancer Center, Tampa, FL; 2. University of South Florida School of Medicine, Tampa, FL.

Introduction: Although sentinel lymph node biopsy (SLNB) is standard of care for patients (pts) with intermediate thickness melanoma, controversy remains on its utility and prognostic value in thick melanoma. We sought to identify the pt and tumor related factors that are predictive for clinically occult nodal metastasis and whether SLNB has prognostic implications in pts with thick melanoma. Methods: From 1999 to 2012, 419 pts with thick melanoma (>4 mm) who underwent SLNB from a single institution were retrospectively reviewed. Pts who presented with clinically positive nodal or distant disease were excluded from the study. Demographic and clinicopathologic characteristics were correlated with nodal status based on SLNB. Univariate (UV) and multivariate (MV) logistic regression analyses were performed. Results: Of 419 pts, 292 (69.7%) were male and the median age was 64. Median Breslow thickness was 6 mm (range 4-25 mm). Overall, 161 pts (38.4%) had a positive sentinel node (SLN), 251 (59.9%) had a negative SLN, and 7 (1.7%) failed to map on lymphoscintigraphy with no SLNB was performed. On UV analysis, ulceration, trunk and extremity location, and presence of satellitosis were predictive of SLN status. Mitotic rate, tumor regression, and Breslow thickness, however, were not predictive of SLN status. On MV analysis, truncal (odds ratio [OR] 4.60, p=0.0003) and extremity (OR 3.17, p=0.008) melanoma, and presence of satellitosis (OR 10.31, p=0.006), were significant predictors of a positive SLN. Desmoplastic histology had a decreased likelihood (OR 0.09, p=0.001) for a positive sentinel lymph node on UV and MV analysis. Conclusions: In thick melanoma, factors historically associated with SLN status (ulceration, Breslow thickness, mitotic rate) were not found to be predictive of positive SLN. However, truncal or extremity primary tumors were more

commonly found to have positive SLNB. Satellitosis was the strongest predictive factor for a positive SLNB and hence appears to indicate patients with thick melanoma at particularly high risk of regional spread.

	Univariate anal	lysis	Multivariate ana	lysis
	OR (95% Wald CI)	p-value	OR (95% Wald CI)	p-value
Age (> 66 vs. ≤ 66)*	0.71 (0.47-1.06)	0.093		
Sex (Female vs. Male)	1.16 (0.76-1.78)	0.484		
Location				
Trunk vs. Head/Neck	4.05 (2.20-7.45)	< 0.0001	4.60(2.03-10.42)	0.0003
Extremities vs. Head/Neck	2.83 (1.56-5.12)	0.001	3.17(1.35-7.42)	0.008
Breslow Thickness (≥6 vs. <6 mm)*	1.21 (0.81-1.80)	0.351		
Histology				
Desmoplastic vs. Superficial spreading	0.07 (0.02-0.26)	< 0.0001	0.09(0.02-0.36)	0.001
Acral Lentiginous vs. Superficial spreading	0.83 (0.32-2.15)	0.706	0.79(0.28-2.25)	0.657
Nodular vs. Superficial spreading	0.89 (0.44-1.82)	0.751	0.82(0.39-1.76)	0.615
Vertical growth phase	0.78 (0.07-8.67)	0.838		
Tumor regression (Absent vs. Present)	0.59 (0.24-1.44)	0.25		
Ulceration	1.66 (1.09-2.54)	0.019	1.43(0.83-2.45)	0.194
Mitotic rate/ sq mm (≥ 5 vs. < 5)*	1.06 (0.69-1.65)	0.784		
Satellitosis	4.63 (1.77-12.11)	0.002	10.31(1.98-53.83)	0.006
* dichoto	mized at median valu	ie		

P227

A Pilot Study of CXCL12/CXCR4 Chemokine Expression in Sentinel Lymph Node Tracts in Cutaneous Melanoma: An Often Overlooked Signaling Pathway M.S. Jones, ^{1*} M. Rivera, ¹ M. De Guzman, ¹ C.L. Puccineli,² S.J. Williams, ¹ J.L. Baynosa, ¹ C.R. St Hill, ¹ D.M. Kirgan.¹ 1. General Surgery, University of Nevada School of Medicine, Las Vegas, NV; 2. University of Nevada School of Medicine, Reno, NV.

Introduction: The chemokine signaling environment of the sentinel lymph node (SLN) tract is an often overlooked but clinically important pathway for tumor metastasis. Our hypothesis is that the CXCR4/CXCL12 receptor/ligand pair, implicated in metastatic melanoma, is present in the lymph node tract of subjects with cutaneous melanoma. Methods: We designed a prospective pilot study of consecutive patients with cutaneous melanoma as the indication for SLN biopsy. Following IRB approval, study subjects were consented, enrolled, and SLN tracts were collected intraoperatively. Immunohistochemical (IHC) staining of the tissue was then used to identify the presence of CXCR4 and CXCL12. IHC images were analyzed by multiple observers in a standardized fashion to determine the degree of receptor/ligand and control staining. Clinicians, investigators and graders were blinded to the subject's clinicopathologic status. Results: At this interim evaluation 10 subjects were enrolled in this study. The median age of subjects was 65 (Range 41-84), 90% were male (n=9). In terms of location, 60% of lesions were truncal, and 40% of lesions involved an extremity. Review of pathologic factors showed mean Breslow thickness of 2.20 (SD=2.10), mean mitotic figures were 1.67/mm2 (SD=2.25). A single subject (10%, n=1) had a positive sentinel node with 90% (n=9) negative on SLNB. IHC images showed expression of CXCR4 in 50% of SLN tracts with an average IHC image score of 2.0 (SD=0.816). CXCL12 was expressed in 100% of SLN tracts with an average IHC image score of 2.50 (SD=0.527). Of note, the one subject with a positive SLN had IHC images identifying only positivity of CXCL12, with negative CXCR4 staining. Conclusion: CXCL12 was identified via IHC images in all SLN tracts. Contrary to our initial hypothesis, CXCR4 was identified in only 50% of tracts. Receptor/ligand interactions of the SLN tract with respect to CXCR4/CXCL12 is a novel field of study that is essential to future understanding of chemokines and their role in melanoma metastasis



Immunohistochemical (IHC) Images of Sentinel Lymph Node Tract Specimens: A) 4',6-Diamidino-2-phenylindole (DAPI) Nuclear Stain B) IHC Image of Positive Sentinel Lymph Node, +CXCL12 C) IHC Image of Negative Sentinel Lymph Node, +CXCL12, +CXCR4

P228

Keystone Flaps can be Performed Safely by Surgical Oncologists without Specific Plastic Surgery Training R.K. Orr,* N. White, R.B. Hird, C. Nguyen. *Gibbs Regional Cancer Center, Spartanburg,* SC.

Introduction: Behan has popularized the Keystone Design Island Perforator flap as an alternative to skin grafting for cutaneous defects from oncologic resection and as an excellent cosmetic alternative to extensive primary closure. Following a publication by the Sydney Melanoma Unit (Ann Surg Oncol 2008:15:2867-73) we began using the Keystone flap and are reporting this prospective experience. Methods: Beginning October 2008, one surgeon performed 88 keystone flaps in 86 patients. The surgeon has experience in cutaneous oncology, but has no formal plastic training and learned the Keystone technique by extensive study of publications. Data were prospectively collected including indications for the procedure, size of the cutaneous defect, and complications. The results during the first half of the experience (through June 2011) were compared to the later experience. Results:, Average age 61.4 (20-92). 59 % were men. 79% had melanoma, 9% basal cell carcinoma, 8% squamous cell, carcinoma, and 1 each Merkel cell and extensive condyloma. 33% trunk, 34% upper extremity, 30% lower extremity, and 3% neck, Mean thickness for melanomas was 1.4 mm (0.3-4.2). Sentinel node biopsies were performed in 55 (14.5% positive). The average cutaneous defect for all patients was 21.4 cm2 (3-88); 25% were greater than 25 cm2. There were no flap losses, returns to the OR, nor hospitalizations related to procedural complications. One major complication occurred: a 50% wound separation that required prolonged healing by secondary intention (15th patient in series). Minor complications occurred in 9 additional patients (9.8%): 5 minor wound defects that healed easily, 2 infections, and 2 that required resuturing of a portion of the wound. 36 flaps were performed during the first half of the experience, with a 22% complication rate, as compared to 2 complications in the last 52 flaps (4%). Conclusions: Keystone flaps may be performed safely by a surgeon without specific plastic surgery training. Major complications are rare, but minor wound complications were frequent during the "learning curve" phase.



P229

Alternative Energy Sources are Ineffective in Preventing Lymph Leaks and Seromas during Minimally Invasive Inguinal Node Dissections T.E. Grotz,* J.W. Jakub. Surgery, Mayo Clinic, Rochester, MN.

Background: Inguinal lymphadenectomy carries significant morbidity. In an effort to reduce this we and others have advocated a minimally invasive approach. Although this has resulted in fewer wound infections and shorter length of stay it has not decreased seroma formation and drain days. We hypothesize that different tissue sealing devices may seal lymphatic channels and reduce seroma formation. Methods: Retrospective cohort study of consecutive patients undergoing minimally invasive inguinal lymphadenectomy by a single surgeon. The first 9 patients underwent the procedure using the harmonic scalpel (Ethicon Endo-Surgery, Cincinnati, OH) and the second cohort of 9 patients underwent the procedure using the LigaSure device (Tyco/Valleylab, Boulder, CO). Results: All cases were completed videoscopically except one, resulting in a conversion rate of 5%. The median operative time for the cases using the harmonic scalpel was significantly shorter (208 vs. 261 minutes, p = 0.02) than the cases using the LigaSure. There was no difference in the median lymph node retrieval 13 (9-19) compared to 15 (7-26) (p = 0.4), the incidence of wound infections, including cellulitis (11% vs 22%, p = 1.0) and the median length of stay (23 hours vs. 23 hours, p =0.66), for the harmonic and Liga-Sure, respectively. Although the median drain duration was shorter for the harmonic scalpel technique (22 vs. 35 days) it did not reach significance p = 0.5. Similarly, there was a higher incidence of seromas using the harmonic scalpel technique (44% vs. 22%) but again it did not reach significance, p = 0.6. Conclusion: Lymphorrhea and seroma formation remain a major morbidity of inguinal lymphadenectomy, and a minimally invasive approach does not resolve this problem. Some animal models have suggested that alternative energy sources coapt lymphatic vessels compared to electrocautery. This has not been our experience in clinical practice and both tissue sealing devices were associated with high incidence of seromas and prolonged drain days. Further investigation is warranted in techniques to limit seroma formation following inguinal lymphadenectomy.

Comparison of alternative energy sources for minimally invasive inguinal lymphadenectomy

Energy Source (N)	Operative Time	Conversion	Number of LNs	SSI	Drain Days	Seroma
Harmonic Scalpel (9)	208	1	13	11%	22	44%
LigaSure (9)	261	0	15	22%	35	22%
p-value	0.02	NS	NS	NS	NS	NS

P230

Sentinel Node Biopsy under Local Anesthesia: The European Institute of Oncology Experience E. Pennacchioli,* A. Intelisano, F. Verrecchia, G. Tosti, F. Baldini, G. Spadola, M. Mosconi, A. Testori. *European Institute of Oncology, Milan, Italy.*

Background: Sentinel node biopsy is an important staging procedure in several tumors like melanoma. We decided to evaluate feasibility, safety and satisfaction of both patient and surgeon about sentinel node biopsy performed under local anesthesia and with single-day hospitalization. Materials and Methods: Since 1999 at EIO Melanoma division a questionnaire about SNB performed under local anesthesia has been submitted to patients and surgeons. SNB is performed at the same time of the wide excision of primary tumor and the local anesthesia approach was proposed only on patients with a single site sentinel node localization, excluding neck and poplyt sentinel nodes. We recorded data about the previous primary lesion, the preoperative medical information given to patients about the procedure to be planned, any symptomatology of pain during the procedure through a scale from 0 to 10, patient's satisfaction, hospitalization setting, drugs used and drugs dosage, availability of anesthetist during the procedure in the event of a patient requiring a sedation and duration of surgery. Results: Since 1999 498 forms were collected. 80% of patients were dismissed the same day and 87% of them were satisfied of the day-hospital setting. Duration of surgery was less than 30 minutes in 53% of cases but 35% of patients expected an even shorter surgery. 50% of patients felt pain during the surgery but the average value from 0 to 10 was 3.8 and the median value was 4. 82% would repeat it again under local anesthesia and 86% would suggest to do so to other patients. Conclusions: SNB can be performed under local anesthesia and in a day surgery setting safely and with patients satisfaction. It can also reduce costs of hospitalization and reach a better impact of surgical treatment on tumor patients quality of life.

P231

Two Decades Single-center Experience of Melphalan-based Isolated Limb Perfusion (ILP) with or without TNF for In-transit

Melanoma Metastases K. Veerman, B.L. Van Leeuwen, H.J. Hoekstra, R. Van Ginkel.* *Surgery, UMCG, Groningen, Netherlands.*

Background In-transit metastases (ITMs) develop in 5-8% of all melanoma patients, often preceding systemic disease and thus influencing survival. This accentuates the importance of ITMs management. In case of rapid recurrence or numerous ITMs, ILP is preferred. This study reports the Groningen perfusion experience with Melphalan (M-ILP) and TNF-Melphalan (TM-ILP) for ITMs. Methods Between 1992 and 2012 57 perfusions (18 M-ILPs; 39 TM-ILPs) were performed and included in this study. Patients with 'limited' ITMs received M-ILP (10-13 mg Melphalan/L limb volume) and patients with 'bulky disease' TM-ILP (1-4 mg TNF). Cox-regression analysis was used to deter-

mine variables with significant impact on time to local progression (TLP) and systemic progression (TSP) and melanoma-specific survival (MSS). For clinical response logistic regression was used. Survival curves were constructed by the Kaplan Meier-method and compared with the log-rank test. Results In 57 ILPs overall response was 90%; 27 complete responses (47%), 27 partial responses (47%), 3 no responses (6%). In 18 M-ILPs 6 complete responses (33%) were observed and in 39 TM-ILPs 21 complete responses (54%, P=0.124). Age below 65 years and low tumor load (<5 ITMs) were independent prognostic favorable factors for developing complete response to ILP (resp. P=0.003; P=0.038). After a median follow-up of 15 (range, 1-144) months local recurrence or disease progression occurred in 36 patients (63%). Absence of CR (P=0.010) and Stage IIIC disease (P=0.002) were independent prognostic factors for progression to systemic disease. Non-ulcerating primary melanoma and complete response to ILP are favorable to MSS (Fig 1, resp. P=0.021, P=0.018). Conclusion Melphalan-based Isolated Limb Perfusion is an effective regional treatment for in-transit melanoma metastases, in case of bulky disease Isolated Limb Perfusion with TNF and Melphalan is preferred

Figure 1 Melanoma-Specific Survival: A MSS vs. Ulceration; B MSS vs. Complete response



P232

Indocyanine Green and Fluorescence Lymphangiography for Sentinel Lymph Node Identification in Melanoma J.M. Cloyd,*

I.L. Wapnir, B.M. Read, R.S. Greco. Surgery, Stanford University, Stanford, CA.

Assessment of the sentinel lymph node (SLN) has been established as a reliable method of determining regional lymph node involvement, one of the most important prognostic indicators in melanoma. SLN mapping with Indocyanine green (IcG) fluorescent lymphangiography is an attractive alternative to technetium-99m sulfur colloid (Tc-99m) and isosulfan blue dye (ISB). We sought to determine the effectiveness of IcG-guided SLN mapping compared to other modalities. Thirty-two consecutive patients with cutaneous melanoma undergoing SLN biopsy were retrospectively reviewed. All patients underwent preoperative lymphoscintigraphy with Tc-99m. After induction of general anesthesia, peritumoral intradermal injections of 4mL ISB and 2mL of IcG were performed. Real time fluorescence imaging was performed using the SPY infrared imaging system (Novadaq Technologies Inc; Bonita Springs, FL). Concordance of the three modalities with histopathology was recorded. IcG was defined as successful if fluorescence was detected in situ and guided the LN dissection. A total of 46 lymph nodes were identified from the 32 patients (range 1-3). The majority of melanomas were extremity based (n=19), were superficial spreading type (n=25) and had SLN localized to the axilla (n=24). Rates of successful in situ detection per lymph node were 43/46 (93.5%) for Tc-99m, 31/46 (67.4%) for ISB and 42/46 (91.3%) for IcG. All but one LN was fluorescent ex vivo. Percentage of patients with at least one LN detected was 32/32 (100.0%) for Tc-99m, 22/32 (68.8%) for ISB and 28/32 (87.5%) for IcG. On univariate logistic regression, age, gender, body mass index, melanoma subtype, Breslow depth, location of primary, histological status of LN, location of LN, radioisotope count, and uptake of blue dye were not associated with failure of IcG fluorescence. There were no complications related to IcG administration. In conclusion, fluorescence lymphangiography with intradermal IcG injection facilitates SLN identification and is more effective than blue dye in melanoma staging.

Malignant Adnexal Tumors of the Skin: A Single-institution Experience T. Ovasiji,* W. Tan, J. Kane, J. Skitzki, V. Francescutti,

N. Khushalani. Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY.

INTRODUCTION: MATS are rare tumors with no consensus on management guidelines. We aimed to examine the natural history of MATS, define treatment paradigms, and identify predictors of improved survival. METHODS: A retrospective review of all MATS treated at our institution from 1990 through 2012 RESULTS: Fifty patients (pts), median age 59.5 vrs (range 22-95), 56% males were identified within the time period. Nearly half (48%) the pts were > 60 yrs. Primary site was head and neck (52%), upper extremities (16%), lower extremities (16%) & trunk (16%). The histologic sub-types by frequency are outlined in the table. Pts most commonly presented with early stage disease (Stage I, 32%) & were mostly node-negative (N0, 88%). The vast majority were T1 (44%) tumors. T2, T3 and T4 tumors were 18%, 2% and 10% respectively (Tx, 26%). Forty-nine pts (98%) had surgical treatment with wide local excision (30%), Mohs (22%) and local excision (46%). Four pts (8%) received adjuvant chemotherapy (CT), and 7 pts received radiation therapy. Six pts (12%) experienced recurrence (3 local, 1 regional and 2 distant recurrences). Median OS was 158 months (95% CI, 52-255). OS at 5 yrs was 62%, and at 10 yrs was 57%. Age > 60 years (HR 12.9, P= 0.0008) was an unfavorable predictor of OS. The 5-yr and 10-yr disease-specific survival was 63%. No association was found between the primary tumor stage and pathologic nodal positivity, though the sample size was small. CONCLUSIONS: In our small series for MATS, prognosis was better for younger patients. While surgery remains the mainstay of therapy, the role of surgical nodal basin staging and adjuvant chemotherapy in MATS needs further investigation.

Histologic subtypes of MATS and their distribution in our series

Histologic Subtype	Number (%)
Eccrine adenocarcinoma	10(20%)
Skin appendage carcinoma	10(20%)
Sebaceous adenocarcinoma	9(18%)
Malignant eccrine poroma	6(12%)
Sclerosing sweat duct adenocarcinoma	6(12%)
Adenoid cystic carcinoma	5(10%)
Malignant eccrine spiradenoma	1(2%)
Malignant nodular hidradenoma	1(2%)
Porocarcinoma	1(2%)
Apocrine adenocarcinoma	1(2%)

P234

Lymph Node Staging for Mucosal Melanoma J. Hui,* H. Wu, A.J. Olszanski, E. Handorf, J.M. Farma. Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA.

Introduction: Mucosal melanomas of the vulva and anorectum are rare and have more aggressive biology than the more common cutaneous melanoma. Because of their rarity, no specific staging system or guidelines exist to prognosticate or aid in therapeutic decision making. This study describes our experience with lymph node (LN) staging for these melanomas by sentinel lymph node biopsy (SLNB) or lymphadenectomy (LAD) and their clinical outcomes. Method: A retrospective chart review was carried out for adult patients diagnosed with melanoma from January 1990 to April 2013, treated at our tertiary referral center. Those with cutaneous, ocular, head and neck, unknown primaries, or metastatic disease at time of diagnosis, and those who presented for only one consultation without treatment were excluded. Patient management was at the discretion of the attending physician. Survival curves were generated using the Kaplan-Meier method and compared using the log-rank test. Results: A total of 2195 melanoma patients were identified; 26 (1.2%) had mucosal melanoma of the vulva, cervix, vagina, or anorectum. Of these, 19 (73%) patients had gynecologic mucosal melanoma (GMM) and 7 (27%) had anorectal mucosal melanoma (ARMM). Median age was 67.5 (range 49-91 years); 92% were females. The majority (84.6%) underwent a wide local excision of the primary. Ten (38.5%) patients did not undergo any nodal staging procedure; 9 (34.6%) had SLNB and 7 (26.9%) had initial elective LAD. Four patients (44.4%) had positive LN on SLNB; 2 went on to have completion LAD with no further positive LN. Two of seven elective LAD (28.6%) yielded positive LN. There was no difference in median post-surgical recurrence free survival or overall survival (OS) between those with SLNB and/or LAD versus no nodal staging. The median OS for ARMM was 12.4 months, which was significantly less than 33.1 months for GMM (P=0.0017). Conclusion: This is a descriptive series of surgical lymph node staging in patients with gynecologic and anorectal mucosal melanoma. Whether a patient had nodal staging or not did not seem to be associated with a difference in survival. Those with ARMM had a significantly decreased median OS than those with GMM.



The overall survival of anorectal mucosal melanoma versus gynecologic mucosal melanoma from time of diagnosis.

P235

PET-CT Identifies Regional Nodal Metastasis in Cutaneous T4 Melanoma M.S. Jones,* M. De Guzman, M. Rivera, J.L. Baynosa, C.R. St Hill, D.M. Kirgan. *General Surgery, University of Nevada School of Medicine, Las Vegas, NV.*

Introduction Positron Emission Tomography-Computed Tomography (PET-CT) has been investigated as an adjunct to more accepted methods of cutaneous melanoma staging. There is a paucity of literature investigating the concordance of sentinel lymph node biopsy (SLNB) findings and PET-CT results in T4 melanoma patients. The objective of this study was to investigate the utility of PET-CT in the preoperative workup of patients with T4 melanoma. Methods Following local IRB approval, a retrospective review was conducted of consecutive subjects having received SLNB for cutaneous T4 melanoma from 2007-2012. Regression analysis was performed to identify clinicopathologic factors associated with PET-CT positivity. Statistical analyses were performed using IBM SPSS Statistics, Version 20 software (Armonk, NY). Results Our review resulted in analysis of 35 subjects. Median age was 61 (Range 34-89) with 40 % female subjects (n=14). Median follow-up for the study was 11 months (Range 0-40 months). Pathologic findings for the overall cohort showed 46.4% (n=13) with positive sentinel nodes, 63.6% (n=21) ulcerated, 33.3% (n=8) lymphovascular invasion, and 20% (n=4) perineural invasion. In followup 32.1% (n=9) had recurrence, 22.2% with local recurrence (n=2). Mean Breslow thickness was 7.4mm (SD=3.5), while mean mitotic figures/mm2 was 5.4 (SD=4.9). None of these factors were significantly different between positive vs. negative PET-CTs. On univariate analysis positive PET-CT was associated with 88.9% positive SLNB compared to 22.2% if PET was negative (p=0.003). Positive PET-CT was also associated with 41.7% positive non-SLN compared to 5.6% with negative PET-CT. Additionally, 54.5% of patients with positive PET-CT had a recurrence vs. 12.5% recurrence with negative PET-CT (p=0.033). Multivariable regression showed only SLNB positivity to be significantly associated with PET-CT positivity (OR 44.0 p=0.004). Conclusions Patients with cutaneous T4 melanoma appear to be a niche group for whom PET-CT may be of utility. T4 melanoma patients with regional nodal metastasis identified on PET-CT may benefit from immediate lymphadenectomy without SLNB, thereby hastening definitive treatment.

The Natural History of Primary Cutaneous Endocrine (Merkel Cell) Carcinoma: 20-year Experience from a Canadian Perspective A. Pooni,* S.S. Brar, A.M. Easson. Department of Surgery, University of Toronto, Toronto, ON, Canada.

Introduction: Merkel Cell Carcinoma(MCC) is a rare, aggressive primary cutaneous neuroendocrine carcinoma. First described in the early 1970s, its natural history remains poorly characterized. Much of what is known about MCC is derived from few single institution series. To date, a Canadian experience has not been described. Methods: A retrospective analysis of our institution's prospective cancer registry was performed to identify all patients diagnosed with MCC between 1988 and 2010. Patient, tumor and treatment variables were collected. Cases were staged using the AJCC 7th edition criteria and analyzed to determine MCC specific outcomes. Results: One hundred and fifty two cases were identified, 19 were excluded due to incomplete staging data. In the remaining 133 cases, the mean age at diagnosis was 71 years (range 38-95) with an average follow up of 33 months. The head and neck(42%) followed by the extremities (36%) were the most common sites of disease. Thirty-four percent of patients presented with stage I disease, 22% with stage II, 25% with stage III and 19% with stage IV. The 5-year overall survival rates were 57%, 46%, 33% and 7% for stages I,II,III,IV respectively (p<0.01). Thirty six percent of patients who presented with local or regional disease recurred, with an average disease free interval of 461 days. In node positive disease the recurrence rate was 47%. Lymph nodes(52%) followed by distant disease(26.2%) were the most common sites of recurrence. 107(81%) patients were treated with wide local excision. Twenty-four percent of node negative patients received radiotherapy compared to 85% of patients with stage III disease. Chemotherapy was reserved for metastatic disease. Conclusion: This study represents the largest series to date describing the Canadian experience with Merkel Cell Carcinoma. The data describes the stage specific natural history of MCC and confirms its aggressive nature. Disease stage at presentation was a predictor of overall survival (p<0.01). To improve patient outcomes, research to clarify stage specific predictors of survival and progress adjuvant therapies is required.

P237

Vaginal and Vulvar Melanoma is Associated with a High Rate of Regional Nodal Disease A. Abbott,* I. Ramirez-Diaz, J. Clara, R.R. Kudchadkar, G.T. Gibney, J. Torres-Roca, N. Rao, A. Trotti, P. Judson, J.L. Messina, V.K. Sondak, R. Wenham, S. Apte, J.S. Zager. *Moffitt Cancer Center, Tampa, FL*.

Introduction: Patients (pts) with vaginal or vulvar melanoma have a poor 5-year survival. Due to the rarity of this disease, limited treatment and outcomes data is available. While surgical excision is standard of care for the primary tumor, the role of sentinel lymph node (SLNB) biopsy, complete lymph node dissection (CLND) and elective CLND (ELND) therapy needs to be defined. Methods: A retrospective review of all pts with vulvar or vaginal melanoma treated at a single institution from 2000 to 2013 was conducted. Clinicopathologic factors and surgical treatment of the nodal basins were analyzed. Results: 35 pts (22 vulvar/13 vaginal), average age of 62 years, were identified. Of the 22 pts with vulvar melanoma, the median Breslow depth was 2.8mm and 12/22 (54%) had metastatic regional nodal disease. 10 pts had SLNB of which 5 (50%) were positive, 4 of whom had a CLND. There were no regional recurrences in the 5 pts with a positive SLN. In those pts with negative SLNB (5/10) there were 2 regional recurrences (false negative rate 28%). 6 pts had an ELND, 4 (66%) of whom had positive nodes in the specimen, 3 went on to have regional recurrence. 6 pts had no surgical nodal evaluation, 1 who developed a regional recurrence. In the vagina cohort the median Breslow depth was 4mm and 5/13 (38%) had metastatic regional nodal disease. 4 pts had a SLNB and none (0%) were positive, 1 pt eventually failed in the regional nodal basin synchronously with local and distant disease. 5 pts had ELND and 2 (40%) had positive nodes. There were no regional recurrences in these pts. 4 pts did not have surgical nodal evaluation, 3 of whom developed regional recurrences. Conclusion: There appears to be a high rate of nodal disease (49%) in this population. SLNB identifies occult disease in a significant percentage of cases and may improve the chance for regional disease control. The high rate of false negative SLNB in vulvar melanoma might reflect ambiguous drainage patterns seen in this population. Larger multi-institutional collaboration studies are needed to better define treatment algorithms.

P238

Long-term follow-up Confirms the Safety and Efficacy of Parotid Sentinel Node Biopsy as a Staging Procedure for Head and Neck Melanoma C. Isom, ^{1*} M.C. Kelley,² J.A. Sosman,³ R.B. Yates,² V. Viar.³ 1. Vanderbilt University Medical Center, Department of General Surgery, Nashville, TN; 2. Vanderbilt University Medical Center, Division of Surgical Oncology, Nashville, TN; 3. Vanderbilt University Medical Center, Division of Hematology-Oncology, Nashville, TN.

Introduction Sentinel lymph node biopsy (SLNB) is an effective staging procedure for melanoma of the trunk and extremities. The accuracy and safety of SLNB for melanomas with lymphatic drainage to the parotid nodes has been questioned. We evaluated the long term outcome of patients undergoing parotid SLNB to determine the safety and efficacy of this procedure. Methods Sixty one patients underwent wide excision and parotid SLNB for clinical stage I and II head and neck melanoma between 07/01/1997 and 06/30/2008. Tc-99m sulfur colloid, blue dye, lymphoscintigraphy, and a gamma probe were used. Clinical and pathological data were collected through a prospective, IRBapproved data repository. Results Most patients were older (mean age 62), males (88%) with melanomas of the ear (32.7%), cheek (19.7%), forehead (19.7%), neck (11.5%), scalp (9.8%), or eyelid/brow (6.6%). Mean tumor thickness was 2.0 +/- 1.9 mm; 23% were ulcerated, 54% had a mitotic rate >1/mm2. SLN were identified in 59/61 (97%) patients. 119 basins were mapped (60 parotid, 54 cervical, 5 other), with 3.4 ± 1.6 SN per basin. Twelve of 61 (19.7%) had tumor-positive parotid SLN. One false negative (FN) result (Accuracy 99%, FN rate 7%) was confirmed after 5 years actuarial follow-up. Seven (11.5%) patients experienced complications, (2 temporary facial nerve paresis). Long-term follow-up was available for 50 patients; 34 (56%) were alive with median overall survival of 83 months. 15 of 50 (30%) developed recurrence with median disease-free survival of 32 months. Conclusion With careful attention to technical details, parotid sentinel node biopsy can be performed with a low rate of serious complications. The procedure is associated with a low long-term false negative rate and is the procedure of choice for staging the parotid nodes in head and neck melanoma.

P239

Sentinel Lymph Node Biopsy for Predicting Recurrence in Invasive Cutaneous Melanoma of the External Ear J. Madden,² K. Hewitt,² J. Hyngstrom,² R.H. Andtbacka,² D. Noyes,¹ T. Bowles.^{1*} 1. Intermountain Medical Center, Murray, UT; 2. University of Utah, Huntsman Cancer Institute, Salt Lake, UT.

Background: Sentinel lymph node biopsy (SLNB) for cutaneous melanoma of the external ear presents unique surgical challenges due to the variable lymphatic drainage pattern of the ear. The purpose of this study was to evaluate the technique of SLNB in patients with melanoma of the ear and its role as a prognostic indicator. Methods: A retrospective chart review of 85 patients with clinical stage I and II cutaneous melanoma of the external ear treated between 2000 and 2011 was conducted. Surgical treatment and patient outcomes were evaluated. The positive predictive value (PPV) and negative predictive value (NPV) with 95% confidence intervals were calculated for SLNB predicting recurrence of melanoma. Results: The mean age was 60 years (range 18-101) and 83.5% of patients were male. The mean Breslow thickness of the primary tumor was 1.25 mm (range 0.18- 5.25 mm), 21.9% of tumors were ulcerated, and the most common anatomic location was the helical rim (64.6%). Surgical resection by wedge excision (including skin and cartilage) was the most common procedure (85.9%); only 2 patients required auriculectomy as primary treatment. Sentinel lymph node biopsy was performed in 51 patients. At least 1 SLN was identified in all patients (range of 1-13, mean = 4). Lymphatic drainage to multiple basins was identified in 20 patients (39.2%), with

drainage to the parotid gland and Level II of the cervical chain most commonly observed. Six of 51 patients (11.8%) had a positive SLNB. Overall, 11 of 85 patients (12.9%) recurred. Of these, 6 had undergone SLNB and 3 of these patients had a positive SLNB. The PPV for a positive SLNB predicting recurrence was 0.5 (0.14-0.86), while the NPV was 0.93 (0.80-0.98). Conclusions: Despite the complex lymphatic drainage pattern of the external ear, sentinel lymph node biopsy for melanoma is technically feasible and with adequate nodal sampling, the negative predictive value of sentinel lymph node biopsy for recurrence is high.

P240

Clinical Utility of Combining PLX4032, a BRAF Inhibitor, with a Multivalent Melanoma Immunotherapeutic Vaccine M. Wallack,² R. Suriano,¹ N. Tuli,¹ A.L. George,¹ J. Geliebter,¹* R.K. Tiwari.¹ *1. New* York Medical College, Valhalla, NY; 2. Metropolitan Hospital, New York, NY.

Introduction: Successful melanoma vaccines require the use of multiple melanoma associated antigens (MAA). We have developed a vaccinia virus based vaccine using multiple primary cell lines, which express a plethora of antigens such as MART-1, tyrosinase, and gp100. This oncolysate vaccine has been tested in a human clinical trial and generated an immunological response. Further, the BRAF genetic lesion is one of the most common mutations and inhibition of its signaling pathway has demonstrated clinical efficacy in melanoma patients. The objective of this study is to examine the possible development of a combinatorial therapeutic approach to treat melanoma combining our MAA rich vaccinia based melanoma vaccine with BRAF inhibitors. Methods: The primary cell lines used in our study were characterized based on the expression of the mutated BRAF gene as well as to their responsiveness upon treatment with PLX4032, a BRAF inhibitor. In addition, the MAA expression of our five primary melanoma cell lines was characterized in vitro upon treatment with PLX4032. The expression of various MAAs was assayed for both at the protein and gene levels. Results: The primary melanoma cell lines used in our study were determined to be either homozygous of heterozygous for the mutated BRAF gene. In addition, the cell lines harboring the mutated BRAF were responsive to treatment with PLX4032 such that inhibition of phosphorylation was observed for the various proteins present in the BRAF cell signaling pathway, namely Mek and Erk. Interestingly, upon treatment with PLX4032, the MAA expression profile of our primary melanoma cells was altered such that we observed increased expression of various antigens such as MART-1, gp100, and tyrosinase both at the protein level and gene level. Conclusion: Our results conclude that treatment of our primary cells with PLX4032 results in the up regulation of various MAAs making them as cytotoxic T-cell targets. These results form the basis of a proposed clinical trial combining PLX4032 with our FDA approved vaccinia based melanoma vaccine.

P241

Surgery for Gastrointestinal Metastasis in Stage IV Melanoma S. Prabhakaran,* R.J. Gonzalez, V.K. Sondak, R.R. Kudchadkar, G.T. Gibney, J.S. Weber, J.S. Zager. *Moffitt Cancer Center, Tampa, FL*.

Introduction: The prognosis of patients (pts) with gastrointestinal (GI) metastasis from melanoma is poor. Surgery remains a therapeutic option to render select pts free of disease (NED) and for palliation of symptoms. We reviewed our single institution experience with surgery for metastatic melanoma to GI sites. Methods: An IRB approved retrospective review was performed on all pts who underwent surgery for GI metastasis from melanoma between 2007 and 2013. Results: 52 pts were identified, the median age was 60 years; 33 (63%) were male. Overall, 34 (65%) pts had systemic treatment prior to surgical intervention. Surgery was performed with curative intent in 14 (27%) and for palliation in 38 (73%). 33 (63%) were symptomatic. Symptoms included

bleeding/anemia (55%), obstruction (39%) and pain (36%). Pts who had surgery to render them NED were mostly asymptomatic (75%). Site of GI metastasis was small bowel in 37 (71%), colon 11 (21%), liver 9 (17%), stomach 4 (7.7%) and spleen 3 (5.8%). 40 (77%) had multiple visceral metastasis noted during surgery. Small bowel resection was most commonly performed in 35 (67%) followed by colon resection 9 (17%), liver resection 5 (9.6%) and splenectomy 3 (5.7%). Eleven (21%) developed complications that included wound infection (4), pelvic abscess (3), venous thrombosis (3), pneumonia and renal failure (1), and anastomotic leak (1). 31 (94%) of the symptomatic pts had subjective symptom relief after surgery. 30-day operative mortality was 0%. Median follow-up period was 9.8 months (0.2-63). Median PFS in pts treated with curative intent was 13.9 months (3.4-56.6). Median OS in these pts was 19.8 months (1.6-58.6) compared to 7.4 (0.2-62.3) in pts undergoing surgery for palliation. Conclusion: Surgery for GI metastasis in melanoma could be safely performed in selected pts with excellent symptom relief and little morbidity. Patients rendered NED have close to a 2 year median OS after surgery. Since rendering pts NED appears to be associated with a prolonged OS, strategies using neoadjuvant targeted or immunotherapies with the goal of reducing tumor burden and number of organs involved followed by surgery should be considered.

Total patients	52	
Apr	Modian 60 years (range 21-79)	-
	Males -33 (6373.)	
50	Females - 19 (37%)	
	Trank - 14 (2%)	
	Extremities - 13 (2%)	
Location of primary	15kN - 10 (19%)	
	Unknown - 14 (275)	
	13contol - 8 (1955)	
Electrotion	Non-adversion 15 (68/E)	
	Elekonom - 29 (595)	
	 I minoiche mm. X(175) 	
Manua	> 15o mm - 12 (2003)	
	Elakarana - 32 (6293)	
	< 1 mm - 10 (1995)	
	100 - 7 mm - 5 (001)	
Tumor Bickney	201 - 4 mm - 8 (195)	
Turner unconcer	5.4 mm - 8 (1905)	
	Enderson - 21 (2001)	
	Start 6 - 9/3 900 2	
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
2020-0223-02-02-02-02-02-02-02-02-02-02-02-02-02-	1	
Stage of initial presentation		
	111 - 11 (219)	
	10 - 10 (10)01 -	
	Landow - Internet	
Intervening Stage III disease	3(3-28(249)	
	No.00 - 24 (40°4.)	
	Mutated -11 (21%)	
BRAF Status	wind type - 14 (27%)	
	Not performed - 27 (52%)	
Systemic therapy prior to support	¥cs - 34 (65%)	
	No - 18 (35%)	
Patient percentation	Symptomatic - 33 (55%) (Bleeding/anemia 18, obstruction 13, pain 12)	
T BENTE PROVIDENCE	Asymptomatic - 19 (17%)	
ECOC Performance States	0 - 24 (46%)	
ECOPTOR BERLINGER	1 - 28 (54%)	
hatest of surgery	Curative - 14 (22%)	
mater or surficy	Publishe - 38 (72%)	
	Sonall bowel - 37 (71%)	
28752523757A5	Colon - 11 (21%)	
Site of Metastasis	Liver - 9 (17%)	
27386781259706456	Stomach - 4 (7.7%)	
	Spicen - 3 (5.8%)	
Republic of methodials	Single - 12 (29%)	
NUMBER OF INCLUSIONS	Multiple - 40 (77%)	
	Small bowel resection - 35 (67%)	
Record and a second second	Colon resection - 9 (17%)	
Procedures performed	Liver reservion - 5 (9.6%)	
	Spienectuony - 3 (5.7%)	
	Osenil 11 (21%)	
	Wound infection 4 (7.8%)	
Construction .	Pelvic absens 3 (5.7%)	
Combast money	Venous threatbasis 3 (5.7%)	
-10120-025-025-0264	Anustomotic leak 1 (2%)	
	Presumonia & roral failure 1 (2%)	
	Yes. 31 (975)	
Symptom relief	No 2 49% (
Progression free survival (PES)	Median 13.9 months (3.4 -56.6)	
	Constitute interest - Median 19.8 months (1.6 - 58.6)	
Overall servival (OS)	Pulliative intere - Modian 7.4 membro 0.2 - 62.3)	

P242

Cloquets Node Trumps Imaging Modalities in the Prediction of Pelvic Nodal Involvement in Patients with Lower Limb Melanomas in Asian Patients with Palpable Groin Nodes Y. Koh, ^{1*} A. Chok, ¹

H. Zheng,² S. Xu,¹ K. Soo,¹ M. Teo.¹ *1. National Cancer Centre, Singapore, Singapore; 2. Saw Swee Hock School of Public Health, Singapore, Singapore.*

Patients with clinically palpable lymph node metastases to the groin are generally managed with superficial groin dissection (SGD) or combined groin dissection (CGD) to control local disease and stage the malignancy. Aim: To evaluate the approach to the extent of nodal dissection in advanced lower limb melanomas with clinically palpable inguinal nodes; to review survival outcomes based on the extent of nodal dissection and nodal disease. Materials and methods: A prospectively maintained database of 12 patients with lower limb melanoma was analysed, they underwent either SGD or CGD within one month of clinical diagnosis of malignancy at the National Cancer Centre Singapore during January 2006 to January 2011. Cloquet's node was assessed based on the frozen section result which guided the decision to proceed to CGD. The correlation of the results of the Cloquet's nodes and radiological imaging to the final histological outcome of groin nodal dissection were compared. Results: The positive predictive value (PPV) of radiological imaging in identifying pelvic nodal disease was 60%. PPV of a positive or indeterminate frozen section result of Cloquet's node was 71.4%. Notably, all patients with a positive frozen section result for the Cloquet's node all had positive pelvic nodal disease, PPV of 100%. Mean disease-free survival (DFS) for all patients is 37.94 months (SE+6.75 months), and mean overall survival (OS) for all patients is 39.31 months (SE+6.97 months). Mean DFS for pelvic node negative patients is 43.5 months (SE+8.32 months), whilst mean DFS for pelvic node positive patients is 30.1 months (SE+10.39 months). There was a trend of better survival in the pelvic node negative patients compared to the node positive patients. However, this was not statistically significant (Log rank test p=0.244). Conclusion: Cloquet's node was shown to be superior to radiological imaging and should be preferentially used to decide on the extent of nodal dissection.

Lymph Node status and correlation with pathological and radiological findings

No.	FNAC of palpable inguinal LN	Sentinel LN biopsy findings	Cloquet's Node Frozen Section/Final Histology	Radiological Suspicion of pelvic node involvement	Extent of dissection	No. of positive nodes	Pelvic Lymph Node Involvement
1	Positive	Not done	Negative/ Negative	Yes	CGD	1	No
2	Negative	Positive	Positive/ Positive	No	CGD	4	Yes
3	Positive	Not done	Negative/ Negative	No	SGD	3	NA
4	Not done	Not done	Positive/ Positive	Yes	CGD	2	Yes
5	Negative	Not done	Negative/Negative	No	SGD	0	NA
6	Positive	Not done	Indeterminate/ Negative	Yes	CGD	1	No
7	Positive	Not done	Positive/ Positive	No	CGD	2	Yes
8	Not done	Not done	Positive/ Positive	Yes	CGD	4	Yes
9	Not done	Positive	Negative/ Negative	No	SGD	4	NA
10	Not done	Positive	Indeterminate/ Negative	No	CGD	1	No
11	Not done	Not done	Negative/ Negative	No	SGD	1	NA
12	Not done	Not done	Positive/ Positive	Yes	CGD	10	Yes

P243

The Clinical Presentation and Management of Castleman's Disease C. Bailey,* L. Fayad, W. Lea, B. Feig. *University of Texas, MD Anderson Cancer, Houston, TX.*

Background: Castleman's Disease (CD) is a rare lymphoproliferative disorder characterized by lymph node hyperplasia. There is limited data on the role of surgery in patients with CD. The primary aim of this study is to analyze the clinical features, treatment approaches and outcomes in patients with CD. Methods: A retrospective review of patients with a histologic diagnosis of CD between 1990 and 2012 was performed. CD was characterized as unicentric or multicentric and further divided according to histologic variant: hyaline vascular (HV), plasma cell (PC) or mixed. Chi-square and Mann-Whitney U test were used to compare clinical variables. Kaplan-Meier method and log-rank test were used for survival analysis. Results: Records from 53 patients were analyzed: 23 had unicentric disease and 30 had multicentric disease. Patients were evenly matched for age, sex and race. There were more patients with plasma cell histology (P<0.001) in the multicentric group (Table). The mean follow-up for the entire cohort was 64 months (median 57 months). Nineteen (82.6%) patients with unicentric disease underwent surgical resection, 1 (4.3%) received systemic therapy and 3 (13%) did not undergo treatment. Four patients (17.4%) developed recurrent disease after complete surgical resection. Only 1 (3.3%) patient with multicentric disease underwent surgical resection, 25 (83.3%) received systemic therapy and 3 (10%) did not undergo any treatment. Three (10%) developed recurrent disease following an initial complete radiographic response to systemic therapy. Patients with unicentric disease had higher 5-year overall survival (OS) compared to multicentric disease (100% vs 80%, P=0.012). There was no difference in 5-year disease free survival (80% vs 84%, P=0.623). Patients with PC histology had worse 5-year OS compared to patients with mixed and HV histology (87% vs 91% vs 100%, P=0.031). Conclusion: Unicentric and multicentric CD are clinically distinct disorders. Complete surgical resection should be recommended for patients with unicentric CD, whereas the role of surgery for patients with multicentric CD needs to be evaluated in prospectively designed studies.

Comparison between clinical features of unicentric and multicentric Castleman's Disease

	Unicentric (N=23)	Multicentric (N=30)	P-value
Mean age	43	48	0.127
	Sex		
Male	8 (34.8%)	11 (36.7%)	
Female	15 (65.2%)	19 (63.3%)	0.887
	Race		
White	19 (82.6%)	19 (63.3%)	-
Black	2 (8.7%)	4 (13.3%)	
Other	2 (8.7%)	7 (23.3%)	0.227
	Presenting Symptoms		
B symptoms	5 (21.7%)	15 (50%)	0.071
Palable lymphadenopathy	8 (34.7%)	14 (46.7%)	0.391
Skin lesions	0	6 (20%)	0.043
Organomegaly	0	2 (6.7%)	0.207
Other symptoms	7 (30.4%)	12 (40%)	0.429
	Lymph Node Distributio	n	
Abdominal	5 (21.7%)	14 (46.7%)	0.061
Mediastinal	6 (26.2%)	20 (66.7%)	0.003
Peripheral	12 (52.2%)	25 (83.3%)	0.014
-	Histology		
Hyaline vascular	9 (39.1%)	8 (26.7%)	
Plasma cell	3 (13%)	19 (63.3%)	
Mixed	11 (47.8%)	2 (6.7%)	
Other	0	1 (3.3%)	< 0.001

P244

Feasibility of 18FDG-directed Lymph Node Surgical Excisional Biopsy for Appropriate Diagnostic Tissue Sampling in Patients with Suspected Lymphoma S.P. Povoski, ^{1*} N.C. Hall,² D.A. Murrey, Jr.,² S. Nichols, ¹ C.L. Wright,² E.W. Martin, Jr.,¹ *1. The Ohio State University, Division of Surgical Oncology, Department of Surgery, Columbus, OH; 2. The Ohio State University, Division of Nuclear Medicine, Department of Radiology, Columbus, OH.*

Background: 18FDG PET/CT imaging is widely utilized in the clinical evaluation of patients with suspected or documented lymphoma. The aim was to describe our cumulative experience with 18FDG-directed lymph node surgical excisional biopsy in patients with suspected lymphoma. Methods: From 06/2007 to 11/2010, 13 patients (mean age 51 (±16; 22-76) years), with suspected new or recurrent lymphoma suggested by 18FDG-avid lesions seen on diagnostic patient PET/CT (pPET/CT) imaging, were injected IV with 18FDG prior to undergoing same-day (S-D) diagnostic lymph node surgical excisional biopsy in the operating room. Various 18FDG detection strategies were used: S-D pre-resection pPET/CT; intraoperative gamma probe (IGP) assessment; clinical scanner PET/CT (cPET/CT) imaging of whole surgically excised tissue specimens (WSETS); specimen gamma well counts (SGWC); and/or S-D post-resection pPET/CT. Results were expressed as mean (±SD; range). Results: S-D 18FDG injection dose was 14.8 (±2.4; 12.5-20.6) mCi. Sites of 18FDG-avid lesions were 4 inguinal, 3 cervical, 3 abdominal/retroperitoneal, 2 axillary, and 1 gluteal region subcutaneous tissue. S-D pre-resection pPET/CT was performed on 4 patients. IGP assessment was performed on 13 patients. cPET/CT imaging of WSETS was performed in 10 cases. SGWC was performed in 6 cases. S-D post-resection pPET/CT imaging was performed on 8 patients. Time from 18FDG injection to S-D pre-resection pPET/CT, IGP assessment, and S-D post-resection pPET/CT were 76 (±8; 64-84), 240 (±63; 168-304), and 487 (±104; 331-599) minutes, respectively. Time from 18FDG injection to cPET/CT of WSETS was 363 (±60; 272-446) minutes. Time from 18FDG injection to GWC was 591 (±96; 420-689) minutes. IGP assessment successfully identified 18FDG-avid lesions in 12/13 patients. Histopathologic evaluation confirmed lymphoma in 12/13 patients and benign disease in 1/13 patients. Conclusions: 18FDG-directed lymph node surgical excisional biopsy for suspected lymphoma is technically feasible for guiding appropriate diagnostic tissue sampling of lymph nodes seen as 18FDG-avid lesions on diagnostic 18FDG PET/CT imaging.

P245

Too Close for Comfort? A Meta-analysis of Margin Size and Local Recurrence in Oral Squamous Cell Carcinoma C.R. Anderson,¹* K. Sisson,² M. Moncrieff.² 1. Norwich Medical School, University of East Anglia, Norwich, United Kingdom; 2. Norfolk and Norwich University Hospital, Norwich, United Kingdom.

Background Excision margins for oral squamous cell carcinoma (OSCC) are poorly understood, and evidence about the effect of margin size on outcome is conflicting. Close (<5mm) and involved (<1mm) pathological margins, as defined by national guidance, are key indicators of the need for adjuvant treatment, despite these definitions not being based on easily identifiable evidence. This review aimed to assess the impact of pathological margin size on local recurrence rates in patients treated with surgery alone. Methods MED-LINE, EMBASE and citation lists were searched for studies that looked at local recurrence following excision of primary OSCC without adjuvant therapy. Five studies met the inclusion criteria, of which four compared recurrence rates in patients with pathological margins clear by less than 5mm with those who had pathological margins clear by 5mm or greater. Results The included studies were sufficiently homogenous for meta-analysis. Recurrence rates were pooled to give a 21% absolute risk reduction (95% confidence interval 12% to 30%, p=<0.00001) in local recurrence with margins clear by more than 5mm. The pooled odds ratio was 0.34 (95% confidence interval 0.21 to 0.54, p=<0.00001) for clear margins as compared to close margins. However, unweighted pooled recurrence rates were 20% in patients with margins clear by more than 5mm, suggesting a 5mm margin is not sufficient in a subset of patients, who may have an intrinsically higher risk of recurrence. Subgroup analysis of T1/2 stage tumours compared to T3/4 stage tumours showed no significant increase in local recurrence with later stage tumours, regardless of margin status. Conclusions The findings of this review corroborate guidance that suggests margins clear by less than 5mm are inadequate and suggest that a 5mm pathological margin should be used as the minimum acceptable margin size in oral squamous cell carcinoma. The 20% recurrence rate in patients with clear margins is significant and suggests further research into this 'high risk' group is needed, to facilitate improvements in outcomes.

P246

Infiltrative Borders Predict a Poor Prognostic Phenotype in Oral Squamous Cell Carcinoma C.R. Anderson, ^{1*} M. Moncrieff,² R. James,² K. Sisson.² *1. Norwich Medical School, University of East*

Anglia, Norwich, United Kingdom; 2. Norfolk and Norwich University Hospital, Norwich, United Kingdom.

Background: The invasive border of oral squamous cell carcinomas is known to be prognostically relevant, but methods of assessment vary widely within the literature. Furthermore, standard histopathological assessment covers a minority of the actual tumour border, calling in to question the efficacy of systems that look at the 'predominant' pattern of invasion. Methods: This study reports the retrospective analysis of a cohort of 180 patients with primary T1/2 OSCC. All patients were treated with curative intent by surgery with or without adjuvant radiotherapy between 1997 and 2011, and all pathology was reviewed for this study by one head and neck pathologist. This study assessed a simple categorisation of infiltrative or cohesive borders, based on the worst pattern of invasion seen. The relationship between the tumour border and both outcome and markers of aggressive disease were explored. Results: On univariate analysis, an infiltrative invasive front was significantly associated with poor outcome in terms of recurrence, disease specific and overall survival (p=<0.01 for all outcome measures). On multivariate analysis, adjusting for adjuvant radiotherapy and all standard pathological variables, an infiltrative invasive front was significantly associated with locoregional recurrence (HR 2.19, 95%CI 1.14 to 4.22, p=0.019), and predicted poor disease free (p=0.033) and disease specific (p=0.048) survival. We also found that infiltrative borders were strongly associated with more traditional markers of aggressive disease, such as perineural (p=<0.001) and lymphovascular (p=<0.001) invasion. Infiltrative borders were also associated with an increased tumour burden, with infiltrative tumours being significantly greater in diameter (p=<0.001) and depth (p=<0.001) than those with cohesive borders. Conclusion: We have demonstrated using a simple, reproducible method of assessing invasive borders allows prediction of prognosis, and that infiltrative borders are an important marker of poor prognostic phenotype. We suggest that it is used, along with other clinical and pathological markers, as an indication for adjuvant therapy.

P247

Oncolytic Adenoviruses Targeting HPV Positive Head and Neck Squamous Cell Carcinomas C.J. LaRocca, ¹* A. Emery,² J. Han,¹ J. Davydova,¹ M. Herzberg,² R. Gopalakrishnan,² M. Yamamoto.¹ *1. University of Minnesota Department of Surgery, Minneapolis, MN; 2. University of Minnesota Department of Diagnostic and Biological Sciences, School of Dentistry, Minneapolis, MN.*

Introduction: The percentage of head and neck squamous cell carcinomas (HNSCC) that are Human Papilloma Virus (HPV) positive has increased in recent years. The HPV E6 and E7 oncogenes are attractive therapeutic targets for conditionally replicative oncolvtic adenoviruses (CRAds). The adenovirus (Ad) E1a CR1 region and HPV E6 are both involved in p53 degradation. Similarly, both the Ad E1a CR2 region and HPV E7 are known to dissociate the Rb-E2F complex. We hypothesize that CRAds with these deletions can replicate selectively in HPV positive cells where the E1a functions are compensated by the expression of HPV E6 and E7 thereby resulting in a therapeutic agent for HPV positive HNSCCs. Methods: Two CRAds were tested both in vitro and in vivo. Crystal violet and MTS assays were used to determine the cytocidal effect of the viruses in multiple HNSCC cell lines. Also, a luciferase assay was used to determine the transduction efficiency of the viruses. Using the UPCI SCC 090 cell line (HPV positive), subcutaneous tumor xenografts were generated in athymic nude mice and subsequently treated with one dose of the CRAds. Results: Two CRAds were generated with infectivity enhancement via a 5/3 fiber modification (5/3 Δ 24 with a partial deletion in CR2 and 5/3 CB016 with deletions in CR1 and CR2). The viral cytocidal effect seen by crystal violet staining and transduction analysis with luciferase expressing vectors indicated that this infectivity enhancement maximized the efficiency of the vectors. In vitro, both viruses demonstrated significant oncolytic effects. The 5/3 CB016 virus was selective for only HPV positive cells, while the 5/3 $\Delta 24$ virus lysed cells regardless of their HPV status. In vivo, both viruses demonstrated anti-tumor effects until eight days after inoculation, which was as strong as the wild type virus. These data indicate that both viruses show antitumor effects in vitro and in vivo, although the 5/3 CB016 virus is more specific to HPV positive HNSCC cells. Conclusion: We have shown that CRAds targeted to HPV positive HNSCCs demonstrate in vivo and in vitro oncolytic effects and have the potential to become an effective treatment modality.

P248

Statin Use is Associated with Increased Survival in Patients with Advanced Epithelial Ovarian Carcinoma H. Medina-Franco,* U.E. Clemente-Gutiérrez, A. Garza-Gangemi. *Surgery, National Institute of Medical Sciences and Nutrition, Mexico City, Mexico.*

Background: Statins are the most common lipid-lowering agents used for the treatment of dyslipidemias. Recent studies have shown that statins improve the prognosis of several epithelial neoplasms. The aim of this study was to analyze the relationship between statin use with progression free survival (PFS) and overall survival among patients diagnosed with epithelial ovarian cancer. Methods: One hundred and twenty one patients who underwent cytoreductive surgery (CRS) for epithelial ovarian carcinoma were analyzed retrospectively. Patients with active statin use at diagnosis or during treatment were compared with a control group. Clinical and pathological factors were described. PFS and overall survival were analyzed with Kaplan Meier method. Significance was considered at p<0.05. Results: Thirteen patients (10.7%) were actively receiving statin therapy at diagnosis or during treatment. The mean age observed for statin users was 55 ±9.7 vs. 54 ±12.2 years for non-users (p=NS). Most patients were diagnosed in a clinically advanced stage: 55.5% were stage IIIC and 21% were stage IV. Most patients had an optimal CRS (68%). Subgroup analysis of patients who were on stage IIIC showed that median PFS and overall survival, were 40.6 and 81.2 months respectively for statin users and 11.5 and 36.8 months, respectively for non-users (p<0.05). Cox regression analysis demonstrated that prognostic factors for improved survival were optimal CRS, statin use and normal albumin levels prior to the surgical intervention. Conclusions: Statin use in patients with stage IIIC ovarian epithelial cancer is associated with improved PFS and overall survival.

P249

A Retrospective Analysis of Kidney Injury after Hyperthermic Intraperitoneal Chemotherapy (HIPEC) E. Sin,* C. Chia, M. Teo. National Cancer Centre Singapore, Singapore, Singapore.

Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been found to prolong survival in patients with malignant peritoneal disease. Kidney injury is a potentially serious morbidity. We look at the rate of acute kidney injury (AKI) and chronic renal failure (CRF) in 47 patients and aim to identify predisposing risk factors. Methods During 2005-2013, we performed CRS and HIPEC on patients with ovarian primaries and peritoneal metastasis. Retrospective data was collected on the patient's demographics, clinical details, peri-operative creatinine levels, peri-operative chemotherapy details, etc. AKI was defined as an increase in serum creatinine of ≥26.5 µmol /L over 48h; CRF was defined as persistent deranged renal function for ≥ 3 months. Results Our 47 patients had a median age of 52(34-74) years. The mean baseline creatinine was 55 µmol/l (38-102) and mean baseline albumin was 35 g/l(13-45). All underwent preoperative chemotherapy with mainly carboplatin/paclitaxel for an average of 7 cycles(3-17) with a mean of 11 months between chemotherapy cessation and operation date. All received intraoperative cisplatin at a median dose of 60 mg/kg at a median temperature of 40 degrees (40-41.5) for a duration of 60 min. Intraoperative blood loss averaged at 1500 mls(200-4600). 76% received post-operative chemotherapy with mainly carboplatin/paclitaxel. 17(36%) experienced postoperative AKI, of which 2(4%) required postoperative inpatient dialysis;10(21%) show resolution of AKI with conservative management within a median of 11 days. 6(13%) had deranged renal function on discharge, and 1(2%) needed long term dialysis. Univariate analysis showed that risk factors for AKI development included preoperative albumin. intraoperative temperature, duration of chemotherapy and blood loss. Risk factors for CRF included the age of the patient and intraoperative blood loss. Conclusion Kidney injury is a significant HIPEC morbidity and identification of risk factors helps improve pre-operative patient selection and optimization, and facilitate closer perioperative monitoring and fluid management in at-risk patients.

P250

Ocular Melanoma When Youve Seen One, You haven't Seen Them All: A Clinical Outcomes Study of 8,165 Patients (1973-2010) K. Mahendraraj,* S. Shrestha, R.S. Chamberlain. *St. Barnabas Medical Center, Livingston, NJ.*

Introduction: Ocular melanoma (OM) comprises less than 5% of all melanomas, with uveal melanoma (UM) being the most common subtype and the most common primary intraocular cancer. Conjunctival melanoma (CM) is a very rare form of OM that differs from UM in both location and clinical behavior. This study examines a large cohort of OM patients and compares demographic and clinical factors affecting outcomes to identify ideal treatment approaches for both UM and CM. Methods: Demographic and clinical data on 277,120 patients with melanoma was abstracted from the Surveillance, Epidemiology, and End Results (SEER) database (1973-2010). Standard statistical analyses were performed. Results: 8,165 OM cases represented 2.9% of all melanomas. UM cases accounted for 92.1% (N=7,516) and CM cases 7.9% (N=649). Mean age-adjusted CM incidence was significantly lower than UM (0.4 per million vs 5.1 per million; p<0.001). Both UM and CM were most common among males, Caucasians and in the 7th decade of life;p<0.001. UM patients presented with localized disease more often than CM. CM had a longer mean overall survival (OS) (15.4 vs. 14.6 years) and lower overall mortality (38.8% vs 46.1%); p<0.05. Primary radiotherapy was associated with prolonged survival compared to surgery for UM (15.8 vs 13.6 years), while surgery resulted in prolonged survival for CM (15.4 vs 6.4 years); p<0.001. Multivariate analysis identified male gender (OR1.1), age over 50 (OR4.0) and distant metastases (OR8.6) as independently associated with increased mortality for OM, p<0.005. In UM, surgery alone (OR2.6) was associated with increased mortality while radiotherapy (OR0.5) was associated with reduced mortality. Conclusions: CM presents more often with localized diseas and is associated with a better OS and lower mortality than UM. Surgery is the primary therapy for CM, while radiotherapy is the primary treatment and prolongs survival in UM. Males, older age, and distant disease are all associated with an increased risk of mortality in OM, with primary surgical treatment being an additional risk factor in UM.

	Variable		Overall	UM	CM
	Frequency, N(%)		8,165	7,516 (92.1)	649 (7.9)
Mean Age-Ad	fjusted Incidence (per	million, ±SD)	5.5 ± 0.1	5.1 ± 0.1	$0.4 \pm 0.0^{*}$
Gender	Mal	c	4,263 (52.2)	3,933 (52.3)	330 (50.8)
	Fema	le	3,902 (47.8)	3,583 (47.7)	319 (49.2)
	Mean age (m	ican ±SD)	61.4±15.3	61.4±15	61.7±18.6
Age	Under	50	1,717 (21)	1,561 (20.8)	156 (24)
	Age 50	-79	5,529 (67.7)	5,144 (68.4)	385 (59.4
	Age 80 and	d above	919 (11.3)	811 (10.8)	108 (16.6)
	Whit	te	7,540 (92.3)	7,000 (93.1)	540 (83.2)
	Hispa	nic	342 (4.2)	287 (3.8)	55 (8.5)
Race	Black		54 (0.7)	40 (0.5)	14 (2.2)
	Others (Pacific Islanders, Native		91 (1.1)	67 (0.9)	24 (3.7)
	Unknown		138 (1.7)	122 (1.6)	16 (2.5)
	Right		4,049 (49.6)	3759 (50)	290 (44.7
	Lef	t	4,025 (49.3)	3,679 (48.9)	346 (53.3
Laterality	Bilate	ral	3 (0.04)	2 (0.03)	1 (0.15)
1	Unspecified		88 (1.1)	76 (1.0)	12 (1.8)
	Locali	zed	6,602 (80.9)	6,126 (81.5)	476 (73.3)
	Regional		601 (7.4)	506 (6.7)	95 (14.6)
Stage	Dista	nt	124 (1.5)	109 (1.5)	15 (2.3)
	Unstaged		838 (10.3)	775 (10.3)	63 (9.7)
	Surgery	only	3,769 (46.2)	3,218 (42.8)	565 (87.1)
	Radiation	n only	3,192 (39.1)	3,232 (43)	6 (0.9)
Treatment	Boti	h	538 (6.6)	527 (7)	15 (2.3)
	Neith	er	504 (6.2)	539 (7.2)	51 (7.9)
	Unkno	wn	162 (2.0)	150 (2.0)	12 (1.8)
Overall surviva	l in years (expressed a	s "mean ± SD")	14.6±0.2	14.6±0.2	15.4±0.9*
Overall Mortality		3,718 (45.5)	3,466 (46.1)	252 (38.8)	
C	ancer specific mortali	ty	1,756 (21.5)	1,870 (24.9)	99 (20)*
Mean cancer-s	specific relative	1-year	96	96	95
surviv	/al (%)	2-year	89	89	88
		5-year	71	70	73

P251

Intraoperative Utilization of a Portable Large Field of View Gamma Camera for Improved Radioguided Surgery A. Terando,* N.C. Hall, S.P. Povoski, J. Phay, S. Nichols, C.L. Wright, E.W. Martin, Jr.. The Ohio State University Wexner Medical Center, Columbus, OH.

Background: Radioguided surgery (RS) is generally used for breast and melanoma sentinel lymph node biopsy (SLN) procedures and for parathyroid adenoma resection. Historically, RS involves preoperative administration of a radiopharmaceutical followed by intraoperative utilization of a handheld gamma detection probe (GDP) for detecting and resecting radioactive foci. We present our experience with a portable large field of view gamma camera (LFOVGC) for improved real-time intraoperative localization and verification of resection of radioactive foci. Methods: A portable LFOVGC was used for imaging during RS. For most cases, intraoperative imaging of the surgical field was acquired prior to incision. Likewise, a handheld GDP was used during the surgical procedure. Intraoperative imaging of the resected specimen and the post-resection surgical field were subsequently acquired. Results: Over a 26 month period, a total of 90 patients underwent LFOVGC imaging. This consisted of 58 99mTc SLN biopsy procedures (28 breast, 27 melanoma, 2 vulvar, and 1 head/neck), 22 99mTc sestambi parathyroid adenoma resections, 4 111In pentetreotide guided surgeries, 3 99mTc DTPA ureter identification studies, 2 99mTc-labeled red blood cells limb perfusion monitoring cases, and 1 111In-labeled white blood cell radioguided surgery. LFOVGC imaging provided clinically-relevant information to the surgeon by: (a) assisting the surgeon in localizing areas of increased radiopharmaceutical accumulation with the handheld GDP, (b) verifying complete resection of targeted radioactive foci, (c) identifying key anatomic structures, and/or (d) monitoring effectiveness of surgical procedures in real-time. Conclusions: Portable LFOVGC imaging can provide useful information as an adjunct to a handheld GDP during RS. Our experience is that LFOVGC imaging assists with localization and verification of resection of radioactive foci beyond the capabilities of a handheld GDP alone. The portable LFOVGC can be used to globally assess the entire surgical field and resultantly direct the surgeon for more precise targeting of radioactive foci with a handheld GDP.

En-bloc Multivisceral Pelvic Resection for Locally Advanced Primary and Recurrent Ovarian Cancer D. Ng,* C. Chia, G. Tan, M. Teo. Department of Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

Aim: A review of a single-centre experience of en-bloc multivisceral pelvic resection as a treatment modality for patients with locally advanced primary and recurrent ovarian cancer. The perioperative outcomes, morbidity and long term oncological outcomes are reviewed. Materials & Methods: Patients undergoing en-bloc multivisceral pelvic resection for recurrent and locally advanced ovarian cancer between January 1993 to March 2013 were identified from a retrospective database. All patients underwent pre-operative staging investigations with CT scan of chest, abdomen and pelvis and pelvic MRI. Locally advanced ovarian cancers is defined as tumours that require a multvisceral resection and all of which have tumors that are clinically bulky with adherence, fixation or invasion into adjacent critical structures on imaging. En-bloc multivisceral pelvic resection is defined as en-bloc removal of pelvic organs to which the primary tumour was adherent to. Structures such as the rectosigmoid and urinary bladder were resected en-bloc where indicated with the lesion. Urological or plastic reconstructions were employed where indicated. Patients were followed up according to a standard protocol of Ca 125 measurements and imaging modalities CT/MRI/PET. The primary outcome measured was overall survival (OS) and secondary outcome measured was disease free survival (DFS). OS was examined by the Kaplan-Meier Method. Results: En-bloc multivisceral pelvic resections were performed in 18 patients with a median age of 59.5. The rate of major postoperative complications was 6% (n=1). There were no mortalities in the perioperative period. All patients were operated with curative intent and negative circumferential margins were achieved in all patients. The 5-year OS for patients with primary and recurrent disease is 60% and 40% respectively (p=0.754). The median survival for patients with recurrent disease is 35 months. The DFS for all patients is 18 months. Conclusion: An aggressive approach with en-bloc multivisceral pelvic resection provides survival benefit to patients with locally advanced primary and recurrent ovarian cancer at acceptable morbidity.

P253

Peroneal Flap: A Versatile and Viable Option for Head and Neck Reconstruction Y. Lin,* K. Yang. *Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.*

Introduction The mainstream flaps of choice for head and neck reconstruction are ALT, radial forearm, fibula, jejunum flaps. Each option is preferred by different surgeons or institutions. For the past 15 years, peroneal flap has been the workhorse in our institution. The goal of this study is to present the peroneal flap as a versatile and viable option for head and neck reconstruction. Materials and Methods Between 1995 and 2012, there were 189 peroneal flaps and 70 ALT flaps used in the head and neck reconstruction by Dr. Kuo-Chung Yang. We retrospectively reviewed the medical records from those surgeries, looking for all the patients' characteristics and perioperative complications. All the applications using peroneal flap to different classifications of defects will be demonstrated for its versatility. The flap failure rates of the peroneal flaps carrying various components were used to evaluate the reliability of its "chimeric" characteristic. The perioperative complications rate of ALT flap was used as a comparison to assess the viability of the peroneal flap. Fisher's exact test was conducted to compare the percentages of different groups. A P value less than 0.05 was considered statistically significant. Results In terms of the versatility of a peroneal flap, it could be reliably harvested as a single-paddle flap, a double-paddle flap, or a "chimeric" flap composed of skin paddles and a muscle bulk to fill a wide variety of defects, ex. a buccal defect, a through-through defect, a hemiglossectomy defect, or a hypopharyngeal defect. An aesthetically pleasing and saliva-leakage preventing neo-commisure could be easily created due to its pliability. The flap failure rates of the peroneal flaps carrying various components are not statistically significantly different (p=0.69), revealing the reliability of its chimeric characteristic. In terms of the viability, there is no statistically significant difference between ALT and peroneal flap in perioperative complications(10% vs 18.5%, p=0.128). Conclusions Due to its reliable chimeric characteristic and comparable complications rates, peroneal flap is a versatile and viable option in the head and neck reconstruction.



a double-paddle chimeric peroneal flap with a muscle bulk

P254

Cutting it Close: Are 10mm Surgical Margins Adequate in Oral Squamous Cell Carcinoma? C.R. Anderson,¹* K. Sisson,² R. James,² M. Moncrieff.² 1. Norwich Medical School, University of East Anglia, Norwich, United Kingdom; 2. Norfolk and Norwich University Hospital, Norwich, United Kingdom.

Background The optimal excision margin for oral squamous cell carcinoma (OSCC) is not well defined. Most centres use a minimum 10mm surgical margin, with the aim of achieving a pathological margin clear by >5mm. However, this is not based on clear evidence, and there has been no research into factors that may affect surgical margin adequacy. Methods This study reports the retrospective analysis of a cohort of 180 patients with primary T1/2 OSCC. All patients were treated with curative intent by surgery with or without adjuvant radiotherapy between 1997 and 2011. The study aimed to assess the adequacy of a 10mm surgical margin in terms of pathological margin size and outcome. Results Data on clinical surgical margin size at the time of excision was available for 81 patients. The mean lateral surgical margin was 11.4mm (SD 4.911) and the mean lateral pathological margin was 4.621mm (SD 3.071), a significant mean difference of 6.798mm (95%CI 5.5594 to 8.0356), p=<0.001, paired T-test. 120 (66.6%) patients had 'close' pathological excision margins of less than 5mm. The only factor that effected pathological margin size at univariate analysis was subsite, with the tongue significantly more likely to have margins >5mm than other subsites (p=<0.001). On logistic regression, poor differentiation was also associated with involved margins as compared to welldifferentiated tumours (OR 0.25, 95% CI 0.06 to 0.97, p=0.046). We found no clear relationship between margin size and recurrence, although involved margins were predictive of overall survival (p=0.052) in patients who did not receive radiotherapy. Conclusions: We conclude that 10mm excision margins are inadequate to give pathological clearance even in low risk tumours. Tumour site and differentiation are predictors of incomplete excision, but the lack of relationship between other intrinsic tumour factors and pathological margins suggest it remains the responsibility of the surgeon to ensure surgical margins are adequate at the time of surgery. Further research should be focussed on surgery, which has curative potential without the morbidity and mortality associated with radiotherapy.

P255

Peritoneal Surface Disease (PSD) from Appendiceal Cancer Treated with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Overview of 481 Cases K.I. Votanopoulos,* G. Russell, R.W. Randle, P.W. Shen, J.H. Stewart,

E.A. Levine. Wake Forest University, Winston Salem, NC.

Background: Appendiceal cancer PSD treated with CRS/HIPEC has shown significant variability in the obtained survival benefit. Methods: A prospective database of 1069 procedures was reviewed for primary, grade, nodal and performance status, resection type, morbidity, mortality and survival. Results: 481 CRS/HIPEC procedures, 317(77.3%) for low grade (LGA) and 93(22.7%) for high grade (HGA) appendiceal primaries, were identified. Median follow up was 44.4 months. 30 and 90 day major morbidity were 27.8% and 9.3% while the 30 and 90 day mortality was 2.7% and 5.6% respectively. Median ICU and hospital stay was 1 and 9 days. In multivariate analysis, Clavien III/IV complications, were related to incomplete CRS (p= 0.0037), involved nodes (p<0.0001) and comorbidities (p=0.003). Multivariate analysis of the LGA patients indicated survival to be dependent on nodal status (p=0.003 HR 3.6), complete cytoreduction (p<0.0001) and preoperative chemotherapy (p=0.04 HR 2.2). The multivariate survival of HGA was dependent on complete cytoreduction (p=0.0003 HR 3.8) and preoperative chemotherapy (p=0.0064 HR 2.5). In patients with complete cytoreduction, median survival for node positive LGA and HGA patients was less than their node negative counterparts. (85 months vs not reached (82% alive at 90 months) and 30 vs 153 months respectively p<0.0001). Conclusions: Positive nodes are associated with decreased survival not only in HGA but also in LGA patients even after a complete cytoreduction. Nodal status is superior to grade of disease as a prognostic indicator of survival. Node negative HGA primaries after complete CRS can obtain a comparable survival benefit to LGA counterparts.

P256

Pancreatic Resection Results across a State-wide Surgical Quality Collaborative R.W. Krell,^{1*} S. Hendren, ¹T.L. Frankel, ¹D. Kwon,² D.A. Campbell Jr,¹ S.L. Wong.¹ *1. Surgery, University of Michigan, Ann Arbor, MI; 2. Henry Ford Health System, Detroit, MI.*

Introduction: Nationally, mortality rates following pancreatic resections average around 6%. Improved results correlate with increased hospital caseloads and regionalization of care. While regional collaboratives may accelerate surgical quality improvement, there is little evidence supporting this for pancreatic procedures. We assessed recent complication and mortality trends following pancreatic resections in a statewide surgical collaborative. Methods: We investigated pancreatic resections in 15 hospitals participating in the Michigan Surgical Quality Collaborative from 2008-2013 (N= 875 patients). We assessed temporal variation in risk-adjusted 30-day mortality, major complication and failure to rescue (defined as mortality following a major complication) rates We then assessed risk-adjusted outcome rates across hospitals according to annual case submission (volume) based on a systematic sampling system (low, medium, and high). Results: The overall 30-day mortality rate was 2.8%, major complication rate 30.3% and failure to rescue rate 7.3% across all patients. While risk-adjusted major complication rates increased over the time period (26.7% in 2008 to 33.1% in 2012, p=0.05), there was a trend towards decreased risk-adjusted mortality rates (2.3% in 2008 to 1.0% in 2012, p=0.07) and noted decreases in failure to rescue rates (10.4% in 2008 to 2.9% in 2012, p=0.02) over time. Riskadjusted major complication rates, mortality rates and failure to rescue rates all decreased in a stepwise fashion according to hospital volume based upon annual case submissions, though the effect was only significant when comparing the high volume and low volume hospitals. The differences are attenuated when comparing the middle and high volume hospitals (Figure). Conclusions: Overall, Michigan hospitals perform well in comparison to nationwide benchmarks for outcomes following pancreatic resections. There is still variation between hospitals, but the differences seem to be improving with time. Continued efforts for the dissemination of best practices in regional quality collaboratives may improve the quality of cancer care across all hospitals.



P257

Patients With Advanced Cancer: Comparing End-of-life Preference between those Undergoing Curative Intent Surgery versus Noncurative Intent Treatment J.R. Schubart, M.J. Green, B. Levi,

A.N. Kulaylat, N.J. Gusani.* Section of Surgical Oncology, Department of Surgery, Penn State College of Medicine, Hershey, PA.

INTRODUCTION We analyzed data from a clinical trial examining the impact of an online decision aid for advance care planning. Our hypothesis was that patients with advanced cancer who had initial curative intent surgery (CIS) would report higher levels of hope, less hopelessness, and would prefer more aggressive end-of-life treatment than those who had non-curative intent treatment (non-CIT). METHODS Hope and hopelessness were measured at baseline and post-intervention using the 12-item Herth Hope Index and 7item Beck Hopelessness scale, respectively. A treatment aggressiveness scale (0-40, higher=more aggressive) was created by summing responses to questions within the decision aid that asked about patient wishes for 8 different treatments (e.g., CPR, ventilation, etc.) under 5 clinical scenarios (e.g., stroke, dementia, etc.). Wilcoxon Rank Sum test was used to compare medians for treatment aggressiveness between groups, and a linear mixed effects model was used to compare mean change in hope and hopelessness from baseline to post-intervention within and between groups. RESULTS Of 159 patients with stage IV non-CNS and non-hematologic cancer, 95 had CIS and 64 had non-CIT. There was a slight increase in hope for the CIS group (41.4 to 42.1, p=0.08) and a slight decrease for the non-CIT group (40.6 to 40.4, p=0.68), but no significant difference between groups (p=0.15). Hopelessness decreased slightly in both groups (CIS: 0.5-0.4, p=0.50; non-CIT: 0.8-0.6, p=0.16) but there was no significant difference between groups (p=0.51). For patients who used the online decision aid (n=79), there was no significant difference in median treatment aggressiveness score between groups. CONCLUSION Patients with advanced cancer who undergo initial CIS do not experience greater hope or less hopelessness than patients who undergo non-CIT. Both report similar desires for aggressiveness of end-of-life treatment. This finding supports the notion that advance care planning should be undertaken for both patients whose treatment is with curative intent and for those whose cancer treatment is palliative.

P258

Baseline Health-related Quality of Life in Elderly Patients with Cancer G.M. Barden, ¹* A.D. Naik, ³ J.N. Cormier, ⁴A. Artinyan, ¹ S. Sansgiry, ² N.J. Petersen, ² D.A. Anaya. ¹ I. Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX; 2. Houston VA Center for Innovations in Quality, Effectiveness and Safety (IQUEST), Houston, TX; 3. Department of Medicine, Baylor College of Medicine, Houston, TX; 4. Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.

Introduction: Global graying will result in a growing number of elderly cancer patients requiring surgical treatment. Given the physical and psychosocial transitions experienced by elderly patients, characterization of baseline HRQoL is critical to understand the challenges faced by the elderly and its impact on postoperative outcomes. The goal of this study was to examine preoperative HRQoL of elderly cancer patients, and to identify specific deficits by comparing HRQoL to the young and non-cancer elderly US population. Methods: This is a prospective cohort study of cancer patients scheduled for surgery at a tertiary referral center (2012-2013). The primary outcome examined was baseline HRQoL, measured using the SF-36 survey. Domain-specific, and Physical Component (PCS) and Mental Component Summaries (MCS) were compared between the young (<65y) and old ($\geq 65y$) cancer patients, and between old cancer patients and US elderly patients without cancer (n=599), age and sex-adjusted. The X2 and t-tests were used for descriptive analysis and comparisons. Results: 232 patients were included; 107 (46%) in the old group. The majority of patients had gastrointestinal malignancies (n=161, 69%). Elderly patients with cancer reported better HRQoL than young cancer patients, with better mean domain-scores in bodily pain (46.8 vs. 43.2;p=0.03), vitality (47.4 vs. 43.8;p=0.04), emotional well-being (52.6 vs. 46.7;p<0.001), and overall better mean MCS scores (51.2 vs. 45.9;p=0.001). Elderly cancer patients, however, reported worse HRQoL than the US elderly healthy population with worse mean domain-scores in physical functioning (40.5 vs. 43;p=0.04), role physical (40.6 vs. 43.3;p=0.02), vitality (47.4 vs. 50.2;p=0.04), social functioning (45.4 vs. 48.3;p=0.04), and overall worse mean PCS-scores (40.8 vs. 43.1;p=0.04). Conclusions: Elderly patients with cancer present with better HRQoL than young cancer patients, primarily driven by better mental health-related functions; however, they have worse HRQOL than non-cancer elderly patients, due to worse physical health-related functions. Future research should explore the association of physical function deficits with postoperative outcomes, including HRQoL.

P259

3-year Recurrence and Survival Outcomes after Sentinel Lymph Node Biopsy with [99mTc] Tilmanocept in Clinically Node-negative Breast Cancer and Melanoma Patients S.P. Povoski,^{1*} J. Kim,² S. Schneebaum.³ 1. The Ohio State University, Columbus, OH; 2. University Hospitals Case Medical Center, Cleveland, OH; 3. Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

INTRODUCTION: Sentinel lymph node biopsy (SLNB) has been shown to be a suitable alternative to full lymph node dissection in clinically node-negative (N0), early-stage breast cancer and melanoma (NSABP B-32, ACOSOG Z-0011, MSLT-1). A phase 3, prospective, multi-institutional, open-label, single arm trial assessed receptor-targeted [99mTc]tilmanocept for intraoperative identification of SLNs in clinically N0 breast cancer and melanoma patients (ClinicalTrials.gov/NCT00671918). As many regional and local recurrences occur in the first 2 years, a voluntary 3-year follow-up study was conducted to assess recurrence and survival outcomes following SLNB in these patients. METHODS: Patients were asked to participate in a 3-year followup study following their participation in the [99mTc]tilmanocept Phase 3 trial. Voluntary enrollment was open to patients with (pN+) or without (pN0) SLN metastases. Recurrence and survival data were to be collected at 6 to 36 months after primary tumor excision and SLNB. The primary objective was to determine regional (i.e., draining lymph node basin) recurrence-free rate after SLNB with [99mTc]tilmanocept. Secondary endpoints were overall recurrence-free rate (including primary tumor excision site, regional, and distal recurrence), disease-specific survival, and overall survival. RESULTS: Of 169 patients completing the Phase 3 trial and eligible for the follow-up study, 109 (64 breast cancer, 45 melanoma) participated and completed ≥1 planned follow-up visit. Table 1 summarizes 3-year recurrence and survival results. Notably, in patients confirmed pN0 after SLNB (n=88; 39 melanoma, 49 breast cancer), the regional recurrence-free rate was 98.8% and the disease-specific survival was 98.6%. CONCLU-SIONS: Low regional recurrence rates and high disease-specific survival rates of pN0 patients after 3 years indicate [99mTc]tilmanocept accurately identifies SLNs (false negative rate of <2%) and is likely predictive of pathological staging. These findings are comparable to previously published outcome data and demonstrate the clinical utility of [99mTc]tilmanocept for SLNB.

Table 1: Summar	v of 3-v	ear recurrence	and	surviva	results
	, ,				

	Cumulative rate estimate derived from Kaplan-Meier curve (number of recurrences or deaths)				
	Breast Cancer	Melanoma	Combined		
Recurrence free rate					
Regional	100% (0)	93.0% (3)*	97.1% (3)		
pN0	100% (0)	97.4% (1)	98.8% (1)		
pN+	100% (0)	60.0% (2)	89.5% (2)		
Overall	96.8% (2)	86.1% (6)	92.3% (8)		
pN0	97.8% (1)	92.1% (3)	95.3% (4)		
pN+	93.3% (1)	40.0% (3)	79.4% (4)		
Disease-specific survival rate	96.6% (2)	95.4% (2)	96.0% (4)		
pN0	97.8% (1)	100% (0)	98.6% (1)		
pN+	92.9% (1)	60.0% (2)	84.2% (3)		
Overall survival rate	91.6% (5)	95.4% (2)	92.7% (7)		
pN0	91.1% (4)	100% (0)	94.5% (4)		
pN+	92.9% (1)	60.0% (2)	84.2% (3)		

* Two of the 3 regional recurrences in melanoma patients were regional-only recurrences. One patient (pN+) had both a regional and a distal recurrence.

P260

Establishment of a Voice Messaging System is Associated with Improved Clinical Outcome in Hepatocellular Carcinoma A. El Mokdad, A. Singal, J.C. Mansour, G.C. Balch, A. Yopp.* UT Southwestern Medical Center, Dallas, TX.

Therapeutic delays after HCC diagnosis is multifactorial and associated with poor outcomes. Voice messaging systems (VMS) communicating abnormal imaging findings to both the ordering and downstream treatment physicians have been developed in an attempt to reduce therapeutic delays. The aim of this study was to evaluate the impact of a VMS communicating outpatient HCC imaging. Methods: On March 1, 2010 a VMS communicating imaging findings consistent with HCC to both ordering physician and HCC clinic was initiated. The VMS notified physicians of abnormal studies ordered on outpatient basis. Prior, the ordering physician relied on electronic reports without notification. We conducted a retrospective review of a prospective HCC database to identify patients diagnosed on outpatient imaging studies two years following and two years prior to initiation of the VMS. Demographics, tumor characteristics, treatment, and survival were compared between the two groups of patients with one-way ANOVA and Chi-squared tests. Survival curves were generated using Kaplan-Meier with log rank test. Results: 44 patients were identified in the two years following initiation of VMS and 46 patients in the 2 years prior. There was no difference in age at diagnosis, gender, or race/ethnicity between the groups. Patients had a predominant HCV etiology (74% vs. 66%, p=ns) and preserved liver function (Child-Pugh Class A, 66% vs. 61%, p=ns). AJCC (stage 1, 61% vs. 57%, p=ns) and BCLC classification (BCLC A, 56% vs. 48%, p=ns) were similar. Patients receiving treatment was similar in both groups (82 % vs. 76%, p=ns) with no difference in modalities. Time from study confirming HCC to subsequent clinic visit (0.6 vs. 3.2 months, p=0.003) and time from clinic visit to treatment (1.5 vs. 2.8 months, p=0.003) was shorter following VMS initiation. Median overall survival following VMS initiation was significantly longer than in the prior period (37.1 vs. 16.6 months, p=0.04). Conclusions: Establishment of a VMS to communicate abnormal imaging findings consistent with HCC is associated with improved survival, most likely due to shorter time to treatment and more streamlined care.

P261

Multidisciplinary Cancer Conferences for Gastrointestinal Malignancies Result in Measureable Treatment Changes J. Oxenberg,* W. Papenfuss, I. Esemuede, K. Attwood, B. Kuvshinoff, V. Francescutti. Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY.

Background: Multidisciplinary cancer conferences (MCC) for gastrointestinal (GI) cancers are recommended worldwide, although variable effect on change in treatment plan as a measure of efficacy has been observed. Methods: Patient data were prospectively collected at the GI MCC. Original treatment plans and levels of certainty were collected prior to presentation. MCC management recommendation changes and final treatments were analyzed. Results: Consecutive cases (n=149) were presented at MCC [115 upper GI (gastric, small bowel, liver, pancreaticobiliary), 34 lower GI]. Median age was 63 years (range 18-91) and 53% were female. Disease sites included pancreaticobiliary (36%), liver (32%), colorectal (23%), gastric and small bowel (10%). The surgical team posted 109 (73%) cases. Reasons for presentation were: questions about progression/metastases (44%), management (26%), diagnosis (21%), pathology (15%), resectability (7%). Physicians were certain of their original plans being the final recommendations in 83.9% (n=125). Total discussion time (\leq 3 minutes) was significantly shorter for older patients (p=0.04). Surgeons gave input in 93% of cases, medical oncologists 57%, radiation oncologists 20%, radiologists 20%, pathologists 11%, and gastroenterologists 6%. Changes in initial proposed management were recommended in 36%; 72% were major (change in treatment modality) and 28% were minor (final plan included original plan). Patients underwent recommended treatments in 77% of cases, a portion of recommended treatments in 5%, or did not follow any recommendations in 18%. Management changes were less likely if surgeons, medical oncologists, and radiation oncologists agreed with the initial plan (p<0.001). The only predictors related to change were (increased) length of discussion (p=0.017) and surgeon agreement with the original plan (p=0.002). Conclusion: Although decision certainty is high prior to discussion, important changes in treatment recommendations occurred in over one-third of patients after MCC. This prospective study demonstrates the value of MCC in a variety of GI cancer sites.

Decision Making and Recommendation for Management Change

		No Change	Change	p-value	Major Change	Minor Change	p-value
n(%	6)	96 (64)	53 (36)		38 (72)	15 (28)	
	Uncertain	17 (18)	7 (13)		2(15)	5(14)	
Level of Certainty	Somewhat certain	35 (37)	25 (47)	0.44	5 (39)	19 (53)	0.68
n (%)	Certain	44 (46)	21 (40)		6 (46)	12 (33)	
Agree with Original Plan	Surgeons	81 (91)	16 (33)	<.001	7 (58)	6(18)	0.02
	Med Onc	50 (91)	18 (56)	<.001	5 (56)	11 (52)	1
n (%)	Rad Onc	16 (94)	4 (25)	<.001	2 (100)	2(18)	0.08
Discussion Time	Median minutes (range)	2 (0-8)	3 (1-7)	0.01	3 (1-5)	3 (1-7)	0.94
	No	17 (17)	10 (19)		2(15)	8 (22)	
Underwent Treatment	Yes	75 (78)	39 (76)	0.85	10 (77)	25 (72)	0.87
n (%)	Partial	4 (4)	3 (6)		1 (8)	2 (6)	

The Impact of Perioperative Transfusions on Cancer Recurrence and Survival following Oncologic Resection C. Peeples,¹ C. Jenkins,^{1*} J. Mangla,¹ T. Riggs,² F. Ivascu,¹ J. Robbins.¹ *1. Beaumont Health System, Royal Oak, MI; 2. Beaumont Research Institute, Royal Oak, MI*

Background: Blood transfusions have been associated with immunologic suppression. Cancer patients undergoing definitive oncologic resection may require blood transfusion during the peri-operative period. A relationship between transfusions, cancer recurrence, and survival has been proposed but not well established. Objectives: The objective was to investigate the association of peri-operative blood transfusions with cancer recurrence and overall survival in patients undergoing definitive oncologic resections. We also evaluated the correlation of timing of the transfusion with recurrence rates. Methods: We did a retrospective review of the tumor registry at a single institution from January 2004 through November 2010. All patients with a diagnosis of brain, colorectal, esophageal, kidney, lung, liver, ovarian, uterine, pancreatic, and stomach cancers who underwent a definitive oncologic resection were included. Peri-operative blood transfusion was defined as the receipt of blood transfusion within 30 days preoperatively, during surgery, or during the first 30 days post operatively. Multivariate analysis adjusted for age, gender and oncologic stage. Results: A total of 2836 patients were included in the analysis. Oncologic stage was associated with proportion of patients transfused (p<0.0001). Overall, 19.2% of patients received at least one transfusion, and 14.4% had recurrence. Transfusion was associated with shorter time to recurrence (30 vs. 36 months, p < 0.001) and risk of recurrence increased with each unit transfused (hazard = 1.09, p < 0.005). Median length of follow up was 37 months. After adjustment for oncologic stage, age, gender, and cancer type, a significant association between cancer recurrence and perioperative blood transfusion remained (hazard = 1.40, p = 0.009). Conclusion: We identified a significant association between peri-operative blood transfusion, cancer recurrence, and mortality following definitive oncologic resection. In addition, risk of recurrence increased with each unit transfused. While our study demonstrated an association, rather than causation, prudence suggests judicious transfusion use.

P263

Underuse of Tri-modality Treatment Impacts Survival for Patients with Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends from the National Cancer Database N. Rueth,* H.Y. Lin, I. Bedrosian, S.F. Shaitelman, N.T. Ueno, Y. Shen, G. Babiera. The University of Texas MD Anderson Cancer Center, Houston, TX.

Introduction: Despite sophisticated advances in breast cancer therapy, guidelines for inflammatory breast cancer (IBC) remain largely unchanged, and studies evaluating contemporary treatment trends are lacking. In this study, we analyzed patient factors that predicted the use of guideline recommended tri-modality treatment (chemotherapy, surgery, and radiation therapy [XRT]) and studied the impact that treatment delivery had on survival. Methods: Using the National Cancer Data Base (NCDB), patients who underwent surgical treatment of non-metastatic IBC from 1998-2010 were identified. We collected patient, tumor, and treatment data and analyzed treatment delivery and associated survival trends over time. Logistic regression and Cox proportional hazard models were used to examine factors predicting treatment and survival, respectively. Results: We identified 10,197 patients who fulfilled study criteria. The use of tri-modality therapy fluctuated annually (58.4%-73.4%). Patients who were older than 54 years, diagnosed earlier in the study period, lived regions of the country outside of the Midwest, or had a higher comorbid score were significantly less likely to receive tri-modality therapy (all $p \leq 0.05$) with

regions of the country outside of the Midwest, or had a higher comorbid score were significantly less likely to receive tri-modality therapy (all p<0.05), with a negative impact on survival. 5- and 10-year survival rates were highest among patients receiving tri-modality treatment (55.4 % and 37.3%) compared to patients who got the combination of surgery + chemotherapy, surgery + XRT, or surgery alone (Figure 1). After adjusting for potential confounding variables, use of tri-modality therapy remained a significant predictor of survival. Conclusions: Our analysis demonstrates that underutilization of tri-modality therapy negatively impacts survival for patients with IBC. The use of tri-modality therapy therapy has increased only marginally with time, and there remain significant predictor sassociated with differences in use of guideline compliant trimodality treatment. We have identified potential barriers to care that may be used to target tri-modality treatment delivery and potentially improve patient outcomes.



P264

The Role of Preoperative Comprehensive Geriatric Assessment to Predict HRQoL in Elderly Cancer Patients G.M. Barden,^{1*} A.D. Naik,³ J.N. Cormier,⁴ A. Artinyan,¹ S. Sansgiry,² N.J. Petersen,² D.A. Anaya.¹ 1. Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX; 2. Houston VA Center for Innovations in Quality, Effectiveness and Safety (IQuEST), Houston, TX; 3. Department of Medicine, Baylor College of Medicine, Houston, TX; 4. Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.

Introduction: Preoperative comprehensive geriatric assessment (CGA) is advocated to help with patient selection and improve the decision-making process in elderly cancer patients. However, the utility of CGA for predicting patient-centered outcomes such as HRQoL, which are particularly relevant to this population, is unknown. The goal of this study was to evaluate the role of using preoperative CGA to examine the association of geriatric conditions with HRQoL in an elderly cancer surgery population. Methods: This is a prospective cohort study of elderly cancer patients (≥65y) scheduled for surgery at a tertiary referral center (2012-2013). Baseline clinical information and CGA data were collected preoperatively; patients were administered validated surveys to examine 8 domains within the CGA (functional status, fatigue level, cognitive function, depression, comorbidities, operative risk, nutrition and social support). The primary outcome was baseline HRQoL, measured using the Physical Component (PCS) and Mental Component Summaries (MCS) of the SF-36 survey. Univariate and stepwise multivariate linear regression were used to examine the association of geriatric conditions with worse HRQoL, while adjusting for important patient and tumor-related factors. Results: 107 elderly cancer patients were included; the majority had gastrointestinal malignancies (71%). CGA identified geriatric conditions in all domains, ranging from 12% for depression to 96% for high-operative risk (Figure 1). After MV linear regression, poor functional status by ADLs 11.3[4.6-18], by IADLs 6.4[0.4-12.4], high fatigue level 8.5[3.3-13.8], and high comorbidity index 6.0[0.7-11.3] were associated with worse PCS HRQoL, and decreasing age 0.4[0.2-0.7], poor functional status by IADLs 5.4[0.6-10.3], and depression 12.6[0.4-18.9] were associated with worse MCS HRQoL. Conclusions: Geriatric conditions captured through preoperative CGA are the most important predictors of worse HRQoL for both physical and mental health in elderly cancer patients, and should be incorporated as part of the preoperative information to guide decisions targeted at improving postoperative HRQoL for this population.



P265

Weight Loss and Postoperative Outcomes in Patients with Advanced Cancer S. Singla,* P. Thirunavukarasu, S.S. Sanghera, S. Nurkin. Roswell Park Cancer Center, Buffalo, NY.

Background: Nutritional status is considered a predictor of post-operative complications in patients undergoing surgery. However, the impact of weight loss as an independent predictor of poor outcome has not been extensively studied in patients with advanced cancer. Methods: Using the American College of Surgeons-National Surgical Quality Improvement Project's (ACS-NSQIP) participant-use file from 2005 until 2011, patients were identified who underwent elective surgery in the setting of disseminated cancer. Patients that had preoperative weight loss (WL) were then compared to non-weight loss patients (NWL). Data on demographics, comorbidities, clinical preoperative and intraoperative variables and 30-day morbidity and mortality were collected and reviewed. A multivariate analysis was conducted to evaluate the association between weight loss and morbidity, serious morbidity and mortality while adjusting for other variables. Results We identified 30,669 patients with disseminated cancer; of these 3,514 patients (11.5%) had weight loss prior to surgery. Compared to NWL patients, WL patients were more commonly men than women (12.6% vs 10.3%, p<.001), black than white (14.6% vs 11.0%, p<.001), and had a lower BMI (23.4 vs 26.7, p<.001). Compared to NWL patients, WL patients had a significantly longer median length of stay, higher rate of surgical site infections, and higher rate of re-intubation, pneumonia, renal insufficiency and failure, cardiac arrest, septic shock, overall morbidity (37.5% vs. 28.4%, p<.001), serious morbidity (23.8% vs. 17.5%, P<.001) and mortality (13.8% vs 6.0%, P<.001). On multivariate analyses, weight loss was an independent predictor of postoperative morbidity (OR 1.3, 95%CI: 1.19-1.42) serious morbidity (OR 1.2, 95% CI: 1.13-1.37) and mortality (OR 1.75, 95% CI: 1.54-1.98). Conclusions: Patients with advanced cancers presenting with weight loss are at a significantly higher risk for post-operative morbidity and mortality. Optimizing nutritional status in these patients is critical before undergoing elective surgical procedures.

P266

Learning Curve and Outcomes of Cytoreduction Surgery and Hyperthermic Peritoneal Chemoperfusion for Peritoneal Malignancies P.M. Polanco,* Y. Ding, K.M. Jordan, L. Ramalingam, J. Heather, M.E. Hogg, A.H. Zureikat, M.P. Holtzman, J. Pingpank, S. Ahrendt, H.J. Zeh, D.L. Bartlett, M.A. Choudry. University of Pittsburgh Medical Center, Pittsburgh, PA.

Introduction: Cytoreduction Surgery(CRS) and hyperthermic chemoperfusion(HIPEC) may improve oncologic outcomes in some peritoneal surface malignancies. This complex procedure may be associated with high complication rates, prolonged hospital length of stay(LOS) and potential mortality. Our objective was to determine the learning curve(LC) of CRS/HIPEC for postoperative and surgical outcomes in a high-volume center. Methods: 370 patients with peritoneal carcinomatosis from mucinous appendiceal neoplasms(MAN=282), malignant peritoneal mesothelioma(MPM=65) and gastric cancer(GC=23) were identified from a prospective database between 2001-2010. Multivariate logistic regression analysis was used to identify independent risk factors for complete cytoreduction and major morbidity (grades 3-5).Riskadjusted sequential probability ratio test(RA-SPRT) was employed to assess the LC of CRS/HIPEC for incomplete cytoreduction and major morbidity using pre-specified odds ratio boundaries derived from previously published data. Moving average(MA) analysis was used to trend hospital and ICU LOS. Results: Complete cytoreduction, major morbidity and 60-day mortality were 83.5%,30% and 1.9% respectively. Higher SPCI was the major independent risk factor for incomplete cytoreduction, while high-grade histology, incomplete cytoreduction and diagnosis of MPM and GC (when compared to MAN) were predictors of major complications after CRS/HIPEC (p<0.05). RA-SPRT chart for incomplete cytoreduction started to decrease after 20 cases and breached the lower boundary(-5.2) at case 96 with subsequent stability; while major morbidity showed a steady decrease after 96 cases, breached the lower boundary(-8.9) at case 188 and remained stable after that, MA analysis revealed a drop followed by stability after initial 100 cases in hospital LOS(+-15 d) and after initial 200 cases in ICU LOS(+-3.5 d). Conclusions: Completeness of cytoreduction, morbidity and mortality rates for CRS/HIPEC at our institution are comparable to previously reported data. Our learning curve analysis reveals that approximately 180 procedures are required to improve operative outcomes.





P267

Multidisciplinary Education for Surgical Oncology Trainees: Results of a National Needs Assessment S. Ganai,^{**} A.S. Akthar,³ O.M. Hahn,¹ R.J. Maggiore,⁴ E.E. Cohen,¹ S.J. Chmura,¹ A. Howard,¹ M.C. Posner,¹ D.W. Golden.¹ *1. The University of Chicago Medicine, Chicago, IL; 2. Southern Illinois University School of Medicine, Springfield, IL; 3. University of Missouri - Kansas City School of Medicine, Kansas City, MO; 4. Oregon Health Sciences University, Portland, OR.*

Introduction: Several training paradigms generate surgeons capable of addressing cancer care, including the new fellowship pathway towards subspecialty certification in Complex General Surgical Oncology. While multidisciplinary oncology curricula (MDOC) have been advocated as an optimal approach to help surgeons gain understanding of associated disciplines, it is uncertain how MDOC have been implemented into training. This study is part of a needs assessment of MDOC focusing on the attitudes of surgical fellowship program directors (PDs) including surgical oncology (SO, n=19), breast oncology (BO, n=32), colorectal (CR, n=57), hepatobiliary (HPB, n=19), and subspecialties (SS: urologic, n=32; gynecologic, n=46; head/neck, n=29; musculoskeletal, n=11; thoracic, n=66). Program response rate was at least 28% based on voluntary site identification (SO 42%, BO 44%, CR 14%, HPB 37%, SS 28%). Responses from 160 trainees. Results: Multidisciplinary tumor board (MDTB) attendance was considered useful for the educational experience of all groups, with 88% of trainees attending MDTBs weekly or more frequently. Formal instruction in medical oncology (MO) was reported more frequently by SO/BO (78%) compared to CR/HPB (36%) and SS (54%) trainees; p<0.01. Formal instruction in radiation oncology (RO) was seen by 87% of SO/BO versus 32% of CR/HPB and 54% of SS trainees; p<0.001. Palliative and geriatric medicine were taught infrequently overall (29% and 13% of trainees, respectively). Among those receiving some instruction in MO or RO, significantly more SO/BO trainees (97% and 93%) were taught via dedicated clinical rotations compared to CR/HPB (0% and 14%) and SS trainees (56% and 50%); p<0.001. Perceived utility of MO/RO rotations was greatest in BO trainees; p<0.01. Conclusions: Differing philosophies towards MDOC may be reflected by training paradigms, with SO/BO programs placing more value on dedicated clinical rotations over didactics or relying solely on MDTBs for oncology instruction. Further survey of PDs may be warranted.

P268

Timing-based Quality Measures for Adjuvant Therapies in Breast and Colorectal Cancer: Reasons for Non-compliance O.M. Rashid,* C. Laronga, K.A. Coyne, T.W. Ross, D. Shibata. *H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.*

Introduction: The Institute of Medicine's report on improving cancer care, along with collaborative efforts of national organizations including the National Quality Forum, has resulted in the development of "accountability measures" which are being increasingly used for hospital accreditation, managed care contracts and Center for Medicare and Medicaid Services quality monitoring. To understand potential coding pitfalls related to the application of these measures, we evaluated adherence at a tertiary care cancer center to determine reasons for non-compliance. Methods: A retrospective review was performed of all eligible cases of breast and colon cancer reported to the American College of Surgeons Commission on Cancer (ACS) at a single institution from 2008 -2012. Coding for compliance was performed using the ACS standards for accountability measures for breast and colon cancer. Timing-based quality indicators for stage I-III breast cancer include radiation therapy administered within 1 year (BCS), hormonal therapy within 1 year (HT), and adjuvant chemotherapy within 120 days of diagnosis (MAC); for stage III colon cancer, the measure is adjuvant chemotherapy within 120 days of diagnosis (ACT). Results: Identified cases included 897 BCS, 1,433 HT, 312 MAC, and 122 ACT, with adherence rates of 95.1%, 94.1%, 87.2%, and 86.9%, respectively. The reasons for non-adherence included patient-centered factors such as patient choice to delay or obtain treatment elsewhere (Table). Other factors coded as nonadherent included delays at outside facilities, lost to follow up, designation of date of diagnosis based on suspicion rather than biopsy, insurance approval, need for other procedures, diagnosis of a second malignancy, and complications. Conclusions: Our center averaged an annual compliance with the adjuvant therapy measures of approximately 90%. Larger scale studies are indicated to determine whether refinements in coding guides that account for patient preferences, clear diagnosis dates and cross-facility care could better reflect quality of care, and also promote improved patient-centered multidisciplinary management.

	BCS	HT	MAC	ACT
Number of gases	897	1,433	312	122
Number of cases	(%)	(%)	(%)	(%)
Non adharant	44	84	40	16
Non-adherent	(4.9)	(5.9)	(12.8)	(13.1)
REASON FOR NON-ADHERENCE	N=44	N=84	N=40	N=16
Lost to follow up	14	35	5	2
-Lost to follow up	(31.8)	(41.7)	(12.5)	(12.5)
Traatmant dalay	30	49	35	14
- Treatment delay	(68.2)	(58.3)	(87.5)	(87.5)
REASON FOR DELAY	N=30	N=49	N=35	N=14
Patient choice	4	21	11	6
Patient choice	(13.3)		(31.4)	(42.9)
Outride delay	22	12	19	4
Outside delay	(73.3)	(24.5)	(54.3)	(28.6)
Diagnosis by suspicion	2	5	4	2
Diagnosis by suspicion	(6.7)	(10.2)	(11.4)	(14.3)
- Insurance delay	1	2	1	1
Insurance delay	(1.8)	(4.1)	(2.9)	(7.1)
Other procedure	0	1	0	0
Oulei procedure	(0)	(2)	(0)	(0)
2nd maliananau	0	1	0	0
2nd mangnancy	(0)	(2)	(0)	(0)
Complications	1	6	0	1
complications	(1.8)	(12.2)	(0)	(7.1)

P269

Credit where Credit is Due: Using Population-based Registries to Identify Treating Hospitals A.C. Saunders, ¹* L. Ji,² A. Cupino,² C. Dyke,³ J.W. Morgan,² C.R. Morris,⁴ S.S. Lum,⁵ N.L. Solomon.⁵ *1. Loma Linda University Medical Center, Loma Linda, CA; 2. Loma Linda University School of Public Health, Loma Linda, CA; 3. SEER Cancer Registry of Greater California, Sacramento, CA; 4. California Cancer Registry, Sacramento, CA; 5. Loma Linda University School of Medicine, Loma Linda, CA.*

Introduction: Population-based cancer registries are often used to assess care received by cancer patients. These registries consolidate information on treating hospitals using the class of case schema developed by the Commission on Cancer, where patients receiving definitive cancer treatment at the reporting hospital are assigned a class of 10 or 20. This study investigates whether the consolidation process has led to inaccuracy in identifying hospitals where the most definitive cancer-directed surgery is performed. Methods: With IRB approval, consolidated data in the California Cancer Registry (CCR) was cross-referenced with raw admission and treatment data provided by California hospitals, using records from 2004-2009 of gastric cancer patients undergoing definitive surgical resection. Results: A total of 3,055 records were reviewed. A class of 10 or 20 was assigned in 2,932 cases, but 345 of these received their definitive surgical treatment at a hospital other than the reporting hospital. Incisional biopsy had been performed at the reporting hospital in 344 of the 345 cases, and this procedure was incorrectly coded in the consolidated data as definitive surgical treatment. A class other than 10 or 20 was assigned in 123 patients, and found to be correct in 121 cases. Thus, coding for a class of 10 or 20 in the CCR carried a positive predictive value of 88%, or 12% error, for correctly identifying the hospital where the most definitive surgical resection was performed (see Table 1). Conclusions: The 12% error seen in the assignment of class of case 10 or 20 has the potential to cause inequitable assignment of risk and reward to hospitals involved in the treatment of gastric cancer. Accurate identification of hospitals where the most definitive cancer-directed surgery is performed is of particular importance when considering quality improvement programs and pay-for-performance models of reimbursement. These findings in a subset of patients should prompt further investigation into the occurrence of similar errors across the CCR and other important cancer databases.

Table 1:		Raw Hos		
		Definitive surgery performed at reporting hospital	Definitive surgery performed at other than reporting hospital	
CCR	Class of Case = 10 or 20	2,587	345	PPV 88%
	Class of Case $\neq 10$ or 20	2	121	NPV 98%
		Sn 99.9%	Sp 26%	

PPV = positive predictive value; NPV = negative predictive value; Sn = sensitivity; Sp = specificity

P270

Predictive Factors of Peritoneal Carcinomatosis from Appendiceal Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy W.A. Jimenez, A. Sardi,* C. Nieroda, M. Sittig, M.F. Nunez, R. MacDonald, V. Milovanov, N. Aydin, V. Gushchin. Surgical Oncology, Mercy Medical Center, Baltimore, MD.

Introduction: Cytoreductive surgery (CRS) associated with hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard of care for peritoneal carcinomatosis (PC) from appendiceal cancer in selected patients. This study evaluates the predictive factors for long term survival of patients with PC from appendiceal cancer treated with CRS/HIPEC in a medical center specializing in peritoneal surface malignancies. Methods: A retrospective analysis of a prospective database of 358 CRS/HIPEC procedures performed identified 202 patients with PC from appendiceal cancer, in whom 233 CRS/HIPECs were performed February 1998 and February 2013. Kaplan-Meier survival curves were used to analyze the survival related to the peritoneal cancer index (PCI), complete cytoreduction (CC 0-1), lymph nodes status (LN), and tumor histopathology. Results: One-hundred-twenty-nine (64%) women and 73 (36%)

men, with mean age of 53.5 years (range 25-81), had a mean follow-up of 36 months. Overall, 77 (38%) low-grade tumor (DPAM) and 125 (62%) highgrade tumor (PMCA) were identified. Overall survival (OS) at 1, 3, 5, and 10 years was 89.6%, 71.4%, 55.7%, and 47.4%, respectively. OS in DPAM patients at 1, 3, and 5 years was 90%, 86.2%, and 82.9%, respectively, with a 5 year OS related to CC 0-1 and incomplete cytoreduction (CC 2-3) of 88% and 46%, respectively (p=0.021). OS in PMCA patients at 1, 3, and 5 years was 89.7%, 62.8%, and 41.3%, respectively (p=<0.001), with 5-year OS related to PCI <>> 20 of 60% and 36%, respectively (p=0.002); CC 0-1 and CC 2-3 of 44% and 0%, respectively (p<0.001); LN(-) and (+) of 61% and 11%, respectively (p<0.001) (Table 1). Grade III/IV complications were present in 15.8%. No perioperative mortality was reported. Conclusion: PMCA histopathology, PCI>20, CC 2-3, and (+)LN are significantly related to worse prognosis in PC from appendiceal cancer undergoing CRS/HIPEC. However, PMCA patients with PCI>20 and CC 0-1 still have 36% and 44% 5-year OS, respectively and should not be denied CRS/HIPEC. Regardless of histopathologic grade, CRS/HIPEC should be attempted if CC 0-1 is a potential outcome

Table 1. Independent variables effecting 5-year overall survival (OS) and median survival (MS) in patients with peritoneal carcinomatosis from appendiceal cancer undergoing CRS/HIPEC

	Entire Population (n=202)			PM	PMCA (n=125)			DPAM (n=77)		
	5-year OS (%)	p-value	MS (months)	5-year OS (%)	p-value	MS (months)	5-year OS (%)	p-value	MS (months)	
PCI <20	66.7	0.020	NR	59.8	0.000	75.6	100	0.145	NR	
PCI >20	54.3	0.020	90.0	35.9	0.002	38.4	79.8	0.145	NR	
CC 0-1	51.4	<0.001	NR	43.9	0.001	52.8	87.8	0.021	NR	
CC 2-3	17.7		18.0	0	<0.001	15.6	45.7	0.021	48	
N(-)	70.5	.0.001	NR	61	.0.001	NR	NA		NA	
N(+)	16.8	<0.001	38.4	11	<0.001	34.8	NA	NA	NA	

NR: Not reached; PMCA: high-grade appendiceal cancer; DPAM: lowgrade appendiceal cancer; PCI: Peritoneal carcinomatosis index; CC: completeness of cytoreduction; LN; Lymph nodes. NA: Not applicable

P271

Barriers to Care at High Volume Centers in Hepatic Surgery G. Wilson,* J.M. Sutton, K. Wima, R.C. Quillin, J.J. Sussman, S.A. Ahmad, M. Edwards, S.A. Shah, D.E. Abbott. *University of Cincinnati, Cincinnati, OH.*

INTRODUCTION: For complex oncologic procedures, high volume (HV) centers have demonstrated superior outcomes. Understanding factors impacting access to care at HV centers may reduce disparities in quality and improve patient outcomes. METHODS: The University Healthsystems Consortium (UHC) database identified 4,147 patients undergoing hepatic lobectomy from 2009-2011. Centers were stratified into tertiles based on the number of procedures performed. Patient socioeconomic status (SES) was determined using a validated SES score. Logistic regression was used to determine how patient demographics contributed to receiving care at a HV center, as well as important clinical outcomes including length of stay, readmission, and cost. RESULTS: Patients treated at HV centers had decreased hospital costs (\$13,984 vs \$16,967, p<0.001) and lower readmission rates (10.64% vs. 16.01%, p<0.001) compared to patients at low volume (LV) centers. Independent predictors for not accessing a HV center included black race (odds ratio [OR]=0.67; 95% CI 0.52-0.85; p=0.001), lower SES class (OR=0.75; 95% CI 0.61-0.93; p=0.009), and higher severity of illness (OR=0.56; 95% CI 0.44-0.72; p<0.001). Black patients receiving care at a HV center had decreased hospital costs (\$15,673 vs. \$17,798, p=0.005) and improved 30 day readmission rates (9.52% vs. 20.69%, p=0.028) compared to blacks patients at LV centers. Similarly, lower SES patients accessing HV center had decreased total length of stay and ICU days (p=0.01 and p<0.001, respectively) and decreased hospital costs (\$15,361 vs. \$17,079, p<0.001). Also, proximity to a HV center was inversely related to receiving care at a HV center. Lower SES patients resided further from HV centers than higher SES patients (149.7 mi vs. 99.2mi, p<0.001). CONCLUSIONS: Patient-specific disparities exist in accessing care in hepatic surgery. Black race, lower patient SES class, and further distance to center are all associated with decreased utilization of a HV center for major hepatic resection. Further efforts should target patients within these demographics to provide access to higher volume hospitals.

P272

What is the Impact of Diaphragmatic Involvement during Cytoreductive Surgery/HIPEC on Short-term Outcomes? B. Franssen,* P. Tabrizian, A. Weinberg, D. Tuvin, D.M. Labow, U. Sarpel. Surgery, Mount Sinai Medical Center, New York, NY.

Introduction Optimal cytoreduction is fundamental in the treatment of peritoneal carcinomatosis (PC) often requiring debulking of the diaphragm. However, the outcome of diaphragmatic stripping and resection during cytoreductive surgery (CRS) followed by Heated Intraperitoneal Chemotherapy (HIPEC) is unknown. The aim of this study is to assess the short-term outcomes of patients undergoing CRS/HIPEC with diaphragmatic involvement. Methods A retrospective chart review from April 2007 to October 2013 of all patients undergoing CRS/HIPEC with curative intent for PC was conducted. Groups 1 and 2 consisted of patients with and without diaphragmatic disease respectively. Univariate and Propensity Score Analysis were used to compare both groups. Results Of a total of 199 patients undergoing CRS/HIPEC, 89 (45%) presented with diaphragmatic disease. Most common diagnoses included appendiceal and colorectal (56%), pseudomyxoma peritoneii (12%), gastric (7%), and ovarian cancers (5%). Characteristics of both groups are summarized in Table 1. The majority of patients had right diaphragmatic involvement 97.7% and 31.8% had bilateral disease. Full thickness resection was performed in 62.5% and was repaired with mesh in 4%. Thoracostomy tubes were used in 51% of patients undergoing full thickness diaphragmatic resection at the time of CRS/HIPEC for an average of 5 days (range 2-12days). Postoperative thoracostomy tubes were placed in 6.8 % of cases. Major complications corresponding to Clavien-Dindo Classification 3-5 were significantly higher in Group 1 (OR 3.7, CL 95% 1.2-11.1 P=0.023), as was the length of hospital stay (9 vs 7 days, p=0.0394). Conclusion Patients with diaphragmatic involvement present with higher tumor burden, requiring prolonged procedures and are less likely to achieve optimal debulking. Although 90 day mortality was not different, once correcting for baseline differences, Group 1 had a 3.7 higher risk of major complications and significant increase in length of stay. Both surgeon and patient should consider the presence of diaphragmatic implants in their preoperative decision making process.

	Table 1.	Preoperative,	Operative	and Posto	perative	Variables
--	----------	---------------	-----------	-----------	----------	-----------

	Group 1: Diaphragm Involvement N=89	Group 2: Without Diaphragm Involvement N=110	P Value
PREOPERATIVE			
Age yrs. Mean (SD)	54 (12)	55(12)	0.58
Female	48(53%)	65 (59%)	0.46
ASA score. Mean (SD)	2.98 (0.49)	2.88 (0.55)	0.20
# of Comorbidities. Mean (SD)	1.04 (0.94)	1.19 (0.80)	0.23
Previous Abdominal Surgery	48(54%)	82(75%)	0.002
OPERATIVE			
Primary Site			
Appendix/pseudomyxoma	41 (46%)	39 (35%)	0.12
Colon	20 (22%)	37 (34%)	0.08
Other	28 (32%)	34 (31%)	
# Organs.Mean (SD)	5.57(2.2)	2.68 (1.9)	< 0.001
PCI score. Mean(SD)	20.5 (7.3)	11.5 (7.64)	< 0.001
Delta PCI Mean (SD)	16.2 (5.7)	9.2 (5.7)	< 0.001
EBL, Mean (SD)	929 (994)	486 (892)	0.001
Duration of surg. min., Mean (SD)	389 (110)	330 (136)	0.009
POSTOPERATIVE			
# Units Transfused, Mean (SD)	2.1 (3.3)	0.8 (2)	0.0073*
CCR score Mean (SD)	0.9 (0.83)	0.5 (0.78)	0.0104*
Length of Stay (days) median (range)	9(3-101)	7(2-99)	0.0394*
ICU Stay (days) median (range)	0(0-45)	0(0-62)	0.0034*
Significant complications at 30 days +	26(29%)	16(15%)	0.0223*
90 day mortality	7 (7.7%)	5 (4.5%)	0.14*

Abbreviations- yrs:years, SD: Standard Deviation, #:Number, PCI: Peritoneal Carcinomatosis Index, EBL:estimated blood loss, surg: surgery, min:minute, CCR:complete cytoreduction, ICU:Intesive Care Unit. + Clavien-Dindo Classification types 3,4,5. * P values derived from Propensity Score Analysis, other P values result from univariate analysis.

P273

Port Site Metastases is an Independent Prognostic Factor in Patients with Peritoneal Carcinomatosis M.F. Nunez, A. Sardi,* C. Nieroda, W.A. Jimenez, M. Sittig, R. MacDonald, V. Gushchin. *Surgical Oncology, Mercy Medical Center, Baltimore, MD*.

INTRODUCTION: Port site metastases (PSM) have been reported after laparoscopy in patients with peritoneal carcinomatosis. We hypothesize that they are an independent predictor of overall survival in patients undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). METHODS: A retrospective review of a prospective database of 350 patients revealed 65 patients who underwent laparoscopy prior CRS/HIPEC. The origin of primary tumors is detailed in Table 1. Previous port sites were excised regardless of tumor involvement. Patients with PSM in the final histopathology were divided into two groups: patients with positive PSM and patients without PSM. Overall survival (OS) was estimated by Kaplan-Meier curves and the Log-Rank Test. Cox regression (hazard ratios (HR) and 95% CIs) was used to test for independent effects of the LN metastases and positive port site involvement on survival. RESULTS: Sixty-five (28%) patients had laparoscopy before CRS/HIPEC. In 45 (69%) patients, diagnostic laparoscopy was performed for suspected malignancy and in 20 (31%) patients the tumor was found incidentally. One hundred and forty-four ports were resected, 41 (29%) ports were positive for malignancy in a total of 22 (34%) patients. Mean overall survival at 1, 3, and 5 years was 86%, 62%, and 57%, respectively. Survival at 1 and 3 years in PSM were 72% and 20%, respectively, compared with patients without PSM, 95% and 79%, respectively (p=<0.001). Positive LN were detected in 13/22 patients with PSM and in 11/43 without PSM. Independent effects on survival shows HR=3.1, CI=1.07-8.82, p=<0.001 for LN metastases and HR=3.4, CI=1.18-9.65, p=<0.001 in patients with positive PSM. CONCLUSION: Port site metastases are common in patients with peritoneal carcinomatosis and independently confer a worse prognosis. It may reflect the tumor biology or potential consequences of laparoscopy.

Table 1. Primary tumor origin, port site metastases and lymph node positivity

TYPE OF TUMOR	PREVIOUS LAPAROSCOPY	PCI>20	(+)LN Total	(+) PSM	(+) LN/ (+) PSM
Appendix	39	8	12	11	6
Colon	6	1	2	1	-
Small Bowel	1	1	1	1	1
Mesothelioma	5	1	-	1	-
Gastric	2	1	2	2	2
Primary Peritoneal	8	3	4	3	2
Ovarian	3	2	3	2	2
Fallopian Tube	1	1	-	1	-
Total	65	18	24	22	13

PCI>20: Peritoneal carcinomatosis index, Total LN (+): Total of patients with lymph nodes positives, PSM (+): Port site metastases, LN/PSM (+): Positive lymph nodes in patients with port site metastases

P274

Significance of Diaphragmatic Resections and Thoracic Chemoperfusion on Outcomes of Peritoneal Surface Disease Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) S. Ahmed,* E.A. Levine, K.R. Swett, R.W. Randle, P.W. Shen, J.H. Stewart, K.I. Votanopoulos. Surgery, Wake Forest Baptist Medical Center, Winston Salem, NC.

Background: Diaphragmatic resection (DR) during CRS/HIPEC exposes the thorax into direct contamination from the peritoneal cavity. It is unknown if synchronous thoracic chemoperfusion should be a part of the operative management of these patients. Methods: A prospective database of 1,078 procedures was analyzed. Type of malignancy, chest perfusion, resection status, comorbidities, morbidity, mortality and overall survival were reviewed. Results: 103 CRS/HIPEC procedures were performed with synchronous DR with a median follow-up of 52 months. 57(55%) were performed for appendiceal and 23 (22%) for colon cancer. DR was related with higher volume of disease as indicated by more organ resections (3.7 vs 2.8 p<0.001) and higher incidence of R2 resections (66 vs 52%, p=0.006). Patients with and without DR had similar 30 day grade III/IV morbidity of 23 vs 17%, with 30-day readmission of 11% vs 15%. Length of ICU care (6 vs 3 days, p=0.15) and hospitalization (17 vs 14 days, p=0.008) were longer with a DR. 90 day mortality was 7.7% for patients with DR vs 3.6% for those without (p=0.05). Comorbidities predicted death (p=0.03). 19 (20%) of DR patients underwent synchronous abdominal and chest chemoperfusion with an associated 30.8% grade III/IV morbidity without mortality. Failure in the chest post DR followed by perfusion was 26% (5/19) vs 5% (4/78) when the thorax was not perfused (p=0.01). Median survival for complete cytoreduction for low-grade appendiceal cancer was 175 months without DR and not reached with DR (p=0.17). Median survival for colorectal cancer patients post complete cytoreduction was 23

months following DR vs 31 without DR (p=0.76). Conclusions: Diaphragmatic resection during CRS/HIPEC is an independent predictor of surgical mortality, incomplete cytoreduction and increased length of hospitalization. Surgical mortality was not related to synchronous thoracic perfusion. Chest perfusion was performed selectively in patients with higher disease burden and was associated with more thoracic recurrence, with unknown impact on overall survival.

P275

Using Implementation Methodology to Develop a Virtual Tumor Board Program Regionally G.M. Barden,^{1*} A.D. Naik,³ J.A. Davila,² A. Artinyan,¹ A. Walder,² N.J. Petersen,² D. Albo,¹ D.H. Berger,¹ D.A. Anaya.¹ *1. Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX; 2. Houston VA Center for Innovations in Quality, Effectiveness and Safety (IQuEST),, Houston, TX; 3. Department of Medicine, Baylor College of Medicine, Houston, TX.*

Introduction: Multidisciplinary evaluation (MDEval) is the current standard for cancer care. Tumor board (TB) conferences are designed to provide such standard. Limited availability of TBs locally hampers the ability to accomplish MDEval, with Virtual TB (VTB) as a possible solution to overcome this limitation. The goal of this study was to implement a Virtual Tumor Board (VTB) Program regionally, using a TB implementation framework, and to examine its success with an implementation model. Methods: A VTB was implemented within a regional network (10 medical centers) in the Veterans Affairs healthcare system (2011-2013). The implementation process focused on developing standardized constructs within a TB implementation framework using a web-based platform: Policy, Organizational, TB structure, TB function. The VTB implementation was examined using the RE-AIM model; Reach (proportion of target institutions reached), Efficacy (proportion of complex cases accomplishing appropriate MDEval, -by NCCN guidelines), Adoption (VTB utilization rates and website hits), Implementation (proportion of cases successfully presented) and Maintenance (Implementation measure beyond 12 months). Descriptive statistics were used to examine each measure and the X2 and t-test were used to compare institutions. Results: 164 VTB cases were presented. The VTB program was successfully implemented in 7 of 9 referring institutions (78% reach). Among selected complex cases (HCC, liver metastasis, pancreatic, and rectal cancer, n=110), appropriate MDEval was accomplished in 102 (93% efficacy). Adoption was fair with 35% utilization of available VTB settings and 294 website hits during the study period. Implementation was good with 97.5% of all requested cases presented successfully; with no difference beyond 12 months (maintenance). There were no differences in any of the measures by institution. Conclusions: Development of a regional VTB program using established implementation methodology is feasible and improves access to MDEval of complex cancers. Future studies should focus on using this information to develop VTB Program performance measures and examine its impact on treatment and long-term outcomes.

P276

Patient Satisfaction with GI Cancer Multidisciplinary Care and GI Cancer Nurse Navigation L.E. McCahill, ^{1*} J. Kokko.² 1. Surgical Oncology, Metro Health Hospital, Wyoming, MI; 2. Lacks Cancer Center, Grand Rapids, MI.

Background: Health care reform, including the Affordable Care Act, calls for increased care coordination and evaluation of patient satisfaction with multidisciplinary care. Various methods to enhance coordination of cancer care have included both nurse navigators and multidisciplinary clinics (MDC). MDCs can be very inefficient for surgeons and navigational services add additional costs to cancer care. While both are widely heralded, there exist no reports of patient satisfaction evaluating their impact on quality of cancer care. Methods: Patients were eligible if newly diagnosed with a GI Cancer (pancreas, liver, colorectal, esophageal/gastric) within the prior 12 months, and they received cancer treatment from at least two cancer specialists (surgical oncology, medical oncology, radiation oncology) and underwent initial evaluation in MDC clinic. A 36-item survey using a 5 point Likert scale (1= strongly agree to 5= strongly disagree) was developed after extensive literature review to evaluate patient satisfaction with 1) timeliness and coordination of initial evaluation 2) coordination of multidisciplinary cancer care 3) effectiveness of MDC evaluation format 4) understanding of initial treatment plan and involvement with treatment decision making and 5) Nurse navigation services. Two survey mailings were performed. Results: Sixty two patients diagnosed between Jan 2010 and July 2012 were mailed surveys, and 26 (42%) were completed. Results of highlighted survey items are shown in Table 1. Conclusion: Patients with newly diagnosed gastrointestinal cancers requiring multi-modality cancer therapy expressed high satisfaction with coordination and quality of cancer care as well as good understanding of treatment and self-involvement with decision making when their initial care utilized both nurse navigation and a multidisciplinary clinic. While this cancer delivery model has additional costs and some inefficiencies for care providers, goals of health care reform appear to be met. This survey can serve as a platform to evaluate care coordination and patient satisfaction for multidisciplinary cancer care.

Patient Satisfaction with M	Multidisciplinary	Cancer	Care
-----------------------------	-------------------	--------	------

Aspect of Multidisciplinary Cancer Care	Strongly Agree	Agree	Lower satisfaction rating (3-5)
Nurse Navigation			
Helpful in coordinating initial care	19 (73%)	10 (38%)	1 (4%)
Listened to health concerns	17 (65%)	7 (27%)	2 (8%)
Addressed symptoms	15 (58%)	9 (35%)	2 (8%)
Kept me informed during treatment	14 (54%)	10 (38%)	2 (8%)
Available during treatment for questions	13 (50%)	10 (38%)	3 (12%)
Important part of my cancer care	15(58%)	8 (31%)	3 (12%)
Multidisciplinary Clinic			
Studies were available at Clinic visit	16 (62%)	10(38%)	0%
Staging studies well coordinated and convenient	12(48%)	12 (48%)	1 (4%)
Adequate time with each doctor	18 (69%)	7 (27%)	1 (4%)
Knew who to contact if questions	16 (64%)	7 (28%)	2 (8%)
Liked seeing all doctors in one clinic visit	13 (57%)	6 (26%)	4 (17%)
Would recommend GI MDC clinic to others	19 (73%)	4 (15%)	3 (12%)
Understanding and Involvement in Treatment decision making			
Doctors addressed emotional needs	13 (50%)	10 (38%)	3 (12%)
Doctors explained Treatment in understandable way	19 (73%)	6 (23%)	1 (4%)
Doctors involved me in treatment decisions	19 (73%)	5 (19%)	2 (8%)
Doctors seemed to communicate well with each other	15 (58%)	9 (35%)	2(8%)
Primary Care doctor well informed about cancer plan	13 (50%)	6 (23%)	7 (27%)
Understood treatment plan at clinic conclusion	13 (52%)	11 (44%)	1 (4%)

P277

The Marriage Defense for Cancer: A National View N.M. Burrish,¹ Z. Chau,² M. Eskander,¹ J.K. Smith,² L. Bliss,¹ S. Ng,¹ J.F. Tseng.^{1*} *1. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; 2. University of Massachusetts Medical School, Worcester, MA.*

Marriage has a reputed association with better outcomes in various diseases including individual malignancies. We investigated the effect of marriage in the top 5 solid tumor cancers in combined lethality and incidence. Methods: Prostate, breast, colon, pancreas and lung cancer patients diagnosed 1998-2009 were identified using Surveillance, Epidemiology and End Results (SEER). Univariate analysis performed using chi-square; Kaplan-Meier for survival; multivariate analyses using Cox proportional hazards. To determine whether any marriage effect was due to early diagnosis, sensitivity analysis was performed, constructing multivariate model with locoregional patients only. Results: 466,259 prostate, 519,893 breast, 311,318 colon, 80,748 pancreas and 461,937 lung cancer patients were identified. Marriage was associated with earlier stage and younger age, and increased likelihood of radiation and/or cancer-directed surgery for all cancers (p< 0.0001). Married patients enjoyed significantly longer survivals (p<0.0001). On multivariate analysis, after adjusting for patient characteristics and clinically important variables, married patients had significantly lower death risk (prostate Hazard Ratio [HR] 0.68, breast 0.66, colon 0.71, pancreas 0.80, lung 0.84). Sensitivity analysis of locoregional patients demonstrated analogous survival advantage in marriage (prostate HR 0.66, breast 0.64, colon 0.66, pancreas 0.84, lung 0.85). Conclusion: Married cancer patients demonstrate improved survival in a large nationwide study. These benefits are not explained by earlier stage at diagnosis; they persist when metastatic patients are eliminated from analysis. Interestingly, those cancers with commonly used screening (prostate, breast, colon) displayed stronger marital impact. In this high-technology age, social factors and their impact on cancer outcomes remain relevant and warrant investigation.

P278

Palliative Local Wound Control in Advanced Malignancy

A. Blakely,* W.G. Cioffi, T.J. Miner. Brown University, Providence, RI. Introduction: Surgical palliation of cancer is best defined as procedures performed with non-curative intent to improve quality of life or control symptoms of advanced malignancy. Soft tissue involvement of advanced malignancies may produce symptoms that significantly reduce quality of life, such as pain or bleeding. Literature on outcomes of palliative resection of soft tissue malignancy for local control is lacking. Methods: Soft tissue resections performed with palliative intent for local control were identified from a prospectively maintained palliative surgery database at a tertiary care center from January 2004 to July 2013. Tumor type, presenting symptom, procedure performed, need for skin graft, and symptom recurrence were recorded. Patients were followed for at least 60 days or until death. Results: 31 patients who underwent palliative soft tissue resection for local control were identified. Primary tumor types included melanoma (n=9, 29.0%), squamous cell carcinoma (n=9, 29.0%), sarcoma (n=5, 16.1%), breast (n=3, 9.7%), and other (n=5, 16.1%). 16 of 31 patients (51.6%) underwent resection for pain, 2 (6.5%) for bleeding, and 13 (41.9%) for local control or other symptoms. Procedures were performed on the trunk (n=17, 54.8%), extremities (n=7, 22.6%), head/neck (n=5, 16.1%), or multiple areas (n=2, 6.5%). 11 of 31 patients (35.5%) underwent axillary, inguinal, or neck lymph node dissection, 17 (54.8%) radical resection, and 3 (9.7%) wound excision. Split-thickness skin graft was performed in 6 of 18 radical resections (33.3%). 5 patients (16.1%) had symptom recurrence at the site of initial palliative procedure, of whom 3 (9.7%) underwent a second palliative procedure. 6 patients (19.4%) had new disease-related symptoms develop during follow-up. 30-day morbidity was 19.4%; mortality was 3.2%, which was due to progression of disease. Conclusions: Palliative surgery for local control of advanced soft tissue malignancy can provide durable symptom relief and improved quality of life. These procedures positively impact patients regardless of primary tumor type or tumor extent. Careful patient selection is important in order to maximize benefit of surgical palliation and minimize morbidity and mortality.

P279

The Detrimental Impact of Intact Primary Tumors in Patients with Metastatic Midgut Carcinoid Tumors J. Harris,^{1*} K. Campbell,¹ B. Huang,¹ M. Evers,¹ S.P. McKenzie,² 1. General Surgery, University of Kentucky, Lexington, KY; 2. Surgical Associates of Austin, Austin, TX.

Background: Single Institution studies have suggested that patients with metastatic midgut carcinoid (MCT) may benefit from resection of the primary tumor regardless of symptoms. We sought to determine if resection of the primary tumor alone in patients with metastatic MCT provided a survival advantage across a national patient sample. Methods: Using the Surveillance Epidemiology and End Results (SEER) database, all patients with American Joint Cancer Committee (AJCC) Stage IV MCT during the years 1992-2009 were identified and stratified by surgical resection of the primary tumor or no surgery. Clinicopathologic characteristics were compared and survival outcomes were assessed by Kaplan-Meier method Cox-regression. Results: Over a 17 year period, we identified 724 patients with stage IV MCT. Of this group 80.1% (n= 583) underwent surgical resection their primary tumor. In the non-surgical group, 21.3% (n=20) had surgical resection recommended but surgery was not performed (SRNP). There was no difference between the groups' gender, age, and race. Patients in the non-surgical arm were slightly more likely to have poorly or de-differentiated tumors than the surgical group. The surgical cohort had a significantly better survival when compared to the non-surgical cohort (median survival (MS) 83

vs. 25 months; p<0.0001). When compared to both the non-surgery—not recommended and surgical resection groups, SRNP patients had significantly worse overall (MS 29 vs. 83 vs. 14 months, respectively; p<0.0001) and disease specific survival (35 vs. 100 vs. 14 months, respectively; p<0.0001). Independent predictors of both decreased overall survival and disease specific survival included were no surgical resection, advanced age, and worse tumor grade (all p values <0.001). Conclusions: Based on this large, national patient sample, and aggressive surgical approach to the primary tumor is warranted in patients with stage IV MCT. Despite its relatively indolent biology, most patients with primary tumors in place succumb to disease within three years.

P280

Using Mobile App Technology for Point of Care Cancer Surgery Risk Assessment P. Thirunavukarasu,* S. Singla, S. Nurkin. Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY.

INTRODUCTION: Accurately assessing surgical risk is difficult. Procedure-specific and patient related factors such as age and comorbid status make the prediction of operative outcomes subjective, and often inaccurate. Previous scoring systems, while more reliable, are time consuming - making them impractical for clinical use. The purpose of this project was to create a mobile solution for fast, point-of-care surgical risk assessment in patients undergoing cancer surgery. METHODS: We extracted data on demographic, clinical, operative and postoperative outcome variables on patients undergoing common surgical oncology procedures for cancer from the National Surgical Quality Improvement Project (NSQIP), 2005 to 2011 database. These include but are not limited to Esophagectomy, gastrectomy, hepatectomy, pancreaticoduodenectomy, colectomy and proctectomy. These data were used to design a mobile application, which allows input of patient/disease related information such as the surgical procedure, age and the American Society of Anesthesiology (ASA) class. RESULTS: This "Cancer Surgery NSQIP App" was developed for mobile devices to predict postoperative outcomes based on selected preoperative NSQIP variables. The application generates instant output to display surgical risks such as mortality, overall morbidity and serious morbidity (sMorbidity). The application also analyses stored NSQIP data to calculate the accurateness of the generated result to the specified patient parameters. Our next steps will be validating this application prospectively in patients undergoing surgery for cancer at our institution. CONCLUSION(S): Mobile communication devices are increasingly key tools for clinicians. Uniting the NSQIP data set with this technology creates a powerful tool for surgical clinical care. It provides a surgeon the ability to give an objective, immediate, point of care risk assessment for patients and their families. This information may be able to help guide physicians and patients in their surgical management, by providing realistic expectations of postoperative outcomes.



P281

Neoadjuvant Pelvic Perfusion may Facilitate Resection of Pelvic Recurrent Rectal Cancer H. Wanebo,¹* G. Begossi,² E. Gustafson,⁴ J. Belliveau.³ 1. Landmark Medical Center, Woonsocket, RI; 2. Alta Bates Summit Medical Center, Oakland, CA; 3. Providence College, Providence, RI; 4. Charlton Memorial Hospital, Fall River, MA.

Introduction: Pelvic recurrence of rectal cancer is a persisting therapeutic challenge in spite of wide spread use of adjuvant/neoadjuvant chemo radiation and wide resection isolated pelvic perfusion (IPP) may facilitate pelvic resection in selected high-risk patients. Patients: IPP was done in 42 patients with locally advanced previously irradiated rectal cancer, 26 as a preoperative therapy and 16 for palliation. A comparative larger non-perfused group included 63 patients with pelvic resection only for recurrent rectal cancer. Method: Isolated pelvic perfusion (60 min) using pump oxygenation (Temp>41 degrees c), chemo agents - 5 FU 1500mg/m2, Cisplatin/Oxaliplatin 100/ 130mg/m2, Mitomycin 10-20- mg/m2, was done in 42 patients (67 IPP). Results (Follow up surgery): Palliative IPP in 16 advanced rectal cancer patients induced significant relief (1-4 months) of narcotic resistant pain (in 70%). Preoperative IPP in 26 locally advanced rectal cancer achieved a clinical path (CR) in 2 patients, and significant regression in 11 patients rendering them resectable. 7 had R0 pelvic resections; of 6 other patients, 4 refused surgery, 2 were medically excluded. Median survival was 24 months in 12 resectable and 30 mos in resected pts (2 pts were 5 year survivors). This is compared to outcome in 63 patients amenable to having pelvic resection alone: 57% had R0 resection (median OS 36 mos), 28% had R1 resection (med OS = 15 mos) and 15% had R2 resection (med OS 21 mos). Conclusion: Neoadjuvant IPP may facilitate selection of recurrent rectal cancer by identifying therapeutic responders likely to benefit from major pelvic resection and excluding non-responders most likely to benefit from non-surgical therapy. The potential to induce regression and facilitate R0 resection merits further exploration.

Comparison of Sizes of Sentinel and Non-sentinel Lymph Nodes in Colorectal Cancers S. Saha,¹* U. Koduru,¹ J.M. Burke,¹ A. Korant,¹ S. Saha,⁴ V. Dhar,² G. Johnston,³ M. Arora,¹ T. Singh,¹ D. Wiese.¹ *1. McLaren Regional Medical Center, Flint, MI; 2. Michigan State University College of Human Medicine, East Lansing, MI; 3. McLaren Macomb Medical Center, Mount Clemens, MI; 4. Dana-Farber Cancer Institute, Boston, MA.*

Background: Sentinel lymph node (SLN) mapping (M) in colorectal cancer (CRCa) with ultrastaging of SLNs find more nodes per patient (Pt) and more metastasis in the SLNs than non-SLNs (NSLNs) compared to conventional method of examination of the specimen. We hypothesized that SLNs may represent a subset of nodes smaller than those detected by routine pathological exam, and hence missed by conventional method of examination. Hence, we compared the sizes of SLNs and NSLNs in CRCa pts undergoing SLNM. Methods:SLNM was done in 365 pts by subserosal peritumoral injections of blue dye for SLNM. Blue stained nodes were tagged as SLNs followed by oncologic resection. SLNs were sectioned at 5 levels, 4 stained with H & E, one with cytokeratin (CK-IHC). The non-SLNs were sectioned at one level and stained with H & E. Greatest diameter of the nodes for sizes were measured on glass slides or from gross examination. Results: Of the total of 5601 LNs (Average 15.3/pt) included, 912 (16%) were SLNs and 4689 (84%) non-SLNs. Of the total lymph nodes removed, 77% were 5mm or less; 69% of positive LNs and 97% of negative LNs were less than 9mm (Table 1). On average, the size of the SLN was bigger (5.7mm) than NSLN (4.0mm). Both positive and negative SLNs were also bigger than positive and negative NSLNs (Table 1). Conclusions: Our study confirms that on average, SLNs are bigger than NSLNs whether positive or negative or as a whole. This also highlights diligent efforts needed by the pathologists, as 77% of all lymph nodes were less than 5mm. Without the lymphatic mapping by the blue dye, some of these small Lymph nodes may be missed, thereby understaging the pts.

Table 1: Comparison	of SLN	and NSLNg	ç sizes(r	mm) in	CRCa p	ots.
---------------------	--------	-----------	-----------	--------	--------	------

Size of lymph node (mm)	Numb	er of all lymph nodes	Posi	tive lymph nodes	Neg	ative lymph nodes	P value¥
1-5	43	330 (77%)	2	15 (37%)	41	15 (82%)	
6-9	9	32 (17%)	18	32 (32%)	7:	50 (15%)	
10-60	3	339 (6%)	17	76 (31%)	1	63 (3%)	N/A
Total	5601		573		5028		1
	Numb	er of all lymph nodes	Posi	tive lymph nodes	Neg	ative lymph nodes	
Patients n=365	SLN	Non-SLN	SLN	Non-SLN	SLN	Non-SLN	
Number of nodes	912	4689	176	397	736	4292	1
Mean size (mm)	5.7	4.0	9.3	7.7	4.8	3.7	< 0.001
Standard deviation	3.6	6.7	6.7	4.9	2.9	2.4	

¥ Fisher's exact test and Chi-square with Yates'

† SLN: Sentinel Lymph Node

ç NSLN: Non-Sentinel Lymph Node

P283

Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: A Peritoneal Surface Malignancy Center Experience N. Aydin, A. Sardi,* C. Nieroda, W.A. Jimenez, M.F. Nunez, M. Sittig, R. MacDonald, V. Gushchin. Surgical Oncology, Mercy Medical Center, Baltimore, MD.

Introduction: Peritoneal mesothelioma is an uncommon malignancy which can be difficult to treat. Cyto-reductive surgery (CRS) and hyperthermic Intraperitoneal Chemotherapy (HIPEC) have evolved as treatment of choice when complete cytoreduction is achieved. This study reports the experience of a peritoneal surface malignancy center on the outcomes of CRS/HIPEC for peritoneal mesothelioma. Methods: A retrospective analysis of a prospective database of 389 CRS/HIPEC procedures identified 23 patients who underwent CRS/HIPEC for peritoneal mesothelioma from 1999-2013. One patient underwent CRS/HIPEC twice. Gender, age at diagnosis, age at surgery, previous surgeries, follow up time, peritoneal cancer index score (PCI), completeness of cytoreduction (CC),pathology and overall survival (OS) were analyzed. Results: There were 11 males and 12 females. Mean age at the time of diagnosis was 55.3 years (range=25.7-71.2) with a mean age at surgery 57.5 years (range=31.5-74.7). Mean follow up time from surgery was 33.6 months (range=0.5-215). The median PCI score was 30.5, 79% had PCI >20. Complete cytoreduction (CC 0-1) was achieved in 78% of cases. Pathology included 21 epithelioid, 1 sarcomatoid and 1 mixed type. At present, 9 patients have no evidence of disease (NED), six are alive with disease. Eight patients are dead, 4 of mesothelioma and 4 of other conditions. Patients with epithelioid mesothelioma without evidence of disease had the highest survival rate (60.8%). Post operative morbidities were experienced in 11 patients (48%), only 3 were grade III. There was one in hospital mortality. One and 5 year OS rates from diagnosis were 86.7 and 65.3%, respectively (95% CI: 64.3-95.5 and CI 35.4-80.6). One and 5 year OS from HIPEC was 71.5 and 65.5%, respectively. (95% CI: 46.9-86.2 and CI: 40.4-82.1). Conclusion: Patients with peritoneal mesothelioma may achieve long term survival when treated with CRS/HIPEC with best results seen in patients with epithelioid histopathology.CRS/HIPEC is strongly recommended for peritoneal mesothelioma.

P284

The Effects of Neoadjuvant Chemotherapy and Radiation Therapy on Outcomes of Pancreaticoduodenectomy D. Lee,* A. Teng,

J. Schwartz, J. Wuamett, F. Attiyeh. Surgery, St. Luke's-Roosevelt Hospital, New York, NY.

Introduction - The purpose of this study was to investigate the effects of preoperative chemotherapy and radiation therapy on postoperative outcomes of pancreaticoduodenectomy (PD). Methods - The ACS-NSQIP Participant User File (PUF) from 2005 to 2010 was used to analyze the outcomes of patients who underwent chemotherapy and radiation therapy prior to PD. Their outcomes were compared to those who underwent PD without neoadjuvant therapy. Preoperative variables and postoperative complications were compared between the two groups. We performed a multivariate binomial logistic regression to analyze factors associated with 30-day mortality and major complications. Results - We identified 4,305 patients who underwent PD for pancreatic malignancies without neoadjuvant therapy and 60 patients who received neoadjuvant therapy. Patients who received neoadjuvant therapy were significantly younger (61.9 ± 9.8 years vs 65.9 ± 11.3 years; p=0.007) and were more likely to have had weight loss in the last six months compared to those who did not (22.8% vs 53.8%; p=0.027). The preoperative cardiovascular, pulmonary, renal, endocrine and hematologic co-morbidities were similar between the two groups. The average operative time for patients undergoing PD after neoadjuvant therapy was significantly longer, with a higher rate of intra and postoperative transfusion requirements. However, the mortality rate, the average length of stay, and the rate of major complications between the two groups were similar (Table 1). On multivariate regression analysis, neoadjuvant therapy was associated with a higher likelihood of receiving intra or postoperative transfusion (OR 2.4, 95% [CI]: 1.1-5.0, p=0.020). Other factors associated with need for transfusion were hematocrit < 30% (OR 1.9, 95% [CI]: 1.4-2.8, p<0.001), history of myocardial infarction (OR 3.4, 95% [CI]: 1.0-11.2, p=0.042), and hypertension (OR 1.5, 95% [CI]: 0.9-2.4, p=0.003). Conclusion - Operative time and transfusion requirements were significantly higher for patients who underwent neoadjuvant chemotherapy and radiation therapy. Neoadjuvant therapy was not associated with an increase in mortality or major complications.

Intraoperative and Postoperativ Events Comparisons

Characterisics	No Chemo/Radiation	Yes Chemo/Radiation	p Value
Anesthesia Time (min)	466.9 ± 138.7	511.3 ± 146.5	0.014
Operative Time (min)	384.1 ± 129.4	420.2 ± 139.2	0.032
Intraoperative/Postoperative Transfusion (Yes)	42 (1.0%)	10 (16.7%)	0.006
Return to OR	319 (7.1%)	3 (5.0%)	0.535
Death	127 (2.8%)	1 (1.7%)	0.593
Days to Death	14.4 ± 8.9	20	0.530
Days to Discharge	13.0 ±12.1	13.7 ± 14.1	0.674
Major Complications	708 (15.7%)	8 (13.3%)	0.620
Myocardial Infarction	29 (0.6%)	2 (3.3%)	0.012
Cardiac Arrest	59 (1.3%)	0 (0%)	0.373
Unplanned Intubation	228 (5.0%)	0 (0%)	0.074
Ventilator Dependence >48 hous	257 (5.7%)	2 (3.3%)	0.433
Pulmonary Embolism	43 (1.0%)	0 (0%)	0.448
Deep Venous Thrombosis	93 (2.1%)	1 (1.7%)	0.821
Acute Renal Failure Requiring Dialysis	49 (1.2%)	1 (1.7%)	0.667
Progressive Renal Insufficiency	28 (0.6%)	0 (0%)	0.541
Cerebral Vascular Accident	21 (0.5%)	0 (0%)	0.597
Coma >24 hours	8 (0.2%)	0 (0%)	0.948
Sepsis	445 (9.9%)	2 (3.3%)	0.091
Septic Shock	182 (4.0%)	3 (5.0%)	0.704
Urinary Tract Infection	222 (4.9%)	2 (3.3%)	0.573
Superficial Wound Infection	435 (9.6%)	8 (13.3%)	0.335
Deep Incisional Wound Infection	98 (2.2%)	2 (3.3%)	0.540
Wound Disrupion	90 (2.0%)	3 (5.0%)	0.101
Organ Space Infection	389 (8.6%)	3 (5.0%)	0.321
Pneumonia	220 (4.9%)	1 (1.7%)	0.250

The Impact of Comorbidity on Costs and Effects of Second-line Treatment among Elderly Metastatic Colon Cancer Patients

A. Woldemichael,¹ E. Onukwugha,¹ Z. Zheng,¹ N. Hanna,¹* B.S. Seal,²

C. Mullins.¹ 1. Surgery, University of Maryland, Baltimore, MD;

2. Bayer Healthcare Phamaceuticals, Wayne, NJ.

Background: The Charleston Co-morbidity Index (CCI) was developed as in hospital mortality indicatory and subsequently used to both predict and adjust survival differences in cancer patients. Comorbidity is also known to influence the cost of providing treatment. We therefore examined how the incremental cost effectiveness of treating metastatic colon cancer (mCC) patients with 2nd line treatment (Tx2) will vary based upon their baseline CCI. Methods: We identified 2,897 elderly (age 66+) mCC patients who received NCCN recommended first-line treatment (Tx1) between 2003 and 2009 in the SEER-Medicare dataset. Approximately 6% and 1% of patients with missing CCI and outlier costs (above \$579,621.9), respectively, were excluded. We categorize patients by their CCI for 12 months prior to diagnosis into three categories: low (CCI=0), medium (CCI=1) and high (CCI=2+). We calculated and compared 5-years incremental costs and effects on patients who received and those who did not receive Tx2. Costs are inflation adjusted to January 2009 dollars using US Medical Price Index (MPI). We adjusted for censoring using Inverse Probability Weighting (IPW) method and selection bias on observables using Propensity Score Bin Bootstrapping method. Results: Among patients who received Tx1, 56% proceeded to receive Tx2. Of those who received Tx2, 67%, 23%, and 10% have low, medium and high comorbidities, respectively. Compared to those who do not received Tx2, patients who received Tx2 with low, medium, and high baseline comorbidities live 18 (se = 4), 253 (se = 4), and 183 (se = 3) days longer and incur added costs of \$66,693 (se = \$675), \$80,217 (se = \$723), and \$49,610 (se = \$1,136), respectively. The median Incremental Cost-Effectiveness Ratios (ICERs) of Tx2 for patients with low, medium, and high comorbidity are \$80,049, \$114,693, and \$151,627, respectively. Conclusions: Survival benefits from receiving Tx2 vary from an average of 18 days to 253 days and added costs from \$49,610 to \$80,217 depending on baseline comorbidity levels. The median ICERs associated with Tx2 increase as baseline comorbidity level of patients increase.



P286

Adjuvant Intraoperative Post-dissection Tumor Bed Chemotherapy: A Novel Approach in Treating Midgut Neuroendocrine Tumors Y. Wang,* M.A. Hall, P. Boudreaux, E. Woltering, L. Anthony.

Y. wang,* M.A. Hall, P. Boudreaux, E. Woltering, L. Anthony LSUHSC - New Orleans, Kenner, LA.

Background: Midgut neuroendocrine tumor (NET) patients are often diagnosed at an advanced stage with extensive mesenteric lymph node and liver metastasis. Even with skillful surgical dissection, macro and microscopic residual disease at the dissection site remains a possibility. We hypothesized these potential tumor residuals in mesenteric lymph node dissection beds can be eliminated safely by a local application of 5-fluouracil (5-FU). Methods: Retrospectively, charts of 62 consecutive midgut NET patients with boggy mesenteric lymphadenopathy underwent cytoreductive debulking surgeries from 1/2007 to 12/2009 were reviewed. Thirty-two (32) patients received an intraoperative application of 5-FU saturated gelfoam strips secured into the mesenteric defect following the extensive lymphadenectomy. Thirty (30) untreated patients served as a control. Results: 5-year survival after cytoreductive surgeries was 22/32 (68.8%) for the treated group, versus 20/30 (66.7%) for the control. 6 patients (6/32, 18.8%) among the study group required additional debulking surgeries, versus 16 patients (16/30, 53.3%) in the controlled group. Upon reoperation, locoregional recurrence was noted in 9 of the 16 patients (56.3%) in the control group, versus only 2/6 (33.3%) of treated patients. Post-op complication rates are similar in the two arms. Conclusion: Intraoperative application of chemotherapy is a safe and effective adjuvant for eliminating any potential microscopic residual disease after extensive cytoreductive surgeries in advanced stage NET patients with mesenteric lymph node metastasis. It provides patients with sustained, slow releasing, high dose of 5-FU within the surgical bed with a negligible side effect profile, whereby reducing local recurrence rates and decreased the need of reoperation. Further study is required to evaluate its effect on long term survival.

P287

A Population-based Assessment of Melanoma: Does Treatment in a Regional Referral Centre Make a Difference? J.D. Rivard, ^{1*} M. Shea-Budgell,² X. Kostaras,² L. Chin-Lenn,¹ G. McKinnon.¹

1. Departments of Surgery and Oncology, University of Calgary, Calgary, AB, Canada; 2. Guideline Utilization Resource Unit, CancerControl Alberta, Calgary, AB, Canada.

Introduction: Regionalization of care to specialized centres has been shown to improve outcomes for several types of cancer including ovarian and pancreas. We sought to determine if regionalization of care has an impact on the outcome of melanoma. Methods: In the province of Alberta, a provincial cancer registry was used to identify patients diagnosed with stage I-IIIC primary melanoma between January 2009 and December 2010. Demographic and pathologic data was captured including biopsy information, definitive excision, and lymph node management. Provincial guidelines recommend excision margins of 1cm for melanomas < 1mm, 1-2cm for melanomas 1-4mm thick, and at least 2cm for melanomas greater than 4mm thick. Guideline adherence for wide local excision (WLE) was based on adjusted pathology margins. Sentinel lymph node biopsy (SLNB) was recommended for all T1b tumors and higher. Chisquared tests were used to compare the outcomes of patients treated at a regional referral centre (RRC) or elsewhere. Results: 148 of 561 patients with primary stage I-IIIC melanoma were identified as having been treated at a RRC. Median follow-up for all patients was 31.7 months. In patients treated at the RRC, melanomas were thicker, more likely to be ulcerated and had a higher mean mitotic rate. Time from diagnosis to SLNB was longer for those patients treated at a RRC (69.1 vs. 56.3 days, p = 0.05). The RRC was more likely to follow guideline recommendations for performing SLNB (81.3% vs. 55.4%, p < 0.005) but not for the extent of WLE (24.3% vs. 38.7%, p = 0.006). There was no difference in regional recurrence rates (2.7% vs. 2.3%%, p = 0.80) or overall recurrence rates, defined as local, regional, or distant (14.2% vs. 10.9%, p = 0.28) between those patients treated at a RRC and those treated elsewhere. Conclusions: The RRC more closely followed guidelines on SLNB but not for WLE. Patients treated at the RRC had a more advanced stage at presentation. Despite these differences, recurrence rates were similar for patients treated at a RRC and elsewhere.

Quality of Life after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Prospective Study from an Asian Cancer Centre W. Tan,* J. Wong, W. Wang, E. Sin, C. Chia, G. Tan, K. Soo, M. Teo. National Cancer Centre Singapore, Singapore, Singapore.

Background Although Cyto-reductive surgery with hyperthermic intra-peritoneal chemotherapy (CRS+HIPEC) has gained acceptance for the treatment of peritoneal carcinomatosis, the data on quality of life (OOL) after treatment remains scarce, particularly among the Asian population. This study assesses the QOL post CRS and HIPEC in an Asian cancer centre. Methods 40 consecutive patients who underwent CRS+HIPEC were enrolled in the study. OOL was measured via the administration of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaires pre-operatively and at three, six and twelve months post-operatively. Changes in quality of life scores of 5 or more were considered significant. Results 40 patients were analysed of which 31 (78%) were females. Median age was 51 years (15 - 59 years). 34 patients had pre-operative ECOG status of 0 while the remaining 6 had ECOG status of 1. CRS + HIPEC were performed for ovarian cancer in 15 patients (38%), colorectal carcinoma in 14 patients (35%) and appendiceal carcinoma in 5 patients (13%). The median intra-operative Peritoneal Carcinomatosis Index (PCI) score was 12 (2 - 34) while the Completeness of Cytoreduction (CC) Score was 0 and 1 in 33 and 7 patients respectively. 3 patients died from progressive disease 3 to 6 months post CRS + HIPEC during the entire study period. The QOL scores of the cohort pre-operatively and at various time points post CRS+HIPEC is illustrated in Table 1. Global health status was non inferior to pre-operative scores after CRS + HIPEC. Significant improvements were seen in physical functioning, emotional functioning and social functioning scores, with the improvement in social functioning score being the most marked. CRS + HIPEC was associated with an improvement in symptoms of nausea/vomiting and loss of appetite. However, patients tend to be more symptomatic from constipation post CRS + HIPEC compared to pre-operatively. Conclusion CRS and HIPEC does not significantly impair QOL and may instead lead to improvement in parameters such physical functioning, emotional functioning and role functioning.

Table 1

Mean QOL Score				N	
QOL Parameter	Pre- Op 3 months 6 (n=40) (n=30)	6 months (n=24)	6 months (n=24)	Pre-Op	
		Functi	on Score		
Global Health	68	63	71	66	-2
Physical Functioning	87	76	86	81	+6
Role Functioning	85	74	85	85	0
Emotional Functioning	80	78	90	88	+8
Cognitive functioning	85	81	89	85	0
Social Functioning	78	81	85	97	+19
		Sympt	om Score		
Fatigue	23	24	21	25	+2
Nausea and vomiting	6	8	3	0	-6
Pain	18	17	9	18	0
Dyspnoea	11	19	11	15	+4
Insomnia	26	20	18	30	+4
Appetite Loss	17	14	11	6	-11
Constipation	16	7	10	21	+5
Diarrhoea	9	10	15	6	-3
Financial Difficulties	30	26	32	33	+3

P289

Outcomes after Emergency Surgery for Colorectal Cancer C. Luu,* J. Velasquez, B.A. Petrie, R. Kumar, B. Lee. *Surgery, Harbor-UCLA Medical Center, Torrance, CA.*

Introduction: Emergency surgery (ES) for colorectal cancer (CRC) has been associated with a poor prognosis. The purpose of this study is to evaluate short and long term outcomes after emergency vs. elective surgery for CRC patients at a large urban county hospital setting. Methods: A retrospective review of 279 patients who received surgery for CRC from 2005 to 2012 was performed. Patient demographics, tumor characteristics, surgical morbidity and mortality, and survival were analyzed. Univariate and multivariate analyses and Cox regression were performed for cohort comparisons and to evaluate overall survival. Results: 29 of 279 patients (10.4%) required ES. Indications for ES included peritonitis, complete bowel obstruction, and intra-abdominal abscess. Of the entire cohort, there were 153 male patients (54.8%) and 126 female patients (45.2%). The average age was 55.5 yrs. There were 37 (13.3%), 136 (48.7%), and 106 (38%) stage I, II, and III patients, respectively. Age, race, and body mass index were similar in patients who did and did not undergo ES. Both groups were also similar in stage, total lymph nodes retrieved, positive lymph node status, and receipt of chemotherapy. All but one patient in each group underwent resection of their primary tumor. There were 12 (4.8%) Clavien grade III or higher post-operative complications in the non-ES group compared to 4 (13.8%) in the ES group (p=0.071). There was only one 30-day mortality, which occurred in a patient who presented with bowel perforation. Average length of stay was 12.1 vs. 19.7 days (p< 0.001) for the non-ES vs. ES group, respectively. Five-yr survival was 74.3% vs. 67.7% for the non-ES vs. ES groups, respectively (p=0.102). On Cox regression, only stage and race were predictive of survival. Median length of follow-up was 33 months. Conclusions: Our study indicates that long term survival is comparable between patients undergoing ES vs. elective resection for CRC. The need for emergency surgery should not preclude an attempt at aggressive oncologic resection.

P290

Resources and Safety Associated with Developing a Peritoneal Surface Malignancy Program in a Community Hospital R.A. Hoefer,* J.P. Wilson. *Surgery, Sentara Careplex Hospital, Newport News,, VA.*

Introduction: In 2005 a peritoneal surface malignancy program was developed, providing cytoreductive surgery and heated intraperitoneal chemotherapy to patients with abdomiinal carcinomatosis within a community hospital. This study was performed to identify the resources expended treating these patients, as well as the safety of performing these procedures in this setting. Methods: A retrospective chart review was performed from 8/2005 to 1/2013 with IRB approval. Results: 63 patients underwent cytoreductive surgery with heated intraperitoneal chemotherapy from 8/2005-1/2013. 10 disease entities were treated, with 68% of patients (43/63) having carcinomatosis from colon, ovary or appendiceal cancers. The average length of procedures was 10.23 hours. 30% of patients underwent a bowel resection (21/63). The average blood lost was 436.3 ml, and 69.8% of patients (44/63) had an average of 1.8 units of blood transfused intra-operatively. 90.5% of patients achieved a complete cytoreduction (57/63). The 30 day operative mortality was 1.6% (1/63). 12.7% of patients required ICU stays (8/63), with 87.3% ((55/63) managed within an Oncology Specialty Unit with hemodynamic monitoring. The average hospital stay was 18.7 days, with 6 (10.5%) patients hospitalized for more than 20 days. 4.8% of patients required readmission (3/63). There were 39 significant complications with 2 patients requiring re-operation. (Table 1) Cost analysis was available from 2007-2012, and the overall direct cost to provide care was \$1,708,660.00 with a direct margin of \$621,085.00. Average supply cost per case was \$4,823.00. Conclusions: The authors conclude that these procedures can be done safely in the community hospital setting, but with significant morbidity and expenditure of hospital resources. The use of a specialized Oncology Unit with monitoring capability, reduced the need for use of the ICU. This significant expenditure of resources did not result in a financial loss to the hospital.

Morbidity Following Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy

Renal Insufficiency	1
Abdominal Abscess	2
Enterocutaneous Fistula	1
Hematologic	14
Gastrointestinal Bleeding	2
Respiratory Failure	4
Intraperitoneal Bleeding	2
Reoperation	2
Pleural Effusion requiring Thoracentesis	5
Central Line Sepsis	1
Pneumonia	2
Wound Infection	1
Supra-ventricular Tachycardia	1
C. Difficile Colitis	1

Complications in 63 consecutive patients

Does First-line Treatment Impact the Cost Effectiveness of Secondline Treatment for Elderly Metastatic Colon Cancer Patients? C. Mullins,¹ A. Woldemichael,¹ Z. Zheng,¹ E. Onukwugha,¹ B.S. Seal,² N. Hanna.¹* *1. Surgery, University of Maryland, Baltimore, MD; 2. Bayer healthcare Pharmaceuticals, Wayne, NJ.*

Background: Randomized clinical trials for second line treatment (Tx2) of metastatic colon cancer (mCC) often have strict inclusion/exclusion criteria regarding prior treatment, yet in the real world there is significant variation. This study aims to determine whether cost effectiveness estimates of Tx2 for mCC patients varies by the regimen they received in first-line treatment (Tx1). Methods: We identified 3.211 elderly (age 66+) mCC patients in the SEER-Medicare dataset who received NCCN recommended Tx1 between 2003 and 2009. Patients were categorized by Tx1 based on a previously published algorithm as fluorouracil and leucovorin (5-FU/LV), irinotecan (IRI), oxaliplatin (OX), or "other," which included IROX or biologics without OX or IRI. Separate 5-year incremental cost-effectiveness of Tx2 were calculated for each Tx1. Approximately 1% of patients with outlier costs were excluded. Patients enrolled in HMOs, lost Part A and/or B, and died of causes other than colon cancer are censored. We adjusted for censoring using the Inverse Probability Weighting(IPW) method. Costs were inflation-adjusted to 2009 dollars using the national monthly medical price index. Results: Among patients who received Tx1, 34% received 5FU, 17% received IRI, 46% received OX, and 3% received other (IROX or Biologics) regimens; 44.5% proceeded to Tx2. Compared to those who do not receive Tx2, patients who received Tx2 following IROX or Biologics, IRI and 5FU in Tx1 live 292 (se = 4), 224 (se = 2), and 191 (se = 2) days longer and incur added costs of \$49,096 (se = \$7,137), \$83,784 (se = \$12,322), and \$91,686 (se = \$10,312), respectively. Recipients of OX in Tx1 did not receive a survival benefit from Tx2, despite additional costs of \$46,849 (se = \$10,468). Conclusions: The real-world survival benefit of Tx2 for elderly mCC patients in SEER-Medicare varied based on Tx1 from potential harm to a mean of 292 days of incremental survival. Similarly, the costs and cost effectiveness of Tx2 varied by Tx1. These results underscore the importance of considering prior treatment when evaluating the benefit of subsequent treatment for elderly mCC patients.



P292

Comprehensive Outcomes Assessment in Patients with Incurable Cancer and Small Bowel Obstruction W.H. Tseng,* J.N. Cormier, B. Badgwell. Surgical Oncology, MD Anderson Cancer Center, HOUS-TON. TX.

BACKGROUND: There is a paucity of data comparing surgical to nonoperative management for patients with malignant small bowel obstruction(MSBO) and optimal outcome measures have not been defined. We sought to define the utilization of procedural and non-procedural management of MSBO and report survival and symptom improvement. METH-ODS:Utilizing a tertiary cancer center database of patients with advanced, incurable malignancy from 2000-06, we identified patients requiring acute surgical consultation for MSBO. Treatment strategies were compared and analyses were conducted to identify variables associated with 90-day survival and ability to resume oral intake. RESULTS:122 patients with MSBO

were identified; 63(52%) received non-procedural management, 29(24%) received procedural(PRO)-based management, and 30(25%) received surgical palliation. The most common cancer types overall were colorectal(27%), genitourinary(12%), and sarcoma(10%). Patients with radiologic evidence of ascites(p=0.002) or carcinomatosis/sarcomatosis(p=0.02) were less likely while patients with an intact primary tumor or recurrence(p=0.03) were more likely to receive surgery. Among patients undergoing surgery, there was one perioperative mortality (3.3%) and 53%of patients had at least one perioperative complication. 63% of patients undergoing surgical palliation were tolerating an oral diet at the time of discharge compared to 65% in the non-procedural and 52% in the PRO group(p=NS). 67% of patients receiving surgical palliation survived >90 days compared to 49% in the non-procedural and 35% in the PRO group(p=0.05). Death within 90 days was associated with the presence of ascites(p=0.03) and/or carcinomatosis/sarcomatosis(p=0.03) while the ability to tolerate oral intake at discharge was associated with albumin level(p=0.002). CONCLUSIONS: Survival outcomes, although clearly related to patient selection, should be included as outcome measures in palliative surgery studies. Symptom improvement is obtained in the majority of patients with MSBO regardless of treatment strategy and there is a need for additional observational studies and clinical trials for these patients.

P293

Long-term Functional Decline in Geriatric Oncology Patients after Treatment is a Major Problem: Instituting a Geriatric Oncology Program to Stabilize Functional Decline P. Somasundar,* H. Khan, N. Reis, K. Perry, J. Stoukides. Surgery, Roger Williams Medical center, Providence., RI.

Hypothesis: Sixty percent of cancer incidence is in >65 years of age. Long term functional decline after treatment is not unusual in these patients (pts) and not well addressed. The goal of the geriatric oncology program is to assess, appropriately intervene during pre-treatment phase and decrease the functional decline. Methods: At the cancer center, pts with newly diagnosed solid cancers (≥65 years) are placed in the program to improve quality. A nurse navigator assesses the pts activities of daily living (ADL), instrumental activities of daily living (IADL), PHQ9 survey for depression, Montreal cognitive assessment scale (MOCA), polypharmacy (≥7drugs), timed up and go test, nutritional survey and comorbidities. Interventions are placed accordingly with an automatic trigger to geriatrician, dietitian, pharmacist, social worker; psychiatry is initiated if issues are identified with assessment. The progress of pts is monitored by an inter-disciplinary team. Pts were assessed at 0, 30, 90 and 180 days for functional decline. Results: The program started November 2012, Recruited 71 pts, male -30. There were 21 surgical pts and 50 non-surgical, 5 pts completed the program. Initial visit 21/71 pts, at 30 days 7/16, at 90 days 9/15 and at 180 days 3/5 pts had interventions done (table 1). During initial visit interventions were done on 17 pts for polypharmacy, 8 pts for nutrition, 6 pts by social worker, 2 pts underwent prehabilitation, 2 pts treated for depression. Severe functional decline identified in 1/5 pts at 180 days. Conclusion Interventions in cancer pts have been addressed during or after treatment with surgery, chemotherapy or radiotherapy. Pretreatment pt factors are important to address in improving pts tolerability to treatment. The treatment of elderly cancer patients is a challenge for primary care physicians, oncological physicians including surgeons. A multi-disciplinary team with focus on the needs of the elderly is important to decrease the long term functional decline effectively and help complete the multi-disciplinary treatment modality.

Assessment for functional decline and Interventions done during the multiple visits

Geriatric Assessment, (Days and Interventions)	Pharmacy	Nutrition	Social Work	Prehabilitation	Psychiatry
Initial visit	17	8	6	2	2
30 days	6	2	2	0	0
90 days	4	2	3	0	0
180 days	3	1	0	0	0

Hepatic Artery Infusion (HAI) for Recurrent or Chemo Resistant Hepatic Malignancy H. Wanebo,¹* S. Redy Sanikommu,² C. Taneja,³ G. Begossi,⁴ F. Cummings,³ J. Belliveau.³ I. Landmark Medical Center, Woonsocket, RI; 2. Hurley Medical Center, Flint, MI; 3. Roger Williams Medical Center, Providence, RI; 4. Alta Bates Summit Medical Center, Oakland, CA.

Introduction: Colorectal Hepatic metastases occur as synchronous (20-25%) or metachronous (60%) lesions with most (75%) being unresectable. Combination chemotherapy is considered to have increased Overall Survival (OS) from 6 months to 21 months as well as enhancing resectability. Addition of biologics (EGFR inhibitors) has shown increased responsiveness >60% in KRAS wild type (Crystal Study) but less than 30% if KRAS mutated . HAI may provide benefit in patients with resistant hepatic metastases. Methods: We reviewed survival outcome in chemo resistant/high risk patients following hepatic artery infusion (HAI) in 21 CRC pts, 10 HCC pts and 6 pts with miscellaneous hepatic metastases. Patients restaged by clinical and lab exam (LFT, Tumor markers), CT, MRI and angiography had operative placement of HAI catheter with infusion pump. Selected resections were done (if reasonable) to augment oncologic outcome. Results: A pilot study of HAI in 36 pts with untreated hepatic metastases showed a measurable volumetric radiologic response in 13(36%) with > 50% volumetric regression in 7 patients (54% and <50% regression in 6 patients (46%). Disease progression occurred in 7/36 (20%) and stable disease was observed in 44% .. The current study included colorectal cancer 22 pts, primary liver cancer 9 pts, and a miscellaneous group (6 pts). The colorectal cancer group consisting of 22 pts, 5 with synchronous cancer and 16 with metachronous lesions had a post HAI median Overall Survival (OS) of 18 mos . Primary liver cancer in 9 pts (HCC in 8 and cholangio CA in 1 pt) included failure of resection in 4 pts, and TACE/RFA in3 pts. Post HAI median OS was 9 months. A third group of pts had been resected for miscellaneous Ca from lung, breast, ballbladder or carcinoid.. Survival post HAI was >60 mos in 2 pts with resected GB ca,and 23/9 mos post HAI in 2BrCa pts and 11 mos/9 mos in Lung Ca/Carcinoid pts. Conclusion: HAI alternating with systemic chemo therapy has apparent survival benefit in selected patients with persistent chemo resistant malignancy from metastatic CRC, HCC or selected miscellaneous cancers (breast, lung, liver, gallbladder cancer) and warrants further study.

P295

Mortality in Surgical Oncology Patients Visiting the Emergency Room (ER) M.R. Bosscher,* B.L. Van Leeuwen, H.J. Hoekstra. University Medical Center Groningen, Groningen, Netherlands.

Aims: To investigate 30-day and long term mortality in surgical oncology patients visiting the ER. Methods: Retrospective chart review of all surgical oncology patients visiting the ER of the University Medical Center Groningen between 01-10-2012 and 01-04-2013. Results: 206 cancer patients, median age 63 (range 18-89) yrs, 112 males (54.4%) and 94 females (45.6%) visited the ER for surgical consultation. Thirty seven pts (17.6%) presented with progressive disease, nine pts (4.4%) with infections due to hematologic malignancy or chemotherapy and in one patient a second malignancy was diagnosed. Five pts (2.4%) were diagnosed with cancer. The remaining 154 pts (74.8%) had symptoms not related to their malignancy. Of the 52 pts with symptoms related to their malignancy 26 pts (50%) had symptoms caused by an intraabdominal tumor mass, 21 pts were admitted and 15 pts underwent a laparotomy for bowel resection, bypass or diverting colostomy. Fourteen pts (26.9%) presented with clinical deterioration of their disease, 11 pts were admitted and all treated conservatively. Eight patients presented with infections due to immune deficiency, 5 were admitted and 5 had a surgical intervention. Three pts (8.1%) presented with complaints of subcutaneous metastasis, not leading to hospital admission. One patient was seen to discuss palliative treatment and was not admitted. The median duration of the post ER admission was 10 (range 1 - 71) days. Thirty-day mortality rate of all surgical ER patients with symptoms related to their malignancy was 26.9% and the long term mortality rate after a median follow up of 273 (range 185-364) days was 51.9%. The median survival of the deceased patients was 30 (0 - 227) days. Half of the deceased patients were already previous diagnosed with distant disease. Conclusions: About 34% of cancer patients who present at the ER with surgical problems have symptoms related to their malignancy, more than one third present with symptoms caused by gastrointestinal obstruction. ER visits of cancer patients requiring surgical oncology consultation and treatment have a 30-day mortality of 26.9% and a long term mortality of 51.9%.

P296

"Getting My Life Back": Complex Abdominal Wall Hernias as a Barrier to Quality of Life in Cancer Survivors R. Nenshi,^{1*} C. Bensimon,² F. Wright,¹ A. Smith,¹ F. Brenneman.¹ I. University of Toronto, Toronto, ON, Canada; 2. Sunnybrook Health Sciences, Toronto, ON, Canada.

Introduction: Increasingly more cancer patients achieve long term survival following multimodal, complex therapeutic regimens involving extensive surgery as well as chemo-radiotherapy. This has increased the number of cancer survivors living with complex abdominal wall hernias (CAWH). Incisional hernias following surgery are common and can occur in up to 20% of patients. Hernias are known to have significant physical, social and emotional repercussions on patients. Study Objective: This qualitative study proposes to explore cancer survivors' experiences before and after the repair of CAWH. Our primary goal is to offer insight into the impact of CAWH on the quality of life of cancer survivors with the view of identifying and addressing gaps in cancer survivorship care. Methods: Data was collected through one-on-one, in-depth semi-structured interviews. Ten pre-operative and eleven post-operative patients were interviewed. Participants met the following inclusion criteria: completed surgery +/- multimodal therapy for cancer; had the presence of a post-operative abdominal wall hernia; were English-speaking; and able to provide consent. Analysis of interviews via comparative analysis techniques and coding strategies were used to identify themes. Results: Participants' views were organized according to the following emerging themes: 1) Struggling to find a sense of normalcy post-cancer treatment; life is described as being restricted/interrupted/on hold/hell; 2) Feeling abandoned; and having few resources or supports to help them manage living with a hernia; 3) Experiencing distress, loss of self-confidence, feeling hopeless about their situation, and hopeful for their future post successful hernia repair. Conclusions: Our findings demonstrate the all-encompassing impact of hernias on the life of cancer survivors. This strongly suggests that hernia management should be viewed as a part and parcel of cancer treatment to improve quality of life in cancer survivors.

P297

Surgical Management of Gastrointestinal Stromal Tumors: An International Multi-institutional Analysis D. Bischof,¹ Y. Kim,¹ F. Quereshy,⁷ P. Karanicolas,⁶ C. Law,⁶ D.G. Blazer III,² S.K. Maithel,³ T. Bauer,⁵ T.C. Gamblin,⁴ T. Pawlik.¹* *1. Surgery, Johns Hopkins Hospital, Baltimore, MD; 2. Duke University Medical Center, Durham, NC; 3. Winship Cancer Institute, Emory University, Atlanta, GA; 4. Medical College of Wisconsin, Milwaukee, WI; 5. University of Virginia, Depart ment of Surgery, Charlottesville, VA; 6. Odette Cancer Centre, Sunnybrook Health Sciences Centre; University of Toronto, Toronto, ON, Canada; 7. Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.*

Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. The aim of this study was to characterize outcomes after resection of GIST in the imatinib era. Methods: 609 patients who underwent surgical resection of GIST from 1998 to 2012 were identified from a multi-institutional database. Clinicopathological characteristics, operative details, and oncologic outcomes were analyzed and defined. Results: Of 609 patients identified, 537 underwent resection for primary, non-metastatic GIST. Median age was 63; 49% were female. Median tumor size was 4.4cm (IQR 3.0-8.0cm) and 65% were symptomatic. The majority of tumors (391, 73%) arose in the stomach. A small subset of patients (44, 8%) underwent neoadjuvant therapy with a tyrosine kinase inhibitor (TKI) for

a median of 30 weeks (IQR 26-52 weeks). The vast majority of patients (506, 94%) underwent R0 resection: multivisceral resection was required in 88 (16%) patients. The majority of patients (505, 94%) had a KIT mutation identified. Based on 2002 NIH criteria, tumors were categorized as very low (89, 17%), low (201, 37%), intermediate (101, 19%) or high risk for recurrence (135, 25%). 112 patients (21%) had adjuvant TKI therapy for a median duration of 56 weeks (IQR 9-56 weeks). Factors associated with receipt of adjuvant TKI included tumor size and site, symptomatic presentation and mitotic rate (all p<0.01). Median follow-up was 30 month and 5-year recurrence-free and overall survival were 75% and 86%, respectively. Factors associated with recurrence included tumor size and site and mitotic rate (all p<0.05). Patients with GIST tumors characterized by a high mitotic rate had a worse recurrence-free (HR=5.0) and overall survival (HR=2.6)(both p<0.05)(Figure). Conclusion: In this large multi-institutional cohort of GIST patients, roughly 20% of patients received TKI therapy in the peri-operative period. At 5-years, 25% of patients experienced a recurrence. Although high-risk patients were the most likely to receive TKI therapy, this subset of patients remained at the highest risk for poor long-term recurrence-free and overall survival.



Figure demonstrating overall survival and recurrence free survival for primary non-metastatic GIST by mitotic rate

P298

Prognostic Factors for Angiosarcoma: Analysis of a Rare Histology Utilizing the SEER Registry E. Bartlett,* B. Zeldow, H. Wachtel, R.E. Roses, D.L. Fraker, P. Gimotty, G.C. Karakousis. *University of Pennsylvania, Philadelphia, PA.*

Introduction: Angiosarcomas represent a rare subtype of soft tissue sarcomas that have been associated with an aggressive behavior and poor prognosis. Given their low incidence, we hypothesized they contributed little to the formulation of the AJCC staging system. We thus sought to identify other factors that could improve risk stratification in a contemporary cohort of patients with angiosarcoma. Methods: Angiosarcomas (ICD-O=9120) were identified from the Surveillance Epidemiology and End Results (SEER) tumor registry (2004-2009). Tumors arising in the central nervous system were excluded. Univariate and multivariate logistic regression were used to identify factors associated with 2-yr disease-specific survival (DSS). Kaplan-Meier curves were generated. Results: 287 patients with angiosarcoma were included in the study. The majority of tumors arose on the trunk (58%), followed by extremity (28%), and visceral sites (15%). The median age at diagnosis was 65 years, and the median DSS was 17 months. 46% of tumors were >5cm, 76% were intermediate/high grade, 7% had nodal involvement, and 35% had metastases at presentation. Age≥70 (2-yr DSS=19% vs. 43%), size>5cm (2-yr DSS=20% vs. 65%), intermediate/high grade (2-yr DSS=37%) vs. 63%), and present metastases (2-yr DSS=10% vs. 56%) were each significantly associated with decreased DSS (each p<0.05), but nodal metastases (2-yr DSS=27% vs. 37%, p=0.58) was not. In a multivariate analysis including only patients with complete data (n=113), age≥70 (OR=5.9, 95% CI=2.0-17.3), size>5cm (OR=7.8, 95% CI=2.9-21.2), and metastases (OR=4.5, 95% CI=1.3-15.7) remained significantly associated with 2-yr DSS. The 2-yr DSS was 76% (95% CI=65%-87%) for age<70 and ≤5cm compared to 52% (95% CI=37%-67%) for age<70 and >5cm, 47% (95% CI=31%-63%) for age≥70 but ≤5cm, 20% (95% CI=7%-33%) for age≥70 and >5cm, and 14% (95% CI=7%-21%) for those with metastases. Figure 1. Conclusion:

Age, size, and metastatic presentation were found to be important prognostic factors for the risk stratification of patients with angiosarcoma. Neither grade nor nodal status were associated with 2-yr DSS in this aggressive histologic subtype.

Figure 1. Survival of Patients with Angiosarcoma by Prognostic Factors



P299

Neoadjuvant Radiation does not Increase Morbidity following Resection of Retroperitoneal Sarcoma D.P. Nussbaum,* P.J. Speicher, A.M. Ganapathi, J.E. Keenan, D.G. Kirsch, D.S. Tyler, D.G. Blazer III. Department of Surgery, Duke University Medical Center, Durham, NC.

Introduction: Neoadjuvant radiation therapy (XRT) has several theoretical benefits in the treatment of retroperitoneal sarcoma (RPS), but widespread use has not been adopted, in part secondary to concerns about treatment toxicity and perioperative morbidity. There are limited data regarding its effect on short-term postoperative outcomes, most of which come from small, single-institution series. Methods: The 2005-2011 NSOIP participant user files were queried for patients undergoing resection of RPS. Subjects were stratified by the use of neoadjuvant XRT. Perioperative variables and outcomes were compared between groups. Groups were then propensity matched using a 2:1 nearest-neighbor algorithm and multivariable logistic regression was performed to assess neoadjuvant XRT as a predictor of outcomes. Results: A total of 786 patients underwent resection of RPS. Neoadjuvant XRT was administered to 72 patients (9.2%). Patients who received neoadjuvant XRT were slightly younger (56.5 vs. 61.5 years, p<0.01), but otherwise the groups were similar with regard to demographics and preexisting comorbidities. After propensity matching, all baseline characteristics between groups were highly similar. Although there was no difference in the rate of contiguous organ resection (61.1 vs. 63.9%, p=0.80) or intraoperative radiation therapy (1.4 vs. 1.1%, p=0.58), median operative time was longer in the neoadjuvant XRT group (278 vs. 219 min, p<0.01). There were no differences in mortality (2.8 vs. 3.1%, p=0.99), major complications (29.2 vs. 25.2%, p=0.55), overall complications (36.1 vs.33.2%, p=0.71), early reoperation (5.6 vs. 7.4%, p=0.81), or length of stay (7 vs. 7 days, p=0.56). Following further adjustment with multivariable logistic regression, we confirmed that there were no differences in 30-day mortality or postoperative morbidity (Figure 1) between patients who did and did not receive neoadjuvant XRT. Conclusions: Neoadjuvant XRT may contribute to increased operative time, but does not appear to increase shortterm morbidity or mortality following resection of RPS. Continued investigation is needed to better define the role for neoadjuvant XRT in the management of RPS.

Figure 1. Adjusted odds of postoperative morbidity and mortality for neoadjuvant XRT



P300

Extremity Sarcoma: An Epidemiologic Study of the Use of Adjuvant Radiotherapy in High-risk Patients S.D. Kachare,* N.A. Vohra, E.E. Zervos, J.H. Wong, T.L. Fitzgerald. *East Carolina University, Brody School of Medicine, Greenville, NC.*

Introduction: Landmark clinical trials on the use of radiotherapy for highrisk sarcomas ushered in the era of limb preservation. Further studies assessing the timing of radiotherapy established the superiority of neoadjuvant regimens in long-term functional outcomes. In order to determine clinical integration of these data we analyzed a national cancer registry. Methods: All patients undergoing limb preserving surgery for stage IIa, IIb and III extremity soft tissue sarcomas from 1988-2010 were identified in the SEER tumor registry. Results: A total of 6,574 patients were identified. The median was age of 58y (range <1-105y). A majority patients were male (53%), white (83%), underwent radiotherapy (66%), had lower extremity tumors (73%), and were stage III (46%). The most common histologic subtype (WHO) was fibrohistiocytic (27%) followed by sarcoma NOS (17.5%), liposarcoma (16.9%), leiomyosarcoma (11.6%), myo/fibromyoblastic (9.4%), other (6.9%), synovial (6.4%), and nerve sheath (4.0%). On univariate analysis location, stage, and histologic subtype were associated with a greater likelihood of undergoing radiotherapy, yet gender, race, age and year of diagnosis were not. On logistic regression significant association with radiotherapy persisted for stage (IIa OR 1, IIb OR 1.26, and III OR 2.74) and histologic subtype. For those treated with radiotherapy, a neoadjuvant approach was associated with African American race (p=0.002), younger age (p=0.005), lower extremity location (p=0.007), stage III tumors (p<0.0001), histologic subtype (p<0.0001), and more recent year of treatment (<0.0001). On logistic regression age (p<0.0001), year of diagnosis (1.04, p=0.0005), stage (p<0.0001), race (other OR 1, white OR 1.24, AA OR 1.58), and histologic subtype remained significantly associated with neoadjuvant treatment. In 1988 8% of those receiving radiotherapy had neoadjuvant compared to 33% in 2010. Conclusions: A substantial number of patients with high-risk extremity sarcomas fail to receive recommended radiotherapy which has changed little over the last 22 years. However, there has been a steady increase in the use of a neoadjuvant approach in those treated.

P301

Accuracy of Percutaneous Biopsy for Retroperitoneal Liposarcoma N. Ikoma,² W.W. Tseng,¹ K. Torres,¹ K.K. Hunt,¹ J.N. Cormier,¹ N. Somaiah,¹ B. Feig.^{1*} 1. University of Texas MD Anderson Cancer Center, Houston, TX; 2. University of Texas health science Center at Houston, Houston, TX.

Introduction: Liposarcoma is the most common histologic subtype of retroperitoneal soft tissue sarcoma. Surgery is the primary treatment, but neoad-juvant therapy (chemotherapy and/or radiotherapy) may be considered in cases of dedifferentiated liposarcoma (DDLS) due to the increased risk of recurrence. Therefore, subtype-specific diagnosis of retroperitoneal liposarcoma is vital for appropriate treatment planning. Methods: We retrospectively reviewed the

medical records of patients registered in our retroperitoneal liposarcoma database. Pathology reports from the operative resection and preoperative biopsy were compared, and the accuracy of the subtype-specific preoperative biopsy assessed. Results: We extracted the records of 120 patients who underwent 137 preoperative biopsies followed by operative resections between 1993 and 2013. Pathological examination following final operative resection revealed 74 cases of well-differentiated liposarcoma (WDLS) and 63 of DDLS. The overall diagnostic accuracy of percutaneous biopsy for identifying liposarcoma subtype was 63.5% (87/137; 83.8% [62/74] for WDLS and 39.7% [25/63] for DDLS, p < 0.01; Table 1). Among 63 DDLS patients, 19 (31%) were diagnosed as WDLS by preoperative biopsy; 56% (14/25) of patients who were correctly diagnosed as DDLS by preoperative biopsy received neoadjuvant therapy; only 21% (8/38) of patients who were not diagnosed as DDLS underwent neoadjuvant therapy (p < 0.01). Among the 74 WDLS patients, 62 patients were correctly diagnosed as WDLS, 7 (11%) received neoadjuvant treatment. Of 5 patients who were incorrectly diagnosed as DDLS by preoperative biopsy, 4 (80%) underwent neoadjuvant therapy (p < 0.01). Conclusion: The accuracy of percutaneous biopsy in the diagnosis of DDLS is extremely low (39.7%). It is important that this low sensitivity of percutaneous biopsy to detect DDLS is taken into account when developing treatment strategies for patients with retroperitoneal liposarcoma. Lack of pathological confirmation of DDLS by percutaneous biopsy should not rule out the potential use of neoadjuvant therapy when other clinical and radiographic findings are suggestive of dedifferentiation.

Sensitivity and specificity of percutaneous biopsy for retroperitoneal dedifferentiated liposarcoma

	Final E	Diagnosis	
Biopsy result	DDLS	WDLS	Total
DDLS	25	5	30
Other	38	69	107
Total	63	74	137

DDLS: dedifferentiated liposarcoma

TDEO: Non amoronitatoa npo	ouroonno
Sensitivity	: 39.7%
Specificity	: 93.2%
False positive rate : 6.8%	
False negative rate : 60.3%	
Positive predictive value	: 69.6%
Negative predictive value	: 64.5%

P303

Predictors of Residual Disease following Unplanned Excision of Unsuspected Soft Tissue Sarcomas R.J. Canter,* C. Lee, Y. Nakache, C. Li, D. Shah, J. Katz, R.D. Boutin, R. Steffner, A.M. Monjazeb. UC Davis, Sacramento, CA.

Introduction: Although unplanned excision of soft tissue sarcomas (STS) is a potential quality of care issue, not all patients will harbor residual disease at re-excision. We sought to determine predictors of residual disease. Methods: We identified 264 patients between January 2008 and July 2012 from a prospectively-maintained academic database with a diagnosis of primary STS of all anatomic sites. Patients with fibromatosis were excluded. 72 patients (32%) were referred after an initial unplanned excision. We evaluated predictors of residual STS following repeat resection, sensitivity/specificity of interval MRI to predict residual STS, and predictors of oncologic outcome. Univariable and multivariable logistic regression was used as appropriate. Results: Mean age was 52, 62% were male, and 70% of tumors were located on the extremity. 34 patients (47%) had the primary tumor excised in fragments at unplanned excision. 54 patients (76%) underwent repeat excision, and 42 (72%) were found to harbor residual STS. Univariable analysis identified only fragmented excision as a significant predictor of residual STS (OR 4.3, 95% CI 1.08 - 15.09, P=0.04), but on multivariable analysis, no variables were significantly associated with residual STS. With a median follow-up of 29 months, multivariable analysis identified final margin, and not fragmented excision, as a significant predictor of local recurrence. If interval MRIs which showed "non-specific enhancement" were considered negative, the sensitivity and specificity of MRI for predicting residual STS were 67% (95% CI 49 - 81%) and 86% (95% CI 57 - 98%), respectively. Conclusion: Approximately 1/3 of STS patients are referred to an academic center after an initial unplanned excision. 72% of patients undergoing repeat excision are found to harbor residual
STS. Although fragmented excision appears to be the most reliable predictor of residual STS, further studies are needed to confirm these results.

P304

Prognostic Factors for Retroperitoneal Sarcomas: Appraisal of the AJCC Staging System T. Tran, M. Qadan,* B.C. Visser, J.A. Norton, G. Poultsides. *Surgery, Stanford University, Stanford, CA*.

Background The prognostic value of the current staging scheme is limited for retroperitoneal sarcomas (RS). The aim of this study was to identify prognostic factors that may influence survival in RS. Methods The SEER registry was queried to identify patients diagnosed with RS. Kaplan Meier analysis was performed to estimate cancer-specific survival. Multivariate survival analysis using Cox's regression model was performed to identify prognostic factors for survival in RS, adjusting for age, histology, tumor size, lymph node evaluation, radiation therapy, extent of disease (EOD), and tumor grade. Results A total of 2,537 RS cases were identified between 1988-2010. Most common histologic subtypes were liposarcoma (LPS) (56.2%), leiomyosarcoma (LMS) (29.4%), and malignant fibrous histiocytoma (MFH) (9.2%). LPS was associated with longer 5-year survival rates compared to LMS and MFH; 72% vs. 50.8% vs. 37.6%, respectively (p<0.001). With respect to tumor size, LPS tumors greater than 20cm were associated with worse survival compared to smaller tumors (p=0.026), LMS tumors less than 10cm were associated with longer survival (p=0.003), and MFH tumors less than 15cm were associated with improved 5-year survival (p=0.017). Lymph node evaluation did not affect survival in RS. With the exception of MFH, EOD was associated with a significant effect on 5-year survival in RS (p<0.001). Well-differentiated LMS and LPS tumors were associated with longer 5-year survival compared to poorly differentiated tumors. Tumor grade did not affect survival in MFH. Conversely, only MFH was associated with a significant effect on survival with radiation therapy (p=0.002). On multivariate analysis, strong predictors of survival for LMS and LPS were tumor grade, tumor size, and EOD. Predictors of survival in MFH included EOD and radiation therapy. Conclusion Histology, tumor size, and EOD are important global prognostic factors for survival in patients with RS. Lymph node evaluation did not influence survival. Given the variable behavior of histologic subtypes and prognostic predictors within each category, incorporating histology when staging RS may improve our ability to prognosticate survival.



P305

Multivisceral Resections for Gastrointestinal Stromal Tumors: Are the Risks Justifiable? D. Abramowitz, J. Racz,* S.S. Brar, M. Jimenez, A. Azin, E. Atenafu, T. Jackson, A. Okrainec, F. Quereshy. *Surgical Oncology, University of Toronto, Toronto, ON, Canada.*

Objectives: Surgical resection of gastrointestinal stromal tumours (GISTs) remains the cornerstone of treatment for non-metastatic disease. Multivisceral resection (MVR) for locally advanced tumours is often required to achieve negative margins. The purpose of this study was to review the peri-operative and long-term oncologic outcomes for patients who required MVR versus single organ resection (SOR) for GISTs. Methods: All patients who underwent surgical resection for GISTs from 2001 to 2011 at a large, tertiary cancer cen-

ter were identified. Short-term and peri-operative outcomes, disease-free survival (DFS) and overall survival (OS) were analyzed. Patient outcomes were evaluated using the Fisher's exact test for categorical variables and the Student's t-test for continuous variables. Survival rates were analyzed using the Kaplan-Meier's product-limit method. Results: Of the 110 patients who underwent surgical resection for GISTs, 33 (30%) underwent MVR while 77 (70%) required SOR. Patients within the two study arms had similar demographic profiles. Tumors in the MVR group were significantly larger (14.98 cm vs. 8.27 cm, p=0.0424) and had a higher mitotic index (51.52%>5/50 vs. 16.88%, p<0.0001). The MVR group had a significantly longer OR duration (359 mins. vs. 195 mins., p=0.0021), higher operative blood loss (1148 mL vs. 309 mL, p=0.0111) and increased number of peri-operative complications (54.55% vs. 33.77%, p=0.0207). There was no significant difference in the final margin status between the two groups (R0 resection: SOR 92.2%, MVR 81.8%, p=0.13). While the 5-year DFS was significantly lower in the MVR group (52.7% vs. 82.8%, p=0.0092), there was no difference in 5-year OS between the two study arms (80.0% vs. 90.5%, p=0.2559). Discussion: Patients in the MVR group had tumours with more aggressive malignant behavior and a significantly higher rate of peri-operative complications. In spite of these factors, there was no difference in the 5-year OS between the two arms. These findings support the use of MVR in the appropriately selected patient. Further studies are necessary to fully define its clinical application.



Figure 1 – Two-year and five-year disease-free survival (DFS) and overall survival (OS) rates for patients who underwent multi-visceral versus single organ resection for gastrointestinal stromal tumors between 2001 and 2011 at a large, tertiary care cancer center.

P306

Use of Neoadjuvant Tyrosine-kinase Inhibitors can Aid in Resection of Gastrointestinal Stromal Tumors A. Cocieru, ¹ K.N. Shah, ¹* P.J. Speicher, ¹ D. Bischoff, ² D.S. Tyler, ¹ T. Pawlik, ² D.G. Blazer III. ¹ *1. Duke University Medical Center, Division of Surgical Oncology, Durham, NC; 2. Johns Hopkins University, Department of Surgery, Baltimore, MD.*

Background: The introduction of tyrosine-kinase inhibitors represents an important advance in the management of gastrointestinal stromal tumors (GIST), but the role of neoadjuvant tyrosine-kinase inhibitor therapy (NTKIT) in the surgical management of these tumors has not been well established. The goal of this study is to explore the ability of NTKIT to downstage GISTs and/or facilitate organ-sparing surgery. Methods: We performed a retrospective bi-institutional analysis of surgically treated GIST patients. Among all GIST patients operated between 2004-2011, we identified 47 patients who were treated preoperatively with NTKIT. Results: The median patient age was 58 years old, and median size of the largest tumor was 9.4 cm (range, 1-24 cm). Patients were symptomatic in 82.9% of cases, and the most common presenting symptoms were pain (44.7%), bleeding (27.7%), and obstruction (21.3%). Primary tumor location included 28 gastric (59.5 %), 13 rectal (27.7%), 3 duodenal (6.4%) and 3 (6.4 %) small bowel tumors. Preoperatively, localized disease was observed in 55.3%, locally advanced in 23.4 %, and metastatic GISTs in 21.3 %. The median duration of NTKIT was 8.5 months, and 89.5% of patients completed neoadjuvant therapy. The main indications for preoperative NTKIT were: large size/difficult location (63.8%), multivisceral involvement (14.8 %) or metastatic disease (21.3 %). Using RECIST criteria, 51.3 % of patients had partial response, 46% had stable disease and 2.5 % had progressive disease. The response to NKIT impacted surgical management in 34% by facilitating one of the following: 1) organ-sparing resection; 2) more limited multivisceral resections for locally advanced tumors; 3) minimally invasive approach to resection; 4) R0 resection in metastatic GIST. R0, R1 and R2 resection was achieved in 78.7%, 6.38 % and 13.2 % of cases respectively. A recurrence rate of 42.6% was observed with median follow up of 27.3 months. Median survival was 102.7 months. Conclusions: NTKIT results in radiographic and clinical response in a substantial number of patients with GISTs, allowing for less extensive and less invasive operations for some of these patients.

P307

Spindle Cell Tumors of the Colon and Rectum N. Ikoma,² Y. Chiang,¹ J.N. Cormier,¹ K. Torres,¹ K.K. Hunt,¹ Y. You,¹ B. Feig.^{1*} *1. Uni*versity of Texas MD Anderson Cancer Center, Houston, TX; 2. University of Texas at Houston, Houston, TX.

Introduction: Spindle cell tumors of the colon and rectum are rare, representing 0.1% of all tumors of the colon and rectum. While the treatment and outcome of patients with Gastrointestinal Stromal Tumors (GIST) are well documented, non- GIST tumors of the colon and rectum are poorly defined. Methods: 1062 histologically confirmed cases of spindle cell tumors of the colon and rectum (1998-2010) were identified from the National Cancer Database. Data collected included: site (colon vs. rectum), tissue of origin, sex, race, age, insurance status, adjuvant treatment, treatment type. Multifactorial survival analysis was performed using a Cox regression model; differences in overall survival (OS) were calculated using a Log-Rank test. Results: 654 (62%) tumors originated in the colon and more colon patients were over 75 compared to patients with rectal tumors (27% vs. 18%, p=0.002). Colon tumors were larger (49% vs. 38% >5cm p<0.001), more likely to be poorly differentiated (31% vs. 18%, p<0.001), and less likely to undergo a local surgical procedure (5% vs. 31%, p<0.001). OS was significantly better for rectal tumors (p<0.001). Risk of death was significantly lower for patients <50 (HR 0.38, 95%CI 0.21-0.70) and 50-64 compared with patients >75 (HR 0.55, 95%CI 0.35-0.86). Patients who underwent locoregional surgery had a risk reduction of death compared to patients that did not have any surgery (HR 2.34, 95%CI 1.51-3.64). For colon tumors, locoregional resection was associated with improved outcomes compared to no surgery (p=0.0005, HR 2.91) or local surgical resection (p= 0.05). Rectal tumors patients <50 (p=.009) and 50-64 (p=0.02) had a reduction in risk of death compared with those >75. In contrast to colon tumors, rectal tumors did not benefit from more extensive surgery (p=0.16). Conclusions: Non-GIST spindle cell tumors of the colon and rectum are a rare clinical entity. In this series, primary site of origin in the rectum was associated with a better survival. More extensive surgery did not confer a survival advantage for rectal tumors. It may be appropriate to spare ano/rectal function if a spindle cell tumor of the rectum can be completely removed with a more limited resection.

P308

A Prospective Multicenter Trial for Limb Sparing with Mild Hyperthermic Isolated Limb Perfusion with Low Dose TNF Alfa and Melphalan in the Treatment of Locally Advanced Soft Tissue Sarcoma of the Extremities H. Martinez Said,¹* A. Tavares,² P. Miranda,³ R. Padilla-Longoria,⁵ M. Cuellar-Hubbe,¹ V. Villavicencio-Valencia,¹ L. Dominguez-Parra,⁴ C. Parra-Torres,⁸ I. Cruz,⁷ F. Lopez-Sachi,⁶ I. Padilla Mota.⁹ 1. Skin Cancer & Soft Tissue Tumors, Instituto Nacional de Cancerologia, Mexico City, Distrito Federal, Mexico; 2. Hospital Regional de Alta Especialidad del bajio, Leon, Guanajuato, Mexico; 3. Centro Médico Nacional "20 de noviembre", Mexico, Distrito Federal, Mexico; 4. Hospital Regional de Alta Especialidad de la Península, Merida, Yucatan, Mexico; 5. Centro Medico ABC, Mexico City, Distrito Federal, Mexico; 6. Centro Médico Naval, Mexico City, Distrito Federal, Mexico; 7. Centro Estatal de Cancerologia, Campeche, Campeche, Mexico; 8. Hospital 10 de Octubre ISSSTE, Mexico City, Distrito Federal, Mexico; 9. Centro Oncologico Estatal, Toluca, Estado de Mexico, Mexico.

Introduction: Because there is no benefit of amputation for locally advanced soft tissue sarcoma of the extremities, limb-sparing surgery has become the gold standard. TNF based isolated limb perfusion (TNF-ILP) has been reported as high efficient treatment to achieve function-preserving surgery in patients candidates to amputation. Most of the experiences with this approach come from single centers of Europe. We report the first prospective multicenter trial in Latinamerica with this approach. Material and Methods: Prospective multicenter trial with analysis of 45 patients with locally advanced soft tissue sarcoma diagnosed histologically, who underwent to TNF-ILP, and the application of training program in Mexico. Results: 47 TNF-ILP were done in 45 patients (20 male - 25 female). Median of age was 44.6 years and median follow up of 14.8 months was reached. Most patients had stage III tumors (86.7%), lower extremity (73.3%), and femoral perfusion was the most common with 19 cases (42%). The major histology was synovial sarcoma and lyposarcoma. Four patients was perfunded with recurrent agressive fibromatosis with no other option than amputation. The global response rate was 77.8%, five patients with complete response included. The limb-sparing rate was 89.9%. The Overall survival for 12, 24 and 36 months was 78%, 58% y 49%, respectively. Conclusion: TNF-ILP is a high effective treatment, and can be done safe in major centers of Mexico.



Fig. 1 Overall Survival in patients with locally advanced soft tissue sarcoma treated with TNF based ILP.

Impact of the Peritoneal Surface Disease Severity Score in Patients with Sarcomatosis Undergoing Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy G. Salti,¹* S. Undevia.² 1. The University of Illinois at Chicago, Chicago, IL; 2. Edward Hospital, Naperville, IL.

Introduction: The Peritoneal Surface Disease Severity Score (PSDSS) staging was introduced as a basis of scoring patients into prognostic groups to improve selection of colorectal cancer patients with peritoneal metastases. It incorporates three categories comprising clinical symptoms, extent of carcinomatosis, and tumor histopathology. This study aims to determine the impact on survival of PSDSS in patients with peritoneal sarcomatosis (PS) undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: A retrospective review of patients with CRS and HIPEC for PS was performed to score patients. Survival was analyzed using the Kaplan-Meier method. Univariate and multivariate analyses were also performed. Overall survival (OS) and disease-free survival (DFS) were evaluated. Results: There were 16 patients with PS who underwent CRS plus HIPEC for PS form 3/2007-7/2013. Of these, 5 (31.3% were PSDSS stage I; 2 patients (12.5%) were PSDSS stage II; 2 patient (12.5%) were PSDSS stage III; and 7 patients (43.8%) were PSDSS stage IV. Median follow-up was 12 mo (4-75). Overall survival (OS) was 39 months. When stratified into two groups (PSDSS I/II vs. PSDSS III/IV), univariate analysis demonstrated PSDSS affecting OS (median not reached vs. 12 mo, p=0.033) and disease-free survival (median 38 mo vs. 8 mo, p=0.004). This impact on survival persisted by multivariate analysis. Conclusion: The PSDSS staging system developed for peritoneal metastases of colorectal does have prognostic impact in patients with PS undergoing CRS and HIPEC and may be utilized in selecting patients undergoing this aggressive treatment approach.

P310

Resection for Recurrent or Residual Retroperitoneal Sarcoma: Is It Worth It? T.D. Hamilton,¹* A.J. Cannell,¹ K. Minji,¹ C. Catton,² M.E. Blackstein,³ B.C. Dickson,⁴ R.A. Gladdy,¹ C.J. Swallow.¹ *1. Surgical Oncology, University of Toronto, Toronto, ON, Canada; 2. Radiation Oncology, University of Toronto, Toronto, ON, Canada; 3. Medical Oncology, University of Toronto, Toronto, ON, Canada; 4. Pathology, University of Toronto, ON, Canada.*

Introduction: Population-based data show that by 5yrs after resection of primary retroperitoneal sarcoma (RPS), over 50% of patients have recurred. Many patients are candidates for re-resection, but morbidity may be high and disease control is uncertain. A related entity is gross residual disease following incomplete primary resection. We reviewed our experience with both recurrent (RC) RPS and residual (RD) RPS, referred to our center for consideration of surgical management. Methods: Patients seen from 1996 through 2012 who had resection of primary RPS at outside institutions were identified from a prospective database. Survival curves were generated by the Kaplan-Meier method and compared by log rank analysis. Results: 45 patients referred with RC (33) or RD (12) disease comprise the study cohort. Median age was 61 (30-85). 69% had liposarcoma.. Prior to primary surgery, cross-sectional imaging (CT/MRI) had been obtained in 30/45 patients, 24 (73%) of those with RC and 6 (50%) of those with RD RPS; core biopsy had been obtained in 6 (18%) of RC and 2 (17%) of RD RPS patients. Of the 45 patients assessed, 15 were deemed inappropriate for resection due to distant metastases (7), multifocality (4), poor performance status (2) or technical unresectability (2); 7 received palliative chemo- and/or radio- therapy (XRT). The median overall survival (OS) in this group was 15mos, and the 5-yr OS was 29%. 30 patients were managed surgically with at least one reresection (range 1-3): 22 of the RC and 8 of the RD group. 23 of the 30 (77%) who had re-resection at our center received pre-op XRT and 5 also received post-op brachytherapy. One patient had pre-op chemotherapy. 30day peri-op mortality was 0 in the RC group, and 13% (1/8) in the RD group. In the 30 who had re-resection, median post-op follow-up was 42mos; median OS was 53mos. OS was worse in the RD vs. RC groups (41 vs. 77mos, see Figure, p=0.02). Median time to re-recurrence was 35mos and 49mos in the

RD and RC groups, respectively (p=ns). Conclusions: Durable disease control and prolonged survival can be achieved in selected patients with RC RPS. RD RPS after initial incomplete gross resection represents a challenging problem.



P311

Bowel Obstruction as a Predictor of Poor Survival in Patients Undergoing Cytoreductive Surgery (CS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) S. Singla,* P. Thirunavukarasu, R. Tuttle, J.A. Alosi, V. Francescutti, J. Skitzki. *Roswell Park Cancer Center, Buffalo, NY.*

Background: CS combined with HIPEC is a treatment option with potential curative intent for select patients with peritoneal carcinomatosis. Despite pre-operative optimization, patients presenting with bowel obstruction often perform worse than their non-obstructed cohorts. Methods: We performed a single institution retrospective review on 112 consecutive patients presenting with peritoneal carcinomatosis between January 2003 and November 2011. All patients who underwent CS and HIPEC were included in the analyses. These patients were divided into two groups; patients with bowel obstruction (BO) and patients without bowel obstruction (NBO). Results: There were 45 males and 67 females with a median age of 53 years (range, 16-79 years). For all patients, the most common site of origin was appendix (n=51, 45.5%), while the most common histology subtype was adenocarcinoma (n=65, 58%). In patients presenting with BO (n=8) at the time of CS/HIPEC, the most common site of origin was colon (n=4), followed by appendix (n=2), small bowel (n=1) and peritoneum (n=1). Three-fourths of these patients (n=6, 75%) were found to have adenocarcinoma on histology. Prior to CS/HIPEC, 4 patients (50%) had presented with bowel obstruction at the time of initial intervention. Further, while 5 (62.5%) patients with BO received pre-operative chemotherapy, 6 (75%) patients required more than one bowel resection during the operation. The median survival in the BO group was 7.7 (95% CI, 0-16.1) months as compared to 66 (95% CI, 40.7-92.4) months in patients with NBO (p<0.005). Conclusions: CS with HIPEC is prolongs survival in select patients with peritoneal carcinomatosis. However, in patients presenting with bowel obstruction the survival appears poor and CS/HIPEC may be considered as palliative in nature in this sub-group.

Survival Analysis



P312

The Accuracy of Predictive Models in the Evaluation of Recurrence Rates for Gastrointestinal Stromal Tumors J. Racz,* S.S. Brar, M. Jimenez, A. Azin, E. Atenafu, T. Jackson, A. Okrainec, F. Quereshy. Surgical Oncology, University of Toronto, Toronto, ON, Canada.

Objective: The incidence and outcome of gastrointestinal stromal tumors (GISTs) continues to evolve with improvements in detection, surgical technique, and adjuvant therapy. Treatment decisions are frequently guided by tumour characteristics related to malignant potential. The purpose of this study was to review the outcomes of patients undergoing surgical resection for GISTs, and to compare the observed with predicted recurrence rate based upon three validated risk stratification systems. Methods: All patients who underwent surgical resection for GISTs from 2001 to 2011 at a large, tertiary cancer center were identified. Demographic profile, clinicopathologic variables and recurrence rates were analyzed. Survival rates were evaluated using the Kaplan-Meier's product-limit method. Concordance indices were calculated for the three risk stratification systems. Results: 110 patients were included in the analysis (median age 59.2, range 28.3 - 92.1 years). Of these patients, 78 (70.9%) underwent surgical resection alone and 28 (25.5%) also received adjuvant therapy. The majority of patients had tumors that were rated very low (4.5%), low (32.7%) or intermediate (22.7%) with respect to malignant behavior. An R0 resection was achieved in 89.1% of patients. Observed 2-year and 5-year recurrence rates in our study were significantly lower than those predicted by the MSKCC nomogram (9.0% vs. 19.65% and 20.2% vs. 27.6%, respectively). The concordance index of the NIH-consensus classification was superior to both the modified NIH-consensus classification and the MSKCC nomogram (0.9216 vs. 0.9127 and 0.8075, respectively). Conclusions: The recurrence rates in our study were significantly lower than those predicted by the MSKCC nomogram. Of all the validated nomograms studied, the NIH-consensus classification was the most concordant with our observed recurrence rates. The relatively low recurrence rate observed in our study may be due to the quality of surgical resection. A novel predictive model that includes margin status may help stratify recurrence-risk for patients with GISTs. Further research is needed to validate this clinicopathologic tool.

P313

Why Go Wide? Outcomes of Marginal Oncologic Surgery in Atypical Neurofibroma and Low-grade MPNST N. Bernthal,^{1*} K. Jones,² A. Putnam,² D. Viskochil,² R. Randall.² *1. UCLA Medical Center, Santa Monica, CA; 2. Huntsman Cancer Institute, University of Utah, Primary Childrens Medical Center, Salt Lake City, UT.*

Intro: While malignant peripheral nerve sheath tumors (MPNST) are among the most aggressive soft tissue sarcomas and benign plexiform neurofibromas pose no metastatic threat, little is known about the natural history of the intermediate nerve sheath lesions: atypical neurofibroma and low-grade MPNST. The present investigation is the first dedicated to the clinical outcomes of atypical neurofibroma and low-grade MPNSTs exclusively. The study also reviews the impact of surgical margins on survival and local recurrence in these lesions. Methods: Retrospective review of 23 consecutive patients with surgically treated atypical neurofibroma (N=11) and low-grade MPNSTs (N=12) and more than one year follow-up at a pediatric hospital between 1998 and 2012. Clinical outcomes including patient survival, presence of metastatic disease, and local recurrence were reviewed. Histology was re-reviewed to confirm diagnosis and classify surgical margins. Results: Twelve patients with low-grade MPNST and 11 with atypical neurofibroma were identified. Median age at time of surgery was 14 years old (range 2-21) and 52% (12/23) of patients were female. Median follow-up was 47 months (range 14-198 months). Nineteen of 23 patients carried an underlying diagnosis of neurofibromatosis type 1 (NF1). Nineteen of 23 patients had positive margins on resection, with an additional three showing plexiform neurofibroma at the surgical margin. Six patients underwent re-resection - three immediately after surgery for "positive margins" and three distantly for painful recurrence (2 low-grade MPNST, 1 atypical neurofibroma). Zero patients died of metastatic MPNST. Discussion: This is the first study dedicated to clinical outcomes in low-grade MPNST and atypical neurofibroma exclusively. In a series in which 19 of 23 patients with intermediate nerve sheath tumors - 11 atypical neurofibromas and 8 low-grade MPNSTs - had frankly positive surgical margins treated with observation, none has died of metastatic MPNST. While further studies are needed, this suggests that wide surgical margins may not be necessary for intermediate nerve sheath tumors and may carry unnecessary surgical morbidity.

P314

Analysis of Factors Affecting Outcome in De-differentiated and Well-differentiated Retroperitoneal Liposarcomas M. Choi,* F. Amersi, B. Balzer, C. Forscher, A.W. Silberman. *Department of Sur*-

gery, Cedars-Sinai Medical Center, Los Angeles, CA.

Introduction: Retroperitoneal (RP) liposarcomas áre rare tumors with high local recurrence rates and poor survival. Surgical resection has been shown to improve outcomes. Our aim was to determine predictors of outcome following surgical resection of well differentiated (WDLS) vs de-differentiated (DDLS) liposarcomas. Methods: We performed a retrospective review of 65 patients who underwent surgical resection for a RP or pelvic WDLS or DDLS between 1987 and 2012. Clinical and pathological variables were used to create univariate and multivariate models for both survival and recurrence. Results: Of the 65 patients, 40 had WDLS and 25 had DDLS. Patients with WDLS were older than patients with DDLS (63 vs. 59.8, p=0.39). Median tumor size was 14.5 cm (range: 10-23 cm) in the WDLS vs. 17.5cm (range: 10.5-30 cm; p=0.63)) in the DDLS group. Patients in the DDLS had significantly more high-grade tumors (80% vs. 37.5%, p=0.002). Although multi-organ resection was more common in the DDLS group (64% vs. 43%, p=0.004), more patients with DDLS had positive margins compared to WDLS patients (76% vs. 32.5%; p=0.0009). Overall survival at 5 and 10 years for patients with WDLS was 64.6% and 53.3% whereas overall survival for DDLS was 57.5% and 30.7%, respectively. Median survival was 10 yrs vs. 6 yrs (p=0.71) for WDLS vs. DDLS, respectively. Median time to recurrence was 2.9 yrs vs. 2.3 yrs (p=0.62) for WDLS vs. DDLS, respectively. In a multivariate analysis, tumor grade was the only significant predictor of survival (p=0.01) in both groups. Resection of multiple (>1) organs did not affect survival regardless of margin status (p=0.053). Finally, tumor grade was the only significant predictor of recurrence on multi-variable analysis (p<0.001 for low/intermediate vs. high). Conclusion: Patients with DDLS have biological differences with larger, higher grade tumors requiring multi-organ resection. Although median time to recurrence was not statistically significant between both groups, higher grade was a significant predictor of mortality and recurrence. Our study suggests that DDLS should be treated with a more aggressive multi-modality approach.

Factors Associated with Improved Prognosis after Pulmonary Resection for Metastatic Sarcoma A. Perhavec, ^{1*} M. Sok, ² J. Zgajnar, ¹ M. Hocevar, ¹ N. Besic. ¹ *I. Institute of Oncology, Ljubljana, Slovenia; 2. University Clinical Center Ljubljana, Ljubljana, Slovenia.*

Introduction The lungs are the most common organ targeted by sarcoma and surgical resection remains the only treatment that could provide cure for such patients. The aim of this study was to evaluate factors that are assosiated with better disease free survival (DFS) and overall survival (OS) after pulmonary resection (PR) for metastatic sarcoma. Patients and methods Altogether 37 consecutive patients underwent PR at our institution with intention to treat lung metastases originating from sarcoma from January 2000 do December 2009. Clinicopathological data were retrospectively collected and prognostic factors assosiated with DFS and OS after the first PR were evaluated using univariate and multivariate analysis. Results Altogether 54 procedures were performed in 37 patients. The mean age of patients was 48 years, 15 were men and 22 women. In nine patients staged procedure was performed for bilateral disease, five patients had one operation and one patient had three operations for recurrent lung metastases. Of 54 procedures performed, 44 were metastasectomies, six lobectomies, one bilobectomy and three pulmectomies. The 5years DFS and OS were 19% and 35%, respectively. In univariate analysis factors assosiated with longer DFS were complete resection (R0) [p=0.025], unilateral disease [p=0.04], no extrapulmonary disease [p=0.001], and number of lung metastases (1-3) [p=0.004], while complete resection (R0) [p<0.001], no extrapulmonary disease [p=0.003] and no discrepancy between the number of lung metastases radiologicaly and histologicaly [p=0.046] were assosiated with longer overall survival. According to multivariate Cox regression model, only complete resection (R0) [HR 0.368, 95% CI 0.148-0.916, p=0.032 for DFS; HR 0.218, 95% CI 0.088-0.541, p=0.001 for OS] and no extrapulmonary disease [HR 0.154, 95% CI 0.054-0.445, p=0.001 for DFS; HR 0.309, 95% CI 0.120-0.799, p=0.015 for OS] were independent prognostic variables for both DFS and OS. Conclusion In our retrospective analysis of PR for metastatic soft tissue and osteogenic sarcoma, we found that only complete resection and no extrapulmonary disease were assosiated with better prognosis.

P316

Multimodality Management of Synovial Sarcoma: Review of Single Institutional Experience M. N M L,^{1*} S.S. Deo,¹ N.K. Shukla,¹

S. Bakhshi,² D. Sharma.³ I. Surgical Oncology, Dr BRAIRCH, All India Institute of Medical Sciences, New Delhi, Delhi, Delhi, India; 2. Medical Oncology, Dr BRAIRCH, All India Institute of Medical Sciences, New Dellhi, Delhi, Delhi, India; 3. Radiation Oncology, Dr BRAIRCH, All India Institute of Medical Sciences, New Dellhi, Delhi, Delhi, India.

Introduction: Soft tissue sarcomas(STS) constitute only 1% of all solid tumors. Synovial sarcomas(SS) constitute 5-10% of all sarcomas and categorized as high grade. There is paucity of literature pertaining to SS from developing countries. Methods: Study population was identified from a prospectively maintained STS database of the Surgical Oncology department at a tertiary cancer center. All patients with Histological diagnosis of SS were included for the analysis. Results: A total of 446 cases of STS were treated between 1995 and 2009 and 80 patients had pathologically proven SS. Median age at diagnosis was 33 years (13-65 years). There were 53 males (66.3%) and 27 females (33.8%). Most common site was proximal lower limb(thigh). Sixty patients presented with prior interventions mainly in the form of marginal excision. Sixty seven patients had tumors more than 5 cm in size and 27 had more than 10 cm size at presentation. Nine patients (11.3%) had palpable lymph node but only 4 showed pathological involvement. As per MSKCC staging 83% had stage III disease and metastasis at presentation was seen in 10 patients; all of them in lungs. Among the extremity sarcomas, 35 (43.8%) patients had limb salvage surgery and the remaining required amputations due to locally advanced disease. Overall 15% of patients required some sort of reconstruction and only 6 had margin positivity. Postoperatively 35 patients received adjuvant radiotherapy and 52 patients received adjuvant chemotherapy (Adriamycin and Ifosfamide). At a median follow up of 59 months, 34 patients (42.5%) had relapse of disease mainly in the lungs (n=27) and 10 patients had local recurrence. At last follow up, 44 patients were disease free, 14 were alive with disease and 22 patients had succumbed to disease with an overall 5 year survival of 52%. Conclusions: Synovial sarcoma is a rare tumor involving younger age group. Lack of awareness among patients and physicians in the developing countries leads to suboptimal surgical intervention and advanced stage at presentation resulting in low limb salvage rate. Despite multi-modality management systemic relapse, mainly in lung, result in a modest 5 year survival of 52%.

P317

Dermatofibrosarcoma Protuberans: An Institutional Experience of 77 Cases and Literature Review T.K. Arora,* T.C. Kostopoulos,

V. Riyaz, J.P. Neifeld. Virginia Commonwealth University, Richmond, VA.

INTRODUCTION: Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing soft tissue malignancy associated with a chromosomal translocation. Initial treatment options include wide local excision or Mohs micrographic surgery. Tumors are known to recur locally. Adjuvant options include radiotherapy and tyrosine kinase inhibitors (TKI). Current guidelines on surgical margins and recurrence rates vary. METHODS: A retrospective study was done of 77 patients with primary or recurrent DFSP treated between 1985-2012. Data was collected from clinical, operative and pathological reports. Clinico-pathological and treatment data were analyzed using the log rank test for univariate analysis. Local recurrence free survival (LRFS) was assessed by the Kaplan-Meier method. RESULTS: Of the 77 patients, 55% were female with a median age of 40. The fibrosarcomatous (FS) variant was present in 16%. The trunk was the most common site (43%). The majority of patients presented with symptoms (84%) and underwent a biopsy (88%). Prior surgery/trauma at the site of the DFSP was noted in 34% of patients. The median duration of the lesion prior to excision was 24 months. Overall, primary, and recurrent group 5 year LRFS was 87%, 85% and 80%, with a median follow up of 3.75 years. On univariate analysis, mitotic rate of >5/10HPF was unfavorable. Age, margin status, size, FS variant, taking fascia or more than fascia were not found to be significant prognostic factors. The median time to LR was 31 months for 7 patients (9%). Although 4 patients developed metastatic disease, no patient died of DFSP in the study period. Reconstructive closure was used in 36% and 74% were treated with surgery alone. Radiotherapy was given to 18 patients and was given more often when margins were positive or close. One patient was treated with a TKL CONCLUSION: The treatment of DFSP in the primary or recurrent setting is surgical excision. Without negative margins or when further surgical excision is not possible, adjuvant XRT is effective. High mitotic index is predictive of a worse RFS. The overall prognosis with complete excision is good.

P318

Does a Multidisciplinary Approach Improve Outcomes in Sacral Chordoma? M.E. Tsang,^{1*} A.J. Cannell,¹ C.J. Swallow,¹ P.W. Chung,² B.C. Dickson,³ A.M. Griffin,⁴ R.S. Bell,⁴ J.S. Wunder,⁴ P.C. Ferguson,⁴ R.A. Gladdy.¹ *1. Surgical Oncology, Mount Sinai Hospital, Department* of Surgery, University of Toronto, Toronto, ON, Canada; *2. Department* of Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada; *3. Department of Pathology, Mount Sinai Hospital, Toronto,* ON, Canada; *4. Orthopedic Oncology, Mount Sinai Hospital, Toronto,* ON, Canada.

INTRODUCTION: Chordomas are slow-growing notochord sarcomas traditionally treated with surgery alone. Complete resection may require removal of adjacent pelvic organs. Our centre has developed a multidisciplinary approach including pre-operative radiation with resection and reconstruction involving multiple surgical specialties. The goal of this study is to report the short- and long-term outcomes of this comprehensive approach METHODS: All patients with a histologically confirmed diagnosis of sacral chordoma from 1989 to 2012 were identified in our prospective database and a retrospective chart review was performed. Data were analyzed using SPSS. RESULTS: Thirtyone patients with a median age of 64.5 years were identified. Eight patients were unresectable or refused surgery; 23 patients were treated with curative intent, including radiotherapy in 78% (18; 15 pre- and 3 post-operatively). Median resected tumor size was 8.8 cm (4.5-15.8), which required sacrectomy at S2 or above in 76%. Median follow up was 60 months (5-261). Early in the series, the operative approach was from the retroperitoneum with the patient in decubitus position, followed by sacrectomy in prone (D+P group; n=6). This was modified to a combined anterior/posterior approach (A+P group), beginning in lithotomy and flipping to prone for sacrectomy (n=17). Median operative time was 594 min (495-820) in the D+P group and 837 min (315-1270) in the A+P group (p=0.1). Median intra-operative transfusions were 21 and 9 units of pRBCs, respectively (p=0.003). Rate of re-operation tended to be higher in the D+P group (75% vs 25%, p=0.06). Rates of image-guided percutaneous drain (25% D+P vs 19%) and administration of TPN (25% D+P vs 24%) were similar. Median length of stay (LOS) was 38.5 days for D+P (17-103) and 29 days (16-88) in the A+P group (p=0.7). Overall survival (OS) and local recurrence free survival (LRFS) at 5 yrs were 85% and 60% in the D+P group compared to 100% and 70% in the A+P group, respectively (OS p=0.24, LRFS p=0.42). CONCLUSIONS: Adjuvant radiation with multi-disciplinary abdomino-sacral resection of sacral chordoma resulted in excellent OS and LRFS, with acceptable peri-operative morbidity and LOS.

P319

A Comparison of Carboplatin with Paclitaxel and Cisplatinum with 5-fluorouracil in Definitive Chemoradiotherapy in Esophageal Cancer Patients J. Honing, J.K. Smit, K.T. Muijs, H.G. Burgerhof, J.T. Plukker,* J.C. Beukema, G.A. Hospers. *Surgical Oncology, Univer-*

sity Medical Center Groningen, Groningen, Groningen, Netherlands.

BACKGROUND: In esophageal cancer (EC) patients not eligible for surgery definitive chemoradiation (dCRT) with curative intent using cisplatinum with 5-fluorouracil (5-FU) is the standard regime. Nowadays carboplatin and paclitaxel are also often used. In this study we compared survival and toxicity rates between both regimens. METHODS: This multicentre study included 102 patients treated in five centres in the North Netherlands from 1996 till 2008. Forty-seven patients received cisplatinum / 5-FU and 55 patients carboplatin / paclitaxel. RESULTS: Overall survival (OS) was not different between the cisplatinum / 5-FU and carboplatin / paclitaxel group (P=0.879, Hazard Ratio [HR] 0.97 confidence interval [CI] 0.62-1.51), with a median survival of respectively 16.1 (CI 11.8-20.5) and 13.8 (CI 10.8-16.9) months. Median disease free survival (DFS) was comparable (P=0.760, HR 0.93 CI 0.60-1.45) between the cisplatinum / 5-FU group (11.1 months, CI 6.9-15.3) and the carboplatin / paclitaxel group (9.7 months, CI 5.1-14.4). Groups were comparable except clinical T-stage was higher in the carboplatin / paclitaxel group (P=0.008), but a high clinical T-stage (cT4) was not related to OS and DFS in a univariate analysis (P=0.250 and P=0.201). A higher percentage of patients completed the carboplatin / paclitaxel regimen (82% compared to 57%, P=0.01). Hematological and non-hematological toxicity (≥ grade 3) was significantly lower in the carboplatin / paclitaxel group (4% and 18%) than in the cisplatinum / 5-FU (19% and 38%, P=0.001). CONCLUSIONS: In this study we show comparable outcome, in terms of DFS and OS for carboplatin / paclitaxel compared to cisplatinum / 5-FU as dCRT treatment in EC patients. Toxicity rates were lower in the carboplatin / paclitaxel group together with a higher treatment compliance. Carboplatin / paclitaxel as an alternative treatment for cisplatinum / 5-FU is a good candidate regimen for further evaluation.

P320

A Comparative Analysis of the Efficacy of Surgical and Non-surgical Modalities for Nodal Staging in Potentially Resectable Nonsmall Cell Lung Cancer P. Shoor,^{1*} D. Hillman,² R.S. Chamberlain.¹ 1. Surgery, Saint Barnabas Medical Center, Livingston, NJ; 2. Saint George's University, True Blue, Grenada.

There have been an increasing number of studies comparing the use of computed tomography, positron emission tomography, or a combination of these imaging modalities for suspected non-small cell lung carcinoma (NSCLC). Additional studies have also being completed comparing minimally invasive diagnostic methods such as endoscopic ultrasound-fine needle aspiration (EUS-FNA) and endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) to mediastinoscopy (MS) for staging NSCLC. Accurate staging of NSCLC is essential for correct clinical management and to avoid unnecessary surgical procedures. This review examines all published reports on the efficacy of imaging, minimally invasive methods and surgical methods for staging NSCLC. A comprehensive search of PubMed and Google Scholar was performed looking at the use of CT, PET, EUS-FNA, EBUS-TBNA, and MS in the staging of NSCLC. Keywords searched included PET/CT, EBUS,

EUS, mediastinoscopy and NSCLC. 38 studies involving 6,869 patients were included. Criteria for inclusion were N>20, publication date after 1995, NSCLC only, and sufficient data to permit calculation of the sensitivity and specificity. Thirty eight distinct studies reported data on various techniques for staging NSCLC. 14 studies (N=2,177) compared CT and PET, demonstrating a sensitivity (Sn) and specificity (Sp) of 27-75%, 34-98% and 25-100%, 76-98% respectively. 5 studies (N=1,280) reported that CT/PET was superior, with a Sn and Sp of 47-94% and 60-92% respectively. 17 studies involving 1,873 patients reported on the efficacy of minimally invasive staging showing that EBUS-TBNA and EUS-FNA were more sensitive than MS, and that EBUS-TBNA was more specific than MS. Overall, minimally invasive staging methods were equivalent to MS, but more accurate that PET/CT. PET/CT staging of NSCLC has a higher Sn and Sp than each study performed alone and a negative PET/CT may avoid unnecessary surgical intervention. Minimally invasive procedures (EUS-FNA/EBUS-TBNA) are equivalent to MS for identifying mediastinal metastases and may effectively replace MS in NSCLC staging in the near future.

Technique	Author, Year	N	Sn (%)	Sp (%)	PPV (%)	NPV (%)	Accuracy (%)	Range of Sn, Sp (%		
				СТ						
	Turkmen et al, 2007	59	66	34	68	43	58	1		
	Kelly et al, 2004	90	46	86	43	87	78]		
	Yasuda et al, 2008	80	27	81	25	82	71]		
	Okamoto et al, 2002	37	75	83	60	91	81	27.75.		
	Dunagan et al, 2001	72	50	87	56	84		34.93		
	Kamiyoshihara et al, 2001	546	33	90	46	84		34.33		
	Osada et al, 2001	335	56	93	77	83				
	Pieterman et al, 2000	102	75	66	50	85				
	Takamochi et al, 2000	401	30	82	30	83				
	RANGE	1722	27-75	34-93	25-77	43-91	58-81			
				PET	Sec. 1					
	Dunagan et al, 2001	81	52	88	61	84	91]		
	Farrell et al, 2000	84	100	92	40	100	86			
Non-	Liewald et al, 2000	78	93	78	69	95		1		
Invasive	Pieterman et al, 2000	102	91	86	74	95	87			
	Roberts et al, 2000	100	88	91	75	96		25-100.76-98		
	Poncelot et al, 2001	64	67	85	43	94	82			
	Turkmen et al, 2007	59	79	76	86	76	78			
	Kelly et al, 2004	90	62	98	89	92	91			
	Cerfolio et al, 2004	129	53	82	22	94	94			
	Yasuda et al, 2008	80	25	90	40	82	77			
	RANGE	867	25-100	76-98	22-89	76-100	77-94			
			P	ET and CT						
	Hwangbo et al, 2009	117	70	60	38	85	62	1		
	Ohnishi et al, 2011	110	47	88	67	76	74	47-94,		
	Cerfolio et al, 2004	129	94	89	43	99	90			
	Lee et al, 2007	765	93	86	22	99	87	00-92		
	Bille et al, 2009	159	59	92	74	82	83	1		
	RANGE	1280	47-94	60-92	38-74	76-99	62-90	1		
				EUS-FNA						
	Szlubowski et al, 2010	120	50	99	93	88				
	Ohnishi et al, 2011	110	49	100	100	78		1		
	Wallace et al. 2008	138	69	100	100	88		49-100, 88-100		
	Wiersema et al. 2001	33	100	88	96	100	98			
	Fritscher-Ravens et al, 2000	25	96	100	100	90	97			
	Wallace et al, 2001	107	87	100	100	68				
	Yasuda et al, 2008	80	56	100	100	90	91			
	RANGE	503	49-100	88-100	93-100	78-100	91-98			
			EE	US-TBNA						
al al an attac	Yasufuku et al. 2011									
vinimaliy	Hwangbo et al. 2009	117	90	100	100	97	97			
Invasive	Szlubowski et al. 2010	120	46	99	93	87		1		
	Ohnishi et al. 2011	110	64	100	100	84				
	Wallace et al. 2008	138	69	100	100	88	-	1		
	Hwantbo et al. 2010	143	84	100	100	93		46-92,		
	Yasuda et al. 2008	80	56	100	100	90	91	92-100		
	Okamoto et al. 2002	37	67	92	67	92	88	1		
	Juhn et al. 2012	151	92	99	84	67	94	1		
	Ernst et al. 2008	120	87	100	100	78	91	1		
	Herth et al. 2008	91	89	100		99		1		
	Swarski et al. 2007	300	96	100	-		96	1		
	RANGE	1560	46-92	92-100	67-100	67-99	88-97	1		
			Med	liastinosco	ew.					
	Vasufuku et al. 2011	153	79	100	100	90	68	1		
	Ernst et al. 2008	120	68	100	100	59	78	1		
	Gilart et al. 2000	106	33	100	100	62	1	1		
	Poncelot et al. 2001	64	33	01	37	89	82	1		
	Contaies,Stawinksi 2003	202	45	88	64	77	74	33-85.		
	a second s	494	1.00	100	100	91	97	88,100		
Surgical	Gdeedo et al. 1997	100	1 78	1 1000				88-100		
Surgical	Gdeedo et al, 1997 Ebner et al, 1990	100	78	100	100	82	93			
Surgical	Gdeedo et al, 1997 Ebner et al, 1999 Hammourf et al, 1999	100	78 81 85	100	100	82	93			
Surgical	Gdeedo et al, 1997 Ebner et al, 1999 Hammoud et al, 1999 De Levn et al, 1996	100 116 1,369	78 81 85 76	100 100 100	100	82 92 87	93			
Surgical	Gdeedo et al, 1997 Ebner et al, 1999 Hammoud et al, 1999 De Leyn et al, 1996 Aaby et al, 1995	100 116 1,369 500 57	78 81 85 76 84	100 100 100	100 100 100	82 92 87 89	93			

Table 1. A comparison of the sensitivity, specificity, PPV, NPV, and accuracy of CT, PET, PET, CT, EUS-FNA, EBUS-TBNA, and mediastinoscopy in the identification of mediastinal metatatase in patients with suspected NSCLC.

Abtreviations: PPV = Positive predictive value; NPV = Negative predicative value; CI = Computed tomography; PEI = Positron emission tomography; EUS-FNA = Endoscopic ultrasound-fine needle biopsy; EBUS-TBNA = Endosronchial ultrasound-ransbronchial needle aspiration; NSCLC = Non-small cell lung carcinoma, Sn = Sensitivity; Sp = Specificity

P321

Actual 5-year Survival after Neoadjuvant Chemotherapy and Resection for Esophageal Adenocarcinoma S. Yeluri,* P. Jose, A. Saha, O. Rotimi, S.L. Dexter, H. Sue-Ling, A.I. Sarela. Upper GI Surgery, St. James's University Hospital, Leeds, United Kingdom.

INTRODUCTION: In the UK, potentially curable oesophageal adenocarcinoma is treated with neo-adjuvant chemotherapy (NC) and radical surgery. We compared the pathological characteristics of actual 5 year survivors and non-survivors, following such treatment, in order to identify prognostic

markers for long survival. METHODS: A database of 356 oesophagectomies [adenocarcinoma, 236(66%); squamous cell carcinoma, 66(19%); other cancers, 54(15%); NC, 226(63%)] performed by 3 surgeons between January 2001 and Sept 2012 was used. All patients with adenocarcinoma, NC and a minimum interval of 5 years following surgery were identified. TNM version 7 was used. Circumferential resection margin (CRM) was considered positive if tumour cells were present within 1 mm of the margin. RESULTS: There were 102 patients (81 men, 79%), with median age 61 years (range, 37-69). 97 patients had an Ivor Lewis operation, 4 had laparoscopically assisted trans-hiatal resection and 1 had a 3-incision procedure: there was one post-operative mortality, with median retrieval of 34 nodes (range, 10-82). 41 (40%) patients were alive at 5 years after surgery; median survival, 90 months (range, 60-144). The remaining 61 patients had median survival of 19 months (range, 3-58). Differences in T and N characteristics between the two groups are shown in table. As compared to non-survivors, 5-year survivors had significantly lower incidence of ypT3/T4 disease [49(81%) vs. 23(56%), p=0.002], node-positive disease [52 (87%) vs. 17(42%), p<0.001], CRM positive status [38(67%) vs. 14(35%), p=0.002].,vascular invasion [50(91%) vs. 17(46%), p<0.001] and lymphatic invasion [33(100%) vs. 13(54%), p<0.001] respectively. Tumour differentiation (p=0.13) was not significantly different in the two groups. On multivariate analyses, ypN1 status (p=0.02, HR=2.34, 95%CI: 1.14, 4.81) and vascular invasion (p=0.006, HR=3.76, 95% CI:1.45, 9.75) independently predicted for long term survival. CONCLUSIONS: 40% of patients with locally advanced oesophageal adenocarcinoma actually survive for at least 5 years following NC and surgery. Achieving a node negative status remains a major predictor of long term survival

Survival		ypT stage				ypN stage			
	TO	T1	T2	T3	T4	NO	N1	N2	N3
≥60 months	2(5)	4(10)	12(29)	21(51)	2(5)	23(58)	11(28)	5(12)	1(2)
<60 months	1(2)	4(7)	6(10)	47(78)	2(3)	8(13)	12(20)	16(27)	24(40)

Number (%)

P322

Impact of Pre-treatment Imaging on Survival of Esophagectomy after Induction Therapy for Esophageal Cancer: Who Should be Given the Benefit of Doubt? L. Erhunmwunsee,* B.R. Englum, T.A. D'Amico, M.W. Onaitis, M.F. Berry. *Duke, Durham, NC.*

Purpose: The benefit of esophagectomy for patients with locally advanced esophageal cancer and possible distant metastatic disease present on initial imaging that is no longer seen after chemoradiation treatment (CRT) is unclear. We examined survival of patients with this clinical scenario who are given "the benefit of doubt" and undergo resection. Methods: A prospective database of patients who underwent esophagectomy after CRT between 2003 and 2009 was queried. A multivariable logistic regression model was developed to predict the impact of preoperative and post-therapy staging characteristics on survival. Survival of patients with and without possible metastatic disease on initial imaging was compared with the log-rank test. Results: During the study period, 70 (32%) of 220 patients who underwent CRT followed by esophagectomy had possible metastatic disease on initial CT or PET imaging. Of the 63 patients who had PET evidence of suspicious metastatic disease, 23 (37%) had possible disease in the lung, 11 (18%) in the liver, 4 (6%) in the pleura and 24 (39%) in other locations. Mean follow-up was 24 months for all patients and 37 months for surviving patients. Overall, survival of patients with and without possible metastatic disease on initial imaging was not significantly different (p=0.4). However, pretreatment PET evidence of a liver lesion (p=.003, OR 3.2, CI 1.5-6.8) significantly predicted worse survival in multivariable analysis, and patients with PET positive liver findings had worse survival compared to all other patients (Figure). In addition none of 10 patients with pathologic metastatic disease at resection, which also predicted significantly worse survival (p=.01, OR 3.1 CI 1.3-7.4), lived longer than 2.5 years. Conclusions: Patients with possible liver metastases on pre-treatment PET and patients with unexpected metastatic disease found at the time of surgery do not benefit from resection. However, patients with pre-treatment imaging that shows possible metastatic disease in sites other than the liver still have reasonable long-term survival after resection.

Kaplan-Meier survival curve for esophageal cancer in patients with and withou suspicion for metastatic disease by CT/PET imaging



P323

Micro-RNAs Up-regulated in Oligometastatic Pulmonary Metastases Decrease Adhesion and Integrin Expression in vitro

A. Uppal,^{1*} S.C. Wightman,¹ S. Ganai,² T.E. Darga,¹ N.N. Khodarev,¹ M.C. Posner,¹ M. Ferguson,¹ R.R. Weichselbaum.¹ *1. General Surgery, University of Chicago, Chicago, IL; 2. Southern Illinois University, Springfield, IL.*

Introduction: Patients may develop tumors that produce only a few metastases over the course of years (oligo-metastatic tumors), or develop multiple metastases in a short time (poly-metastatic tumors). We identified micro-RNAs (miRNAs) increased in lung metastases of oligo-metastatic patients relative poly-metastatic patients. These miRNAs may play a role in determining metastasis number and rate of progression by reducing cell adhesion through suppression of integrins involved in binding to extracellular matrix. These findings may help identify means for controlling metastatic spread. Methods: miRNAs up-regulated in oligo-metastatic pulmonary metastasectomy samples were analyzed with the Diana mirPath pathway prediction algorithm. The TargetScan and Diana-microT algorithms identified eight miRNAs with multiple predicted integrin targets involved in cell adhesion. Matrigel adhesion assays and qPCR quantification of miRNA and target mRNA levels were performed on MDA-MB-435 cells transiently transfected with an miRNA mimic or a negative control. Results: We identified Integrins $\alpha 2$, $\alpha 4$, αV , $\beta 1$, $\beta 3$, and β8 as cell adhesion molecules that are potential targets of eight differentially regulated micro-RNAs identified from patient samples. Four of the eight micro-RNAs (mir-135a, -369, -544 and -655) decreased cell adhesion by 31%, 72%, 37%, and 29% vs. negative control (all p<0.01). These 4 miRNAs decreased expression of integrin α4 mRNA by 20-60% (all p<0.05), integrin αV mRNA by 25-50% (all p<0.05) and integrin β8 mRNA by 30-60% (all p<0.05) compared to a negative control. Integrin $\alpha 2$, $\beta 1$, and $\beta 3$ mRNA levels were not significantly decreased. Conclusions: Individual miRNAs over-expressed in clinical samples of oligo-metastases are able to suppress cell adhesion and multiple integrin mRNAs in vitro. Suppression of integrins by these miRNAs may be partially responsible for decreased adhesion. Over-expression of these miR-NAs or suppression of their targets may play a role in novel metastasis prevention therapies.

P324

Post-neoadjuvant Treatment Staging with PET and EUS is not Necessary in the Management of Resectable Esophageal Adenocarcinoma (EAC) B.L. Broussard,* S. Reddy, D. Partain, C.M. Contreras, M. Heslin, T. Wang. Surgery, University of Alabama at Birmingham, Birmingham, AL.

Introduction: EAC is a devastating diagnosis with poor long-term survival. Most patients are treated with neoadjuvant chemoradiation. Modalities used to diagnose, stage, and re-stage EAC have been studied without clear evidence of a superior protocol. Positron emission topography (PET) and endoscopic ultrasound (EUS) are common diagnostic/staging tools. In the present study, we wished to determine whether PET and/or EUS were predictive of tumor response and long-term survival. Methods: We reviewed all patients with the diagnosis code for esophageal cancer in the University of Alabama at Birmingham University Hospital tumor registry from 2000-2010 who underwent surgery following staging PET scans and EUS. Survival data was calculated using Kaplan-Meier analysis. Results: 402 patients were treated for EAC at our institution from 2000-2010. 100 patients underwent attempted therapeutic resection after staging PET and EUS. 32 patients were found to have no cancer on final pathology. Patients with complete pathological response had better long-term survival than patients with residual disease (median survival 33.5 months vs. 16.6 months, 5-year survival 44.0% vs. 23.3%, P=0.026). EUS did not correlate to final pathology in regards to T-stage (R²= 0.091, 33% accuracy) or N-stage (sensitivity 30%, specificity 85%, positive predictive value 47%, negative predictive value 28%, accuracy 67%). Change in avidity on PET scan was also unable to predict final pathological diagnosis (change in SUVmax 50.6% complete responders vs. 46.6% non-responders, P=0.65). The absolute avidity on PET scan did not differ between the two groups (mean, complete responders 4.89 SUV vs. incomplete responders 5.30 SUV, P=0.55). Conclusions: Patients with complete pathological response after neoadjuvant therapy for EAC have better long term outcomes than those with residual cancer. Neither PET scan nor EUS was predictive of response following neoadjuvant therapy. We recommend abandoning PET and EUS for evaluating loco-regional response after therapy and advocate that all appropriate patients undergo resection for curative intent.

P325

Actual 5-year Survival after Eesophagectomy for Squamous Cell Carcinoma following Neoadjuvant Chemotherapy P. Jose, S. Yeluri,* A. Saha, O. Rotimi, S.L. Dexter, H. Sue-Ling, A.I. Sarela. Upper GI Surgery, St. James's University Hospital, Leeds, United Kingdom.

INTRODUCTION: We compared the pathological characteristics of actual 5 year survivors and non-survivors, following neo-adjuvant chemotherapy and radical surgery for squamous cell carcinoma (SCC) of the oesophagus, in order to identify prognostic markers for long survival. METHODS: A database of 356 oesophagectomies [adenocarcinoma, 236(66%); squamous cell carcinoma, 66(19%); other cancers, 54(15%); neoadjuvant chemotherapy, 226(63%)] performed by 3 surgeons between January 2001 and Sept 2012 was used. All patients with SCC, neo-adjuvant chemotherapy and a minimum interval of 5 years following surgery were identified. TNM version 7 was used. Circumferential resection margin (CRM) was considered positive if tumour cells were present within 1 mm of the margin. RESULTS: There were 41 patients (20 men, 49%), with median age 61 years (range, 41-77).36 patients had an Ivor Lewis operation, and 5 had a 3-incision procedure; median retrieval of 34 nodes (range, 11-104). 22 (54%) patients were alive at 5 years after surgery; median survival, 83 months (range, 60-140). The remaining 19 patients had median survival of 14 months (range, 4-57). Differences in T and N characteristics between the two groups are shown in table below. As compared to nonsurvivors, 5-year survivors had significantly lower incidence of ypT3/T4 disease [17(90%) vs.11 (50%), p=0.009] and lympho-vascular invasion [14(78%) vs. 8(38%), p=0.013]. CRM positive status (p=0.07), node positive status (p=0.1), and tumour differentiation (p=0.85) were not statistically significant between the two groups. Node positive status (p=0.006) and T3/T4 stage (p=0.046) predicted for poor long term overall survival across the group of patients. CONCLUSIONS: T and N stage remain important determinants of long term survival after radical treatment for oesophageal SCC. Even after curative resection, overall survival in patients with adverse pathological variables is a sixth of the survival seen in patients with favourable pathological features.

Survival			ypT Stag	ge			ypN S	tage	
	TO	T1	T2	T3	T4	N0	N1	N2	N3
≥60 months	4(18)	5(23)	2(9)	11(50)	0	11(50)	5(23)	6(27)	0
<60 months	0	0	2(10)	14(74)	3(16)	5(26)	9(47)	3(16)	2(11)

number(%)

P326

Freedom from Recurrence after Induction Cisplatin/5-FU/RT versus Carboplatin/paclitaxel/RT in Patients with Esophageal Cancer A.A. Thomay,* S. Su, A.J. Freidant, K.J. Ruth, I.A. Astsaturov, B. Burtness, C.S. Denlinger, E. Dotan, M.J. Hall, J.E. Meyer, P.C. Shah, S.J. Cohen, W.J. Scott. Fox Chase Cancer Center, Philadelphia, PA.

Background: The optimal neoadjuvant treatment regimen for esophageal cancer has yet to be defined. Methods: We analyzed a prospective database of esophageal cancer patients treated with cisplatin/5-FU/RT (A) or carboplatin/paclitaxel/RT (B) then esophagectomy. Endpoints were pathologic response (pCR), recurrence, and overall survival. Covariates (age, gender, clinical stage, Charlson comorbidity index (CCI), and ECOG PS) were adjusted via propensity score weighting from logistic regression. Differences in survival curves were compared using weighted Kaplan Meier methods and Wilcoxon tests. Landmark analysis compared differences in outcomes at least six months after surgery. Results: From January 2008 to June 2013, 71 patients received induction RT (50.4 Gy), with 38 and 33 patients in groups A and B, respectively. Patient demographics were similar. Operative procedure, R0 resections, and operative complications did not differ (operative mortality 1/71, 1.4%; anastomotic leak rate 10% A vs. 9% B, p=1.0). Median follow-up was 18.2 and 9.1 months for groups A and B, respectively. There was no difference in overall survival (p=0.88) or total number of recurrences (11/38, 29% A vs. 10/33, 30% B). Landmark analysis revealed a difference in recurrence at least 6 months after surgery: time to recurrence was shorter in group B (median time to recurrence 31 mos A vs. 18 mos B, p=0.02). pCR was seen in 13/38 (34%) A and 9/33 (27%) B (p=0.53). In patients with pCR, there was a trend toward more recurrences in group B (2/13, 15% A v 4/9, 44% B, p=0.14). Conclusions: Six months after surgery patients receiving induction carboplatin/paclitaxel/RT had shorter time to recurrence compared to cisplatin/5-FU/RT. In those with pCR a trend towards increased distant recurrences was seen with carboplatin/paclitaxel/RT, which may have less systemic efficacy in esophageal cancer than cisplatin/5-FU/RT. This should be evaluated in larger series.



P327

Circular-stapled Esophagogastric Anastomoses and Need for Dilation in Patients Undergoing Minimally Invasive (MIS) Ivor Lewis Esophagectomy after Induction Chemoradiation for Esophageal Cancer A.A. Thomay,* S. Su, A.J. Freidant, D.M. Edmondson, P.C. Shah, W.J. Scott. *Fox Chase Cancer Center, Philadelphia, PA*.

Background: Concern exists that circular-stapled anastomoses are associated with a higher rate of stricture formation after MIS Ivor Lewis esophagectomy than either linear-stapled or hand-sewn techniques. Methods: Retrospective analysis identified 45 patients who received induction chemoradiation and MIS Ivor Lewis esophagectomy. Operations were performed by a single surgeon from October 2010 through July 2013. Analyzed variables included age, sex, race, comorbidity index, ECOG PS, nutritional status, intra-operative technique, complications, recurrence, and survival, Results; Mean age 63 years, 91% white, 82% male, 67% GE junction tumors, adenocarcinoma (91%), and 89% cstage IIB or above. 76% presented with dysphagia; 42% had associated weight loss (mean 12%). All 45 received induction chemotherapy (platinum based), with 41 patients receiving concomitant radiation (median 50.4 Gy, range 45-57.6 Gy). 98% had R0 resections with a mean of 26 LNs harvested. An EEA stapler was utilized for all anastomoses, the final 28 via transoral method. The majority of anastomoses were covered with omentum (82%). Pyloric injection of botulinum toxin was utilized for gastric emptying (91%). Median length of hospital stay was 11 days. Perioperative complication rate was 64% (Table 1). Pathologic complete response rate was 38%. Median follow-up was 11.8 months (range 2.2-32.8) and demonstrated 7 deaths (3 cancer related), 6 patients with distant recurrences and no local recurrences. 7 patients (15.6%) developed strictures requiring dilation. Conclusions: Minimally invasive Ivor Lewis esophagectomy after chemoradiation is safe, with acceptable morbidity and desirable oncologic outcomes. Using the circularstapled approach, the rate of anastomotic leak is low, while the rate of stricture requiring dilation is similar to that reported for linear-stapled and handsewn anastomoses.

Table 1 - 30-Day Morbidity and N	Nortality by Clavien Classification
----------------------------------	-------------------------------------

COMPLICATIONS	n (%)
MINOR - GRADE I	
Atelectasis (without bronch)	2 (4.4)
Ileus	1 (2.2)
Recurrent Nerve Palsy	2 (4.4)
Nausea / Emesis	2 (4.4)
MINOR - GRADE II	
Wound Infection	2 (4.4)
Tachyarrythmia	10 (22.2)
Pneumonia	4 (8.9)
Bacteremia	3 (6.7)
Hemorrhage	0 (0)
DVT	2 (4.4)
Chylothorax (without intervention)	1 (2.2)
MAJOR - GRADE III	
Atelectasis (bronch)	0 (0)
Anastomotic Leak	3 (6.7)
Pericardial Tamponade	1 (2.2)
Pneumothorax	2 (4.4)
MAJOR - GRADE IV	
Renal Failure	0 (0)
Myocardial Infarction	0 (0)
Ischemic Stroke	0 (0)
Respiratory Failure	1 (2.2)
MAJOR - GRADE V	
Death	0 (0)

P328

Implementation of a Tobacco Cessation Program in a Thoracic Surgical Oncology Clinic M. Steliga,* C.P. Barone, E.L. Boone, P.L. Franklin. *Thoracic Surgery, UAMS, Little Rock, AR.*

Many patients in a thoracic surgery oncology clinic smoke. Impaired wound healing and increased respiratory complications are linked to smoking, and long term survival may be impacted by cardiovascular disease, emphysema and metachronous tumors. Although quitting smoking has proven benefits, nicotine addiction is challenging to overcome, leading to a nihilistic view of cessation. Unaided cessation has a poor success rate (<5%), while a combination of physician recommendation, counseling by certified tobacco treatment specialists (TTS), individualized pharmacotherapy and follow up can improve cessation. A multidisciplinary team from thoracic surgery, nursing and respiratory therapy was assembled to provide multifaceted, evidencebased tobacco treatment in our thoracic oncology surgery clinic. After institutional board review approval, all patients were queried for tobacco use, and any patient actively smoking underwent brief intervention by the surgeon (who is a TTS) and referred for more in depth counseling to a dedicated in-clinic TTS. For convenience, the counseling was done in a private room adjacent to the clinic rooms. Demographic data, smoking data, drug/alcohol use and medication use were prospectively recorded. Follow up visits were in the hospital, upon return to clinic and/or by phone. Exhaled breath carbon monoxide confirmed initial active use and successful cessation. Over the initial seven months, 60 active smokers received brief intervention by the surgeon and referral to an in-clinic TTS counselor. Despite physician recommendation, the convenience, and the free service, 23/60 patients refused to meet the TTS counselor. Of the patients who agreed to meet with the TTS, consented to enroll in the program, and agreed to follow up contact (24/60), 17/24 (70.8%) quit and remained abstinent at last contact. Integrating TTS in a surgery oncology clinic can be done. For those who enroll and consent to follow up, our pilot data demonstrates excellent



short-term cessation. Ongoing enrollment, follow up, and expansion within

our institution will allow better understanding of tobacco cessation services

P329

The Impact of Surveillance after Lobectomy for Stage IA Non-small Cell Lung Cancer M.K. Mallipeddi,* W.R. Eltaraboulsi, A.R. Shoffner, I.A. Naqvi, T.A. D'Amico, M.W. Onaitis, M.F. Berry. Duke University Medical Center, Durham, NC.

OBJECTIVE: The purpose of this study was to determine reintervention rates that result from surveillance after lobectomy for stage IA non-small cell lung cancer (NSCLC). METHODS: The incidences of recurrent disease and metachronous primaries were determined for all patients who underwent lobectomy for stage IA NSCLC without induction or adjuvant therapy from 1996 to 2010 at a single institution and were followed for at least two years or until the development of new or recurrent disease. Disease free intervals and Kaplan-Meier survival curves were compared using Mann-Whitney and log-rank tests, respectively. RESULTS: Of 316 patients who met the inclusion criteria during the study period, 50 patients (16%) developed recurrent disease (15 local only, 35 distant) and 45 patients (14%) had new primaries. Surveillance with CT scan was performed on 260 patients, and found 18/50 recurrences (7 local, 11 distant) and 37/45 new primaries in asymptomatic patients. Surveillance with chest x-ray was performed on 53 patients and found 5 recurrences (3 local, 2 distant) and 2 new primaries in asymptomatic patients. In contrast, 26 recurrences (4 local, 22 distant) and 6 new primaries were discovered due to symptoms. Recurrence was incidentally found in one patient who had stopped pursuing follow up. On average, recurrent disease was found 22.1±18.8 months and new primaries were found 52.2±31.1 months after lobectomy (p<0.001). Repeat surgery alone was utilized in 58% (26/45) of new primaries but only 27% (4/15) of local recurrences. Chemotherapy or radiotherapy was administered to 68% (34/50) of patients with recurrent disease. Five-year survival after discovery of new primary disease was 50.8±9.6% and five-year survival after discovery of recurrent disease was 4.5±3.1% (p<0.0001, Figure). CONCLUSIONS: Surveillance after lobectomy for stage IA NSCLC frequently finds either recurrent or new primary disease. Most patients with recurrent disease can be treated but survival is poor. Most patients with new primary disease can undergo surgical resection with reasonable survival.



Unadjusted Kaplan-Meier survival curve for patients after discovery of new primary or recurrent disease.

Follow-up Imaging for Radiologically-detected Anastomotic Leakage after Oesophagectomy L. Stevens, G. Armstrong, M. Michel, A. Saha,* S. Yeluri, H. Sue-Ling, S.L. Dexter, A.I. Sarela. *St. James's University Hospital, Leeds, United Kingdom.*

Introduction The mainstay of management of late presenting or radiologically detected leaks after oesophagectomy in our unit is non-operative with water-soluble contrast swallow tests until the leak has healed. This study aimed to describe our experience with radiologically detected leaks. Methods From January 2008 to August 2013, 192 patients underwent oesophagectomy for oesophageal cancer. Standard practice within our unit is to perform a watersoluble contrast swallow test within a week after surgery. 10 patients had incomplete data and 7 patients did not have any post-operative imaging and were excluded. A radiological leak was defined as one only detected on post-operative imaging with no adverse clinical signs. Results Of 175 patients included in this study, there were 3 clinical leaks (1.7%) and 12 radiological leaks (6.7%). 74 patients had a sutured anastomosis (42%) and 120 patients had a stapled anastomosis. Median time between surgery and first swallow was 7 days (range, 4-22). Six patients had other imaging prior to first planned swallow; in all of these patients, computed tomography of the chest and abdomen with oral contrast was performed for clinical reasons (suspected intra-abdominal or thoracic sepsis) within 7 days of surgery. All radiological leaks healed with non-operative management comprising radiological drainage of any collections, total parenteral nutrition and a strict 'nil-by-mouth' policy; none required operative re-intervention. Of the 12 patients with radiologically-detected leaks, 2 had no further swallows. The remaining 10 patients received weekly swallow tests until the leak had healed. Only two patients' leaks had healed within 14 days with a further 4 patients healing within 28 days and 2 patients within 35 days. Conclusions Anastomotic leakage was demonstrated in 7% of patients by routine post-operative water-soluble contrast and none required operative re-intervention. Only two patients had healed within 14 days. These data suggest that routine post-operative swallow assessment is important to detect leakage and that further swallow tests should not be performed until at least 14 to 28 days after first imaging.

P331

Precise Early Detection of Lung Cancer and Immune Circuit O. Kshivets.* *surgery, Kaluga Cancer Center, Kaluga, Russian Federation.*

Objective: Significance of immune circuit in terms of early detection of lung cancer (LC) was investigated. Methods: In trial (1987-2013) consecutive cases after surgery, monitored 48 LC patients (LCP) (m=40, f=8; lobec-

tomies=48) with pathologic stage IA (tomor size=1.6±0.4 cm; squamous=21, adenocarcinoma=25, large cell=2; T1N0M0=48; G1=16, G2=21, G3=11, 5year survival=100%), 282 patients with lung non-malignant pathology (NMP) (m=188, f=94; pneumonectomies=5, lobectomies=179, segmentectomies=98; non-malignant tumors=100; abscess=112; tuberculoma=70) and 120 healthy donors (HD) (m=69, f=51) were reviewed. Variables selected for study were input levels of immunity blood parameters, sex, age, TNMG. Blood samples were evaluated for IgG, IgM, IgA, natural antibodies, circulating immune complexes. The percentage, absolute count and total population number (per human organism) of CD3, CD19, CD4, CD8, CD16, CD1, CDw26, monocytes, CD4+2H, CD8+VV, leukocytes, lymphocytes, polymorphonuclear and sticknuclear leukocytes were estimated. The laboratory blood studies also included input levels of NST (tests of oxygen dependent metabolism of neutrophils spontaneous and stimulated by Staphylococcus aureus or by Streptococcus pyogenes), index of stimulation of leukocytes by Staphylococcus aureus or Streptococcus pyogenes, index of thymus function, phagocytic number, phagocyte index, index of complete phagocytosis. Differences between groups were evaluated using discriminant analysis, clustering, nonlinear estimation, structural equation modeling, Monte Carlo, bootstrap simulation and neural networks computing. Results: It was revealed that early detection of LC from NMP and HD (n=402) significantly depended on: CD4+2H, CD8+VV, CD4, B, CD16, monocytes (P=0.017-0.000). Neural networks computing, genetic algorithm selection and bootstrap simulation revealed relationships of early detection of LC and monocytes (rank=1), CD4+2H (rank=2), CD19 (3), CD8+VV (4), CD4 (5), CD16 (6). Correct detection of early LCP was 100% by neural networks computing (error=0.000; area under ROC curve=1.0). Conclusion: Early detection of LC from NMP and HD significantly depended on immune cell circuit.

P332

MicroRNA-133a Regulates the mRNAs of Two Invadopodia-related Proteins, FSCN1 and MMP14, in Esophageal Cancer N. Akanuma,* I. Hoshino, Y. Akutsu, K. Murakami, Y. Isozaki, T. Maruyama, T. Toyozumi, H. Suito, N. Sekino, H. Matsubara. Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.

Background: FSCN1 and matrix metalloproteinase 14 (MMP14) are both invadopodia-related proteins. We herein elucidate the tumorigenicity of these proteins and identify novel therapeutic agents in esophageal squamous cell carcinoma (ESCC). Methods: FSCN1 and MMP14 were evaluated by immunohistochemistry (IHC) in 140 surgically resected ESCC specimens. The role of FSCN1 and MMP14 and the role of miR-133a were established using knockdown and transfection strategies in ESCC cells, respectively. The expressions of FSCN1, MMP14 and miR-133a were evaluated in 84 specimens. Results: Neither FSCN1 nor MMP14 was detected in the normal epithelium by IHC staining. Patients with positive FSCN1 staining showed significantly higher T and clinical stages and a higher rate of recurrence. Patients with positive MMP14 staining showed significantly higher T, N and clinical stages, a higher level of lymphatic invasion and vascular invasion and higher rates of recurrence. A multivariate analysis of the IHC findings revealed the expression of either of these proteins to be an independent poor prognostic factor. The co-expression of these proteins correlated with the worst overall survival (OS) rate out of all the examined factors. The knockdown of FSCN1 or MMP14 led to a significant decrease of the mRNA or protein and decrease in the proliferation and invasion of ESCC cells. However, the knockdown of FSCN1 did not lead to a decrease in MMP14 mRNA or protein. Similarly, the knockdown of MMP14 did not affect the expression of FSCN1 mRNA or protein. Transfection of a miR-133a mimic decreased the mRNA and protein levels of both FSCN1 and MMP14 and led to a significant decrease in proliferation and invasion. An RNA analysis in 84 specimens revealed a significant correlation between FSCN1 and MMP14 expressions, and significant inverse correlations between FSCN1 and miR-133a and between MMP14 and miR-133a. A significantly poorer OS was observed among patients with a lower miR-133a expression. Conclusions: The combined expression of FSCN1 and MMP14 is associated with a poor prognosis, and miR-133a, which regulates their mRNAs, can serve as a strong tumor suppressor of ESCC.



Is it Time to Abandon the 5cm Margin Rule during Resection of Distal Gastric Adenocarcinoma? A Multi-institution Study of the U.S. Gastric Cancer Collaborative M.H. Squires,^{1*} D.A. Kooby,¹ G. Poultsides,⁴ T. Pawlik,² S.M. Weber,³ C.R. Schmidt,⁵ K.I. Votanopoulos,⁶ R.C. Fields,⁷ A. Ejaz,² A.W. Acher,³ D.J. Worhunsky,⁴ N. Saunders,⁵ D.S. Swords,⁶ L.X. Jin,⁷ C. Cho,³ M. Bloomston,⁵ E. Winslow,³ M.C. Russell,¹ K. Cardona,¹ C.A. Staley,¹ S.K. Maithel.¹ *1. Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA; 2. The Johns Hopkins University School of Medicine, Baltimore, MD; 3. University of Wisconsin School of Medicine and Public Health, Madison, WI; 4. Stanford University Medical Center, Palo Alto, CA; 5. The Ohio State University Comprehensive Cancer Center - The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH; 6. Wake Forest University, Winston Salem, NC; 7. Washington University in St. Louis, St. Louis, MO.*

Background A proximal margin distance of 5cm is advocated for resection of gastric adenocarcinoma (GAC). We assessed the prognostic value of proximal margin (PM) distance and a positive PM on survival after resection of distal GAC. Methods All pts who had resection of GAC from 2000-2012 at 7 institutions of the U.S. Gastric Cancer Collaborative were included. Pts with positive distal margins or 30-day mortality were excluded. The prognostic value of PM distance (assessed in 0.5cm increments) and a positive PM on overall (OS) and recurrence-free survival (RFS) after resection of distal tumors (antrum/body) was assessed by Kaplan-Meier and multivariate (MV) regression. Results A total of 465 pts underwent resection of distal GAC. 435 had R0 resections; 30 pts had a positive PM (R1). 141 pts had Stage I and 324 pts had Stage II-III tumors. Median FU was 44mos. For R0 pts, mean PM distance was 5.3cm. Median OS of pts with a margin >5cm was 51mos. Median OS for pts with a PM distance >3.0cm (n=289) was also 51mos and was superior to a PM ≤3.0cm (n=146; 32mos, p=0.001). The prognostic value of margin distance was stage-specific. On MV analysis of Stage I, PM >3.0cm was associated with improved OS (HR 0.33; 95%CI: 0.14-0.78; p=0.01). In Stage II-III, PM >3.0cm was not associated with improved OS (Table); OS was dictated by T-stage and nodal involvement. Overall, an R1 proximal margin was associated with decreased OS compared to R0 (21 vs 44mos, p=0.01). However, an R1 proximal margin had no impact on OS in Stage II-III tumors (p=0.17). Margin distance or a positive PM was not associated with RFS, regardless of stage. **Conclusion** The prognostic value of the proximal margin distance and a negative proximal margin after resection of distal gastric cancer is stage-specific. In Stage I, a >3cm margin. In Stage II-III disease, neither the distance of the proximal margin inproved overall survival as a 5cm margin. In Stage II-III disease, neither the distance of the proximal margin nor a negative proximal margin impact survival, due to other adverse pathologic factors. This may affect intraoperative decisions regarding extent of resection.

Multivariate	Regression	Analysis	for	Overall	Survival,	Stratified	by
Tumor Stage	e						

	Stage I tumors (n=141)	Stage II-III tumors	(n=324)
Variable	HR (95%CI)	p-value	HR (95%CI)	p-value
ASA Class	2.06 (1.03-4.12)	0.04	1.19 (0.83-1.73)	0.36
Albumin <3.0	1.33 (0.20-8.68)	0.77	1.05 (0.62-1.77)	0.86
T Stage T1 T2 T3 T4	Ref 1.84 (0.47-7.24) 	0.38 	Ref 3.10 (0.69-13.99) 3.14 (0.74-13.21) 4.40 (1.04-18.61)	0.14 0.12 0.04
N Stage N0 N1 N2 N3a N3b	Ref 2.05 (0.54-7.77) 	0.29	Ref 1.09 (0.58-2.02) 1.19 (0.67-2.09) 1.82 (1.02-3.26) 2.27 (1.09-4.73)	0.79 0.56 0.04 0.03
Tumor Size >4cm	0.79 (0.25-2.52)	0.70	0.89 (0.60-1.33)	0.57
Perioperative Transfusion	2.59 (1.04-6.49)	0.04	1.09 (0.69-1.72)	0.71
Proximal Margin >3.0cm	0.33 (0.14-0.78)	0.01	0.88 (0.60-1.28)	0.50

P334

BCAR3 is Important for Peritoneal Dissemination in Pancreatic Cancer S.R. Cader,¹* E. Flate,¹Y. Heakal,¹R.A. Moffitt,¹P. Kuan,¹ J.M. Anderson,² M.A. Hollingsworth,² R. Miller,¹J. Yeh.¹ I. UNC, Chapel Hill, NC; 2. University of Nebraska Medical Center, Omaha, NE.

Introduction: Nearly all patients with pancreatic cancer die of metastatic disease. In order to improve patient survival, it is imperative to understand the molecular mechanisms underlying metastasis. BCAR3 (breast cancer antiestrogen resistance-3) has been previously shown to contribute to aggressive breast tumor phenotypes. Microarray analysis of normal pancreas, patient primary and metastatic tumors, suggested a role for BCAR3 in metastatic pancreatic cancer. Here we report a novel role for BCAR3 in pancreatic cancer. Methods: BCAR3 knockdown was accomplished using shRNA and transwell migration and invasion assays performed in pancreatic cancer cell lines. Tissue microarrays (TMA) were prepared from formalin-fixed paraffin-embedded tissue sections using a 2 mm punch. The arrays contained 270 samples with triplicate cores of normal, primary and metastatic tissue from 15 metastatic pancreatic cancer patients. Fluorescence immunohistochemistry (IHC) was performed using an antibody against BCAR3 and high resolution acquisition of fluorescently stained slides was performed in Spectrum (Aperio) and automated quantitative analysis (AQUA). Results: Microarray analysis of 54 normal pancreas, 195 tumor and 53 metastatic samples demonstrated that BCAR3 gene expression was significantly upregulated in metastatic tumors compared to either normal pancreas (p<0.0001) or primary tumors (p=0.0086). Resected patient tumors with high BCAR3 expression correlated with poor survival (p=0.005). Knockdown of BCAR3 significantly decreased the ability of cell lines (SW1990 and CFPAC) to migrate and invade (p=0.01). BCAR3 staining was cytoplasmic, with higher concentration in tumor epithelium compared to stroma (p<0.001). BCAR3 expression was significantly greater in peritoneal metastases compared to primary pancreatic tumors (p=0.036). Conclusion: BCAR3 is critical for pancreatic cancer cell line migration and invasion, and is associated with poorer survival in patients with resectable pancreatic cancer. BCAR3 also appears to be most important for peritoneal dissemination in patients, a common mode of spread in pancreatic cancer.

Combined Proteasome and MEK Inhibition Results in Enhanced Growth Inhibition of Patient-derived Pancreatic Ductal Adenocarcinoma T. Newhook,^{1*} J.M. Lindberg,¹ S.J. Adair,¹ A.J. Kim,¹ J. Parsons,² T. Bauer.¹ *1. University of Virginia, Department of Surgery, Charlottesville, VA; 2. University of Virginia, Department of Microbiology, Immunology, and Cancer Biology, Charlottesville, VA.*

Background: Survival for patients with pancreatic ductal adenocarcinoma (PDAC) remains dismal and more effective therapeutic strategies for these patients are needed. As mutations in the KRAS oncogene are important drivers of PDAC progression, rational therapeutic strategies for patients include targeting the RAS pathway. We hypothesized that MEK inhibition results in a unique dependence on a functioning proteasome and that combination treatment with MEK inhibitor plus proteasome inhibitor will result in enhanced growth inhibition in orthotopic patient-derived xenografts (PDX) from pancreatic cancer. Methods and Results: Gene expression profiling was performed on 15 early passage orthotopic PDX tumors and bioinformatic analysis revealed that expression of genes comprising components of the 26S proteasome were upregulated in tumors from patients with shorter survival (data not shown). Patient-derived KRAS-mutant (Tumor 608 and 366) and KRASwild type (Tumor 738) PDAC cell lines were treated with MEK1/2 inhibitor trametinib and escalating concentrations of the proteasome inhibitor bortezomib. In all three cell lines, trametinib inhibited cell proliferation and all tumor cell lines were sensitive to bortezomib exhibiting sub micromolar IC50s (Fig. 1A). To assess the in vivo consequences of proteasome inhibition, mice were engrafted with patient-derived tumors orthotopically and treated with control, trametinib, bortezomib, and combination therapy. Combination therapy with trametinib and bortezomib was more effective than either treatment alone (Fig. 1B) indicating that blocking RAS-MEK-ERK signaling potentiates the sensitivity of tumor cells to proteasome inhibition. Conclusions: Combination therapy with a proteasome inhibitor plus MEK inhibitor results in significant growth inhibition of patient-derived PDAC tumors. Our observations support the idea that inhibition of RAS signaling with FDA approved inhibitors of MEK1/2 reveals a window of therapeutic vulnerability, in that pancreatic cancer cells are more sensitive to inhibition of a functioning proteasome.



P336

Pancreatic Circulating Tumor Cells as a Diagnostic Adjunct in Pancreatic Cancer J.S. Ankeny,^{1*} S. Hou,² M. Song,² M.M. Rochefort,¹ M.D. Girgis,¹ W.H. Isacoff,³ H. Tseng,² J.S. Tomlinson.¹ *1. Department* of Surgery, University of California, Los Angeles, Los Angeles, CA; 2. Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA; 3. Department of Hematology & Oncology, University of California, Los Angeles, Los Angeles, CA.

Background: Circulating tumor cells (CTCs) may improve our ability to diagnose pancreatic ductal adenocarcinoma (PDAC), obtain pure molecular information uncontaminated by stromal cells, and accurately stage patients at the time of diagnosis. Therefore, we evaluated CTCs as an adjunctive diagnostic biomarker for PDAC. Methods: We performed a prospective analysis on 50 consecutive, pre-treatment patients with either suspicion for, or recent diagnosis of PDAC. Venous blood samples (2 mL) were evaluated for the presence and number of CTCs utilizing a novel microfluidic NanoVelcro "chip" enhanced by anti-EpCAM enrichment. CTCs were defined by size ($\geq 10 \, \mu m$) and by immunocytochemistry staining pattern (DAPI+/CK+/CD45-). Additionally, KRAS mutational status was assessed in 3 patients to confirm PDAC origin of CTCs. Results: Of the 50 patients, 32 had PDAC and 18 had nonmalignant pathology on tissue biopsy. CTCs were detected in 20 of 32 (62.5%) patients with PDAC, and in 1 of 18 (5.5%) patients with non-malignant pathology. CTC numbers were significantly higher in PDAC versus non-malignant patient groups (p < 0.001). Receiver operating characteristic (ROC) curve analysis determined optimal ability for CTCs to distinguish between PDAC and non-malignant disease with detection of \geq 1 CTC. At this cut-off, the specificity of CTCs for the diagnosis of PDAC was 94.4%, PPV 95.2%, and NPV 58.6%. The area under the ROC curve (AUROC) was 0.793 (95% CI = 0.671-0.916, p < 0.001), indicating overall ability for CTC detection to discriminate PDAC from non-malignant disease. Additionally, in patients with a diagnosis of PDAC, CTC number correlated with stage and patients with ≥ 2 CTCs were 11.6 times more likely to harbor systemic disease. Conclusions: In this study, CTCs were a useful adjunct for diagnosis of PDAC. Additionally, ≥ 2 CTCs strongly correlated with stage IV disease. Longer follow-up and addition of outcomes data is needed to firmly establish CTCs as a predictive biomarker in PDAC.



a) NanoVelcro "chip" capture of CTCs. b) A typical DAPI+, CK+, CD45- CTC adjacent to WBCs. c) Comparison of CTC enumeration in benign and malignant patients. d) Comparison of mean CTC counts as a function of disease stage.

P337

Primary Tumor in the Pancreas Potentiates the Formation of Liver Metastasis in a Murine Model of Pancreatic Cancer R. Panni,* D. Sanford, T. Nywening, B. Belt, P. Goedegebuure, D. DeNardo, D. Linehan. *Washington University in St. Louis, St louis, MO*.

Introduction: Pancreatic cancer (PC) is currently the fourth leading cause of death and the mortality rate approaches 100% due to early metastatic spread. Metastasis is a multistep process; the tumor cells acquire mesenchymal features. enter the circulation and extravasate into the parenchyma of distant organs, and develop macro metastasis. Our group and others have shown that PC induces changes at the cellular level in the liver long before the establishment of metastasis. Based on our preliminary experiments, we hypothesized that primary tumor in the pancreas primes the liver to augment implantation of metastatic tumor cells. Methods: In order to study the impact of primary tumor on systemic mechanisms that might facilitate metastatic progression, we implanted a mouse PC cell line, KCKO, orthotopically in the tail of the pancreas, in wild type (WT) mice. Ten days later, we compared changes in the liver by flow cytometry and RT-PCR and injected an mCherry+ luciferase expressing, murine PC cell line (Pan02) in the inferior pole of the spleen and performed hemi-splenectomy. Mice in both groups (N=10 per group) were imaged for bioluminescence after splenic injections on days 5, 10, 15 and 20 in order to detect metastasis. Results: Mice with primary tumor in the pancreas had a significant increase in monocyte and macrophage populations in the liver at day 6 after tumor implantation. RT-PCR was also conducted for the quantification of gene expression level, for genes associated with monocyte mobilization and changes in the microenvironment i.e. CCL2, CSF1, s100a4, s100a8, CXCL12, LOX, VEGFa (p<0.01)(Fig 1A). Our results showed that all mice with primary tumor acquired liver metastasis after splenic injection of Pan02 however, only 40% of mice without primary tumor developed liver metastasis (p=0.0016), by day 15 (Fig 1B&C). Conclusion: We demonstrate that primary tumor in the pancreas significantly increases the incidence and burden of liver metastasis in a murine model of PC. Our results suggest that PC primes the microenvironment in the liver, which plays a key role in implantation of tumor cells, and establishment of metastasis.



Functional BRM Promoter Polymorphisms, Pancreatic Adenocarcinoma Risk and Survival M. Segedi,¹* L. Anderson,² O. Espin-Garcia,¹ A. Borgida,¹ T. Bianco,¹ D. Cheng,¹ Z. Chen,¹ P. Devalben,¹ M. Brown,¹ R. Hung,¹ M. Cotterchio,² S. Gallinger,¹ W. Xu,¹ D. Reisman,³ G. Liu,¹ S.P. Cleary.¹ J. Princess Margaret Cancer Centre-University Health Network-Ontario Cancer Institute, University of Toronto, Toronto, ON, Canada; 2. Mount Sinai Hospital-Lunenfeld Research Institute, Toronto, ON, Canada; 3. University of Florida, Gainsville, FL.

Background: Variant alleles of two promoter polymorphisms in the BRM gene (BRM-741, BRM -1321), create MEF2D transcription binding sites that lead to epigenetic silencing of BRM, the key catalytic component of the SWI/SNF chromatin remodeling complex (PMID:23524580). BRM suppression can be reversed pharmacologically (PMID: 21478905). Our group and others have reported associations with lung, head & neck, and hepatocellular cancer risk (PMIDs: 21478907, 23322154, 23359823). We have also reported associations with lung and esophageal cancer prognosis (ASCO 2013; abstr 11057 & 4077). In this analysis, we assessed risk and survival associations with pancreatic cancer. Methods: A population-based case-control study was conducted in Ontario with 623 histologically-confirmed pancreatic adenocarcinoma cases and 1192 age/gender distribution-matched controls (PMID: 23908141). Survival of cases was obtained through the Ontario Cancer Registry. Logistic and Cox proportional hazard regression models were fitted, adjusting for relevant covariates. Results: Median age was 65 years; 52% were male; 53% had received a curative resection; Stage I (8%), II (55%), III (14%), IV (23%); 79% received chemotherapy; 83% had died. In the risk analysis, the adjusted odds ratios were 1.01 (95%CI:0.1-2.0) and 0.96 (95%CI:0.7-1.3) for the homozygous variants of BRM-741 and BRM-1321, respectively, when each was compared to wildtype; adjusted odds ratio of double-homozygotes was 1.11 (95%CI:0.80-1.53) when compared to the double-wildtype. In contrast for the survival analysis, the hazard ratios (adjusted for age, stage, receipt of curative surgery, receipt of chemotherapy, and packyears) were 2.19 (95%CI: 1.9-2.5) for BRM-741 and 1.94 (95%CI: 1.7-2.2) for BRM-1321, per each unit increase in variant alleles. Compared with the double-wildtype, the adjusted hazard ratio for carrying no, one, and two homozygous (double-homozygous) variants were 2.14 (95%CI:1.6-2.8), 4.17 (95%CI:3.0-5.7), and 8.03 (95%CI: 5.7-11.4), respectively. Conclusions: Two functional promoter BRM polymorphisms were not associated with pancreatic adenocarcinoma risk, but are strongly associated with survival.

Tumor-induced STAT3 Activation in Monocytic-Myeloid Derived Suppressor Cells Enhances Cancer Stem Cells in Human Pancreatic Cancer T. Nywening,* P. Roheena, D. Sanford, B. Belt, J. Mitchem, D. DeNardo, P. Goedegebuure, D. Linehan. Surgery, Washington University in St. Louis, Saint Louis, MO.

Introduction: Pancreatic cancer (PC) is associated with a dense, fibrotic stroma & infiltration of leukocytes that provide an immune privileged tumor microenvironment Aldehyde dehydrogenase-1 activity in PC identifies cancer stem cells (CSCs) that are responsible for tumor initiation and its activity has been correlated with poor overall prognosis in human PC. Myeloid cells have been shown to impact tumor stemness but the impact of tumor infiltrating monocytic myeloid derived suppressor cells (Mo-MDSC) on ALDH1 Bright CSCs and epithelial to mesenchymal transition (EMT) is not well understood. Methods: Mo-MDSC (Mouse: CD11b+/Gr1+/Ly6G-/Ly6Chi & Human: CD14+/ HLADR-/low) were isolated and co-cultured with mouse and human PC cell lines, respectively. Flow-cytometry, RT-PCR, western blotting and functional studies including invasion assays were performed to study the phenotypic and functional changes in the tumor cells after co-culture with Mo-MDSC. Results: Human PC promotes conversion of CD14+ monocytes to Mo-MDSC (Fig 1A). RT-PCR revealed significant upregulation of markers associated with EMT in tumor cells co-cultured with MDSC (Fig 1B). Invasion assays showed that PC cells co-cultured with Mo-MDSC were more invasive, confirming the EMT phenotype. Flow cytometry revealed that the ALDH1 Bright population increases in PC cell lines after co-culture with Mo-MDSC (Fig 1C) & results in increased spheroid formation. We further found that Mo-MDSC co-cultured with tumor cells upregulated pSTAT3. A STAT3 inhibitor diminished ALDH1 Bright CSC populations (Fig 1C) & function, confirming the importance of this pathway in Mo-MDSC dependant enhancement of tumor plasticity. Conclusion: Our data suggest that the PC tumor microenvironment transforms monocytes to Mo-MDSC by STAT3 activation which increase the frequency of ALDH1Bright CSCs and promote EMT. Therefore, targeting STAT3 activation may be an effective therapeutic strategy in combination with conventional chemotherapy in PC.



Clinical Significance in the Diagnosis Lymph Node Metastasis in Patients with Gastric Cancer by Intraoperative RT-PCR System with Multiple Markers S. Yanagita,* Y. Uenosono, T. Arigami, T. Hagihara, S. Ishigami, S. Natsugoe. Department of Digestive Surgery, Breast and Thyroid Surgery, Field of Oncology, Kagoshima University, Kagoshima, Kagoshima, Japan.

INTRODUCTION: The results of two multicenter trials for the clinical application of sentinel node (SN) navigation surgery (SNNS) in patients with gastric cancer in Japan pointed out that the sensitivity of intraoperative diagnosis of SN metastasis to be improved (sensitivity 48.8-79%) (J Clin Oncol. 2013, Gastric Cancer 2013). And the sensitivity of OSNA (one-step nucleic acid amplification) with CK19 as a single marker in diagnosis of lymph node metastasis was reported to be 83.3% (Gastric Cancer 2013). We investigated the clinical utility of intraoperative RT-PCR system with multiple markers. METH-ODS: 143 cases (cT1=122, cT2=21) were enrolled in this study. All patients received surgical resection with lymphadenectomy. A total of 1568 lymph nodes were harvested (cT1; n=1273, cT2; n=288). All dissected lymph nodes were divided into two pieces and one was submitted for hematoxylin and eosin (HE) staining and the other was submitted for intraoperative RT-PCR assay (total process time 40 minutes) with CK19 and CEA as markers. The sensitivity of RT-PCR was estimated based on the pathological diagnosis. RESULTS: 10.6% and 19% in patients with cT1 (n=13) and cT2 (n=4) were diagnosed as pN+ by HE staining, respectively. 34 lymph nodes in cT1 and 7 lymph nodes in cT2 were diagnosed as pN+ by HE staining. 1) Patients-based results, the sensitivity of RT-PCR with positivity in CK19 only and CEA only was 88.9% (cT1; 84%, cT2; 100%) and 83.3% (cT1; 84%, cT2; 80%), respectively. The sensitivity of RT-PCR with positivity in CK19 or CEA was 88.9% (cT1; 84%, cT2; 100%), respectively. 2) Lymph node-based results, the sensitivity of RT-PCR with positivity in CK19 only and CEA only was 78% (cT1; 73%, cT2; 100%) and 68.3% (cT1; 64%, cT2; 85%), respectively. The sensitivity of RT-PCR with positivity in CK19 or CEA was 80% (cT1; 76%, cT2; 100%), respectively. Conclusion: Intraoperative RT-PCR system improved the sensitivity in diagnosis of lymph node metastasis based on the pathological diagnosis and the sensitivity was better in diagnosis with multiple markers than with single marker.

P342

No Survival Benefit with Multimodality Adjuvant Therapy for Margin Negative T2N0 Gastric Adenocarcinoma with Optimal Lymphadenectomy H. In,^{1*} S. Sharpe,¹ M.S. Baker,² M.S. Talamonti,² M.C. Posner.¹ *1. Surgery, University of Chicago, Chicago, IL; 2. NorthShore University HealthSystems, Evanston, IL.*

Background The benefit of adjuvant therapy following resection of early stage, node-negative gastric adenocarcinoma following an R0 resection is unclear. Methods The National Cancer Data Base (NCDB) was used to identify patients with a T2N0 gastric adenocarcinoma who underwent an R0 resection. Patients treated with neoadjuvant therapy and those for whom lymph node count was unavailable were excluded from the analysis. Kaplan-Meier and Cox regression analyses were used to evaluate differences in overall survival among patients who received postoperative chemotherapy, chemoradiation or no further treatment, while adjusting for age, race, Charlson score, tumor size, grade, tumor location, type of surgery and whether ≥ 15 lymph nodes were examined. Results 8,039 patients underwent margin negative resection for T2N0 gastric cancer between 1985 and 2011. Eighty-six percent received no adjuvant therapy, 5.6% received chemotherapy only and 8.9% received chemoradiation. 72.5% had fewer than 15 nodes examined. With a median follow-up of 42.1 months, the 5-year overall survival was 53.2% for all patients, 64.5% for those who received adjuvant therapy and 51.4% for those who did not (p <0.0001). Multivariate Cox regression identified higher Charlson score. < 15 lymph nodes examined, higher tumor grade and tumor location in the gastric cardia as factors associated with significantly decreased overall survival. Among patients who had <15 lymph nodes examined, there was a 5-year overall survival benefit for adjuvant chemotherapy (HR=0.84, p=0.046) and adjuvant chemoradiotherapy (HR=0.77, p<0.001) over no additional therapy. However, for patients who had ≥ 15 nodes examined, neither adjuvant chemotherapy (p=0.315) nor adjuvant chemoradiotherapy (p=0.494) provided an overall survival benefit compared to resection alone. Conclusions Adequate lymph node dissection and staging is critical in directing optimal treatment of patients with early gastric cancer. Under-staging and suboptimal resection of regional lymph nodes may explain the benefit of adjuvant therapy after an R0 resection for patients with T2N0 gastric cancer.

Benefit of adjuvant therapy according to whether 15 nodes were examined (adjusted model)

	<15 no (n	des examined =5,832)	≥ 15 no (n	des examined =2,207)
	HR	p-value	HR	p-value
No adjuvant therapy (n=6,876)	ref		ref	
Chemotherapy (n=449)	0.84	0.046	0.86	0.315
Chemoradiation (n=714)	0.77	< 0.001	0.91	0.494

P343

Early Postoperative Intraperitoneal Chemotherapy (EPIC) after Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Carcinomatosis Results in Greater Morbidity G.H. Tan,* C. Chia, W. Ong, K. Soo, M. Teo. National Cancer Centre Singapore, Singapore, Singapore.

Introduction: Peritoneal carcinomatosis (PC) is increasingly being treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with or without early postoperative intraperitoneal chemotherapy (EPIC). Since January 2000, we have performed 140 CRS + HIPEC procedures. Prior to November 2012, all patients were administered EPIC for 5 days post CRS + HIPEC. Since then, we have ceased EPIC. We hypothesize that HIPEC with EPIC results in more postoperative complications, as compared to HIPEC alone. Methods: A prospective database of consecutive patients undergoing CRS + HIPEC in a single institution between January 2000 and July 2013 was reviewed. Patients included in the study were treated between January 2008 to July 2013, in order to eliminate learning curve bias. Out primary end point was postoperative complication rates. Results: 72 patients who underwent CRS + HIPEC for PC of ovarian, colorectal, appendiceal, mesothelioma and primary peritoneal origins were included in the study. 48 patients received EPIC after CRS + HIPEC, and 34 patients did not receive EPIC. HIPEC was with mitomycin C or cisplatin, and EPIC was with 5-FU or oxaliplatin, depending on the primary tumour. Overall, 29 of 72 patients (40%) suffered postoperative complications, however the rate of high-grade complications was significantly higher in the EPIC group (56% vs. 15%, p=0.014). Hospitalization duration was also significantly longer in the EPIC group (16 days vs. 12 days, p= 0.002). Conclusion: The use of EPIC after CRS + HIPEC for PC is associated with a significantly increased rate of highgrade complications, and results in longer hospitalization.

P344

Laparoscopic versus Open Gastrectomy for Gastric Adenocarcinoma in the West: A Case-control Study K.J. Kelly,* L. Selby, J. Chou, M. Capanu, K. Dukleska, M.F. Brennan, D.G. Coit, V.E. Strong. *Memorial Sloan-Kettering Cancer Center, New York, NY.*

Introduction: Laparoscopic (lap) resection is widely accepted for early, dis-tal gastric cancer, but remains controversial for locally-advanced and proximal tumors, which are more common in Western patients (pts). This study aimed to compare outcomes following lap versus open gastrectomy in West-ern pts with gastric adenocarcinoma. Methods: Ninety consecutive pts who underwent lap gastrectomy from Nov 2005 to April 2013 were compared with 90 pts who had open resection during the same time period. Pts were matched for age, stage, body mass index, and procedure (distal versus total gastrec-tomy). Endpoints were short and long term

perioperative outcomes. Results: Overall, 68 pts (38%) had locallyadvanced disease (stage II or III), and 54 (30%) had proximal tumors. Total gastrectomy was performed in 56 pts (31%). There was no difference in the use of neoadjuvant therapy between the groups (26% lap vs 36% open). In the lap group, operative time was longer (median 240 vs 165 minutes; p < 0.01), and blood loss was less (100 vs 150 mL; p < 0.01). There was no difference in number of lymph nodes retrieved (median 20 in both groups). Duration of epidural use was less in the lap group (3 vs 4 days; p = 0.02). Minor complications were less in the lap group in the early (27% vs 16%) and late (17% vs 7%) postoperative periods. There were no dif-ferences in major complications or 30-day mortality. Length of stay was less in the lap group (5 versus 7 days) but this was not statisticallysignificant. Adju-vant therapy was given to 40% of pts in the lap group vs 26% in the open (p = 0.01). Median follow-up for survivors was 18.8 months (31.1 for open, 11.0 for lap). There was no difference in RFS or DSS. In a subset analysis of 68 pts with stage II/III disease, lap resection was associated with a higher likelihood of receiving adjuvant therapy than open (82% versus 51%; p < 0.01). Con-clusions: Lap gastrectomy for gastric adenocarcinoma was associated with decreased blood loss, pain, and morbidity, and a greater likelihood of receiving adjuvant therapy compared to open. These data suggest that the lap approach is safe and effective for select pts with locally-advanced and proximal tumors.

Clinicopathologic Characteristics of Patients Undergoing Open vs Lap Gastrectomy for Gastric Adenocarcinoma

Variable	All (N = 180)	Open (N = 90)	Laparoscopic (N = 90)	P-value
*Age (years)	64 (20-87)	64 (26-86)	64 (20-87)	NS
**Female Gender	87 (48.3%)	35 (38.9%)	52 (57.8%)	0.01
BMI (kg/m2)	27.6 (16.1-43.7)	28.1 (16.1-39.6)	26.8 (18.6-43.7)	NS
Neoadjuvant Therapy	55 (30.6%)	32 (35.6%)	23 (25.6%)	0.11
Adjuvant Therapy	59 (32.8%)	23 (25.6%)	36 (40.0%)	0.01
Procedure				NS
Distal Gastrectomy	124 (68.9%)	62 (68.9%)	62 (68.9%)	
Total Gastrectomy	26 (31.1)	28 (31.1)	28 (31.1)	
Operation Time (minutes)	200 (62-478)	165 (62-478)	240 (109-445)	< 0.01
Blood Loss (mL)	100 (5-1500)	150 (5-1500)	100 (5-1500)	< 0.01
Epidural Duration (days)	3 (2-6)	4 (3-6)	3 (2-5)	0.02
Minor Complication				
Early (within 30 days)	38 (21%)	24 (27%)	14 (16%)	< 0.01
Late (31 days-6 months)	21 (12%)	15 (17%)	6(7%)	0.03
Major Complication				
Early (within 30 days)	23 (13%)	11 (13%)	12 (14%)	0.80
Late (31 days-6 months)	15 (8%)	5 (6%)	6(7%)	0.11
30-Day Mortality	1 (<1%)	0	1 (1%)	-
Lauren Diffuse Type	66 (37.9%)	35 (38.9%)	31 (36.9%)	0.84
Stage				NS
0/1	112 (62.3%)	55 (61.1%)	57 (63.4%)	
II / III	68 (37.7%)	35 (38.9%)	33 (36.6%)	
Lymph Nodes Removed	20 (10-54)	20 (12-46)	20 (10-54)	0.47

*Continuous variables expressed as median (range).

**Categorical variables expressed as N (%). BMI: Body Mass Index; NS: Not Significant.

P345

Ethnicity is the Strongest Predictor of Lymph Node Status in Patients with Early Gastric Cancer S. Fukuhara,^{1*} M.M. Montgomery,¹ M. Yabe,¹ S. Itagaki,² S.T. Brower,¹ M.S. Karpeh.¹ *1. Beth Israel Medical Center, New York, NY; 2. Mount Sinai Medical Center, New York, NY.*

INTRODUCTION: Ethnicity has long been suspected to affect survival in patients with gastric adenocarcinoma. However, the clinicohistopathological impact of ethnicity on early gastric cancer (EGC) is not known. This study aims to assess if ethnicity carries sufficient prognostic implication to influence current treatment strategies for EGC. METHODS: From 2000 to 2013, 1010 patients were registered in the Gastric Cancer Tumor Registry. Of these, 280 underwent gastrectomy performed by US surgeons and 102 patients (10.1% of all gastric cancer patients) had pathological confirmation of EGC by US pathologists. A retrospective analysis of pathological and clinical prognostic indicators was performed. RESULTS: The study population consisted of 37 (36%) Asians and 65 (64%) non-Asians (26 (26%) Caucasians, 25 (25%) Hispanics, 13 (13%) African-Americans, and one (1%) Pacific Islander). Of these, one (4.4%) Asian and 3 (9.3%) non-Asians with T1a lesions had lymph node metastasis (LNM) (p=0.479), while one (7.1%) Asian and 16 (48.9%) non-Asians with T1b lesions (p=0.007). Overall, 2 (5.4%) Asians and 19 (29.2%) non-Asians had LNM (p=0.004). The mean number of lymph nodes retrieved was 15.7 in Asians and 17.6 in non-Asians (p=0.473). Univariate analysis comparing the clinico-histopathological characteristics in each group did not reveal significant difference regarding histotype, size, grade, location, morphology, or lym-phovascular invasion, except for the LNM rate and mean body mass index (23.2 in Asian versus 26.6 in non-Asian,

p=0.0001). Multivariate analysis showed that age (OR, 0.901; 95% CI, 0.82-0.99; p=0.03), Asian ethnicity (OR, 0.0001; 95% CI, 0.0001-0.49; p=0.03), tumor size (OR, 2.24; CI, 1.13- 4.45; p=0.02), presence of lymphovascular invasion (OR, 31.1; CI, 1.24- 774; p=0.04) were significant predictors for LNM. CONCLUSIONS: This unique study demonstrated that Asian ethnicity in EGC is associated with a significantly decreased rate of LNM in comparison to non-Asians, despite similar histopathological characteristics of each group, suggesting that non-Asian ethnicity may be an independent predictor for LNM, possibly due to more aggressive tumor biology.

P346

Ca 19-9 Response to Neoadjuvant Therapy Predicts Outcome in Pancreatic Adenocarcinoma B.A. Boone,* J. Steve, M.S. Zenati, M.E. Hogg, A.H. Zureikat, H.J. Zeh. Surgery, University of Pittsburgh, Pittsburgh, PA.

Introduction: Baseline Ca 19-9 is a useful prognostic marker in pancreatic ductal adenocarcinoma (PDA), however only a limited number of studies have examined the significance of a change in Ca 19-9 following neoadjuvant therapy. Methods: All patients receiving neoadjuvant therapy for PDA from 7/2010-2/2013 were retrospectively reviewed. Patients with a normal pre-treatment Ca 19-9 (<33 U/mL) were excluded. Resection rate, R0 rate, need for venous resection and overall survival were correlated to Ca 19-9 response. Fischer exact test, Kaplan-Meier analysis and multivariate analysis were used to evaluate data. Results: 79 patients were eligible for study (22 patients with resectable disease, 40 borderline resectable (BR) and 17 with locally advanced disease (LA)). A variety of chemotherapies +/- radiation were utilized during the study period (56% chemotherapy alone, 44% chemoradiation). The overall R0 resection rate was 67% (82% resectable, 70% BR, 41% LA). 56 patients (71%) had a decrease in Ca 19-9 of >50% with neoadjuvant treatment. For all patients, there was a trend towards a Ca 19-9 response of > 50% predicting R0 resection (OR 2.5, p=0.077). In BR patients, Ca 19-9 response of > 50% predicted R0 resection (OR 4.2, p=0.05). In BR patients with an increase in Ca 19-9, 0 of 5 (0%) underwent R0 resection compared with 80% of the remaining cohort (p=0.001). The rate of complete pathologic response was 29% in patients who had a Ca 19-9 response of >90% versus 0% in the remaining patients (p<0.001). A Ca 19-9 response of >50% resulted in improved overall survival (28.0 vs. 11.1 months, p<0.0001, Figure 1). An increase in Ca 19-9 during treatment had an adverse effect on survival (10.2 vs. 28.0 months, p<0.0001). Ca 19-9 response of > 50% was an independent predictor of survival on multivariate analysis (p<0.0001, HR 0.26 [95% CI 0.13-0.55]). Conclusion: Ca 19-9 response to neoadjuvant therapy has prognostic value, predicting R0 resection rate and survival. This data supports the use of CA19-9 as a biomarker of response to neoadjuvant therapy. Incorporation of this easily obtainable biomarker into future clinical trials may facilitate more rapid evaluation of novel regimens.

Ca 19-9 Response to Neoadjuvant Treatment



Loss of 5-Lipoxygenase Reduces Pancreatic Neoplasia with Low and High Levels of Omega-6 Fatty Acids through a Pro-survival Mecha-nism L. Knab,¹* K. Ma,² L. Zhu,² L. Cai,² M. Heiferman,² A. Samiei,² J. Belotte,² J. Heiferman,² K. Adrian,² D. Bentrem,¹ P. Grippo.² 1.Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL; 2. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.

Introduction: High omega-6 (ω -6) diets yield elevated serum levels of arachidonic acid and are metabolized to leukotrienes by 5-lipoxygenase (5-LO), an enzyme that is upregulated in human pancreatic cancer. Diets rich in ω -6 fatty acids have been shown to increase proliferation in pancreatic cancer (PC) and neoplastic cells both in vitro and in vivo. This study aims to determine the effect of 5-LO deletion on pancreatic lesions in a mouse model, including mice fed high ω -6 diets, and in human pancreatic duct epithelial (HPDE) cells treated with fatty acids (FA) with and without the 5-LO activating protein (FLAP) inhibitor, MK-886. Methods: EL-Kras/5-LO null and wild type mice were sacrificed at age 6-9 months of age and evaluated for number of pancreatic lesions. Some mice were fed high fat diets with varying ω-3:ω-6 FA ratios: 1:125 (high ω-6), 2.5:1 (high ω-3), or 1:15 (control). In vitro, HPDE cells were treated for 48 hours either with FA alone or FA with MK-886. Cell lysates were analyzed for pAKT, a pro-survival marker, expression using Western blot analysis. Results: The EL-Kras/5LO-/- mice were found to have significantly fewer lesions compared to heterozygous and wild-type mice. Among the EL-Kras/5LO-/- mice, those fed a high ω-6 diet were found to have a significant increase in lesions compared to the group fed a high ω-3 diet. In vitro, HPDE cells treated with FA and MK-886 were found to have decreased levels of pAKT compared to those cells treated with FA alone. Conclusions: Complete loss of 5-LO in a preclinical setting led to reduced frequency of mutant Kras-induced pancreatic lesions, implying a similar response in developing neoplastic lesions in human pancreas. Furthermore, a high ω-6 diet resulted in increased pancreatic lesions compared to a high ω -3 diet in the presence of a 5-LO knockout, suggesting that 5-LO contributes to pancreatic tumorigenesis, though this is not solely responsible for lesion formation (Cox-2). Finally, human pancreatic ductal cells recapitulated in vivo findings and suggest that the effects of 5-LO may function through pAKT.

P348

Syndecan-1 Liposomes Specifically Target Pancreatic Adenocarcinoma C. Kimbrough,^{1*} M.E. Egger,¹ T. Dupre,² C. England,² K.M. McMasters,¹ L. McNally.² *1. Department of Surgery, University of Louisville, Louisville, KY; 2. Department of Medicine, University of Louisville, Louisville, KY.*

Introduction: Nanoparticles that target extracellular receptors have emerged as a novel approach in the treatment and imaging of solid tumors. However, most current imaging modalities have limited resolution to study nanoparticle accumulation within tissue. Multispectral Optoacoustic Tomography (MSOT) is a recent imaging advance that promises tissue resolution up to 150 µm. In this study, we hypothesized that Syndecan-1 ligand would effectively target insulin-like growth factor 1 receptors (IGF1-R) overexpressed in pancreatic tumors, and using MSOT we evaluated Syndecan-1 liposomes as vehicles for targeted drug delivery. Methods: IGF1-R expression on multiple pancreatic cell lines was demonstrated with Western blot, with cell binding of Syndecan-1 labeled liposomes confirmed in vitro by flow cytometry. Luciferase-expressing S2VP10 cells were then orthotopically injected into the pancreas of SCID mice. At day 14 post-implantation, the mice were systemically injected with Syndecan-1 labeled liposomes encapsulating CF-750 dye. Delivery and uptake of Syndecan-1 liposomes was evaluated in vivo with MSOT at 6 hour intervals and confirmed with fluorescent imaging. Tumor uptake of liposomes was confirmed ex vivo and compared to off-target accumulation. Results: IGF1-R was well expressed on S2VP10 cells on western blot compared to controls. Flow cytometry of S2VP10 cells incubated with Syndecan-1 liposomes demonstrated increased dye uptake compared to cells exposed to naked liposomes alone (79.0% vs 27.6%), indicating successful cell binding in vitro. Upon in vivo injection of Syndecan-1 liposomes, accumulation within the pancreatic tumor was observed using MSOT as early as 6 hours after injection, with peak accumulation at 12 hours (Fig. 1). Ex vivo fluorescent imaging of the pancreatic tumors confirmed dye uptake within the tumor (4100 counts/sec) and decreased uptake within the liver (36 counts/sec) and kidney (670 counts/sec). Conclusion: High-resolution axial imaging using MSOT demonstrates preferential accumulation of Syndecan-1 liposomes throughout pancreatic tumors. These targeted liposomes show promise as a drug delivery system for treating pancreatic adenocarcinoma.



Fig. 1: Signal from fluorescent dye indicates focal accumulation of liposomes within a pancreatic tumor.

P349

Serum MMP7 as a Preoperative Prognostic Marker for Patients with Pancreatic Ductal Adenocarcinoma S.C. Wang,* H. Nathan, M. D'Angelica, R. DeMatteo, Y. Fong, T. Kingham, W. Jarnagin, M.F. Brennan, P. Allen. *Memorial Sloan-Kettering Cancer Center, New York, NY.*

Introduction Elevated serum matrix metalloproteinase 7 (MMP7) has been reported to be associated with metastatic pancreatic ductal adenocarcinoma (PDA). We evaluated preoperative serum MMP7 level as a prognostic marker in PDA patients with potentially resectable disease and compared its utility with preoperative levels of cancer antigen 19-9 (CA 19-9). Methods Preoperative MMP7 were measured from 134 consecutive patients from 2004-2008 who had available serum samples. These patients had resectable disease as determined by preoperative imaging. CA 19-9 results were available for 92 patients. Patients were stratified into a poor outcome group (PG) defined by unresectable disease at operation or recurrence-free survival (RFS) <12 months or a favorable outcome group (FG) where RFS >12 months. Wilcoxon ranksum test and receiver operating characteristics (ROC) curve were used for analysis. Results Advanced T stage, nodal disease, and the presence of vascular invasion were associated with higher MMP7. Area under ROC for MMP7 as a prognostic marker for PG was 0.60 (0.496 to 0.70). When MMP7 was >13.5 ng/mL, the result was 97% specific for PG and the positive predictive value (PPV) was 95%. Twenty of 134 patients (15%) had MMP7 >13.5 ng/mL. At operation, 3 patients had distant disease and 5 had locally unresectable (LU) tumors. Of the 12 patients resected, 11 had RFS <12 months. When CA 19-9 was >700 U/mL, it was 96% specific for PG and the PPV was 95%. Twentyone of 92 patients (23%) had CA 19-9 >700 U/mL. At operation, 3 had metastases and 3 had LU disease. Of the 15 patients resected, 14 had RFS <12 months. Using both assays (either MMP7 >13.5ng/mL or CA 19-9 >700U/mL), the sensitivity for PG increased from 19% and 30%, respectively, to 46%. MMP7 >13.5ng/mL correctly predicted PG in 8 of 16 patients who had preoperative CA 19-9 <155U/mL and in 3 of 16 patients with normal CA 19-9 (<37U/mL). Conclusion Elevated serum MMP7 was associated with poor outcomes in patients who presented with radiographically resectable disease. MMP7 and CA19-9 may be used together to more accurately stratify patients prior to operation.

Very Elevated Serum MMP7 and CA 19-9 Are Highly Specific in Predicting Poor Outcomes in PDA patients

3	M	MP7	CA	19-9	Combined		
	>13.5ng/mL	.<13.5ng/mL	.>700 U/mL	<700 U/mL	MMP7 >13.5ng/mL and/or CA 19-9 >700 U/mL	MMP7 <13.5ng/mL and CA 19-9 <700 U/m	
Patients	20 (15%)	114 (85%)	21 (23%)	71 (77%)	33 (36%)	59 (64%)	
Sensitivity	19	9%	30)%	46	%	
Specificity	9	7%	96	5%	92	%	
PPV	95	5%	95	5%	94%		
NPV	3	1.6%	3/	166	30	CL.	

PPV: Positive Predictive Value; NPV: Negative Predictive Value

P350

A Multidisciplinary Clinic for Pancreatic Cancer Improves Utilization of Therapy S.C. Schiffman,* Y. Shuai, Y. Ding, C. Valko, S. Winters, D.L. Bartlett, A.H. Zureikat, H.J. Zeh, M.E. Hogg. University of Pittsburgh Medical Center, Pittsburgh, PA.

Background: The purpose of this study is to evaluate the impact of a multidisciplinary clinic (MDC) on the treatment of patients with pancreatic ductal adenocarcinoma (PDA). We hypothesized that early multidisciplinary input into clinical decision making might improve the time to treatment, clinical trial participation, utilization of multi-modality therapy, increase utilization of neoadjuvant therapy, and survival. Methods: Using cancer registry data, patients with PDA from 2008-2012 were analyzed. Outcomes of patients evaluated at the MDC were compared to patients not evaluated at the MDC (non-MDC). Results: 1408 patients were identified: 557 (40%) MDC and 851 patients (60%) non-MDC. MDC were younger than non-MDC (68 vs 70; p=0.0045). MDC were more likely to be an earlier stage than non-MDC (p=0.0005): I - 4% vs 4%, II - 54% vs 43%, III - 11% vs 9%, and IV - 32% vs 44%. MDC were more likely to participate in a clinical trial than non-MDC (28% vs 14%; p<0.0001). MDC were more likely to receive treatment than non-MDC (90% vs 71%; p<0.0001). More MDC received neoadjuvant therapy than non-MDC (16% vs 8%; p<0.0001). MDC were more likely to receive 2 (38% vs 24%; p<0.0001) or 3 (12% vs 9%; p=0.018) types of therapy than non-MDC. No difference in median time from diagnosis to first treatment in MDC than non-MDC (0.95 vs 0.92 mos; p=0.69). After adjusting for age, stage, and therapy, no statistical difference in median DFS (17 vs 12 mos; p=0.11), time to recurrence (38 vs 34 mos; p=0.075), or OS (41 vs 35 mos; p=0.134) was seen. Conclusions: Patients evaluated in a MDC were more likely to receive treatment, multimodality therapy, neoadjuvant therapy, and participate in a clinical trial. Evaluation in an MDC did not delay treatment or change survival.

P351

The Effect of Perioperative Transfusion on Recurrence and Survival following Gastric Cancer Resection: A 7-institution Analysis of 765 Patients From the U.S. Gastric Cancer Collaborative M.H. Squires, ^{1*} D.A. Kooby,¹ G.A. Poultsides,² S.M. Weber,³ M. Bloomston, ⁴ R.C. Fields, ⁵ T. Pawlik,⁷ K.I. Votanopoulos,⁶ C.R. Schmidt,⁴ A. Ejaz,⁷ A.W. Acher,³ D.J. Worhunsky,² N. Saunders,⁴ D.S. Swords,⁶ L.X. Jin,⁵ C.S. Cho,³ E. Winslow,³ K. Cardona,¹ M.C. Russell, ¹ C.A. Staley,¹ S.K. Maithel.¹ *1. Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA; 2. Stanford University Medical Center, Palo Alto, CA; 3. University of Wisconsin School of Medicine and Public Health, Madison, WI; 4. The Ohio State University Comprehensive Cancer Center – The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH; 5. Washington University in St. Louis, St. Louis, MO; 6. Wake Forest University, Winston Salem, NC; 7. The Johns Hopkins University, School of Medicine, Baltimore, MD.*

Background: Whether perioperative blood transfusion has a negative prognostic effect on recurrence and survival in patients undergoing resection of gastric adenocarcinoma (GAC) is unknown. **Methods:** All patients who underwent resection for GAC from 2000-2012 at 7 institutions were identified. The effect of transfusion on recurrence-free (RFS) and overall survival (OS) in the context of adverse clinicopathologic variables was examined by univariate (UV) and multivariate (MV) regression analyses. **Results:** Out of 965 patients, 765 underwent curative intent, R0 resection. Median follow-up for survivors was 44 months; 30-day deaths were excluded. Median estimated blood loss (EBL) was 250cc and 166 patients (22%) received perioperative RBC transfusions. 5-yr RFS was 51% in transfused and 61% in non-transfused patients (p=0.01). Median OS was decreased in patients receiving transfusions (19 vs 50 months, p<0.001). On MV analysis, transfusion remained an independent risk factor for decreased RFS (HR 2.8; 95% CI: 1.2-6.5; p=0.01) and decreased OS (Table), regardless of EBL or need for splenectomy. Timing (intraoperative vs postoperative) and volume (number of units) did not alter the effect of transfusion is associated with decreased recurrence-free and overall survival following resection of gastric cancer, independent of adverse clinicopathologic factors. This supports the judicious use of perioperative transfusion during resection of gastric cancer.

M	uli	tivar	iate	Cox	Regress	ion An	alysi	is for	· Overall	Survi	val
---	-----	-------	------	-----	---------	--------	-------	--------	-----------	-------	-----

Variable	HR	95%CI	p-value
No splenectomy, no transfusion Splenectomy, no transfusion No splenectomy, transfusion Splenectomy and transfusion	Ref 2.0 1.6 2.8	1.2-3.5 1.2-2.2 1.5-5.3	0.01 0.005 0.001
EBL >250cc	1.0	0.8-1.3	1.0
Tumor Size >4cm	0.9	0.7-1.2	0.4
Location Distal Proximal GE Junction	Ref 0.9 1.7	0.6-1.3 1.1-2.7	0.5 0.03
T-stage T1 T2 T3 T4	Ref 2.1 3.0 4.2	1.2-3.7 1.9-4.9 2.6-7.1	0.006 <0.001 <0.001
Nodal Stage N0 N1 N2 N3a N3b	Ref 1.3 1.5 2.1 3.6	0.8-1.9 1.0-2.3 1.4-3.2 2.1-6.2	0.3 0.05 <0.001 <0.001
Adjuvant Therapy	0.4	0.3-0.6	< 0.001

P353

Fluorescence-guided Surgery of Pancreatic Cancer using Activatable Cell Penetrating Peptides (ACPPs) in Orthotopic Mouse Models C.A. Metildi,¹ S. Kaushal,¹ C.N. Felsen,¹ Q.T. Nguyen,¹ R.Y. Tsien,¹ R.M. Hoffman,² M. Bouvet.^{1*} *1. Surgery, University of California San Diego, La Jolla, CA; 2. University of California San Diego and Anti-Cancer, Inc., San Diego, CA.*

Introduction: We have previously developed fluorescence guided surgery (FGS) of pancreatic cancer using GFP and fluorescent antibodies. In this report, we evaluated the efficacy of activatable cell penetrating peptides (ACPPs), cleavable by MMP-2 and MMP-9, conjugated to Cy5 fluorophores to label primary pancreatic cancer for FGS in orthotopic mouse models. Methods: We established orthotopic mouse models of human pancreatic cancer using tumor fragments of the human MIA PaCa-2-GFP pancreatic cancer cell line. Two weeks after tumor implantation, the tumors were resected with bright light surgery (BLS) or FGS. FGS was performed with a fluorescence-dissecting microscope two hours after periorbital injection of ACPPs. Completeness of resection was assessed at the time of surgery by visualizing GFP-expressing cells in the surgical site. Postoperatively, whole body imaging of the mice was used to assess for recurrence. At eight weeks, mice were sacrificed to evaluate pancreatic tumor burden, as well as local and distant recurrence. Results: Cy-5conjugated ACPPs permitted clear visualization of tumor margins for FGS. With FGS, no residual tumor was detected in the postoperative surgical site in all 16 mice. One mouse out of 16 undergoing BLS had evidence of residual tumor postoperatively. At eight weeks, mice in the BLS group demonstrated larger primary tumors compared to mice in the FGS group (1.72 g ± SE 0.58 vs 0.25 g ± SE 0.14 respectively, p=0.026). Mean disease-free survival (DFS) was significantly lengthened from 5.33 weeks in the BLS group to 7.38 weeks in the FGS group (p=0.02). Furthermore, recurrence rates were lower in the FGS group (38% vs 73%, p=0.049). This translated into a lower local and distant recurrence rate for FGS compared to BLS (31% vs 67% and 25% vs 60%, respectively). Conclusions: We have shown that ACPPs can effectively label primary pancreatic tumor for improved resection resulting in better outcomes post-resection. ACPPs have potential to improve surgical outcomes in patients

with pancreatic cancer and should be directly compared with fluorescence antibodies and genetic reporters.



Fluorescence imaging of pancreatic cancer with ACPPs. A) brightfield image, B) fluorescence image, C) composite image. p=pancreas, s=spleen

P354

Utility of Staging Laparoscopy in Pancreatic Head Adenocarcinoma in the Era of High-quality Cross-sectional Imaging L.X. Jin,* J.R. Weese, W.G. Hawkins, D. Linehan, S.M. Strasberg, R.C. Fields. *Weakington University in St. Louis MO*

Washington University in St. Louis, St. Louis, MO.

Introduction: Staging laparoscopy (SL) can improve accuracy of staging in pancreatic head adenocarcinoma (PHAc) and can help avoid unnecessary laparotomies in patients with occult metastatic or unresectable disease. However, the added value of staging laparoscopy in the modern era of high-quality cross-sectional imaging is not well defined. Methods: Patients undergoing treatment with curative intent for PHAc between 2005 and 2012 were reviewed, including patients who underwent pancreaticoduodenectomy with or without SL or failed laparotomy (FL) with or without SL. Only imaging performed at our institution was reviewed. Pancreatic protocol CT (PPCT) was defined as oral and IV contrast-enhanced thin-slice helical CT obtained in arterial, pancreatic parenchymal and portal venous phases. High-quality preoperative imaging (HQPI) was defined as either PPCT or MRI/MRCP. Results: Between 2005 and 2012, 528 patients with potentially resectable PHAc went to the OR for staging and/or resection, of which 473 patients (90%) had HQPI (Figure). One hundred and forty-one patients (30%) underwent laparoscopy, which showed unresectable disease in 44 patients (31%). The rate of unresectable disease was significantly higher among patients who underwent SL as a separate procedure (n=30/37, 81%) when compared with those who underwent SL as an add-on to planned laparotomy (n=14/105, 13%; p<0.0001). The most common findings on positive SL were liver metastases (38%), locally-advanced unresectable disease (25%), and positive cytology (7%). Of the 97 patients (69%) with negative SL, 19 (20%) went on to failed laparotomy. Among these patients, the most common reasons for failure were unresectable vascular involvement (47%), liver metastases (21%), and lymph node metastases (16%). Conclusions: In the era of high-quality cross-sectional imaging, SL identified occult unresectable disease in 31% of patients with pancreatic head adenocarcinoma who were selected to undergo the procedure. Therefore, SL remains a valuable tool in identifying advanced disease and preventing laparotomy in select patients with pancreatic head adenocarcinoma.

Figure. Reasons for failure in patients with pancreatic head adenocarcinoma (PHAc) taken to the OR with curative intent.



Molecular Profiling in Gastric Cancer: Examining Potential Targets for Chemotherapy J.T. Miura,* T.T. Jayakrishnan, D. Eastwood, F. Johnston, S. Tsai, K.K. Christians, K.K. Turaga, T.C. Gamblin. *Medical College of Wisconsin, Milwaukee, WI*.

Introduction: Current NCCN guidelines recommend perioperative epirubicin (E), cisplatin (C), and 5-fluorouracil (F) along with other triple agent derivations as first line therapeutic approaches for operable gastric adenocarcinoma (GC). In this study, we utilized molecular profiling to evaluate expression of chemotherapy targeted biomarkers associated with ECF therapy for GC. Methods: Surgically obtained GC specimens were analyzed by immunohistochemistry for TOP2A, TS, and ERCC1 expression (Caris Life Sciences, Phoenix) from 2009-2012. Actionable gene targets were analyzed for mutually exclusive or simultaneous expression. Results: A total of 230 GC specimens were analyzed. The median age of patients was 61 (IQR: 50-72) years with the majority being male (n= 139, 60%). IHC actionable targets included: 60% (n=138) high TOP2A, 55% (n=127) negative ERCC1, and 63% (n=145) negative TS, indicating potential benefit from E, C and F respectively. When analyzing for simultaneous expression profiles of the three genes, only 24 % (n=55) of patients had gene expression levels that suggested sensitivity to all three agents (ECF). Moreover, biomarker results of 6.5% (n=15) of patients demonstrated a potential complete lack of sensitivity to first line ECF therapy. Overall, 61% (n=140) of patients had molecular profiles that indicated sensitivity to two or more agents. Conclusions: Biomarker analysis of GC suggests that there is potential for TOP2A, TS and ERCC1 to define patients who have the greatest likelihood of deriving benefit from ECF therapy. 93.5% of patients had the biomarker profile that predicted sensitivity to at least one of these agents. Prospective controlled studies are required to validate the role of TOP2A, TS and ERCC1 in routine management of GC patients.



P356

Risk Factors for Non-infectious Wound Complications following Open Upper Gastrointestinal Surgery: Subset Analysis of a Phase 3 RCT A. Takeno,^{1*} F. Junya,² M. Hirao,³ H. Hatano,⁴ S. Endo,⁵ J. Kawada,⁶ M. Yamasaki,⁷ S. Kobayashi,⁷ Y. Akamaru,⁸ T. Mizushima,⁷ J. Shimizu,⁹ K. Umeshita,⁷ T. Tsujinaka,¹⁰ T. Ito,¹¹ M. Mori,⁷ Y. Doki.⁷ *1. Surgery, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; 2. Surgery, NTT West Osaka Hospital, Osaka, Japan; 3. Surgery, Osaka National Hospital, Osaka, Japan; 4. Surgery, Toyonaka Municipal Hospital, Osaka, Japan; 5. Surgery, Higashiosaka City General Hospital, Osaka, Japan; 6. Surgery, Osaka General Medical Center, Osaka, Japan; 7. Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan; 8. Surgery, Osaka-Koseinenkin-Hospital, Osaka, Japan; 9. Surgery, Osaka Rosai Hospital, Osaka, Japan; 10. Surgery, Kaizuka City Hospital, Osaka, Japan; 11. Complementary and Alternative Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.*

Introduction: A phase 3 RCT with the incidence of wound complications (WCs) following open gastrointestinal (GI) surgery, depending on whether subcuticular sutures or staples are used, as a primary endpoint was performed. (UMIN000002480) We investigated risk factors for non-infectious WCs following open upper GI surgery as a subset analysis of the main trial. Wethods: We assessed WCs of 789 patients undergoing elective open upper GI surgery out of 1080 patients enrolled in the main trial. Risk factors for non-infectious

WC were investigated by univariate and multivariate analysis in several clinical factors. Results: The types of diseases were 771 gastric cancers, 14 gastrointestinal stromal tumors, and 4 others. The types of procedures were 402 distal gastrectomy, 289 total gastrectomy, 35 proximal gastrectomy, and 54 others. WCs occurred in 68 of 789. Forty-three were superficial surgical site infections, and 25 were non-infectious WCs (14seroma, 7 wound separation, 1 hematoma, and 3 others). Types of wound closure (subcuticular sutures 6/376, stapler 19/413, RR: 0.336, 95%CI: 0.133-0.851, p=0.022) and drain insertion (drain insertion 14/661, no drain 11/128, RR: 0.230, 95%CI: 0.102-0.518, p=0.0004) showed significant differences in the incidence of non-infectious WCs in univariate analysis. These factors were also identified as independent risk factors in multivariate analysis (subcuticular sutures RR: 0.337, 95%CI: 0.132-0.861, p=0.023, drain insertion RR: 0.223, 95%CI: 0.092-0.543, p=0.001) Conclusions: Subcuticular sutures and drain insertion are useful to reduce the risk of non-infectious WCs following open upper GI surgery.

P357

The Effect of Postoperative Morbidity on Survival after Resection for Gastric Adenocarcinoma: Results from the U.S. Gastric Cancer Collaborative L.X. Jin, ¹* L.E. Moses, ¹ Y. Yan, ¹ M.H. Squires, ² S.M. Weber, ⁶ M. Bloomston, ⁴ G. Poultsides, ³ K.I. Votanopoulos, ⁷ T. Pawlik, ⁵ W.G. Hawkins, ¹ D. Linehan, ¹ S.M. Strasberg, ¹ A.W. Archer, ⁶ A. Ejaz, ⁵ D.A. Kooby, ² C.R. Schmidt, ⁴ D.S. Swords, ² D.J. Worhunsky, ³ S.K. Maithel, ² R.C. Fields. ¹ I. Washington University in St. Louis, St. Louis, MO; 2. Emory University, Atlanta, GA; 3. Stanford University, Palo Alto, CA; 4. The Ohio State University Comprehensive Cancer Center – The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH; 5. Johns Hopkins University, Baltimore, MD; 6. University of Wisconsin School of Medicine and Public Health, Madison, WI; 7. Wake Forest University, Winston-Salem, NC.

Background: The negative impact of postoperative complications (POCs) on survival is well documented for many cancer types, but has not been well described in gastric cancer. Here, we evaluated the effect of POCs on survival after surgery for gastric cancer in a cohort of patients from a multi-institutional database. Methods: Patients who underwent surgery with curative intent for gastric adenocarcinoma between 2000-2012 from participating institutions of the U.S. Gastric Cancer Collaborative were analyzed. Patients who died within 30 days of surgery were excluded. Ninety-day postoperative complication data were collected. Survival probabilities were estimated by Kaplan-Meier analysis and compared using the log-rank test. Results: A total of 853 patients from seven institutions met inclusion criteria. Median follow-up was 28 months. The overall complication rate was 40% (n=344). The most frequent complication types were infectious (25%, including surgical site infection [8%]), and anastomotic leak (6%). Seven percent of patients underwent reoperation during the same hospitalization. Five-year overall survival (OS) for patients without perioperative complications was 54%, compared with 39% for patients with POCs (p=0.001). Disease free survival (DFS) at five years was 61% for patients without POCs compared to 49% in patients with POCs (p=0.002). Patients without POCs were significantly more likely to receive adjuvant therapy (55% vs 42%; p<0.001). Conclusions: In a large, multi-institutional cohort, POCs were associated with decreased survival in patients undergoing surgery for gastric adenocarcinoma. This may be due, in part, to the negative impact of complications on the receipt of adjuvant therapy. Efforts aimed at reducing perioperative morbidity are important not only for short-term surgical outcomes, but also for enhancing long-term oncologic outcomes in patients with gastric cancer.

Figure. Kaplan-Meier estimates of [A] Overall Survival (OS) and [B] Disease Specific Survival (DSS) for patients undergoing surgery with curative intent for adenocarcinoma of the stomach between 2000 and 2012 (n=853) stratified by presence or absence of postportaive complications.



P358

Central Pancreatectomy and Distal Pancreatectomy for Pancreatic Neck Lesions Result in Equivalent Long-term Pancreatic Function and Fistula Formation M.P. Kim,^{1*} H. Tran Cao,¹ M.H. Katz,¹ P.W. Pisters,¹ S.A. Curley,¹ J. Vauthey,¹ T. Aloia,¹ D. Evans,² J.E. Lee,¹ J.B. Fleming.¹ 1. The University of Texas M.D. Anderson Cancer Center, Houston, TX; 2. Medical College of Wisconsin, Milwaukee, WI.

Introduction: The surgical management of pancreatic neck or proximal body lesions is controversial and consists of either central pancreatectomy (CP) or distal pancreatectomy (DP). Compared to DP, advocates of CP cite potential benefits as spleen conservation and putative long-term preservation of endocrine and exocrine pancreatic function. We compared the incidence of postoperative pancreatic fistulae (POPF) and endocrine/exocrine insufficiency among patients who underwent CP versus DP. Methods: A retrospective review of a prospectively maintained database identified patients who underwent CP or DP for primary lesions of the pancreas between 1994 and 2012. Clinicopathologic data from both patient groups were analyzed for long-term utilization of pancreatic enzyme replacement therapy (PERT) and insulin/oral hypoglycemic agents. Patients were assessed for POPF formation based on clinical grade B or C criteria. Results: Indications for CP (n=20) included pancreatic neuroendocrine tumor (PNET, n=9), intraductal papillary mucinous neoplasm (IPMN, n=6), solid pseudopapillary neoplasm (SPN, n=3), and serous cystadenoma (SC, n=1). Indications for DP (n=195) included PNET (n= 105), mucinous cystic neoplasms (MCN, n=54), SPN (n=15), IPMN (n=9), and other (n=12). Median follow-up times for CP and DP patients were 25.6 and 50.3 months, respectively. The incidence of POPF in the CP patient group was 18% compared to 20% in the DP group (p=0.41). Postoperative exocrine insufficiency as determined by long-term use of PERT for CP and DP groups were 15% and 18.5%, respectively (p=0.35). Postoperative endocrine insufficiency managed with insulin and/or oral hypoglycemic agents was 25% in the CP group compared to 32.3% in the DP group (p=0.25). All patients who experienced POPF were successfully managed by percutaneous drainage. Conclusion: DP permits successful oncologic resection of pancreatic neck lesions in appropriately selected patients without an added risk of long-term exocrine and endocrine insufficiency. The incidence of POPF is comparable among patients who underwent CP or DP and can be managed non-operatively.

P359

Bi-specific T Cell Therapy for Pancreatic Cancer S. Mohammed,^{1*} U. Anurathapan,² R. Chan,² R. Mucharla,² H. Heslop,² C. Rooney,² M.K. Brenner,² A. Leen,² J. Vera.² 1. Department of Surgery, Baylor College of Medicine, Houston, TX; 2. Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX.

Background: Adoptive T cell therapy directed to tumor-associated antigens (TAAs) by transgenic expression of chimeric antigen receptors (CARs) can produce tumor response, even in patients with resistant disease. However, targeting a single TAA may lead to selection of the nontargeted TAA population and tumor immune escape. Bi-specific T-cell therapy targeting two distinct TAAs, MUC1 and PSCA, both overexpressed in pancreatic cancer, may enhance the potency of adoptive immunotherapy. Methods: Peripheral blood mononuclear cells were transduced with retroviral vectors encoding CAR-MUC1 or CAR-PSCA. Short and long-term anti-tumor activity was assessed by chromium release and co-culture assay, respectively, using the tumor cell lines CAPAN1, K562 and DU145. Results: After retroviral transduction, T cells stably expressed CAR-MUC1 (83±4%) and specifically killed MUC1+ cell lines, CAPAN1 and DU145, but not MUC1- 293T cells (35±5%, 23±4% and 3±2% specific lysis, respectively, 10:1 Effector:Target). When MUC1+ targets were cultured with CAR-MUC1 T cells, >60% of CAPAN1 and >40% of DU145 were killed after initial treatment but were subsequently resistant. Immunohistochemistry of resistant tumor cells demonstrated lack of MUC1 expression. This observation was confirmed in an artificial model using 293T cells engineered to express either MUC1/mOrange+ or PSCA/GFP+, which illustrated exquisite specificity of T-cells but a weakness when targeting a heterogeneous tumor. Therefore, a second CAR targeting PSCA was generated. This was stably expressed on T cells (89±2%) and killed PSCA+ CAPAN1 and DU145 cells, with no effect on control PSCA- 293T (48±6%, 41±46% and 4±2% specific lysis, respectively, 10:1 E:T). Finally, we assessed anti-tumor activity when both CAR-modified products were combined. When tumor cells expressing both TAAs were treated with CAR-MUC1 and CAR-PSCA T-cells, we saw additive anti-tumor effects with $76\pm10\%$ killing of CAPAN1 versus only $35\pm6\%$ and $48\pm6\%$, respectively, using CAR-MUC1 and CAR-PSCA T cells individually. Conclusion: The combination of CARs that target two distinct TAAs expressed on cancer cells (PSCA and MUC1) may prevent tumor immune escape and enhance the potency of adoptive T cell transfer.

P360

Immune Response in Metastatic Regional Lymph Nodes from Pancreatic Adenocarcinoma may Predict Patient Outcome E. Nizri,* N. Sternbach, F. Gerstenhaber, G. Lahat, J. Klausner. *Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.*

Background: Regional lymph nodes (RLNs) may be considered the first site for metastasis from primary tumor. As RLNs are exposed to tumoral antigens and contain all immunological machinery to mount an effective immune response, we hypothesized that tumor-immune interaction in RLNs could suggest tumor escape or immunity. Methods: Histological sections from metastatic RLNs of 55 pancreatic ductal adenocarcinoma (PDAC) patients were retrospectively evaluated for architectural parameters, peritumoral T, B and dendritic cells, and T helper lineage markers by immunohistochemistry. Histological data was correlated with overall survival (OS) expressed in months. Results: Primary tumor size and perivascular invasion did not correlate with OS in patients with RLN metastases, however, perineural invasion did; 29.2±2.3 vs. 13.9±1.5 (p<0.001). Preserved RLN architecture was associated with longer OS vs. tumor-induced architectural changes; 39.8±9.6 vs. 23.5±0.2 (p<0.05), respectively. The presence of desmoplasia in RLN did not confer adverse outcome ($OS=21.3\pm2.5$ for patients without vs. $OS=19.5\pm1.87$ for those with desmoplasia, p=0.66). High number of peritumoral CD8+ cells in RLN was associated with longer survival; 22±7.15 vs. 14.8±2.2 (p<0.05). Accordingly, T helper skewing toward Th1, as measured by T-bet expression, had the same effect on OS. The number of CD20+ and CD4+ peritumoral cells in RLN was not associated with prognosis, possibly to due to the large number of the latter in intact LNs. Conclusions: CD8+ tumor-infiltrating cells and Th1-deviated immune response in RLN may point to a subgroup of PDAC patients with protective immune response. These findings may indicate that tumor immunity in RLN affects prognosis.

P361

Impact of External-beam Radiation Therapy on Outcomes among Patients with Resected Gastric Cancer: A Multi-institutional Analysis A. Ejaz, ¹* G. Spolverato, ¹Y. Kim, ¹M.H. Squires, ²S.M. Weber, ³ G. Poultsides, ⁴ K.I. Votanopoulos, ⁵ M. Bloomston, ⁶ R.C. Fields, ⁷ D.A. Kooby, ² A.W. Acher, ³ D.J. Worhunsky, ⁴ D.S. Swords, ⁵ N.D. Saunders, ⁶ L.X. Jin, ⁷ C. Cho, ³ C.R. Schmidt, ⁶ J. Herman, ¹ S.K. Maithel, ² T. Pawlik. ¹ I. Johns Hopkins University, Baltimore, MD; 2. Emory University, Atlanta, GA; 3. University of Wisconsin, Madison, WI; 4. Stanford University, Stanford, CA; 5. Wake Forest University, Winston-Salem, NC; 6. The Ohio State University, Columbus, OH; 7. Washington University, St. Louis, MO.

Background: Use of perioperative chemotherapy (CTx) alone versus chemoradiation therapy (cXRT) in the treatment of resectable gastric cancer remains varied. We sought to define the utilization and effect of CTx alone versus cXRT on patients having undergone curative-intent resection for gastric cancer. Methods: Using the U.S. Gastric Cancer Collaborative database, we identified 505 patients between 2000 and 2012 with gastric cancer who received perioperative therapy in addition to curative-intent resection. The impact of perioperative therapy on survival was analyzed by the use of propensity-score matching of clinicopathologic factors among patients who received CTx alone versus cXRT. Results: Median patient age was 62 years and the majority of patients were male (58%). Surgical resection involved either partial gastrectomy (54%) or total gastrectomy (46%). On pathology, median tumor size was 5.0 cm; most patients had a T3 (37%) or T4 (36%) lesion and lymph node metastasis (74%). Margin status was R0 in most patients (89%). 211 (42%) patients received perioperative CTx alone whereas the remaining 294 (58%) patients received 5-FU based cXRT. Factors associated with receipt of cXRT were younger age (OR 0.98), T3 tumors (OR 1.52), and lymph node metastasis (OR 2.03) (all P < .05). Recurrence occurred in 214 (39%) patients. At a median follow-up of 28 months, median overall survival (OS) was 33.4 months and 5-year survival was 36.7%. Factors associated with worse OS included tumor size (HR 1.1), T-stage (HR 1.5), and lymph node metastasis (HR 1.58) (all P<0.05). In contrast, receipt of cXRT was associated with improved long-term OS (CTx alone: 21 months vs. cXRT 45 months; p<0.001). In the propensity-matched multivariate model that adjusted for tumor size, T-stage, and nodal status, cXRT remained associated with an improved long-term disease-free (HR 0.43) and overall (HR 0.41) survival (both P<0.001). Conclusions: XRT was utilized in 58% of patients undergoing curative-intent resection for gastric cancer. Using propensity- matched analysis, cXRT was an independent factor associated with improved recurrence-free and overall survival.

P362

Usefulness of Laparoscopic Narrow-band Imaging for the Diagnosis of Peritoneal Metastasis in Patients with Gastric Cancer

H. Kikuchi,* K. Kamiya, S. Miyazaki, I. Iino, H. Yoshihiro, M. Ohta, T. Sakaguchi, H. Konno. Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.

INTRODUCTION: The peritoneum is one of the most frequent and lethal locations of recurrence in patients with advanced gastric cancer. Accurate diagnosis of peritoneal metastasis is important for improving outcomes, but it is difficult using conventional modalities. Staging laparoscopy is often used to diagnose peritoneal metastasis in patients with advanced gastric cancer, but accurate detection of metastasis can be difficult. We evaluated the usefulness of laparoscopic narrow-band imaging (NBI) versus conventional laparoscopic white-light imaging (WLI) for the diagnosis of peritoneal metastasis. METH-ODS: We excised 25 white nodules from the parietal peritoneum of 17 patients with gastric cancer and suspected peritoneal metastasis. The WLI and NBI findings were compared with the pathological findings. RESULTS: All the peritoneal lesions examined were observed as white nodules on WBI. Intranodular vessels were evaluated by WLI and NBI for: (1) vessel dilatation, (2) vessel tortuousness, (3) vessel heterogeneity, and (4) brown spots. Each individual abnormal finding had a diagnostic accuracy of less than 76% with or without NBI. Detection of any one abnormal finding had a sensitivity, specificity, and accuracy of 50%, 84.6%, and 68%, respectively, on WLI and 91.7%, 69.2%, and 80%, respectively, on NBI, for detection of peritoneal metastasis. Detection of any one abnormal finding on NBI plus clear demarcation of the nodule on WLI had a sensitivity of 91.7%, specificity of 92.3%, and accuracy of 92% for detection of peritoneal metastasis. Pathological examination showed that a brown spot detected on NBI correlated with dilated vessels around cancer cells. CONCLUSIONS: NBI was more sensitive for the detection of dilated microvessels than WLI. We developed a new diagnostic strategy for accurate detection of peritoneal metastasis using four NBI findings (vessel dilatation, vessel tortuousness, vessel heterogeneity, and brown spot), and clear demarcation on WLI. NBI could be a useful tool for the diagnosis of peritoneal metastasis during staging laparoscopy.

P363

A Novel AMP Kinase Activator Sensitizes Pancreatic Cancer to Radiation L.A. Shirley,^{1*} M. Yang,² C. Chou,² A. Estrada-Bernal,¹ T. Williams,¹ M. Bloomston,¹ C. Chen.² 1. The Ohio State University Wexner Medical Center, Columbus, OH; 2. The Ohio State University College of Pharmacy, Columbus, OH.

Background: Metformin, through activation of adenosine monophosphate kinase- α (AMPK α), inhibits the mTOR pathway, resulting in radiosentization in various cancer types, including breast, lung, and sarcoma. We used a newly derived small molecule activator of AMPKa, OSU-53D, to assess its role as a radiosensitizer in pancreatic cancer. Methods: We calculated in vitro radiation dose response of OSU-53D in three pancreatic cancer cell lines (Mia-PaCa-2, BxPC-3, AsPC-1). Sub-therapeutic concentrations of either OSU-53D or metformin were combined with increasing doses of radiation and survival determined by clonogenic assay. Cells treated with increasing concentrations of OSU-53D for 24 hours followed by 4 Gy of radiation were lysed at multiple timepoints for immunoblotting. We used immunostaining to analyze foci of the DNA damage marker y-H2A.x. Results: Pre-treatment with OSU-53D led to increased cell killing by radiation in all three cell lines, with the greatest degree of radiosensitization in MiaPaCa-2 cells, having a dose-enhancement factor of 1.62. Addition of OSU-53D to radiation increased expression of the DNA damage marker y-H2A.x in a concentration- dependent manner. Immunocytochemical analysis at various timepoints after combined treatment showed increased γ -H2A.x foci at 1hour after radiation, with persistence of foci at up to 24 hours, which was not seen with radiation alone, suggesting delayed DNA damage repair. Western blot analysis revealed increased expression of the apoptosis marker cleaved PARP and autophagic marker LC3-B with increasing concentrations of OSU-53D combined with radiation. Of note, pre-treatment of pancreatic cancer cell lines with therapeutic doses of metformin followed by radiation could not recapitulate the radiosensitization observed with OSU-53D. Conclusions: Pre-treatment with a novel AMPK α activator OSU-53D increased pancreatic cancer cell killing when combined with radiation. This combination led to increased expression of markers of DNA damage, apoptosis, and autophagy, revealing possible mechanisms of action. Taken together, we demonstrate that OSU-53D is a novel radiosensitizer which could improve therapeutic response in pancreatic cancer.

P364

C6 Ceramide Potentiates Paclitaxel and Gemcitabine-mediated Anti-tumor Effects against Pancreatic Cancer in vivo and in vitro via Inhibition of Pro-survival PI3k/AKT/mTOR and ERK/MAPK Pathways H. Wanebo,^{1*} S. Lu,² C. Cao,² D. Shrayer,¹ W. Bowen.² *1. Landmark Medical Center, Woonsocket, RI; 2. Brown University, Providence, RI.*

Introduction: Survival of pancreatic cancer is about 5%, emphasizing need to develop new treatment strategies. Our studies suggest C6 Ceramide (C6Cer) may be a useful chemotherapeutic adjunct.. Methods: Cell culture, MTT assay,,Western Blot,SCID mouse xenograft. Results:Co-administration of Gemcitabine(Gem) or Paclitaxel (Taxol) and C6Ceramide (C6Cer) significantly increased cell death/apoptosis in pancreatic cancer (PanCa) cells (L3.6, PANC-1 and MIA PaCa-2) in vitro, compared to chemo or C6-Cer alone. Similar synergism was seen with Cetuximab(Cetux) in spite of common KRAS mutations which induce Cetux resistance. Cetux had no cytostatic effect alone in Panc.Ca cell lines, but this was markedly enhanced by C6Cer . Combination of C6-Cer with Gem or Taxol significantly decreased p-AKT and p-GSK-3a/B (PI3K/AKT pathway), p-S6 and p-4E-BP1 (mTORC1 pathway, and p-ERK (Ras/MEK/ERK pathway) in L3.6 PanCa cells. Inhibitors of PI3K/Akt (LY294002), mTORC1 (rapamycin), and MEK/ERK (U0126) mimicked cytotoxic effect of C6-Cer on L3.6 cell when combined with Taxol or Gem. This was also reflected on levels of p-AKT, p-S6/p-4E-BP1, and p-ERK, where Gem alone had no effect in contrast to the combination with respective inhibitor which significantly decreased levels of target phosphoprotein. This indicates an association of effect on cell signaling pathways, including inhibition of prosurvival PI3k/AKT/mTOR and ERK/MAPK/KRAS mutant pathways enhancing cytotoxicity by Gem or Taxol. Similar in-vivo results occured in SCID mouse xenograft model.growing L3.6 cell line cancers, C6 Cer with Gem or Taxol induced significant tumor regression and survival vs. chemo or C6 Cer alone. Conclusion . Results suggest that inhibition of pro- survival pathways by C6 Cer significantly enhances chemo-toxicity of Gem, Taxol, and Cetuximab, in vitro and in vivo. This regimen may have value in therapy against Panc Ca, and possibly other aggressive cancers and also suggests value of C6Cer with Taxol (not used for Panc Ca) or Cetuximab which is ineffective in KRAS mutant .cancer.

P365

Does Inadequate Lymph Node Staging Impact Survival in Resected Gastric Cancer? J. Datta,^{1*} M. Gupta,¹ R.S. Lewis,¹ R. Mamtani,² D. Stripp,³ R.R. Kelz,¹ J.A. Drebin,¹ D.L. Fraker,¹ G.C. Karakousis,¹ R.E. Roses.¹ *1. Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; 2. Department of Medicine, Veteran Affairs Medical Center, Philadelphia, PA; 3. Department of Radiation Oncology, Veteran Affairs Medical Center, Philadelphia, PA*.

INTRODUCTION: National guidelines recommend examination of ≥ 15 lymph nodes for adequate staging of resectable gastric adenocarcinoma (GA). We examined (1) factors predicting inadequate lymph node staging (LNS; <15 LN); and (2) the relationship between LNS and overall survival (OS). METHODS: The National Cancer Data Base was queried for patients with Stage I-III GA who underwent gastrectomy between 1998 and 2011. Patients who received neoadjuvant radiotherapy were excluded. Models

were developed to identify factors predicting inadequate LNS and any association between LNS and OS. RESULTS: Of 19,356 patients (median age 68 years, 63.0% male), a majority (60.2%) received inadequate LNS. Median number of LN examined was 12 (IQR 5-19). Excluding gender, all demographic, pathologic, or operative variables evaluated were independently associated with inadequate LNS (all p<0.001). Surgery at a community hospital (OR 2.08, 95% CI 1.78-2.42), partial gastrectomy (OR 1.90, 95% CI 1.67-2.16), tumor size<2 cm (OR 1.82, 95% CI 1.61-2.06), and age>76 years (OR 1.56, 95% CI 1.38-1.77) were the strongest predictors of inadequate LNS on multivariate analysis (all p<0.001). Survival analyses included 9,189 patients with a minimum follow-up of 5 yrs. Median, 1-yr, and 5-yr survival in this cohort was 35.4 months, 75%, and 40% respectively. Median survival after inadequate LNS was significantly worse than that after adequate LNS (32.9 vs 41.3 mo; log-rank p<0.001), regardless of AJCC stage subgroup (I: 61.2 vs 86.1; II: 25.4 vs 41.2; III: 15.3 vs 23.1 mo; all p<0.001). On multivariate Cox regression analysis, inadequate LNS conferred an increased risk of death (HR 1.26, 95% CI 1.17-1.35; p<0.001). R1 resection (HR 1.98), AJCC Stage III (HR 1.96), age>76 years (HR 1.73), tumor size>5 cm (HR 1.43), and surgery at a community hospital (HR 1.20) were other strong predictors of worse OS (all p<0.001, table). CONCLUSIONS: Adequate LNS is achieved in a minority of patients. Inadequate LNS is independently associated with worse overall survival. Whether this association reflects a therapeutic benefit of regional lymphadenectomy, stage migration, or other unaccounted for factors warrants further investigation.

	Hazard Ratio (95%	Multivariate
Variable	Confidence Interval)	p-value
Age quartiles (years)		
<56	Ref	NA
56-66	1.13 (1.01-1.25)	0.03
67-76	1.34(1.20 - 1.51)	<0.001
>76	1.73 (1.54-1.95)	<0.001
Race		
White	Ref	NA
Black	0.97 (0.88-1.07)	0.57
Asian	0.68(0.59 - 0.77)	<0.001
Other (American Indian, Pacific Islander)	0.87(0.73 - 1.05)	0.15
Hispanic ethnicity		
No	Ref	NA
Yes	0.78(0.70-0.88)	<0.001
Insurance type		
Private	Ref	NA
Medicare	0.98(0.62 - 1.55)	0.94
Medicaid	1.13(1.04 - 1.22)	0.005
Other (VA Military etc.)	0.76(0.64 - 0.89)	0.001
Uningurad	0.93(0.73 - 1.19)	0.58
Median Income	0.95(0.75-1.19)	0.58
>\$46,000	Ref	NA
<\$46,000	1 10 (1 03 - 1 17)	0.003
Facility Type	1.10(1.05-1.17)	0.005
Academic/Research	Ref	NA
Community Cancer Program	120(108 - 134)	<0.001
Comprehensive Community Cancer Center	1.16(1.08 - 1.24)	<0.001
Tumor Size	1.10(1.00 1.24)	
<2 cm	Paf	NA
2-5 cm	1 37 (1 25 - 1 50)	<0.001
25 cm	1.37(1.20-1.50) 1.43(1.20-1.57)	<0.001
A ICC Clinical Stage	1.45 (1.50-1.57)	~0.001
Stage I	Ref	NA
Stage II	1 42 (1 31 - 1 53)	<0.001
Stage III	1.96(1.80 - 2.12)	<0.001
Tumor Grade	1.50(1.00-2.12)	0.001
Well/moderately differentiated	Ref	NA
Boorly/un_differentiated or anaplastic	1 18 (1 10 - 1 26)	<0.001
Type of gastrectomy	1.10(1.10 1.20)	-0.001
Near Total/Total	Ref	NA
Subtotal/Partial	0.90 (0.81 - 0.99)	0.05
Combined with partial aconhageal resection	1.04(0.03 - 1.16)	0.50
Multivisceral/En bloc	1.04(0.93 - 1.10) 1.01(0.88 - 1.15)	0.92
Tumor Margins	1.01(0.88-1.15)	0.92
PO PO	Paf	NA
P1	1.08 (1.78 - 2.21)	<0.001
P2	1.58(1.78-2.21) 1.62(1.20-2.24)	0.001
R2	1.03(1.20-2.24) 1.41(1.28-1.56)	<0.002
Timing of multimodality tharany	1.41 (1.20 - 1.50)	~0.001
No chemotradiothermy (cureary only)	Pof	NA
Adjugant or parion chamotradiotherany	1 10/1 11 - 1 20)	<0.001
Adjuvant of periop chemotradiomerapy	1.19(1.11-1.28)	-0.001
Lymph Node Staging (LNS)		
Adequate LNS	Ref	NA
Inadequate LNS	1.26(1.17 - 1.34)	< 0.001

Table: Multivariable Cox Regression Identifying Predictors of Overall Survival Among Patients with Resectable Stage I-III Gastric Adenocarcinoma

P366

Nasoenteric Catheter or Jejunostomy as a Route for Nutrition after Major Upper Gastrointestinal Operations F.A. De Vasconcellos Santos, ^{1*} L.T. Lacerda, ² M. Kansaon, ² A.J. Wainstein, ¹ A. Drummond-Lage, ¹ L.J. Torres, ¹ M.D. Correia. ³ *1. Surgery, ONCAD, Belo Horizonte, Minas Gerais, Brazil; 2. Mater Dei Hospital, Belo Horizonte, Minas Gerais, Brazil; 3. Clinics Hospital - UFMG, Belo Horizonte, Minas Gerais, Brazil.*

INTRODUCTION: Curative treatment of upper gastrointestinal tract neoplasms is complex and associated with high morbidity and mortality. In general, the patients are already malnourished, and early postoperative enteral nutrition is recommended. However, there is no consensus concerning the best enteral access route in these cases. METHODS: A prospective randomized trial was performed from 2008 to 2012 with 59 patients who underwent esophagectomy, total gastrectomy or pancreaticoduodenectomy. Four of the patients did not agree to the randomization, and 13 were excluded. Thus, of the 42 included patients, 21 received nasoenteric tubes, and 21 received jejunostomies. RESULTS: The two groups were similar in demographic and clinical aspects. The nasoenteric (NE) and jejunostomy groups received early enteral therapy in 71,4% and 61,9% of cases (p>0.05), respectively. The median length of enteral therapy use was lesser in the NE group (8.5 vs. 15.3 days), but the difference was not statistically significant. The NE group required the introduction of parenteral therapy more frequently compared with the jejunostomy group (p<0.05). Complications related to the enteral route occurred in 38% and 28.5% of patients (p>0.05) in the NE and jejunostomy groups, respectively. In the NE group, there were four losses and four tube obstructions, and in the jejunostomy group, there were two losses, four obstructions and two cases of leakage around the tube. In the latter group, patients who used the therapy for a longer time had tube complications (p<0.05) and had longer ICU and hospital stays (p<0.05). CONCLUSION: In conclusion, both enteral routes are associated with the same number of complications. However, the presence of jejunostomies allows enteral therapy for longer time periods, especially when patients have complications, thus avoiding the need for parenteral nutrition.

P367

What is the Optimal Multimodality Approach to Siewert II/III Gastroesophageal Junction Adenocarcinoma? A Population-based Analysis J. Harris,^{1*} B. Huang,¹ P.C. McGrath,¹ S.P. McKenzie.² 1. General Surgery, University of Kentucky, Lexington, KY; 2. Surgical Associates of Austin, Austin, TX.

Introduction: Despite intensive investigation, the optimal multimodal approach (MMA) to proximal gastric adenocarcinoma (PGC) remains controversial. The purpose of this study was to determine if an optimal surgical and MMA to PGC could be determined through population based analysis. Methods: Using both the Surveillance, Epidemiology, End Result(SEER) and Kentucky Cancer Registries(KCR), all patients with surgical resected PGC captured from 2004-2010 were analyzed. Results: 2079 patients with resected PGC were identified from SEER and 175 patients from KCR. In both groups, the vast majority (>93%) had cancer of the cardia. Based on SEER, 285 patients underwent proximal esophagogastrectomy, 1484 patients underwent total gastrectomy with distal esophagectomy, and 310 patients underwent total gastrectomy with en bloc resection of other organs. Adjuvant radiation occurred in 44% of patients. (504 neoadjuvant, 408 adjuvant). Adjuvant radiation therapy provided a clear survival advantage in stage II/III disease (all p values <0.005), Radiation sequence and surgery type provided no clear benefit in survival. Based on the KCR analysis, inclusion of chemotherapy, alone or in concert with radiation, or as a neoadjuvant or adjuvant approach, provided no clear optimal strategy to effect survival. When all adjuvant strategies were considered, only neoadjuvant chemoradiation predicted improved survival (HR 0.46, CI 0.26-0.84). Conclusion: Based on these population analyses, no optimal surgical approach to PGC impacts survival. While strategies including chemoradiation improve survival, optimal sequencing of multimultimodal therapy is yet to be determined.

P368

Evaluation of PET Response to Neoadjuvant Therapy for Patients with Gastric and GEJ Adenocarcinoma J. Hernandez,^{1*} V. Beylergil,¹ D. Goldman,¹ L.H. Tang,¹ D.H. Ilson,¹ R. Downey,¹ V.E. Strong,¹ M. Shah,² M. Gönen,¹ H. Schoder,¹ D.G. Coit.¹ *1. Memorial Sloan-Kettering Cancer Center, New York, NY; 2. Cornell University, New York, NY.*

Background: Although neoadjuvant therapy is commonly utilized to treat localized gastric and gastro-esophageal junction (GEJ) adenocarcinoma, the implications of response to therapy as measured by PET imaging remain poorly defined. Our aims in undertaking the study were to determine if changes in PET avidity correlate with histologic response, and to determine the best predictor(s) of disease-free and overall survival. Methods: We reviewed a prospective database to identify patients with gastric and GEJ adenocarcinoma who were evaluated with PET imaging prior to and following neoadjuvant treatment. Spearman rank correlation was used to analyze the relationship between changes PET scans and histologic response. Cox proportional hazards regression was used to assess the relationship between imaging and pathologic parameters, and disease-free and overall survival. Results: Since 2002, 216 patients of median age 63 years met our criteria. At last follow-up (median 22 months, range: 0 - 119), 118 patients recurred or died. The median DFS and OS for expired patients were 7.5 months (range: 0-62) and 14 months (range: 0 - 69), respectively. Between baseline and follow-up PET imaging (median 63 days, range: 15 - 454), 170 patients were treated with chemotherapy and 46 patients with chemoradiotherapy. The median change in SUV was 43% (range: -300 -100.0%) and the median histologic tumor response was 50% (range: 0 - 100%). No association was identified with the use of chemoradiation (as compared to chemotherapy alone) and change in SUV (p=0.8). We identified a significant relationship between change in SUV and histologic response (r=0.32, p<0.01). Furthermore, the change in SUV was related to both DFS and OS on univariate analysis, as was tumor response and pathologic stage (Table). On multivariate analysis only pathologic stage, and specifically the presence of lymph node metastases, was related to DFS (p<0.01) or OS (p<0.01). Conclusions: Following neoadjuvant therapy for gastric and GEJ adenocarcinoma, PET response is prognostic, although pathologic nodal status is the best predictor of outcome.

OUTCOME	VARIABLE	HR (95% CI)	p-Value
Overall Survival	SUV Change	0.95 (0.91-0.98)	0.01
	Tumor Response	0.94 (0.89-1.00)	0.04
	Radiation	1.10 (0.68-1.76)	0.71
	Stage	0.29 (0.17-0.50)	<0.01
Disease-free Survival	SUV Change	0.96 (0.92-0.99)	0.02
	Tumor Response	0.94 (0.89-0.99)	0.02
	Radiation	1.20 (0.77-1.89)	0.42
	Stage	0.23 (0.14-0.38)	<0.01

P370

Clinicopathologic Characteristics and Prognostic Predictors of Survival in Patients with Stage IV Gastric Cancer: A Single Institutions Experience with Cytoreductive Surgery (CS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) C. Ihemelandu,* P. Sugarbaker. Surgery, MedStar Washington Hospital Center, Washington, DC.

Introduction: - Most stage IV gastric cancer patients present with nonoperable disease, and even in those with operable disease, rates of relapse are high and prognosis is poor. Our aim was to analyze the clinicopathologic characteristics, prognostic factors, and overall survival associated with stage IV gastric cancer Methods: - A retrospective analysis of a tumor registry for all patients treated for stage IV gastric cancer between 1991-2012 at a tertiary institution. Results: - Of 231 patients there were 127(55.0%) males vs. 104(45.0%) females. The mean age at diagnosis was 66 years. Seventy-eight (33.8%) patients presented with a signet ring vs. 153(66.2%) with an intestinal histology. Twenty-six (11.3%) patients were treated with CS and HIPEC vs. 64(27.7%) and 141(61%) respectively who were treated with surgery and systemic chemotherapy, and no surgical intervention. In univarate analysis signet ring tumors had a better overall median survival 5 vs. 3 months (p=0.04). Amongst the cohort of patients treated with CS and HIPEC the median survival was 40 months for the signet ring histology vs. 8 months for the intestinal. Median survival time was 14 months for patients treated with CS and HIPEC vs. 6 and 2 months respectively for those treated with surgery and systemic chemotherapy or no surgery. One, 3 and 5 year survival was 51%, 38% and 29% respectively for patients treated with CS and HIPEC vs.39%, 16% and 9%, and 14%, 2% and 0% for surgery and no surgery. Significant predictors of an improved survival in multivariate analysis were a young age at diagnosis (p<0.000), treatment with CS and HIPEC (p<0.000). Gender, race, tumor pathology, use of radiation therapy and systemic chemotherapy did not achieve significant status. Conclusion: - Young age at diagnosis and use of CS and HIPEC are independent predictors for an improved overall survival in patients diagnosed with stage IV gastric cancer. Paradoxically signet ring pathology demonstrated an improved survival over the intestinal pathology when treated with CS and HIPEC.

A Comprehensive Assessment of Neoadjuvant Therapy for Pancreatic Adenocarcinoma: Results from the National Cancer Database (NCDB) R.S. Lewis,* J.A. Drebin, D.L. Fraker, C.M. Vollmer. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Introduction: Limited, early experience from specialty centers suggests neoadjuvant therapy for pancreatic adenocarcinoma (PDAC) holds promise for enhancing patient selection, improving survival, or both. A comprehensive, contemporary assessment of its utilization on a national scale is lacking. Methods: Surgical patients with diagnoses of invasive PDAC between 1998-2010 were identified from the NCDB. Neoadjuvant patients (NA) were defined as those who received chemotherapy and/or radiation before surgery. NA and surgery-first patients (SF) were compared and survival analysis was conducted on patients treated between1998-2005. Results: Among 232,539 PDAC patients overall, 43,724 were SF. 2,680 NA cases (5% of surgeries) were contributed by 532 institutions, 10 of which provided 31% of the cases. The use of NA doubled (6-12% of surgical PDAC) between 2006-2010. One-third of NA patients had chemotherapy only. When compared to SF patients, NA patients were treated in academic centers more often (66.4% vs. 51.9%: P<0.001). Charlson comorbidity scores did not differ. Only 17% of NA patients were clinical T4, suggesting few were locally advanced. Median days from diagnosis to surgery were 122 in NA patients. Mean postoperative stay was shorter in NA patients (11.0d vs. 12.0d; P<0.001). 30-day surgical mortality for NA was 2.8% vs. 4.9% for SF (P<0.001). Additional systemic therapy was applied to 29.3% of NA patients postoperatively. NA patients had median survival from diagnosis of 19.9 vs. 15.3m in SF (P<0.001); however, long-term survival was equivalent (5-year=14% in both). Survival benefit was observed for NA in all Stages except Stage I. There was significant regional and institutional variation in NA survival rates Conclusion: National utilization of NA therapy has increased significantly in recent years, and now represents a common treatment path for patients with PDAC. Although this does not reflect an intention-to-treat analysis. NA functions well as a patient selection technique, as it improves postoperative outcomes. Furthermore, NA therapy appears to improve survival in advanced stage disease but not in earlier tumors.

P372

Limited Esophagogastrectomy with Jejunal Interposition for Gastro-esophageal Junction (GEJ) Adenocarcinoma: A Good Option for Early and Select Cases with Advanced Disease D. Yakoub,* E. Paulus, L. Stone, A.S. Livingstone, D. Franceschi. University of Miami-Division of Surgical Oncology, Miami, FL.

Introduction The need for radical resection and extensive lymphadenectomy for early adenocarcinoma of the distal esophagus and GEJ has recently been challenged. We aimed to evaluate outcomes of limited esophagogastrectomy with jejunal interposition (EG+JI) and compare it with our data for more radical esophagectomies. Methods A retrospective review of prospective database of limited EG+JI procedures performed between 2007 and 2011 was done. Only patients with GEJ adenocarcinomas (Siewert I, II and III) were included. End points were short- and long-term perioperative outcomes and 2 year survival. Comparison was made with trans-thoracic (TTE) and transhiatal esophagectomy (THE) done for the same type of tumors. Results Out of 148 patients with GEJ tumors, 123 had THE, 12 had TTE and 13 had EG+JI. There was no differences between groups as measured by Charlson comorbidity index. For those who had EG+JI, 11 were males and mean age was 62 (range: 42-82). One patient had Stage 0, 5 had stage I, 2 had stage II and 5 had stage III. Neoadjuvant chemotherapy was used in 4 patients and chemoradiation was used in one, while 8 received neither. R0 resection was achieved in all patients. Between 3 and 19 lymph nodes were harvested. Mean postoperative length of stay was 9.3 days (range 7-17 days). Overall morbidity was 46%, anastomotic leakage (15%), pulmonary, cardiac complications and wound infection (7.7%) each. Two highly comorbid patients died within 30 days because of acute myocardial infarction and pneumonia sepsis. Otherwise, all other patients fitted into survival curves predicted by their disease stage. Two year survival was 54%. There were no significant differences in perioperative outcomes in patients with stages I and II compared to those with stage III disease. There was no significant difference in perioperative outcomes and overall survival when compared to THE and TTE. Conclusion Limited EG+JI is a valid replacement technique for early GEJ tumors with comparable overall morbidity and mortality to more radical procedures. It may also be considered for select locally advanced tumors.

Variable	EG+JI (n=13)	TTE (n=12)	THE (n=123)
M/F	11/2	10/2	100/23
Age (Mean ±SD)	62±12.1	62.2±15.5	63.7±12.1
Pathological Stage			
0	1(7.7%)	0	18(14.6%)
I	5(38.5%)	1(8.3%)	25(20.3%)
II	2(15.3%)	2(16.6%)	35(28.5%)
III	5(38.5%)	9(75%)	42(34.1%)
IV	0	0	3(2.4%)
Histological Grade			
Well differentiated	0	0	6(4.9%)
Moderately differentiated	8(61.5%)	5(41.6%)	60(48.8%)
Poorly differentiated	5(38.5%)	7(58.3%)	57(46.3%)
Neoadjuvant therapy			
None	8(61.5%)	2(16.6%)	21(17.1%)
Chemotherapy alone	4(30.8%)	9(75%)	86(69.9%)
Chemoradiation	1(7.7%)	1(8.3%)	16(13%)
Lymph nodes (Mean ±SD)	100		
Retrieved	10.5±4.8 (R=3-19)	14.8±9 (R=6-40)	15.8±8.6 (R=3-48)
Positive	1.9±2.8 (R=0-8)	4.3±7 (R=0-26)	2.5±4.5 (R=0-23)
Length of stay (Mean±SD in days)	9.3±3.6	17.5±16.5	12.9±9.3
Overall morbidity	6(46%)	6(50%)	52(42.3%)
Leakage	2(15.3%)	1(8.3%)	20(16%)
Pulmonary	1(7.7%)	2(16.6%)	11(9%)
Cardiac	1(7.7%)	2(16.6%)	17(13.8%)
Sepsis	2(15%)	1(8.3%)	9(7.3%)
Wound infection	1(7.7%)	2(16.6%)	11(9%)
30 day mortality	2(15%)	1(8%)	6(4.8%)
2-years survival (%)	54	41	60

Table 1. Comparative data for GEJ adenocarcinoma patients undergoing surgical resection with curative intent.

P373

Unique Cellular Interactions between Pancreatic Cancer Epithelial Cells and the Omentum G. Lahat,* V. Feygenzon, S. Lowenstein, N. Lubezky, J. Klausner. *Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.*

Background: Omental spread is not uncommon in pancreatic ductal adenocarcinoma (PDAC), reflecting end- stage disease and short survival. The aim of the present study was to investigate cellular interactions between PDAC epithelial cells and the omentum. Methods: A xenograft nude mouse model was used to evaluate the potential in-vivo effect of human omentum on PDAC tumor growth. H&E stain of all human omantal samples was utilized to determine their exact compounds. Condition medium (CM) of non- cancerous human omental cells, incubated for 24h, was used to investigate its in-vitro effects on PANC-1 and Mia PaCa-2 cellular growth, migration, invasion and resistance to chemotherapy, A non-targeted proteomic approach was used to study the omental proteome. Results: An in-vivo experiment showed an increased PDAC tumor growth rate of PANC-1 cells co-localized with human omentum as compared to cancer cells only (p<0.05). H&E stain of paraffin- embedded omental tissues (n=10) mostly identified visceral fat cells (95%), fibroblasts, endothelial cells, and seldom-lymphocytes. Utilizing an in vitro model, we found that omental CM increased PDAC cellular growth and reduced apoptosis induced by Gemcitabine. In addition, omental CM enhanced PDAC cellular migration and invasion capacities. Our data depict that omental CM significantly enhanced endothelial cells tube formation, suggesting its role as a pro- angiogenic factor in the microenvironment of PDAC omental metastases. Using a robust proteomic approach we compared non-cancerous omental samples (n=5) to same patients subcutaneous samples (n=5). In this analyses we identified numerous distinctive omental proteins related to high metabolic activity and increased cellular stress, potentially involved in the formation and progression of PDAC omental metastasis. Conclusion: These findings provide several insights into the cellular interactions between the omentum and PDAC cells. Understanding the molecular mechanisms of this lethal event can provide knowledge of PDAC progression and metastasis which may eventually identify novel diagnostic, prognostic, and therapeutic targets.

P374

Intraoperative Assessment of the Pancreatic Neck Margin during Pancreaticodoudenectomy for Adenocarcinoma is Unlikely to Benefit the Patient Y.M. Hashim,¹* K.M. Trinkaus,² D. Linehan,¹ S.S. Strasberg,¹ R.C. Fields,¹ W.G. Hawkins.¹ *1. Washington University* School of Medicine - Department of Surgery, St. Louis, MO; 2. Wash-

ington University School of Medicine - Division of Biostatistics, St. Louis, MO.

Introduction: Pancreas cancer is the fourth leading cancer death in the United States. Surgery is considered the only potential cure. A positive surgi-

cal margin has been shown to negatively impact survival. However the benefit of intraoperative assessment of the neck margin with subsequent additional resection remains controversial. Is a positive neck margin an indicator of poor biology? Does additional resection benefit patients? Methods: A retrospective review of patients who underwent pancreaticodoudencetomy for pancreatic adenocarcinoma between 1997 and 2012 was performed. Logistic regression was used to identify the association of the neck margin frozen section (FS) status with other predictors of prognosis. The overall survival (OS) was calculated using Kaplan Meier method. Results were expressed as p-values and odds ratio estimates with 95% confidence intervals Result: Frozen section of neck margin was obtained in 412 patients and 29 were identified intraoperatively as R1. Twenty five patients underwent additional resection and thirteen patients (52%) were converted to an R0 resection after assessing all margins. Female patients were 3.8 times more likely than male patients to have a positive FS margin. Each additional cm of tumor size increased the odds of a positive FS margin by 36%. Patients with any positive permanent section were about 3.5 times more likely than those with negative permanent sections to have a positive FS. Among the 29 patients with positive initial FS, there was no significant difference in OS between patients who were converted to R0 and those who remained R1, p = 0.3. The only independent predictor of survival on multivariate analysis was nodal status p = 0.002. Conclusion: The only independent predictor of survival was nodal metastasis. Extending the resection to achieve a negative margin did not improve OS. Assessment of neck margin FS adds expense and time to pancreaticoduodenectomy. These data suggest that intraoperative FS is unlikely to yield significant benefit. More comprehensive evaluation of the utility of this common practice should be conducted.

P375

Routine Cyst Fluid Cytology is not Indicated in the Evaluation of Pancreatic Cystic Lesions L.A. Shirley,* J. Walker, S. El-Dika, S. Krishna, P. Muscarella, C. Ellison, C.R. Schmidt, M. Bloomston. *The Ohio State University Wexner Medical Center, Columbus, OH.*

Background: The diagnostic workup of cystic lesion of the pancreas often involves endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) of cyst contents. In addition to CEA and amylase measurement, fluid is routinely sent for cytologic examination. We evaluated the diagnostic utility of these cytologic findings in clinical decision-making. Methods: A retrospective review was performed of patients who underwent EUS-guided pancreatic cyst aspiration. Findings from axial imaging and EUS were reviewed and compared to cyst fluid cytology. Results: A total of 167 patients were reviewed. In the 48 patients who had suspicious findings on ultrasound, such as combined solid and cystic lesions, presence of enhanced or thickened cyst walls, confluence of thick septations, or intramural nodules, cytology yielded diagnostic information in 89.6% of cases (43 patients). However, in the 119 patients where no solid or suspicious components were revealed on ultrasound, fluid cytology vielded no significant diagnostic results in any case. In all cases where mucin was noted on cytologic review, thick fluid was also seen at the time of aspiration. Conclusions: In the absence of suspicious radiologic or EUS findings, cytologic analysis of pancreatic cyst fluid yields no benefit. In such cases, fluid that would otherwise be sent for cytologic evaluation would be better served for other purposes, such as molecular analysis or banking for future research.

P376

Utilization of Laparoscopy for Resections of Stomach and Esophagus Cancers: Is Hospital the Deciding Factor? L. Bliss, ¹* Z. Chau, ² C.J. Yang, ¹ J.K. Smith, ² E.R. Witkowski, ² E. Ragulin-Coyne, ² S. Ng, ¹ J.F. Critchlow, ¹ A.J. Moser, ¹ J.F. Tseng. ¹ *1. Beth Israel Deaconess Medical Center, Cambridge, MA; 2. University of Massachusetts Medical School, Worcester, MA.*

Background: Foregut surgery is technically complex. Outcomes for such high-stakes operations receive increasing scrutiny and the use of minimally invasive approaches has been further adopted. This study aims to determine national trends in laparoscopy utilization and patient outcomes for potentially curative cancer resections of the esophagus and stomach. Methods: Retrospective review of all esophageal and gastric cancer resections in the Nation wide Inpatient Sample during 1998 to 2011. Univariate analyses of sex, race, admission status, Elixhauser comorbidity score, year, insurance, hospital characteristics, procedure, and center volume were performed by chi-square.

Cochran-Armitage test was used for trends. Logistic regressions were used to model inpatient mortality, complications and laparoscopy. Results: From 1998 to 2011, 120,527 and 25,540 patients (nationally-weighted records) underwent gastrectomies and esophagectomies for cancer. From early (1998-2002) to late (2008-2011) study years, inpatient mortality decreased from 6.69% to 3.88% (<0.0001) and complications increased from 27.41% to 31.63% (<0.0001) for gastrectomy. Similarly, inpatient mortality decreased from 9.75% to 5.53% (<0.0001) and complications increased from 37.69% to 43.07% (<0.0001) for esophagectomy. Use of laparoscopy in gastrectomy increased from 1.64% to 5.89% (p <0.0001) and in esophagectomy from 0.80% to 5.74% (<0.0001). Patients undergoing laparoscopy had lower inpatient mortality (3.13% vs. 5.96%, p=0.0010) and were less likely to experience complications (26.20% vs. 31.47%, p=0.0121). After adjustment, independent predictors of the use of laparoscopy included elective admission, female sex, resection after 2003 and resection at a large (vs. medium), urban, teaching high volume center (vs. low volume center) in the Northeast (vs. Midwest and South). Conclusions: Inpatient mortality and complications for gastrectomy and esophagectomy have improved over the past decade. Use of minimally invasive techniques is expanding with associated superior patient outcomes. Resection hospital characteristics drive which patients undergo laparoscopy for esophagus and stomach cancers.



P377

Integrin-linked Kinase is Upregulated in the Stroma of Pancreatic Cancer and Expression Patterns are Associated with Survival L.A. Shirley,¹* B. Swanson,¹ W. Frankel,¹ T. Bekaii-Saab,¹ M. Bloomston,¹ C. Chen.² 1. The Ohio State University Wexner Medical Center; Columbus, OH; 2. The Ohio State University College of Pharmacy, Columbus, OH

Background: Integrin-linked kinase (ILK), a serine/threonine protein kinase that normally plays a role in cell-extracellular matrix interactions, has been shown to promote invasion in pancreatic cancer. Due to these functions of ILK, we wanted to examine ILK expression in the stroma of several pancreatic specimen types and, in cancer, determine if a relationship exists between ILK expression in the tumor and its surrounding stroma. Methods: A tissue microarray (TMA) of pancreatic cancer samples (n=37) was stained for ILK expression by immunohistochemistry and scored zero (no expression) to three (high expression) in both tumor and stroma. Stromal ILK expression was also scored in 34 samples of chronic pancreatitis and 15 of normal pancreatic tissue. For cancer samples, a clinical database was queried to compare survival based on ILK expression in the tumor, stroma, and the relationship between the two. Results: ILK expression was significantly higher in the stroma of pancreatic cancers versus tumors in the same tissue (mean score 2.34 vs. 1.32, p <0.001). Stromal ILK expression was significantly higher in cancer as compared to normal pancreas (mean score 0.73, P<0.001) and chronic pancreatitis (mean score 1.38, p<0.001). Neither tumor nor stromal expressions alone were associated with overall survival. However, a review of expression patterns revealed that patients who had equal, or balanced, expression of ILK in tumor and stroma had a worse prognosis (median OS 7.8 months) than those with unbalanced expression (13.8 months, p=0.006, figure 1), even when stratified by nodal status (node positive 8.0 vs. 13.9 months, node negative 5.3 vs. 13.8 months, p=0.03). Conclusion: Stromal ILK expression increases from normal pancreas to chronic

pancreatitis to pancreatic cancer. Thus, ILK inhibition may provide a way to specifically target the tumor microenvironment while sparing normal stroma. Additionally, in patients with cancer, balanced expression in tumor and stroma was associated with worse survival, revealing a possible role of ILK in the crosstalk between tumor and stroma and progression of disease.



P378 Morbidity and Mortality Associated with Gastrectomy: National Surgical Quality Improvement Project Review W. Papenfuss,* M. Kukar, K. Attwood, S. Nurkin, N. Wilkinson. *Roswell Park Cancer Institute, Buffalo, NY.*

Background: Gastrectomy for the treatment of gastric cancer remains a mainstay of therapy and may be curative in early stage disease. Unfortunately, surgery alone is inadequate for advanced stage disease and as such more aggressive surgery (en bloc resection or extended lymphadenectomy) are often advocated. Unfortunately, surgical complications may delay or make impossible the delivery of adjuvant therapy. Understanding the actual measured incidence of these complications is needed for multidisciplinary planning and patient counseling. Material and Methods: The American College of Surgeons-National Surgical Quality Improvement Project (ACS-NSQIP) database was queried for patients who underwent gastrectomy for malignancy (ICD-9- 151.X) at participating NSQIP hospitals from 2005-2010. Thirty day mortality and morbidity were evaluated. Results: 2,580 patients underwent gastrectomy for malignancy divided as total gastrectomy (TG) 999 (38.7%) and partial gastrectomy (PG) 1581 (61.3%). Overall, serious morbidity occurred in 23.6% and the 30 day mortality 4.1% Patients receiving a TG where younger and healthier than those receiving a DG for the following measured criteria: age, diabetes, COPD and HTN. Serious morbidity and mortality were significantly higher in the TG group than PG group, 29.3% vs. 19.9%, p<.001 and 5.4% vs. 3.4%, p<.001, respectively. The inclusion of additional procedures increased the risk for serious morbidity and mortality for the following: splenectomy (ORs = 2.1 and 2.9), pancreatectomy (ORs = 2.0 and 3.5), esophagectomy (ORs = ns and 3.5) or colectomy (ORs = 2.3 and 3.6). All were statistically significant. Abdominal lymphadenectomy decreased the risk of mortality; OR = 0.468 and p = 0.028. Conclusions: Gastrectomy for cancer as currently practiced carries a high morbidity and mortality. Inclusion of additional major procedures further increases these risks. The addition of lymphadenectomy was not associated with increased morbidity or mortality.

P379

Elevated Neutrophil to Lymphocyte Ratio (NLR) in Gastric Cancer Portends Poor Prognosis Regardless of Stage N.D. Saunders,* E. Haverick, J.H. Howard, S. Abdel-Misih, M. Bloomston,

C.R. Schmidt. Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH.

Background: The neutrophil-to-lymphocyte ratio (NLR) is a marker for systemic inflammation and is associated with outcome in many cancers. After

IRB approval, we reviewed our experience in patients with gastric cancer who underwent resection to determine if preoperative NLR was associated with outcome. Methods: The records of 194 consecutive patients who underwent partial or total gastrectomy for gastric adenocarcinoma were retrospectively reviewed. There were 148 (76%) patients with preoperative complete blood count (CBC) and differential allowing calculation of NLR. These were divided into those with NLR \geq 5 and those with NLR < 5. Baseline patient and tumor factors as well as outcomes were compared between the groups. Patients who died within 30 days of operation (N=4, 2.7%) or who underwent operations for palliative intent (N=16, 11%) were excluded from the outcomes analysis. Results: There were 19 patients (13%) with preoperative NLR \ge 5. Smoking use was associated with NLR \geq 5 (P=0.02, Chi-square), and there was a trend for association with palliative intent of operation (P=0.06, Chi-square). Median overall survival (OS) in the 128 patients examined for outcome analysis was 28.4 months NLR > 5 was associated with median OS of 10.6 months compared to 28.4 months if NLR was < 5 (P=<0.01, log rank). Median recurrence-free survival was 9.7 months if NLR was ≥ 5 and was not reached in the NLR < 5 group (P=0.04, log rank). Pathologic stage and preoperative NLR were both independently associated with OS by multivariate analysis (Cox proportional-hazards). NLR \ge 5 was associated with poor outcome even in patients with pathologic stage I or II disease (Figure, P<0.01, log rank). Conclusions: Elevated NLR \ge 5 is associated with poor outcome in patients with gastric cancer after resection. This is true even for patients with earlier stages of disease. Since NLR is easily calculated from a preoperative CBC with differential, this should be done for patients with gastric cancer before initial therapy. Elevated NLR in the setting of otherwise early clinical stage gastric cancer might prompt the treating oncologist to consider neoadjuvant therapy.



Figure - Overall survival in patients with stage I/II gastric cancer compared for those with NLR \ge 5 or < 5.

P380

Actual 5-year Survival for Chemotherapy-naïve Patients with N0 Gastric Adenocarcinoma M. Michel, L. Stevens, A. Saha,* S. Yeluri, H. Sue-Ling, S.L. Dexter, A.I. Sarela. *St. James's University Hospital, Leeds, United Kingdom.*

Introduction Identification of biologic factors associated with recurrence and survival after curative resection N0 gastric adenocarcinoma may extend the role and utility of adjuvant therapy for some patients. This study aimed to describe pathological characteristics and patterns of recurrence of patients with node-negative gastric cancer and outline prognostic factors for survival. Methods A database of all gastrectomies for cancer performed by 3 surgeons from September 2001 to September 2013 contained 381 patients and was used to identify patients with a minimum follow-up interval of 5 years and N0 disease. The standard practice included D2 lymphadenectomy. Results From September 2001 to September 2008, 236 patients had gastrectomy for gastric cancer of which75 (32%) had nodenegative disease. 8 patients received neo-adjuvant chemotherapy and 6 patients had incomplete data and were excluded from this study. Of the remaining 61 patients, 36 had subtotal gastrectomy; the other 25 patients had total gastrectomy. Median lymph node yield was 35 nodes (range, 7-48); more than 15 nodes were retrieved in 52 patients (85%). T-stage was T0 (4 patients, 7%), T1 (24, 38%), T2 (24, 39%) or T3 (9 patients, 16%). Six patients (10%) developed recurrent disease; 5 had T2 disease and 1 had T3 disease; 4 had poor differentiation and 3 had vascular invasion. At least 15 lymph nodes were retrieved from all patients . Sites of metastases were in the peritoneum (2 patients; disease-free intervals, DFI, 2 years and 8 years), liver (2; DFI, 16 months and 18 months), breast (1; DFI, 9 months) and pancreas (1; DFI, 25 months). Overall actual 5-year survival was 76%. Conclusions Chemotherapy naïve patients with adequately staged (> 15 nodes) N0 gastric adenocarcinoma had actual 5 year survival of 76%. The risk of recurrence was predicted by poorly differentiated tumour.

P381

Significance of Anatomic Site on Prognosis in Gastrointestinal Stromal Tumors (GIST) M. Kukar,^{1*} A. Groman,² A. Kapil,¹ S.R. Grobmyer,³ S.N. Hochwald.¹ *1. Roswell Park Cancer Institute, Surgical Oncology, Buffalo, NY; 2. Roswell Park Cancer Institute, Biostatistics, Buffalo, NY; 3. Cleveland Clinic, Section of Surgical Oncology, Cleveland, OH.*

Introduction: Several series of resected GISTs have identified tumor size and mitotic rate as prognostic variables and have indicated that GISTs in uncommon locations have worse survival. Our large database analysis aims to determine the prognostic significance of GISTs in the esophagus, colon and rectum. Methods: The Surveillance Epidemiology and End Results (SEER) database was queried from 1990 to 2009 using CS SCHEMA v0203 and histology codes 33, 37, 39, 40, 41. Using site specific surgery codes, patients undergoing surgical resection were identified. Characteristics of esophageal, small intestine, colon and rectum GISTs were each compared to gastric GISTs using univariate and multivariate analysis. Results: 4817 GISTs (34 Esophageal, 2933 Gastric, 1555 Small intestine, 139 Colonic and 156 rectal) were identified. There was a 24% increase in overall incidence in 2005-2009 as compared to 2000-2004 (3.9 to 4.8/10,000/year). Univariate and multivariate predictors of worse survival in all patients and in surgical resection group include age, race, gender, advanced stage, tumor size > 10cm, no surgical intervention and anatomical location. Overall median survival was 99 months in all patients vs.113 months in surgical resection group (Esophageal 61 vs. 97 months, Gastric 101 vs. 124 months, Small intestine 103 vs. 107 months, Colonic 52 vs. 68 months, Rectal 105 vs. 131 months respectively). Survival for surgical resection group was worst in colonic GIST group>small intestine>gastric=esophageal=rectum, Figure 1. Conclusions: Our results show a rising incidence in GIST and challenges previous findings by demonstrating that esophageal, rectal and gastric GISTs have similar survival. In addition, this is the first study to demonstrate that colonic GISTs have decreased survival compared to rectal GISTs.



Figure 1: Overall survival in resected GIST patients based on anatomical location.

P382

Factors Predictive of Survival in Patients with Node-negative Pancreatic Cancer: Implications for Selective Treatment A.R. Cyr, A. Asghar, S.L. Mott, H. Hoshi, J.R. Howe, J.J. Mezhir.* Surgical Oncology and Endocrine Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA.

Introduction: Prognostic variables in patients with node negative pancreatic cancer may be different than those with node positive disease, which is the dominant predictor of survival in patients with pancreatic cancer following resection. Since data on this subgroup of patients are limited, the objective of this study is to evaluate variables associated with survival following resection in patients with node negative disease. Methods: A retrospective review of a pancreatectomy database was performed and survival was evaluated and compared between patients with node negative (N-) and node positive (N+) pancreatic cancer. Patients who died within 90 days of resection or who had gross residual disease (R2/M1) were excluded. Results: There were 201 patients who met criteria for analysis; 136 patients (67.7%) had a margin negative resection (R0) and 65 (32.3%) had microscopic positive disease (R1). There were 87 patients (43.9%) with N- disease, and 123 (69.9%) were treated with adjuvant therapy. At a median follow-up of 28 months (range 3.3-194.7), 140 patients died (75.3%). On univariate analysis, factors associated with worse survival included R1 resection, advanced T stage, and N+ disease. Independent predictors of survival on multivariate analysis included R1 resection and N+ disease. Adjuvant therapy was not associated with improved survival for the entire cohort. When evaluated separately in a univariate analysis, patients with N- disease had worse survival with R1 resection, which was not significant in N+ patients. Adjuvant therapy was associated with a significant improvement in survival in patients with N+ disease, however patients with N- disease had equivalent survival whether or not they received adjuvant therapy (Figure). Conclusions: In this study, patients with N- pancreatic cancer had different factors that predict outcome compared to those with N+ disease. These include the significance of negative margins and the lack of improvement in survival from adjuvant therapy. These data highlight the biologic differences in behavior of N- vs. N+ pancreatic cancer, which have important implications for patient specific treatment.



Figure. Overall survival following resection in patients with N- and N+ pancreatic cancer with and without adjuvant therapy.

P383

Metabolomic Profiling of Gastrointestinal Stromal Tumor (GIST) and its Response to Imatinib Therapy D. Yakoub,¹* V. Marks,²

A. Paz Mejia,³ J. Walls,² J. Trent,³ A.S. Livingstone.¹ 1. University of Miami-Division of Surgical Oncology, Miami, FL; 2. University of Miami-Division of Chemistry, Miami, FL; 3. University of Miami-Division of Medical Oncology, Miami, FL.

Background: There is a growing need for novel drugs to treat resistant GIST. The goal of this study was to evaluate the time course of metabolic changes in GIST cells treated with the tyrosine kinase inhibitor imatinib mesylate. Methods: Human GIST T1 cells were incubated with imatinib 0.5 mM. IH-NMR spectra were acquired using a 500MHz NMR spectrometer equipped with a cryoprobe head at 298 K. One-dimensional NOESYpr1D pre-saturation pulse program was used. Spectra were imported into the NMR Suite Processor. Effect was measured in extracted cell pellets and media at 24 and 48 hours and compared with controls to assess global metabolic profiles including drug effect on glucose metabolism, energy state and lipid metabolism. Results: By 48 hours, cells shifted from cytosolic glycolysis towards the mitochondrial Krebs cycle, as indicated by glucose initial increase then significant decrease with latate production and minimal changes in pyruvate; in addition to elevated glutamine and glutamate synthesis. Proline, alanine, AXP, glutathione,

succinate mildly increased denoting initial cellular stress response. Aspartate, isoleucine, leucine, myoinositol, tyrosine, valine and especially cell membrane phospholipids as phosphocholine, mildly increased while glycerophosphocholine significantly decreased denoting inhibited growth and invasiveness. Creatine, choline, phenyl-alanine and taurine showed minimal changes. Volatile molecules as formate increased of unclear significance. Conclusion: Metabolomic profiling of GIST cells exposed to signal transduction modulators supplements molecular findings and provides further mechanistic insights into longitudinal changes of the mitochondrial and glycolytic pathways of oncogenesis, it can potentially provide novel as well as complementary therapeutic targets.



Figure 1. GIST cell extracts metabolite concentration trends over time when incubated with imatinib mesylate (spectra referenced to DSS, normalized data)

P384

CT-based Assessment of Sarcopenia as an Outcome Predictor in Patients Undergoing Pancreaticoduodenectomy J.P. Namm,^{1*}

W. Dale,² A. Palakodeti,¹ J.A. Hemmerich,² S.J. Stocker,³ R. Rothman,² A. Kamm,¹ E.C. Poli,¹ M.S. Baker,³ M.S. Talamonti,³ E. Choi,¹ M.C. Posner,¹ J.B. Matthews,¹ K.K. Roggin.¹ *1. Department of Surgery, University of Chicago, Chicago, IL; 2. Section of Geriatrics and Palliative Medicine, Department of Medicine, University of Chicago, Chicago, IL; 3. Department of Surgery, NorthShore University Health Center, Evanston, IL.*

Objective: Pancreaticoduodenectomy (PD) is associated with high perioperative morbidity. Up to 35% of older patients undergoing PD demonstrate characteristics of frailty according to geriatric assessments. Sarcopenia, characterized by decreased muscle mass and strength, is an important component of frailty and is associated with adverse clinical outcomes. We investigated whether pre-operative, standardized CT-based assessments of sarcopenia independently predicted surgical outcomes following PD. Methods: An analysis of pre-operative, pre-contrast phase abdominal CT scans was performed on surgical outcomes in a prospective cohort of patients undergoing a PD from 2007 to 2013 (n=99). Blinded to outcomes, the psoas muscle cross-sectional area was measured at the level of the L3 vertebra and normalized to the subject's height as the total psoas area (TPA) index to assess muscle mass. The attenuation of the psoas muscle was measured in Hounsfield units (HU) to assess muscle strength. Multivariate logistic and linear regressions were used to analyze the impact of sarcopenia on outcomes which include complications, length of stay (LOS), return to ICU, and discharge to a skilled nursing facility (SNF) while controlling for age, body mass index (BMI), comorbidities, American Society of Anesthesia score (ASA), and serum albumin. Results: The sample was 86% men with a median age of 67 years (range 28-88). The mean TPA index was 5.88 \pm 1.53 cm²/m² and the mean psoas muscle HU was 47 \pm 7. TPA index correlated with return to ICU (OR 2.00, p=0.07) and discharge to a SNF (OR 0.69, p=0.084). Psoas muscle HU was an independent predictor for LOS (β -0.33, p=0.047) and return to ICU (OR 0.82, p=0.022). BMI was predictive of pancreatic fistula (OR 1.17, p=0.023), return to ICU (OR 0.79, p=0.041), and wound dehiscence (OR 1.2, p=0.031). Conclusion: TPA index and psoas muscle HU are CT-based measures of sarcopenia which are easily measured on pre-operative scans of patients undergoing PD. In addition to other pre-operative clinical assessments, TPA index and psoas muscle HU can be used to predict PD complications including return to ICU and LOS.

P385

The Causes for Readmissions after Pancreatic Resections which are Preventable E. Sadot,* L. Ser Yee, P. Allen, M. Gönen, J. Groeger, T. Kingham, M. D'Angelica, R. DeMatteo, W. Jarnagin, Y. Fong. Sur-

gery, Memorial Sloan Kettering Cancer Center, New York, NY.

Background: As an effort to decrease healthcare expenditure, hospital readmission rates have recently been brought to the forefront of policymakers' attention. Our goal was to clarify the extent and identify reversible factors for readmission after pancreatic resections in a dedicated high volume center. Methods: Medical records of patients who underwent pancreatic resection between 2008-2012 were reviewed. Results: A total of 400 patients were reviewed. The 30-day and 90-day readmission rates were 23% and 30%, respectively. Whipple procedure was performed in 59% of patients and distal pancreatectomy in 31%. Most of the indications were neoplastic tumors (94.3%) which originated mainly from the pancreas (88.2%). The most common causes for 30-day readmissions were surgery related infections and anastomotic leaks (50%), and then drain malfunction (12%). The average interval between discharge and 30-day readmission was 9.4+6.77 days. Multivariate analysis identified the following risk factors: complication grade 3 (OR=2.3; CI: 1.3-5.2; P=0.009), discharge with drain (OR-3.5; CI: 1.7-7.5; P=0.001), total pancreatectomy (OR-6.8; CI: 1.4-32; P=0.02), and preoperative bilirubin (OR=1.1; CI: 1.02-1.2; P=0.01). The independent risk factors for 90-day readmissions were: malignant tumor (OR=2.6, CI: 1.2-5.4, P=0.01), delayed gastric emptying (OR=3.6; CI: 1.1-11; P=0.03), and anastamotic leak (OR=4.7; CI: 2.3-9.5; P<0.001). The leading causes for admissions of patients between 31-90 days after discharge were: non specific symptoms (41%) and non surgical infections (21%). Twenty-eight patients visited our Urgent Care Center (UCC) at a range of 1-60 days after discharge but were not admitted. Their most common diagnosis was wound infection (36%). Survival analysis demonstrated no difference for any of the readmission groups. Conclusions: our results demonstrate that effort should be directed toward the 30day group in which the causes and the risk factors are mainly surgery related as opposed to the 90-day group which is influenced by the natural history of the cancer.

Analy	/sis	of	factors	associated	with	30-dav	readmissions:
u i i cu i y		U .	1001010	abboonatoa	*****	00 44,	1000010101

Covariates	Readmitted (n=91)	Not Readmitted (n=307)	p-value	Multivariate analysis (OR; CI)	p-value
Age At Surgery, year (n)	65±13 (91)	67±11 (307)	0.13		
Bilirubin total (preoperative), (n)	2.5±4.1 (90)	1.5±2.9 (304)	0.01	1.1; 1.02-1.2	0.01
Operative Procedure:					
Whipple (n)	65% (59)	57% (176)	0.2		
Distal pancreatectomy (n)	23% (21)	34% (103)	0.06		
Total pancreatectomy (n)	5.5% (5)	0.01% (3)	0.02	6.8; 1.4-32	0.02
Central pancreatectomy (n)	5.5% (5)	3.6% (11)	0.4		
Multivisceral resection (n)	1.1% (1)	2% (6)	0.6		
Other Pancreatic resection (n)	1.1% (1)	4.5% (14)	0.12		
Malignant Tumor (n)	72% (65)	67% (206)	0.36		
Positive Margin (n)	11%(10)	9% (307)	0.6		
T3-T4 (n)	51% (47)	50% (154)	0.8		
Node Positive (n)	37% (34)	39% (120)	0.68		
Discharge with Drain (n)	34% (31)	8% (25)	< 0.001	3.5; 1.7-7.5	0.001
Discharge Disposition:					
home (n)	60% (55)	76% (232)	0.005		
with VNS (n)	37% (34)	23% (70)	0.005		
to rehab (n)	2.2% (2)	1.6% (5)	0.7		
Postoperative Complications:					
Any Complication (n)	67% (61)	46% (142)	< 0.001		
Complication G1-G2 (n)	30% (27)	35% (108)	0.3		
Complication G3 (n)	37% (34)	11% (34)	< 0.001	2.6; 1.3-5.2	0.009
Any Anastomotic Leak (n)	29% (28)	7.5% (23)	< 0.001		
Pancreatic leak (n)	23% (21)	6% (19)	< 0.001		
Intra-abdominal abscess (n)	12% (11)	4% (13)	0.006		
Postoperative transfusions (n)	33% (30)	61% (205)	0.009		
ICU stay (grade 4 complication)	7.7% (7)	7.8% (24)	0.97		

Radiographic Response to Neoadjuvant FOLFIRINOX for Advanced Non-metastatic Pancreatic Cancer is not Required to Proceed with Resection J. Onesti, ^{1*} M. Blazer,² T. Williams, ³ R.M. Goldberg, ⁴ T. Bekaii-Saab, ⁴ M. Bloomston.¹ *1. Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH; 2. Pharmacy, The Ohio State Wexner Medical Center, Columbus, OH; 3. Radiation Oncology, The Ohio State Wexner Medical Center, Columbus, OH; 4. Medical Oncology, The Ohio State Wexner Medical Center, Columbus, OH.*

Background: Response to neoadjuvant therapy in advanced pancreatic cancer is notoriously difficult to assess. We sought to determine if radiographic response (or lack thereof) following neoadjuvant FOLFIRINOX in advanced nonmetastatic pancreatic cancer was predictive of true resectability. Methods: Patients treated with neoadjuvant FOLFIRINOX for borderline resectable (BR) or locally advanced (LA) pancreatic adenocarcinoma were reviewed. Imaging before and after chemotherapy were compared to operative findings and, when applicable, the final pathology. Results: Seventeen patients were included (10 LA and 7 BR). FOLFIRINOX was given for an average of 2.8 (range 1-6) months. Radiographic response was seen in 5 (29%), stable disease in 6 (35%), and progression in 6 (35%) (Table). Three were not offered resection due to metastatic disease (N=1) or unreconstructable vascular invasion (N=2). The remainder (N=14) were explored, despite the anticipated need for vascular resection (N=11). Twelve (71%) were resected with 10 having negative margins. Major vascular resection was only required in 3 (1 venous, 2 arterial). There were no postoperative deaths. Conclusions: Lack of radiographic response to neoadjuvant FOLFIRINOX for advanced non-metastatic pancreatic cancer does not predict unresectability. Major vascular involvement (with suitable replacement) should not deter the surgeon and will often not be required. Patients with traditionally unresectable disease who have undergone neoadjuvant FOLFIRINOX can still be considered for potentially curative surgery regardless of the degree of radiographic response.

	Radiographic Assessment			
	Progressed	Stable	Improved	
N	6	6	5	
LA/BR	4/2	5/1	1/4	
Explored	3 (50%)	6 (100%)	5 (100%)	
Resected	2 (33%)	5 (87%)	5 (100%)	
Vascular Resection	0	3	0	
R0	2 (100%)	4 (80%)	4 (80%)	

LA: Locally Advanced

BR: Borderline Resectable

P387

Factors Associated with Recurrence in Lymph Node-negative Gastric Adenocarcinoma: Results from the U.S. Gastric Cancer Collaborative L.X. Jin,^{1*} M.H. Squires,² G. Poultsides,³ K.I. Votanopoulos,⁴ S.M. Weber,⁵ M. Bloomston,⁶ T. Pawlik,⁷ W.G. Hawkins,¹ D. Linehan,¹ S.M. Strasberg,¹ A.W. Archer,⁵ K. Cardona,² C. Cho,⁵ D.A. Kooby,² E.A. Levine,⁴ E. Winslow,⁵ N.D. Saunders,⁶ G. Spolverato,⁷ S.K. Maithel,² R.C. Fields.¹ *1. Washington University in St. Louis, St. Louis, MO; 2. Emory University, Atlanta, GA; 3. Stanford University Medical Center, Palo Alto, CA; 4. Wake Forest School of Medicine, Winston-Salem, NC; 5. University of Wisconsin School of Medicine and Public Health, Madison, WI; 6. The Ohio State University Comprehensive Cancer Center – The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH; 7. Johns Hopkins University, Baltimore, MD.*

Background: Lymph node (LN) status is a predictor of recurrence after gastrectomy for gastric adenocarcinoma. Clinicopathologic predictors of recurrence in patients with node-negative disease are less well established. Methods: Patients who underwent surgery with curative intent for gastric adenocarcinoma from between 2000 and 2012 from participating institutions of the U.S. Gastric Cancer Collaborative were analyzed. Patients who died within 30 days of surgery were excluded. Univariate and multivariate analysis of clinicopathologic factors associated with recurrence was performed. Results: Nine-hundred sixty-five patients from seven institutions were included in the analysis. Three-hundred forty-five (36%) had LN(-) disease, of whom 63 (18%) had disease recurrence after a median follow-up of 24 months. The most common patterns of recurrence were: peritoneal alone (44%), liver (22%), or combined liver/peritoneal (9%). This distribution did not differ significantly from LN(+) disease. Univariate analysis identified tumor size, linitis plastica, diffuse histology, poor differentiation, signet ring histology, T stage \geq 3, perineural invasion, and lymphvascular invasion as risk factors for recurrence. On multivariate analysis, T stage \geq 3 (OR 3.6, 95% CI=1.7-7.5) and poorly differentiated histology (OR 2.4, 95% CI=1.2-4.9) were independent predictors of recurrence (Table). Conclusions: Despite the presence of negative lymph nodes, patients with T stage \geq 3 and poorly differentiated histology are at high risk of recurrence after gastrectomy for adenocarcinoma of the stomach. These factors, along with other patient and treatment-related variables, may be used to select patients who may benefit from more aggressive adjuvant therapy and to guide subsequent surveillence for disease recurrence.

Clinicopathologi intent in patie	c risk factors ents with lym	for recurren ph node neg	ce after rese ative gastric	ction with cancer (n=	curative =345)
	No Recurren	nce (n=282)	Recurrent	e (n=63)	
Variable	# of pts.	%	# of pts.	%	p value
Tumor size (x, sd)	3.3 (2.8)		5.1 (3.7)		< 0.001
T Stage					< 0.001
Tla	63	22%	4	6%	
T1b	74	26%	9	14%	
T2	42	15%	4	6%	
T3*	48	17%	21	33%	
T4a	18	6%	12	19%	
T4b	8	3%	7	11%	
Grade					0.001
Well	34	12%	3	5%	
Moderate	88	31%	10	16%	
Poor*	102	36%	38	60%	
Linitis plastica	5	2%	5	8%	0.007
Diffuse histology	39	14%	15	24%	0.05
Signet ring histology	83	29%	29	46%	0.021
LVI	37	13%	16	25%	0.017
PNI	26	9%	18	29%	< 0.001

* T stage≥3 and poorly differentiated histology are independent predictors of recurrence.

P388

Sarcopenia does not Accurately Predict Outcomes in Patients Undergoing Pancreatic Resections J. Onesti, ¹* G. Wright, ¹S.E. Kenning, ¹M.T. Tierney, ²M.G. Doherty, ³M.H. Chung. ⁴ 1. General Surgery, Grand Rapids Medical Education Partners/Michigan State University College of Human Medicine, Grand Rapids, MI; 2. Radiology, Grand Rapids Medical Education Partners/Michigan State University College of Human Medicine, Grand Rapids, MI; 3. Advanced Radiology Services, Grand Rapids Medical Education Partners/Michigan State University College of Human Medicine, Grand Rapids, MI; 4. Surgical Oncology, Spectrum Health Medical Group, Grand Rapids Medical Education Partners/Michigan State University College of Human Medicine, Grand Rapids, MI.

Background Recent studies have suggested that core muscle area and density may aid in predicting outcomes from major abdominal surgeries. Pancreatic resections, including those for patients with adenocarcinoma, have not been analyzed independently. Methods A total of 272 consecutive pancreatic resections from July 2005 to July 2011 were reviewed. Lean psoas muscle area (LPMA) was calculated by measuring the area and density of the psoas muscles at the level of the fourth lumbar vertebra, then correcting for fatty infiltrate. Preoperative risk factors including LPMA, comorbidities, albumin (g/dl), weight loss, age and gender were analyzed with a primary endpoint of overall survival as determined by Cox proportional hazards regression. Secondary endpoints, including complications, hospital length of stay, discharge destination and readmission, were evaluated using multiple and logistic regression analysis, as appropriate. Statistical analyses were then repeated to include only patients with adenocarcinoma. Results The study sample included 53% males, 63% proximal pancreatico-duodenectomies, and 52% adenocarcinoma. The mean age was 64 years, and the mean preoperative albumin was 3.4 g/dl. Complications were noted in 42% of patients, with 23% developing a Clavien-Dindo

(CD) grade III or IV complication. The majority (80%) of patients were discharged home, and 1.5% died in the peri-operative period. LPMA was predictive of discharge destination on univariate analysis (p = 0.02), but failed to show significance on multivariate analysis (p = 0.11). The mean length of follow up was 31.2 months (range 0-94), and 40% required at least one readmission. Only CD III or IV complications predicted readmission (OR 2.2: 95% CI 1.2-4.0). In patients with adenocarcinoma, age and albumin were the only preoperative factors predictive of mortality (additional ten years of age: HR 1.03: 95% CI 1.01-1.05; one additional g/dl of albumin: HR 0.50: 95% CI 0.34-0.71). Conclusions Using multivariate analysis, LPMA does not accurately predict overall survival, complications, discharge destination or readmission for patients undergoing pancreatic resection, benign or malignant.

P389

Practice Patterns and Outcome Differences for Distal Pancreatectomy in Surgeons with and without Fellowship Training S. Wu,* S. Woo, Y. Akmal. *Kaiser Permanente Los Angeles, Los Angeles, CA.*

INTRODUCTION: Recent data show that pancreatic cases account for a small percentage of general surgery training and that outcomes for major pancreatic resections are improved when performed by high-volume surgeons. Fellowship training provides additional experience for these complex procedures. While fellowship training exists, many patients undergo pancreatic resections by non-fellowship trained surgeons. OBJECTIVE: To compare operative approaches and postoperative outcomes of distal pancreatectomy performed by surgeons with and without Surgical Oncology/Hepatobiliary fellowship training. METHODS: A retrospective review of all patients who underwent distal pancreatectomy between 2005 and 2011 at twelve Southern California Kaiser Permanente Foundation Hospitals. Patients who had concurrent major organ resection or underwent surgery for trauma were excluded. RESULTS: A total of 231 patients underwent distal pancreatectomy among 52 surgeons; 16 (31%) were fellowship trained and 36 (69%) were not. Of 105 cases performed by fellowship trained surgeons, 44 (42%) were performed laparoscopically compared to 35 of 126 (28%) cases by the non-fellowship trained group. There was a significantly higher rate of the laparoscopic approach with fellowship trained surgeons (p = 0.0266). There was also a higher rate of spleen preservation in the fellowship trained group (36% vs 11%, p = 0.0001). There was no difference in rate of complications (52% vs 52%, p = 1.0) or rate of pancreatic leak (34% vs. 25%, p = 0.1489) for the non-fellowship trained versus fellowship trained groups. CONCLUSION: Surgical Oncology/Hepatobiliary fellowship trained surgeons are more likely to use a laparoscopic approach and to preserve the spleen during distal pancreatectomy compared to non-fellowship trained surgeons. The rates of short-term postoperative complications and pancreatic leak were similar for both groups. However, advanced training does influence surgical approach but it is unclear if impacts longterm outcomes

P390

Pancreatic Adenocarcinoma in Young Patients: A Single Institution Experience over 32 Years F. Alemi,* J. Koller, S. Damle, B. Lin, V.J. Picozzi, T. Biehl, S. Helton, A. Alseidi, F. Rocha. Virginia Mason Medical Center, Seattle, WA.

BACKGROUND: Pancreatic adenocarcinoma (PDAC) typically presents in an older population and little is known about its prognosis in younger patients. The current study sought to evaluate the epidemiology, treatments, and outcomes in a cohort of PDAC patients under 50. METHODS: All PDAC patients aged 50 years or younger at diagnosis evaluated at a single institution from 1980-2012 were identified from administrative databases and medical records. Clinicopathologic parameters including demographics, staging, surgical management, and oncologic therapy was collected. Survival analysis was performed using the Kaplan-Meier method. RESULTS: Two hundred twenty-six patients were identified, 59% male and 41% female. The distribution by ages 30-34, 35-39, 40-44, 45-50 was 8, 22, 49, and 147 respectively. Fifty-four percent of patients had a family history of adenocarcinoma, and 61% had a history of alcohol use. Primary tumor location was 83% in the head and/or uncinate process, and 17% in the neck, body, or tail of the gland. The median overall survival (OS) was 11.0 months (95% CI 8.8-12.8) with a median follow-up of 12.0 months. Median OS by decade was 6.4 months (95% CI 3.6-8.7) for 25 patients in 1980s, 8.1 months (95% CI 6.1-11.8) for 44 patients in 1990s, and 13.0 months (95% CI 10.6-17.3) for 157 patients in the 2000s. Forty-six (23.3%) underwent pancreatectomy with a median OS of 25.7 months (95% CI 19.9-32.8) for AJCC stage 0 (n=3), IA (n=1), IB (n=4), IIA (n=2), IIB (n=21), III (n=3) and IV (n=1) disease. Fifty-nine patients (29.9%) presented with locally advanced, unresectable disease while 92 (46.7%) presented with metastatic disease with a median OS of 12.3 months (95% CI 10.4-16.7) and 7.3 months (95% CI 5.6-8.8) respectively. Of the resected patients, 21.7% were treated with neoadjuvant chemotherapy, 84.7% received adjuvant chemotherapy, and 63.0% underwent adjuvant chemoradiation. CONCLUSIONS: The majority of PDAC patients younger than 50 present with inoperable disease. Survival data suggest that these patients have a similar prognosis to the general PDAC population despite their younger age, ability to undergo pancreatectomy and tolerate (neo)adjuvant therapy.





P391

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review J.H. Helm, J.T. Miura, J.A. Glenn, R. Marcus, G. Larrieux, T.T. Jayakrishnan, A.E. Donahue, S. Tsai, T.C. Gamblin, K.K. Turaga, F.M. Johnston.* Surgery, Medical College of Wisconsin, Milwaukee, WI.

Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS and HIPEC), has led to improved outcomes for patients with malignant peritoneal mesothelioma (MPM) over the last decade. Recent literature published has demonstrated varied outcomes with regards to survival benefit. A systematic review was undertaken to synthesize the survival outcomes from recently published literature. Methods: Using Metaanalysis of Observational Studies in Epidemiology (MOOSE) guidelines a pre-specified search strategy was used to abstract data from PubMed, CINAHL, the Cochrane Library, and EMBASE databases. Mortality rates were calculated by the DEALE method, and random effects modeling was used to synthesize the data. Publication bias was assessed using Beggs plot. Results: Of 6528 citations, we identified 86 articles for full text review and 13 articles were included. Outcomes were available for 373 patients with a median age of 54 years (IQR 51-55). The predominant histology was epithelioid mesothelioma (75%, 189 of 253 reported), while sarcomatoid/biphasic occurred in 12.6% (32 of 253). CRS+HIPEC was performed using cisplatin based regimens in 12 studies, and mitomycin only based regimen in 1 study (12 patients). Almost 22% (8-38%) of patients received systemic chemotherapy in addition to HIPEC. Complete macroscopic cytoreduction was achieved in 67% (±33%), with a median PCI score of 20 (±7). The summarized mortality rate was 0.19 (-0.04, 0.42), with a predicted 1 and 5 year survival of 83% and 39% respectively. Studies showed substantial heterogeneity in regimens utilized, variables assessed, and reporting of toxicity. Quality of studies varied significantly with many studies possessing high risk of bias. Conclusions: CRS+HIPEC offer patients promising 1 and 5 year survival compared to historical controls. The increased emphasis on completeness of cytoreduction and incorporation of systemic chemotherapy, especially for aggressive histology is novel over the previous decade. Our data is limited by the heterogeneity of the included studies.

Factors Associated with Failure to Operate for Localized Pancreatic Adenocarcinoma M. Strohl, ^{1*} S. Raigani, ¹ J. Hardacre, ² J. Ammori, ² J. Kim. ² 1. Case Western Reserve University School of Medicine, Cleveland, OH; 2. Division of Surgical Oncology University Hospitals Case Medical Center, Cleveland, OH.

Background: Surgery is potentially curable for patients with early stage pancreatic cancer. The primary aim of this study was to identify factors that are associated with not receiving surgery in patients with localized pancreatic adenocarcinoma using the Surveillance, Epidemiology and End Results (SEER) database. A secondary aim was to evaluate the effect of receiving surgery on disease-specific survival. Methods: The study population included patients diagnosed with SEER historic stage A localized pancreatic adenocarcinoma between 1988-2010 in 17 SEER registries from across the United States. Exclusion criteria included unknown site-specific surgery status, multiple primary malignancies, unstaged, non-invasive, regional, or distant disease at diagnosis, non-cancer directed surgery, and biopsy only. Univariate and multivariate methods were employed to determine which factors were associated with the failure to undergo surgery. Kaplan-Meier log-rank tests and cox proportional hazards regression modeling were used to determine factors associated with disease-specific survival. Results: Of 6,742 patients diagnosed with localized pancreatic adenocarcinoma, 1,715 patients (25.4%) received surgical treatment. There was no significant change in the utilization of surgery over time. On multivariate analysis, patients were less likely to undergo surgery if they were older than 50 years, black, unmarried, located in regions outside the East, had pancreatic head or body lesions, had higher tumor grades, or had tumor size >2 cm (P<0.0001). Patients who did not undergo surgery had significantly worse disease-specific survival than patients who underwent surgery (6 vs 27 months, P<0.0001). Factors independently associated with survival were surgical treatment (HR 3.09 95% CI 2.82-3.38), age, sex, year of diagnosis, marital status, tumor grade and size. Discussion: These results are the first to use the SEER database to analyze factors associated with surgery as a treatment for localized pancreatic cancer. While not all patients with localized disease are candidates for curative resection, there is an opportunity for educating patients and physicians about the potential benefits of surgery.

P393

Does Age Affect Clinical Presentation, Treatment, or Outcomes in Gastric Adenocarcinoma? A Multi-institutional Study of the U.S. Gastric Cancer Collaborative J.W. Etra, ¹* M.H. Squires, ¹ G. Poultsides, ² S.M. Weber, ³ M. Bloomston, ⁴ R.C. Fields, ⁵ T. Pawlik, ⁶ K.I. Votanopoulos, ⁷ C.R. Schmidt, ⁴ A. Ejaz, ⁶ A.W. Acher, ³ D.J. Worhunsky, ² N.D. Saunders, ⁴ D.S. Swords, ⁷ L.X. Jin, ⁵ C. Cho, ³ E. Winslow, ³ K. Cardona, ¹ D.A. Kooby, ¹ C.A. Staley, ¹ S.K. Maithel, ¹ M.C. Russell. ¹ *1. Department of Surgical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; 2. Stanford University, Stanford, CA; 3. University of Wisconsin School of Medicine and Public Health, Madison, WI; 4. The Ohio State University Wexner Medical Center, Columbus, OH; 5. Washington University in Saint Louis, Saint Louis, MO; 6. Johns Hopkins University, Baltimore, MD; 7. Wake Forest University, Winston Salem, NC.*

Background: The relationship of presentation and treatment variables to survival in young gastric adenocarcinoma (GAC) patients is not well defined. The aim of this study was to determine survival differences across various age groups and to evaluate clinical, pathologic, and treatment factors that may influence survival. Methods: All pts undergoing curative intent resection of GAC between 2000-2012 from the U.S. Gastric Cancer Collaborative were analyzed. Pts who died within 30 days of operation and those with Stage IV disease or R2 resection were excluded. Clinicopathologic and treatment variables in the context of age (<40, 40-64, \geq 65) were examined by univariate (UV) and multivariate (MV) regression analyses to assess impact on overall survival (OS). Results: 810 pts met inclusion criteria; these included 28 pts <40yo (3.5%), 356(43.9%) age 40-64 and 426 (52.6%) ≥65yo. Median OS was 39 mo. There was no difference in OS between age groups (p=0.225). On UV analysis for age groups <40, 40-64, ≥65 there were significant differences: male gender (46% vs 53% vs 61%; p=0.043), diffuse type GAC (47% vs 41% vs 21%; p<0.001), poor/undifferentiated GAC (82% vs 74% vs 57%; p<0.001), signet ring (67% vs 53% vs 30%; p<0.001), T3-4 tumors (63% vs 68% vs 55%; p=0.002), and N2-3 disease (52% vs 47% vs 36%; p=0.004). Despite no difference in tumor location, younger pts were more likely to undergo total gastrectomy (50% vs 45% vs 36%; p=0.031). Rates of adjuvant chemoradiation (65% vs 46% vs 24%;p<0.001) were also higher in pts <40yo. On MV analysis for survival, diffuse GAC, N2/N3 disease, T3/T4 status, receipt of neoadjuvant chemotherapy, and receipt of adjuvant chemoradiation were associated with OS (Table). Conclusion: In those patients undergoing curative surgical resection for gastric cancer, patients <40yo present with more advanced disease but receive more aggressive operations and are more likely to receive adjuvant therapy. Given these findings, their overall survival is equivalent to that of older patients, supporting continued aggressive treatment in young patients with advanced disease.

Multivariate Regression Analysis for Overall Survival in All Resected GAC Patients (N=810)

	p-value	Hazard Ratio	95% Confidence Interval
Gender	0.706	1.07	0.76-1.50
Diffuse Type	0.039	1.53	1.02-2.28
Poorly or Undifferentiated	0.641	1.10	0.73-1.66
Signet Ring	0.508	0.88	0.61-1.28
N2/N3	0.012	1.61	1.11-2.32
T3 or T4	< 0.001	2.49	1.64-3.76
Total Gastrectomy	0.071	1.35	0.97-1.87
Positive Surgical Margin	0.537	1.23	0.64-2.36
Neoadjuvant Chemotherapy	0.034	1.69	1.04-2.74
Neoadjuvant CXRT	0.683	1.28	0.39-4.17
Adjuvant Chemotherapy	0.410	0.82	0.51-1.31
Adjuvant CXRT	0.013	0.59	0.40-0.90

CXRT = chemotherapy & radiation therapy

P394

A Multi-institutional Study Comparing the use of the AJCC 7th Edition Esophageal versus Gastric Staging System for Gastroesophageal Junction Cancer in a Western Population F.A. Adeshuko,^{1*} M.H. Squires,¹ G. Poultsides,² T. Pawlik,³ S.M. Weber,⁴ C.R. Schmidt,⁵ K.I. Votanopoulos,⁶ R.C. Fields,⁷ A. Ejaz,³ A.W. Acher,⁵ D.J. Worhunsky,² N.D. Saunders,⁵ D.S. Swords,⁶ L.X. Jin,⁷ C. Cho,⁴ M. Bloomston,⁵ E. Winslow,⁴ M. Russell,¹ C.A. Staley,¹ D.A. Kooby,¹ S.K. Maithel,¹ K. Cardona.¹ *1. Division of Surigcal Oncology, Emory University, Atlanta, GA; 2. Department of Surgery, Stanford University, Stanford, CA; 3. Department of Surgical Oncology, University, Baltimore, MD; 4. Department of Surgical Oncology, University of Wisconsin, Madison, WI; 5. Division of Surigcal Oncology, Ohio State University, Columbus, OH; 6. Department of Surgery, Wake Forest University, Winston-Salem, NC; 7. Department of Surgery, Washington University, St. Louis, MO.*

INTRODUCTION: Controversy exists over the staging of gastroesophageal junction (GEJ) adenocarcinomas within the esophageal system of the AJCC 7th edition. Studies from the East suggest that GEJ tumors are better stratified within the gastric system. The aim of our study was to assess the adequacy of the AJCC 7th esophageal (E7) vs gastric (G7) staging systems for GEJ tumors in a Western population. METHODS: All pts who underwent curative resection of GEJ adenocarcinoma from 2000-2012 at 7 academic institutions within the U.S. Gastric Cancer Collaborative were identified. Pts with Siewert type 1 tumors and those who died within 30 days were excluded. Survival was assessed according to the E7 and G7 systems. RESULTS: Fifty-one pts underwent resection of GEJ tumors. Median age was 63 with 63% of pts having poorly-differentiated tumors. The median f/u was 18mos. The E7 staging system did not adequately stratify patients by T or N stage with a loss of distinctiveness between T1-3(T1vsT2,p=0.58; T2vsT3,p=0.08) and N0-3 (N0vsN1,p=0.09; N1vsN2,p=0.66; N2vsN3,p=0.29) tumors. Similarly, the G7 system was not able to appropriately stratify patients by T or N stage with a loss of distinctiveness between T1-3(T1vsT2,p=0.58; T2vsT3,p=0.13) and N0-3(N0vsN1, p=0.09; N1vsN2,p=0.66, N2vsN3a,p=0.37, N3a vs N3b,p=0.39) stages. On final stage analysis (Figure), the outcomes were similar between both systems and neither the E7 nor G7 systems, with the exception of the G7 stage I vs II, adequately stratified pts by stage(E7: IvsII,p=0.07; IIvsIII,p=0.23; G7: IvsII,p=0.02; IIvsIII,p=0.13). The E7 system includes histologic grade to further stratify pts, however grade itself was not associated with survival (p=0.27) and it did not improve the ability to stratify pts. CONCLUSION: Our multiinstitutional study identifies limitations in the proper stratification of patients with GEJ adenocarcinomas using either the AJCC 7th esophageal or gastric systems. The classification of GEJ adenocarcinoma within either the esophageal or gastric staging systems needs to be further studied in a larger patient population.

Overall survival of patients undergoing curative resection for GEJ adenocarcinoma stratified by the AJCC E7 and G7 staging systems



P395

Morbidity in Long-term Survivors after Pancreatoduodenectomy for Pancreatic Adenocarcinoma K.T. Chen,^{2*} J.P. Hoffman.¹ 1. Fox Chase Cancer Center, Philadelphia, PA; 2. St. Luke's Hopsital, New Bedford, MA.

Background: Because the focus of pancreatoduodenectomy for pancreatic adenocarcinoma is placed on disease-free and overall survival, morbidity in long-term survivors is not well described. We sought to evaluate outlong-term survivors of pancreatic cancer comes of after pancreatoduodenectomy. Methods: We identified 30 patients from our prospectively collected database of patients with pancreatic adenocarcinoma who had undergone pancreatoduodenectomy, and who were without evidence of disease with at least 40 months of follow-up. Demographics, treatment and pathologic characteristics were collected for review. Data with regards to long-term sequelae were also collected, particularly those complications requiring additional procedures and the development of metachronous cancers. Results: The median length of follow up was 83 months, with 60% of patients still alive. Half the patients were male, and the median age at diagnosis was 70 years. With regard to treatment, 80% of patients received chemoradiation, with half of these patients receiving it in the neoadjuvant setting. All patients received an R0 resection, although two patients required at least partial resection of the superior mesenteric or portal veins. Thirty-three percent of patients had N1 disease. Forty-four percent of patients did not have any significant subsequent sequelae. In the remainder, four patients (13%) developed ascites requiring repeated paracentesis or Denver shunt, with median time to development (MTD) of 63 months. Six patients (20%) developed a biliary stricture requiring stent placement (MTD 56 months), one patient developed portal venous thrombosis requiring a venous stent (MTD 52 months), and 3 patients (10%) experienced clinically significant anastomotic ulcers (MTD 47 months). With regards to metachronous cancers, 2 patients developed subsequent lymphomas (MTD 92 months). Conclusions: Long-term survivors of patients who undergo pancreatoduodenectomy for pancreatic adenocarcinoma will develop significant late sequelae, which often can manifest more than three to five years after surgery. Continued follow-up and counseling is warranted.

P396

Preoperative Staging of Gastric Adenocarcinoma with CT Gastrography and 3-D Reconstruction: Report of a Pilot Study J.B. Hamner,* R. Nelson, B. Lee, G. Singh, J. Park, J. Kim. *City of Hope, Duarte, CA.*

Background: Accurate staging is important to determine the sequence of treatment options for patients with gastric adenocarcinoma. In this study we evaluate the accuracy of CT gastrography with 3D reconstruction (CTG) in predicting the stage of gastric adenocarcinoma. Methods: A pilot study was conducted on patients with biopsy-proven gastric adenocarcinoma who underwent preoperative CTG. Patients consumed effervescent granules and pre and post contrast CT was performed in multiple positions. This allowed distention of different regions of the stomach while excluding local invasion of adjacent organs. CTG findings were used to determine extent of disease, as measured by T and N stage. Staging results from both CTG and endoscopic ultrasound (EUS) were compared, with concordance rates measured against final pathologic stage. Results: A pilot cohort of 7 patients with a mean age of 66 years underwent preoperative CTG. In addition, EUS and complete surgical resection were performed in 6 of 7 patients (86%); one patient had EUS and CTG but did not undergo surgery, while another patient had CTG and surgery but not EUS. Both CTG and EUS accurately predicted surgical stage in 5 of 6 patients (83%). CTG was 100% accurate in predicting T stage in tumors \geq T2, whereas EUS understaged a T4 lesion noted on CTG. When examining N stage, CTG correctly predicted surgical N stage in 5 of 5 (100%) patients, however EUS correctly predicted nodal disease in 4 of 5 patients (80%). In the single non-surgical patient, CTG and EUS both staged the patient as T3N2, however only CTG was able to further stage this patient as M1. Conclusion: This pilot study demonstrated that CTG with 3D reconstruction accurately predicts staging in patients with gastric adenocarcinoma. Although its use in early gastric cancers (T1) may be limited, it compares favorably to EUS in tumors T2 or greater. In addition, CTG appears superior to EUS in detecting nodal and distant metastases. The use of CTG may be an effective tool in guiding pre-operative treatment decisions and could also reduce medical expenses in patients who would otherwise receive both a standard staging CT and EUS.

P397

Irreversible Electroporation and Pancreatic Cancer Surgery: Longterm Outcomes from a Single Institution N. Ali,* M.M. Shah, K.M. El-Hayek, J. Wey, M. Walsh, S. Chalikonda. *Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, OH.*

Introduction: Irreversible electroporation (IRE) is a newer ablation technologythat has evolved and is being utilized worldwide for many oncologic purposes. Typically it is used in the setting of pancreatic cancer for lesions that are deemed unresectable or margin accentuation for borderline resectable lesions. We present our long term outcomes with IRE since our institutions utilization in 2010. Methods: Retrospective review of a prospectively maintained database of patients undergoing surgery with inter-operative use of IRE at a single institution from December 2010 until July 2013. Results: IRE was performed in 26 patients. All ablations were performed inter-operatively. IRE was part of the treatment strategy for borderline resectable pancreatic tumors, and a majority of these patients underwent neoadjuvant chemotherapy and radiation therapy (NCR). IRE was utilized for margin accentuation for resected lesions, and was primary treatment for tumors found to be unresectable due to mesenteric vascular involvement. Of the 26 patients, 12 (46%) underwent pancreaticoduodenectomy (PD), 3 (12%) distal pancreatectomy (DP), 8 (31%) biliary and enteric bypass for unresectable pancreatic head tumors, and 3 (12%) IRE alone for unresectable body and tail lesions. Mean survival for resected patients (both PD and DP) was 327 days (range 82-728). Mean survival for unresected lesions was 222 days (range 24-648). Kaplan-Meier survival curve for all patients undergoing IRE shows 81% of patients survive for 1 year, with drop-off as seen(Figure 1). Comparison of those receiving NCR wit IRE showed 1.3 times longer survival than those with IRE alone. 86% of patients treated were recurrence free at 6 months. There were no morbidity or mortality attributed to IRE during the study period. Conclusion: IRE is can be used for both margin accentuation and primary treatment for unresectable lesions. Our outcomes show good disease free and overall survival for both borderline resectable and unresectable lesions. We believe that IRE should be part of treatment algorithm for patients with borderline resectable disease and can be safely performed in the majority of patients.



Figure 1: Overall survival for IRE patients, with number at risk above the x-axis.

P398

Neutrophil-lymphocyte Ratio as Predictor of Surgical Mortality and Survival in Complex Surgery of Upper Gastrointestinal Tract H. Medina-Franco,* R. Cortés-González, K. Jaramillo, M.E. Velázquez-Dohorn, C. Chan-Nu. Surgery, National Institute of Medical Sciences and Nutrition, Mexico City, Mexico.

INTRODUCTION: The neutrophil-lymphocyte ratio (NLR) has been proposed as a marker of systemic inflammatory response and as prognostic tool in various malignant neoplasms. We evaluate the impact of elevated preoperative NLR as predictor of outcome in patients with upper gastrointestinal tract resection for malignant neoplasms in a tertiary referal center in Mexico City. METHODS: A retrospective study was carried out on patients with upper gastrointestinal tract resection for malignancy from January 2007 to December 2012. Patient demographic, clinical, and laboratory data were collected at the time of hospital admission and during follow-up. Comorbidities were registered with the Charlson score and complications were recorded according to Clavien score. NLR was considered high when >5. Variables associated with morbidity and mortality were analyzed using the chi square test for categorical variables and the Student's t test for the continuous variables. Survival was calculated with the Kaplan-Meier method and curves were compared with the log-rank test. Statistical significance was considered at p<0.05. RESULTS: A total of 397 patients (52% women) with a mean age of 56 years were included. The most common surgical procedures were Whipple (50.9%) followed by gastrectomy (35%). Surgical morbidity was 41.3% and mortality 7.1%. Factors associated with significant surgical complications (Clavien > 3) were: low body mass index (<18), AJCC stage > III, ASA > III, Charlson >4 and transfusion requirement. Factors associated with mortality were old age (> 70), high NLR, AJCC stage > III and Charlson >4. On multivariate analysis, only high NLR ratio and Charlson > 4 remain significant. High NLR was associated with lower survival rate at three years (69.1 vs. 57.3%; p=0.014). CONCLUSION: High NLR could be a predictor of surgical mortality and survival in cancer resection of upper gastrointestinal tract.

Morphometric Predictors of Morbidity following Pancreatectomy K. Jaap, M. Hunsinger, E. Stefanowicz, J. Anthony, N. Woll,

K. McGinty, M. Shabahang, J. Blansfield.* Geisinger Medical Center, Danville, PA.

BACKGROUND: Pancreas cancer is the fourth leading cause of cancer related death in the United States. Surgical therapy for pancreas cancer has high risk of complication, even at high volume centers, and is associated with significant morbidity. The objective of this study was to compare different clinical and morphometric features of patients undergoing pancreatectomy in order to predict associated morbidity. METHODS: This is a retrospective review of all patients undergoing pancreatectomy at a tertiary care institution from December 2004-April 2012. Demographics, comorbidities, body mass index (BMI), and albumin levels were examined at time of diagnosis. Morphometric parameters on pre-operative computed tomography (CT) scan were measured, including measurement of psoas muscle cross sectional area, perinephric fat, and abdominal wall fat. Patients were placed into quartiles for each of these morphometric parameters for comparison. Thirty day morbidity and mortality were compared between groups. RESULTS: One hundred five patients underwent pancreatectomy during the study period (52 men, 53 women; average age 66). Median BMI was 28.4 kg/m2, and average albumin level was 3.77 g/dL. Psoas muscle area correlated with risk of surgical complication with the lowest quartile having a 46% complication rate, compared to 18% in the highest (p<0.04). Perinephric fat also correlated with surgical complications with the lowest quartile having a 7.6% complication rate versus 37% in the highest (p<0.02). Abdominal wall fat did not correlate with surgical complications. Finally, comparison was made between groups with different degrees of muscle mass linked with degree of obesity based on BMI. There was a strong statistically significant correlation between high psoas muscle mass and low BMI for low surgical complications compared to the group with low muscle mass and high BMI (p<0.0001). CONCLUSIONS: Patients undergoing pancreatic surgery with pre-operative sarcopenia in combination with high fat content have higher rates of major surgical complications. The results of this study suggest noninvasive pre-operative testing can be used to quantify post-operative risk in pancreatic surgery.

P400

Interobserver Variability in Contrast-enhanced CT and Wholebody FDG-PET in the Staging of Gastric Adenocarcinoma: A Single Institution 12-year Review O.K. Serrano,* C. Love, K. Huang, T. Abraham, M. Kitano, D.A. Bernstein, R. Da Silva, P. Friedmann, D. Milstein, S.K. Libutti, T.J. Kennedy. *Surgery, Albert Einstein College of Medicine, Bronx, NY.*

INTRODUCTION: The role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography (FDG-PET) in the staging work-up of gastric adenocarcinoma has not been clearly defined. The aim of this study was to assess the interobserver variability between contrast-enhanced computed tomography (CT) and FDG-PET in the staging of gastric adenocarcinoma. METHODS: We performed a retrospective chart review of all patients treated at our institution for gastric adenocarcinoma between 2000 and 2012. We identified all patients who had undergone a contrast-enhanced CT and FDG-PET before initiating treatment. The CT scans were evaluated by an experienced blinded body radiologist and the PET scans were independently evaluated by 2 experienced blinded nuclear physicians. Disease stage was assessed, looking at tumor, locoregional and distant lymph node disease, and metastasis. The results were analyzed using 2x2 contingency table analysis and the variability between modalities was determined by kappa-statistics. RESULTS: At our institution we identified 897 patients who had biopsy-proven gastric adenocarcioma and 202 (22.5%) had a contrast-enhanced CT and an FDG-PET as part of their staging work-up. Of these, imaging from 123 patients was available for independent review. There appeared to be greater variability between CT and FDG-PET for the detection of primary tumor (kappa = 0.097) and distant lymph node disease (kappa = 0.175) while there seemed to be a fair agreement for the detection of locoregional lymph nodes (kappa = 0.335) and metastatic disease (kappa = 0.237). CONCLUSIONS: In the staging of patients with gastric adenocarcinoma, FDG-PET serves as a valuable adjunct to CT, especially when evaluating lymph node disease.

A Qualitative Study of Patient and Clinician Attitudes regarding Surveillance following Resection of Pancreatic and Periampullary Cancer R. Deobald, ^{1*} E. Cheng, ¹ Y. Ko, ² F. Wright, ² P. Karanicolas.² 1. University of Toronto, Toronto, ON, Canada; 2. Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.

Background: Pancreatic carcinoma is the fourth leading cause of cancer death in North America. Following surgical resection, most patients will develop recurrence within two years. Intense follow-up is often recommended; however, the impact on survival is unknown. We sought to qualitatively assess patient and clinician attitudes towards follow-up and the perceived benefits and challenges. Methods: The research team developed a semi-structured interview guide. Purposive sampling identified patients who had undergone curative attempt resection and were in active surveillance or had developed recurrence. Clinicians involved in patient care were also interviewed. Themes were derived using standard qualitative methods. Results: Fifteen patients and seven clinicians were interviewed. Patient themes included (1) Limited understanding of disease prognosis; (2) Desire for reassurance through follow-up; (3) Desire to know if and when recurrence occurred; (4) Challenging treatments; (5) Minimal difficulties with the follow-up protocol; and (6) Limited role of family doctors in pancreatic cancer follow-up. Clinician themes included (1) Expectation that patients are aware of recurrence risk; (2) Desire to provide reassurance to patients; (3) Support for intense follow-up protocol despite lack of supporting evidence; (4) Secondary goals for surveillance; (5) Perceived patient challenges in follow-up; (6) Openness to family doctors doing follow-up. Overall, the dominant theme was one of disconnect between patients and clinicians in the understanding of the disease and its prognosis. Conclusion: Patients with pancreatic or periampullary cancer have an intense need for reassurance and obtain this through the follow-up process. Consequently they express few difficulties with follow-up despite the intensity of testing. Oncologists recognize this desire for reassurance and provide it through follow-up despite the lack of evidence to show benefit. There appears to be a disconnect between patients and clinicians in the understanding of the disease and its prognosis suggesting further work is needed to improve patient-physician communication.

P402

Outcomes of Laparoscopic Resection of Gastrointestinal Stromal Tumors Stratified by Tumor Size A.M. Zihni,* A. Kuehnle, J.A. Cavallo, R. Shuddhadeb, M.M. Frisella, W.G. Hawkins, S.M. Strasberg, D. Linehan, M.M. Awad, R.C. Fields, B.D. Matthews. *Dept of Surgery, Washington University in St Louis, St Louis, MO.*

Introduction: The safety of minimally invasive techniques has been described for the resection of gastric gastrointestinal stromal tumors (gGIST). However, few studies have examined the outcomes of laparoscopic (lap) gGIST resection stratified by tumor size. We hypothesized that lap gGIST resection would be associated with favorable perioperative and postoperative outcomes and that no differences in perioperative outcomes will be noted in resections of larger tumors compared to smaller ones. Methods: Retrospective review of patients who underwent lap gGIST resection at our institution from 2000-2013 was performed. Cases converted from lap to open were not included in analysis. Mean continuous outcome variables were compared between T2 (2-5cm tumor size) and T3 (5-10cm) resections using student's t-test. Margin status, pre-discharge mortality, and recurrences were compared between T2 and T3 resections with two-tailed z-tests. P<0.05 was considered the threshold for significance. Results: 75 patients were identified, comprising the largest lap gGIST series in the literature. 5 lap to open conversions (6.25% of attempted lap cases) occurred during this period of time. Mean follow-up (±SEM) was 33.0±3.6 months. 10 of 14 T1 gGIST specimens resected (71%) were incidentally discovered lesions in specimens from various laparoscopic operations, and this group was therefore excluded from comparison. T3 tumors were significantly larger than T2 tumors in our series. No significant differences were noted in patient age, gender, ASA score, or operative time between the T2 and T3 groups (Table 1). The recurrence rate was higher in T3 tumors, though this difference did not reach significance (p=0.08). No lap resections were attempted on tumors >10cm. Conclusions: Our group performed a retrospective review of lap gGIST resections stratified by tumor size. Conversions, pre-discharge mortality, and recurrence were rare in our series. We did not detect any differences in perioperative or long term outcomes when comparing T2 and T3 resections. Our data suggest that lap resection of selected tumors up to T3 is a safe and effective treatment modality at a high volume center.

Table 1.	Tumor < 2cm	Tumor 2-5cm	Tumor 5-10cm
n	14	41	20
Age (y)	65.7	63.2	61.0
Gender (M)	43%	59%	45%
Follow-up (m)	19.0	35.2	37.5
ASA Score	2.8	2.5	2.5
Operative Time (min)	162.5	121.9	141.1
EBL (cc)	49.6	61.3	93.0
Tumor Size (cm)	1.1	3.3	6.1*
Positive Margins (%)	18.0%	2.5%	5.6%
Return to Reg Diet (d)	1.9	3.6	2.8
LOS (d)	2.7	4.1	3.3
Pre-Discharge Mortality (%)	7.10%	0%	0%
Recurrences (per 100 person- years)	0.00	0.86	5.03

*p<0.05

P403

Neoadjuvant Therapy for Pancreatic Cancer in Patients over Age 75 J.T. Miura,* A.N. Krepline, K. Duelge, B. George, P.S. Ritch,

B.A. Erickson, J.P. Thomas, A. Mahmoud, E.J. Quebbeman,

K.K. Turaga, F. Johnston, K.K. Christians, T.C. Gamblin, D. Evans,

S. Tsai. Medical College of Wisconsin, Milwaukee, WI.

Introduction: Multiple treatments in series may be difficult for older patients (pts) to tolerate. We sought to examine the outcomes associated with neoadjuvant therapy in older pts with resectable (R) or borderline resectable (BLR) pancreatic cancer (PC). Methods: Pts ≥75 years (O) with those <75 (Y) with R or BLR PC receiving neoadjuvant therapy from 2008-2012 were identified. Clinicopathologic and treatment data were abstracted Completion of all therapy was defined as the receipt of neoadjuvant therapy followed by surgical resection. Results: We identified 181 pts; 20.8% (n=16) of R and 12.5% (n=13) of BLR were >75 years. Older pts had higher Charlson Comorbidity Index (CCI) (median: 4 vs. 2, p<0.01), more hospitalizations during neoadjuvant therapy (50% vs. 28%, p=0.04) and were less likely to complete all therapy as compared to Y pts (72.4 vs. 89.5%, p<0.01). Poor performance status was the most common reason for failure to complete all therapy in O vs. Y pts (17.2% vs. 0.7%; p<0.01). Higher CCI (OR 0.25; 95% CI: 0.08-0.74, p=0.01) and advanced clinical stage (OR 0.17; 95%CI: 0.06-0.48, p<0.01) were associated with failure to complete all therapy. Among pts who completed all therapy, no significant differences in complication rates (15.0 vs. 15.3%, p=0.33), median length of hospital stay (10 vs. 9 days, p=0.29), or 30 day readmission rates (10 vs. 11.9%, p=0.81) were observed. Median overall survival of the 181 pts was 19.7 and 26.4 months (p=0.04) for O and Y pts respectively. In contrast, of 138 pts who completed all therapy, there was no difference in survival between O vs. Y pts (24.3 mo vs. 36.7 mo, p=0.20). Conclusions: After neoadjuvant therapy, 25% of pts>75 years of age will not undergo surgical resection. The most common reason for not completing all therapy is a decline in performance status. Whether neoadjuvant therapy improves the selection of older pts who should not undergo an operation or prevents successful resection of pts who may have tolerated an operation is unclear. With evolving paradigms of treatment sequencing, the management of PC pts with advanced age will require further assessment.



A Population-based Cohort Study of Factors Predicting Management Strategy in Metastatic Gastric Cancer A. Mahar,^{1*} L. Helyer,² M. Dixon,³ J. Vasilevska-Ristovksa,⁴ C. Law,⁵ P. Peng,¹ N. Coburn.⁵ *1. Public Health Sciences, Queen's University, Kingston, ON, Canada; 2. Dalhouse University, Halifax, NS, Canada; 3. Maimonides Medical Center, Brooklyn, NY; 4. Sunnybrook Research Institute, Toronto, ON, Canada; 5. University of Toronto, Toronto, ON, Canada.*

Background: The majority of gastric cancer (GC) patients present with metastatic disease, for whom the benefit of aggressive treatment is unclear. Understanding factors predicting treatment choice may help future decision-making. Methods: A population-based cohort study of patients diagnosed with M1 stage IV (6th Ed) GC in Ontario 04/01/2005-03/31/2008 was performed. Patients who received treatment were categorized as 1) chemotherapy or chemoradiation, 2) surgery alone, 3) surgery with either chemotherapy or radiation and 4) all treatments. Characteristics compared among treatment groups included patient, disease and health system factors. Polytomous logistic regression using backward selection identified independent predictors of treatment strategy. Odds ratios (OR) and 95% confidence intervals (CI) were reported. Results: 898/1433 M1 patients received oncologic management. Among treatment strategies, the distribution of the number and type of metastatic sites, primary tumor locations, Charlson scores, number and type of symptoms and receipt of care from a high volume physician differed significantly. On multivariate regression, patients with a tumor located in the gastroesophageal junction (OR: 0.37 95%CI 0.20-0.66), proximal (OR 0.41 95%CI 0.048-0.41) and entire stomach (OR 0.30 95%CI 0.1-0.79) were less likely than those with a tumor in the distal stomach to receive all three treatment modalities. Patients with bleeding (OR 2.00 95%CI 1.26-3.18) or symptoms of major obstruction (OR 1.49 95%CI 0.91-2.44) had increased odds of receiving all three treatment modalities compared to chemotherapy or chemoradiation. Patients who saw a high volume physician had a significantly increased odds of receiving all three treatments versus chemotherapy or chemoradiation alone compared to those who did not see a high volume physician (OR 2.49 95%CI 1.58-3.93). Additional factors significantly associated with decreased odds of receiving all three treatments included symptoms of malnutrition, signs of advanced disease and liver metastases. Conclusion: Disease, patient and system characteristics all played a role in determining which oncologic strategies were provided.

P405

Gastric Cancer Outcomes and Survival: Findings from a Large Population-based Study A. El-Sedfy,²* M. Dixon,³ A. Mahar,⁴ J. Vasilevska-Ristovksa,¹ R. Seevaratnam,¹ R. Cardoso,¹ B. Zagorski,¹ L. Paszat,¹ L. Helyer,⁵ C.J. Swallow,⁶ C. Law,⁷ N. Coburn.⁷ *1. Sunny*brook Research Institute, Toronto, ON, Canada; 2. Department of Surgery, Saint Barnabas Medical Center, Livingston, NJ; 3. Department of Surgery, Maimonides Medical Center, Brooklyn, NY; 4. Department of Public Health Sciences, Queen's University, Kingston, ON, Canada; 5. Department of Surgery, Dalhousie University, Halifax, NS, Canada; 6. Department of Surgery, University of Toronto, Toronto, ON, Canada; 7. Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

BACKGROUND: Although the incidence of gastric cancer (GC) has declined, it still remains one of the most common causes of cancer-related mortality worldwide. The aim of this study is to describe the demographic, tumor and clinical characteristics at a population-level. METHODS: We performed a primary chart review for all GC patients diagnosed April 2005 to March 2008 in Ontario. Survival analysis was performed using Kaplan-Meier analysis. RESULTS: During the study period, 2516 patients were diagnosed with GC. The reported demographic data included the following: 65% men, 35% women, 88.4% urban population, 11.6% rural population, 52.4% of patients were over the age of 70 years and 9.2% were below age 50 years. Although 52.7% of this cohort had no previous hospitalization, the majority of patients had major symptoms (61.4%) at the time of diagnosis and had AJCC Stage IV disease (66.9%). Early GC was found in 11.2% of patients. Tumors were located at the gastroesophageal junction in 26.1% of cases and distal stomach in 37.4% of cases. Of the patients that underwent surgery, 16.5% had positive proximal margins, while 21.7% had positive distal margins. Median length of hospitalization (interquartile range) was 12 days (9-20 days). Median number of lymph

nodes (LN) harvested (interquartile range) was 13 LNs (8-19 LNs). The median overall survival times for AJCC stage 0, II, IIIa, IIIb and IV were 72, 58.5, 29.8, 18.4 and 6.9 months, respectively. CONCLUSIONS: While this data confirms the fact that the Province of Ontario has a low prevalence of GC, it also demonstrates that different stages of GC have distinct demographic, tumor and clinical characteristics. Our population-level assessment reveals an elevated proportion of diagnosis at AJCC stage IV and an elevated positive margin rate after resection.

P406

Pancreatic Fistulae in Patients Undergoing Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) and Distal Pancreatectomy are more Severe than those Undergoing Distal Pancreatectomy Alone S. Downs-Canner,* D. Magge, Y. Ding, L. Ramalingam, J. Heather, S. Ahrendt, M.P. Holtzman, J. Pingpank, A.H. Zureikat, H.J. Zeh, D.L. Bartlett, M.A. Choudry. University of Pittsburgh Medical Center, Pittsburgh, PA.

Introduction: We compared the rate of pancreatic fistulae in patients undergoing distal pancreatectomy and HIPEC to patients undergoing distal pancreatectomy alone. Methods: Between 2001 and 2012, demographics, clinicopathologic and perioperative details, including pancreatic fistula rates, and long-term outcomes were reviewed in patients undergoing distal pancreatectomy as a component of cytoreductive surgery and HIPEC for peritoneal carcinomatosis of appendiceal (n=31) or colorectal (n=23) origin and compared to patients undergoing minimally invasive or open distal pancreatectomy without HIPEC (n=66) for locally resectable pancreatic adenocarcinoma. Pancreatic fistulae were graded according to the International Study Group of Pancreatic Surgery system. Results: Overall pancreatic leak rate was not different between the two groups however the severity of leak was different between the HIPEC cohort and both the distal pancreatectomy cohort (table) and open distal pancreatectomy cohort. Patients in the HIPEC group were younger, had a higher rate of ICU admission and longer hospital length of stay (19.4 vs. 8.3 days). HIPEC patients with leak did not differ in their extent of debulking, length of stay or post-operative complications including wound infection, cardiac and pulmonary complications, ileus and delayed gastric emptying compared to HIPEC patients without leak. Conclusion: When they occur, pancreatic fistulae in patients undergoing distal pancreatectomy and HIPEC are more severe than in those undergoing distal pancreatectomy alone however there is no difference in life-threatening type C leaks.

Leaks by type in patients undergoing distal pancreatectomy in setting of HIPEC vs distal pancreatectomy alone

	No Leak	Type A Leak	Type B Leak	Type C Leak
HIPEC	46 (39.7%)	0 (0%)	13 (11.2%)	1 (0.9%)
No HIPEC	40 (34.5%)	12 (10.3%)	4 (3.4%)	0 (0%)

Fisher's exact test p-value < 0.0001

P407

Population-based Outcomes of Laparoscopic and Open Gastrectomy M. Dixon,² A. El-Sedfy,³* A. Mahar,⁴ J. Vasilevska-Ristovksa,¹ R. Seevaratnam,¹ R. Cardoso,¹ B. Zagorski,¹ L. Paszat,¹ L. Helyer,⁵ C.J. Swallow,⁶ C. Law,⁷ N. Coburn.⁷ *1. Sunnybrook Research Institute, Toronto, ON, Canada; 2. Department of Surgery, Maimonides Medical Center, Brooklyn, NY; 3. Department of Surgery, Saint Barnabas Medical Center, Livingston, NJ; 4. Department of Public Health Sciences, Queen's University, Kingston, ON, Canada; 5. Department of Surgery, Dalhousie University, Halifax, NS, Canada; 6. Department of Surgery, University of Toronto, Toronto, ON, Canada; 7. Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.*

BACKGROUND: Curative intent treatment for gastric cancer (GC) involves a gastrectomy with lymphadenectomy. A laparoscopic approach may offer benefits, however large multi-center studies are lacking. The aim of this study is to examine short and long term outcomes of laparoscopic gastrectomy (LG) vs. open gastrectomy (OG) for GC on a population-level. METH-ODS: A retrospective, provincial chart review of GC patients diagnosed April 2005 to March 2008, for whom an operative note existed, was performed. Outcomes measured were tumor-node-metastasis stage at presentation, location

of tumor, number of lymph nodes (LN) retrieved, specimen margins, length of operation, length of stay (LOS), postoperative blood-product transfusions (BPT) and overall survival (OS). RESULTS: A total of 392 patients underwent a resection of which 337 (86.0%) were an OG and 55 (14.0%), a LG. There was no significant difference in 30-day mortality (5.6% OG; 7.3% LG; p=0.547). Median operative time (interquartile range [IR]) was longer for LG compared to OG (280 min (230-245 min) vs. 255 min (210-305 min); P=0.0251). Median LOS (IR) for OG was 12 days (9-19) compared to 8 days (6-19) for LG (p=0.126). Proximal margins were positive in 9.9% of OG, compared to 3.7% of LG (p=0.284). Distal margins were positive in 8.8% of OG,

compared to 11.1% of LG (p=0.422). Median number of LNs harvested (IR) in OG was 14 LNs (8-20 LNs) compared with 10 LNs (6-13 LNs) in LG (p=0.0034). BPTs occurred in 142 (42.1%) and 17 (30.9%) patients from OG and LG, respectively (p=0.116). The 5-year OS for OG is 45.6% vs. 50.5% for LG (p=0.837). CONCLUSIONS: Our population-level assessment reveals similar 30-day mortality rates in both OG and LG. Although non-significant, LG had a trend towards shorter LOS and fewer BPTs. In regards to oncological principles, while both groups had similar margin status results, LG had significantly less LNs harvested during lymphadenectomy. Significant selection bias likely exists for patients chosen for LG.
Relevant Financial Disclosures Oral and Poster Abstracts presented at 67th SSO Annual Cancer Symposium March 12-15, 2014 Phoenix, Arizona

Disclosures Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the Society of Surgical Oncology (SSO) policy, all educational planners, presenters, instructors moderators, authors, reviewers and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. This includes the disclosure of all financial relationships with a commercial interest of a spouse or partner. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. ACCME does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the SSO. (Please note that Posters were not certified for credit.)

The following Oral Abstract and Poster Main Authors and Presenters have disclosed financial relationships with commercial interests:

Andtbacka, Robert 52 Advisory Board: Amgen Inc.; Consultant: Amgen Inc.

Faries, Mark 54 Advisory Board: Amgen; Other: Unpaid Proctor, Decatur Systems

Martin, Robert 1, 44 Consultant: Bayer/Onyx

Martinez Said, Hector P204, P308 Advisory Board: Boehringer Ingelheim, Bristol Myers Squibb, Roche, Merck Sharp & Dohme Mullins, C. Daniel P291 Advisory Board: Amgen, Bayer, Genentech, Pfizer; Grant: Amgen, Bayer, Pfizer; Research, Bayer, Pfizer; Consultant, Speaker Honorarium: Pfizer

Saiura, Akio P177 Honorarium: Bristol Myers, Chugai, Merk Serono

Schwarz, Roderich 84 Speaker: Genentech, Novartis

Wagman, Lawrence 23 Speaker: Bristol-Myers-Squibb

Aalders, Kim P10 Abbott, Andrea P237 Abbott, Daniel 82 Abdelgadir Adam, Mohamed P145 Abdelsattar, Zaid 24, 63 Abe, Shoko 10 Abramowitz, Dan P305 Adeshuko, Folashade P181, P394 Adesove, Taiwo P150 Adkisson, Cameron P143 Ahmed, Shuja P274 Aimaq, Rahim P191 Ajkay, Nicolas P5 Akanuma, Naoki P332 Alabbas, Haytham P135 Alakus, Hakan 20 Al-Azhri, Jamila P65 Alemi, Farzad P390 Ali, Noaman P397 Alsaied, Osama 43 Amini, Albert P179 Anantha Sathyanarayana, Sandeep P154, P155 Anderson, Caroline P192, P245, P246, P254 Angeles, Christina P209, P201 Ankeny, Jacob P336 Aoyagi, Tomoyoshi P122 Araujo, Raphael P169 Arena, Elizabeth P222 Arora, Tania P317 Artinyan, Avo V6 Aukema, Tjeerd 86 Awad, Ziad V8 Avdin, Nail P283 Azab, Basem P190 Baba, Hironobu P120 **Bagaria**, Sanjay P199 Bailey, Christina P102, P243 **Barbie, Thanh P89** Barden, Gala P258, P264, P275 **Bartlett, Edmund P298** Bates, Benjamin P193 Beane, Joal 4 **Beasley**, Georgia 49 **Bedrosian, Isabelle P18** Bennett, Adam 61 Bennett, Joseph P192 Bennett, Sean 28 **Bergquist, John P76 Bernthal, Nicholas P313**

The following Oral Abstract and Poster Main Authors and Presenters have reported that they have no

relevant financial relationships with commercial interests to disclose:

Besic, Nikola P12, P153 **Bilchik**, Anton 21 Bischof, Danielle 69, P297 **Blakely, Andrew P278** Blank, Sima P167 **Blansfield, Joseph P399 Bliss, Lindsav P376 Bloomquist, Erica P14 Bloomston**, Mark 92 **Boland**, Genevieve 53 Boone, Brian 5, P346 **Bosscher, Marianne P295 Boughey, Judy P59 Bouvet, Michael P353 Bowles, Tawnya P239** Brahmbhatt, Rushin P55 Braun, Josef P103 **Broussard, Brett P324 Brown**, Daniel P40 Brown, Erin P166 Brueske, Kevin P217 **Budde, Cristina P95** Buijs, Maria P114 **Bulte, Joris P44 Burga**, Rachel P97 Burrish, Nikki P277 Cader, Sonia P334 Calata, Jed P98 Canter, Robert P303 **Carpenter, Kendall P202** Ceelen, Wim P105, P125 Chan, Carlos P47 Chawla, Akhil P21 Chen, Kathryn P395 Chikman, Bar P66 Choi, Michael P314 **Choudry, Mohammad Haroon P113** Chow, Oliver P111 Cintolo-Gonazelz, Jessica P205 Clarke, Callisia P126 Clovd, Jordan P232 Cocieru, Andrei P306 **Condren**, Audree P85 Cooper, Amanda P178 Coopey, Suzanne P11 Corona-Cruz, J. Francisco 87, V1 Cucher, Daniel P211 Cyr, Anthony P382 Datta, Jashodeep 15, P365 De Andrade, James P71

De Smet, Lieselotte P105 de Vasconcellos Santos, Fernando P366 Deobald, Ray P401 DePeralta, Danielle P172 Deutsch, Gary 67 Dhage, Shubhada 11 **Dias-Santos**, Daniela 47 DiGiovanni, Ryan P131 Dineen, Sean 76 **Dixon, Mathew P407 Dooley, William P33** Downs-Canner, Stephanie P113, P406 Dudeja, Vikas P187 Duelge, Kaleb P173 Egger, Michael 55 Ejaz, Aslam P361 Elmore, Leisha P41 El Mokdad, Ali P260 El-Sedfy, Abraham P405, P407 Eng, Oliver P195 Erdahl, Lillian P23 Erhunmwunsee, Loretta P322 Esquivel, Jesus 25, 26 **Essner**, Richard 58 Etra, Joanna P393 Fana, Melissa P72 Farley, Clara P207 Farguhar, Douglas P152 Feig, Barry P301, P307 Fong, Jonathan P49 Fong, Zhi Ven P110 Forster, Meghan P202 Franceschi, Dido P73 Frankel, Timothy 41 Franssen, Bernardo P272 Fujitani, Kazumasa 6 Fukuhara, Shinichi V7, P345 Gage, Michele P15 Gallagher, Kristalyn P79 Gamenthaler, Andrew P124 Ganai, Sabha P267 Ganesan, Nivetha P18 Gangi, Alexandra P38 Gawad, Wael P117 Geliebter, Jan P240 Giles, Brian P199 **Giordano**, Nicholas P140 **Gnerlich, Jennifer P77** Gonzalez, Segundo P67 Gooch, Jessica 9 Grant, Michael P53 Gratian, Lauren 30 Greenup, Rachel P37 Gremonprez, Félix 27 Gronchi, Alessandro 72 **Gross, Molly P101**

Grotz, Travis P218, P229 Grover, Surbhi P1 Gusani, Niraj P257 Hallet, Julie P157 Hamilton, Trevor P310 Hamner, John P396 Hanna, Nader P121, P285, P291 Harris, Jennifer P279, P367 Hashim, Yassar P374 Hauch, Adam 33, P139 Hellan, Minia P193 Helm, Joseph P391 Hendrix, Ashlev P28 Henry, Leonard 48 Hernandez, Jonathan P368 Heslin, Martin 59 Hetu, Jessika P119 Hieken, Tina P61, P197 Hiotis, Spiros P167 Hoefer, Richard P290 Honing, Judith P319 Hsueh, Eddy P217 Hu, Yinin 57 Hugen, Niek P99 Hui, Jane P234 Huismans, Anna P220 Ihemelandu, Chukwuemeka P370 Ikoma, Naruhiko P301, P307 In, Haejin P163, P342 **Inchauste, Suzanne P223** Isom, Chelsea P238 Itano, Osamu P180 Ito, Fumito P219 Jackson, Nicole P188 Jakub, James V4 Jaap, Kathryn P399 Javakrishnan, Theius P118 Jenkins, Christina P262 Jimenez, Ramon P63 Jimenez, William P270 Jin, Linda P354, P357, P387 Johnston, Fabian P391 Jones, Douglas 73 Jones, Maris P227, P235 Jose, Paul P325 Kachare, Swapnil P300 Kam, Jeffrey P43 Kanumuri, Prathima 13, P48 Katz, Steven 40 Kauffmann, Rondi 12, 31, P42 Kelly, Kaitlyn 71, P344 Kenny, Timothy P78 Khan, Hadi P127 Khreiss, Mohammad P184 Kiernan, Colleen 35, P51 Kikuchi, Hirotoshi P362

Kim, Michael P358 Kim, Minhyung P200 **Kimbrough, Charles P348** Kirane, Amanda P36 **Kirchoff, Daniel P221** Kluger, Michael 78, P159 Knab, Lawrence P347 Kobayashi, Hirotoshi P96 Koh, Ye Xin P242 Koslow, Starr P32 Krell, Robert P256 Kroon, Hidde 50, P212 Kshivets, Oleg P331 Kukar, Moshim 37, 68, 80, P381, V2 Lahat, Guy 74, P373 Lai, Lily P54 Lai, Victoria P149 Lancaster, William P208 LaRocca, Christopher P247 Laronga, Christine P35, P88 Lautner, Meeghan P70 Lavy, Ron P66 Lee, David P284 Lerner, Jonathan P156 Leung, Anna P8 Lewis, Russell P371 Li, Pamela P92 Liederbach, Erik P58 Lin, Ying-Sheng P253 Lindberg, James 96 Look Hong, Nicole 56 Lubezky, Nir 74 Luna-Perez, Pedro P107 Lushaj, Entela 85 Luu, Carrie P289 Luvimbazi, David P34 Mackey, Aimee 14 Madden, Jesse P239 Maffuz-Aziz, Antonio P68 Mahar, Alvson P404 Mahendraraj, Krishnaraj P90, P133, P147, P174, P250 Mallipeddi, Mohan P329 Maloney, James 85 Mann, Gregory P49 Mansour, John 61 Margenthaler, Julie P41, P89 Mathew, Jesna P189 McAuliffe, Priscilla P40 McCahill, Laurence P276 Medina-Franco, Heriberto P39, P248, P398 Metildi, Cristina P353 Mezhir, James P382 Michel, Martin P380 Milgrom, Sarah 19 Miller, Marian P50

Miura, John P171, P355, P403 Miyashita, Tomoharu 83 Mohamed, Hossam 36 Mohammed, Somala P83, P359 Mongiu, Anne P84 Muilenburg, Diego 51 N M L, Manjunath P316 Nadeem . Hasan P118 Nagahara, Makoto P31 Nagahashi, Masavuki P3 Nakhlis, Faina P57, P84 Namm, Jukes P82, P384 Nason. Katie 79 Nathan, Hari 60 Nenshi, Rahima P296 Neves, Rogerio P203 Newhook, Timothy 95, P335 Ng, Deanna P252 Nguyen, Trang P168 Niebling, Maarten P220 Nizri, Eran P360 Nunez, Maria P273 Nussbaum, Daniel P299 Nywening, Timothy P340 O'Connor, Victoria 70 Ojo, Adewuni P75 Okkabaz, Nuri P123 Okumura, Hiroshi 81 **Oltmann, Sarah P151** Onesti, Jill P386, P388 **Orr. Richard P228 Oxenberg**, Jacqueline P261 Oyasiji, Tolutope P233 Ozao-Choy, Junko P214 Pandalai, Prakash P223 Panni, Roheena P337 Papenfuss, Wesley P378 Parikh, Alexander 31 Park, Do Joong 90 Parvez, Elena P81 Paulus, Elena P213 Pawlik, Timothy 39, 69, P297 Pennacchioli, Elisabetta P230 Peeples, Claire P262 Perhavec, Andraz P315 Petric, Rok P153 Philips, Prejesh 98 Platt, Jennica P29 Plukker, John P319 Pockaj, Barbara P56 Polanco, Patricio P266 Pooni, Amandeep P236 Porembka, Matthew P165 Porter, Geoffrev P80 Portschy, Pamela P69 Povoski, Stephen P244, P259

Prabhakaran, Sangeetha P241 Press, Danielle P137 **Proctor, Erica P52** Qadan, Motaz P304 Racz, Jennifer P305, P312 **Radomski, Michal P128** Rajaei, Mohammad P144 **Randle, Reese P129** Raoof, Mustafa P164 **Rashid. Omar P268** Read, Rebecca P225, V5 **Reyna**, Chantal P24 **Rickles, Aaron P17 Rivard, Justin P287 Rizzo, Monica P207 Robinson, Kristin P7 Rodriguez, Rodrigo P134 Roland, Christina P148 Romero Arenas, Minerva P146** Rose, J. Bart P176 **Rosen, Jennifer P140 Rowland, Kathryn P136 Rubio, Isabel P25** Rueth, Natasha P263 Ruszczyk, Melanie P22 Sadot, Eran P161, P385 Saha, Arin P330, P380 Saha, Sukamal P282 Saied Calvino, Abdul P158 Saigal, Anupama P87 Saito, Hidehito P219 Salti, George P309 Samples, Jennifer P9 Sanford, Dominic 97 Sardi, Armando P270, P273, P283 Saunders, Aaron P269 Saunders, Neil P379 Schiffman, Suzanne P350 Schmidt, Hank P26 Schneble, Erika P6 Schoellhammer, Hans P175 Schubart, Jane P257 Segedi, Maja P338 Sepesi, Boris 88 Serrano, Oscar P400 Serrano Aybar, Pablo P183 Shabahang, Mohsen P78, P189 Shah, Anushi P186 Shah, Kevin P306 Sham, Jonathan 46, P194 Shapiro, Mia P130 Sharpe, Susan P20 Sherman, Scott 29 Shirley, Lawrence P363, P375, P377 Shoor, Priya P320 Showalter, Shavna P1

Sin, Eliza P249 Singla, Smit P141, P265, P311 **Smith, Franz P196** Smith, Roger V6 Snyder, Rebecca 64 Soares, Kevin P109 Somasundar, Ponnandai P293 Somnay, Yash P142 Spanheimer, Philip 17 Speicher, Paul 94 Spillane, Andrew V5 Squires, Malcolm 32, 89, P333, P351 Stavrou, Eleni P94 Steiman, Jennifer P16, P45 Steliga, Matthew P328 Stevens, Lewis P330 Strohl, Madeleine P392 Sugahara, Kazuki P115 Sun, Susie P8 Sutton, Jeffrey 66 Swistel, Alexander V3 **Tabrizian**, Parissa P108 Takeno, Atsushi P356 Tan, Grace P343 Tan, Winson Jianhong P288 Taniguchi, Masahiko P160 Terando, Alicia P251 **Terhune**, Julia P93 **Teshome**, Mediget 3 Thirunavukarasu, Pragatheeshwar 22, P116, P280 Thomay, Alan P326, P327 Thorn, Mitchell 42 **Tignanelli, Christopher P170** Tran Cao, Hop 62, P162 Tran, Thuy P304 **Trappey, Alfred 16** Tsai, Susan P173 **Tsang, Melanie P318** Tseng, Jennifer P216, P277 Tseng, Warren P292 Tummel, Evan 8 **Tuttle, Rebecca P224** Uehara, Keisuke P104 Uenosono, Yoshikazu 91 Ugras, Stacy P19 Untch, Brian 34 **Uppal, Abhineet P323** Van Broekhoven, Danique 75 Van Ginkel, Robert P231 van Rooijen, Stefanus P106 Veerman, Kelly P231 Verberne, Charlotte 2 Villescas, Victoria P62 Voci, Amy P86 Vos, Elvira P4

Votanopoulos, Konstantinos P255 Vu, Huan P91 Wachtel, Heather 38 Wai, Christina P132 Wallace, Anne P46 Wallack, Marc P240 Wanebo, Harold P281, P294, P364 Wang, Bo P138 Wang, Sam P349 Wang, Yi-Zarn P286 Warren Peled, Anne P60 Wasif, Nabil 65 Wecsler, Julie P64 Weiss, Matthew 93 Weixler, Benjamin 18 Wexelman, Barbara P74 Wightman, Sean P198 Wikholm, Lauren P30 Wilfong, Chandler P215 Wilson, Gregory P271 Wilson, Niamey P27 Woldemichael, Andinet P285 Worhunsky, David 77 Wright, G. Paul P13 Wu, Daniel P2 Wu, Susana P389 Yakoub, Danny P372, P383 Yamamoto, Maki P206, P226 Yamaoka, Yusuke P112 Yanagita, Shigehiro P341 Yeluri, Sashidhar P321, P325 Yopp, Adam 45, P260 Zih, Francis P182 Zihni, Ahmed P402 Zoon, Christine P210

AUTHOR INDEX

67th Annual Cancer Symposium Society of Surgical Oncology March 12–15, 2014 Phoenix, Arizona

A A'Amar, O.M. P140 Aalders, K.C. P10 Abad, J. 48 Abbott, A. P69, P237 Abbott, D.E. 66, 82, 98, P271 P192 Abdel-Misih, R.Z. Abdel-Misih. S. P379 Abdelgadir Adam, M. P145 Abdelhalim, A. 37 Abdelsattar, Z.M. 24, 63 Abe, S.E. 10 P180 Abe, Y. Abi Jaoude, W. 85 Abraham, T. P400 Abramowitz, D. P305 Abu-Khalaf, M. P48 Acher, A.W. 89, P333, P351, P361, P393, P394 Adair, S.J. 95, 96, P335 Adelaja, I. P94 Aden, J. 16 Adeshuko, F.A. P181, P394 Adesoye, T. P150 8, P79 Adkins, L. ., P143 Adkisson, C.D. Adrian, K. P347 Adsay, N. 32 P126 Agarwal, A.K. Agrawal, A. P46 Ahmad, S.A. 66, 82, P271 Ahmadiyeh, N. P57 Ahmed, S. P274 Ahrendt, G. P16, P45 Ahrendt, S. P266, P406 Ahrendt, S.A. P113 Ahuja, N. 93, P109 P191 Aimaq, R. Ajkay, N. P5, P14 Akamaru, Y. P356 Akanuma, N. P332 P389 Akmal, Y. Aksoy, E. P137 Akthar, A.S. P267 14, P37 Akushevich, I. Akutsu, Y. P332 76 Al Sannaa, G. Al-Azhri, J. P65 Al-Qurayshi, Z. 33, 36, P139 P103, P135 Alabbas, H. Alaeddine, M. P116 20 Alakus, H. Alam, A. P190 Alatrash, G. P21 Albarracin, C. P18 P162 Albino, V. Albo, D. P275 Albright, J. 70. P222 Alemi, F. P390 Alexandrescu, S. 39 Alghamdi, H. P65 Ali, N. P397 Alimi, Y. P207 P137 Aliyev, S. Alkayyal, A. 28 P2 Allam, E.S.

Allard, M.	72
Allegood, J.	P3
Allegra, C.J.	23
Allen, J.	47
Allen, P.34, 41, P	161, P165,
P16	9, P349, P385
Alnaji, R.M.	80
Aloia, T.	P358
Aloia, T.A.	P178
Alosi, J.A.	P200, P311
Alsaied, O.	43, P187
Alseidi, A.	P390
Alvarez, M.L.	P56
Alvarez-Downing,	, M.M. P223
Amatruda, T.	52
Ambrosone, C.	P22
Amersi, F.	P314
Amini, A.	P171, P179
Ammori, J.	P392
Ananth, A.A.	28
Anantha Sathyan	arayana, S.
	P154, P155
Anaya, D.A. P25	08, P264, P275
Andersen D	39
Anderson, B.	P203
Anderson, C.	F 192
Anderson, C.R.	P240, P240, D254
Anderson I M	F204 D334
Anderson KS	P56
Anderson I	D338
Andthacka RH	52 P230
Angeles C.V	P201 P209
Ankeny, J.S.	P336
Anthony, J.	P399
Anthony, L.	P286
Anurathapan, U.	P359
Aoyagi, T.	P3, P122
Apte, S.	P237
Araujo, R.	P169
Arbeev, K.	14, P37
Archer, A.W.	P357, P387
Arena, E.A.	70, P222
Arias, A.	20
Arigami, T.	81, 91, P341
Ariyan, C.E.	P201, P209
Armeson, K.	P208
Armstrong, G.	P330
Armstrong, K.	P27
Armstrong, M.J.	P143
Arora, M.	P282
Arora, I.K.	P317
Arribas, J.	P25
Arrieta-Rodriguez	2, O.G. 87
Arrington, A.	P86
Artinyan, A. V6	, P258, P264,
Acaoka T	P2/5
Asauna, I.	P112
Asyrial, A.	7302 10 D150
Astesturov I A	40, 1100
Asisalui UV, I.A.	F320
nay, 3.1VI. Atonafu ⊑	F223
Atoria C	1 303, F312 60
Attiveh F	P284
,yon, 1.	1 204

Attwood. K.22. 37.	80. P261.	Belotte
	P378	Belsky,
Auer, R.A.	28	Belt, B.
August, D.A.	P195	Ben-Da
Augustine, C.	49	Bennet
Aukema, T.	86	Bennet
Avini. D.	P122	Bennet
Avisar, F.	P65	Benser
Awad, M.M.	P402	Bensim
Awad Z	V8	Bentrer
Awuah B	P52	Berber
Axelrod D	11	Berger
Avala A	P97	Berger
Avcart S	P108	Bergau
Avdin N	P270 P283	Bermar
Azab B	P190	Borneta
Azad N	P109	Bornth
Δzin Δ	P305 P312	Borry
Azoulay D	P150	Borry M
~20ulay, D.	1155	Bosio I
		Botzold
R		Beukor
Paha L	D100	Deuker
Daba, n. Dabialay MJ	F 120	Devers
Dabiers O		Beylerg
Sablera, G.	P70, P263	Bezooi
Sach, P.B.	60 D000	Bianco
Байgwell, Б.	P292	Bieni, I
Bagaria, S.	P 199	I.J. BIIC
Banary, N.	5	D11.1.1
Balley, C. 62	2, P102, P243	BIICNIK,
Bair, I.B.	P/1	Billings
Baker, M.S. P163	3, P342, P384	Birkme
Bakhshi, S.	P316	Birsen,
Balachandran, A.	P1/8	Bischol
Balch, C.M.	P204	Bischol
Balch, G.C.	61, P260	Bitz, C.
Baldini, F.	P230	Blackst
Ballman, K.V.	3	Blais, E
Balzer, B.	P314	Blake-C
Banerjee, S.	43, P187	Blakely
Bang, Y.	6	Bland,
Barbie, I.	P89	Blank,
Barden, G.M. P25	8, P264, P275	Blansfie
Bargallo-Rocha, E	. 87	Blaszko
Barone, C.P.	P328	Blazer,
Barrett, M.T.	P56	Blazer
Barrio, A.V.	P5, P14	
Bartlett, D.L. 5, I	P113, P128,	Bliss, L
P184, P266	6, P350, P406	Bloom,
Bartlett, E. 38, 54	l, P152, P298	Bloomo
Bates, B.	P193	Bloomo
Bauer, T. 39, 69,	95, 96, P297,	Blooms
	P335	F
Baxter, N.N.	P29	F
Baynosa, J.L.	P227, P235	
Beane, J.D.	4	Blum, A
Bear, H.	P91, P210	Blumga
Beasley, G.	49	Bogach
Beasley, G.M.	51	Bökker
Bednarski, B.	P126	Boland
Bedrosian, I. P1	8, P70, P263	Bold, R
Beg, M.	P154, P155	Bonave
Begossi, G.	P281, P294	Bonefa
3ekaii-Saab, T. 92	2, P377, P386	Bonval
Bell, R.S.	P318	Boolbo
Belliveau, J.	P281, P294	Boone,

Belotte, J.	P347
Belsky, M.	P113
Belt, B. 97, P337,	P340
Ben-David, K.	80
Bennett, A.	61
Bennett, J.J.	P192
Bennett, S.A.	28
Bensenhaver, J.	P52
Bensimon, C.	P296
Bentrem, D.	P347
Berber, E.	P137
Berger, D.H.	P275
Berger, D.L.	P110
Bergquist, J.R.	P76
Berman, R.	11
Bernstein, D.A.	P400
Bernthal, N.	P313
Berry, J.S.	P6, 16
Berry, M.F. P322,	P329
Besic, N. P12, P153,	P315
Betzold, R.	3, P79
Beukema, J.C.	P319
Bevers, T.B.	P18
Beylergil, V.	P368
Bezooijen, R.	P114
Bianco, T.	P338
Biehl, T. Bigio,	P390
I.J. Bilchik, A.	P140
	67, 70
Bilchik, A.J.	21
Billingsley, K.G.	P95
Birkmeyer, N.J.	63
Birsen, U.	P137
Bischoff, D. 69,	P297
Bischoff, D.	P306
Blackstoin ME	P210
Blackstein, W.E.	F310
Blake-Corda M	95, 90 87
Blakely A	P278
Bland K I	59
Blank S	P167
Blansfield, J. P78, P189.	P399
Blaszkowsky. L.	47
Blazer, M. 92,	P386
Blazer III, D.G. 69, P297.	P299.
,, -,	P306
Bliss, L. P277,	P376
Bloom, S.W.	P190
Bloomquist, E.	P14
Bloomquist, E.V.	P5
Bloomston, M. 89, 92, F	9333,
P351, P357, P361,	P363,
P375, P377, P379,	P386,
P387, P393,	P394
Blum, A.B. P200,	P215
Blumgart, L.	P169
Bogachek, M.	P71
BOKKERINK, G.M.	P106
Boland, G.	53
DUID, K.	
Bonaveniura, M. P10	o, r45
Ronotae L	Doo
Bonetas, E. Bonvalot S	P83
Bonetas, E. Bonvalot, S. Boolbol, S	P83 72 P92
Bonetas, E. Bonvalot, S. Boolbol, S. Boone, B.A. 5, P184	P83 72 P92 P346

Boone, E.L.	P328
Boosalis, V.A.	P130
Borger, D.	39
Borgida, A.	P338
Bosch, S.L.	P106
Bosscher, M.R.	P295
Boudreaux, P.	P286
Boughey J.C. P23 P59	P61
200g/103, 0.0. 1 20, 1 00,	P76
Boutin, B.D.	P303
Bouton, M.	P30
Bouvet M	P353
Bowen W	P364
Bowles T	P239
Bowser I	48
Boyd T	P63
Braam H I	P106
Bradley-Dunlon D	P211
Brady MS	P201
Brahmbhatt R D	D55
Bror SS D226 D205	D212
Braun I	P102
Brokko A	D151
Brokkon D	1151
Diekkeil, n.	40
Brennan, M.F. 14, 34, 71,	P344,
Bronnomon E	F349
Bronner MK	F290
Brock I	P509
Brod A M	15/
Broomo LT	25
Brouppord R I	00
Brower S T	F324
Brown DD	F 345
Brown E	P166
Brown, E.	F 100
Brown B	16
Bruceko K A	D017
Brusse Kaizer M	D111
Buddo C N	F 114
Budde, C.N.	F90
Builo MM	F100
Bulto	F114
Burgo DA 40 40 DOZ	F44
Burga, N.A. 40, 42, F97,	F100
Burgernof, H.G.	P319
Burke E E	00
Burke, E.E.	P09
Burrieb NIM	P282
Burrish, N.M.	P2//
Burness, B.	P326
Busaldy, N.L.	P140
Bullerileid, L.	P128
Buyse, M. Do	23
Byrne, M. Pos	o, P73
С	
Cader, S.R.	P334
Cai, L.	P347
Calata, J.F.	P98
Callegaro, D.	72
Calverley, V.	P80
Cameron, J.	93

P208 P279

63, P256

Camp, E.R. Campbell, K.

Campbell Jr, D.A.

Cance, W.G.	
	37, P141
Cannell A.I	P310 P318
	T 010, T 010
Canter, R.	P166
Canter, B.J.	P303
Cao, C.	P364
Capanu, M.	P344
Caravan D	D170
Caravan, P.	P1/2
Cardona, K. 32	89 P181
	., 00, 1 .0., D000 D004
P333, P351, P387	, P393, P394
Cardoso, R.	P405, P407
Carleon C W	007
Canson, G.w.	F207
Carpenter, K.	10, P202
	D105
Carpizo, D.R.	P 195
Carr. J.C.	17
Carty CE	D142
Carty, S.E.	F 143
Casali, P.	72
Cato S	DOO
Cale, S.	F 92
Catton, C.	P310
	53
Caudie, A.	55
Cauley, C.E.	P11
Cavallo I A	P402
	1 402
Ceelen, W. 27	, P105, P125
Cerullo	38 P152
	00,1102
Chabaud, S.	P119
Chabot I	78
Chabot, J.	70
Chadha, M.	P92
Chaopar A B	13 D/8
Chaypai, A.D.	10, 140
Chagpar, R.	P137
Chalikonda S	P307
orialitorida, O.	1 007
Chamberlain, R.S.	P90, P133,
P147 P174	P250 P320
	, 1 200, 1 020
Chan, C.H.	P47
Chan K	56
	505
Chan, R.	P359
Chan-Nu C	P398
	1 000
	D0/0
Chang, A.	P219
Chang, A. Chang, G.J. 62	P219 P102 P126
Chang, A. Chang, G.J. 62	P219 P102, P126, P126
Chang, A. Chang, G.J. 62 Chang, K.K.	P219 P102, P126 , 71
Chang, A. Chang, G.J. 62 Chang, K.K. Chatteriee, D.	P219 P102, P126, 71 P148
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D.	P219 P102, P126, 71 P148
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z.	P219 P102, P126, 71 P148 P277, P376
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A	P219 , P102, P126 71 P148 P277, P376 P21
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A.	P219 , P102, P126 71 P148 P277, P376 P21
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A.	P219 , P102, P126 71 P148 P277, P376 P21 P124
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111,	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111,	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58,	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144,
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58,	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P151
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58,	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363 P377 P142, P144, P151
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363 P377 P142, P144, P151 P395
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, I.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P151 P395 P2 52
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, L.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363 P377 P142, P144, P151 P395 P2, 52
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P151 P395 P2, 52 P72
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P151 P395 P2, 52 P72 12 P50
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S.	P219 , P102, P126 71 P148 P277, P376 P124 , P195, P363, P377 P142, P144, P151 P395 P2, 52 P72 12, P50
Chang, A. Chang, G.J. 62, Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P1111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S. Chen, Y. 71, P119	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363 P377 P142, P144, P151 P395 P2, 52 P72 12, P50 , P175, P191
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S. Chen, Y. 71, P119. Chen, Z.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363 P377 P142, P144, P151 P395 P2, 52 P72 12, P50 , P175, P191 P111 P338
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S. Chen, Y. 71, P119. Chen, Z.	P219 711 P148 P277, P376 P124 P195, P363 P377 P142, P144, P195 P2, 52 P72 12, P50 , P175, P191 P111, P338
Chang, A. Chang, G.J. 62, Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S. Chen, Y. 71, P119, Chen, Z. Chen, Z.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P195 P2, 52 P2, 52 P72 12, P50 , P175, P191 P111, P338 P338
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S. Chen, Z. Chen, Z. Cheng, D. Cheng, E.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P151 P395 P2, 52 P72 12, P50 , P175, P191 P111, P338 P338 P401
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S. Chen, Y. 71, P119, Chen, Z. Cheng, D. Cheng, E.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P151 P395 P2, 52 P72 12, P50 , P175, P191 P111, P338 P338 P40
Chang, A. Chang, G.J. 62, Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S. Chen, Y. 71, P119, Chen, Z. Cheng, D. Cheng, L. Cheng, J.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P151 P35 P2, 52 P2, 52 P72 12, P50 , P175, P191 P111, P338 P338 P401 P81
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P1111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S. Chen, S. Chen, Z. Cheng, D. Cheng, J. Cheng, X.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P195 P2, 52 P72 12, P50 , P175, P191 P111, P338 P401 P81
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, K.T. Chen, R. Chen, S. Chen, S. Chen, Y. 71, P119 Chen, Z. Cheng, D. Cheng, E. Cheng, J. Cheng, X.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P195 P2, 52 P72 12, P50 , P175, P191 P111, P338 P338 P401 P81
Chang, A. Chang, G.J. 62, Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S. Chen, Y. 71, P119, Chen, Z. Cheng, D. Cheng, L. Cheng, J. Cheng, J. Cheng, X. Cheng, X. Cherqui, D.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P155 P2, 52 P72 12, P50 , P175, P191 P111, P338 P338 P401 P81 45 P159
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P1111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S. Chen, S. Chen, Z. Cheng, D. Cheng, J. Cheng, X. Cherqui, D. Chia C. P240. P	P219 , P102, P126 71 P148 P277, P376 P124 , P195, P363, P377 P142, P144, P195, P363 P2, 52 P72 12, P50 , P175, P191 P111, P338 P401 P811 P81 P45 P159
Chang, A. Chang, G.J. 62, Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, K.T. Chen, K.T. Chen, S. Chen, Y. 71, P119 Chen, Z. Cheng, D. Cheng, E. Cheng, J. Cheng, X. Cheng, X. Cheng, C. P249, P.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P151 P395 P2, 52 P72 12, P50 , P175, P191 P111, P338 P338 P401 P81 45 P159 252, P288,
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P1111, Chen, H. 21, 58, Chen, K.T. Chen, K.T. Chen, R. Chen, S. Chen, S. Chen, S. Chen, S. Chen, J. Cheng, D. Cheng, J. Cheng, X. Cheng, X. Cheng, C. P249, P	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P151 P395 P2, 52 P2, 52 P2, 52 12, P50 , P175, P191 P111, P338 P401 P338 P401 P81 45 P159 252, P288, P343
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, K.T. Chen, K.T. Chen, R. Chen, S. Chen, Y. 71, P119. Chen, Z. Cheng, D. Cheng, D. Cheng, J. Cheng, X. Cherqui, D. Chian, C. P249, P Chiang, Y.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P195, P367 P142, P144, P151 P395 P2, 52 P72 12, P50 , P175, P191 P111, P338 P401 P81 45 P159 252, P288, P343 P307
Chang, A. Chang, G.J. 62, Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, K.T. Chen, K.T. Chen, P. Chen, S. Chen, Y. 71, P119 Chen, Z. Cheng, D. Cheng, E. Cheng, J. Cheng, X. Cheng, X. Cherqui, D. Chiang, Y. Chiang, Y.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363 P377 P142, P144, P151 P395 P2, 52 P72 12, P50 , P175, P191 P111, P338 P338 P401 P159 252, P288, P343 P307
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P1111, Chen, H. 21, 58, Chen, K.T. Chen, K.T. Chen, R. Chen, P. Chen, S. Chen, Y. 71, P119, Chen, Z. Cheng, D. Cheng, D. Cheng, J. Cheng, X. Cheng, X. Cheng, X. Cheng, Y. Chiang, Y. Chikman, B.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P195, P363, P377 P142, P144, P151 P395 P2, 52 P72 12, P50 , P175, P191 P111, P338 P401 P81 45 P159 252, P288, P343 P307 P66
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, K.T. Chen, K.T. Chen, P. Chen, S. Chen, Y. 71, P119. Chen, Z. Cheng, D. Cheng, D. Cheng, J. Cheng, J. Cheng, X. Cherqui, D. Chiang, Y. Chiang, Y. Chiang, P.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P195, P365 P2, 52 P72 12, P50 , P175, P191 P111, P338 P338 P401 P81 45 P159 252, P288, P343 P307 P66 P287
Chang, A. Chang, G.J. 62, Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P1111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, R. Chen, S. Chen, S. Chen, Y. 71, P119 Chen, Z. Cheng, D. Cheng, J. Cheng, J. Cheng, X. Cheng, X. Cheng, X. Cheng, Y. Chiang, Y. Chikman, B. Chin-Lenn, L.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P195 P2, 52 P72 12, P50 , P175, P191 P111, P338 P338 P401 P119 252, P288, P343 P307 P666 P287
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P1111, Chen, H. 21, 58, Chen, K.T. Chen, R. Chen, R. Chen, P. Chen, S. Chen, Y. 71, P119. Chen, Z. Cheng, D. Cheng, J. Cheng, J. Cheng, X. Cherqui, D. Chian, C. P249, P Chiang, Y. Chikman, B. Chin-Lenn, L. Chmielowski, B.	P219 , P102, P126 71 P148 P277, P376 P124 , P195, P363, P377 P142, P144, P195, P363, P377 P142, P144, P151 P395 P2, 52 P12, P20 , P175, P191 P111, P338 P401 P811 P338 P401 P815 252, P288, P343 P307 P66 P287 58
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, K.T. Chen, K.T. Chen, R. Chen, S. Chen, Y. 71, P119 Chen, Z. Cheng, D. Cheng, J. Cheng, J. Cheng, X. Cheng, X. Cheng, X. Cheng, X. Cheng, Y. Chiang, Y. Chiang, Y. Chiang, B. Chin-Lenn, L. Chmielowski, B. Chmura, S. J.	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P151 P395 P2, 52 P72 12, P50 , P175, P191 P111, P338 P401 P81 45 P159 252, P288, P343 P307 P66 P287 58 P267
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P1111, Chen, H. 21, 58, Chen, K.T. Chen, L. Chen, P. Chen, S. Chen, Y. 71, P119, Chen, S. Cheng, D. Cheng, D. Cheng, J. Cheng, J. Cheng, X. Cheng, X. Cheng, X. Cheng, Y. Chiang, Y. Chiang, Y. Chimelowski, B. Chmura, S.J.	P219 , P102, P126 P148 P277, P376 P124 , P195, P363, P377 P142, P144, P195, P363 P2, 52 P72 12, P50 , P175, P191 P111, P338 P401 P159 252, P288, P343 P307 P66 P287 58 P267
Chang, A. Chang, G.J. 62. Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, C. 19, P1111, Chen, H. 21, 58, Chen, K.T. Chen, K.T. Chen, R. Chen, R. Chen, S. Chen, Y. 71, P119. Chen, Z. Cheng, D. Cheng, D. Cheng, J. Cheng, J. Cheng, X. Cherqui, D. Chiang, Y. Chiang, Y. Chiang, Y. Chiang, S.J. Chmura, S.J. Cho, C. 98, P150, Cho, C. 98, P150,	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P195, P367 P2, 52 P72 12, P50 , P175, P191 P111, P338 P401 P151 P159 252, P288, P343 P307 P66 P287 58 P267 P333, P361,
Chang, A. Chang, G.J. 62 Chang, K.K. Chatterjee, D. Chau, Z. Chawla A. Chen, A. Chen, A. Chen, C. 19, P111, Chen, H. 21, 58, Chen, K.T. Chen, K.T. Chen, K.T. Chen, R. Chen, S. Chen, Y. 71, P119, Chen, Z. Cheng, D. Cheng, D. Cheng, J. Cheng, X. Cheng, X. Cheng, X. Cheng, X. Cheng, Y. Chiang, Y. Chiang, Y. Chiang, B. Chin-Lenn, L. Chmura, S.J. Cho, C. 98, P150, P387	P219 , P102, P126 71 P148 P277, P376 P21 P124 , P195, P363, P377 P142, P144, P151 P395 P2, 52 P72 12, P50 , P175, P191 P111, P338 P401 P81 45 P159 252, P288, P343 P307 P66 P287 58 P267 P333, P361, P393, P394

Cho, C.S.	89, P351
Cho, E.	37, 68
Choi, E.	P384
Choi, M.	P314
Chok, A.	P242
Choti, M.	93
Chou, C.	P363
Chou, J.	P344
Choudry, M.A.	P113, P266,
Chave O C	P406
Christians KK	
DIT	PI/I, PI/3,
Christie NA	9, 1 333, 1 403 79
Chugh B	43 P187
Chung MH	P13 P388
Chung, P.W.	P318
Cintolo-Gonazelz	. J. P205
Cioffi, W.G.	P278
Cisneros, B.	P164
Clara, J.	P237
Clark, K.	P42
Clark, W.	P124
Clarke, C.N.	P126
Clary, B.M.	94
Cleary, R.K.	63
Cleary, S.P.	P183, P338
Clemente-Gutierr	ez, U.E. P39
Clemente-Gutiérr	ez, U.E. P248
Clifton, G.T.	P6, 16
Cloyd, J.M.	P232
Coburn, N. P182	2, P404, P405,
0	P407
Cocieru, A.	P306
Coarington, H.	
Cohen E E	F20, F03 P267
Cohen S.I	P326
	D201 D244
Coll, D.G. 34, 90	, F201, F344,
	P368
Coleman IA	F200
	34 D5
Collett, A.E.	P3
Collins, J.P.	P43
Colombo, C.	72
Comfere, N.I.	P197
Condren, A.	P85
Conrad, C.	P178
Conte, C.	P154, P155
Contreras, C.M.	P324
Cooper, A.	P1/8
Coopey, S.	
Coppela S	F47, F74 72
Corben A	9
Cormier IN 3	53 76 P258
P264. P29	2. P301. P307
Cornacchi. S.D.	_,,, P81
Corona-Cruz, J.	V1. 87
Corr, S.	P164
Correia, M.D.	P366
Cortés-González,	R. P398
Cosgrove, D.	39
Cote, G.	P146
Cotterchio, M.	P338

50 P268

S189

Coventry, B.J.	50
Coyne, K.A.	P268
Coyne, R.	P18
Crago, A.M.	73
Crane, C.	P178
Critchlow, J.F.	P376
Crocenz, T.	1
Cruse, C.W. P196, P206,	P226
Cruz, I.	P308
Cruz-Rodriguez, A.	V1
Cucher. D.J.	P211
Cuellar-Hubbe, M. P204.	P308
Cumminas. F.	P294
Cunliffe. H.E.	P56
Cupino, A.	P269
Curley, S.A. P162, P164.	P358
Curry, J.	53
Cusack Jr., J.C.	P110
Cvr. A.R.	P382
Czerniecki B.I. 15 P27	54
P93.	P205
,	

D

P322, P329
41, P161, P165,
169, P349, P385
P400
20
P384
P150
36
P300
1 0 0 1
P198, P323
15, P365
40
P275
P247
P172
P71
P. 17
P201
2
. P227, P235
lazar, J. P204
P105
s Santos. F.A.
P366
P44, P99, P106
P167
P23, P55, P59
P72
71
50 D007
52, F207
41, P97, P161,
109, P349, P385
P337, P340
9
P62
36
P326
P316
P182, P401
P172
58

Deshpand, V.	3	39, 47	El-Hayek, K.M.
Deshpande, A.		P41	El-Rayes, B.
Deutsch, G.	P154,	P155	El-Sedfy, A.
Deutsch, G.B.	e	67. 70	Elferink, M.A.
Devalben, P.		P338	Elkin, E.B.
Dexter SI P321	P325	P330	Ellenhorn, J.D.
Doxiol, 0.2. 1 021,	. 020,	P380	Ellison, C.
Dhage S		11	Elmore I
Dhar V		P282	Eltaraboulsi W
Dhungel B		P216	A
Di Como I A	POO	D17/	Fndo S
Diac Santos D	1 30,	11/4	End C
Diakoon B C	D210	-+/ D210	Eng. O.S
Dickson, D.C.	D16	F310 D15	England C
Diego, E.	FIC	D100	Englum P.D
Dietz, D.		F120	Erigiuiii, D.N.
Diggs, D.S.			
DiGiovanna, Ivi.		P48	Emunmwunsee
DiGiovanni, R.M.		P131	Erickson, B.A.
Dineen, S.	B 050	76	
Ding, Y. P266,	P350,	P406	Erika, R.
Dittus, R.S.		64	Ernlund, A.
Dixon, M. P404,	P405,	P407	Ernst, R.
Dobler, P.C.		49	Esemuede, I.
Doherty, M.G.		P388	Esgueva, A.
Doki, Y.		P356	Eskander, M.
Dolzan, V.		P153	Espat, N. 40
Dominguez-Parra, L		P308	Espejo-Fonseca
Dominguez-Reyes,	C.A.	P68	Espin-Garcia, C
Donahue, A.E.		P391	Espina, V.
Dooley, W.C.		P33	Esquivel, J.
Dotan, E.		P326	Esserman, L.J.
Dove, J.		P78	Essner, R.
Downey, R.		P368	Estrada-Bernal,
Downs-Canner, S.	P113,	P406	Estrella, J.
Drabick, J.		P203	Etra, J.W.
Drebin, J.A.	P365.	P371	Etzioni. D.A.
Drummond-Lage, A		P366	Euhus, D.
Drury, P.		P43	Evans D P14
Du. L.		P51	P ⁻
Dubner, S.	P154	P155	Evers. M.
Dudeia V	,	P187	
Duelge K	P173	P403	
Duiim I F		P44	1
Dukleska K	71	P344	Faby B
Dumur C I	71,	P210	Fana MD
Duncan M.D.		83	Farias M.P. F
Duncari, M.D.		D76	Falles, M.D. 5
Duponi, S.C.		F/U D0/0	Earia I
Dupre, I.		F340	Fails, J.
Dupi, A.			Farkas, n.
Dullennaver, J.		P02	Farrey, C.
Dуке, С.		P269	Farma, J.M.
			Farqunar, D.
Г			Farqunar, D.R.
Ľ		DOCC	⊢arrar, C.
Easson, A.M.		P236	⊢arrugia, H.
Eastwood, D.		P355	⊢ayad, L.
Eaton, A.		9	Feig, B. 62, 76
Ebata, T.		P104	
Edmondson, D.M.		P327	⊢eig, R.
Edwards, M.	82,	P271	Feldman, S.M.
Egger, M.E.	55,	P348	Felsen, C.N.
Eguale, T.	P103,	P135	Ferguson, M.

Ejaz, A. 89, P333, P351, P357, P361, P393, P394

P260

P375

El Mokdad, A.

El-Dika, S.

LI-nayes, D.	32
El-Sedfy, A. P405,	P407
Elferink, M.A.	P99
Elkin, E.B.	60
Ellenhorn J D	70
Ellison C	D375
Elmoro I	D/1
	F41
Eltarabouisi, W.R. Emery,	P329
A.	P247
Endo, S.	P356
Eng, C.	P137
Eng, O.S.	P195
England, C.	P348
Englum, B.R.	P322
Erdahl, L.M.	P23
Frhunmwunsee, I	P322
Erickson B A P17	3
Elickson, D.A. 1170	, , ,
P179,	P403
Erika, R.	P107
Ernlund, A.	11
Ernst, R.	P102
Esemuede, I.	P261
Esgueva, A.	P25
Eskander, M.	P277
Espat. N. 40. 42. P97.	P158
Espeio-Fonseca, A.B.	P68
Espin-Garcia O	P338
Espin-Garcia, O. Espina V	1 000
Espina, v.	
	20, 20
Esserman, L.J.	P60
Essner, R.	58
Estrada-Bernal, A.	P363
Estrella, J.	P148
Etra IW	
Lua, 0. VV.	P393
Etzioni, D.A.	P393 65
Etrioni, D.A. Euhus. D. P28	P393 65 8. P36
Eta, 6.W. Etzioni, D.A. Euhus, D. P149 P173 P	P393 65 3, P36
Etzioni, D.A. Euhus, D. P28 Evans, D. P149, P173, P	P393 65 3, P36 178, P403
Etzioni, D.A. Euhus, D. P28 Evans, D. P149, P173, P P179, P358,	P393 65 3, P36 178, P403 P270
Etzioni, D.A. Euhus, D. P28 Evans, D. P149, P173, P P179, P358, Evers, M.	P393 65 3, P36 178, P403 P279
Etzioni, D.A. Euhus, D. P28 Evans, D. P149, P173, P P179, P358, Evers, M.	P393 65 3, P36 178, P403 P279
Etzioni, D.A. Euhus, D. P28 Evans, D. P149, P173, P P179, P358, Evers, M.	P393 65 3, P36 9178, P403 P279
Etzioni, D.A. Euhus, D. P28 Evans, D. P149, P173, P P179, P358, Evers, M. F	P393 65 9, P36 9178, P403 P279
Etzioni, D.A. Euhus, D. P28 Evans, D. P149, P173, P P179, P358, Evers, M. F Fahy, B.	P393 65 8, P36 178, P403 P279 P134
Etzioni, D.A. Euhus, D. P28 Evans, D. P149, P173, P P179, P358, Evers, M. F Fahy, B. Fana, M.D.	P393 65 8, P36 9178, P403 P279 P134 P72
Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P.	P393 65 9, P36 9178, P403 P279 P134 P72 221,
Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P.	P393 65 9, P36 178, P403 P279 P134 P72 221, P222
Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P.	P393 65 9, P36 178, P403 P279 P134 P72 221, P222 47
Etzioni, D.A. Euhus, D. P28 Evans, D. P149, P173, P P179, P358, Evers, M. F Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R.	P393 65 3, P36 178, P403 P279 P134 P72 221, P222 47 P17
Etzioni, D.A. Euhus, D. P28 Evans, D. P149, P173, P P179, P358, Evers, M. F Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farley, C.	P393 65 3, P36 9178, P403 P279 P134 P72 221, P222 47 P17 P207
Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farkas, R. Farley, C. Farma, J.M. P132	P393 65 9, P36 178, P403 P279 P134 P72 221, P222 47 P17 P207 P234
Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farkas, R. Farma, J.M. P132, Faroubar, D	P393 65 8, P36 178, P403 P279 P134 P279 P134 P221, P222 47 P17 P207 P234 P152
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fara, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farley, C. Farquhar, D. Earquhar, D. Earquhar, D.	P393 65 65 9, P36 178, P403 P279 P134 P222 47 P207 P207 P207 P234 P152 234
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farley, C. Farma, J.M. P132, Farquhar, D. Farquhar, D.R. Farra, C	P393 65 8, P36 P178, P403 P279 P134 P222 47 P122 47 P227 P234 P152 38 P172
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farley, C. Farma, J.M. P132, Farquhar, D. Farquhar, D.R. Farrar, C. Farma, L.	P393 65 3, P36 (178, P403 P279 P134 P72 221, P122 47 P17 P207 P234 P172 38 P172 38 P172
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Faries, M. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farley, C. Farma, J.M. P132, Farquhar, D. Farquhar, D. Farrar, C. Farrugia, H. Farrugia, H.	P393 65 3, P36 (178, P403 P279 P134 P72 221, P222 47 P17 P207 P234 P172 28 P172 28 P172 P39
Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farkas, R. Farkas, R. Farey, C. Farma, J.M. P132, Farquhar, D. Farquhar, D. Farrugia, H. Farrugia, H. Fayad, L.	P393 65 3, P36 (178, P403 P279 P134 P72 221, P222 47 P17 P224 7 P17 P207 P234 P172 38 P172 P49 P243
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Faray, B. Fana, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farkas, R. Farkas, R. Farkas, R. Farkas, R. Farkas, R. Farkas, R. Farkas, C. Farma, J.M. P132, Farquhar, D.R. Farquhar, D.R. Farquhar, D.R. Farrugia, H. Fayad, L. Feig, B. 62, 76, P243, P3	P393 65 3, P36 (178, P403 P279 P134 P72 221, P222 47 P17 P2234 P172 238 P172 243 P172 P49 P243 301,
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Faray, B. Fana, M.D. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Faries, J. Farkas, R. Farkas, R. Farkas, R. Farley, C. Farma, J.M. P132, Farquhar, D. Farquhar, D. Farquhar, D.R. Farrugia, H. Farayad, L. Feig, B. 62, 76, P243, P3	P393 65 3, P36 (178, P403 P279 P134 P72 221, P222 47 P17 P224 47 P172 238 P172 38 P172 243 301, P307
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Faray, B. Fana, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farkas, R. Farkas, R. Farkas, R. Farkas, R. Farayahar, D. Farquhar, D. Farquhar, D.R. Farquhar, D.R. Farrugia, H. Farrugia, H. Fayad, L. Feig, B. 62, 76, P243, P3 Feig, R.	P393 65 3, P36 (178, P403 P279 P134 P72 221, P222 47 P17 P224 P17 P234 P172 P38 P172 P49 P243 301, P307 76
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fara, M.D. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Faries, J. Farkas, R. Farkas, R. Farkas, R. Farkas, R. Farkas, R. Farkas, R. Farkas, R. Farendar, D. Farquhar, D. Farquhar, D. Farquhar, D. Farquhar, D. Farrugia, H. Fayad, L. Feig, B. 62, 76, P243, P3 Feig, R. Feldman, S.M. P75	P393 65 3, P36 (178, P403 P279 P134 P72 221, P222 47 P17 P227 P234 P172 P49 P243 301, P307 76 5, P87
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fara, M.D. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Faries, J. Farkas, R. Farkas, R. Farkas, R. Farley, C. Farma, J.M. P132, Farquhar, D. Farquhar, D. Farquhar, D. Farquhar, D. Farquhar, D. Farrugia, H. Fayad, L. Feig, B. 62, 76, P243, P3 Feig, R. Feldman, S.M. P75 Felsen, C.N.	P393 65 8, P36 (178, P403 P279 P134 P72 221, P72 221, P17 P224 P17 P207 P234 P172 P49 P243 301, P207 P243 901, P307 76 5, P87 7853
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. F Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farley, C. Farma, J.M. P132, Farquhar, D. Farquhar, D. Farquhar, D. Farquhar, D. Farquhar, D. Farquhar, D. Farquhar, D. Farrugia, H. Fayad, L. Feig, B. 62, 76, P243, P3 Feig, R. Feldman, S.M. P75 Felsen, C.N. Ferguson, M.	P393 65 8, P36 (178, P403 P279 P134 P72 221, P72 P222 47 P17 P224 P17 P207 P234 P172 P307 P243 301, P307 76 5, P353 P323
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faris, J. Farkas, R. Farkas, R. Farequhar, D. Farquhar, D. Farquhar, D. Farquhar, D. Farrugia, H. Fayad, L. Feig, B. 62, 76, P243, P3 Feig, R. Feldman, S.M. Ferguson, M. Ferguson, P.C	P393 65 8, P36 (178, P403 P279 P134 P72 221, P222 47 P17 P224 7 P17 P207 P234 P172 238 P172 P49 P243 301, P307 76 6, P87 P353 P323 P318
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Fara, M.B. Farkas, R. Farkas, R. F	P393 65 8, P36 (178, P403 P279 P134 P72 221, P222 47 P17 P224 7 P17 P207 P234 P172 P38 P172 P49 P243 301, P307 76 5, P87 P353 P323 P318 P328
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. F Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Farkas, R. Farkas, R.	P393 65 3, P36 (178, P403 P279 P134 P72 221, P222 47 P17 P224 47 P17 P227 P17 P234 P172 P333 01, P307 76 5, P87 P353 P318 P318 P338
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fahy, B. Fana, M.D. Faries, M.B. 54, P214, P. Faries, M.B. 54, P214, P. Fara, C. Farma, J.M. P132, Farquhar, D. Farquhar, D.R. Farrugia, H. Farquhar, D.R. Farrugia, H. Fayad, L. Feig, B. 62, 76, P243, P3 Feig, R. Feldman, S.M. P75 Felsen, C.N. Ferguson, M. Ferguson, M. Ferguson, P.C. Fernandez, R. Fermandez-del Castillo, C.	P393 65 3, P36 (178, P403 P279 P134 P72 221, P222 47 P172 P234 P172 78 P172 P49 P49 P49 P49 P43 301, P307 76 5, P353 P318 P332 P318 P332 P318 P332 P353 P353 P353 P353 P353 P353 P353
Etzioni, D.A. Etzioni, D.A. Euhus, D. P149, P173, P P179, P358, Evers, M. Fana, M.D. Faries, M.B. 54, P214, P. Faries, M. Faries, M. Faries, M. Faries, M.	P393 65 8, P36 (178, P403 P279 P134 P72 221, P222 47 P17 P227 P234 P172 P49 P243 301, P307 76 5, P87 P353 P318 P333 47 39, 47

P397

Feygenzon, V. Fiel, M.	P373 P167
P354, P357	, P361, P374,
P387, P393	3, P394, P402
Figg, R.E. Finn, R.	63 58
Fiore, M.	72
Fisher, D.	P200, P215
Fisher, K.J. Fitzgerald TI	P206, P226 P300
Fitzpatrick, E.	15
Flate, E.	P334
Fleming, J.B. P148	8, P178, P358 P213
Fogelman, D.R.	P178
Fong, J.	P43, P49
Fong, Y. 41, P161	, P165, P169,
Fong, Z.	P110
Forcione, D.	47
Forscher, C.	P314
Fortino, J.	P216
Foshag, L.J.	P221
Foster, G.	P81
Fowble. B.	P60
Fraker, D.L. 38, 54	I, P152, P298,
Franceschi D. D.	P365, P371
Francescutti. V. 2	22. 68. P224.
P233	3, P261, P311
Frankel, T.L.	41, P256
Franklin, P.L.	P328
Franssen, B.	P272
Fratkin, M.	P91
Frazier, C.	P62
Frazier, T.G.	P5, P14
Freer, P.E.	P47
Frelick, A.	P320, P327 P24
Friedmann, P.	P400
Frisella, M.M.	P402
Fry, W.	P86
Fuchs, B.C.	P172
Fujitani, K.	6 V7 P345
Fulp, W.	P35, P88
Funk, P.	P186
Furtaro, D.M.	P110 P160
Fusaki, N.	P219
G	
Gabordi, R.	P28
Gadd, M.	P11, P74
Gagel, NI. Gagel, R.F.	P15 P146
Gaitonde, S.G.	82
Gallagher, K.	8, P79
Gallinger, S.	P183, P338

P171, P173, P179	P297
P355, P391	, P403
Gamenthaler, A.	P124
Gamper, C.	P109
Ganai, S. P198, P267	', P323
Ganapathi, A.M.	P299
Ganesan, N.	P18
Gangi, A.	P38
Ganjoo, K.N.	// D105
Gannon J	F 195 80
Gaona-Luviano P	P39
Garber, J.E.	P11
Garcia, D.	P85
Garcia-Aguilar, J. 19	9, P111
Garg, N.	P178
Garza-Gangemi, A. P39	, P248
Gawad, W.M.	P117
Geliebter, J.	P240
Geller, D.A.	23
George R D172 D170	P240
Georgiade G	, F403 1 <i>1</i>
Gershenwald J F	53
Gerstenhaber, F.	P360
Gholami, S.	77
Ghosh, P.	20
Giblin, E.M.	P15
Gibney, G.T. P237	', P241
Gibson, M.K.	79
Gidley, P.W.	P146
Gigot, J.	39
Giles, B.	P199
Giles, M.H.	50
Gillego, A.	PQ2
Gimotty, P. 54	. P298
Ginther, C.	58
Giordano, N.I	P140
Girais M.D.	P336
Girgis, M.D.	3 D38
Giuliano, A.E.	0,100
Gladuy, n.A. F310	, F310 P0
Glazebrook K N P6	1 P76
Glenn, J.A.	P391
Gnerlich, J.L.	P77
Goedegebuure, P. 97, F	P337,
-	P340
Gold, J.S.	P130
Goldberg, R.M.	P386
Golden, D.W.	P267
Goldfarb, M.	P156
Goldsmith C	P368
Golshan M	57 P8/
Gomez-Argumosa, V.	V1
Gönen M P161 D165	P160
P368	B. P385
Gong K	,
Gonzalos M	oc D101
	P134
GONZAIEZ, L.G.	P56
D0112a162, n.J. P190, P2	. P241
1 220	., · - / I

Gonzalez, S.J.	P67	Han, S.	6	Hocevar, M.	P315	Ihemelandu, C.	P370
Gooch, J.	9	Han, Y.	10	Hochwald, S.N.	V2, 80, P381	lida, S.	P120
Goodman, K.A.	19, 90	Han-Kwang, Y.	6	Hodak, S.P.	P143	lino, I.	P362
Gopalakrishnan, R.	P247	Handorf, E.	P234	Hodgson, N.	P81	Ikeda, M.	P112
Gorgun, E.	P123	Hanna, N. P12 ⁻	I, P285, P291	Hoefer, R.A.	P290	Ikenaga, M.	P112
Govsyeyev, N.	P206, P226	Hanseman, D.J.	66, 82	Hoekstra, H.J.	P220, P231,	Ikoma, N.	V7, P301, P307
Gracely, E.J.	P5	Hansen, H.J.	P101		P295	llson, D.H.	90, P368
Graham, L.	P210	Haraguchi, N.	91, P112	Hoffman, J.P.	P395	Imnadze, M.	34
Granata, V.	P162	Hardacre, J.	P392	Hoffman, R.M.	P353	In, H.	P163, P342
Grant, M.D.	P53	Hardee, M.	P79	Hotstetter, W.L.	88	Inchauste, S.M.	P223
Gratian, L.	30	Harismendy, O.	20	Hogg, M.E. P184	4, P266, P346,	Ingram, D.	76
Gray, R.J.	P7, 65	Harmon, J.W.	83	11.0	P350	Inoue, Y.	P1//
Greco, R.S.	P232	Harris, J.	P279, P367	Hollander, L.	P63	Inselman, J.W.	P197
Green, M.J.	P257	Hartmann, L.C.	P55	Hollenbeak, C.	P8	Intelisano, A.	P230
Greene, A.	/8	Hashim, Y.IVI.	P374	Hollingsworth, IVI.	.A. P334	loroanescu, G.	P77
Greenup, R.	14		P300	Holmes, H.M.	P1/8	ISacoli, W.H.	P330
Greenup, R.A.	P37	Hauch, A. 3.	D270	Holtzman, M.P.	P113, P266,	Isnigami, S.	81, 91, P341 D120
Gregory, L. f.	F1/2			Hong C	F400	Isniguro, ivi.	F120
Greig, F.D.	F 103	Hawkins, W.G.	-354, P357,	Hong TS	7 D110	ISHII, IVI.	F100
Grienson	21	House R	+, F307, F402	Honing I	47, F110 P210	Isnikawa, I.	F120
Griffin A M	40 D318	Hayse, D.	13	Honor C	70	Isom, C.	F 230
Grille	P72	Hoakal V	D334	Hooke M A	72 D51	Itagaki S	P345
Grinno P	D3/7	Heather I D12	2 P266 P406	Horowitz N R	13 P/8	Itagani, O.	P180
Grohmver S B	D381	Heiferman I	D, 1 200, 1 400	Horton I	10, 140	Ito E	P210
Groeger J	P385	Heiferman M	P3/7	Hochi H	D383	Ito, T	P356
Groeschl RT	1 303	Heimbach IK	P186	Hoshino I	D330	ltuarte PH	P175
Groman A	68 P381	Hellan M	P103	Hoskin TI	P23 P55 P50	lvascu F	P262
Gronchi A	72	Helm J H	P391	Hospers G A	P319	lwasaki Y	6
Gross M F	P101	Helton S	P390	Hostetter B	48	Iwata N	P120
Grossmann I	2 P114	Helver I P80 I	P404 P405	Hou S	P336	Izmer A	27 P105
Grotz T.E. V/A P	107 D218		404, 1 403, P407	Howard A	P267	121101, 74.	P162
GIUIZ, T.L. V4, T	P229	Hemmerich J A	P384	Howard J H	P222 P379	1220, 1.	1102
Grover S	P1	Henderson M	50	Howe J.B.	29 P382		
Grubbs E G	P146	Hendren S	63 P256	Howell G M	P143		ſ
Grünhagen D	75	Hendrix A	P28	Hsu C	P30	.laan K	, P399
Gueller, U.	18	Henry, L.B.	48	Hsueh, E.	. 66	Jabi, E	80
Guidi. A.J.	P11	Henry-Tillman, R.	P79	Hsueh, E.C.	P217	Jackson, M.	P17
Gulec. S.		Hormon I	00 0001				P188
	48	nemian. J.	93. P361	Hu. C.	62. P102	Jackson, N.R.	
Gupta, M.	48 77. P365	Hernandez. J.	93, P361 P368	Hu, C. Hu. M.I.	62, P102 P146	Jackson, N.R. Jackson, R.	P196
Gupta, M. Gupta, S.	48 77, P365 44	Hernandez, J. Hernandez Irizarry	93, P361 P368 v. R.C. V4	Hu, C. Hu, M.I. Hu, T.	62, P102 P146 P188	Jackson, N.R. Jackson, R. Jackson. T.	P196 P305. P312
Gupta, M. Gupta, S. Gusani. N.J.	48 77, P365 44 P257	Hernandez, J. Hernandez Irizarry Herrera Loeza. S.	93, P361 P368 y, R.C. V4 G. P170	Hu, C. Hu, M.I. Hu, T. Hu, Y.	62, P102 P146 P188 57	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A.	P196 P305, P312 23
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270.	48 77, P365 44 P257 P273, P283	Hernandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A	93, P361 P368 v, R.C. V4 G. P170 . V1, 87	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B.	62, P102 P146 P188 57 P279, P367	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E.	P196 P305, P312 23 P109
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E.	48 77, P365 44 P257 P273, P283 P281	Hernandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M.	93, P361 P368 y, R.C. V4 G. P170 . V1, 87 P247	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K.	62, P102 P146 P188 57 P279, P367 P400	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W.	P196 P305, P312 23 P109 V4, P59, P229
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F.	48 77, P365 44 P257 P273, P283 P281 59	Hernandez, J. Hernandez, J. Hernandez Irizary Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzberg, D.O.	93, P361 P368 y, R.C. V4 G. P170 . V1, 87 P247 P95	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, Q.	62, P102 P146 P188 57 P279, P367 P400 P130	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E	P196 P305, P312 23 P109 V4, P59, P229). 34
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D.	48 77, P365 44 P257 P273, P283 P281 59 P209	Hernandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M.	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P247 P95 59, P324	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, Q. Huang, W.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R.	P196 P305, P312 23 P109 V4, P59, P229). 34 P246, P254
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D.	48 77, P365 44 P257 P273, P283 P281 59 P209	Hernandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H.	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P247 P95 59, P324 P359	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, Q. Huang, W. Huang, X.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y.	P196 P305, P312 23 P109 V4, P59, P229 0. 34 P246, P254 90
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D.	48 77, P365 44 P257 P273, P283 P281 59 P209	Hernandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Hestley, A.	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P247 P95 59, P324 P359 P207	Hu, C. Hu, M.I. Hu, T. Huang, B. Huang, K. Huang, Q. Huang, W. Huang, X. Huang, X. Hudis, C.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161	Jackson, N.R. Jackson, R. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K.	P196 P305, P312 23 P109 V4, P59, P229 0. 34 P246, P254 90 P398
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D.	48 77, P365 44 P257 P273, P283 P281 59 P209	Hermandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Hestley, A. Hetu, J.	93, P361 P368 4, R.C. V4 G. P170 . V1, 87 P247 P95 59, P324 P359 P207 P119	Hu, C. Hu, M.I. Hu, T. Huang, B. Huang, K. Huang, Q. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, S	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68	Jackson, N.R. Jackson, R. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4	P196 P305, P312 23 P109 V4, P59, P229 0. 34 P246, P254 90 P398 1, P161, P165,
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197	Hermandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Hestley, A. Hetu, J. Hewitt, K.	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P247 P95 59, P324 P359 P207 P119 P239	Hu, C. Hu, M.I. Hu, T. Huang, B. Huang, K. Huang, Q. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, S. Hugen, N.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99	Jackson, N.R. Jackson, R. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1	P196 P305, P312 23 P109 V4, P59, P229 0. 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B. Hagihara, T.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341	Herman, J. Hernandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T.	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P247 P95 59, P324 P359 P207 P119 P239 P180	Hu, C. Hu, M.I. Hu, T. Huang, B. Huang, K. Huang, Q. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hugen, N. Hughes, K.S.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74	Jackson, N.R. Jackson, R. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S.	P196 P305, P312 23 P109 V4, P59, P229). 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B. Hagihara, T. Hahn, O.M.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267	Hermandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W.	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26	Hu, C. Hu, M.I. Hu, T. Huang, B. Huang, K. Huang, K. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hughes, K.S. Hughes, M.S.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223	Jackson, N.R. Jackson, R. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T.	P196 P305, P312 23 P109 V4, P59, P229). 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118,
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6	Hermandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G.	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26 P17	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, Q. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hugen, N. Hughes, K.S. Hughes, M.S. Hui, J.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234	Jackson, N.R. Jackson, R. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T. P1	P196 P305, P312 23 P109 V4, P59, P229). 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16	Hermandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61,	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, Q. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hughes, K.S. Hughes, M.S. Huismans, A.M.	62, P102 P146 P188 57 P279, P367 P400 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T. P1 Jayaraman, S.	P196 P305, P312 23 P109 V4, P59, P229). 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P98
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F. Halevy, A.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16 P66	Hermandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23 P76	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61, 6, P197, P218	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, Q. Huang, W. Huang, X. Hudis, C. Hugen, N. Hughes, K.S. Hughes, M.S. Huismans, A.M. Hung, R.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220 P338	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T P1 Jayaraman, S. Jenkins, C.	P196 P305, P312 23 P109 V4, P59, P229). 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P98 P262
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F. Halevy, A. Hall, M.A.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16 P66 P286	Hermandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23 P70 Hilchie-Pye, A.	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61, 6, P197, P218 P80	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, Q. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hugen, N. Hughes, K.S. Hughes, M.S. Huismans, A.M. Hunsinger, M.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220 P338 P78, P399	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T P1 Jayaraman, S. Jenkins, C. Jensen, E.H.	P196 P305, P312 23 P109 V4, P59, P229). 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P98 P262 43
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F. Halevy, A. Hall, M.A. Hall, M.J.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16 P66 P286 P326	Hermandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23 P70 Hilchie-Pye, A. Hill, E.	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61, 6, P197, P218 P80 P208	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, C. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hugen, N. Hughes, K.S. Hughes, M.S. Huismans, A.M. Hunsinger, M. Hunsinger, M.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220 P338 P78, P399 76, P301, P307	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T P1 Jayaraman, S. Jenkins, C. Jensen, E.H. Jespen, K.	P196 P305, P312 23 P109 V4, P59, P229). 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P98 P262 43 20
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F. Halevy, A. Hall, M.A. Hall, M.J. Hall, N.C.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16 P66 P286 P326 P244, P251	Herman, J. Hernandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23 P70 Hilchie-Pye, A. Hill, E. Hill, J.S.	93, P361 P368 , R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61, 5, P197, P218 P80 P208 10, P202	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, X. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, K. Hughes, K.S. Hughes, M.S. Hughes, M.S. Hui, J. Huismans, A.M. Hunsinger, M. Hunsinger, M. Hunt, K.K. 3, 7 Huth, J.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220 P338 P78, P399 76, P301, P307 P36	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T P1 Jayaraman, S. Jenkins, C. Jensen, E.H. Jespen, K. Ji, L.	P196 P305, P312 23 P109 V4, P59, P229). 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P98 P262 43 20 P269
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F. Halevy, A. Hall, M.A. Hall, M.J. Hall, N.C. Halle, D.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16 P66 P286 P326 P244, P251 21	Hermandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23 P70 Hilchie-Pye, A. Hill, E. Hill, J.S. Hilliard, E.	93, P361 P368 (, R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61, 5, P197, P218 P80 P208 10, P202 P9	Hu, C. Hu, M.I. Hu, T. Hu, T. Huang, B. Huang, K. Huang, C. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hugen, N. Hughes, K.S. Hughes, M.S. Hui, J. Huismans, A.M. Hunsinger, M. Hunsinger, M. Hunt, K.K. 3, 7 Huth, J. Hwang, E.S.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220 P338 P78, P399 76, P301, P307 P36 14, P37	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T P1 Jayaraman, S. Jenkins, C. Jensen, E.H. Jespen, K. Ji, L. Jiagge, E.	P196 P305, P312 23 P109 V4, P59, P229 0. 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P98 P262 43 20 P269 P52
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F. Halevy, A. Hall, M.A. Hall, M.J. Hall, N.C. Halle, D. Hallet, J.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16 P66 P286 P326 P244, P251 21 P157, P182	Herman, J. Hernandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23 P70 Hilchie-Pye, A. Hill, E. Hill, J.S. Hilliard, E. Hillman, D.	93, P361 P368 (, R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61, 6, P197, P218 P80 P208 10, P202 P9 P320	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, C. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hugen, N. Hughes, M.S. Hughes, M.S. Hui, J. Huismans, A.M. Hunsinger, M. Hunsinger, M. Hunsinger, M. Hunt, K.K. 3, 7 Huth, J. Hwang, E.S. Hwang, H.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220 P338 P78, P399 76, P301, P307 P36 14, P37 P22	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T P1 Jayaraman, S. Jenkins, C. Jensen, E.H. Jespen, K. Ji, L. Jiagge, E. Jiang, B.	P196 P305, P312 23 P109 V4, P59, P229 0. 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P98 P262 43 20 P269 P52 49
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F. Haley, A. Hall, M.A. Hall, M.J. Hall, N.C. Halle, D. Hallet, J. Hamid, O.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16 P66 P286 P326 P286 P326 P244, P251 21 P157, P182 P214	Hermandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23 P70 Hilchie-Pye, A. Hill, E. Hill, J.S. Hilliard, E. Hillman, D. Hiotis, S.	93, P361 P368 (, R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61, 5, P197, P218 P80 P208 10, P202 P9 P320 P167	Hu, C. Hu, M.I. Hu, T. Hu, T. Huang, B. Huang, K. Huang, C. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hugen, N. Hughes, K.S. Hughes, M.S. Huismans, A.M. Hunsinger, M. Hunsinger, M. Hunsinger, M. Hunt, K.K. 3, 7 Huth, J. Hwang, E.S. Hwang, H. Hyngstrom, J.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220 P338 P78, P399 76, P301, P307 P36 14, P37 P22 P239	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T P1 Jayaraman, S. Jenkins, C. Jensen, E.H. Jespen, K. Ji, L. Jiagge, E. Jiang, B. Jimenez, C.	P196 P305, P312 23 P109 V4, P59, P229 0. 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P98 P262 43 20 P269 P52 49 P146
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. H Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F. Haley, A. Hall, M.A. Hall, M.A. Hall, M.A. Hall, N.C. Halle, D. Hallet, J. Hamid, O. Hamilton, T.D.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16 P66 P286 P326 P286 P326 P244, P251 21 P157, P182 P214 P310	Hermandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23 P70 Hilchie-Pye, A. Hill, E. Hill, J.S. Hilliard, E. Hillman, D. Hiotis, S. Hiramatsu, K.	93, P361 P368 (, R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61, 5, P197, P218 P80 P208 10, P202 P9 P320 P167 P104	Hu, C. Hu, M.I. Hu, T. Hu, T. Huang, B. Huang, K. Huang, Q. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hugen, N. Hughes, K.S. Hughes, M.S. Hui, J. Huismans, A.M. Hunsinger, M. Hunsinger, M. Hunsinger, M. Hunt, K.K. 3, 7 Huth, J. Hwang, E.S. Hwang, H. Hyngstrom, J. Hyung, W.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220 P338 P78, P399 76, P301, P307 P36 14, P37 P22 P239 6	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T. P1 Jayaraman, S. Jenkins, C. Jensen, E.H. Jespen, K. Ji, L. Jiagge, E. Jiang, B. Jimenez, C. Jimenez, M.	P196 P305, P312 23 P109 V4, P59, P229 0. 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P98 P262 43 20 P269 P52 49 P146 P305, P312
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. H Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F. Halevy, A. Hall, M.A. Hall, M.A. Hall, M.A. Hall, N.C. Halle, D. Hallet, J. Hamid, O. Hamilton, T.D. Hamilton, T.D.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16 P66 P286 P326 P244, P251 21 P157, P182 P214 P310 P396	Hermandez, J. Hernandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23 P76 Hilchie-Pye, A. Hill, E. Hill, S. Hilliard, E. Hilliard, E. Hilliard, E. Hilliard, S. Hiramatsu, K. Hirao, M.	93, P361 P368 P368 (, R.C. V4 G. P170 . V1, 87 P947 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61, 5, P197, P218 P80 P208 10, P202 P9 P320 P167 P104 P112, P356	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, C. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hugen, N. Hughes, K.S. Hughes, M.S. Hui, J. Huismans, A.M. Hunsinger, M. Hunsinger, M. Hunsinger, M. Hunt, K.K. 3, 7 Huth, J. Hwang, E.S. Hwang, H. Hyngstrom, J. Hyung, W.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220 P338 P78, P399 76, P301, P307 P36 14, P37 P22 P239 6	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T. P1 Jayaraman, S. Jenkins, C. Jensen, E.H. Jespen, K. Ji, L. Jiagge, E. Jiang, B. Jimenez, C. Jimenez, R.	P196 P305, P312 23 P109 V4, P59, P229 0. 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P262 43 20 P269 P52 49 P146 P305, P312 P63
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. H Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F. Halevy, A. Hall, M.A. Hall, M.A. Hall, M.A. Hall, N.C. Halle, D. Hallet, J. Hamid, O. Hamilton, T.D. Hamrahian, A.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16 P66 P286 P326 P244, P251 21 P157, P182 P214 P310 P396 P137	Hermandez, J. Hernandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23 P76 Hilchie-Pye, A. Hill, E. Hill, S. Hilliard, E. Hilliard, E. Hilliard, E. Hilliard, S. Hiramatsu, K. Hirao, M. Hird, R.B.	93, P361 P368 P368 (, R.C. V4 G. P170 . V1, 87 P947 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61, 5, P197, P218 P80 P208 10, P202 P9 P320 P167 P104 P112, P356 P228	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, C. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hugen, N. Hughes, K.S. Hughes, K.S. Hughes, M.S. Hui, J. Hunsinger, M. Hunsinger, M. Hunsinger, M. Hunsinger, M. Hunsinger, M. Hunsinger, M. Hunt, K.K. 3, 7 Huth, J. Hwang, E.S. Hwang, H. Hyngstrom, J. Hyung, W.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220 P338 P78, P399 76, P301, P307 P36 14, P37 P22 P239 6	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T. P1 Jayaraman, S. Jenkins, C. Jensen, E.H. Jespen, K. Ji, L. Jiagge, E. Jiang, B. Jimenez, C. Jimenez, R. Jimenez, R.	P196 P305, P312 23 P109 V4, P59, P229 0. 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P368 P262 43 20 P269 P52 49 P146 P305, P312 P63 P270, P273, P270, P273,
Gupta, M. Gupta, S. Gusani, N.J. Gushchin, V. P270, Gustafson, E. Guyton, F. Gyorki, D. H Habermann, E.B. Hagihara, T. Hahn, O.M. Hahn, S. Hale, D.F. Halevy, A. Hall, M.A. Hall, M.A. Hall, M.A. Hall, M.A. Hall, N.C. Halle, D. Hallet, J. Hamid, O. Hamilton, T.D. Hamrahian, A. Han, E.	48 77, P365 44 P257 P273, P283 P281 59 P209 P197 91, P341 P267 6 P6, 16 P66 P286 P326 P244, P251 21 P157, P182 P214 P310 P396 P137 P34	Hermandez, J. Hernandez, J. Hernandez Irizarry Herrera Loeza, S. Herrera-Gomez, A Herzberg, M. Herzig, D.O. Heslin, M. Heslop, H. Heslop, H. Hestley, A. Hetu, J. Hewitt, K. Hibi, T. Hicken, W. Hicks, D.G. Hieken, T.J. P23 P70 Hilchie-Pye, A. Hill, E. Hill, S. Hilliard, E. Hilliard, E. Hillman, D. Hiotis, S. Hiramatsu, K. Hirao, M. Hird, R.B. Hirshfield, K.M.	93, P361 P368 (, R.C. V4 G. P170 . V1, 87 P95 59, P324 P359 P207 P119 P239 P180 26 P17 , P59, P61, 5, P197, P218 P80 P208 10, P202 P9 P320 P167 P104 P112, P356 P228 P94	Hu, C. Hu, M.I. Hu, T. Hu, Y. Huang, B. Huang, K. Huang, C. Huang, W. Huang, X. Hudis, C. Huerta-Bahena, C. Hugen, N. Hughes, K.S. Hughes, M.S. Hui, J. Huismans, A.M. Hunsinger, M. Hunsinger, M. Hunsinger, M. Hunt, K.K. 3, 7 Huth, J. Hwang, E.S. Hwang, H. Hyngstrom, J. Hyung, W.	62, P102 P146 P188 57 P279, P367 P400 P130 P3, P122 45 P161 J. P68 P99 P11, P47, P74 P223 P234 P212, P220 P338 P78, P399 76, P301, P307 P36 14, P37 P22 P239 6	Jackson, N.R. Jackson, R. Jackson, T. Jacobs, S.A. Jaffee, E. Jakub, J.W. Jakubowski, C.E James, R. Janjigian, Y.Y. Jaramillo, K. Jarnagin, W. 4 P1 Jawad, M.S. Jayakrishnan, T. P1 Jayaraman, S. Jenkins, C. Jensen, E.H. Jespen, K. Ji, L. Jiagge, E. Jiang, B. Jimenez, C. Jimenez, R. Jimenez, R.	P196 P305, P312 23 P109 V4, P59, P229 0. 34 P246, P254 90 P398 1, P161, P165, 69, P349, P385 P72 T. P108, P118, 71, P355, P391 P98 P262 43 20 P269 P52 49 P146 P305, P312 P63 P270, P273, P283

Jin, L.X. 89, P136, P333, F	P351,	Ke
P354, P357, P361,	P387,	Ke
P393,	P394	Ke
Jonns, C. P35	, P88	Ke
Jonnson, F.E.	P2	Ke
Jonnson, G.L.	P170	Ke
Jonnson, R. P16	6, P45	Kr
Johnston, F. P1/1, P1/3,	P179,	Kr
P300,	P403	NI Kh
Johnston, F.M. F106,	F 39 1	
	F202	
Jones, D.W.	73 D212	Ki/
Jones, K.	PS13	Ki
Jones MS P227	P235	Ki
Jordan K M	P266	Kil
Jose P. P321.	P325	Kil
Judson, P.	P237	Kil
Junghans, R.P. 40, P97.	P158	Kil
Junva. F.	P356	Ki
		Ki
		Ki
K		
Kachare, S.D.	P300	Ki
Kadison, A. P154,	P155	Ki
Kadri, H.S.	P167	Ki
Kaifi, J.	P208	Ki
Kalinski, P.	P128	Ki
Kam, J.	P43	Ki
Kam, P.C.	P212	Ki
Kamiya, K.	P362	Ki
Kamm, A.	P384	
Kandil, E. 33, 36, P139,	P188	Ki
Kane, J. 68, P224,	P233	Ki
Kanehira, K.	80	KI
Kang, Y.	P148	KII
Kansaon, M.	P366	KII
Kaniov A	D66	
Kapil A	F00 D281	Ki
Kanners I	86	Kit
Karakousis C.C. 29 54	D150	Kit
P209	P365	Kit
Karanicolas P 69 P182	P207	K
	P401	K
Karpeh M.S	P345	K
Karunamurthy, A.	P116	Kl
Katz, J.	P303	Kl
Katz, M.H. P178,	P358	Kli
Katz, S.C. 40, 42, P97,	P158	Kl
Kauffman, S.	P193	Kl
Kauffmann, R. 12, 31	, P42	Kr
Kaufman, H.	52	Kr
Kaufman, K.	P7	Kr
Kauh, J.	1	Kc
Kaur, H.	P102	Kc
Kaushal, S.	P353	Kc
Kawada, J.	P356	Kc
Kearney, T.J.	P94	Kc
Keenan, J.E.	P299	Kc
Kelley, M.C.	P238	Kc
Kelly, K.J. 71,	P344	Ko
Kelsen, D.P.	90	KC
кеіz, н.н. 38, P152, Колдо А	P305	KC V-
Kennedy T I	F 100 D400	r\C Ka
Renneuy, I.J.	1 400	r\C

Kenning, S.E.		P388
Kenny, T.		P78
Kerros, C.		P21
Kessler H		P123
Kooolor, I.		
Ressier, J.		F175
Ketelsen, D.		P9
Khakpour, N.	P24.	P67
Khan H	P127	P293
Khara DD	1 127,	40
Knare, P.D.		40
Khodarev, N.N.	P198,	P323
Khreiss, M.		P184
Khushalani N	D22/	DOGO
Kilusilalalii, N.	FZZ4,	F233
Kidwell, K.		P52
Kiernan, C.M.	35.	P51
Kievit F		46
Kilovit, T.		
KIKUCHI, A.		P120
Kikuchi, H.		P362
Killelea. B.	13	P48
Kiluk IV D24 D3	5 D67	D88
Kliuk, J.V. F24, F3	ы, гол	, F00
Kim, A.J.		P335
Kim, H.J.		98
Kim I D/6 D05 D	0175 D	250
MIII, J. F40, F95, F	-175, F	209,
	P392,	P396
Kim, M.	P200,	P215
Kim, M.P.		P358
Kim DT		D102
КШП, Г. І.		F 103
Kim, Y. 39, 69,	P297,	P361
Kimbrouah. C.	55.	P348
Kimchi E	,	D208
	~	D00
King, I.	9	, P32
Kingham, T. 41, P	161, P1	65,
-	P349.	P385
Kinney A	,	D13/
Kinney, A.	1	F 134
Kirane, A.		P36
Kirchoff, D.D.		P221
Kirgan D.M	P227	P235
Kiraah D.C	·/,	
Kirsch, D.G.		P299
Kirstein, L.		P94
Kita. Y.		81
Kitanawa H		83
Kilayawa, Ti.		00
Kitagawa, Y.		P180
Kitago, M.		P180
Kitano M		P400
Klaase, J.M.		P114
Klauber-DeMore, N.		P9
Klausner, J. 74.	P360.	P373
Kleer C	,	P52
		T 02
Klemens, A.		P30
Klimberg, V.	8	, P79
Klomp, H.		86
Kluger MD	70	
Klugel, M.D.	70,	F159
Knab, L.		P347
Knechtle, W.		P207
Knoll G M		P13
Ke V		
NO, 1.		P401
Kobayashi, H.	P96,	P120
Kobavashi, S.		P356
Kooborginsky M		000
Rocherginsky, ivi.		F 02
Koduru, U.		P282
Koh, Y.		P242
Kokko J		P276
Kollor I		
Noiler, J.		r390
Komenaka, I.		P30
Kona. I.		P81
Koniaris I		P79
Koninano, L.		173
Koning, A.H.		۲4

Konno, H. Konstantinovic, M. I Kooby, D.A. 32, 89, P333, P351, P P387, F	P362 P206, P226 98, P181, 357, P361, P393, P394	Larrieu Lassing Lauren Lautne Lavy, F
Koppert, L.B.	P4	Law, C
Korant, A.	P282	
Korourian, S.	8, P79	Lazar,
Koru-Sengul, I.	P65, P73	Le Ces
Koslow S	P32	Le rec
Kostaras, X.	P287	Leach.
Kostopoulos, T.C.	P317	LeBea
Kotamraju, V.	P115	Lee, A
Kotru, A.	P189	Lee, B
Kowdley, K.	P176	Lee, C
Kozono, T.	91	Lee, D
Krell, R.W.	63, P256	Lee, D
Krepline, A.N. P1	73, P179,	Lee, J.
Krhin B	P403	Lee, J.
Krishna S	P375	Lee, J.
Kroon, H.M.	50. P212	Lee, N
Krotneva, S. F	P103, P135	Lee, S
Krouse, R.S.	P211	Leen, /
Kruper, L. 12	2, P42, P50	Leinwa
Kshivets, O.	P331	Leitch,
Ku, G.Y.	90	Leong,
Kuan, P.	P334	Leongi
Kudchadkar, R.R. H	237, P241	Lerner
Kuennie, A. Kuerer H	P402 P70	Lester,
Kuk D	71	Leuna
Kukar, M. V2, 37, 68	3. 80. P141.	Levi. B
F F	P378, P381	Levine
Kulak, M.V.	17, P71	
Kulaylat, A.N.	P257	Levy, F
Kulkarni, S.	P82	Lew, J
Kumar, R.	P289	Lewis,
Kumar, S. P22	2, 37, P141	LI, C.
Kunterman ME	P09 D146	LI, J.
Kupiernan, M.E. Kuvshinoff B	P261	LI, L.
Kwak, F.	47	ы, г.
Kwon. D.	P256	Li, I.
Kyei, I.	P52	Li, Y.
		Libutti,
т		Licata,
L		Lichter
Labow, D.M.	2108, P272	Lipdor
Lacerda, L.I.	P366	
Laule, D. LaFramboise WA	P109	Lillomo
Lahat. G. 74. F	P360, P373	Lim. S.
Laheru, D.	93	Lin, B.
Lai, L.	P54, P191	Lin, H.
Lai, V.	P149	Lin, Y.
Laing, C.	1	Lindbe
Lancaster, W.	P208	Lindbe
Lane, D.	P18	Lineha
Lang, J.E.	P64	P354,
Lannin, D.K. Lara-Garcia, ⊑ A	13, 148	Liotta,
Lara-Garcia, E.A.	۷۱ P9/17	
Laronga C. P2/ I	P35 P67	Lju G
Laronga, O. 124, 1	P88, P268	Liu, H.
	,	,

Larrieux, G.	P391
Lassinger, B.	P83
Laurent, A.	P159
Lautner, M.A.	P70
Lavy B	P66
Law, C. 69, P157, P297,	P404,
P405	6, P407
Lazar, A.	76
Le Cesne, A.	72
Le Pechoux, C.	72
Lea, W.	P243
Leach, L.	59
Lee, A.Y.	73
Lee, B. P289	, P396
Lee, C. Lee, D.	P303 P284 P73
Lee, J. 51, 67	, P221
Lee, J.E. 53, P148, P178	, P358
Lee, J.K.	95
Lee, M. P24, P35, P6	7, P88
Lee, S.	P159
Lee, S.L.	P140
Leen, A.	P359
Leinwand, J.	78
Leitch, A. P2	8, P36
Leong, T.	P38
Leongito, M.	P162
Lerner, J.	P156
Lester, S. Po	P84
Leung, A.M.	P8
Leung, K.	P183
Levi, B. Levine, E.A. P129, P255	P257 , P274, P387
Levy, R.M.	79
Lew, J.I.	P138
Lewis, R.S. P365	P303
Li, C.	P303
Li, J.	P181
Li, L.	45
Li, P.	P92
Li, I.	P132
Li, Y.	P176
Libutti, S.K.	P400
Licata, L.	P158
Lichtentnal, M. Liederbach, E. P2	08 0, P58 P60
Ligh, C. Lillemoe, K.D. Lim, S.M.	47 P198
Lin, B.	P390
Lin, H.Y. P70	, P263
Lin, Y.	P253
Lindberg, J.	96
Lindberg, J.M. 39, 95	, P335
P354, P357, P374, P387	7, P402
Liotta, L.A.	5
Liscum, K.	P83
Liu, E.	31
Liu, G.	P338
Liu, H.	P164

Livingstone, A.S.	P73, P372,	Mansour, O.	P117	Merchant, N.	31, 98	Mosconi, M.	P230
	P383	Marcadis, A.	P138	Messina, J.L.	P196, P206,	Mose, E.S.	20
Loeffler, A.G.	P150	Marcos, G.	P107		P226, P237	Moser, A.J.	P376
Lohse, C.	P186	Maroue P	P201	Metildi, C.A.	P353	Moses, L.E.	P357
LOOK HONG, N.	56	Marganthalar I A		Meyer, J.E.	P326	Mott, S.L.	P382
Lopez-Sachi, F.	P308	Margeliaa I	P2, P41, P89	Mico E	P382	Mucharla D	P183
Loscalzo, IVI.	F42 P57	Maria de Lourdes	P20, P00	Miceli B	F05, F73 72	Mueller I	F309 P82
Lotief M	P117	Markman M	25	Michol M	D220 D290	Muhsen S	P32
Lotze M.T	5	Marks V	P383	Michel, M.	F330, F360	Muiis KT	P319
Love. C.	P400	Martin, R.	1, 44, 55	IVIICK, N.	15	Muilenbura, D.J.	51
Lovrics. P.J.	P81	Martin, R.C.	98	Milgrom, S.	19	Mullins. C. P12	1. P285. P291
Lowenstein, S.	74, P373	Martin-Tellez, K.S.	V1, 87	Miller, E.E.	P55	Mumper, R.J.	P9
Lowy, A.M.	20, 25, P115	Martin, Jr., E.W.	P244, P251	Miller, M.	P50	Munjal, S.	22
Lu, K.C.	P95	Martinez, M.	P30	Miller, R.	P334	Murakami, K.	P332
Lu, S.	P364	Martinez Said, H.	P204, P308	Mills, J.	P216	Murayama, K.	P27
Luan, W.	P167	Martinez-Said, H.	V1, 87	Milovanov, V.	P270	Murphy, L.M.	P55
Lubezky, N.	74, P373	Martz, B.K.	P77	Milstein, D.	P400	Murrey, Jr., D.A.	P244
Luketich, J.D.	79	Maruyama, T.	P332	Milstien, S.	P3, P122	Muscarella, P.	92, P375
Lum, S.S.	P269	Marx, H.	P175	Miner, I.J.	P278	Mylander, C.	P15
Luna-Perez, P.	P107	Marzban, S.	P196	Mineyev, N.	P64		
Lushaj, E.	85	Mascaro, P.	P138	Minji, K.	P310	N	
Luu, C.	P289	Masso-Weich, P.	P22	Minoshima, S.	46		Doto
Luu, D.	P33	Mater, M.	P13	Miranda, P.	P308	N M L, M.	P316
Luu, I.	P34	Matnew, J.	P189	Micustin S	P38	Nabavizaden, N.	P95
Luyinibazi, D.	F34 D214	Matsupara, n.	F332 01	Mitcholl	F 149 D127	Naueeni, n.	F110 D21
Ly, I.	F214	Matsumoto, M. Matsushita D	01	Mitchem	P340	Nagahashi M	P3 P122
		Matthews RD	P402	Mittendorf F	P6 16 P21	Naganashi, M.	P104
Μ		Matthews, J.B.	P384	Miura IT P1	71 P355 P301	Nagorney D M	P186
Ma. C.X.	P89	Maxwell, J.F.	29		P403	Nagtegaal, LD.	P99, P106
Ma, 6.74	P347	May. C.	76	Mivake, M.	P112	Naik, A.D. P25	8. P264. P275
Ma. Q.	40	May, K.S.	80	Mivamoto, A.	P112	Nakache, Y.	P303
Macatangay, J.D.	P151	May, R.	68	Miyamoto, S.	P142	Nakagawara, H.	83
MacDonald, R.	P270. P273.	Mazzola, E.	P11	Miyaoka, R.	46	Nakamori, S.	P112
,	P283	Mazzu, Y.	73	Miyashita, T.	83	Nakhlis, F.	P57, P84
Macedo-Perez, E.	O. 87	McAuliffe, P. F	216, P40, P45	Miyata, R.	V7	Namm, J.P.	P82, P384
Machac, J.	P85	McCahill, L.E.	P276	Miyazaki, M.	P112	Naqvi, I.A.	P329
Macke, R.	85	McCall, L.M.	3	Miyazaki, S.	P362	Narayanan, S.	P195
Mackey, A.	14, P37	McCann, S.E.	P22	Mizusawa, J.	6	Nason, K.S.	79
Madden, J.	P239	McCarthy, K.	P17	Mizushima, T.	P356	Nathan, H.	60, P349
Maddox, K.	P124	McCarthy, M.	P79	Moffitt, R.A.	P170, P334	Natsugoe, S.	81, 91, P341
Madiedo, A.	P138	McCormack, E.	40, P158	Mohamed, H.	36	Nearing, E.	P176
Madsen, E.	P10	McCoy, K.L.	P143	Mohamed, S.H.	. 36	Neese, P.Y.	57
Maeda, A.	P104	McCullough, A.E.	P56	Mohammed, S.	P83, P359	Neifeld, J.P.	P317
Mattuz-Aziz, A.	P68	McGinty, K.	P399	Moley, J.F.	P136	Nelson, J.	P1/6
Maggiero D.	P400	McGrath, P.C.	P307	Molldrom	P 137	Nelson, R. Nepobi, R.	12, 84, P396
Mabar A P40	F207 4 P405 P407	McGuire, K.	P16, P45	Monorioff M		Neusni, n.	F290 P203
Mahandrarai K	4, F403, F407	McGwin, G.	59	Mone M C	245, P246, P254 P101	Neves, n.i. Newbook T	95 96 P335
	7 P174 P250	McKenzie, S.P.	P279, P367	Mongiu A	P8/	Newman I A	90, 90, 1 000 P52
Mahmoud A P17	3 P179 P403	McKinnon, G.	P287	Moniazeh A M	P303	Nfonsam V	P131
Mainthia R	64	McLaughlin, J.	P29	Montgomery M	IM V7 P345	Na D	P252
Maithel, S.K. 32	69.89.98.	McMasters, K.M.	44, 55, 98,	Moonev. B.	P67	Na. S.	P277. P376
P181, P297	7, P333, P351,		P348	Moore, D.	P195	Nguyen, C.	42, P228
P357, P361, P38	7, P393, P394	McNally, L.	P348	Mooring, J.W.	40	Nguyen, Q.T.	P353
Makary, M.	93	McNeil, S.	59	Morancho, B.	P25	Nguyen, S.	62, P126
Maker, A.V.	P98	Mecham, E.M.	P101	Morgan, A.	P78	Nguyen, T.	P168
Makino, I.	83	Medina-Franco, H.	P39, P248,	Morgan, J.W.	P269	Ni, C.	P176
Mallipeddi, M.K.	P329		P398	Mori, M.	P31, P356	Nichols, S.	P244, P251
Maloney, J.	85	Meguerditchian, A.	P103, P135	Moroz, K.	36	Niebling, M.	P220
Mamtani, R.	P365	Mehran, R.J.	_ 88	Morris, C.R.	P269	Nieroda, C. P27	0, P273, P283
Mangla, J.	P262	Melnik, M.K.	P13	Morrow, M.	9, P19	Nikiforov, Y.E.	P143
Mann, G.	P43	Melstrom, L.G.	P195	Morton, D.L.	54, P214, P221,	Niland, J.	P50, P54
Mann, G.B.	P49	Menke-Pluijmers, I	м.в. Р4		P222	Nishikawa, K.	P112
Mansour, J.C.	61, P260	Merajver, S.	P52	Mosca, P.J.	49	Nissan, A.	21

Nizri, E.	P360
Nodora, J.	P30
Norton, J.A.	77, P304
Nour, S.G.	P181
Noyes, D.	52, P239
Nunez, M.F. P270, P	273, P283
Nurkic, S.	P1
Nurkin, S. P265, P	280, P378
Nussbaum, D.P.	94, P299
Nywening, T. 97, P	337, P340
Nzara, R.	P69
O'Connell, M.J. O'Connor, R.P. O'Connor, V. O'Dorisio, T.M. Obdeijn, I. Ochoa, D. Ohene-Yeboah, M. Ohlson, E. Ohori, N.P. Ohta, M. Ohta, T. Ojo, A.S. Okada, T. Okazaki, S. Okita, K. Okkabaz, N. Okrainec, A. Olivier, A. Olivier, A. Olivier, A. Olivier, A. Oliszanski, A.J. Olszewski, A. Oltmann, S.C. P Omoto, I. Onaitis, M.W. P Onesti, J. Olszewski, A. Oltmann, S.C. P Onoto, I. Onaitis, M.W. P Onesti, J. Onaitis, M.W. Onukwugha, E. P12 Oostendorp, L.D. Oppong, J.K. Orr, R.K. Oshima, G. Ottesen, R. Ouellette, J. Owaki, T. Oxenberg, J. Oyasiji, T. Ozao-Choy, J.	23 70 67, 70 29 P4 8, P79 P52 P131 P143 P362 83 P75 73 P120 P219 P123 305, P312 81 P71 52 P234 P127 144, P151 81 322, P329 386, P388 P343 1, P285, P291 P13 P52 P228 P349 P193 81 P50, P54 P193 81 P261 P233 P214
P	P196
Padhya, T.	P308
Padilla Mota, I.	P108
Padilla-Longoria, R.	P113
Palaia, R.	P162
Palakodeti, A.	P384
Pandalai, P.	P223
Panni, R.	97, P337
Papanichael, M.	P6, 16
Papenfuss. W. P	261, P378

Papin, J.A. Pappas, T.N. Paquette, I.M. Parikh, A. Park, A. Park, B. Park, D. Park, J. 46, P7	95, 96 94 66 31, 98 P32 6 90 '1, P175, P194, P396
Park, J.J. Parker, C. Parker, N. Parra-Torres, C. Parsons, J. Partain, D. Partridge, E. Parvez, E. Pass, S. Paszat, L.	P175 P70 P178 P308 95, 96, P335 P324 59 P81 P28 P405, P407
Patel, N. Patel, R.K. Patil, S. Patterson, C. Pattyn, P. Paulus, E. Pawlik, T. 39, 6 P306, P3 P361, P3	P26, P85 64 P19 P125 P213, P372 9, 89, 93, P297, 33, P351, P357, 887, P393, P394
Paz Mejla, A. Peche, W. Pederson, A. Peeples, C. Pelossof, R. Peng, G. Pennacchioli, E. Peoples, G.E. Perez, A.	P383 P101 P62 P262 P111 P217 P404 P230 P6, 16 94
Perez, S. Perhavec, A. Perrier, N.D. Perry, K. Pesce, C. Peters, M. Peters, N. Petersen, N.J.	P6, 16, P207 P315 P146 P293 P20, P58 54 63 P258, P264, P275
Peterson, B.L. Peterson, M.R. Peterson, S.K. Petre, E. Petrella, T. Petrelli, N.J. Petric, R. Petric, R. Petroni, G.R. Petrosko, P.	49 20 P146 56 23, P192 P153 P289 57 P113
Petzel, M.Q. Peyrat, P. Pfeffer, L. Phan, G.Q. Phay, J. Philips, A. Philips, S. Picon, A.	P178 P119 P213 P223 P251 P21 98 31 P190

Picozzi, V.J.	P390	Ragulin-Coyne, E.	P376
Pietron, A.V.	P72	Rahbari, R.	P137
Pingpank, J.	P113, P128,	Raigani, S.	P392
Piorkowski P I	P266, P406	Rajael, M.	P144
Pioteur DW	F 03	Ramalingam I	P266 P406
Pisters, P.W.	P358	Ramirez-Diaz I	P237
Plank, A.	P78	Ramiaun A	P103 P135
Plail, J.	7 D1/1	Randall, R.	P313
Plaiz, T.	57,1 141	Randle, R.W. P129	. P255. P274
Platz, I.A.	80	Randolph, G.	P139
Plukker, J.T.	P319	Rao, N.	P237
Pockaj, B.	P56	Rao, R.	P28, P36
Pockaj, B.A.	P7, 65	Raoof, M.	P164
Point, G.R.	P97	Rashid, A.	P148
Polanco, P.M.	P266	Rashid, N.U.	P130
Poli, E.C.	P384	Rashid, O.M.	P268
Polubriaginof, F.	P11	Ravi, V.	76
Ponniah, S.	P6, 16	Rawal, B.	P199
Pooni, A.	P236	Raza, S.	P57
Poremoka, IVI.	P105	Read, B.M.	P232
Porter G	F20, F03	Read, F.	V5 D225
Portschy P	P69	Reddy S	V3, F223 P324
Posner M C	P163 P198	Redy Sanikommu	S. P294
P267, P32	23. P342. P384	Reed. S.	30. P145
Postma. E.	P10	Reidy-Lagunes, D.	34
Poultsides, G. 7	7, P304, P333,	Reis, N.	P293
P357, P361, P38	37, P393, P394	Reisman, D.	P338
Poultsides, G.A.	89, P351	Remon, J.	P105
Povoski, S.P. P2	44, P251, P259	Remzi, F.H.	P123
Prabhakar, B.S.	P98	Reparez, L.	P86
Prabhakaran, S.	P241	Rescigno, J.	P92
Press, D.	P137	Ressler, B.	48
Preya, A.	P75, P87	Reuther, R.	P170
Price, C.I.	P62	Reyna, C.	P24
Prieto, V.	53	RICE, D.	88
Proctor E	F20 P52	Richards MK	P140
Propescu I	39	Rickles A	P17
Protic. M.	21	Rigas, T.	P262
Puccineli, C.L.	P227	Rilling, W.	1
Puia. C.	P218	Ring, A.	P64
Puleo, C.A. P19	96, P206, P226	Ritch, P.S. P173,	P179, P403
Pulitzer, M.	P209	Rivard, J.D.	P287
Punj, V.	P64	Rivera, M.	P227, P235
Pura, J.	30	Rivoire, M.	P119
Putnam, A.	P313	Riyaz, F.	P317
		Rizzo, M.	P207
0		Robbins, J.	P262
Quadra M		Robert, B.	P67
Qadan, M.	P304	Robinson, K.A.	P7
Qiau, N.	71	Rocha E	P176 P300
Qill, L. Quebbeman E I	D173 D170	Roche C A	P11
	. 1173,1179, P403	Rochefort, M.M.	P336
Quereshy, F. 69	9. P297. P305.	Rodriguez, R.A.	P134
,	P312	Rodriguez-Bigas. N	I.A. 62. P126
Quillin, R.C.	P271	Rodríguez-Cuevas,	S.A. P68
Quillo, A.R.	55	Rodriguez-Diaz, E.	P140
		Roggin, K.K.	P384
~		Roheena, P.	P340
R		Rojas-Marin, C.E.	V1
Hacz, J.	P305, P312	Holand, C.L.	P148
Hadisky, D.C.	P55	Roman, S.	30, P145
nduomski, IVI.	P128	numero Arenas, M.	A. P146

Rooney, C.	P359
Rose, A.K.	P43
Rose, J.	P176
Rosen, C.B.	P186
Rosen, J.E.	P140
Rosenberg, S.A.	4, P223
Roses, D.	11
Roses, R.E.	P298, P365
Rosman, M.	P15
Ross, M.I.	49, 52, 53
Ross, T.W.	P268
Roth, J.	88
Rothman, R.	P384
Rotimi, O.	P321, P325
Roumie, C.L.	64
Rowland, K.J.	P136
Royal, R.E.	49, 53, P223
Rubin, D.M.	P165
Rubio, I.T.	P25
Rudloff, U.	4
Rudolph, R.	P62
Rueth, N.	P263
Ruoslahti, E.	P115
Russell, G.	P255
Russell, M.	P394
Russell, M.C. 32	2, 89, P181,
P207, P333	3, P351, P393
Ruszczyk, M.	P22
Ruth, K.J.	P326
Ruvalcaba-Lim, E.	P68
Ryan, D.P.	47

S

Sabel, M.S. P219 Saclarides, C. P65 Sadot, E. P161, P385 P321, P325, P330, Saha, A. P380 Saha, S. P282 Sahi, S. 28 P158 Saied Calvino, A. Saigal, A. P87 P219 Saito, H. P177 Saiura, A. Sakaguchi, K. P104 Sakaguchi, T. P362 Sakamoto, E. P104 Sakr, M. P117 P32 Sakr, R. Salem, B. P52 Salmans Lacross, J. P83 P202 Salo, J.C. Salti, G. P309 Saluja, A. 43, P187 Samiei, A. P347 P9 Samples, J. Samuels, M.L. 20 Sanchez-Galvez, X. P204 Sanchez-Garcia, S. 26 Sanfilippo, R. 72 97, P337, P340 Sanford, D. Sanghera, S.S. P265 Sangwan, V. 43. P187 Sansgiry, S. P258, P264 Santoro, P. P192

Santos, E.	P97
Sarantou, T.	P202
Sardi, A. P270, P273,	P283
Sarela, A.I. P321, P325, F	P330,
	P380
Sarff, M.	P216
Sarmiento, J.M.	32
Sarnaik, A.A. P196, P206.	P226
Sarpel, U. P108,	P272
Sasaki, K.	81
Sasako, M.	6
Sato, T.	44
Saul, R.	P107
Saund, M.S.	P130
Saunders, A.C.	P269
Saunders, N. 89, P333,	P351
Dauriuers, N.D. F301, F P387 P393	-379, P30/
Shitany H	P60
Scaife. C.L.	P101
Schaake, E.	86
Schedin, P.	P22
Scheer, A.S.	P182
Schiffman, S.C.	P350
Schlette, E.	P126
Schmidt, C.R. 89, 92, P3	333,
P351, P357, P361,	P375,
P379, P393,	P394
Schmidd B M	0, FOD 18
Schneble F	P6 16
Schneebaum, S.	P259
Schneider, D.F. P144,	P151
Schneider, R.	11
Schoder, H.	P368
Schoellhammer, H.F.	P175
Schreeder, M.	1
Schubart, J.R.	P257
Schuster, D.M.	32
Schuurman, M.	P220
Scriwad, R.D.	20
Schwarz B F 4	FZ04
Scodeller. P.	P115
Scoggins, C.R. 44, 5	55, 98
Scott, W.J. P326,	P327
Seal, B.S. P121, P285,	P291
Sears, A. F	P6, 16
Seevaratnam, R. P405,	P407
Segedi, M.	P338
Seitelman, E.	P210
Sekino N	P332
Selby I	P344
Semple, J.	P29
Sempoux, C.	39
Sener, S.	P64
Sepesi, B.	88
Ser Yee, L. P161,	P385
Serpell, J.	50
Serrano, O.K.	P400
Serrano Aybar, P.	
OLULIA MALERIA	P183
Shabahang, M. P78, P1	P183 89,
Shabahang, M. P78, P1	P183 89, P399 P186

Shah. A.R. P7	6 SI	ack. R.	P178
Shah. D. P30	3 SI	akev. D.	33. P139
Shah. F.A. 8	3 SI	amon. D.J.	21.58
Shah, K.N. P30	6 SI	linaluff. C.L.	57
Shah, M. P36	8 SI	lipak. S.	P189
Shah, M.M. P39	7 SI	ump. C.H.	P114
Shah, N. P19	0 Sr	medlev. W.	59
Shah, P.C. P326, P32	7 Sr	midt. M.	P10
Shah, S.A. 66, 82, P27	1 Sr	mit. J.K.	P319
Shah, S.S. P61, P7	6 Sr	mith. A.	P296
Shaitelman, S.F. P70, P26	3 Sr	mith, B.L.	P11, P74
Shakir M P18	4 Sr	mith D	12
Sham JG 46 P19	4 Sr	mith D D	84
Shaniro M P13	0 Sr	mith F	P196
Shariff M P19	0 Sr	mith .I	19
Sharma A P7	5 Sr	mith JK	P277 P376
Sharma D P31	6 Sr	mith M M	P77
Sharma B	1 Sr	mith RA	Ve
Sharpe S P58 P163 P34	2 Sr	mithers B	50
Sharpe S M P2	0 Sr	molkin MF	57
Shea-Budgell M P28	7 Sr	now B	. 07 P35 P88
Shellito PC P11	/ 01 0 Sr	nvder R A	64
Shen P P12	0 01 9 Sr	nyder S	PQ
Shen PW/ 2255 227		nyuer, O.	03
Shen V P70 P26	4 00 2 C/	Dares, K.	90 P100
Shell, I. $F70, F20$	0 0		F 109
Sherny D M D22	9 GU 9 GV	obel, H.	
Shehra D D104 D26	0 00		
Shindid, D. F124, F20		ok, IVI.	F315
Shinnizu, J. F33 Shinodo M P19	0 30	olit, D.	41 D260
Shirlov I A D262 D275 D27	7 8	olomon S	F209 D161
Shinley, L.A. F303, F375, F37	1 0	oloritori, S.	C 25 DE1
Shoffpor A D D22		omoioh N	.0. 33, F31
Shoor D D22	9 30	omacundar	D D107 D002
S11001, F. F32	0 30	omasundari	F. FIZ7, FZ93
Showalter, S.L. P	1 00		
Shrayer, D. P36	4 0	ondok VK	F 142
Shrestha. S. P25	0 30	onuak, v.K.	F190, F200,
Shuai V P35	0 6/	ong M	F220, F237, F241
Shuddhadah P P40	0 30 0 6/	ong, w.	E D26 D25
Shukla NK P21	6 6		
Siamaknour-Beihani S P		00, R.	D/0
	9 30 7 9	oran A	D16 D45
			20 D1/5
Sieger, E. F12	4 30 2 C/	osa, J.A.	50, F 145
Signason, E.N. 113	2 0	osinan, J.A.	F 200
Silberman A W P21	3 34 1 84	pauola, G.	DM 17 D71
	4 04 0 04	pannenner,	D11 D7/
SIIII, IVI. 54, 67, 70, 7221, 722 Sin E		pechi, IVI.	FII, F74
Sin, E. F249, F20	0 54	peicher, P.J	. 49, 94, P145,
Singar, A. F20	0	ningal C	F299, F300
Singer, S. 71, 7	3 54	piegei, 5.	P3, P122
Singh, G. P175, P191, P39	6 SP	pillane, A.J.	V5, P225
Singh, S. Pib	1 5		
Singh, I. P28	2 5	polverato, G	a. P361, P387
Singni, A.D. 5, P16	8 So	quires, M.H.	. 32, 89, 98, P181,
Singla, S. 22, P141, P224,		P333, I	P351, P357, P361,
P265, P280, P31	 7 0		P387, P393, P394
Siperstein, A. P13	7 Si	reeramoju, I	P. P36
Sippei, R.S. P144, P15	i St	HIII, C.R.	P227, P235
SISCO, M. P5	o St	acchiotti, S	. 72
Sisson, K. P245, P246, P25	4 St	ager, V.	P222
Sittig, M. P270, P273, P28	ও St	ainken, B.F	40, P158
SKIDDER, J.M. 62, P12	o St ≁	aley, C.A.	32, 89, P333,
Skinner, K.A. P1	1		P351, P393, P394
Skitzki, J. 68, P200, P215	, St	allings Man	in, M.L. P55
P224, P233, P31	i St	iang, M.I.	P143

P36

Starostik, P.	P22
Staveley-O'Carrol	l, K. P208
Stavrou, E.	P94
Steen, S.	P222
Stefanowicz, E.	P399
Steiman I	P303 P16 P45
Steinherg S	1 10, 1 43 1 P223
Steliga, M.	P328
Stempel, M.	9. P19
Sternbach, N.	P360
Steve, J.	P168, P346
Stevens, L.	P330, P380
Stewart, J.H. P12	9, P255, P274
Stocker, S.J.	P384
Stojadinovic, A.	21
Stone, L.	P372
Stoukides, J.	P293
Strasberg, S.	
Strasberg, S.M.	P354, P357, P387 P402
Strasberg S S	P374
Stratford, J.	P170
Strazisar, B.	P12
Stripp, D.	P365
Strobbe, L.	P10, P44
Strohl, M.	P392
Stromberg, A.J.	55
Strong, V.E. 34, 9	0, P344, P368
Su, S.	P326, P327
Sue-Ling, H.	P321, P325,
Curabara K N	P330, P380
Sugarbakar P	P115 P270
Sugarbaker, F.	17
Sugihara K P	31 P96 P120
Suh. H.	P140
Suito, H.	P332
Sukhumalchandra	a, P. P21
Sun, S.	P8
Sun, W.	P35, P88
Suriano, R.	P240
Sussman, J.J.	66, 82, P271
Sutton, J.M.	66, 82, P271
Swallow, C.J.	P310, P318,
Swanson B	P377
Swett, K.R.	P129. P274
Swisher, S.G.	88
Swistel, A.J.	V3
Swords, D.S. 89	ə, P333, P351,
P357, P36	1, P393, P394
Syed, A.	98
Symanowski, J.	10
Szabo, J.	P26, P85
Sznyter, L.	P154, P155
ozymoniika, J.	FIIU
_	
Т	
Taback, B.	P109 D070
Tafra I	P100, P2/2
Taira, ∟. Tai I	- 15 28
Taiima. H.	83
Takabe, K.	P3, P122

lakagane, A.		6
Takahashi, H.		P120
Takeno A		P356
Takono, 74.		D104
lakeuchi, ⊑.		P104
Talamonti, M.S. P	163, P	342,
		P384
Talati C		22
Talati, O.		~~~
Iam, A.		44
Tambet, T.		P115
Tan G	P252	P288
Ton C L	. 202,	D242
ian, G.H.		P343
Tan, W.	P233,	P288
Tanabe, K.K.		P172
Tanaia C		P294
		00
lanese de Souza, C	<i>.</i>	_ 28
Tang, L.H.	90,	P368
Tang, P.		P17
Tang D		P74
rany, n.		
i aniguchi, M.		P160
Tannenbaum, S.L.	P65	, P73
Taskin, H.F.		P137
Toub DN		78
Taud, R.N.		- 10
Tavares, A.		P308
Teertstra. J.		86
Tena Δ		P28/
		1 204
Ieo, M. P242, P	249, P	252,
	P288,	P343
Terando, A.		P251
Torachima M		6
		0
Ierhune, J.		P93
Terracina, K.P.		P122
Torrior P		72
Tashama M		12
iesnome, M.		- 3
		-
Testori, A.		P230
Testori, A. Thaver, S.P		P230 47
Testori, A. Thayer, S.P.	00.5	P230 47
Testori, A. Thayer, S.P. Thirunavukarasu, P.	22, P	P230 47 116,
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265,	22, P P280,	P230 47 116, P311
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A.	22, P P280,	P230 47 116, P311 P81
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thoma, C. B.	22, P P280,	P230 47 116, P311 P81 P95
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R.	22, P P280,	P230 47 116, P311 P81 P95
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P.	22, P P280, P179,	P230 47 116, P311 P81 P95 P403
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N.	22, P P280, P179,	P230 47 116, P311 P31 P95 P403 90
Testori, A. Thayer, S.P. Phirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomas, N.	22, P P280, P179, P326.	P230 47 116, P311 P81 P95 P403 90 P327
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thomas, J.E.	22, P P280, P179, P326,	P230 47 116, P311 P81 P95 P403 90 P327 P212
Testori, A. Thayer, S.P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomas, A.A. Thomay, A.A.	22, P P280, P179, P326, 50,	P230 47 116, P311 P81 P95 P403 90 P327 P212
Testori, A. Thayer, S.P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, M.	22, P P280, P179, P326, 50,	P230 47 116, P311 P95 P403 90 P327 P212 59
Testori, A. Thayer, S.P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, Z.J.	22, P P280, P179, P326, 50,	P230 47 116, P311 P95 P403 90 P327 P212 59 51
Testori, A. Thayer, S.P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, Z.J. Thom M 42	22, P P280, P179, P326, 50,	P230 47 116, P311 P81 P95 P403 90 P327 P212 59 51 P158
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, M. Thompson, Z.J. Thorn, M. 42	22, P P280, P179, P326, 50,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, M. Thompson, Z.J. Thorn, M. 42 Thorpe, P.	22, P P280, P179, P326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thompson, J.F. Thompson, J.F. Thompson, Z.J. Thorn, M. 42 Thorpe, P. Tierney, M.T.	22, P P280, P179, P326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P327 59 51 P158 45 P388
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, Z.J. Thorn, M. Thorpe, P. Tierney, M.T. Tignanelli, C.	22, P P280, P179, P326, 50,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomas, N. Thompson, J.F. Thompson, M. Thompson, Z.J. Thorpe, P. Tierney, M.T. Tignanelli, C. Tillatt, E.	22, P P280, P179, P326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, M. Thompson, Z.J. Thorn, M. Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E.	22, P P280, P179, P326, 50,	P230 47 116, P311 P81 P403 90 P327 P212 59 51 P158 45 P388 P170 P17
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thompson, J.F. Thompson, M. Thorpson, M. Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L.	22, P P280, P179, P326, 50,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 P17 63
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, Z.J. Thorn, M. 42 Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Ting, D.	22, P P280, P179, P326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 P17 63 47
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomas, N. Thompson, J.F. Thompson, Z.J. Thorn, M. Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Times, D. Tiwari B K	22, P P280, P179, P326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 85 P388 P170 P17 63 47 P240
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thompson, J.F. Thompson, M. Thompson, Z.J. Thorn, M. 42 Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Ting, D. Tiwari, R.K.	22, P P280, P179, P326, 50,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 P177 63 47 P240
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, J.F. Thompson, Z.J. Thorn, M. 42 Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Times, M.L. Times, M.L. Timg, D. Tiwari, R.K. Tojima, Y.	22, P P280, P179, P326, 50,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 845 P388 P170 P17 63 47 P240 P104
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, Z.J. Thorne, M. Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Times, M.L. Timg, D. Tiwari, R.K. Tojima, Y. Tolnitch, L.	22, P P280, P179, P326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 63 47 P240 P104 P37
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomas, N. Thompson, J.F. Thompson, Z.J. Thorn, M. Thornpson, Z.J. Thorn, M. Tignanelli, C. Tillett, E. Times, M.L. Times, M.L. Times, M.L. Timar, R.K. Tojima, Y. Tolnitch, L. Tomlinson, J.S.	22, P P280, P179, P326, 50, , P97,	P230 47 1116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 P176 47 P240 P377 P240 P336
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thompson, J.F. Thompson, M. Thompson, Z.J. Thorne, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Ting, D. Tiwari, R.K. Tojima, Y. Tolnitch, L. Tomlinson, J.S. Tonn	22, P P280, P179, P326, 50,	P230 47 116, P311 P95 P403 90 P327 P212 51 P158 45 P388 P170 63 47 P240 P104 P336
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, J.F. Thompson, Z.J. Thorn, M. 42 Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Tominson, J.S. Topp, T. Tonninson, J.S.	22, P P280, P179, P326, 50,	P230 47 116, P311 P95 P403 90 P327 P212 59 518 P158 45 P388 P170 P17 63 47 P240 P174 P336 P336 P80
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomas, N. Thompson, J.F. Thompson, J.F. Thompson, Z.J. Thorn, M. 42 Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Togina, Y. Tolnitch, L. Tomlinson, J.S. Topp, T. Torisu-Itakura, H.	22, P P280, P179, 9326, 50, , P97,	P230 47 1116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 63 47 P170 63 47 P240 P174 P376 P376 P240 P104 P377 P336 P306 P324 P324 P336 P324 P324 P324 P324 P324 P324 P324 P324
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thompson, J.F. Thompson, M. Thompson, Z.J. Thorn, M. 42 Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Ting, D. Tiwari, R.K. Tojima, Y. Tolnitch, L. Tomlinson, J.S. Topp, T. Torisu-Itakura, H. Torphy, R.J.	22, P P280, P179, P326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 P176 63 47 P240 P376 P336 P376 P336 P376 P336 P336 P336
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomas, N. Thompson, J.F. Thompson, J.F. Thompson, M. Thompson, M. Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Ting, D. Tiwari, R.K. Tojima, Y. Tolnitch, L. Tomlinson, J.S. Topp, T. Torres K 76	22, P P280, P179, P326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 P17 P336 P80 P214 P337 P336 P80 P214 P377 P336 P307 P170 P210 P170 P170 P170 P170 P170 P170 P170 P1
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, J.F. Thompson, Z.J. Thorn, M. 42 Thorne, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Ting, D. Tiwari, R.K. Tojima, Y. Tolnitch, L. Tomlinson, J.S. Topp, T. Torisu-Itakura, H. Torres, K. 76, Torres, K. 76, Terree, L.	22, P P280, P179, 9326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 P17 63 47 P240 P174 P336 P80 P214 P170 P307
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, J.F. Thompson, Z.J. Thorn, M. 42 Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Torign, P. Torisu, R.K. Tojima, Y. Tolnitch, L. Tomlinson, J.S. Topp, T. Torisu-Itakura, H. Torphy, R.J. Torres, L.J.	22, P P280, P179, 9326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 P170 63 47 P240 P174 P376 P307 P306 P307 P366
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomas, N. Thompson, J.F. Thompson, J.F. Thompson, Z.J. Thorne, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Ting, D. Tiwari, R.K. Tojima, Y. Tolnitch, L. Tomlinson, J.S. Topp, T. Torisu-Itakura, H. Torres, K. Tor, S., Torres, L.J. Torres-Pelayo, J.	22, P P280, P179, 9326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 51 P158 45 P388 P170 P17 63 47 P240 P170 P376 P80 P104 P377 P3366 P80 P204
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, J.F. Thompson, J.F. Thompson, J.F. Thompson, J.F. Thorne, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Toring, D. Tiwari, R.K. Tojima, Y. Tolnitch, L. Tomlinson, J.S. Topp, T. Torres, K. Torres, K. Torres, L.J. Torres-Pelayo, J. Torres-Roca. J.	22, P P280, P179, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 518 P158 45 P388 P170 P17 63 47 P336 P80 P214 P170 P336 P307 P307 P307 P307 P204 P307 P307 P204 P307 P307 P307 P307 P307 P307 P307 P307
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, Z.J. Thorne, M. Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Torigina, Y. Tolnitch, L. Tomlinson, J.S. Topp, T. Torisu-Itakura, H. Torphy, R.J. Torres, L.J. Torres, L.J. Torres-Pelayo, J. Torres-Roca, J. Toeti G.	22, P P280, P179, 9326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 59 51 P158 45 P388 P388 P170 P17 63 47 P336 P307 P336 P204 P307 P307 P307 P306 P204 P237 P326 P202
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, J.F. Thompson, Z.J. Thorn, M. 42 Thorpe, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Torina, P. Torisu, R.K. Tojima, Y. Tolnitch, L. Torlisu, R.K. Topp, T. Torisu-Itakura, H. Torphy, R.J. Torres, L.J. Torres, L.J. Torres-Pelayo, J. Torres-Roca, J. Tosti, G.	22, P P280, P179, 50, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 P170 63 47 P170 P170 78366 P214 P170 P307 P306 P204 P237 P230 P237
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thompson, J.F. Thompson, M. Thompson, M. Thompson, M. Thorne, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Ting, D. Tiwari, R.K. Toing, D. Tiwari, R.K. Toinitch, L. Torlinson, J.S. Torpisu-Itakura, H. Torphy, R.J. Torres, K. Tor, S. Torres, L.J. Torres-Pelayo, J. Torsti, G. Toy, K.	22, P P280, P179, P326, 50, , P97,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 P17 P336 P80 P214 P37 P336 P80 P214 P377 P336 P204 P307 P306 P204 P307 P306 P204 P307 P306 P307 P306 P307 P306 P307 P307 P307 P307 P307 P307 P307 P307
Testori, A. Thayer, S.P. Thirunavukarasu, P. P141, P265, Thoma, A. Thomas, C.R. Thomas, J.P. Thomas, N. Thomay, A.A. Thompson, J.F. Thompson, J.F. Thompson, J.F. Thompson, J.F. Thorne, M. Thorne, P. Tierney, M.T. Tignanelli, C. Tillett, E. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Times, M.L. Toring, D. Tiwari, R.K. Tojima, Y. Tolnitch, L. Tomlinson, J.S. Topp, T. Torrisu-Itakura, H. Torres, K. Torres, L.J. Torres, Pelayo, J. Torres-Pelayo, J. Torse, G. Toy, K. Toyozumi, T.	22, P P280, P179, 50, 50, P326, 50, P326, 70, P326, 70, P326, 70, P301,	P230 47 116, P311 P95 P403 90 P327 P212 59 51 P158 45 P388 P170 P17 63 47 P336 P336 P336 P337 P336 P307 P307 P307 P307 P307 P307 P307 P307

Tran, T.	P304
Tran Cao, H. 62,	P162, P358
Trappey, A.	16
Trappey, A.F.	P6
Trent. J.	P383
Trinkaus, K.M.	P374
Tripathy, D.	P64
Trotti. A.	P237
Tsai S. P171 F	2173 P179
P355.	P391. P403
Tsang, A.	P195
Tsang, M.E.	P318
Tsena. H.	P336
Tsena. J.	P216
Tsena. J.F.	P277, P376
Tseng, W.H.	P292
Tseng, W.W.	P301
Tsien, R.Y.	P353
Tsikitis, V.L.	P95
Tsujinaka, T.	6, P356
Tuli, N.	P240
Tully, D.	P34
Tummel, E.	8, P79
Turaga, K.K.P108,	P118, P171,
P173, P179, P355,	P391, P403
Turner, B.	P17
Turner, R.R.	P214
Tuttle, R.	P224, P311
Tuttle, T.M.	P69
Tuvin, D.	P272
Tyler, D.S. 49, 51,	94, P299,
-	P306
TT	
U Llabikada V	01
	01

Uchikado, Y.	81
Uehara, K.	P104
Ueno, N.T.	P263
Uenosono, Y.	81, 91, P341
Uetake, H.	P120
Ugras, S.	P19
Umeshita, K.	P356
Undevia, S.	P309
Untch, B.R.	34
Uppal, A.	P198, P323
Urbauer, D.L.	P146

V

48
41
86
P350
75
P10, 75
77
P99
2
P4
P231
86
75
P231, P295
P10
86
P106

Van Tinteren, H.	86
VanderWalde, A.	52
Vanhaecke, F.	27, P105
Vaporciyan, A.	88
Varadhachary, G.	P178
Vasilevska-Ristovks	sa, J. P404,
	P405, P407
Vauthey, J.	P178, P358
Veerman, K.	P231
Velasquez, J.	P289
Velázquez-Dohorn,	M.E. P398
Venkatasubramania	an, P.N. P77
Vera, J.	P359
Verberne, C.	2
Verhoef, C.	P4, 75
Verrecchia, F.	P230
Verschuer, V.V.	P4
Vervaet, C.	P105
Vetto, J.	P216
Viar, V.	P238
Vickers, S.	43, P187
Viehl, C.T.	18
Villavicencio-Valenc	cia, V. P204,
	P308
Villescas, V.V.	P62
Virgo, K.S.	P2
Viskochil, D.	P313
Visscher, D.W.	P55
Visser, B.C.	77, P304
Vito, C.	12, P42, P50
VOCI, A.E.	P86
Vollmar, N.A.	P300
von Euw E	F371 58
von Holzen II	18
Von Waagner, W.K.	P190
Vos. E.L.	P4
Votanopoulos, K I	89. P129
P255, P274,	P333, P351.
P357, P361, P387,	P393, P394
Vreeland, T.J.	P6, 16
Vu, H.	P91

W

Wachtel, H.	38, P152,	P2	98
Wagman, L.D.			23
Waguespack, S	.G.	P1	46
Wai, C.J.		P1	32
Wainberg, Z.A.			21
Wainstein, A.J.		P3	66
Walder, A.		P2	75
Walker, J.		P3	75
Wallace, A.		Ρ	46
Wallace, M.		Ρ	72
Wallack, M.		P2	40
Walls, B.		P1	96
Walls, J.		P3	83
Walsh, G.L.			88
Walsh, M.		P3	97
Walters, D.M.			96
Wan, W.		Ρ	91
Wanebo, H. P2	281, P294,	P3	64
Wang, B.		P1	38
Wang, E.		Ρ	20

=	D		550		5000	10 1	5.40
Wang, F.	P60	Wicha, M.	P52	Wu, S.	P389	Ying, J.	P18
Wang, J.	11	Wieckowski, E.	P128	Wu, W.	93	Yip, L.	P143
Wang, L.	31, 40	Wiese, D.	P282	Wuamett, J.	P284	Yip, R.	P34
Wang, Q.	P167	Wiggers, T.	2	Wunder, J.S.	P318	Yoon, C.	90
Wang, S.C.	P349	Wightman, S.C.	P198, P323	Wyrwicz, A.M	<i>I</i> . P77	Yoon, C.H.	P130
Wang, T.	P324	Wikholm, L.	P30			Yoon, S.S.	71, 90
Wang, T.S.	P149	Wilfong, C.	P200, P215			Yopp, A.	45, 61, P260
Wang, W.	76, P288	Wilkinson, N.	P378		X	Yoshihiro, H.	P362
Wang, Y.	P286	Williams, P.	P91	Xie, X.	P28	Yost, S.	20
Wang-Gillam, A.	97	Williams, S.J.	P227	Xin, W.	95	You, Y. 62,	P102, P126, P307
Wapnir, I.L.	P232	Williams, T.	P363, P386	Xing, Q.	P34	Young-Woo,	K. 6
Wargo, J.	47	Wilson, C.	P33	Xu, S.	15, P205, P242	Yu, X.	P142
Warneke, C.	53	Wilson, F.	P27	Xu, W.	P338	Yue, B.	P196
Warren Peled, A.	P60	Wilson, G.	82, P271				
Warschkow, R.	18	Wilson, G.C.	66				
Warshaw. A.L.	47	Wilson, J.P.	P290		Y		Ζ
Wasif, N.	P7, 65, P199	Wilson, L.	P164	Yabe, M.	P345	Zacharias A	.I P108
Wauters, C.A.	P44	Wilson, N.	P27	Yaqi, H.	P180	Zager, J.S.	49. 51. 52. P196.
Weber JS	P241	Wima K	66 82 P271	Yakoub D	P73 P372 P383	P206	P226 P237 P241
Weber SM 8	0 08 P150	Winchester D.I	P20 P58	Yamada A	P3 P122	Zadorski B	P405 P407
D222 D251	D257 D261	Winder D	70	Vamamoto k	C D110	Zagorski, D. Zaboor H	70
D28-	7 D303 D301	Winglow E	80 08 P150	Vamamoto, I		Zavdfudim \	/ D186
Wooder I	7, F393, F394 D64	D222 D251 D2	09, 90, F130, 97 D202 D204	ramamoto, r	VI. F200, F220,		
Weerseinghe D	F04	Mintero S	07, F393, F394	Vamaaka V	F 247 D110		D246 D250 D406
		Withers, S.	F350	Yamaaaki M	F112	F 104, F200,	F340, F350, F400
Weese, J.R.	P354	WITKOWSKI, E.H.	P3/6	Yamasaki, IVI	I. P356	Zeidow, B.	P298
Wei, A.C.	P183	WO, J.	47, P110	Yan, J.	P34	Zenati, M.S.	P184, P346
Weichselbaum, R.	R. P163,	Woldemichael, A	. P285, P291	Yan, M.	48	Zervos, E.E.	P300
	P198, P323	Wolff, R.A.	P178	Yan, Y.	P357	Zettl, A.	18
Weigel, R.J.	17, P71	Wolfgang, C.	93	Yanagita, S.	91, P341	Zgajnar, J.	P315
Weinberg, A.	P272	Woll, N. P7	78, P189, P399	Yang, C.H.	P213	Zhang, J.	28
Weiss, B.	P30	Wolmark, N.	23	Yang, C.J.	P376	Zhang, M.	46
Weiss, M.	93	Woltering, E.	P286	Yang, J.C.	4	Zhang, Y.	P217
Weixler, B.	18	Wong, J.	P288	Yang, K.	P253	Zhang, Z.	P85
Weksler, B.	79	Wong, J.H.	P300	Yang, M.	P363	Zhao, D.	P33
Weltz, C.	P26	Wong, J.Y.	P206, P226	Yang, R.L.	15	Zhao, X.	P124
Wenham, R.	P237	Wong, S.L.	24, 63, P256	Yao, J.C.	P148	Zheng, H.	P242
Wevers, K.	P220	Woo, S.	P389	Yao, K.	P20, P58, P77	Zheng, L.	93, P109
Wexelman, B.	P74	Woodfield, G.W.	17	Yates, R.B.	P238	Zheng, Z.	P121, P285, P291
Wey, J.	P397	Woods, C.	P121	Ye, H.	P72	Zhu, A.	39, P167
Whang, E.E.	P130	Wooldridge, R.	P36	Yeh, A.	P116	Zhu, C.	P164
White, D.	4	Worhunsky, D.J.	77, 89, P333,	Yeh. J.	P170. P334	Zhu, L.	P347
White, E.J.	57	P351, P357, P36	1. P393. P394	Yeh, M.	46	Zhu, W.	P64
White, N.	P228	Wright, C.L.	P244, P251	Yeluri S F	P321 P325 P330	Zih, F.S.	P182
White R	10	Wright F	P296 P401	roluli, O. T	P380	Zihni A M	P402
White B B	94	Wright G	P13 P388	Von TW	P1/0	Zoon C.K	P210
White .Ir B I	P202	Wright JP	08 08	Yeung B	46 P10/	Zuber M	1210
Whiteside M	P51	Wu D	50 50	Vim I	10 P2/	Zuber, IVI. Zuroikat A L	
Whiting CK	P101	Wu H	1°2 D094	Ving A K	D1/A		D_{1} D, P113, P116,
winning, C.K.	FIVI	ννu, Π.	F234	ning, A.N.	F 140	P128,	P346, P350, P406